COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS CROSS-REFERENCE TO RELATED APPLICATIONS This International Patent Application claims priority to United States Provisional Patent Application No.63/403,988, filed September 6, 2022 and United States Provisional Patent Application No.63/492,547, filed March 28, 2023, the contents of which applications are incorporated by reference in their entireties herein. TECHNICAL FIELD [0001] The present invention relates to combination therapies for treatment of various medical conditions. Specifically, the present invention relates to a combination of a metal channel activator and a modulator of the trans-activation response element (TAR) DNA-binding protein 43 (TDP-43) for treatment of neurological and neurodegenerative disorders. In particular, the metal channel activator may target the Kv7 family of voltage- gated potassium (K ⁺ ) channels. BACKGROUND [0002] Metal channel activators (openers) are associated with a wide range of physiological functions including the regulation of the electrical properties of excitable cells. Metal channels control the follow of metal ions such as Potassium (K ⁺ ) and Sodium (Na ⁺ ) across a cell membrane. A primary function of these channels in the brain is to regulate the neuronal action potential. Several neurologic disorders are potentially due to dysregulation of metal channels. [0003] Potassium (K ⁺ ) channels, present on the plasma membranes of most cell types, are the most diverse class of all ion channels. Potassium channels of the Kv7 family of voltage-gated potassium (K ⁺ ) channels are of particular therapeutic interest due to their importance in neurological conditions such as excitability disorders including Amyotrophic lateral sclerosis (ALS). There are five members of the Kv7 family of voltage-gated potassium (K ⁺ ) channels, including Kv7.1, Kv7.2, Kv7.3, Kv7.4, and Kv7.5. [0004] Metal channel activators have been reported to be useful for treatment of various neurological and neurodegenerative disorders. Thus far, only one metal channel activator, Retigabine, has been FDA approved. Retigabine is used as anticonvulsant for the treatment of epilepsy. Further Kv7 channel activators have been proposed for the treatment of many conditions including substance abuse and mood disorders (Vigil FA, Carver CM, Shapiro MS. Pharmacological Manipulation of K _v 7 Channels as a New Therapeutic Tool for Multiple Brain Disorders. Front Physiol.2020 Jun 19;11:688. doi: 10.3389/fphys.2020.00688). There remains a need, however, for new therapies utilizing Kv7. One solution is combining metal channel activators with other therapeutic agents to significantly improve treatment outcomes. [0005] TDP-43 (also known as TARBP and more formally known as transactive response DNA binding protein 43 kDa) is a multifaceted regulator of transcription and translation. TDP-43 enacts this function through both RNA and DNA binding domains. Although only a subset of patients with ALS have a genetic mutation related to TDP-43, aggregates of TDP-43 have been identified in 97% of ALS cases. These aggregates may be due to post translational modifications including ubiquitination, phosphorylation, acetylation, PARylation, and methylation, or due to mislocalization away from the nucleus. Counteracting these multifaceted aggregates is a major therapeutic objective for ALS. [0006] More generally, a pathological form of the transactive response (TAR) DNA binding protein (TDP-43) is known to bind to RNA in stress granules to form membraneless, amyloid-like TDP-43 aggregates in the cytoplasm of ALS motor neurons. Such aggregates cause RNA dysregulation, which contributes to disease pathogenesis of amyotrophic lateral sclerosis (ALS) and other neurologic or neurodegenerative diseases. TDP-43 binders are known to prevent binding of TDP-43 to RNA, so they may be potentially useful to stop or at least slow down progression of ALS or another neurologic or neurodegenerative disease in a patient. [0007] Current treatment options for ALS and other neurological or neurodegenerative disorders are limited. For example, Riluzole is an approved treatment for ALS. Riluzole is believed to have anti-excitotoxic method of action, in part, through an anti- glutaminergic/Na+ blocking pathway. However, hyperexcitability may be a consequence of increased Na+ or decreased K+ conductance depending on age and disease stage. Analysis of K+ channels in sporadic ALS postmortem spinal cords suggests hypermethylation, down-regulation, and decreased K+ channel expression, suggesting a dysregulated potassium current in ALS pathology. Several aspects are not clear, such as whether hyperexcitability is intrinsic or synaptic, and how long it persists. [0008] It is disclosed that both modulating K+ channels and preventing binding of TDP- 43 to RNA as a result of a treatment regimen will more effectively treat ALS or other neurologic or neurodegenerative diseases. Therefore, administering a K+ channel modulator (or other metal ion channel modulator) in combination with a TDP-43 modulator will have a greater benefit than either therapy administered alone. As an alternative to a TDP-43 modulator, modulators of protein targets other than TDP-43 may be utilized which are effective to disaggregate TDP-43 or treat TDP-43 proteinopathies. Additionally, one or more K+ channel activators or TDP-43 modulators may have a dose-dependent adverse effect limiting their therapeutic window. However, the combination of a K+ channel activator and TDP-43 modulator will allow for use of lower doses of one or more of the K+ channel activator or TDP-43 modulator, to achieve improved treatment efficacy while reducing adverse effects, if any. It is disclosed that a Kv7 activator in combination with a TDP-43 modulator will more effectively treat, prevent, and/or slow the progression of ALS or other neurologic or neurodegenerative diseases compared to current available treatments. [0009] Described herein are compositions and methods for combination therapies of Kv7 openers with TDP-43 modulators. The combination therapies have treatment capabilities greater than Kv7 openers or TDP-43 modulators alone, and may be particularly useful for neurological diseases. Pharmaceutical compositions combining these agents may also be useful for treatment of a pain or depressive disorder. These two agents target distinct molecular targets associated with neurological diseases and neurodegenerative disorders such as ALS. Specifically, the Kv7 channel opener reduces excitability, and TDP-43 modulators reduce aggregation of TDP-43. We have found that combining Kv7 opener and a TDP-43 modulator will yield improved treatment outcomes as described herein. SUMMARY [0010] The present invention is directed to combination therapies including a metal channel activator and a TDP-43 modulator. [0011] In an embodiment, provided is a pharmaceutical composition including a metal channel activator and a TDP-43 modulator. [0012] In another embodiment, disclosed is a method for treating or preventing a disease that involves TDP-43, including administering to a subject the pharmaceutical composition. [0013] In another embodiment, disclosed is a method for treating or preventing a disease associated with TDP-43 proteinopathies, including administering to a subject the pharmaceutical composition. [0014] In another embodiment, disclosed is a method for treating or preventing diseases that involve excess amounts of TDP-43 in the cytosol, including administering to a subject the pharmaceutical composition. DETAILED DESCRIPTION [0015] The following detailed description is provided to aid those skilled in the art in practicing the present invention. Exemplary embodiments will hereinafter be described in detail. However, these embodiments are only exemplary, and the present disclosure is not limited thereto but rather is defined by the scope of the appended claims. Those of ordinary skill in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present disclosure. [0016] Accordingly, the embodiments are merely described below, by referring to structures and schemes, to explain aspects of the present description. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items. The term "or" means "and/or." Expressions such as "at least one of," when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list. [0017] It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments. [0018] It is understood that the terms "comprises" and/or "comprising," or "includes" and/or "including" when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof. [0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting. It will be further understood that the terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein. [0020] As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present invention. [0021] The articles "a" and "an" refer to one or to more than one (i.e., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, "an element" means one element or more than one element. [0022] As used herein, when specific definition is not otherwise provided, the term "substituted" refers to a group substituted with deuterium, a halogen (-F, -Cl, -Br, -I), a hydroxy group (-OH), an amino group (-NH ₂ ), a carboxyl group (-CO ₂ H), a substituted or unsubstituted C1-C10 amine group, a nitro group (-NO ₂ ), a C1-C10 alkyl group, a C3- C10 cycloalkyl group, a C6-C12 aryl group, a C1-C10 alkoxy group, a C1 to C10 trifluoroalkyl group such as a trifluoromethyl group (-CF ₃ ) and the like, or a cyano group (-CN) instead of at least one hydrogen of a substituting group or compound. [0023] As used herein, “modulator”, “modulators”, and “modulating”, when describing compounds, describe compounds that may enact their effect through a number of mechanisms of action including but not limited to: binding to the active site of a protein, binding to a region of the protein away from the active site, causing relocalization of a protein, inducing degradation of a protein, inducing stabilization of a protein, causing a conformational change in a protein, decreasing the activation threshold for a protein, increasing the activation threshold for a protein, altering posttranslational modifications for a protein, reducing the transcription of a gene, increasing the transcription of a gene, reducing the translation of an mRNA transcript, increasing the translation of an mRNA transcript, disrupting an interaction between two proteins, and stabilizing an interaction between two proteins; wherein the protein may be the target of modulation or an intermediary protein which is associated with modulation of the target protein. Modulators of the targets described herein (i.e., Kv7 and TDP-43) may each or both be small molecule compounds, proteins, antibody fragments or antibodies, or any other construct effecting modulation. [0024] As used herein, “TDP-43 modulator” may target TAR DNA binding protein 43 (TDP-43), or other human proteins known in the art to modulate TDP-43, including but not limited to mitochondrial permeability transition pore (mPTP), phosphatidylinositol-3- phosphate 5-kinase type III (PIKfyve), Cytochrome P450 Family 51 Subfamily A Member 1 (CYP51A1), and Forkhead Box O (FOXO) family proteins. TDP-43 modulators may target any other human protein modulating or effecting modulation of TDP-43, as appreciated by a person of skill in the art. [0025] As used herein, “neurological disease” refers to a disease or disorder which affects the brain and/or nerves found elsewhere in the body. Such neurologic diseases may include: Absence of the Septum Pellucidum, Acid Lipase Disease, Acute Disseminated Encephalomyelitis, Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Agnosia, Aicardi Syndrome, Aicardi-Goutieres Syndrome, Alexander Disease, Alpers' Disease, Alternating Hemiplegia, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Anencephaly, Angelman Syndrome, Antiphospholipid Syndrome, Aphasia, Apraxia, Arachnoid Cysts, Arachnoiditis, Arteriovenous Malformation, Asperger Syndrome, Ataxia Telangiectasia, Ataxias and Cerebellar or Spinocerebellar Degeneration, Atrial Fibrillation and Stroke, Attention Deficit- Hyperactivity Disorder, Autism Spectrum Disorder, Back Pain, Barth Syndrome, Batten Disease, Behcet's Disease, Bell's Palsy, Benign Essential Blepharospasm, Binswanger's Disease, Brachial Plexus Injuries, Brain and Spinal Tumors, Brown- Sequard Syndrome, CADASIL, Canavan Disease, Carpal Tunnel Syndrome, Central Cord Syndrome, Central Pain Syndrome, Central Pontine Myelinolysis, Cephalic Disorders, Cerebellar Degeneration, Cerebellar Hypoplasia, Cerebral Aneurysms, Cerebral Arteriosclerosis, Cerebral Atrophy, Cerebral Cavernous Malformation, Cerebral Hypoxia, Cerebral Palsy, Cerebro-Oculo-Facio-Skeletal Syndrome (COFS), Charcot-Marie-Tooth Disease, Chiari Malformation, Chorea, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Pain, Coffin Lowry Syndrome, Colpocephaly, Coma, Complex Regional Pain Syndrome, Congenital Myasthenia, Congenital Myopathy, Corticobasal Degeneration, Craniosynostosis, Creutzfeldt-Jakob Disease, Cushing's Syndrome, Dandy-Walker Syndrome, Deep Brain Stimulation for Movement Disorders, Dementia, Dementia With Lewy Bodies, Dermatomyositis, Developmental Dyspraxia, Diabetic Neuropathy, Dravet Syndrome, Dysautonomia, Dysgraphia, Dyslexia, Dyssynergia Cerebellaris Myoclonica, Dystonia, Empty Sella Syndrome, Encephalitis Lethargica, Encephaloceles, Encephalopathy, Epilepsy, Erb- Duchenne and Dejerine-Klumpke Palsies, Essential Tremor, Fabry Disease, Fahr's Syndrome, Familial Periodic Paralyses, Farber's Disease, Febrile Seizures, Fibromuscular Dysplasia, Foot Drop, Friedreich Ataxia, Frontotemporal Dementia, Functional Neurologic Disorder, Gaucher Disease, Generalized Gangliosidoses, Gerstmann's Syndrome, Gerstmann-Straussler-Scheinker Disease, Giant Axonal Neuropathy, Glossopharyngeal Neuralgia, Guillain-Barré Syndrome, Headache, Hemicrania Continua, Hemifacial Spasm, Hereditary Neuropathies, Hereditary Spastic Paraplegia, Herpes Zoster Oticus, Holmes-Adie Syndrome, Holoprosencephaly, Huntington's Disease, Hydranencephaly, Hydrocephalus, Hydromyelia, Hypersomnia, Hypertonia, Hypotonia, Inclusion Body Myositis, Incontinentia Pigmenti, Infantile Neuroaxonal Dystrophy, Infantile Refsum Disease, Infantile Spasms, Inflammatory Myopathies, Iniencephaly, Isaacs' Syndrome, Joubert Syndrome, Kearns-Sayre Syndrome, Kennedy's Disease, Kleine-Levin Syndrome, Klippel-Feil Syndrome, Klippel- Trenaunay Syndrome (KTS), Klüver-Bucy Syndrome, Krabbe Disease, Kuru, Lambert- Eaton Myasthenic Syndrome, Landau-Kleffner Syndrome, Learning Disabilities, Leigh's Disease, Lennox-Gastaut Syndrome, Lesch-Nyhan Syndrome, Leukodystrophy, Lipid Storage Diseases, Lipoid Proteinosis, Lissencephaly, Locked-In Syndrome, Machado- Joseph Disease and Spinocerebellar Ataxia, Megalencephaly, Melkersson-Rosenthal Syndrome, Meningitis and Encephalitis, Menkes Disease, Meralgia Paresthetica, Metachromatic Leukodystrophy, Microcephaly, Migraine, Miller Fisher Syndrome, Mitochondrial Myopathies, Moebius Syndrome, Monomelic Amyotrophy, Motor Neuron Diseases, Moyamoya Disease, Mucolipidoses, Mucopolysaccharidoses, Multi-Infarct Dementia, Multifocal Motor Neuropathy, Multiple Sclerosis, Multiple System Atrophy, Multiple System Atrophy with Orthostatic Hypotension, Muscular Dystrophy, Myasthenia Gravis, Myoclonus, Myopathy, Myotonia, Myotonia Congenita, Narcolepsy, Neuroacanthocytosis, Neurodegeneration with Brain Iron Accumulation, Neurofibromatosis, Neuroleptic Malignant Syndrome, Neurological Complications of AIDS, Neurological Complications of Lyme Disease, Neurological Consequences of Cytomegalovirus Infection, Neurological Sequelae Of Lupus, Neuromyelitis Optica, Neuronal Migration Disorders, Neurosarcoidosis, Neurosyphilis, Neurotoxicity, Niemann-Pick Disease, Normal Pressure Hydrocephalus, Occipital Neuralgia, Ohtahara Syndrome, Olivopontocerebellar Atrophy, Opsoclonus Myoclonus, Orthostatic Hypotension, Paraneoplastic Syndromes, Paresthesia, Parkinson's Disease, Paroxysmal Choreoathetosis, Paroxysmal Hemicrania, Parry-Romberg Syndrome, Pelizaeus-Merzbacher Disease, Peripheral Neuropathy, Periventricular Leukomalacia, Pervasive Developmental Disorders, Pinched Nerve, Piriformis Syndrome, Pituitary Tumors, Polymyositis, Pompe Disease, Porencephaly, Post-Polio Syndrome, Postural Tachycardia Syndrome, Primary Lateral Sclerosis, Progressive Multifocal Leukoencephalopathy, Progressive Supranuclear Palsy, Prosopagnosia, Pseudotumor Cerebri, Rasmussen's Encephalitis, Refsum Disease, Repetitive Motion Disorders, Restless Legs Syndrome, Rett Syndrome, Reye's Syndrome, Sandhoff Disease, Schilder's Disease, Schizencephaly, Septo-Optic Dysplasia, Shaken Baby Syndrome, Shingles, Sjögren's Syndrome, Sleep Apnea, Sotos Syndrome, Spasticity, Spina Bifida, Spinal Cord Infarction, Spinal Cord Injury, Spinal Muscular Atrophy, Stiff-Person Syndrome, Striatonigral Degeneration, Stroke, Sturge-Weber Syndrome, Subacute Sclerosing Panencephalitis, SUNCT Headache, Swallowing Disorders, Sydenham Chorea, Syncope, Syringomyelia, Tabes Dorsalis, Tardive Dyskinesia, Tarlov Cysts, Tay-Sachs Disease, Tethered Spinal Cord Syndrome, Thoracic Outlet Syndrome, Thyrotoxic Myopathy, Todd's Paralysis, Tourette Syndrome, Transient Ischemic Attack, Transmissible Spongiform Encephalopathies, Transverse Myelitis, Traumatic Brain Injury, Tremor, Trigeminal Neuralgia, Tropical Spastic Paraparesis, Troyer Syndrome, Tuberous Sclerosis, Vasculitis Syndromes of the Central and Peripheral Nervous Systems, Von Hippel-Lindau Disease (VHL), Wallenberg's Syndrome, Wernicke- Korsakoff Syndrome, Whiplash, Whipple's Disease, Williams Syndrome, Wilson Disease, and Zellweger Syndrome. [0026] As used herein, the term “metal channel activator” is construed to include both metal channel activator and pharmaceutically acceptable salt thereof. [0027] As used herein, the term “TDP-43 modulator” is construed to include both TDP- 43 modulator and pharmaceutically acceptable salt thereof. [0028] As used herein, the term “AUC” is the definite integral of the concentration of a drug in blood, cerebrospinal fluid, target organ, or any other physiologically relevant site after a dose is given as a function of time. AUC in this context is used to measure the total exposure to the drug across time. AUC can be evaluated over a definite time interval or estimated based on the integral drug concentrations measured over a time interval extrapolated to infinite time. [0029] As used herein, the term “Cmax” is the highest concentration of a drug in the blood, cerebrospinal fluid, target organ, or any other physiologically relevant site after a dose is given. [0030] As used herein, the term “Tmax” is the time taken after administration for a drug to reach its highest concentration in the blood, cerebrospinal fluid, target organ, or any other physiologically relevant site after a dose is given. [0031] As used herein, the term “proteinopathies” refers to diseases characterized by an accumulation or aggregation of a single protein, or multiple proteins. Proteinopathies include but are not limited to: Creutzfeldt–Jakob disease and other prion diseases, Alzheimer's disease, Parkinson's disease, amyloidosis, multiple system atrophy, Amyotrophic lateral sclerosis (ALS), Frontotemporal Lobar Degeneration, and Lewy Body Dementia. [0032] Additional aspects will be set forth in part of the description which follows and, in part, will be apparent from the description. [0033] In the formulas set forth below, it is set out with substituents and definitions, and it should be clear to the reader that substituents and definitions are numbered (e.g., R ¹ , R ² , Y, etc.) and are intended to apply within a given formula. Numberings that are repeated across formulas are intentional and should be each read within the context of each particular formula. METAL CHANNEL ACTIVATORS [0034] Amyotrophic lateral sclerosis (ALS) is a neurological disorder characterized by progressive upper and lower motor neuron degeneration, leading to muscular atrophy and eventually fatal paralysis. A now appreciated characteristic of ALS is hyperexcitability of motor neurons (Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G, Berry JD, Brown RH Jr, Cudkowicz ME, Bean BP, Eggan K, Woolf CJ. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep.2014 Apr 10;7(1):1-11. doi: 10.1016/j.celrep.2014.03.019. Epub 2014 Apr 3. PMID: 24703839; PMCID: PMC4023477). Mutations in metal channels, and in particular mutations in the Kv7 family of voltage-gated potassium (K ⁺ ) channels have been implicated in hyperexcitability disorders (Jepps TA, Barrese V, Miceli F. Editorial: Kv7 Channels: Structure, Physiology, and Pharmacology. Front Physiol.2021 Apr 16;12:679317. doi: 10.3389/fphys.2021.679317. PMID: 33935812; PMCID: PMC8085343). The Kv7 family includes Kv7.1-7.5 corresponding to the KCNQ1-5 genes. Kv7 channel activators, a subset of metal channel activators, can reduce hyperexcitability of neurons. This suggests that treatment of ALS patients with Kv7 channel activators may reduce ALS symptomology. Thus, in combination with TDP-43 as described herein, effective treatment outcomes are obtained for ALS. [0035] Examples of metal channel activators including Kv7 channel activators are disclosed in Formulas 1 – 170, the “Further embodiments” section, and in the corresponding referenced applications. Formula 1 [0036] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 1. Such compounds are described in US Patent No 9,481,653, issued November 1, 2016, and corresponding to US Application No.14/853,815 filed September 14, 2015; and US Publication No 20210188782A1, published June 24, 2021, and corresponding to US Application No.17/127,231 filed December 18, 2020; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 1, these references incorporated by reference herein control. [0037] In an embodiment, the Kv7 channel activator is a compound according to formula 1: rmula 1 wherein D is optionally substituted C _3-6 carbocyclyl, optionally substituted C _2-5 heterocyclyl, isopropyl, or t-butyl; Bz is optionally substituted benzoimidazol-1,2-diyl; A is C _1-8 alkyl; X is F; and Y is H, F, Cl, Br, I, or a moiety having a molecular weight of 15 Da to 300 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br. [0038] In further embodiments, D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t-butyl. [0039] In further embodiments, D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t-butyl, wherein each substituent of D and Y, if present, independently has a molecular weight of 15 Da to 200 Da and consists of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br. [0040] In another embodiment, the Kv7 channel activator is a compound according to formula 1 wherein, D is optionally substituted C _3-6 carbocyclyl, optionally substituted C _2-5 heterocyclyl, isopropyl, or t-butyl; Bz is optionally substituted benzoimidazol-1,2-diyl; A is C _1-8 alkyl; X is H, F, CF ₃ , optionally substituted phenyl, or optionally substituted pyridinyl; and Y is H, F, Cl, Br, I, or a moiety having a molecular weight of 15 Da to 300 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br. [0041] In further embodiments, D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t-butyl. [0042] In further embodiments, each substituent of D, X, and Y, if present, independently has a molecular weight of 15 Da to 200 Da and consists of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br. [0043] In further embodiments, R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , —CO ₂ CH ₂ CH ₃ , C _{1- 4} alkyl, or C _1-4 hydroxyalkyl. [0044] In further embodiments, X is optionally substituted phenyl. [0045] In further embodiments, X is CF ₃ . [0046] In further embodiments, X is optionally substituted pyridinyl. [0047] In further embodiments, X is H. [0048] In further embodiments, Y is H. [0049] In further embodiments, Y is OH. [0050] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of:

Formula 2 [0051] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 2. Such compounds are described in US Patent No.9,481,653 issued November 1, 2016 and corresponding to US Application No. US14/853,815 filed September 14, 2015; US Patent No.9,914,708, issued March 13, 2018 and corresponding to US Application No.15/339,590 filed October, 31; US patent No 10,385,025, issued August 20, 2019 and corresponding to US Application No. 15/879,792 filed January 25, 2018; US Patent No.10,906,877 issued on February 2, 2021 and corresponding to US Application No.16/460,449 filed July 2, 2019; US Patent No.10,851,067 issued on December 1, 2020 and corresponding to US Application No. 16/358,642 filed March 19, 2019; US Patent No.11,261,162 issued on March 1, 2022 and corresponding to US Application No.17/077,068 filed October 22, 2020; US Publication No.20210188782A1, published June 24, 2021 and corresponding to US Application No.17/127,231 filed December 18, 2020; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 2, these references incorporated by reference herein control. [0052] In an embodiment, the Kv7 channel activator is a compound according to formula 2: Formula 2 , wherein D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t-butyl; A is C _2-8 alkyl; X is H, F, CF ₃ optionally substituted phenyl, or optionally substituted pyridinyl; Y is H, F, Cl, Br, I, or a moiety having a molecular weight of 15 Da to 300 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; R ¹ is F, Cl, Br, CN, OCH ₃ , CHF ₂ , CF ₃ , C _1-4 —CO ₂ -alkyl, C _1-4 alkyl, — CH ₂ CO ₂ H, —CH ₂ CO ₂ CH ₂ CH ₃ or —CH ₂ CON(CH ₃ ) ₂ , or C _1-5 hydroxyalkyl; and R ² , R ³ , and R ⁴ are independently H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br. [0053] In further embodiments, Y is H, F, CF ₃ , OH, C _1-5 O-alkyl, C _0-6 alkylamino, optionally substituted tetrahydropyranyl, or C _0-6 fluoroalkylamino. [0054] In further embodiments R ¹ is Cl, Br, —OCH ₃ , —CN, —CF ₃ , —CH ₂ OH, — COOCH ₂ CH ₃ , —C(CH ₃ ) ₂ OH, —CHOHCH ₂ CH ₃ , —CHOHCH ₃ , —CHF ₂ , —CH(CH ₃ ) ₂ , — C(CH ₂ CH ₃ ) ₂ OH, —CH ₂ COOCH ₂ CH ₃ , —CH ₂ C(CH ₃ ) ₂ OH, —CH ₂ COOH, or — CH ₂ CON(CH ₃ ) ₂ . [0055] In further embodiments, R ² is H, F, —CH ₂ OH, —CO ₂ Me, or —C(CH ₃ ) ₂ OH. [0056] In further embodiments, R ³ is H. [0057] In further embodiments, R ⁴ is H, —CH ₃ , or —CF ₃ . [0058] In further embodiments, R ¹ is Cl, Br, CN, OCH ₃ , CF ₃ , —CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl. [0059] In further embodiments, X is optionally substituted phenyl. [0060] In further embodiments, X is CF ₃ . [0061] In further embodiments, X is optionally substituted pyridinyl. [0062] In further embodiments, X is H. [0063] In further embodiments, Y is H. [0064] In further embodiments, Y is OH. [0065] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of:

[0066] In further embodiments, the Kv7 channel activator is a compound according to formula 2 wherein, D is optionally substituted cyclobutyl, or t-butyl; A is C _2-8 alkyl; X is H, CF ₃ , or optionally substituted phenyl; Y is H or OH; R ¹ is CN or C _1-4 hydroxyalkyl; and R ² , R ³ , and R ⁴ are independently H, or F. [0067] In further embodiments, R ¹ is CN, —C(CH ₃ ) ₂ OH, or —CH ₂ C(CH ₃ ) ₂ OH. [0068] In further embodiments, R ² is F. [0069] In further embodiments, R ³ is H. [0070] In further embodiments, R ⁴ is H. [0071] In further embodiments, R ¹ is CN. [0072] In further embodiments, R ¹ is C _1-4 hydroxyalkyl. [0073] In further embodiments, X is optionally substituted phenyl. [0074] In further embodiments, X is CF ₃ . [0075] In further embodiments, X is H. [0076] In further embodiments, Y is H. [0077] In further embodiments, Y is OH. [0078] In further embodiments, the Kv7 channel activator is a compound according to formula 2 wherein, D is cyclobutyl; A is C _1-8 alkyl; X is CF ₃ ; Y is H; R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , —CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, —CH ₂ OH, — CO ₂ Me, or —C(CH ₃ ) ₂ OH; R ³ is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and R ⁴ is H, —CH ₃ , or —CF ₃ ; or D is optionally substituted cyclobutyl; A is C _1-8 alkyl; X is CF ₃ ; Y is H; R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , —CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, —CH ₂ OH, —CO ₂ Me, or —C(CH ₃ ) ₂ OH; R ³ is H; and R ⁴ is H, —CH ₃ , or —CF _3; or D is t-butyl; A is C _1-8 alkyl; X is H; Y is H; R ¹ is Cl, Br, CN, OCH ₃ , CF ₃ , — CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, —CH ₂ OH, —CO ₂ Me, or — C(CH ₃ ) ₂ OH; R ³ is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and R ⁴ is H, —CH ₃ , or —CF ₃ ; or D is t-butyl; A is C _1-8 alkyl; X is CF ₃ ; Y is H; R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , — CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, —CH ₂ OH, —CO ₂ Me, or — C(CH ₃ ) ₂ OH; R ³ is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and R ⁴ is H, —CH ₃ , or —CF ₃ ; or D is cyclobutyl; A is C _1-8 alkyl; X is H; Y is methyl(2,2,2-trifluoroethyl)amino; R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , —CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, — CH ₂ OH, —CO ₂ Me, or —C(CH ₃ ) ₂ OH; R ³ is H; and R ⁴ is H, —CH ₃ , or —CF ₃ ; or D is cyclobutyl; A is C _1-8 alkyl; X is CF ₃ ; Y is dimethylamino; R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , —CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, —CH ₂ OH, — CO ₂ Me, or —C(CH ₃ ) ₂ OH; R ³ is H; and R ⁴ is H, —CH ₃ , or —CF ₃ ; or D is optionally substituted cyclobutyl, optionally substituted phenyl, or optionally substituted C _2-5 alkyl, wherein the optional substituents are selected from —CH ₃ and F; A is C ₁ alkyl; X is substituted cyclobutyl, wherein the substituent is F;Y is H; R ¹ is selected from H, C3 hydroxyalkyl, CN, F, or Cl; R ² is selected from H, CN, F, Br, or — OCF ₃ ; R ³ is selected from H, F, or —OCH ₃ ; R ⁴ is H or F; and wherein when X is substituted with 2 fluorine atoms, the fluorine atoms are not geminal; or a pharmaceutically acceptable salt thereof; [0079] In an embodiment, the Kv7 channel activator is a compound according to formula 2. Wherein, R ¹ , R ² , R ³ , and R ⁴ are independently H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br. [0080] In further embodiments, Y is H, F, CF ₃ , OH, C _1-5 O-alkyl, C _0-6 alkylamino, optionally substituted tetrahydropyranyl, or C _0-6 fluoroalkylamino. [0081] In further embodiments, R ¹ is H, Cl, Br, —OCH ₃ , —CN, —CF ₃ , —CH ₂ OH, — COOCH ₂ CH ₃ , —C(CH ₃ ) ₂ OH, —CHOHCH ₂ CH ₃ , —CHOHCH ₃ , —CHF ₂ , —CH(CH ₃ ) ₂ , — C(CH ₂ CH ₃ )OH, —CH ₂ COOCH ₂ CH ₃ , —CH ₂ C(CH ₃ ) ₂ OH, —CH ₂ COOH, or — CH ₂ CON(CH ₃ ) ₂ . [0082] In further embodiments, R ² is H, F, —CH ₂ OH, —CO ₂ Me, or —C(CH ₃ ) ₂ OH. [0083] In further embodiments, R ³ is H. [0084] In further embodiments, R ⁴ is H, —CH ₃ , or —CF ₃ . [0085] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof. [0086] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof. [0087] In further embodiments the Kv7 channel activator is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [0088] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [0089] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0090] In further embodiments, the compound is:

or a pharmaceutically acceptable salt thereof. [0091] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0092] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0093] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0094] In further embodiments, the compound is:

or a pharmaceutically acceptable salt thereof. [0095] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0096] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0097] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0098] In further embodiments, the compound is:

or a pharmaceutically acceptable salt thereof. [0099] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [0100] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [0101] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of: [0102] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0103] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0104] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0105] In further embodiments, the compound is:

or a pharmaceutically acceptable salt thereof. [0106] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0107] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0108] In further embodiments, the compound is:

or a pharmaceutically acceptable salt thereof. [0109] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0110] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0111] In further embodiments, the compound is:

or a pharmaceutically acceptable salt thereof. [0112] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0113] In further embodiments the compound is: or a pharmaceutically acceptable salt thereof. [0114] In an embodiment of Formula 2, D is optionally substituted cyclobutyl, or t-butyl; A is C _2-8 alkyl, X is H, CF ₃ , or optionally substituted phenyl, Y is H or OH, R ¹ is CN or C _1-4 hydroxyalkyl; and R ² , R ³ , and R ⁴ are independently H, or F. In a further embodiment, R ¹ is CN, -C(CH ₃ ) ₂ OH, or -CH ₂ C(CH ₃ ) ₂ OH. In a further embodiment, R ² is F. In a further embodiment, R ³ is H. In a further embodiment, R ⁴ is H. In a further embodiment, R ¹ is CN. In a further embodiment, R ¹ is C _1-4 hydroxyalkyl. In a further embodiment, X is optionally substituted phenyl. In a further embodiment, X is CF ₃ . In a further embodiment, X is H. In a further embodiment, Y is H. In a further embodiment, Y is OH. [0115] In an embodiment of Formula 2, D is cyclobutyl; A is C _1-8 alkyl, X is CF ₃ , Y is H, R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , -CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, -CH ₂ OH, -CO ₂ Me, or -C(CH ₃ ) ₂ OH; R ³ is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl or B; and R ⁴ is H, -CH ₃ , or -CF ₃ . [0116] In an embodiment of Formula 2, D is optionally substituted cyclobutyl, A is C _1-8 alkyl, X is CH ₃ , Y is H, R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , -CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, -CH2OH, -CO2Me, or -C(CH3)2OH; R ³ is H; and R ⁴ is H, -CH3, or -CF ₃ . [0117] In an embodiment of Formula 2, D is t-butyl; A is C _1-8 alkyl; X is H; Y is H; R ¹ is Cl, Br, CN, OCH ₃ , CF ₃ , -CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, - CH ₂ OH, -CO ₂ Me, or -C(CH ₃ ) ₂ OH; R ³ is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and R ⁴ is H, -CH ₃ , or -CF ₃ . [0118] In an embodiment of Formula 2, D is t-butyl; A is C _1-8 alkyl; X is CF ₃ ; Y is H; R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , -CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, - CH ₂ OH, -CO ₂ Me, or -C(CH ₃ ) ₂ OH; R ³ is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and R ⁴ is H, CH ₃ , or CF ₃ . [0119] In an embodiment of Formula 2, D is cyclobutyl; A is C _1-8 alkyl; X is H; Y is methyl(2,2,2-trifluoroethyl)amino; R ¹ is H, Cl, Br, CN, OCH ₃ , CF ₃ , -CO ₂ CH ₂ CH ₃ , C _1-4 alkyl, or C _1-4 hydroxyalkyl; R ² is H, F, -CH ₂ OH, -CO ₂ Me, or -CH(CH ₃ ) ₂ OH; R ³ is H; and R ⁴ is H, -CH ₃ , or -CF ₃ . [0120] In an embodiment of Formula 2, D is optionally substituted cyclobutyl, optionally substituted phenyl, or optionally substituted C _2-5 alkyl, wherein the optional substituents are selected from -CH ₃ and F; A is C ₁ alkyl, X is substituted cyclobutyl, wherein the substituent is F; Y is H; R ¹ is selected from H, C ₃ hydroxyalkyl, CN, F, or Cl; R ² is selected from H, CN, F, Br, or -OCF ₃ ; R ³ is selected from H, F, or -OCH ₃ ; R ⁴ is H or F; and wherein when X is substituted with 2 fluorine atoms, the fluorine atoms are not geminal; or a pharmaceutically acceptable salt thereof. Formula 3 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 3. Such compounds are described in US Patent No. 8,293,911 issued on October 23, 2012 and corresponding to US Application No. 11/894,877 filed August 22, 2007; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 3, this reference incorporated by reference herein controls. [0121] In an embodiment, the Kv7 channel activator is a compound according to formula 3: Formula 3 , wherein, R ₁ and R ₂ , vary independently, and are selected from the group consisting of H, CN, halogen, CH ₂ CN, OH, CH ₂ F, CHF ₂ , CF ₃ , CF ₂ CF ₃ , C ₁ -C ₆ alkyl, C(═O)C ₁ -C ₆ alkyl; NH—C ₁ -C ₆ alkyl; N(C ₁ -C ₆ alkyl)-C ₁ -C ₆ alkyl, NHC(═O)C ₁ -C ₆ alkyl, C(═O)N(CH ₃ ) ₂ , C(═O)N(Et) ₂ , C(═O)NH ₂ , C(═O)NH—C ₁ -C ₆ alkyl, SO ₂ NH ₂ , NHSO ₂ —C ₁ -C ₆ alkyl; C(═O)OC ₁ -C ₆ alkyl, OC(═O)C ₁ -C ₆ alkyl, OC ₁ -C ₆ alkyl, SC ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, (CH ₂ ) _m C ₃ -C ₆ cycloalkyl, C ₃ -C ₆ cycloalkenyl, (CH ₂ ) _m C ₃ -C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, C ₂ - C ₆ alkynyl, Ar, (CH ₂ ) _m thienyl, (CH ₂ ) _m imidazolyl, (CH ₂ ) _m pyrazyl, (CH ₂ ) _m oxazolyl, (CH ₂ ) _m isoxazolyl, (CH ₂ ) _m thiazolyl, (CH ₂ ) _m isothiazolyl, (CH ₂ ) _m phenyl, (CH ₂ ) _m pyrrolyl, (CH ₂ ) _m pyridyl, and (CH ₂ ) _m pyrimidyl, Wherein m=zero, 1, or 2; Ar is a 5- to 10-member mono- or bicyclic aromatic group, optionally containing 1-4 ring heteroatoms selected independently from N, O, and S; or R ₁ and R ₂ , together with the ring carbon atoms to which they are attached, form a 5- or 6-member fused ring; wherein said fused ring may be saturated, unsaturated, or aromatic, and said fused ring optionally contains one or two heteroatoms selected independently from the group consisting of O, N, and S; R′ is selected from the group consisting of H, halogen, phenyl, 2-(N,N-dimethylamino)ethyl, CF ₃ , OC ₁ -C ₃ alkyl and C ₁ -C ₃ alkyl; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, CN, halogen, CF ₃ , OCF ₃ , OC ₁ -C ₃ alkyl, and C ₁ -C ₃ alkyl; X is O or S; Y is O or S; q=1 or zero; and R ₅ is selected from the group consisting of C ₁ - C ₆ alkyl, (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w CH ₂ C ₃ -C ₆ cycloalkyl, CH ₂ (CHR ₆ ) _w C ₃ - C ₆ cycloalkyl, CR ₆ ═CH—C ₃ -C ₆ cycloalkyl, CH═CR ₆ —C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w C ₅ - C ₆ cycloalkenyl, CH ₂ (CHR ₆ ) _w C ₅ -C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, Ar, (CHR6)wAr, CH2(CHR6)wAr, and (CHR6)wCH2Ar, wherein w=zero, 1, 2, or 3; Ar is a 5- to 10-member mono- or bicyclic aromatic group, optionally containing 1-4 ring heteroatoms selected independently from the group consisting of N, O, and S; and R ₆ is selected from the group consisting of H or C ₁ -C ₃ alkyl; where all cycloalkyl and cycloalkenyl optionally contain one or two ring heteroatoms selected independently from N, O, and S; wherein all alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkynyl, aryl, and heteroaryl groups in R ₁ , R ₂ , R′, R ₃ , R ₄ , R ₅ , R ₆ , and Ar are optionally substituted with one or two substituents selected independently from the group consisting of C ₁ -C ₃ alkyl, halogen, OH, OEt, OMe, CN, CH ₂ F, OCF ₃ , and CF ₃ ; and wherein, additionally, all cycloalkyl and heterocycloalkyl groups are optionally substituted with a carbonyl group. [0122] In further embodiments, R ₁ and R ₂ , vary independently, and are selected from the group consisting of H, halogen, CF ₃ , C ₁ -C ₆ alkyl, C(═O)C ₁ -C ₆ alkyl, C(═O)OC ₁ - C ₆ alkyl, OC(═O)C ₁ -C ₆ alkyl, OC ₁ -C ₆ alkyl, SCH ₃ , C ₃ -C ₆ cycloalkyl, (CH ₂ ) _m C ₃ - C ₆ cycloalkyl, phenyl, pyridyl, pyrrolyl, thienyl, (CH ₂ ) _m phenyl, (CH ₂ ) _m pyrrolyl, and (CH ₂ ) _m pyridyl; wherein said cycloalkyl groups optionally contain one or two heteroatoms selected independently from the group consisting of O, N, and S; wherein said alkyl, cycloalkyl, phenyl, pyrrolyl, and pyridyl groups are optionally substituted with one or two groups selected, independently, from halogen, methyl, ethyl, or trifluoromethyl; and wherein m is zero, 1, or 2; R′ is selected from the group consisting of H, halogen, phenyl, 2-(N,N-dimethylamino)ethyl, CF ₃ , OC ₁ -C ₃ alkyl and C ₁ -C ₃ alkyl; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, halogen, CF ₃ , OCF ₃ , OC ₁ -C ₃ alkyl, and C ₁ -C ₃ alkyl; X is O or S; Y is O or S; q=1 or 0; R ₅ is selected from the group consisting of C ₁ -C ₆ alkyl, (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w CH ₂ C ₃ -C ₆ cycloalkyl, CH ₂ (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, CR ₆ ═CH—C ₃ -C ₆ cycloalkyl, CH═CR ₆ —C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w C ₅ -C ₆ cycloalkenyl, CH ₂ (CHR ₆ ) _w C ₅ -C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, Ar, (CHR ₆ ) _w Ar, CH ₂ (CHR ₆ ) _w Ar, and (CHR ₇ ) _w CH ₂ Ar; wherein w=0-3; Ar is selected from the group consisting of phenyl, pyrimidyl, or pyridyl, and a 5-member heteroaromatic ring; wherein said heteroaromatic ring contains 1 or 2 ring heteroatoms selected independently from the group consisting of N, O, and S; and R ₆ is selected from the group consisting of H and methyl; wherein all cycloalkyl and cycloalkenyl groups in R5 optionally contain one or two ring heteroatoms selected independently from the group consisting of N, O, and S; and wherein all alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkynyl, aryl, and heteroaryl groups in R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , and Ar are optionally substituted with one or two substituents selected independently from the group consisting of C ₁ -C ₃ alkyl, halogen, OEt, OMe, and trifluoromethyl. [0123] In further embodiments, R ₁ and R ₂ , vary independently, and are selected from the group consisting of H, halogen, CF ₃ , C ₁ -C ₆ alkyl, C(═O)C ₁ -C ₆ alkyl, C(═O)OC ₁ - C ₆ alkyl, OC(═O)C ₁ -C ₆ alkyl, OC ₁ -C ₆ alkyl, SCH ₃ , (CH ₂ ) _m cyclopropyl, (CH ₂ ) _m cyclobutyl, (CH ₂ ) _m cyclopentyl, (CH ₂ ) _m cyclohexyl, (CH ₂ ) _m oxazolyl, (CH ₂ ) _m isoxazolyl, (CH ₂ ) _m thiazolyl, (CH ₂ ) _m isothiazolyl, (CH ₂ ) _m phenyl, (CH ₂ ) _m pyrrolyl, (CH ₂ ) _m pyridyl, and (CH ₂ ) _m pyrimidyl; wherein said cyclopentyl and said cyclohexyl groups optionally contain one or two ring heteroatoms selected independently from the group consisting of O, N, and S; wherein said alkyl, cycloalkyl, phenyl, pyrrolyl, and pyridyl groups are optionally substituted with one or two groups selected, independently, from the group consisting of halogen, CH ₃ , ethyl, and CF ₃ ; and m is zero, 1, or 2; R′ is selected from the group consisting of H, halogen, CF ₃ , and C ₁ -C ₃ alkyl; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, halogen, CF ₃ , OCF ₃ , OC ₁ -C ₃ alkyl, and C ₁ - C ₃ alkyl; X is O or S; Y is O; q=1 or 0; R ₅ is selected from the group consisting of C ₁ - C ₆ alkyl, (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w CH ₂ C ₃ -C ₆ cycloalkyl, CH ₂ (CHR ₆ ) _w C ₃ - C ₆ cycloalkyl, CR ₆ ═CH—C ₃ -C ₆ cycloalkyl, CH═CR ₆ —C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w C ₅ - C ₆ cycloalkenyl, CH ₂ (CHR ₆ ) _w C ₅ -C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, Ar, (CHR ₆ ) _w Ar, CH ₂ (CHR ₆ ) _w Ar, and (CHR ₆ ) _w CH ₂ Ar; wherein w=0-3, Ar is selected from the group consisting of phenyl, pyridyl, and a 5-member heteroaromatic ring, wherein said heteroaromatic ring contains 1 or 2 ring heteroatoms selected independently from the group consisting of N, O, and S; R ₆ is H or methyl; wherein all cycloalkyl and cycloalkenyl groups optionally contain one or two ring heteroatoms selected independently from the group consisting of N, O, and S; and wherein all alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkynyl, aryl, and heteroaryl groups in R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , and Ar are optionally substituted with one or two substituents selected independently from the group consisting of C ₁ -C ₃ alkyl, halogen, OMe, OEt, and CF3. [0124] In further embodiments, R ₁ and R ₂ , vary independently, and are selected from the group consisting of H, halogen, CF ₃ , OC ₁ -C ₃ alkyl, C ₁ -C ₆ alkyl, C(═O)OC ₁ -C ₃ alkyl, OC(═O)C ₁ -C ₃ alkyl, and C(═O)C ₁ -C ₃ alkyl; R′ is selected from the group consisting of H, F, CH ₃ , and ethyl; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, F, Cl, CF ₃ , OCF ₃ , OC ₁ -C ₃ alkyl, and C ₁ -C ₃ alkyl; and R ₅ is C ₁ -C ₆ alkyl, (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w CH ₂ C ₃ -C ₆ cycloalkyl, CH ₂ (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, or (CHR ₆ ) _w Ar, CH ₂ (CHR ₆ ) _w Ar, or (CHR ₆ ) _w CH ₂ Ar. [0125] In further embodiments, R ₂ is H or F; R′ is H; R ₃ is selected from the group consisting of H, CH ₃ , OCH ₃ , CF ₃ , OCF ₃ , and Cl; R ₄ is selected from the group consisting of CH ₃ , OCH ₃ , CF ₃ , OCF ₃ , and Cl; and R ₅ is C ₃ -C ₆ alkyl or (CH ₂ ) _w C ₃ -C ₆ cycloalkyl. [0126] In further embodiments, R ₁ is halogen or CF ₃ ; R ₂ is H or F; R′ is H; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, CH ₃ , OCH ₃ , CF ₃ , OCF ₃ , or Cl; and R ₅ is selected from the group consisting of C ₁ -C ₆ alkyl, (CHR ₆ ) _w C ₃ - C ₆ cycloalkyl, (CHR ₆ ) _w CH ₂ C ₃ -C ₆ cycloalkyl, CH ₂ (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, CR ₆ ═CH—C ₃ - C ₆ cycloalkyl, CH═CR ₆ —C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w C ₅ -C ₆ cycloalkenyl, CH ₂ (CHR ₆ ) _w C ₅ - C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, Ar, (CHR ₆ ) _w Ar, CH ₂ (CHR ₆ ) _w Ar, and (CHR ₆ ) _w CH ₂ Ar. [0127] In further embodiments, R ₁ is halogen or CF ₃ ; R ₂ is H or F; R′ is H; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, CH ₃ , OCH ₃ , CF ₃ , OCF ₃ , or Cl; and R ₅ is selected from the group consisting of C ₁ -C ₆ alkyl, (CHR ₆ ) _w C ₃ - C ₆ cycloalkyl, (CHR ₆ ) _w CH ₂ C ₃ -C ₆ cycloalkyl, CH ₂ (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, CR ₆ ═CH—C ₃ - C ₆ cycloalkyl, CH═CR ₆ —C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w C ₅ -C ₆ cycloalkenyl, CH ₂ (CHR ₆ ) _w C ₅ - C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, Ar, (CHR ₆ ) _w Ar, CH ₂ (CHR ₆ ) _w Ar, and (CHR ₆ ) _w CH ₂ Ar. Formula 4 [0128] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 4. Such compounds are described in US Patent No.8,293,911 issued on October 23, 2012 and corresponding to US Application No.11/894,877; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 4, this reference incorporated by reference herein controls. [0129] In an embodiment, the Kv7 channel activator is a compound according to formula 4: Formula 4 , wherein, R ₁ is selected from the group consisting of H, halogen, CN, CH ₂ CN, CF ₃ , C ₁ - C ₆ alkyl, OCH ₃ , (C═O)OCH ₃ , O(C═O)CH ₃ , OCF ₃ , (CH ₂ ) _m C ₃ -C ₆ cycloalkyl, phenyl, and pyridyl; R ₂ is selected from the group consisting of H, F, OCH ₃ , CH ₃ , and CF ₃ ; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, F, Cl, CF ₃ , OCF ₃ , OC ₁ -C ₃ alkyl, or C ₁ -C ₃ alkyl; and R ₅ is selected from the group consisting of C ₁ - C ₆ alkyl, (CHR ₆ ) _w C ₃ -C ₆ cycloalkyl, (CHR ₆ ) _w CH ₂ C ₃ -C ₆ cycloalkyl, CH ₂ (CHR ₆ ) _w C ₃ - C ₆ cycloalkyl, CR6═CH—C3-C6 cycloalkyl, CH═CR6—C3-C ₆ cycloalkyl, (CHR6)wC ₅ - C ₆ cycloalkenyl, CH ₂ (CHR ₆ ) _w C ₅ -C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, Ar, (CHR ₆ ) _w Ar, CH ₂ (CHR ₆ ) _w Ar, and (CHR ₆ ) _w CH ₂ Ar, wherein w=0-3; Ar is phenyl, furyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, or pyridyl; and R ₆ is C ₁ -C ₃ alkyl; wherein all alkyl, cycloalkyl, aryl, and heteroaryl groups in R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , and Ar are optionally substituted with one or two substituents selected independently from the group consisting of C ₁ -C ₃ alkyl, halogen, OCH ₃ , OCH ₂ CH ₃ , CN, and CF ₃ . [0130] In other embodiments, R ₁ is selected from the group consisting of H, F, Cl, Br, CF ₃ , C ₁ -C ₆ alkyl, OCH ₃ , CH ₂ OCH ₃ , CH ₂ CH ₂ OCH ₃ , CH ₂ OCH ₂ CH ₃ , and OCH ₂ CH ₃ ; R′ is selected from the group consisting of H, CH ₃ , CH ₂ CH ₃ , or halogen; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, F, Cl, CF ₃ , OCF ₃ , OCH ₃ , and CH ₃ ; and R ₅ is selected from the group consisting of C ₁ -C ₆ alkyl, CH ₂ C ₃ - C ₆ cycloalkyl, CH ₂ CH ₂ C ₃ -C ₆ cycloalkyl, CH═CH—C ₃ -C ₆ cycloalkyl, CH═CH—C ₅ - C ₆ cycloalkenyl, CH ₂ C ₅ -C ₆ cycloalkenyl, CH ₂ CH ₂ C ₅ -C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, and (CH2)wAr; wherein w=1 or 2; Ar is selected from the group consisting of phenyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, furyl, thienyl, pyrrolyl, and pyridyl; wherein all alkyl, cycloalkyl, aryl, and heteroaryl groups in R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , and Ar are optionally substituted with one or two substituents selected independently from the group consisting of CH ₃ , halogen, OCH ₃ , OCH ₂ CH ₃ , CN, and CF ₃ . [0131] In other embodiments, R ₁ is selected from the group consisting of H, F, Cl, Br, CF ₃ , C ₁ -C ₆ alkyl, OCH ₃ , CH ₂ OCH ₃ , CH ₂ CH ₂ OCH ₃ , CH ₂ OCH ₂ CH ₃ , and OCH ₂ CH ₃ ; R′ is selected from the group consisting of H, CH ₃ , CH ₂ CH ₃ , or halogen; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, F, Cl, CF ₃ , OCF ₃ , OCH ₃ , and CH ₃ ; and R ₅ is selected from the group consisting of C ₁ -C ₆ alkyl, CH ₂ C ₃ - C ₆ cycloalkyl, CH ₂ CH ₂ C ₃ -C ₆ cycloalkyl, CH═CH—C ₃ -C ₆ cycloalkyl, CH═CH—C ₅ - C ₆ cycloalkenyl, CH ₂ C ₅ -C ₆ cycloalkenyl, CH ₂ CH ₂ C ₅ -C ₆ cycloalkenyl, C ₂ -C ₆ alkenyl, and (CH ₂ ) _w Ar; wherein w=1 or 2; Ar is selected from the group consisting of phenyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, furyl, thienyl, pyrrolyl, and pyridyl; wherein all alkyl, cycloalkyl, aryl, and heteroaryl groups in R ₁ , R ₂ , R ₃ , R ₄ , R ₅ , R ₆ , and Ar are optionally substituted with one or two substituents selected independently from the group consisting of CH ₃ , halogen, OCH ₃ , OCH ₂ CH ₃ , CN, and CF ₃ . Wherein, R ₁ is selected from the group consisting of F, CF ₃ , Cl, CH ₃ , CH ₂ CH ₃ , SCH ₃ , OCH ₃ , CH ₂ OCH ₃ , CH ₂ OCH ₂ CH ₃ , OCF ₃ , phenyl, thienyl, and H; R ₂ is selected from the group consisting of H, F, Cl, and OCH ₃ ; R′ is selected from the group consisting of H, F, CH ₂ CH ₃ , and CH ₃ ; R ₃ and R ₄ vary independently, and are selected from the group consisting of H, Cl, CH ₃ , CF ₃ , OCH ₃ , and OCF ₃ ; and R ₅ is selected from the group consisting of C ₄ -C ₆ alkyl, (CH ₂ ) _w Ar, and (CH ₂ ) _w C ₅ -C ₆ cycloalkyl; wherein w is 1, 2, or 3. [0132] In other embodiments, R ₁ is selected from the group consisting of F, CF ₃ , Cl, CH ₃ , OCH ₃ , CH ₂ OCH ₃ , and H; R ₂ is selected from the group consisting of H, F, CH ₃ , and Cl; R′ is H; R ₃ is selected from the group consisting of H, Cl, CH ₃ , CF ₃ , OCH ₃ , and OCF ₃ ; R ₄ is selected from the group consisting of Cl, OCH ₃ , and CH ₃ ; and R ₅ is C ₄ - C ₆ alkyl or 2-cyclopentyl ethyl. [0133] In other embodiments, R ₃ and R ₄ are both CH ₃ or both OCH ₃ ; and R ₅ is C ₅ - C ₆ alkyl. [0134] In other embodiments, R′ and R ₂ are H; R ₃ and R ₄ are both methyl; and R ₅ is C ₅ - C ₆ alkyl or (CH2)wC5-C6 cycloalkyl; wherein w is 1, 2, or 3. [0135] In other embodiments, the compound is selected from the group consisting of: N- (2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluorome thyl)phenyl)-3,3- dimethylbutanamide; N-(4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3 ,3- dimethylbutanamide; N-(2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6- (trifluoromethyl)phenyl)-3-cyclopentylpropanamide; N-(2-chloro-4-(6-fluoro-3,4- dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethylphenyl)-3,3-d imethylbutanamide; N-[2- chloro-4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methyl phenyl]-3,3-dimethylbutanamide; N- [2-chloro-4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-6-tri fluoromethyl phenyl]-3- cyclopentylpropionamide; N-[2,6-dimethyl-4-(6-trifluoromethyl-3,4-dihydro-1H- isoquinolin-2-yl)-phenyl]-3,3-dimethylbutanamide; N-[2-chloro-6-trifluoromethyl-4-(6- trifluoromethyl-3,4-dihydro-1H-isoquinolin-2-yl)-phenyl]-3,3 -dimethylbutanamide; N-[2- chloro-4-(6-chloro-3,4-dihydro-1H-isoquinolin-2-yl)-6-triflu oromethyl phenyl]-3,3- dimethylbutanamide; N-[4-(6-chloro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethyl - phenyl]-3,3-dimethylbutanamide; N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6- dimethyl phenyl]-3,3-dimethylbutanamide; N-[2-chloro-4-(7-fluoro-3,4-dihydro-1H- isoquinolin-2-yl)-6-trifluoromethyl-phenyl]-3,3-dimethylbuta namide; N-[4-(7-fluoro-3,4- dihydro-1H-isoquinolin-2-yl)-2,6-dimethyl-phenyl]-3,3-dimeth ylbutanamide; N-[2-chloro- 4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-6-methylphenyl] -3,3-dimethylbutanamide; N- [2-chloro-4-(7-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-6-met hylphenyl]-3,3- dimethylbutanamide; N-[2-chloro-6-methyl-4-(6-trifluoromethyl-3,4-dihydro-1H- isoquinolin-2-yl)-phenyl]-3,3-dimethylbutanamide; N-[2-chloro-4-(6-chloro-3,4-dihydro- 1H-isoquinolin-2-yl)-6-methyl-phenyl]-3,3-dimethylbutanamide ; N-[2-chloro-4-(6-fluoro- 3,4-dihydro-1H-isoquinolin-2-yl)-phenyl]-3,3-dimethylbutanam ide; N-[4-(6-fluoro-3,4- dihydro-1H-isoquinolin-2-yl)-2-methyl-phenyl]-3,3-dimethylbu tanamide; N-[4-(6-fluoro- 3,4-dihydro-1H-isoquinolin-2-yl)-2-trifluoromethylphenyl]-3, 3-dimethylbutanamide; N-[2- chloro-4-(6-trifluoromethyl-3,4-dihydro-1H-isoquinolin-2-yl) -phenyl]-3,3- dimethylbutanamide; N-[4-(7-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2-trifluorom ethyl- phenyl]-3,3-dimethylbutanamide; 3,3-dimethyl-N-[2-trifluoromethyl-4-(7-trifluoromethyl- 3,4-dihydro-1H-isoquinolin-2-yl)-phenyl]butanamide; N-[4-(6-methoxy-3,4-dihydro-1H- isoquinolin-2-yl)-2,6-dimethyl-phenyl]-3,3-dimethylbutanamid e; N-[4-(3,4-dihydro-1H- isoquinolin-2-yl)-2-methoxy-6-methyl-phenyl]-3,3-dimethylbut anamide; N-[2-chloro-4- (3,4-dihydro-1H-isoquinolin-2-yl)-6-trifluoromethoxy-phenyl] -3,3-dimethylbutanamide; N- [4-(3,4-dihydro-M-isoquinolin-2-yl)-2,6-dimethoxy-phenyl]-3, 3-dimethylbutanamide; N- [2,6-dimethyl-4-(7-trifluoromethyl-3,4-dihydro-1H-isoquinoli n-2-yl)-phenyl]-3,3-dimethyl butanamide; N-[2,6-Dimethyl-4-(6-trifluoromethyl-3,4-dihydro-1H-isoquino lin-2-yl)- phenyl]-3,3-dimethyl-thiobutanamide; [2,6-Dimethyl-4-(6-trifluoromethyl-3,4-dihydro-1H- isoquinolin-2-yl)-phenyl]-carbamic acid ethyl ester; and N-[2,6-Dimethyl-4-(7- trifluoromethyl-3,4-dihydro-1H-isoquinolin-2-yl)-phenyl]-3,3 -dimethyl butanamide. Formula 5 In another embodiment, the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in US Patent No.8,993,593 issued on March 31, 2015 and corresponding to US Application No.12/698,070 filed February 1, 2010; US Publication No. US20220265634A1, published August 25, 2022 and corresponding to US Application No.17/668,340 filed February 9, 2022;which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 5, these references incorporated by reference herein control. [0136] In an embodiment, the Kv7 channel activator is a compound according to formula 5: Formula 5 , optionally wherein the compound is substituted at any position. Formula 6 [0137] In another embodiment, the Kv7 channel activator may be the following compound (ezogabine, also known as retigabine) or a pharmaceutically acceptable salt thereof. Ezogabine is a compound according to formula 6: In the case of any conflict of terminology in the context of Formula 6, these references incorporated by reference herein control. ula 6 , or, optionally, wherein the compound is substituted at any position. Formula 7 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 7. Such compounds are described in US Patent No. 10,526,328 issued on January 7, 2020 and corresponding to US Application No. 16/124,853 filed September 7, 2018; US Patent No.10,106,536 issued on October 23, 2018 and corresponding to US Application No.15/591,844 filed on May 10, 2017; US Patent No.9,650,376 issued on May 16, 2017, and corresponding to US Application No. 14/776,271 filed March 17, 2014;; US Publication No. US20220060208A1, published February 24, 2022 and corresponding to US Application No.17/277,145 filed January 14, 2019; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 7, these references incorporated by reference herein control. [0138] In an embodiment, the Kv7 channel activator is a compound according to formula 7: mula 7 , wherein, L is CH2; R ¹ is optionally substituted cyclic C3H5, wherein the optional substituent of R ¹ is CF ₃ ; R ² is optionally substituted cyclobutyl; R ³ is optionally substituted C ₃ alkyl, wherein the optional substituent of R ³ is OH; R ⁴ is H; and R ⁵ is H; or wherein, L is CH ₂ ; R ¹ is optionally substituted C ₂ alkyl, wherein the optional substituents of R ¹ are independently CF ₃ or CH ₃ ; R ² is optionally substituted cyclobutyl; R ³ is optionally substituted C ₃ alkyl, wherein the optional substituent of R ³ is OH; R ⁴ is H; and R ⁵ is H; or wherein, wherein L is CH ₂ , CF ₂ , CHCH ₃ , CH ₂ CH ₂ , C ₃ H ₆ , CH ₂ O, C ₂ H ₄ O, or C ₃ H ₆ O with the O of CH ₂ O, C ₂ H ₄ O, or C ₃ H ₆ O bonded with R ¹ ; wherein R ¹ is optionally substituted C _1-2 alkyl, optionally substituted C _5-10 cycloalkyl, optionally substituted C _{1- 12} —O-alkyl, optionally substituted C _6-10 aryl, optionally substituted C _6-10 —O-aryl, or optionally substituted C _2-9 heterocyclyl, wherein the optional substituents of R ¹ are independently R ^A , F, Cl, CN, OR ^A , CF ₃ , NR ^A R ^B , COR ^A , CO ₂ R ^A , OCOR ^A , NR ^A COR ^B , CONR ^A R ^B , wherein R ^A and R ^B are independently H or C _1-12 alkyl; wherein R ² is optionally substituted C _2-4 acyclic alkyl, optionally substituted cyclobutyl, optionally substituted C _6-10 aryl, or optionally substituted C _2-9 heterocyclyl, wherein the optional substituents of R ² are independently F, Cl, Br, I, CN, C _1-6 alkyl, C _1-6 —O-alkyl, C _{1- 6} alkylamine, C _1-6 aminoalkyl, C _1-6 aminoacyl, C _1-6 alkylthio, or C _1-6 alkylsulfonyl; wherein R ³ , R ⁴ , and R ⁵ are independently H, F, Cl, Br, I, CN, optionally substituted C _1-12 alkyl, optionally substituted C _1-12 —O-alkyl, optionally substituted C _2-9 heterocyclyl, optionally substituted C _6-10 aryl, optionally substituted C _2-9 —O-heterocyclyl, optionally substituted C _6-10 O-aryl, optionally substituted C _1-12 acylamino, optionally substituted C _{1- 12} aminoacyl, or optionally substituted C _1-12 aminoalkyl, wherein the optional substituents of R ³ , R ⁴ , or R ⁵ are independently F, Cl, Br, I, CN, C _1-6 alkyl, C _1-6 —O-alkyl, C _{1- 6} alkylamine, C _1-6 aminoalkyl, C _1-6 aminoacyl, C _1-6 acylamino, C _1-6 alkylthio, or C _{1- 6} alkylsulfonyl. [0139] In further embodiments, R ² is optionally substituted C ₄ H ₉ , optionally substituted cyclobutyl, optionally substituted C _6-10 aryl, or optionally substituted C _2-9 heterocyclyl. [0140] In further embodiments, R ² is optionally substituted C ₄ H ₉ , or optionally substituted cyclobutyl. [0141] In further embodiments, R ² is optionally substituted phenyl, or optionally substituted C _2-9 heterocyclyl. [0142] In further embodiments, R ¹ is optionally substituted phenyl. [0143] In further embodiments, R ¹ is optionally substituted phenyl. [0144] In further embodiments, R ¹ is optionally substituted cyclopentyl or optionally substituted cyclohexyl. [0145] In further embodiments, R ¹ is C _2-4 —O-alkyl. [0146] In further embodiments, R ¹ is optionally substituted tetrahydrofuranyl or optionally substituted tetrahydro-2H-pyranyl. [0147] In further embodiments, R ¹ is selected from the group consisting of:

[0148] In further embodiments, R ² is selected from the group consisting of: [0149] In further embodiments, R ³ is CF ₃ , Cl, CN, OCH ₃ , or H. [0150] In further embodiments, R ¹ is selected from the group consisting of:

[0151] In further embodiments, R ⁴ is CH ₃ , CF ₃ , Cl, or H. [0152] In further embodiments, R ² is selected from the group consisting of: [0153] In further embodiments, the Kv7 channel activator is selected from the group consisting of:

[0154] In further embodiments, the Kv7 channel activator is selected from the group consisting of:

Formula 8 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 8. Such compounds are described in US Patent No. 9,650,376, published on February 4, 2014 and corresponding to US Application No. 14/776,271 filed March 17, 2014; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 8, this reference incorporated by reference herein controls. [0155] In an embodiment, the Kv7 channel activator is a compound according to formula 8: Formula 8 , wherein, L is CH ₂ , CF ₂ , CHCH ₃ , CH ₂ CH ₂ , C ₃ H ₆ , CH ₂ O, C ₂ H ₄ O, or C ₃ H ₆ O with the O of CH ₂ O, C ₂ H ₄ O, or C ₃ H ₆ O bonded with R ¹ ; wherein R ¹ is optionally substituted C _1-2 alkyl, optionally substituted C _5-10 cycloalkyl, optionally substituted C _1-12 —O-alkyl, optionally substituted C _6-10 aryl, optionally substituted C _6-10 —O-aryl, or optionally substituted C _{2- 9} heterocyclyl, wherein the optional substituents of R ¹ are independently R ^A , F, Cl, CN, OR ^A , CF ₃ , NR ^A R ^B , COR ^A , CO ₂ R ^A , OCOR ^A , NR ^A COR ^B , CONR ^A R ^B , wherein R ^A and R ^B are independently H or C _1-12 alkyl; wherein R ² is optionally substituted C _2-4 acyclic alkyl, optionally substituted cyclobutyl, optionally substituted C _6-10 aryl, or optionally substituted C _2-9 heterocyclyl, wherein the optional substituents of R ² are independently F, Cl, Br, I, CN, C _1-6 alkyl, C _1-6 —O-alkyl, C _1-6 alkylamine, C _1-6 aminoalkyl, C _1-6 aminoacyl, C _1-6 alkylthio, or C _1-6 alkylsulfonyl; wherein R ³ , R ⁴ , and R ⁵ are independently H, F, Cl, Br, I, CN, optionally substituted C _1-12 alkyl, optionally substituted C _1-12 —O-alkyl, optionally substituted C _2-9 heterocyclyl, optionally substituted C _6-10 aryl, optionally substituted C _{2- 9} —O-heterocyclyl, optionally substituted C _6-10 O-aryl, optionally substituted C _{1- 12} acylamino, optionally substituted C _1-12 aminoacyl, or optionally substituted C _{1- 12} aminoalkyl, wherein the optional substituents of R ³ , R ⁴ , or R ⁵ are independently F, Cl, Br, I, CN, C _1-6 alkyl, C _1-6 —O-alkyl, C _1-6 alkylamine, C _1-6 aminoalkyl, C _1-6 aminoacyl, C _{1- 6} acylamino, C _1-6 alkylthio, or C _1-6 alkylsulfonyl. [0156] In further embodiments, R ² is optionally substituted C ₄ H ₉ , optionally substituted cyclobutyl, optionally substituted C _6-10 aryl, or optionally substituted C _2-9 heterocyclyl. [0157] In further embodiments, R ² is optionally substituted C ₄ H ₉ , or optionally substituted cyclobutyl. [0158] In further embodiments, R ² is optionally substituted phenyl, or optionally substituted C _2-9 heterocyclyl. [0159] In further embodiments, R ¹ is optionally substituted phenyl. [0160] In further embodiments, R ¹ is optionally substituted phenyl. [0161] In further embodiments, R ¹ is optionally substituted cyclopentyl or optionally substituted cyclohexyl. [0162] In further embodiments, R ¹ is C _2-4 —O-alkyl. [0163] In further embodiments, R ¹ is optionally substituted tetrahydrofuranyl or optionally substituted tetrahydro-2H-pyranyl. [0164] In further embodiments, R ¹ is selected from the group consisting of:

[0165] In further embodiments, R ² is selected from the group consisting of: [0166] In further embodiments, R ³ is CF ₃ , Cl, CN, OCH ₃ , or H. [0167] In further embodiments, R ¹ is selected from the group consisting of:

[0168] In further embodiments, R ⁴ is CH ₃ , CF ₃ , Cl, or H.

[0169] In further embodiments, R ² is selected from the group consisting of: Formula 9 [0170] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 9. Such compounds are described in International Publication No. WO2021023616A1, published February 11, 2021 and corresponding to International Application No. PCT/EP2020/071514 filed July 30, 2020; International Publication No. WO2019161877A1, published August 29, 2019 and corresponding to International Application No. PCT/EP2018/054057 filed February 20, 2018; US Publication No. US20220280455A1, published September 8, 2022 and corresponding to US Application No.17/631,762 filed July 30, 2020; US Publication No. US20210032196A1, published February 4, 2021 and corresponding to US Application No.16/943,872 filed July 30, 2020; US Publication No. US20210032196A1, published February 4, 2021 and corresponding to US Application No.16/943,872 filed July 30, 2020;, , which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 9, these references incorporated by reference herein control. [0171] In an embodiment, the Kv7 channel activator is a compound according to formula 9: Formula 9 wherein, R1 is selected from the group consisting of C ₁ -C ₆ alkyl, CF ₃ , CH ₂ CF ₃ , CF ₂ CHF ₂ , C ₃ -C ₈ cycloalkyl, wherein said C ₃ -C ₈ cycloalkyl may be substituted with 1 or 2 substituents selected from the group consisting of C ₁ -C ₃ alkyl, F, CHF ₂ and CF ₃ ; and R2 is H, C ₁ -C ₆ alkyl or CF ₃ ; or R1 and R2 combine to form C ₃ -C ₅ cycloalkyl optionally substituted with 1 or 2 F, CHF2 or CF3; and R3 is C1-C3 alkyl or CH2O—C1-3 alkyl, said C ₁ -C ₃ alkyl or CH ₂ O—C ₁ -C ₃ is alkyl substituted with C≡N, 3 F or C ₃ -C ₅ cycloalkyl; R4 is selected from the group consisting of OCF ₃ , or OCHF ₂ [0172] In further embodiments, R4 is OCF ₃ or OCHF ₂ . [0173] In further embodiments, R3 is selected from the group consisting of CH ₂ —O— CF ₃ , CH ₂ —O— cyclopropyl, CH ₂ —C≡N. [0174] In further embodiments R1 is C ₃ -C ₄ cycloalkyl optionally substituted with 1 or 2 C ₁ -C ₃ alkyl, F, CHF ₂ or CF ₃ . [0175] In further embodiments, R1 and R2 combine to form cyclobutyl optionally substituted with 1 or 2 F and R4 is OCF ₃ or OCHF ₂ . [0176] In further embodiments, the Kv7 channel activator is selected from the group consisting of: (S)—N—((R)-2-cyclopropoxy-1-(3-(difluoromethoxy) phenyl)ethyl)-3- hydroxy-4,4-dimethylpentanamide; (S)—N—((R)-1-(3-(difluoromethoxy)phenyl)-2- (trifluoromethoxy)ethyl)-3-hydroxy-4,4-dimethylpentanamide; (S)—N—((R)-1-(3- (trifluoromethoxy)phenyl)-2-(trifluoromethoxy)ethyl)-3-hydro xy-4,4- dimethylpentanamide; (S)—N—((S)-2-cyano-1-(3-(trifluoromethoxy)phenyl)ethyl)- 3- hydroxy-4,4-dimethylpentanamide; (S)—N—((S)-3-cyano-1-(3-(trifluoromethoxy)phenyl) propyl)-3-hydroxy-4,4-dimethylpentanamide; (R)—N-(2-cyclopropoxy-1-(3- (trifluoromethoxy) phenyl)ethyl)-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide; (R)—N- (2-cyclopropoxy-1-(3-(difluoromethoxy) phenyl)ethyl)-2-(3,3-difluoro-1- hydroxycyclobutyl)acetamide; (R)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3- (difluoromethoxy)phenyl)-2-(trifluoromethoxy)ethyl)acetamide ; and (S)—N-(2-cyano-1- (3-(trifluoromethoxy) phenyl)ethyl)-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide or a pharmaceutically acceptable salt of any of these compounds. [0177] _{In further embodiments, the Kv7} channel activator is selected from the group consisting of (R)—N—((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phe nyl)ethyl)-3-hydroxy-4,4- dimethylpentanamide; (S)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentana mide; (S)-3-hydroxy-4,4- dimethyl-N—((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl) pentanamide; (R)-3-hydroxy- 4,4-dimethyl-N—((S)-1-(3-(2,2,2-trifluoroethoxy) phenyl)ethyl)pentanamide; (R)—N— ((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl) -3-hydroxy-3-(1-(trifluoro- methyl)cyclopropyl)propanamide; (S)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-hydroxy-3-(1-(trifluoro- methyl)cyclopropyl)propanamide; (R)—N—((R)-2-(difluoromethoxy)-1-(3- (trifluoromethoxy)phenyl)ethyl)-3-hydroxy-3-(1- (trifluoromethyl)cyclopropyl)propanamide; (S)—N—((R)-2-(difluoromethoxy)-1-(3- (trifluoromethoxy)phenyl) ethyl)-3-hydroxy-3-(1-(trifluoromethyl)cyclopropyl) propanamide; (R)-3-(3,3-difluorocyclobutyl)-N—((R)-2-(difluoromethoxy)- 1-(3- (difluoromethoxy)phenyl)ethyl)-3-hydroxypropanamide; (S)-3-(3,3-difluorocyclobutyl)- N—((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)et hyl)-3- hydroxypropanamide; (R)-3-(3,3-difluorocyclobutyl)-N—((R)-2-(difluoromethoxy)- 1-(3- (trifluoromethoxy)phenyl) ethyl)-3-hydroxypropanamide; (S)-3-(3,3-difluorocyclobutyl)- N—((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)e thyl)-3- hydroxypropanamide; (S)-3-(3,3-difluorocyclobutyl)-N—((S)-1-(3- (difluoromethoxy)phenyl)butyl)-3-hydroxypropanamide; (R)-3-(3,3-difluorocyclobutyl)- N—((S)-1-(3-(difluoromethoxy) phenyl)butyl)-3-hydroxypropanamide; (S)—N—((R)-2- (difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(1-e thylcyclopropyl)-3- hydroxypropanamide; (R)—N—((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phe nyl) ethyl)-3-(1-ethylcyclopropyl)-3-hydroxypropanamide; (S)—N—((S)-1-(3- (difluoromethoxy)phenyl)butyl)-3-hydroxy-4,4-dimethylpentana mide; (S)—N—((S)-1-(3- (difluoromethoxy)phenyl)-4,4-difluorobutyl)-3-hydroxy-4,4-di methylpentanamide; (S)— N—((S)-1-(3-(difluoromethoxy)phenyl)-3,3-difluoropropyl)-3 -hydroxy-4,4- dimethylpentanamide; (S)—N—((S)-1-(3-(difluoromethoxy) phenyl)ethyl)-3-hydroxy-4,4- dimethylpentanamide; (R)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(2-(difluorometho xy)- 1-(3-(difluoromethoxy)phenyl) ethyl)acetamide; (R)-2-(3,3-difluoro-1-hydroxycyclobutyl)- N-(2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)a cetamide; (S)-2-(3,3- difluoro-1-hydroxycyclobutyl)-N-(1-(3-(difluoromethoxy)pheny l)butyl)acetamide; (S)-2- (3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(difluoromethoxy) phenyl)-4,4- difluorobutyl)acetamide; (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3- (trifluoromethoxy) phenyl)propyl)acetamide; (S)—N-(3,3-difluoro-1-(3- (trifluoromethoxy)phenyl)propyl)-2-(3,3-difluoro-1-hydroxycy clobutyl)acetamide; (S)— N—((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)et hyl)-3-hydroxy-4,4- dimethylpentanamide; (R)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-(1-fluorocyclopropyl)-3-hyd roxybutanamide; (S)—N— ((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl) ethyl)-3-(1-fluorocyclopropyl)-3- hydroxybutanamide; (S)—N—((R)-2-(difluoromethoxy)-1-(3- (trifluoromethoxy)phenyl)ethyl)-3-(1-fluorocyclopropyl)-3-hy droxybutanamide; (R)—N— ((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl) ethyl)-3-(1-fluorocyclopropyl)-3- hydroxybutanamide; (R)-3-cyclopropyl-N—((R)-2-(difluoromethoxy)-1-(3- (trifluoromethoxy)phenyl) ethyl)-3-hydroxybutanamide; (S)-3-cyclopropyl-N—((R)-2- (difluoromethoxy)-1-(3-(trifluoromethoxy) phenyl)ethyl)-3-hydroxybutanamide; (R)—N— ((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl) -5,5,5-trifluoro-3-hydroxy-3- methylpentanamide; (S)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-5,5,5-trifluoro-3-hydroxy-3-m ethylpentanamide; (R)— N—((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)et hyl)-3-hydroxy-3,5- dimethylhexanamide; (S)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-hydroxy-3,5-dimethylhexanam ide; (S)—N—((R)-2- (difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydr oxy-3,4- dimethylpentanamide; (R)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-hydroxy-3,4-dimethylpentana mide; (S)—N—((R)-2- (difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-(3,3 -dimethylcyclobutyl)-3- hydroxypropanamide; (R)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-(3,3-dimethylcyclobutyl)-3- hydroxypropanamide; (S)-3- cyclopentyl-N—((R)-2-(difluoromethoxy)-1-(3-(difluorometho xy)phenyl)ethyl)-3- hydroxypropanamide; (R)-3-cyclopentyl-N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-hydroxypropanamide; (R)-3-(1-fluorocyclopropyl)-3- hydroxy-N—((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)eth yl)butanamide; and (S)-3- (1-fluorocyclopropyl)-3-hydroxy-N—((R)-2-methoxy-1-(3- (trifluoromethoxy)phenyl)ethyl)butanamide; or a pharmaceutically acceptable salt of any of these compounds. [0178] In further embodiments, the Kv7 channel activator is a compound according to formula 8 wherein R ¹ is selected from the group consisting of C ₁ -C ₆ alkyl, CF ₃ , CH ₂ CF ₃ , CF ₂ CHF ₂ , C ₃ -C ₈ cycloalkyl, wherein said C ₃ -C ₈ cycloalkyl may be substituted with 1 or 2 F, CHF2 or CF3, and R ² is H, C1-C6 alkyl or CF3; or R ¹ and R ² combine to form C3- C ₅ cycloalkyl optionally substituted with 1 or 2 F, CHF ₂ or CF ₃ ; R ³ is C ₁ -C ₃ alkyl or CH ₂ O—C _1-3 alkyl, said C ₁ -C ₃ alkyl or CH ₂ O—C _1-3 alkyl may optionally be substituted with 1 or 2 F; and R ⁴ is selected from the group consisting of OCF ₃ , OCH ₂ CF ₃ or OCHF ₂ . [0179] In further embodiments, R ⁴ is OCF ₃ or OCHF ₂ . [0180] In further embodiments, R ² is H or CH ₃ . [0181] In further embodiments, R ³ is CH ₂ O—C _1-3 alkyl. [0182] In further embodiments, R ¹ is C ₃ -C ₄ cycloalkyl optionally substituted with 1 or 2 F, CHF ₂ or CF ₃ . [0183] In further embodiments, R ¹ is t-butyl and R ² is H and R ⁴ is OCF ₃ , OCH ₂ CF ₃ , OCHF ₂ or CF ₃ . [0184] In further embodiments, R ¹ and R ² combine to form cyclobutyl optionally substituted with 1 or 2 F and R ⁴ is OCF ₃ , OCH ₂ CF ₃ , OCHF ₂ or CF ₃ . [0185] In further embodiments, the Kv7 channel activator is selected from the group consisting of: (S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3- (trifluoromethoxy)phenyl]ethyl]pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3- (trifluoromethoxy)phenyl]ethyl]pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3- (2,2,2- trifluoroethoxy)phenyl) ethyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1- (3-(2,2,2- trifluoroethoxy)phenyl) ethyl)pentanamide, (S)-N-((S)-1-(3- (difluoromethoxy)phenyl)ethyl)-3- hydroxy-4,4-dimethylpentanamide, (R)-N-((S)-1-(3- (difluoromethoxy)phenyl)ethyl)-3- hydroxy-4,4-dimethylpentanamide, (S)-3-hydroxy-4,4- dimthyl-N-((S)-1-(3- (trifluoromethyl)phenyl)ethyl)pentanamide (R)-3-hydroxy-4,4- dimethyl-N-((S)-1-(3- (trifluoromethyl)phenyl)ethyl)pentanamide, (S)-3-hydroxy-4,4- dimethyl-N-((S)-1-(3- (trifluoromethoxy)phenyl)propyl)pentanamide, (R)-3-hydroxy-4,4- dimethyl-N-((S)-1-(3- (trifluoromethoxy)phenyl)propyl)pentanamide, (S)-3-(3,3- difluorocyclobutyl)-3-hydroxy-N-((S)- 1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)- 1-(3- (trifluoromethoxy)phenyl)ethyl)propanamide, (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2- trifluoroethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2- trifluoroethoxy)phenyl)ethyl)pentanamide, (S)-3-(1-(difluoromethyl)cyclopropyl)-3- hydroxy- N-((S)-1-(3-(trifluoro- methoxy)phenyl)ethyl)propanamide, (R)-3-(1- (difluoromethyl)cyclopropyl)-3-hydroxy- N-((S)-1-(3- (trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-hydroxy-N-((S)-1-(3- (trifluoromethoxy)phenyl)ethyl)-3-(1- (trifluoromethyl)cyclopropyl)propanamide, (S)-3- hydroxy-N-((S)-1-(3- (trifluoromethoxy)phenyl)ethyl)-3-(1- (trifluoromethyl)cyclopropyl)propanamide, (S)- 3-hydroxy-4-methyl-N-((S)-1-(3- (trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3- (trifluoromethoxy)phenyl)ethyl)pentanamide, N-((R)-2-(difluoromethoxy)-1-(3- (trifluoromethoxy)phenyl)ethyl)-3-(R)-hydroxy- 4,4-dimethylpentanamide, N-((R)-2- (difluoromethoxy)-1-(3- (trifluoromethoxy) phenyl)ethyl)-3-(S)-hydroxy- 4,4- dimethylpentanamide, (S)-3-hydroxy-N-((R)-2-methoxy-1-(3- (trifluoromethoxy)phenyl)ethyl)-4,4- dimethylpentanamide, (R)-3-hydroxy-N-((R)-2- methoxy-1-(3-(trifluoromethoxy) phenyl)ethyl)- 4,4-dimethylpentanamide, (S)-2-(3,3- difluoro-1-hydroxycyclobutyl)-N-(1-(3- (trifluoromethoxy)phenyl)ethyl)acetamide, (S)-2- (1-hydroxycyclobutyl)-N-(1-(3-(2,2,2- trifluoroethoxy)phenyl)ethyl)acetamide, (3R)-3- hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2- trifluoroethoxy)phenyl]ethyl]-3- (trifluoromethyl)pentanamide, (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2- trifluoroethoxy)phenyl]ethyl]-3- (trifluoromethyl)pentanamide, 4,4,4-Trifluoro-3-hydroxy- N-[(1S)-1-[3- (trifluoromethoxy)phenyl]ethyl]-3- (trifluoromethyl)butanamide, (R)-4,4,5,5- tetrafluoro-3-hydroxy-3-methyl-N- ((S)-1-(3- (trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl- N- ((S)-1-(3- (trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-5,5,5-trifluoro-3-hydroxy- 3-methyl-N-((S)-1- (3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-5,5,5-trifluoro-3- hydroxy-3-methyl-N-((S)-1- (3-(trifluoro methoxy)phenyl)ethyl)pentanamide, (R)-3-(1- fluorocyclopropyl)-3-hydroxy-N-((S)-1- (3-(trifluoromethoxy)phenyl)ethyl)butanamide, (S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1- (3-(trifluoro- methoxy)phenyl)ethyl)butanamide, (R)-2-(1-hydroxycyclopentyl)-N-(2-methoxy-1-(3- (trifluoromethoxy)phenyl)ethyl)acetamide, (R)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3- (2,2,2- trifluoroethoxy)phenyl)ethyl)butanamide, (S)-3-cyclopropyl-3-hydroxy-N-((S)-1- (3-(2,2,2- trifluoroethoxy)phenyl)ethyl)butanamide, (R)-4,4,4-trifluoro-3-hydroxy-3- methyl-N-((S)-1- (3-(2,2,2- trifluoroethoxy)phenyl)ethyl)butanamide, and (S)-4,4,4- trifluoro-3-hydroxy-3-methyl-N-((S)-1- (3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide or a pharmaceutically acceptable salt of any of these compounds. Formula 10 [0186] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 10. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009, and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2004058739A1, published July 15, 2004 and corresponding to International Application No. PCT/DK2003/000906 filed December 18, 2003; US patent No.7,368,472 issued May 6, 2008 and corresponding to US Application No.10/540,075 filed December 18, 2003; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 8, these references incorporated by reference herein control. [0187] In an embodiment, the Kv7 channel activator is a compound according to formula 10: ormula 10 wherein R ¹ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl and hydroxy-C _3-8 -Cycloalk(en)yl; R ² and R ^2′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, aryl, C _3-8 -cycloalk(en)yl-C _{1- 6} -alk(en/yn)yl, aryl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl and hydroxy-C _3-8 - cycloalk(en)yl; R ³ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, aryl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl-C _3-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, aryl-C _3-8 -cycloalk(en)yl, NR ¹⁰ R ^10′ —C _1-4 -alk(en/yn)yl, NR ¹⁰ R ^10′ —C _3-8 -Cycloalk(en)yl and hydroxy-C _3-8 -cycloalk(en)yl; wherein: R ¹⁰ and R ^10′ are independently selected from the group consisting of hydrogen, C1-6-alk(en/yn)yl, C3-8- cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy- C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 - alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ¹⁰ and R ^10′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; X is CO or SO ₂ ; Z is O or NR ⁴ , wherein: R ⁴ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl and hydroxy-C _3-8 -cycloalk(en)yl; or R ³ and R ⁴ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms, and the ring formed by R ³ and R ⁴ and the nitrogen atom is optionally substituted with one or more substituents independently selected from C _1-6 -alk(en/yn)yl, aryl and aryl-C _1-6 - alk(en/yn)yl; q is 0 or 1; and Y represents a heteroaryl of one of the following formulas:

wherein: W is O or S; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 0 or 1; and each R ⁵ is independently selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, aryl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl-C _1-6 -alk(en/yn)yl, acyl, halogen, halo-C _1-6 -alk(en/yn)yl, alk(en/yn)yloxy, —CO—NR ⁶ R ^6′ , cyano, nitro, —NR ⁷ R ^4′ , —S—R ⁸ , —SO ₂ R ⁸ , and SO ₂ OR ⁸ ; wherein: R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl and aryl; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C1-6-alk(en/yn)yl, aryl and acyl; and R ⁸ is selected from the group consisting of C1-6- alk(en/yn)yl, C _1-6 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl and NR ⁹ R ^9′ ; wherein: R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or a pharmaceutically acceptable salt thereof. [0188] In further embodiments, the Kv7 channel activator is selected from the group consisting of: {2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phe nyl}- carbamic acid ethyl ester; {2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}- carbamic acid ethyl ester; {2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]- phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]- phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(6-chloro-3-methoxy-benzo[b]thiophen-2- ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; {(2-Amino-4-[(benzo[b]thiophen-2- ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(5-methyl-thiophen-2- ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(4-bromo-3-methoxy- thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(5-phenyl- thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(3-chloro- thiophen-2-ylmethyl-amino]-phenyl}-carbamic acid ethyl ester; (2-Amino-4-{[4-(4-chloro- benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino}-phenyl )-carbamic acid ethyl ester; {2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-ca rbamic acid ethyl ester; {2-Amino-4-[(5-fluoro-benzofuran-3-ylmethyl)-amino]phenyl}-c arbamic acid ethyl ester; {2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; {2- Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbam ic acid ethyl ester; {2- Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbam ic acid ethyl ester; {2- Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; {2-Amino-4- [(5-chloro-thiophen-2-ylmethyl)-ethyl-amino]-phenyl}-carbami c acid ethyl ester; {2- Amino-4-[(benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbam ic acid ethyl ester; {2- Amino-4-[(5-dimethyl-amino-benzo[b]thiophen-3-ylmethyl)-amin o]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(5-dimethyl-amino-3-methyl-benzo[b]thiophen-2-yl methyl)- amino]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(5-fluoro-thiophen-2-ylmethyl)- amino]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)- amino]-phenyl}-carbamic acid propyl ester; {2-Amino-4-[(benzo[b]thiophen-3-ylmethyl)- amino]-phenyl}-carbamic acid propyl ester; N-{2-Amino-4-[(5-chloro-thiophen-2- ylmethyl)amino]phenyl}-2-(4-fluoro-phenyl)-acetamide; N-{2-Amino-4-[(5-chloro- thiophen-2-ylmethyl)amino]phenyl}-3,3-dimethyl-butyramide; and pharmaceutically acceptable salts thereof. [0189] In further embodiments, the Kv7 channel activator is a compound according to the formula: or a pharmaceutically acceptable salt thereof. [0190] In further embodiments, the Kv7 channel activator is selected from the group consisting of: 2-Cyclopentyl-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-aceta mide; N- (2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyrami de; N-(4,6-Dimethyl-2- morpholin-4-yl-pyrimidin-5-yl)-2-(4-fluoro-phenyl)-acetamide ; Hexanoic acid (2,6- difluoro-4-morpholin-4-yl-phenyl)-amide; 2-Cyclopentyl-N-(4,6-dimethyl-2-morpholin-4- yl-pyrimidin-5-yl)-acetamide; N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl-phenyl)- propionamide; N-(2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-3,3-dimethyl- butyramide; [2-Amino-4-(2,4,6-trimethyl-benzylamino)-phenyl]-carbamic acid ethyl ester; 2- Cyclopentyl-N-(2-methoxy-6-methyl-4-morpholin-4-yl-phenyl)-a cetamide; and pharmaceutically acceptable salts thereof. [0191] In further embodiments, the Kv7 channel activator is a compound according to formula 10 wherein: R ¹ is selected from the group consisting of hydrogen, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 - alk(en/yn)yl and hydroxy-C _3-8 -cycloalk(en)yl; R ² and R ^2′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, aryl, C _3-8 - cycloalk(en)yl-C1-6-alk(en/yn)yl, aryl-C1-6-alk(en/yn)yl, acyl, hydroxy-C1-6-alk(en/yn)yl and hydroxy-C _3-8 -cycloalk(en)yl; R ³ is selected from the group consisting of hydrogen, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, aryl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl-C _1-6 - alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, aryl-C _3-8 -cycloalk(en)yl, NR ¹⁰ R ^10′ —C _1-6 - alk(en/yn)yl, NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl and hydroxy-C _3-8 -cycloalk(en)yl, wherein: R ¹⁰ and R ^10′ are independently selected from the group consisting of hydrogen, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 - alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, or R ¹⁰ and R ^10′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; X is CO or SO ₂ ; Z is O or NR ⁴ , wherein: R ⁴ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl and hydroxy-C _3-8 -cycloalk(en)yl; or R ³ and R ⁴ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms, the ring formed by R ³ and R ⁴ and the nitrogen atom is optionally substituted with one or more substituents independently selected from C _1-6 -alk(en/yn)yl, aryl and aryl-C _1-6 - alk(en/yn)yl; q is 0 or 1; and Y represents a heteroaryl of formula: , wherein: W is S; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 0 or 1; and each R ⁵ is independently selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, aryl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl-C _1-6 -alk(en/yn)yl, acyl, halogen, halo-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, —CO—NR ⁶ R ^6′ , cyano, nitro, — NR ⁷ R ^7′ , —S—R ⁸ , —SO ₂ R ⁸ , and SO ₂ OR ⁸ , wherein: R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and aryl; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8- cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl and acyl; and R ⁸ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl and —NR ⁹ R ^9′ , wherein: R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; or a pharmaceutically acceptable salt thereof. [0192] In further embodiments, R ¹ is selected from the group consisting of hydrogen and C _1-6 -alk(en/yn)yl. [0193] In further embodiments, at least one of the substituents R ² and R ^2′ is a hydrogen atom. [0194] In further embodiments both R ² and R ^2′ are hydrogen atoms. [0195] In further embodiments, X is CO. [0196] In further embodiments, q is 0. [0197] In further embodiments, q is 1 and Z is an oxygen atom. [0198] In further embodiments, R ³ is selected from the group consisting of C _1-6 - alk(en/yn)yl and aryl-C _1-6 -alk(en/yn)yl. [0199] In further embodiments, R ³ is C _1-6 -alk(en/yn)yl. [0200] In further embodiments, R ³ is aryl-C _1-6 -alk(en/yn)yl. [0201] In further embodiments, W is a sulfur atom. [0202] In further embodiments, Y is of formula: wherein: W is S; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 0 or 1; and each R ⁵ is independently selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, aryl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl-C _1-6 -alk(en/yn)yl, acyl, halogen, halo-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, —CO—NR ⁶ R ^6′ , cyano, nitro, — NR ⁷ R ^7′ , —S—R ⁸ , —SO2R ⁸ , and SO2OR ⁸ , wherein: R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and aryl; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl and acyl; and R ⁸ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl and —NR ⁹ R ^9′ , wherein: R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl. [0203] In further embodiments, Y is of formula:

wherein: W is S; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 0 or 1; and each R ⁵ is independently selected from the group consisting of C1-6-alk(en/yn)yl, C3-8- cycloalk(en)yl, aryl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl-C _1-6 -alk(en/yn)yl, acyl, halogen, halo-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, —CO—NR ⁶ R ^6′ , cyano, nitro, — NR ⁷ R ^7′ , —S—R ⁸ , —SO ₂ R ⁸ , and SO ₂ OR ⁸ , wherein: R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and aryl; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl and acyl; and R ⁸ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, aryl and —NR ⁹ R ^9′ , wherein: R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl. Formula 11 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 11. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009, and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2004058739A1, published July 15, 2004 and corresponding to International Application No. PCT/DK2003/000906 filed December 18, 2003; US patent No.7,368,472 issued May 6, 2008 and corresponding to US Application No.10/540,075 filed December 18, 2003; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; International Publication No. WO2004082677A1, published September 30, 2004 and corresponding to International Application No. PCT/DK2004/000186 filed March 18, 2004; International Publication No. WO2004080950A1, published or issued September 23, 2004 and corresponding to International Application No. PCT/DK2004/000162 filed March 12, 2004; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 11, these references incorporated by reference herein control. [0204] In an embodiment, the Kv7 channel activator is a compound according to formula 11: Formula 11 wherein: s is 0 or 1; U is O, S, SO ₂ , SO ₂ NR ¹¹ , CO—O or CONR ¹¹ ; wherein: R ¹¹ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ² and R ¹¹ together with the nitrogen atom to which R ¹¹ is attached form a 5-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; q is 0 or 1; X is CO or SO ₂ ; with the proviso when X is SO ₂ , then q is 0; Z is O or S; R ¹ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; R ² is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, halogen, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 - cycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, NR ¹⁰ R ^10′ —C _1-6 -alk(en/yn)yl, NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl and NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; wherein: R ¹⁰ and R ^10′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 - alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yl; or R ¹⁰ and R ^10′ together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; and provided that: when R ² is halogen or cyano, then s is 0; and when s is l and R ² is a hydrogen atom or acyl, then U is O or S; R ³ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, heterocycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yl- heterocycloalk(en)yl, heterocycloalk(en)yl-C1-6-alk(en/yn)yl, Ar, Ar—C1-6-alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar-heterocycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, Ar—C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, Ar—C _1-6 -alk(en/yn)yl- heterocycloalk(en)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-C _1-6 - alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yloxy- heterocycloalk(en)yl, Ar-oxy-C _1-6 -alk(en/yn)yl, Ar—C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-carbonyl-C _1-6 - alk(en/yn)yl, C _3-8 -cycl oal k(en)yl-C _1-6 -alk(en/yn)yl oxy-carbonyl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-heterocycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl-C _3-8 - cycloalk(en)yl, hydroxy-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-heterocycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl- heterocycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl-Ar, halo-C _3-8 -cycloalk(en)yl-Ar, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl-Ar, halo-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl-Ar, cyano- C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, cyano-C _1-6 - alk(en/yn)yl-heterocycloalk(en)yl, acyl-C _1-6 -alk(en/yn)yl, acyl-C _3-8 -cycloalk(en)yl, acyl- heterocycloalk(en)yl, acyl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl-C _1-6 -alk(en/yn)yl-C _{3- 8} -cycloalk(en)yl, acyl-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, NR ¹² R ^12′ , optionally substituted NR ¹² R ^12′ —C _1-6 -alk(en/yn)yl, optionally substituted NR ¹² R ^12′ —C _3-8 - cycloalk(en)yl, and optionally substituted NR ¹² R ^12′ —C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; wherein: R ¹² and R ^12′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 - alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar- heterocycloalk(en)yl, Ar-oxy-C _1-6 -alk(en/yn)yl, Ar-oxy-C _3-8 -cycloalk(en)yl, Ar-oxy-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar-oxy-heterocycloalk(en)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 - alk(en/yr)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _{1- 6} -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ¹² and R ^12′ together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; provided that: when R ³ is NR ¹² R ^12′ , then q is 0; and Y represents a group of the following formulas: wherein: the line represents a bond attaching the group represented by Y to the carbon atom; W is O or S; V is N, C or CH; T is N, NH or O; a is 0, 1, 2 or 3; b is 0, 1, 2, 3 or 4; c is 0 or 1; d is 0, 1, 2 or 3; e is 0, 1 or 2; f is 0, 1, 2, 3, 4 or 5; g is 0, 1, 2, 3 or 4; h is 0, 1, 2 or 3; j is 0, 1 or 2; k is 0, 1, 2 or 3; and each R ⁵ is independently selected from the group consisting of a C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, Ar-oxy, Ar-oxy-C _1-6 -alk(en/yn)yl, Ar-oxy-C _3-8 -cycloalk(en)yl, C _1-6 - alk(en/yn)yl-heterocycloalk(en)yl, Ar-oxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, C _1-6 - alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy, C _1-6 - alk(en/yn)yloxy-carbonyl, halogen, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo- C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, —CO—NR ⁶ R ^6′ , cyano, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, NR ⁷ R ^7′ , S—R ⁸ and SO ₂ R ⁸ ; or two adjacent R ⁵ together with the aromatic group form a 5-8 membered ring that optionally contains one or two heteroatoms; wherein: R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and Ar; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, Ar, heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, heterocycloalk(en)yl-C _3-8 - cycloalk(en)yl, heterocycloalk(en)yl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, heterocycloalk(en)yl-Ar and acyl; or R ⁷ and R ^7′ together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; and R ⁸ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycl oal k(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, Ar and —NR ⁹ R ^9′ ; wherein R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; or a pharmaceutically acceptable salt thereof. [0205] In further embodiments, the Kv7 channel activator is selected from the group consisting of: {4-[(Benzofuran-2-ylmethyl)-amino]-2-methylphenyl}-carbamic acid propyl ester; {4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2-methylphenyl}-ca rbamic acid ethyl ester; {4-[(Benzo[b]thiophen-2-ylmethyl)-amino]-2-methylphenyl}-car bamic acid ethyl ester; {2-Methyl-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-c arbamic acid ethyl ester; [4-(4-Isopropyl-benzylamino)-2-methylphenyl]-carbamic acid ethyl ester; [4-(4- Fluoro-benzylamino)-2-methylphenyl]-carbamic acid propyl ester; (4-{[4-(4-Chloro- benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino}-2-meth ylphenyl)-carbamic acid propyl ester; {4-[(5-Methyl-thiophen-2-ylmethyl)-amino]-2-methylphenyl}-ca rbamic acid propyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-amino]-2-methylphenyl}-car bamic acid propyl ester; {4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2-methylphenyl}-ca rbamic acid propyl ester; {4-[(Benzo[b]thiophen-2-ylmethyl)-amino]-2-methylphenyl}-car bamic acid propyl ester; {2-Methyl-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-c arbamic acid propyl ester; [4-(4-Isopropyl-benzylamino)-2-methylphenyl]-carbamic acid propyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-amino]-2-chlorophenyl}-car bamic acid ethyl ester; {4- [(5-Chloro-thiophen-2-ylmethyl)-amino]-2-chlorophenyl}-carba mic acid ethyl ester; {4- [(Benzo[b]thiophen-2-ylmethyl)-amino]-2-chlorophenyl}-carbam ic acid ethyl ester; [2- Chloro-4-(4-isopropyl-benzylamino)-phenyl]-carbamic acid ethyl ester; [2-Chloro-4-(4- fluoro-benzylamino)-phenyl]-carbamic acid propyl ester; 2-Chloro-4-{[4-(4-chloro- benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino)-phenyl }-carbamic acid propyl ester; {4-[(5-Methyl-thiophen-2-ylmethyl)-amino]-2-chlorophenyl}-ca rbamic acid propyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-amino]-2-chlorophenyl}-car bamic acid propyl ester; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-c arbamic acid propyl ester; {4-[(Benzo[b]thiophen-2-ylmethyl)-amino]-2-chlorophenyl}-car bamic acid propyl ester; {4-[(Benzofuran-2-ylmethyl)-amino]-2-chlorophenyl}-carbamic acid propyl ester; {4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2-cyanophenyl}-car bamic acid ethyl ester; {4- [(Benzo[b]thiophen-2-ylmethyl)-amino]-2-methoxyphenyl}-carba mic acid methyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-amino]-2-methoxyphenyl}-ca rbamic acid isopropyl ester; {4-[(4-Fluoro-benzyl)-(methyl)amino]-2-methoxyphenyl}-carbam ic acid propyl ester; [4-(Benzo[b]thiophen-2-ylmethyl-(methyl)amino)-2-methoxy-phe nyl]-carbamic acid propyl ester; {4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methoxy- phenyl}- carbamic acid propyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-(methyl)amino]-2- methoxy-phenyl}-carbamic acid propyl ester; {2-Methoxy-4-[methyl-(5-methyl-thiophen- 2-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester; {4-[(4-Fluorobenzyl)-(methyl)- amino]-2-isopropoxyphenyl}-carbamic acid ethyl ester; [4-(3-Fluorobenzylamino)-2- methoxyphenyl]-carbamic acid ethyl ester; [4-(4-Isopropylbenzylamino)-2- methoxyphenyl]-carbamic acid ethyl ester; {2-Methoxy-4-[(3-methylthiophen-2- ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; [4-(2,4-Difluorobenzylamino)-2- methoxyphenyl]-carbamic acid ethyl ester; [2-Cyclopentyloxy-4-(4- methoxybenzylamino)-phenyl]-carbamic acid ethylester; [2-Cyclopentyloxy-4-(3-fluoro- 2-methylbenzylamino)-phenyl]-carbamic acid ethyl ester; [4-(3-Fluoro-2- methylbenzylamino)-2-phenethyloxyphenyl]-carbamic acid ethyl ester; [2-Benzyloxy-4- (3-fluoro-2-methylbenzylamino)-phenyl]carbamic acid ethyl ester; [2-Benzyloxy-4-(4- methylsulfanylbenzylamino)-phenyl]-carbamic acid ethyl ester; {4-[(Benzo[b]thiophen-3- ylmethyl)-amino]-2-cyclopentyloxyphenyl}-carbamic acid ethyl ester; [4-(3-Fluoro-2- methylbenzylamino)-2-isopropoxyphenyl]-carbamic acid ethyl ester; [2-Benzyloxy-4-(3- methoxybenzylamino)-phenyl]-carbamic acid ethyl ester; {4-[(Benzo[1,3]dioxol-5- ylmethyl)-amino]-2-isopropoxyphenyl}-carbamic acid ethyl ester; {4-[(5-Bromo-thiophen- 2-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester; {4-[(5-Chloro-thiophen-2- ylmethyl)-amino]-phenyl}-carbamic acid propyl ester; [2-Cyano-4-(4- isopropylbenzylamino)-phenyl]-carbamic acid ethyl ester; {4-[(5-Bromo-thiophen-2- ylmethyl)-(methyl)amino]-2-methyl phenyl}-carbamic acid propyl ester; {4-[(4- Isopropylbenzyl)-(methyl)amino]-2-methyl phenyl}-carbamic acid propyl ester; {2- Methyl-4-[methyl-(4-trifluoromethyl-benzyl)-amino]-phenyl}-c arbamic acid propyl ester; {2-Methyl-4-[methyl-(4-methylsulfanyl-benzyl)-amino]-phenyl} -carbamic acid propyl ester; {4-[(4-tert-Butyl-benzyl)-(methyl)amino]-2-chlorophenyl}-car bamic acid ethyl ester; {2-Chloro-4-[methyl-(4-trifluoromethyl-benzyl)-amino]-phenyl }-carbamic acid ethyl ester; {2-Chloro-4-[methyl-(4-methylsulfanyl-benzyl)-amino]-phenyl} -carbamic acid ethyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-(methyl)amino]-2-chlorophe nyl}-carbamic acid propyl ester; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-p henyl}-carbamic acid propyl ester; {4-[(4-tert-Butyl-benzyl)-(methyl)amino]-2-chlorophenyl}-car bamic acid propyl ester; {2-Chloro-4-[methyl-(4-trifluoromethyl-benzyl)-amino]-phenyl }-carbamic acid propyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-(methyl)amino]-2-trifluoro methyl- phenyl}-carbamic acid ethyl ester; {4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2- trifluoromethyl-phenyl}-carbamic acid ethyl ester; {4-[(4-Isopropyl-benzyl)- (methyl)amino]-2-trifluoromethyl-phenyl}-carbamic acid ethyl ester; {4-[(4-tert-Butyl- benzyl)-(methyl)amino]-2-trifluoromethyl-phenyl}-carbamic acid ethyl ester; {4-[Methyl- (4-trifluoromethyl-benzyl)-amino]-2-trifluoromethyl-phenyl}- carbamic acid ethyl ester; {4- [Methyl-(4-methylsulfanyl-benzyl)-amino]-2-trifluoromethyl-p henyl}-carbamic acid ethyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-(methyl)amino]-2-trifluoro methyl-phenyl}- carbamic acid propyl ester; {4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2- trifluoromethyl-phenyl}-carbamic acid propyl ester; {4-[(4-Isopropyl-benzyl)- (methyl)amino]-2-trifluoromethyl-phenyl}-carbamic acid propyl ester; {4-[(4-tert-Butyl- benzyl)-(methyl)amino]-2-trifluoromethyl-phenyl}-carbamic acid propyl ester; {4-[Methyl- (4-trifluoromethyl-benzyl)-amino]-2-trifluoromethyl-phenyl}- carbamic acid propyl ester; {4-[Methyl-(4-methylsulfanyl-benzyl)-amino]-2-trifluoromethy l-phenyl}-carbamic acid propyl ester; {4-[(5-Bromo-thiophen-2-ylmethyl)-(methyl)amino]-2-cyanophen yl}- carbamic acid propyl ester; {4-[(4-tert-Butyl-benzyl)-(methyl)amino]-2-cyanophenyl}- carbamic acid propyl ester; {2-Cyano-4-[methyl-(4-trifluoromethyl-benzyl)-amino]- phenyl}-carbamic acid propyl ester; {2-Bromo-4-[(5-bromo-thiophen-2-ylmethyl)- (methyl)amino]phenyl}-carbamic acid propyl ester; {2-Bromo-4-[(5-chloro-thiophen-2- ylmethyl)-(methyl)amino]-phenyl}-carbamic acid propyl ester; {2-Bromo-4-[(4- isopropylbenzyl)-(methyl)amino]-phenyl}-carbamic acid propyl ester; {2-Bromo-4-[(4- tert-butyl-benzyl)-(methyl)amino]-phenyl}-carbamic acid propyl ester; {2-Bromo-4- [methyl-(4-trifluoromethyl-benzyl-amino]-phenyl}-carbamic acid propyl ester; [2-Iodo-4- (4-isopropyl-benzylamino)-phenyl]-carbamic acid propyl ester; [4-(4-tert-Butyl- benzylamino)-2-iodophenyl]-carbamic acid propyl ester; [2-Iodo-4-(4-trifluoromethyl- benzylamino)-phenyl]-carbamic acid propyl ester; [2-Iodo-4-(4-methylsulfanyl- benzylamino)-phenyl]-carbamic acid propyl ester; {2-Iodo-4-[4-(4-methylpiperazin-1-yl)- benzylamino]-phenyl}-carbamic acid propyl ester; {4-[(5-Bromo-thiophen-2- ylmethylyamino]-2-trifluoromethyl-phenyl}-carbamic acid ethyl ester; {4-[(5-Chloro- thiophen-2-ylmethyl)-amino]-2-trifluoromethyl-phenyl}-carbam ic acid ethyl ester; [4-(4- tert-Butyl-benzylamino)-2-trifluoromethyl-phenyl]-carbamic acid ethyl ester; [4-(4- Methylsulfanyl-benzylamino)-2-trifluoromethyl-phenyl]-carbam ic acid ethyl ester; {4-[(5- Bromo-thiophen-2-ylmethyl)-amino]-2-trifluoromethyl-phenyl}- carbamic acid propyl ester; [4-(4-Isopropylbenzylamino)-2-trifluoromethyl-phenyl]-carbam ic acid propyl ester; [4-(4-tert-Butyl-benzylamino)-2-trifluoromethyl-phenyl]-carb amic acid propyl ester; [2- Trifluoromethyl-4-(4-trifluoromethyl-benzylamino)-phenyl]-ca rbamic acid propyl ester; [4- (4-Dimethylamino-benzylamino)-2-trifluoromethyl-phenyl]-carb amic acid propyl ester; [4- (4-Methylsulfanyl-benzylamino)-2-trifluoromethyl-phenyl]-car bamic acid propyl ester; {4- [(5-Bromo-thiophen-2-ylmethyl)-amino]-2-cyanophenyl}-carbami c acid propyl ester; {4- [(5-Chloro-thiophen-2-ylmethyl)-amino]-2-cyanophenyl}-carbam ic acid propyl ester; [2- Cyano-4-(4-trifluoromethyl-benzylamino)-phenyl]-carbamic acid propyl ester; {2-Bromo- 4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester; {2-Bromo- 4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester; [2-Bromo- 4-(4-isopropylbenzylamino)-phenyl]-carbamic acid propyl ester; [2-Bromo-4-(4-tert-butyl- benzylamino)-phenyl]-carbamic acid propyl ester; [2-Bromo-4-(4-trifluoromethyl- benzylamino)-phenyl]carbamic acid propyl ester; [2-Bromo-4-(4-methylsulfanyl- benzylamino)-phenyl]-carbamic acid propyl ester; N-{4-[(5-Bromo-thiophen-2-ylmethyl)- amino]-2-methoxyphenyl}-butyramide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2- methoxyphenyl}-butyramide; N-[4-(4-Isopropylbenzylamino)-2-methoxyphenyl]- butyramide; N-[4-(4-tert-Butyl-benzylamino)-2-methoxyphenyl]-butyramide; N-[2- Methoxy-4-(4-trifluoromethyl-benzylamino)-phenyl]-butyramide ; {4-[(5-Chloro-thiophen- 2-ylmethyl)-amino]-2-furan-2-yl-phenyl}-carbamic acid propyl ester; [2-Furan-2-yl-4-(4- isopropylbenzylamino)-phenyl]-carbamic acid propyl ester; [5-(4-Fluorobenzylamino)- biphenyl-2-yl]-carbamic acid propyl ester; {5-[(5-Chloro-thiophen-2-ylmethyl)-amino]- biphenyl-2-yl}-carbamic acid propyl ester; [5-(4-Isopropylbenzylamino)-biphenyl-2-yl]- carbamic acid propyl ester; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)- (methyl)amino]-phenyl}-2-phenylacetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-(methyl)amino]-phenyl}-3,3-dimethylbutyramide; N-{2-Chloro-4-[(5-chloro- thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-3-phenylpropiona mide; N-{2-Chloro-4-[(5- chloro-thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-butyramid e; Pentanoic acid {2- chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-phen yl}-amide; Cyclopropanecarboxylic acid {2-chloro-4-[(5-chloro-thiophen-2-ylmethyl)- (methyl)amino]-phenyl}-amide; Cyclobutanecarboxylic acid {2-chloro-4-[(5-chloro- thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-amide; Cyclopentanecarboxylic acid {2- chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-phen yl}-amide; Cyclohexanecarboxylic acid {2-chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]- phenyl}-amide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino] -phenyl}-2- thiophen-2-yl-acetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino] - phenyl}-2-(3-methoxy-phenyl)-acetamide, N-{2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-(methyl)amino]-phenyl)-2-(4-chloro-phenyl}-acetami de; N-{2-Chloro-4-[(5- chloro-thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-2-(4-meth oxy-phenyl)-acetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino] -phenyl)-2-(4-fluoro- phenyl}-acetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino] - phenyl}-3-cyclohexylpropionamide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)- amino]-phenyl}-2,2-dimethylpropionamide; N-{2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-amino]-phenyl}-2-phenoxyacetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-amino]-phenyl}-2-phenyl acetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-amino]-phenyl}-3,3-dimethylbutyramide; N-{2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-amino]-phenyl}-butyramide; Pentanoic acid {2-chloro-4-[(5-chloro-thiophen-2- ylmethyl)-amino]-phenyl}-amide;Cyclopropanecarboxylic acid {2-chloro-4-[(5-chloro- thiophen-2-ylmethyl)-amino]-phenyl}-amide; Cyclobutanecarboxylic acid {2-chloro-4-[(5- chloro-thiophen-2-ylmethyl)-amino]-phenyl}-amide; Cyclopentanecarboxylic acid {2- chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]phenyl}-amide ; Cyclohexanecarboxylic acid {2-chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-a mide; N-{2-Chloro-4- [(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-2-thiophen-2- yl-acetamide; N-{2-Chloro- 4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-2-(3-methox yphenyl)-acetamide; N-{2- Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-2-(4 -chlorophenyl)-acetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl} -2-(4-methoxyphenyl)- acetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl} -2-(4- fluorophenyl)-acetamide; 2,3-Dihydro-benzo[1,4]dioxine-6-carboxyl acid {2-chloro-4-[(5- chloro-thiophen-2-ylmethyl)-amino]-phenyl}-amide; 2,3-Dihydro-benzofuran-5-carboxylic acid {2-chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-a mide; N-{2-Chloro-4- [(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-3-cyclohexylp ropionamide; N-{4-[(5- Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methyl-phenyl}- 2,2- dimethylpropionamide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methyl - phenyl}-2-phenyl acetamide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2- methyl-phenyl}-3,3-dimethylbutyramide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)- (methyl)amino]-2-methyl-phenyl}-3-phenylpropionamide; N-{4-[(5-Chloro-thiophen-2- ylmethyl)-(methyl)amino]-2-methyl-phenyl}-butyramide; 2,2,2-Trichloro-N-{4-[(5-chloro- thiophen-2-ylmethyl)-(methyl)amino]-2-methyl-phenyl}-acetami de; Cyclopropanecarboxylic acid {4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-2- methyl-phenyl}-amide; Cyclobutanecarboxylic acid {4-[(5-chloro-thiophen-2-ylmethyl)- (methyl)amino]-2-methylphenyl}-amide; Cyclopentanecarboxylic acid {4-[(5-chloro- thiophen-2-ylmethyl)-(methyl)amino]-2-methyl phenyl}-amide; Cyclohexanecarboxylic acid {4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methylph enyl}-amide; N-{4-[(5- Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methylphenyl}-2 -thiophen-2-yl-acetamide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methyl phenyl}-2-(3- methoxyphenyl)-acetamide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2- methyl phenyl}-malonamic acid methyl ester; 2-(4-Chlorophenyl)-N-{4-[(5-chloro- thiophen-2-ylmethyl)-(methyl)amino]-2-methylphenyl}-acetamid e; N-{4-[(5-Chloro- thiophen-2-ylmethyl)-(methyl)amino]-2-methyl phenyl}-2-(4-methoxyphenyl)-acetamide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methyl phenyl}-2-(4- fluorophenyl)-acetamide; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-(methyl)amino]-2- methylphenyl}-3-cyclohexylpropionamide; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)- (methyl)amino]-phenyl}-carbamic acid phenyl ester; {2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-(methyl)amino]-phenyl}-carbamic acid benzyl ester; {2-Chloro-4-[(5-chloro- thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-carbamic acid isobutyl ester; {2-Chloro-4- [(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-carba mic acid butyl ester; {2- Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-phen yl}-carbamic acid hexyl ester; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-p henyl}-carbamic acid 4-nitrobenzyl ester; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-p henyl}- carbamic acid but-3-enyl ester; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)- (methyl)amino]-phenyl}-carbamic acid but-2-ynyl ester; {2-Chloro-4-[(5-chloro-thiophen- 2-ylmethyl)-(methyl)amino]-phenyl}-carbamic acid 2,2-dimethylpropyl ester; {2-Chloro-4- [(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-carba mic acid 2-chlorobenzyl ester; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]-p henyl}-carbamic acid 3-chloropropyl ester; {2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino]- phenyl}-carbamic acid 2-benzyloxyethyl ester; 3-{2-Chloro-4-[(5-chloro-thiophen-2- ylmethyl)-(methyl)amino]-phenyl}-1-methyl-1-propyl-urea; 1-{2-Chloro-4-[(5-chloro- thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-3-(2-fluoropheny l)-urea; N-{2-Chloro-4-[(5- chloro-thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-2,2,2-tri fluoroacetamide; N-{2- Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-2,2, 2-trifluoroacetamide; N-{5- [(5-Chloro-thiophen-2-ylmethyl)-amino]-4′-dimethylamino-bi phenyl-2-yl}-2-(4- fluorophenyl)-acetamide; N-{2-Chloro-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)amino] - phenyl}-2-(4-chlorophenyl)-acetamide; [4-(3-Fluoro-4-trifluoromethyl-benzylamino)-2- methylphenyl]-carbamic acid ethyl ester; 2-(4-Fluorophenyl)-N-{2-methyl-4-[(6-p- tolyloxypyridin-3-ylmethyl)-amino]-phenyl}-acetamide; N-[2-Methyl-4-(4-trifluoromethyl- benzylamino)-phenyl]-butyramide; 2-(4-Fluorophenyl)-N-{2-methyl-4-[6- trifluoromethylpyridin-3-ylmethyl)-amino]-phenyl}-acetamide; Pentanoic acid {4-[(5- chloro-thiophen-2-ylmethyl)-(methyl)amino]-2-methylphenyl}-a mide; 3,3-Dimethyl-N-{2- methyl-4-[(6-p-tolyloxypyridin-3-ylmethyl)-amino]-phenyl}-bu tyramide; [2-Methyl-4-(4- trifluoromethyl-benzylamino)-phenyl]-carbamic acid ethyl ester; N-{2-Chloro-4-[(5- chloro-thiophen-2-ylmethyl)-(methyl)amino]-phenyl}-2-(4-chlo rophenyl)-propionamide; [4-(4-Chloro-benzylamino)-2-methylphenyl]-carbamic acid ethyl ester; {4-[(6-Methoxy- benzo[b]thiophen-2-ylmethyl)-amino]-2-methylphenyl}-carbamic acid propyl ester; {4- [(5=Chloro-thiophen-2-ylmethyl)-amino]-2-quinolin-3-yl-pheny l}-carbamic acid ethyl ester; {4-[(5-Dimethylamino-3-methyl-benzo[b]thiophen-2-ylmethyl)-a mino]-2- methylphenyl}-carbamic acid propyl ester; 3,3-Dimethyl-N-{2-methyl-4-[(6- trifluoromethylpyridin-3-ylmethyl)-amino]-phenyl}-butyramide ; N-(4-{[6-(4- Cyanophenoxy)-pyridin-3-ylmethyl]-amino}-2-methylphenyl)-2-( 4-fluorophenyl)- acetamide; {2-Benzyloxy-4-[(4-fluorobenzyl)-(methyl)amino]-phenyl}-thio carbamic acid S-ethyl ester; {2-Cyclopentyloxy-4-[(4-fluorobenzyl)-(methyl)amino]-phenyl} - thiocarbamic acid S-ethyl ester; N-{4-[(6-Chloropyridin-3-ylmethyl)-amino]-2- methylphenyl}-2-(4-fluorophenyl)-acetamide; {4-[(7-Dimethylamino-benzo[b]thiophen-2- ylmethyl)-amino]-2-methylphenyl}-carbamic acid propyl ester; 1-{2-Cyclopentyloxy-4-[(4- fluorobenzyl)-(methyl)amino]-phenyl}-3-ethyl-urea; 2-Amino-4-methyl-pentanoic acid [2- methyl-4-(4-trifluoromethyl-benzylamino)-phenyl]-amide; {4-[(6-Methoxy- benzo[b]thiophen-2-ylmethyl)-amino]-2-methylphenyl}-carbamic acid ethyl ester; 2- Amino-4-methyl-pentanoic acid [2-methyl-4-(4-trifluoromethyl-benzylamino)-phenyl]- amide; 2-(4-Fluorophenyl)-N-{2-methyl-4-[(4-methyl-2-phenylpyrimidi n-5-ylmethyl)- amino]-phenyl}-acetamide, 3,3-Dimethyl-N-{2-methyl-4-[(2-phenylpyrimidin-5-ylmethyl)- amino]-phenyl}-butyramide; {4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2-pyridin-3-yl- phenyl}-carbamic acid ethyl ester; 1-Amino-cyclopropanecarboxylic acid [2-methyl-4-(4- trifluoromethyl-benzylamino)-phenyl]-amide; {4-[(5-Chloro-thiophen-2-ylmethyl)-amino]- 2-pyridin-4-yl-phenyl}-carbamic acid ethyl ester; N-[2-Methyl-4-(4-trifluoromethyl- benzylamino)-phenyl]-2-piperidin-1-yl-acetamide; N-(4-{[5-(4-Chlorophenoxy)-1,3- dimethyl-1H-pyrazol-4-ylmethyl]-amino}-2-methylphenyl)-2,2-d imethylpropionamide; 2,2-Dimethyl-N-{2-methyl-4-[(6-phenoxypyridin-3-ylmethyl)-am ino]-phenyl}- propionamide; N-[2-Methyl-4-(4-trifluoromethyl-benzylamino)-phenyl]-2-pyrr olidin-1-yl- acetamide; [4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2-(6-methoxypyridi n-3-yl)-phenyl]- carbamic acid ethyl ester; 4-[(3-Methyl-4-propoxycarbonylamino-phenyl amino)-methyl]- benzoic acid methyl ester; N-[2-Methyl-4-(4-trifluoromethyl-benzylamino)-phenyl]-2- morpholin-4-yl-acetamide; 2,2-Dimethyl-N-{2-methyl-4-[(3-methyl-5-phenylisoxazol-4- ylmethyl)-amino]-phenyl}-propionamide; {4-[(5-Chloro-thiophen-2-ylmethyl-amino]-2- iodophenyl}-carbamic acid ethyl ester; N-{4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2- iodophenyl}-2-(4-fluorophenyl)-acetamide; {4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2- quinolin-5-yl-phenyl}-carbamic acid ethyl ester; and pharmaceutically acceptable salts thereof. [0206] In further embodiments, the Kv7 channel activator is a compound according to formula 11, wherein: s is 0 or 1; U is O, S, SO ₂ , SONR ¹¹ , or CONR ¹¹ ; wherein: R ¹¹ is hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, or C3-8-cycloalk(en)yl-C1-6 -alk(en/yn)yl; or R ² and R ¹¹ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms; q is 0 or 1; X is CO or SO ₂ ; with the proviso that q is 0 when X is SO ₂ ; Z is O or S; R ¹ is hydrogen, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 - alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo -C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en) yl or cyano-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl; R ² is hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar— C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 - cycloalk (en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halogen, halo-C _1-6 - alk(en/yn)yl, halo-C _3-8 -cycloalk (en)yl, halo -C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 cycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, NR ¹⁰ R ^10′ —C _1-6 -alk(en/yn)yl, NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl or NR ¹⁰ R ^10′ —C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; wherein: R ¹⁰ and R ^10′ are each independently hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _{1- 6} -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl or cyano-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ¹⁰ and R ^10′ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms; with the proviso that: when R ² is halogen or cyano, then s is 0; and when s is 1 and R ² is a hydrogen atom or acyl, then U is O or S; R ³ is C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, heterocycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yl-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yloxy-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _3-8 -cycloalk(en)yl, C _1-6 - alk(en/yn)yloxy-heterocycloalk(en)yl, C _1-6 -alk(en/yn)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, C _{3- 8} -cycloalk(en)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy - carbonyl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy -heterocycloalk(en)yl, hydroxy-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, hydroxy-C1- ₆ -alk(en/yn)yl -C _3-8 -cycloalk(en)yl, hydroxy-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, halo - C _3-8 -cycloalk(en)yl, halo-heterocycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo -C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano- C _3-8 -cycloalk(en)yl -C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, cyano- C _1-6 -alk(en/yn)yl -heterocycloalk(en)yl, acyl-C _1-6 -alk(en/yn)yl, acyl-C _3-8 -cycloalk(en)yl, acyl-heterocycloalk(en)yl, acyl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl-C _1-6 - alk(en/yn)yl-C _3-8 -cycloalk(en)yl, acyl-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, NR ¹² R ^12′ , optionally substituted NR ¹² R ^12′ -C _1-6 -alk(en/yn)yl, optionally substituted NR ¹² R ^12′ -C _3-8 - alk(en/yn)yl, or optionally substituted NR ¹² R ^12′ -C _3-8 -alk(en/yn)yl-C _1-6 -alk(en/yn)yl; wherein: R ¹² and R ^12′ are each independently hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 - cycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar-heterocycloalk(en)yl, Ar-oxy- C _1-6 -alk(en/yn)yl, Ar-oxy-C _3-8 -cycloalk(en)yl, Ar-oxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar-oxy -heterocycloalk(en)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 - cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano- C _3-8 -cycloalk(en)yl, or cyano -C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ¹² and R ^12′ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms; with the proviso that when R ³ is NR ¹² R ^12′ then q is 0; and Y is a group of formula: wherein: “|” represents a bond attaching the group represented by Y to the carbon atom; V is C or CH; and k is 0, 1, 2 or 3; and each R ⁵ is independently C1-6-alk(en/yn)yl, C3-8- cycloalk (en)yl, C _3-8 -cycloalk(en) yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 - cycloalk(en)yl, Ar—C _3-8 -cycloalk (en)yl-C _1-6 -alk(en/yn)yl , Ar-oxy, Ar-oxy-C _{1- 6} alk(en/yn)yl, Ar-oxy-C _3-8 -cycloalk(en)yl, C _1-6 -alk (en/yn)yl -heterocycloalk(en)yl, Ar-oxy- C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, C _1-6 -alk (en/yn)yloxy, C _3-8 -cycloalk(en)yloxy, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy, C _1-6 -alk(en/yn)yloxy-carbonyl, halogen, halo-C _{1- 6} -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, — CO—NR ⁶ R ^6′ , cyano, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk (en)yl, cyano-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, NR ⁷ R ^7′ , S—R ⁸ or SO ₂ R ⁸ ; or two adjacent R ⁵ groups taken together with the aromatic group form a 5-8 membered ring, which optionally contains one or two heteroatoms; wherein: R ⁶ and R ^6′ are each independently hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl or Ar; R ⁷ and R ^7′ are each independently hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, heterocycloalk(en)yl-C _1-6 -alk (en/yn)yl, heterocycloalk(en)yl-C _3-8 -cycloalk(en)yl, heterocycloalk(en)yl-C _3-8 -cycloalk(en)yl-C _1-6 -alk (en/yn)yl, heterocycloalk(en)yl-Ar or acyl; or R ⁷ and R ^7′ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms; and R ⁸ is hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar or —NR ⁹ R ^9′ ; wherein: R ⁹ and R ^9′ are each independently hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl or C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; or salts thereof. [0207] In further embodiments, R ¹ is C _1-6 -alk(en/yn)yl or a hydrogen atom. [0208] In further embodiments, s is 0. [0209] In further embodiments, s is 1. [0210] In further embodiments, U is an oxygen atom. [0211] In further embodiments, R ² is hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, halogen, halo-C _1-6 -alk(en/yn)yl or cyano; with the provisos that when R ² is halogen or cyano, then s is 0; and when s is 1 and R ² is a hydrogen atom, then U is O or S. [0212] In further embodiments, Z is an oxygen atom. [0213] In further embodiments, Z is a sulfur atom. [0214] In further embodiments, q is 0. [0215] In further embodiments, q is 1. [0216] In further embodiments, X is CO. [0217] In further embodiments, R ³ is C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, heterocycloalk (en)yl-C _{1 -6} -alk(en/yn)yl, heterocycloalk(en)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar-oxy-C _1-6 -alk (en/yn)yl, Ar—C _1-6 - alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, halo- C _1-6 -alk(en/yn)yl, NR ¹² R ^12′ , optionally substituted NR ¹² R ^12′ —C _1-6 -alk(en/yn)yl, or optionally substituted NR ¹² R ^12′ —C _3-8 -cycloalk(en)yl. [0218] In further embodiments, R ¹² and R ^12′ are each independently hydrogen, C _1-6 - alk(en/yn)yl or Ar. [0219] In further embodiments, V is CH. [0220] In further embodiments, each R ⁵ is independently C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yl-heterocycloalk(en)yl, Ar, C _1-6 -alk(en/yn)yloxy, Ar-oxy, C _1-6 -alk(en/yn)yloxy- carbonyl, halogen, halo-C _1-6 -alk(en/yn)yl, NR ⁷ R ^7′ , S—R ⁸ or SO ₂ R ⁸ ; or two adjacent R ⁵ groups taken together with the aromatic group form a 5-8 membered ring, which optionally contains one or two heteroatoms. [0221] In further embodiments, both R ⁷ and R ^7′ are C _1-6 -alk(en/yn)yl. [0222] In further embodiments, R ⁸ is C _1-6 -alk(en/yn)yl or Ar. [0223] In further embodiments, the Kv7 channel activator is selected from the group consisting of: 2-(4-Fluorophenyl)-N-{2-methyl-4-[(6-p-tolyloxypyridin-3-ylm ethyl)-amino]- phenyl}-acetamide; 2-(4-Fluorophenyl)-N-{2-methyl-4-[(6-trifluoromethylpyridin- 3- ylmethyl)-amino]-phenyl}-acetamide; 3,3-Dimethyl-N-{2-methyl-4-[(6-p-tolyloxypyridin-3- ylmethyl)-amino]-phenyl }-butyramide; 3,3-Dimethyl-N-{2-methyl-4-[(6- trifluoromethylpyridin-3-ylmethyl)-amino]-phenyl}-butyramide ; N-(4-{[6-(4- Cyanophenoxy)-pyridin-3-ylmethyl]-amino}-2-methylphenyl)-2-( 4-fluorophenyl) - acetamide; N-{4-[(6-Chloropyridin-3-ylmethyl)-amino]-2-methylphenyl}-2- (4- fluorophenyl)-acetamide; or 2,2-Dimethyl-N-{2-methyl-4-[(6-phenoxypyridin-3-ylmethyl)- amino]-phenyl }-proprionamide; or a salt thereof. [0224] In further embodiments, the Kv7 channel activator is a compound according to formula 11 wherein: U is O, S or NR ^2′ ; s is 0 or 1; X is CO or SO ₂ ; Z is O, S or NR ⁴ ; wherein R ⁴ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, hydroxy-C1-6-alk(en/yn)yl and hydroxy-C _3-8 -cycloalk(en)yl; q is 0 or 1; R ¹ and R ^1′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, halo-C _1-6 - alk(en/yn)yl and halo-C _3-8 -cycloalk(en)yl; R ² is selected from the group consisting of hydrogen, halogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, acyl, hydroxy-C _1-6 - alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl and cyano; provided that: when R ² is halogen or cyano, then s is 0; and when s is 1 and U is NR ^2′ , then R ^2′ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar— C _3-8 -cycloalk(en)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, halo-C _{1- 6} -alk(en/yn)yl and halo-C _3-8 -cycloalk(en)yl; or R ² and R ^2′ together form a 5-8 membered saturated or unsaturated ring that optionally contains one further heteroatom; R ³ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl and halo- C _3-8 -cycloalk(en)yl; and Y represents a group of the following formulas:

wherein: the line represents a bond attaching the group represented by Y to the nitrogen atom; W is O or S; a is 0, 1, 2 or 3; b is 0, 1, 2, 3 or 4; c is 0 or 1; d is 0, 1, 2 or 3; e is 0, 1 or 2; f is 0, 1, 2, 3, 4 or 5; g is 0, 1, 2, 3 or 4; h is 0, 1, 2 or 3; and each R ⁵ is independently selected from the group consisting of a C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, Ar, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar—C _1-6 -alk(en/yn)yl, acyl, C _1-6 - alk(an/en/yn)yloxy, halogen, halo-C _1-6 -alk(en/yn)yl, —CO—NR ⁶ R ^6′ , cyano, nitro, — NR ⁷ R ^7′ , —S—R ⁸ and SO ₂ OR ⁸ ; or two adjacent R ⁵ substituents together with the aromatic group form a 5-8 membered saturated or unsaturated ring that optionally contains one or two heteroatoms; wherein: R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl and Ar; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, Ar and acyl; and R ⁸ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar and — NR ⁹ R ^9′ ; wherein R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; with the provisos that; when R ⁵ is SO ₂ OR ⁸ then R ⁸ is not —NR ⁹ R ^9′ ; and when R ⁵ is SO ₂ R ⁸ , then R ⁸ is not a hydrogen atom; or a pharmaceutically acceptable salt thereof; with the proviso that the compound of formula I is not: N-[4-[[(4- aminophenyl)amino]methyl]phenyl]-acetamide; N-[4-[[(4-amino-2- methylphenyl)amino]methyl]phenyl]-acetamide; N-[4-[[(4-amino-3- methylphenyl)amino]methyl]phenyl]-acetamide; 2-[[[4- (acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyr idinyl)- benzamide; N- [4- [ [(3 ,4, 5-trimethoxyphenyl)amino]methyl]phenyl] -acetamide; N-[4-[[(5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-2- naphthalenyl)amino]methyl]phenyl]-acetamide; N-[4-[[[3-(lH- imidazol-l-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide; N-[4-[[[2-(lH-imidazol-l- ylmethyl)phenyl]amino]methyl]phenyl]-acetamide; N-[4-[[(4-amino-3,5- dichlorophenyl)amino]methyl]phenyl]- acetamide; N-[4-[[(2,4-diamino-6- quinazolinyl)amino]methyl]phenyl]- acetamide; or N-[4-[[(2,4-diamino-6- quinazolinyl)amino]methyl]phenyl]- acetamide. [0225] In further embodiments, R ¹ and R ¹ ' are independently selected from the group consisting of hydrogen and C _1-6 -alk(en/yn)yl. [0226] In further embodiments, at least one of R ¹ and R ¹ ' is a hydrogen atom. In further embodiments, s is 1. [0227] In further embodiments, s is 0. [0228] In further embodiments, R ² is selected from the group consisting of hydrogen, C _{1- 6} -alk(en/yn)yl, Ar and halogen, provided that when R is halogen, then s is 0. [0229] In further embodiments, U is NR ² ' and at least one of R and R ² ' is a hydrogen atom. [0230] In further embodiments, both R ² and R ² are hydrogen atoms. [0231] In further embodiments, X is CO. [0232] In further embodiments, q is 0. [0233] In further embodiments, q is 1. [0234] In further embodiments, Z is an oxygen atom. [0235] In further embodiments, R ³ is C _1-6 - alk(en/yn)yl. [0236] In further embodiments, each R ⁵ is independently selected from the group consisting of a C _1-6 -alk(en yn)yl, C _3-8 - cycloalk(en)yl, Ar, cyano, halogen, halo-Cι _-6 - alk(en/yn)yl and C _1-6 - alk(an/en/yn)yloxy or two adjacent substituents together form a 5- 8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms. [0237] In further embodiments, the Kv7 channel activator is selected from the group consisting of: {2-Amino-4-[(4-tert-butyl phenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; (2-Amino-4-phenylaminomethyl-phenyl)-carbamic acid ethyl ester; [2-Amino- 4-(aphthalene-2-ylaminomethyl)-phenyl]carbamic acid ethyl ester; [2-Amino-4-(p- tolylamino-methyl)-phenyl]carbamic acid ethyl ester; {2-Amino-4-[(4- trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(4- chlorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(3- fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(4- fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(2- fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; [2-Amino-4-(biphenyl-4- ylaminomethyl)-phenyl]-carbamic acid ethyl ester; {2-Amino-4-[(2,4- difluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(4- methoxyphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(4- cyclohexylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; [2-Amino-4-(indan-5- ylaminomethyl-phenyl]-carbamic acid ethyl ester; {2-Amino-4-[(4- isopropylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(4- butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; {2-Amino-4-[(4-chloro-3- fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(2,4- dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(2,3- dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(3,5- dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(3,4- dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(3- trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(3- fluoro-4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino- 4-[(3,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(4- cyanophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(4-fluoro-3- trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(3- chloro-4-methylphenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[(3- chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; [2-Amino-4-(m- tolylaminomethyl)phenyl]carbamic acid ethyl ester; {2-Amino-4-[1-(4- chlorophenylamino)ethyl]phenyl}carbamic acid ethyl ester; {2-Amino-4-[1-(4- trifluoromethylphenylamino)ethyl]phenyl}carbamic acid ethyl ester; N-{2-Amino-4-[(3- fluorophenylamino)methyl]phenyl}-2,2-dimethylpropionamide; {4-[(4- Chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {4-[(4- Trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester; {4-[(4- Chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {4-[(4- Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester; {4-[(4- Chlorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester; {2-Methyl-4-[(4- trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester; {4-[(3,4- Difluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester; {4-[(3- Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester; {2-Chloro-4-[(4- chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Chloro-4-[(4- trifluoromethyl-phenylamino)-methyl]phenyl}-carbamic acid ethyl ester; {2-Chloro-4-[(4- fluorophenylamino)methyl]phenyl}-carbamic acid ethyl ester; {2-Chloro-4-[(3- fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Chloro-4-[(3,4- dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {2-Chloro-4-[(4-chloro-3- fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester; {4-[(4- Chlorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl ester; {4-[(4-Chloro-3- fluorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl ester; {2-Fluoro-4-[(4- trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester; {4′-Dimethylamino- 5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester; {4′- Dimethylamino-5-[(4-trifluoromethylphenylamino)methyl]biphen yl-2-yl}carbamic acid ethyl ester; {4′-Chloro-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}ca rbamic acid ethyl ester; {4′-Chloro-5-[(4-trifluoromethylphenylamino)methyl]bipheny l-2-yl}carbamic acid ethyl ester; N-{4-[(4-chlorophenylamino)methyl]phenyl}butyramide; N-{4-[(3,4- dichlorophenylamino)methyl]phenyl}butyramide; N-{4-[(4-chloro-3- fluorophenylamino)methyl]phenyl}butyramide; N-{4-[(4-fluoro-phenylamino)methyl]-2- methyl phenyl}butyramide; N-{4-[(3-fluorophenylamino)methyl]-2- methylphenyl}butyramide; N-{4-[(4-chlorophenylamino)methyl]-2- methylphenyl}butyramide; N-{4-[(3,4-dichlorophenylamino)methyl]-2- methylphenyl}butyramide; N-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-methyl phenyl}butyramide; N-{2-chloro-4-[(4- trifluoromethylphenylamino)methyl]phenyl}butyramide; N-{2-chloro-4-[(4- fluorophenylamino)methyl]phenyl}butyramide; N-{2-chloro-4-[(3- fluorophenylamino)methyl]phenyl}butyramide; N-{2-chloro-4-[(4- chlorophenylamino)methyl]phenyl}butyramide; N-{2-chloro-4-[(3,4- dichlorophenylamino)methyl]phenyl}butyramide; N-{2-chloro-4-[(4-chloro-3- fluorophenylamino)methyl]phenyl}butyramide; N-{2-fluoro-4-[(3- fluorophenylamino)methyl]phenyl}butyramide; N-{4-[(4-chlorophenylamino)methyl]-2- fluorophenyl}butyramide; N-{2-fluoro-4-[(4- trifluoromethylphenylamino)methyl]phenyl}butyramide; N-{-4-[(3,4- dichlorophenylamino)methyl]-2-fluorophenyl}butyramide; N-{4-[(4-chloro-3- fluorophenylamino)methyl]-2-fluorophenyl}butyramide; and pharmaceutically acceptable salts thereof. [0238] In further embodiments, the Kv7 channel activator is a compound according to formula 11 wherein: U is O, S or C s is O or 1; X is CO or SO ₂ ; Z is O, S or NR. , wherein R ⁴ is selected from the group consisting of hydrogen, Cι-6-alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en yn)yl and hydroxy-C _3-8 -cycloalk(en)yl; q is O or 1; R ¹ and R ¹ ' are independently selected from the group consisting of hydrogen, C _\ . ₆ -alk(en/yn)yl, C3 _-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, acyl, hydroxy-Cι _-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, halo-C _1-6 - alk(en/yn)yl and halo-C _3-8 -cycloalk(en)yl; R is selected from the group consisting of hydrogen, halogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-Cι _-6 - alk(en/yn)yl, Ar, Ar-C _1-6 - alk(en/yn)yl, Ar-C _3-8 -cycloalk(en)yl, acyl, hydroxy-Cι _-6 - alk(en/yn)yl, hydroxy- C _3-8 -cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl and cyano; provided that when R ² is halogen or cyano then s is 0; when s is 1 and U is NR ² ' then R ² ' is selected from the group consisting of hydrogen, C _1-6 -alk(en yn)yl, C _-8 - cycloalk(en)yl, C _3-8 -cycloallc(en)yl-Cι _-6 - alk(en/yn)yl, Ar, Ar-C _1-6 -alk(en/yn)yl, Ar-C _3-8 - cycloalk(en)yl, acyl, hydroxy- .. ₆ -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, halo-C _1-6 - alk(en/yn)yl and halo-C _3-8 - cycloalk(en)yl; or R ² and R ² ' together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom; R ³ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-Cι _-6 -alk(en/yn)yl, Ar, Ar-C _1-6 -alk(en/yn)yl, Ar-C _3-8 - cycloalk(en)yl, hydroxy- Cι-6-alk(en/yn)yl, hydroxy-C3-8-cycloalk(en)yl, halo-Cj.6-alk(en/yn)yl and halo-C3-8- cycloalk(en)yl; and Y is selected from groups according to a formula selected from the group consisting of: wherein: the line represents a bond attaching the group represented by Y to the nitrogen atom; W is O or S; a is 0, 1, 2 or 3; b is O, 1, 2, 3 or 4; c is 0 or 1; d is 0, 1, 2 or 3; e is 0, 1 or 2; f is O, 1, 2, 3, 4 or 5; g is 0, 1, 2, 3 or 4; h is 0, 1, 2 or 3; and each R ⁵ is independently selected from the group consisting of a C _1-6 - alk(en yn)yl, C _3-8 - cycloalk(en)yl, Ar, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en yn)yl, Ar- Cι _-6 -alk(en/yn)yl, acyl, C _1-6 - alk(an/en/yn)yloxy, halogen, halo-Cι _-6 -alk(en/yn)yl, -CO-NR ⁶ R ⁶ ', cyano, nitro, -NR ⁷ R ⁷ ', - S-R ⁸ , -SO ₂ R ⁸ and SO ₂ OR ⁸ , or two substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms; R ⁶ and R ⁶ ' are independently selected from the group consisting of hydrogen, C _\ . ₆ -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and Ar; R ⁷ and R ⁷ ' are independently selected from the group consisting of hydrogen, C _\ . ₆ -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar and acyl; and R ⁸ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-Cι _-6 - alk(en/yn)yl, Ar and -NR ⁹ R ⁹ ; wherein R ⁹ and R ⁹ ' are independently selected from the group consisting of hydrogen, C ₆ -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl; with the provisos that when R ⁵ is SO ₂ OR ⁸ then R ⁸ is not -NR ⁹ R ^9' and when R ⁵ is SO ₂ R ⁸ , then R ⁸ is not a hydrogen atom; or salts thereof; with the proviso that the compound of formula I is not: 2-[[[4- (acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyr idinyl)- benzamide; N-[4- [[(3,4,5-trimethoxyphenyl)amino]methyl]phenyl]-acetamide; N-[4-[[(5,6,7,8-tetrahydiO- 5,5,8,8-tetramethyl-2- naphthalenyl)amino]methyljρhenyl]-acetamide; N- [4- [ [[3 -( 1 H- imidazol- 1 -ylmethyl)phenyl]amino]methyl]phenyl] - acetamide; N-[4-[[[2-(lH-imidazol-l- ylmethyl)phenyl]amino]methyl]phenyl]-acetamide; N-[4-[[[4-( IH-imidazol- 1 - ylmethyl)phenyl]amino]methyl]phenyl]- acetamide; N-[4-[[(4-amino-3,5- dichlorophenyl)ammo]methyl]phenyl]- acetamide; N-[4-[[(2,4-diamino-6- quinazolinyl)amino]methyl]phenyl]- acetamide; or N-[4-[[(2,4-diamino-6- quinazolinyl)amino]methyl]phenyl]- acetamide. [0239] In further embodiments, the Kv7 channel activator is a compound according to formula 11 wherein: wherein U is O, S or NR ² s is O or 1; X is CO or SO ₂ ; Z is O, S or NR , wherein R is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _{3- 8} -cycloalk(en)yl, C ₃ -s-cycloaUc(en)yl-Cι _-6 -alk(en/yn)yl, hydroxy-Cι _-6 -alk(en/yn)yl and hydroxy-C _3-8 -cycloalk(en)yl; q is O or 1; 11 ' R and R are independently selected from the group consisting of hydrogen, Cι_ ₆ -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C ₁ . ₆ -alk(en/yn)yl, acyl, hydroxy-Cι _-6 -alk(en/yn)yl, hydroxy-C _3-8 - cycloalk(en)yl, halo-C ₁ _. ₆ -alk(en/yn)yl and halo-C ₃ . ₈ -cycloalk(en)yl; R is selected from the group consisting of hydrogen, halogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-Cι _-6 -alk(en yn)yl, Ar, Ar-Cι _-6 - alk(en yn)yl, Ar-C _3-8 -cycloalk(en)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy- C _3-8 -cycloalk(en)yl, halo-Cι _-6 -alk(en/yn)yl, halo-C _3-8 - cycloalk(en)yl and cyano; provided that when R ² is halogen or cyano then s is 0; when s is 1 and U is NR ² then R ^2' is selected from the group consisting of hydrogen, C _1-6 - alk(en/yn)yl, C _-8 -cycloalk(en)yl, C . ₈ -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, Ar, Ar-C _1-6 - alk(en/yn)yl, Ar-C ₃ . ₈ -cycloalk(en)yl, acyl, hydroxy-C^ ₆ -alk(en/yn)yl, hydroxy-C _3-8 - cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl and halo-C _3-8 - cycloalk(en)yl; or R and R together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom; R ³ is selected from the group consisting of C1-6-alk(en/yn)yl, C3-8- cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en yn)yl, Ar, Ar-C _1-6 -alk(en/yn)yl, Ar-C _3-8 - cycloalk(en)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, halo-Ci- ₆ -alk(en yn)yl and halo-C _3- s-cycloalk(en)yl; and Y is selected from groups according to a formula selected from the group consisting of: [0240] wherein, the line represents a bond attaching the group represented by Y to the nitrogen atom; W is O or S; a is 0, 1, 2 or 3; h is 0, 1, 2, 3 or 4; c is 0 or 1; d is 0, 1, 2 or 3; e is 0, 1 or 2; f is O, 1, 2, 3, 4 or 5; is 0, 1, 2, 3 or 4; h is 0, 1, 2 or 3; and each R ⁵ is independently selected from the group consisting of a Cι _-6 - alk(en/yn)yl, C ₃ . ₈ - cycloalk(en)yl, Ar, Cs-s-cycloall^ei^yl-Ci-e-all^en/^yl, Ar- Cι _-6 -alk(en/yn)yl, acyl, C _1-6 - alk(an/en/yn)yloxy, halogen, halo-C _1-6 -alk(en/yn)yl, -CO-NR ⁶ R ^6' , cyano, nitro, -NR ⁷ R ⁷ ', - S-R ⁸ , -SO ₂ R ⁸ and SO ₂ OR ⁸ , or two substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms; R ⁶ and R ⁶ are independently selected from the group consisting of hydrogen, C _\ . ₆ -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and Ar; R ⁷ and R ⁷ ' are independently selected from the group consisting of hydrogen, Cj. ₆ -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, Cs-s-cycloall^en l- -e-all^en/yn l, Ar and acyl; and R ⁸ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, Ar and -NR ⁹ R ⁹ ; wherein R ⁹ and R ⁹ ' are independently selected from the group consisting of hydrogen, Q. ₆ -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 - cycloalk(en)yl-Cι _-6 -alk(en yn)yl; with the provisos that when R ⁵ is SO ₂ OR ⁸ then R ⁸ is not -NR ⁹ R ⁹ ' and when R ⁵ is SO ₂ R ⁸ , then R ^s is not a hydrogen atom; or salts thereof for increasing ion flow in a potassium channel of a mammal such as a human. Formula 12 [0241] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 12. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009, and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2004096767A1, published November 11, 2004 and corresponding to International Application No. PCT/DK2004/000283 filed April 23, 2004; US Publication No. US20060264496A1 published November 23, 2006 and corresponding to US Application No.10/551,738 filed April 23, 2003; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 12, these references incorporated by reference herein control. [0242] In an embodiment, the Kv7 channel activator is a compound according to formula 12: Formula 12 wherein, the dotted line represents an optional bond; R ¹ and R ^1′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 - cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, cyano-C1-6-alk(en/yn)yl, cyano- C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ¹ and R ^1′ together with the carbon atom to which they are attached form a 3-8 membered saturated or unsaturated ring that optionally contains 1 or 2 heteroatoms; s is 0 or 1; U is O, NR ¹¹ , S, SO ₂ , SO ₂ NR ¹¹ , CO—O or CO—NR ¹¹ ; wherein: R ¹¹ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycl oal k(en)yl, and C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; or R ² and R ^2′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; R ² is selected from the group consisting of hydrogen, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 - alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, halogen, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 - cycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, —NO ₂ , NR ¹⁰ R ^10′—C 1 _-6 - alk(en/yn)yl, NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl and NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; wherein: R ¹⁰ and R ^10′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-Cl _— 6-alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _{1- 6} -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ¹⁰ and R ^10′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; with the proviso that; when R ² is NO ₂ , halogen or cyano, then s is 0; and when R ² , R ² is a hydrogen atom or acyl and s is 1, then U is NR ¹¹ , O or S; wherein the group —(U) _s —R ² is linked to position 4 or 6 of the indole or indoline; q is 0 or 1; Z is O or S; X is CO or SO ₂ ; with the proviso that when q is 0, then X is SO ₂ ; R ³ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, heterocycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yl-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, Ar, Ar—C _1-6 - alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar-heterocycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1- 6-alk(en/yn)yl, Ar—C1-6-alk(en/yn)yl-C3-8-cycloalk(en)yl, Ar—C1-6-alk(en/yn)yl- heterocycloalk(en)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-C _1-6 - alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yloxy- heterocycloalk(en)yl, Ar-oxy-C _1-6 -alk(en/yn)yl, Ar—C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-carbonyl-C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, hydroxy- C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-heterocycloalk(en)yl, hydroxy-C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, hydroxy- C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-heterocycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 - alk(en/yn)yl-C _3-8 -cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, halo-C _1-6 - alk(en/yn)yl-Ar, halo-C _3-8 -cycloalk(en)yl-Ar, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl-Ar, halo-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl-Ar, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 - cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, cyano-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, acyl-C _1-6 -alk(en/yn)yl, acyl-C _3-8 -cycloalk(en)yl, acyl-heterocycloalk(en)yl, acyl-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, acyl-C _1-6 - alk(en/yn)yl-heterocycloalk(en)yl, —NR ¹² R ^12′ , optionally substituted NR ¹² R ^12′ —C _1-6 - alk(en/yn)yl, optionally substituted NR ¹² R ^12′ —C _3-8 -cycloalk(en)yl, and optionally substituted NR ¹² R ^12′ —C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; wherein: R ¹² and R ^12′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 - cycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 - alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano- C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; or R ¹² and R ^12′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; with the proviso that when R ³ is NR ¹² R ^12′ , then q is 0; and Y represents a group of formula from the group: wherein: the line represents a bond attaching the group represented by Y to the carbon atom; W is O or S; T is N, NE or O; L is N, C or CH; a is 0, 1, 2 or 3; b is 0, 1, 2, 3 or 4; c is 0 or 1; d is 0, 1, 2 or 3; e is 0, 1 or 2; f is 0, 1, 2, 3, 4 or 5; g is 0, 1, 2, 3 or 4; h is 0, 1, 2 or 3; j is 0, 1, 2 or 3; with the provisos that: when T is a nitrogen atom, then j is 0, 1, 2 or 3; and when T is NH or an oxygen atom, then j is 0, 1 or 2; k is 0, 1, 2, 3 or 4; and each R ⁵ is independently selected from the group consisting of a C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar-thio, Ar- oxy, acyl, C _1-6 -alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yloxy, halogen, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, —CO—NR ⁶ R ^6′ , cyano, cyano-C _1-6 -alk(en/yn)yl, cyano- C _3-8 -cycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, —NR ⁷ R ^7′ , —S—R ⁸ and —SO ₂ R ⁸ ; or two adjacent R ⁵ substituents together with the aromatic group to which they are attached form a 4-8 membered ring that optionally contains one or two heteroatoms; wherein: R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and Ar; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar and acyl; and R ⁸ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar and —NR ⁹ R ^9′ ; wherein R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; provided that when R ⁸ is —NR ⁹ R ^9′ , then R ⁵ is not —S—R ⁸ , or a pharmaceutically acceptable salt thereof. with the proviso that the compound of formula I is not: N-[1-(phenylmethyl)-1H-indol-5-yl]-Methanesulfonamide; N-[1-[(4-fluorophenyl)methyl]-1H-indol-5-yl]-Methanesulfonam ide; N-[2,3-dihydro-1- (phenylmethyl)-1H-indol-5-yl]-Methanesulfonamide; N-[1-(phenylmethyl)-1H-indol-5-yl]- N′-4-quinolinyl-Urea; N-[1-(phenylmethyl)-1H-indol-5-yl]-N′-4-quinolinyl-Urea; or 1-(1- benzyl-5-indolinyl)-3-phenyl-Urea; or salts thereof. [0243] In further embodiments, least one of R ¹ or R ^1′ is a hydrogen atom. [0244] In further embodiments, R ¹ and R ^1′ are hydrogen atoms. [0245] In further embodiments, s is 0. [0246] In further embodiments, s is 1. [0247] In further embodiments, R ² is a hydrogen atom. [0248] In further embodiments, R ² is NO ₂ or a halogen atom. [0249] In further embodiments, U is NR ¹¹ . [0250] In further embodiments, R ¹¹ is a hydrogen atom. [0251] In further embodiments, X is CO. [0252] In further embodiments, X is SO ₂ . [0253] In further embodiments, q is 0. [0254] In further embodiments, q is 1. [0255] In further embodiments, Z is an oxygen atom. [0256] In further embodiments, R ³ is selected from the group consisting of C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar-oxy-C _1-6 -alk(en/yn)yl, Ar— C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl and —NR ¹² R ^12′ ; with the proviso that when R ³ is NR ¹² R ^12′ then q is 0. [0257] In further embodiments, R ³ is NR ¹² R ^12′ , q is 0 and R ¹² and R ^12′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, Ar and Ar—C _1-6 - alk(en/yn)yl, or R ¹² and R ^12′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms. [0258] In further embodiments, each R ⁵ is independently selected from the group consisting of C _1-6 -alk(en/yn)yl, Ar, Ar-thio, Ar-oxy, halogen and halo-C _1-6 -alk(en/yn)yl or two adjacent R ⁵ together with the aromatic group to which they are attached form a 4-8 membered ring which optionally contains one or two heteroatoms. [0259] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-[4-Chloro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol -5-yl]-3,3- dimethylbutyramide; N-[4-Chloro-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-i ndol- 5-yl]-3,3-dimethylbutyramide; [1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid propyl ester; N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-C-phenyl- methanesulfonamide; 4-Fluoro-N-[1-(4-fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]- benzamide; N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethy lbutyramide; N- [1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-thiophen-2- ylacetamide; N-[1-(4- Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)- acetamide; 3-[1-(5- Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-1,1-di isopropylurea; Morpholine- 4-carboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]- amide; Pyrrolidine-1-carboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]- amide; [1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]- carbamic acid 2- benzyloxyethyl ester; 3-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl ]-1- methyl-1-propylurea; [1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]- carbamic acid tert-butyl ester; N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol- 5-yl]-C-phenyl-methanesulfonamide; Butane-1-sulfonic acid [1-(5-chlorothiophen-2- ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide; N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-4-fluorobenzamide; N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide; N-[1-(5-Chlorothiophen-2-ylmethyl)- 2,3-dihydro-1H-indol-5-yl]-2-phenoxyacetamide; N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide; N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-butyramide; Cyclopentanecarboxylic acid [1-(5-chlorothiophen-2- ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide; N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-2-thiophen-2-ylacetamide; N-[1-(5-Chlorothiophen-2-ylmethyl)- 2,3-dihydro-1H-indol-5-yl]-isonicotinamide; N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-4-dimethylaminobenzamide; N-[1-(5-Chlorothiophen-2-ylmethyl)- 2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide; N-[1-(5-Chlorothiophen-2- ylmethyl)-2,3-dihydro-1H-indol-5-yl]-6-trifluoromethylnicoti namide; 1-tert-Butyl-3-[1-(5- chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-urea; 1-[1-(5-Chlorothiophen-2- ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-ethyl urea; 1-Benzyl-3-[1-(5-chlorothiophen-2- ylmethyl)-2,3-dihydro-1H-indol-5-yl]-urea; 1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-3-phenethyl urea; 1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro- 1H-indol-5-yl]-3-thiophen-2-ylurea; 1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H- indol-5-yl]-3-thiophen-3-ylurea; [1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5- yl]-carbamic acid propyl ester; 2,2-Dimethyl-N-[6-nitro-1-(4-trifluoromethylbenzyl)-2,3- dihydro-1H-indol-5-yl]-propionamide; N-[1-(5-Chlorothiophen-2-ylmethyl)-6-nitro-2,3- dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide; 2-(4-Fluorophenyl)-N-[6-nitro-1-(4- trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide; N-[1-(5-Chlorothiophen-2- ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophen yl)-acetamide; N-[1-(5- Chlorothiophen-2-ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl ]-3,3-dimethylbutyramide; N-[6-Amino-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-in dol-5-yl]-3,3- dimethylbutyramide; N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol- 5-yl]- 2,2-dimethylpropionamide; N-[6-Amino-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H- indol-5-yl]-2,2-dimethylpropionamide; N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3- dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide; N-[6-Amino-1-(4- trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimeth ylbutyramide, N-[6-Amino-1- (4-fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbuty ramide; N-[6-Amino-1-(3- fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3 ,3-dimethylbutyramide; N-[1- (5-Chlorothiophen-2-ylmethyl)-1H-indol-5-yl]-3,3-dimethylbut yramide; N-[6-Bromo-1-(4- trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimeth ylbutyramide; N-[6-Bromo-1- (5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3 -dimethylbutyramide; N-[1- (4-Chlorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbuty ramide; 3,3-Dimethyl-N-[1- (4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-butyram ide; N-[1-(4- Isopropylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbuty ramide; N-[1-(3-Fluoro-4- trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimeth ylbutyramide; N-[1-(6- Chlorobenzo[1,3]dioxol-5-ylmethyl)-2,3-dihydro-1H-indol-5-yl ]-3,3-dimethylbutyramide, N-[1-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-2,3-dihyd ro-1H-indol-5-yl]-3,3- dimethylbutyramide; N-[1-(2-Chloro-5-trifluoromethylbenzyl)-2,3-dihydro-1H-indol -5-yl]- 3,3-dimethylbutyramide; N-{1-[5-(4-Chlorophenoxy)-1,3-dimethyl-1H-pyrazol-4- ylmethyl]-2,3-dihydro-1H-indol-5-yl}-3,3-dimethylbutyramide; 3,3-Dimethyl-N-[1-(6-p- tolyloxy-pyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-buty ramide; N-{1-[6-(4- Chlorophenyl sulfanyl)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-3,3 - dimethylbutyramide, N-{1-[6-(4-Cyanophenoxy)-pyridin-3-ylmethyl]-2,3-dihydro-1H- indol-5-yl}-3,3-dimethylbutyramide; 3,3-Dimethyl-N-[1-(6-trifluoromethylpyridin-3- ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide; 3,3-Dimethyl-N-[1-(3-methyl- benzo[b]thiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-buty ramide; N-[1-(6-Fluoro-4H- benzo[1,3]dioxin-8-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3- dimethylbutyramide; 3,3- Dimethyl-N-[1-(6-phenoxypyridin-3-ylmethyl)-2,3-dihydro-1H-i ndol-5-yl]-butyramide; 3,3- Dimethyl-N-[1-(3-methyl-5-phenyl-isoxazol-4-ylmethyl)-2,3-di hydro-1H-indol-5-yl]- butyramide, N-(1-Benzo[b]thiophen-2-ylmethyl-2,3-dihydro-1H-indol-5-yl)- 3,3- dimethylbutyramide; N-{1-[1-(4-Fluorophenyl)-5-methyl-1H-pyrazol-4-ylmethyl]-2,3 - dihydro-1H-indol-5-yl}-3,3-dimethylbutyramide; 3,3-Dimethyl-N-[1-(5-methyl thiophen-2- ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide; 3,3-Dimethyl-N-[1-(4-pyrrol-1-yl- benzyl)-2,3-dihydro-1H-indol-5-yl]-butyramide; N-[1-(4-Chlorobenzyl)-2,3-dihydro-1H- indol-5-yl]-2-(4-fluorophenyl)-acetamide; 2-(4-Fluorophenyl)-N-[1-(4- trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide; 2-(4-Fluorophenyl)-N-[1-(4- isopropylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide; 2-(4-Fluorophenyl)-N-[1-(3- fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-a cetamide; N-[1-(6- Chlorobenzo[1,3]dioxol-5-ylmethyl)-2,3-dihydro-1H-indol-5-yl ]-2-(4-fluorophenyl)- acetamide; N-[1-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-2,3-dihyd ro-1H-indol-5- yl]-2-(4-fluorophenyl)-acetamide; N-[1-(2-Chloro-5-trifluoromethylbenzyl)-2,3-dihydro- 1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide; N-{1-[5-(4-Chlorophenoxy)-1,3-dimethyl- 1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-2-(4-fluor ophenyl)-acetamide; N-{1-[6- (4-Cyanophenoxy)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5- yl}-2-(4-fluorophenyl)- acetamide; 2-(4-Fluorophenyl)-N-[1-(3-methyl-benzo[b]thiophen-2-ylmethy l)-2,3- dihydro-1H-indol-5-yl]-acetamide; N-[1-(6-Fluoro-4H-benzo[1,3]dioxin-8-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide; 2-(4-Fluorophenyl)-N-[1-(6- phenoxypyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-acetam ide; N-(1- Benzo[b]thiophen-2-ylmethyl-2,3-dihydro-1H-indol-5-yl)-2-(4- fluorophenyl)-acetamide; 2- (4-Fluorophenyl)-N-{1-[1-(4-fluorophenyl)-5-methyl-1H-pyrazo l-4-ylmethyl]-2,3-dihydro- 1H-indol-5-yl}-acetamide; 2-(4-Fluorophenyl)-N-[1-(5-methylthiophen-2-ylmethyl)-2,3- dihydro-1H-indol-5-yl]-acetamide; 2-(4-Fluorophenyl)-N-[1-(4-pyrrol-1-yl-benzyl)-2,3- dihydro-1H-indol-5-yl]-acetamide; and pharmaceutically acceptable salts thereof. Formula 13 [0260] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 13. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009, and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 13, these references incorporated by reference herein control. [0261] In an embodiment, the Kv7 channel activator is a compound according to formula 13. Formula 13 wherein: q is 0 or 1; W is O or S; X is CO; Z is O; R1 is selected from the group consisting of halogen, cyano, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy and C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy; R2 is selected from the group consisting of halogen, cyano, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo- C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy, optionally substituted phenyl and optionally substituted pyridyl; wherein the phenyl and pyridyl are optionally substituted with one or more substituents independently being halogen, C _1-6 -alk(en/yr)yl, C _3-8 -cycloalk(en)yl or C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; R3 is selected from the group consisting of C _1-10 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar—C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl and Ar; and each of R4, R5, R6 and R7 is independently selected from the group consisting of hydrogen and Ar; as the free base or a salt thereof. [0262] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl-phenyl)-2-(4-f luoro-phenyl)- acetamide; 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-morpholin-4-yl- phenyl)- acetamide; N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl-phenyl)-3-cycl opentyl- propionamide; N-(2-Chloro-6-cyano-4-morpholin-4-yl-phenyl)-3-cyclohexyl- propionamide; 2-Cyclopentyl-N-(2,6-dimethyl-4-thiomorpholin-4-yl-phenyl)-a cetamide; 2-Cyclopentyl-N-[2,6-dimethyl-4-(2-phenyl-morpholin-4-yl)-ph enyl]-acetamide; 2- Cyclopentyl-N-[2,6-dimethyl-4-(2-phenyl-thiomorpholin-4-yl)- phenyl]-acetamide; 2- Cyclopentyl-N-[2,6-dimethyl-4-(3-pyridin-3-yl-thiomorpholin- 4-yl)-phenyl]-acetamide; 2- Cyclopentyl-N-{2,6-dimethyl-4-[2-(4-trifluoromethyl-phenyl)- thiomorpholin-4-yl]-phenyl}- acetamide; N-{4-[2-(2-Chloro-phenyl)-thiomorpholin-4-yl]-2,6-dimethyl-p henyl}-2- cyclopentyl-acetamide; 2-Bicyclo[2.2.1]hept-2-yl-N-(2,6-dimethyl-4-morpholin-4-yl- phenyl)-acetamide; 2-Cyclohexyl-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-acetam ide; 3-(3,4-Difluoro-phenyl)-N-(2,6-dimethyl-4-morpholin-4-yl-phe nyl)-propionamide; 2- Cyclopentyl-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-acetami de; (2,6-Dimethyl-4- morpholin-4-yl-phenyl)-carbamic acid butyl ester; 2-(4-Chloro-phenyl)-N-(2,6-dimethyl-4- morpholin-4-yl-phenyl)-acetamide; 2,3-Dihydro-benzofuran-2-carboxylic acid (2,6- dimethyl-4-morpholin-4-yl-phenyl)-amide; 3-Cyclohexyl-N-(2,6-dimethyl-4-morpholin-4- yl-phenyl)-propionamide; 3-Cyclopentyl-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)- propionamide; N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-2-(4-fluoro-phenyl) -acetamide; N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-2-thiophen-2-yl-ace tamide; N-(2,6-Dimethyl-4- morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide; Hexanoic acid (2,6-dimethyl-4- morpholin-4-yl-phenyl)-amide; 2-Cycloheptyl-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)- acetamide; (2,6-Dimethyl-4-morpholin-4-yl-phenyl)-carbamic acid benzyl ester; (2,6- Dimethyl-4-morpholin-4-yl-phenyl)-carbamic acid 2-chloro-benzyl ester; 3,5,5-Trimethyl- hexanoic acid (2,6-dimethyl-4-morpholin-4-yl-phenyl)-amide; Octanoic acid (2,6- dimethyl-4-morpholin-4-yl-phenyl)-amide; Heptanoic acid (2,6-dimethyl-4-morpholin-4- yl-phenyl)-amide; N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-2-phenyl-acetamide; 2-(3,4- Dichloro-phenyl)-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-ac etamide; 2-(4-Allyloxy-3- chloro-phenyl)-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-acet amide; N-(2,6-Dimethyl-4- morpholin-4-yl-phenyl)-2-(3-trifluoromethyl-phenyl)-acetamid e; N-(2,6-Dimethyl-4- morpholin-4-yl-phenyl)-2-naphthalen-2-yl-acetamide; 3-(3-Chloro-phenyl)-N-(2,6- dimethyl-4-morpholin-4-yl-phenyl)-propionamide; N-(2,6-Dimethyl-4-morpholin-4-yl- phenyl)-2-(3,4-dimethyl-phenyl)-acetamide; 2-(3-Bromo-phenyl)-N-(2,6-dimethyl-4- morpholin-4-yl-phenyl)-acetamide; 2-(3-Chloro-phenyl)-N-(2,6-dimethyl-4-morpholin-4- yl-phenyl)-acetamide; N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-2-p-tolyl-acetamide ; N- (2,6-Dimethyl-4-morpholin-4-yl-phenyl)-2-m-tolyl-acetamide; 2-(3,4-Difluoro-phenyl)-N- (2,6-dimethyl-4-morpholin-4-yl-phenyl)-acetamide; N-(2,6-Dimethyl-4-morpholin-4-yl- phenyl)-2-(3-fluoro-phenyl)-acetamide; N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl- phenyl)-3-cyclohexyl-propionamide; N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl- phenyl)-2-(3-fluoro-phenyl)-acetamide; N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl- phenyl)-propionamide; N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl-phenyl)- butyramide; N-(2-Chloro-4-morpholin-4-yl-6-trifluoromethyl-phenyl)-2-(3- fluoro-phenyl)- acetamide; N-(2-Chloro-4-morpholin-4-yl-6-trifluoromethyl-phenyl)-2-cyc lopentyl- acetamide; 2-Cyclopentyl-N-{2,6-dimethyl-4-[2-(4-trifluoromethyl-phenyl )-morpholin-4- yl]-phenyl}-acetamide; N-{4-[2-(2-Chloro-phenyl)-morpholin-4-yl]-2,6-dimethyl-pheny l}-2- cyclopentyl-acetamide; 2-Cyclopentyl-N-{4-[2-(4-fluoro-phenyl)-morpholin-4-yl]-2,6- dimethyl-phenyl}-acetamide; 2-(2-Chloro-phenyl)-N-(2,6-dimethyl-4-morpholin-4-yl- phenyl)-acetamide; Pentanoic acid (2,6-dimethyl-4-morpholin-4-yl-phenyl)-amide; 4- Methyl-pentanoic acid (2,6-dimethyl-4-morpholin-4-yl-phenyl)-amide; 2-Cyclopent-2- enyl-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-acetamide; 5-Methyl-hexanoic acid (2,6- dimethyl-4-morpholin-4-yl-phenyl)-amide; 3-Methyl-pentanoic acid (2,6-dimethyl-4- morpholin-4-yl-phenyl)-amide; Hex-5-enoic acid (2,6-dimethyl-4-morpholin-4-yl-phenyl)- amide; 3-Ethyl-pentanoic acid (2,6-dimethyl-4-morpholin-4-yl-phenyl)-amide; 2- Cyclopentyl-N-(4-morpholin-4-yl-2-pyridin-3-yl-6-trifluorome thyl-phenyl)-acetamide; 2- Cyclopentyl-N-(5-morpholin-4-yl-3-trifluoromethyl-biphenyl-2 -yl)-acetamide; 2- Cyclopentyl-N-(4′-fluoro-5-morpholin-4-yl-3-trifluoromethy l-biphenyl-2-yl)-acetamide; 2- Cyclopentyl-N-(4′-methyl-5-morpholin-4-yl-3-trifluoromethy l-biphenyl-2-yl)-acetamide, 2- Cyclopentyl-N-(3′-methyl-5-morpholin-4-yl-3-trifluoromethy l-biphenyl-2-yl)-acetamide; 2- Cyclopentyl-N-(3′,4′-difluoro-5-morpholin-4-yl-3-trifluo romethyl-biphenyl-2-yl)-acetamide; 2-(4-Fluoro-phenyl)-N-(4-morpholin-4-yl-2-pyridin-3-yl-6-tri fluoromethyl-phenyl)- acetamide; 2-Cyclopentyl-N-(2,6-diethyl-4-morpholin-4-yl-phenyl)-acetam ide; 2- Cyclopentyl-N-(2,6-diisopropyl-4-morpholin-4-yl-phenyl)-acet amide; 2-Cyclopentyl-N- (2,6-difluoro-4-morpholin-4-yl-phenyl)-acetamide; Hexanoic acid (2,6-difluoro-4- morpholin-4-yl-phenyl)-amide; N-(2,6-Difluoro-4-morpholin-4-yl-phenyl)-3,3-dimethyl- butyramide; N-(2,6-Difluoro-4-morpholin-4-yl-phenyl)-2-(3-fluoro-phenyl) -acetamide; 2- Cyclopent-2-enyl-N-(2,6-difluoro-4-morpholin-4-yl-phenyl)-ac etamide; 2- Bicyclo[2.2.1]hept-2-yl-N-(2,6-difluoro-4-morpholin-4-yl-phe nyl)-acetamide; 2- Bicyclo[2.2.1]hept-2-yl-N-(2-methyl-4-morpholin-4-yl-6-trifl uoromethyl-phenyl)- acetamide; 5-Methyl-pentanoic acid (2-methyl-4-morpholin-4-yl-6-trifluoromethyl- phenyl)-amide; 5-Methyl-hexanoic acid (2-methyl-4-morpholin-4-yl-6-trifluoromethyl- phenyl)-amide; 2-Cyclopent-2-enyl-N-(2-methyl-4-morpholin-4-yl-6-trifluorom ethyl- phenyl)-acetamide; 2-Cyclopentyl-N-(2-methyl-4-morpholin-4-yl-6-trifluoromethyl - phenyl)-acetamide; Hexanoic acid (2-methyl-4-morpholin-4-yl-6-trifluoromethyl-phenyl)- amide; 3,3-Dimethyl-N-(2-methyl-4-morpholin-4-yl-6-trifluoromethyl- phenyl)-butyramide; 2-(3,4-Difluoro-phenyl)-N-(2-methyl-4-morpholin-4-yl-6-trifl uoromethyl-phenyl)- acetamide; Hexanoic acid (2-methoxy-6-methyl-4-morpholin-4-yl-phenyl)-amide; 2- Cyclopentyl-N-(2-methoxy-6-methyl-4-morpholin-4-yl-phenyl)-a cetamide; N-(2-Methoxy- 6-methyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide; 2-(3,4-Difluoro-phenyl)-N- (2-methoxy-6-methyl-4-morpholin-4-yl-phenyl)-acetamide; 2-Cyclopent-2-enyl-N-(2- methoxy-6-methyl-4-morpholin-4-yl-phenyl)-acetamide; 2-(3-Fluoro-phenyl)-N-(2- methoxy-6-methyl-4-morpholin-4-yl-phenyl)-acetamide; 2-Bicyclo[2.2.1]hept-2-yl-N-(2- methoxy-6-methyl-4-morpholin-4-yl-phenyl)-acetamide; 4-Methyl-pentanoic acid (2- methoxy-6-methyl-4-morpholin-4-yl-phenyl)-amide; 5-Methyl-Hexanoic acid (2-methoxy- 6-methyl-4-morpholin-4-yl-phenyl)-amide; N-(2-Chloro-6-methyl-4-morpholin-4-yl- phenyl)-2-(3-fluoro-phenyl)-acetamide; and N-(2-Chloro-6-methyl-4-morpholin-4-yl- phenyl)-2-cyclopentyl-acetamide; as the free base or a pharmaceutically acceptable salt thereof. Formula 14 [0263] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 14. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2008 and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2006029623A1, published March 23, 2006 and corresponding to International Application No. PCT/DK2005/000560 filed September 2, 2005; US Patent No.7,601,870, issued October 13, 2009 and corresponding to US Application No.11/312,664 filed December 20, 2005; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 14, these references incorporated by reference herein control. [0264] In an embodiment, the Kv7 channel activator is a compound according to formula 14: Formula 14 wherein, Z is O or S; q is 0 or 1; each of R ¹ and R ² is independently selected from the group consisting of halogen, cyano, amino, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _3-8 -heterocycloalk(en)yl, Aryl, Heteroaryl, halo-C _1-6 - alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yloxy, C3-8-cycloalk(en)yloxy, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy, and C3- ₈ -heterocycloalk(en)yloxy; R ³ is selected from the group consisting of C _1-8 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl-C _1-6 -alk(en/yn)yl, Aryl-C _3-8 - cycloalk(en)yl, Aryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _3-8 -heterocycloalk(en)yl-C _1-6 - alk(en/yn)yl, C _1-6 -alk(en/yn)yl-C _3-8 -heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, Heteroaryl-C alk(en/yn)yl, Heteroaryl-C _3-8 -cycloalk(en)yl, Heteroaryl-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, amino-C _1-6 -alk(en/yn)yl, amino-C _3-8 -cycloalk(en)yl, amino-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy-C _1-6 - alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl and halo-C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl; and R ⁴ is selected from the group consisting of halogen, cyano, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _3-8 - heterocycloalk(en)yl, Aryl, Heteroaryl, Aryl-C _1-6 -alk(en/yn)yl, Aryl-C _3-8 -cycloalk(en)yl, Aryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl-C _3-8 -heterocycloalk(en)yl, halo-C _1-6 - alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _{1- 6} -alk(en/yn)yl-C _3-8 -heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, NR ⁵ R ⁶ and R ⁷ NH—C _1-6 - alk(en/yn)yl; wherein: R ⁵ and R ⁶ are independently selected from the group consisting of hydrogen, Aryl-C _1-6 -alk(en/yn)yl, Aryl-C _3-8 -cycloalk(en)yl, Aryl-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Heteroaryl-C _1-6 -alk(en/yn)yl, Heteroaryl-C _3-8 -cycloalk(en)yl and Heteroaryl-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, with the proviso that R ⁵ and R ⁶ are not hydrogen at the same time; and R ⁷ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl, halo-C _1-6 -alk(en/yn)yl, halo-C _{3- 8} -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl-C _1-6 -alk(en/yn)yl, Aryl-C _{3- 8} -cycloalk(en)yl and Heteroaryl; or a pharmaceutically acceptable salt thereof. [0265] In further embodiments, the Kv7 channel activator is selected from the group consisting of: Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; N-(4-Bromo-2,6- dimethyl-phenyl)-2-(4-fluoro-phenyl)-acetamide; N-(2-Bromo-4,6-dimethyl-phenyl)-2-(4- fluoro-phenyl)-acetamide; N-(2-Bromo-4,6-dimethyl-phenyl)-3,3-dimethyl-butyramide; N- (2-Bromo-4,6-dimethyl-phenyl)-2-cyclopentyl-acetamide; N-(2-Bromo-4,6-dichloro- phenyl)-3,3-dimethyl-butyramide; N-(2-Bromo-4,6-dichloro-phenyl)-2-(4-fluoro-phenyl)- acetamide; N-(2-Bromo-4,6-dichloro-phenyl)-2-cyclopentyl-acetamide; Heptanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; Cyclohexanecarboxylic acid (4-bromo-2,6- dimethyl-phenyl)-amide; N-(4-Bromo-2,6-dimethyl-phenyl)-2-thiophen-2-yl-acetamide; 2- Phenyl-cyclopropanecarboxylic acid (4-bromo-2,6-dimethyl-phenyl)-amide; N-(4-Bromo- 2,6-dimethyl-phenyl)-2-(4-chloro-phenyl)-acetamide; Pentanoic acid (4-bromo-2,6- dimethyl-phenyl)-amide; Octanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; N-(4- Bromo-2,6-dimethyl-phenyl)-2-cyclopentyl-acetamide; 2-Bicyclo[2.2.1]kept-2-yl-N-(2,4- difluoro-6-morpholin-4-yl-phenyl)-acetamide; (S)-2-Amino-N-{2,6-dimethyl-4-[methyl-(4- trifluoromethyl-benzyl)-amino]-phenyl}-3- methyl-butyramide; (S)-2-Amino-4-methyl- pentanoic acid {2,6-dimethyl-4-[methyl-(4-trifluoromethyl-benzyl)-amino]-ph enyl}-amide; (4-Bromo-2,6-dimethyl-phenyl)-carbamic acid ethyl ester; (4-Bromo-2,6-dimethyl- phenyl)-carbamic acid propyl ester; N-(2-Amino-4-bromo-6-methyl-phenyl)-3,3-dimethyl- butyramide; 2-Cyclopentyl-N-{2,6-dimethyl-4-[2-(4-trifluoromethyl-phenyl )-pyrrolidin-1- yl]-phenyl}-acetamide; N-(4-Azepan-1-yl-2,6-dimethyl-phenyl)-2-cyclopentyl-acetamid e; 2-Cyclopentyl-N-(2,6-dimethyl-4-pyrrol-1-yl-phenyl)-acetamid e; N-(3′-Amino-3,5- dimethyl-biphenyl-2-yl)-2-(4-fluoro-phenyl)-acetamide; N-(4′-Dimethylamino-3,5- dimethyl-biphenyl-2-yl)-2-(4-fluoro-phenyl)-acetamide; N-(2,4-Dimethyl-6-quinolin-3-yl- phenyl)-2-(4-fluoro-phenyl)-acetamide; 2-(4-Fluoro-phenyl)-N-(4′-hydroxy-3′-methoxy- 3,5-dimethyl-biphenyl-2-yl)-acetamide; 2-(4-Fluoro-phenyl)-N-(3′-hydroxy-3,5-dimethyl- biphenyl-2-yl)-acetamide; 2-(4-Fluoro-phenyl)-N-(2′-methanesulfonylamino-3,5-dimethy l- biphenyl-2-yl)-acetamide; N-(4′-Isopropyl-3,5-dimethyl-biphenyl-2-yl)-3,3-dimethyl- butyramide; 2-Cyclopentyl-N-(3,5-dimethyl-biphenyl-2-yl)-acetamide; N-(4′-Fluoro-3,5- dimethyl-biphenyl-2-yl)-2-(4-fluoro-phenyl)-acetamide; N-(3,5-Dimethyl-3′,5′-bis- trifluoromethyl-biphenyl-2-yl)-2-(4-fluoro-phenyl)-acetamide ; N-(3′-Acetylamino-3,5- dimethyl-biphenyl-2-yl)-2-(4-fluoro-phenyl)-acetamide; 2-(4-Fluoro-phenyl)-N-(2′- methoxy-3,5-dimethyl-biphenyl-2-yl)-acetamide; N-(3,5-Dimethyl-4′-vinyl-biphenyl-2-yl)- 2-(4-fluoro-phenyl)-acetamide; N-(3′-Cyano-3,5-dimethyl-biphenyl-2-yl)-2-(4-fluoro- phenyl)-acetamide; N-(3,5-Dimethyl-3′-trifluoromethoxy-biphenyl-2-yl)-2-(4-fl uoro- phenyl)-acetamide; N-[2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-4,6-dimethyl-phenyl ]-2-(4- fluoro-phenyl)-acetamide; N-[2,4-Dimethyl-6-(2,2,5-trimethyl-2,3-dihydro-benzofuran-7- yl)-phenyl]-2-(4-fluoro-phenyl)-acetamide; N-[2,6-Dimethyl-4-(4-trifluoromethyl- benzylamino)-phenyl]-acetamide; N-{2,6-Dimethyl-4-[methyl-(4-trifluoromethyl-benzyl)- amino]-phenyl}-acetamide; {4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2,6-dimethyl- phenyl}-carbamic acid propyl ester; [4-(4-Fluoro-benzylamino)-2,6-dimethyl-phenyl]- carbamic acid propyl ester; [2,6-Dimethyl-4-(4-trifluoromethyl-benzylamino)-phenyl]- carbamic acid propyl ester; [4-(3-Fluoro-4-trifluoromethyl-benzylamino)-2,6-dimethyl- phenyl]-carbamic acid propyl ester; {2,6-Dimethyl-4-[(4-methyl-2-phenyl-pyrimidin-5- ylmethyl)-amino]-phenyl}-carbamic acid propyl ester; {2,6-Dimethyl-4-[(6-p-tolyloxy- pyridin-3-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester; {4-[(6-Methoxy-pyridin-3- ylmethyl)-amino]-2,6-dimethyl-phenyl}-carbamic acid propyl ester; {4-[(3-Fluoro-4- trifluoromethyl-benzyl)-methyl-amino]-2,6-dimethyl-phenyl}-c arbamic acid propyl ester; 2-Cyclopentyl-N-[2,6-dimethyl-4-(4-trifluoromethyl-benzylami no)-phenyl]-acetamide 2- Cyclopentyl-N-{2,6-dimethyl-4-[methyl-(4-trifluoromethyl-ben zyl)-amino]-phenyl}- acetamide; 2-Cyclopentyl-N-{2,6-dimethyl-4-[(6-trifluoromethyl-pyridin- 3-ylmethyl)- amino]-phenyl}-acetamide; N-{2,6-Dimethyl-4-[(6-trifluoromethyl-pyridin-3-ylmethyl)- amino]-phenyl}-3,3-dimethyl-butyramide; N-{2-Bromo-4-[(5-chloro-thiophen-2-ylmethyl)- amino]-6-trifluoromethyl-phenyl}-3-cyclohexyl-propionamide; {4-[(3-Fluoro- phenylamino)-methyl]-2,6-dimethyl-phenyl}-carbamic acid ethyl ester; {2,6-Dimethyl-4- [(4-trifluoromethyl-phenylamino)-methyl]-phenyl}-carbamic acid ethyl ester; 2- Cyclopentyl-N-{4-[(3-fluoro-phenylamino)-methyl]-2,6-dimethy l-phenyl}-acetamide; N-{4- [(3-Chloro-phenylamino)-methyl]-2,6-dimethyl-phenyl}-2-cyclo pentyl-acetamide; 2- Cyclopentyl-N-{4-[(3-methoxy-phenylamino)-methyl]-2,6-dimeth yl-phenyl}-acetamide; N- {4-[(4-Chloro-phenylamino)-methyl]-2,6-dimethyl-phenyl}-2-cy clopentyl-acetamide; 2- Cyclopentyl-N-{4-[(3,4-difluoro-phenylamino)-methyl]-2,6-dim ethyl-phenyl}-acetamide; 2-Cyclopentyl-N-{2,6-dimethyl-4-[(4-trifluoromethyl-phenylam ino)-methyl]-phenyl}- acetamide; 2-Cyclopentyl-N-[2,6-dimethyl-4-(p-tolylamino-methyl)-phenyl ]-acetamide; 2- Cyclopentyl-N-{2,6-dimethyl-4-[(3-trifluoromethyl-phenylamin o)-methyl]-phenyl}- acetamide; 2-Cyclopentyl-N-{-4-[(3,5-difluoro-phenylamino)-methyl]-2,6- dimethyl- phenyl}-acetamide; {4-[(4-Fluoro-phenylamino)-methyl]-2,6-dimethyl-phenyl}-carb amic acid propyl ester; {4-[(4-Chloro-phenylamino)-methyl]-2,6-dimethyl-phenyl}-carb amic acid propyl ester; {2,6-Dimethyl-4-[(4-trifluoromethyl-phenylamino)-methyl]-phe nyl}- carbamic acid propyl ester; {4-[(3,5-Difluoro-phenylamino)-methyl]-2,6-dimethyl-phenyl}- carbamic acid propyl ester; {4-[(3-Fluoro-phenylamino)-methyl]-2,6-dimethyl-phenyl}- carbamic acid propyl ester; N-(4-Bromo-2-methyl-6-morpholin-4-yl-phenyl)-3,3-dimethyl- butyramide; {4-[(4-Methoxyphenylamino)-methyl]-2,6-dimethylphenyl}-carba mic acid propyl ester; (R)-2-Amino-4-methylpentanoic acid [2,6-dimethyl-4-(4- trifluoromethylbenzylamino)-phenyl]-amide; Pentanoic acid (4-[(4-chlorophenylamino)- methyl]-2,6-dimethylphenyl)-amide; 2-(4-Chlorophenyl)-N-[4-(4-chlorophenylamino)- methyl]-2,6-dimethyl phenyl)-acetamide; {2,6-Dimethyl-4-[(4- trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid 2-methoxyethyl ester; N-{4- [(5-Chloro-pyridin-2-ylamino)-methyl]-2,6-dimethylphenyl}-2- cyclopentylacetamide; 2- Cyclopentyl-N-{4-[(2,6-dichloro-pyridin-4-ylamino)-methyl]-2 ,6-dimethylphenyl}- acetamide; N-{2-Chloro-6-methyl-4-[(6-trifluoromethyl-pyridin-3-ylmethy l)-amino]- phenyl}-2-(3-fluoro-phenyl)-acetamide; N-[2-Chloro-6-trifluoromethyl-4-(4- trifluoromethylbenzylamino)-phenyl]-2-cyclopentylacetamide; [2-Amino-6-methyl-4-(4- trifluoromethylbenzylamino)-phenyl]-carbamic acid ethyl ester; 3,3-Dimethyl-N-{2- methyl-6-morpholin-4-yl-4-(4-trifluoromethylbenzylamino)-phe nyl}-butyramide; 2- Cyclopentyl-N-{2,6-dichloro-4-[(4-fluoro-phenylamino)-methyl ]-phenyl}-acetamide; 2- Cyclopentyl-N-{2,6-dichloro-4-[(5-trifluoromethylpyridin-2-y lamino)-methyl]-phenyl}- acetamide; and pharmaceutically acceptable salts thereof. [0266] In further embodiments, Z is O or S; q is 0; R ¹ and R ² are each independently selected from the group consisting of halogen, cyano, amino, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl, halo-C _1-6 -alk(en/yn)yl, halo-C _{3- 8} -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, C _3-8 - cycloalk(en)yloxy, and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy; R ³ is selected from the group consisting of C _1-8 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, Aryl-C _1-6 -alk(en/yn)yl, Aryl-C _3-8 -cycloalk(en)yl, Aryl-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, amino-C _1-6 -alk(en/yn)yl, amino-C _3-8 -cycloalk(en)yl, amino-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy-C _1-6 - alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl and halo-C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl; and R ⁴ is selected from the group consisting of halogen, cyano, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl, Aryl-C _3-8 - cycloalk(en)yl, Aryl-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8- cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, NR ⁵ R ⁶ and R ⁷ NH—C _1-6 - alk(en/yn)yl; wherein: R ⁵ and R ⁶ are each independently selected from the group consisting of hydrogen, Aryl-C _1-6 -alk(en/yn)yl, Aryl-C _3-8 -cycloalk(en)yl, Aryl-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, and C _3-8 - cycloalk(en)yl-C _1-6 alk(en/yn)yl, with the proviso that R ⁵ and R ⁶ can not both be hydrogen; and R ⁷ is selected from the group consisting of C _1-6 -alk(en/yn)yl; C _3-8 - cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl, halo-C _1-6 -alk(en/yn)yl, halo-C _{3- 8} -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl-C _1-6 -alk(en/yn)yl, and Aryl-C _3-8 -cycloalk(en)yl; with the proviso that the compound of formula I is not N-(4- Bromo-2,6-dimethyl-phenyl)-2-cyclopentyl-acetamide; or a pharmaceutically acceptable salt thereof. [0267] In further embodiments, R ¹ and R ² are each independently selected from the group consisting of halogen, amino, C _1-6 -alk(en/yn)yl, Aryl, and halo-C _1-6 -alk(en/yn)yl. [0268] In further embodiments, R ³ is selected from the group consisting of C _1-8 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl-C _1-6 - alk(en/yn)yl, Aryl-C _3-8 -cycloalk(en)yl, and amino-C _1-6 -alk(en/yn)yl. [0269] In further embodiments, R ⁴ is selected from the group consisting of halogen, C _1-6 - alk(en/yn)yl, NR ⁵ R ⁶ and R ⁷ NH—C _1-6 -alk(en/yn)yl, wherein R ⁵ , R ⁶ and R ⁷ are as previously defined. [0270] In further embodiments, R ⁴ is NR ⁵ R ⁶ , wherein R ⁵ and R ⁶ are independently selected from the group consisting of hydrogen, Aryl-C _1-6 -alk(en/yn)yl, and C _1-6 - alk(en/yn)yl, with the proviso that R ⁵ and R ⁶ cannot both be hydrogen. [0271] In further embodiments, R ⁴ is R ⁷ NH—C _1-6 -alk(en/yn)yl, wherein R ⁷ is Aryl. [0272] In further embodiments, any Aryl is optionally substituted with one or more substituents independently selected from the group consisting of amino, halogen, cyano, C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, hydroxy, C _1-6 -alk(en/yn)yloxy, halo-C _1-6 - alk(en/yn)yloxy, di-(C _1-6 -alk(en/yn)yl)amino, C _1-6 -alk(en/yn)yl-CO—NH— and C _1-6 - alk(en/yn)yl-sulfonamide; or two adjacent substituents may together with the Aryl group to which they are attached form a 4-8 membered ring, which is optionally substituted with one or more C1-6-alk(en/yn)yl groups. [0273] In further embodiments, the Kv7 channel activator is a compound according to formula 14, wherein: Z is O or S; q is 0; R ¹ and R ² are each independently selected from the group consisting of halogen, cyano, amino, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy, and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy; R ³ is selected from the group consisting of C _1-8 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl-C _1-6 - alk(en/yn)yl, Aryl-C _3-8 -cycloalk(en)yl, Aryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, amino-C _{1- 6} -alk(en/yn)yl, amino-C _3-8 -cycloalk(en)yl, amino-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _{1- 6} -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 - cycloalk(en)yl and halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; and R ⁴ is selected from the group consisting of halogen, cyano, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl, Aryl-C _3-8 -cycloalk(en)yl, Aryl-C _3-8 -cycloalk(en)yl-C _{1- 6} -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, NR ⁵ R ⁶ and R ⁷ NH—C _1-6 -alk(en/yn)yl; wherein: R ⁵ and R ⁶ are each independently selected from the group consisting of hydrogen, Aryl-C _1-6 -alk(en/yn)yl, Aryl-C _3-8 -cycloalk(en)yl, Aryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, with the proviso that R ⁵ and R ⁶ cannot both be hydrogen; and R ⁷ is selected from the group consisting of C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl, halo-C _1-6 - alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Aryl-C _1-6 - alk(en/yn)yl, and Aryl-C _3-8 -cycloalk(en)yl; with the proviso that the compound of formula I is not N-(4-Bromo-2,6-dimethyl-phenyl)-2-cyclopentyl-acetamide; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent. Formula 15 [0274] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 15. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009 and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2006092143A1, published September 8, 2006 and corresponding to International Application No. PCT/DK2006/000123 filed March 2, 2006; US Patent No.7,812,020, issued October 12, 2010 and corresponding to US Application No.11/817,340 filed March 2, 2006; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 15, these references incorporated by reference herein control. [0275] In an embodiment, the Kv7 channel activator is a compound according to formula 15: Formula 15 wherein, q is 0 or 1; each of R ¹ and R ² is independently selected from the group consisting of halogen, cyano, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy and C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy; and R ³ is selected from the group consisting of C _1-8 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, optionally substituted Aryl-C _1-6 -alk(en/yn)yl, optionally substituted Aryl-C _3-8 -cycloalk(en)yl, optionally substituted Aryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yl-C _3-8 - heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _3-8 -heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yl, C _3-8 -heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, Heteroaryl-C _1-6 -alk(en/yn)yl, Heteroaryl-C _3-8 -cycloalk(en)yl, Heteroaryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, NR ⁴ R ⁵ — C _1-6 -alk(en/yn)yl, NR ⁴ R ⁵ —C _3-8 -cycloalk(en)yl NR ⁴ R ⁵ —C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-C _1-6 - alk(en/yn)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy-C1-6-alk(en/yn)yl, halo-C1-6- alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl and halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; wherein each of R ⁴ and R ⁵ is independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; as the free base or a pharmaceutically acceptable salt thereof. [0276] In further embodiments, the Kv7 channel activator is selected from the group consisting of: (2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-carbamic acid benzyl ester; (2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-carbamic acid 2-chloro-benzyl ester; 2-(4- Chloro-phenyl)-(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)- acetamide; 2-Phenyl- cyclopropanecarboxylic acid (2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-amide; N-(2,4- Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-2-thiophen-2-yl-acet amide; 3-Cyclohexyl-N-(2,4- dimethyl-6-morpholin-4-yl-pyridin-3-yl)-propionamide; (2,4-Dimethyl-6-morpholin-4-yl- pyridin-3-yl)-carbamic acid isobutyl ester; 3-(3-Chloro-phenyl)-N-(2,4-dimethyl-6- morpholin-4-yl-pyridin-3-yl)-propionamide; N-(2,4-Dimethyl-6-morpholin-4-yl-pyridin-3- yl)-2-(3,5-dimethyl-phenyl)-acetamide; N-(2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-3- p-tolyl-propionamide; 2-(3-Chloro-phenyl)-N-(2,4-dimethyl-6-morpholin-4-yl-pyridin -3-yl)- acetamide; 2-(3,4-Dichloro-phenyl)-N-(2,4-dimethyl-6-morpholin-4-yl-pyr idin-3-yl)- acetamide; N-(2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-2-thiophen-3- yl-acetamide; N- (2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-2-p-tolyl-aceta mide; 2-(3-Bromo-phenyl)-N- (2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-acetamide; N-(2,4-Dimethyl-6-morpholin-4- yl-pyridin-3-yl)-2-(3-trifluoromethyl-phenyl)-acetamide; N-(2,4-Dimethyl-6-morpholin-4- yl-pyridin-3-yl)-2-phenyl-acetamide; 3,5,5-Trimethyl-hexanoic acid (2,4-dimethyl-6- morpholin-4-yl-pyridin-3-yl)-amide; Octanoic acid (2,4-dimethyl-6-morpholin-4-yl-pyridin- 3-yl)-amide; N-(2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-2-naphthalen- 2-yl- acetamide; Heptanoic acid (2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-amide; N-(2,4- Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-2-(3,4-dimethyl-phen yl)-acetamide; 2-Cyclohex- 1-enyl-N-(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-acetam ide; N-(2,4-Dimethyl-6- morpholin-4-yl-pyridin-3-yl)-2-(4-methoxy-3-methyl-phenyl)-a cetamide; N-(2,4-Dimethyl- 6-morpholin-4-yl-pyridin-3-yl)-2-(4-methoxy-phenyl)-acetamid e; N-(2,4-Dimethyl-6- morpholin-4-yl-pyridin-3-yl)-3-(4-methoxy-phenyl)-propionami de; N-(2,4-Dimethyl-6- morpholin-4-yl-pyridin-3-yl)-2-m-tolyl-acetamide; N-(2,4-Dimethyl-6-morpholin-4-yl- pyridin-3-yl)-2-(4-fluoro-phenyl)-acetamide; N-(2,4-Dimethyl-6-morpholin-4-yl-pyridin-3- yl)-3,3-dimethyl-butyramide; N-(2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-2-(3-fluoro- phenyl)-acetamide; 2-Bicyclo[2.2.1]kept-2-yl-N-(2,4-dimethyl-6-morpholin-4-yl-p yridin-3- yl)-acetamide; 2-(3,4-Difluoro-phenyl)-N-(2,4-dimethyl-6-morpholin-4-yl-pyr idin-3-yl)- acetamide; 4-Methyl-pentanoic acid (2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-amide; 2-Cyclopent-2-enyl-N-(2,4-dimethyl-6-morpholin-4-yl-pyridin- 3-yl)-acetamide; 2- Cyclohexyl-N-(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-ac etamide; 5-Methyl-hexanoic acid (2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-amide; 2-Cyclopentyl-N-(2,4-dimethyl- 6-morpholin-4-yl-pyridin-3-yl)-acetamide; 3-Cyclopentyl-N-(2,4-dimethyl-6-morpholin-4- yl-pyridin-3-yl)-propionamide; Hexanoic acid (2,4-dimethyl-6-morpholin-4-yl-pyridin-3- yl)-amide; N-(4-Chloro-2-methoxy-6-morpholin-4-yl-pyridin-3-yl)-2- cyclopentylacetamide; N-(2-Chloro-4-methoxy-6-morpholin-4-yl-pyridin-3-yl)-2- cyclopentylacetamide; N-(2-Chloro-4-methoxy-6-morpholin-4-yl-pyridin-3-yl)-3,3- dimethylbutyramide; N-(4-Chloro-2-methoxy-6-morpholin-4-yl-pyridin-3-yl)-3,3- dimethylbutyramide; N-(4-Chloro-2-methoxy-6-morpholin-4-yl-pyridin-3-yl)- propionamide; and pharmaceutically acceptable salts thereof. [0277] In further embodiments, q is 0 or 1; R ¹ and R ² each is independently selected from the group consisting of halogen, cyano, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy and C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy; and R ³ is selected from the group consisting of C _1-8 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, optionally substituted aryl-C _1-6 -alk(en/yn)yl, optionally substituted aryl-C _3-8 -cycloalk(en)yl, optionally substituted aryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yl-C _3-8 - heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _3-8 -heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yl-C _3-8 -heterocycloalk(en)yl-C _1-6 -alk(en/yn)yl, heteroaryl-C _1-6 -alk(en/yn)yl, heteroaryl-C _3-8 -cycloalk(en)yl, heteroaryl-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, NR ⁴ R ⁵ — C _1-6 -alk(en/yn)yl, NR ⁴ R ⁵ —C _3-8 -cycloalk(en)yl, NR ⁴ R ⁵ —C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, halo-C _1-6 - alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl and halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, wherein: R ⁴ and R ⁵ each is independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl. Formula 16 [0278] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 16. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009 and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 16, these references incorporated by reference herein control. [0279] In an embodiment, the Kv7 channel activator is a compound according to formula 16: Formula 16 wherein: q is 0 or 1; R ¹ and R ² are independently selected from the group consisting of hydrogen and optionally substituted aryl-C _1-6 -alk(en/yn)yl, provided that R ¹ and R ² are not both hydrogen; or R ¹ and R ² together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing a further heteroatom; R ² and R ⁴ are independently selected from hydrogen, halogen, cyano, amino, C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, C1-6-alk(en/yn)yloxy, C3-8- cycloalk(en)yloxy, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy, halo-C _1-6 -alk(en/yn)yloxy, halo-C _3-8 -cycloalk(en)yloxy and halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy, provided that R ³ and R ⁴ are not both hydrogen; and R ⁵ is selected from the group consisting of C _{1- 10} -alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, optionally substituted aryl-C _1-6 - alk(en/yn)yl and optionally substituted aryl; as the free base or a pharmaceutically acceptable salt thereof. [0280] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimid in-5-yl]-2- cyclopentylacetamide; N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimid in- 5-yl]-3,3-dimethylbutyramide; N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)- pyrimidin-5-yl]-2-(4-fluorophenyl)-acetamide; Hexanoic acid [4-amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]-amide; N-[4-Amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]-2-(3-chloropheny l)-acetamide; 2- Cyclopentyl-N-(4,6-dimethyl-2-morpholin-4-yl-pyrimidin-5-yl) -acetamide; N-(4,6- Dimethyl-2-morpholin-4-yl-pyrimidin-5-yl)-3,3-dimethylbutyra mide; N-(4,6-Dimethyl-2- morpholin-4-ylpyrimidin-5-yl)-2-(4-fluorophenyl)-acetamide; 2-(3,4-Difluorophenyl)-N- (4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)-acetamide; N-(4,6-Dimethyl-2-morpholin-4- ylpyrimidin-5-yl)-2-(3-fluorophenyl)-acetamide; and Hexanoic acid (4,6-dimethyl-2- morpholin-4-ylpyrimidin-5-yl)-amide; as the free base or a pharmaceutically acceptable salt thereof. Formula 17 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 17. Such compounds are described in International Publication No. WO2007065449A1, published June 14, 2007 and corresponding to International Application No. PCT/DK2006/050039 filed September 7, 2006; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 17, this reference incorporated by reference herein controls. [0281] In an embodiment, the Kv7 channel activator is a compound according to formula 17: Formula 17 , wherein: q is 0 or 1; R ¹ and R ² are independently selected from the group consisting of hydrogen and optionally substituted aryl-C _1-6 -alk(en/yn)yl, provided that R ¹ and R ² are not both hydrogen, or R ¹ and R ² together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing a further heteroatom;R ³ and R ⁴ are independently selected from hydrogen, halogen, cyano, amino, C _1-6 - alk(en/yn)yl, C _3-8 - cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yloxy, C _3-8 - cycloalk(en)yloxy, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy, halo-C _1-6 -alk(en/yn)yloxy, halo-C _3-8 -cycloalk(en)yloxy and halo-C _3-8 -cycloalk(en)yl- C _1-6 -alk(en/yn)yloxy, provided that R ³ and R ⁴ are not both hydrogen;R ⁵ is selected from the group consisting of C _1-10 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, optionally substituted aryl-C _1-6 - alk(en/yn)yl and optionally substituted aryl; as the free base or salts thereof. [0282] In further embodiments, q is 0. [0283] In further embodiments, q is 1. [0284] In further embodiments, R ¹ and R ² are independently selected from hydrogen and optionally substituted aryl-C _1-6 -alk(en/yn)yl, provided that R ¹ and R ² are not both hydrogen. [0285] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing a further hetero atom. [0286] In further embodiments, said further hetero atom is oxygen. [0287] In further embodiments, said ring is a 6 membered ring. [0288] In further embodiments, said ring is a morpholine ring. [0289] In further embodiments, R ³ and R ⁴ are independently selected from amino and C _1-6 -alk(en/yn)yl, preferably methyl. [0290] In further embodiments, R ⁵ is selected from the group consisting of C _1-10 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, optionally substituted aryl-C _1-6 - alk(en/yn)yl and optionally substituted aryl. [0291] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimid in-5-yl]-2- cyclopentylacetamide, N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimid in- 5-yl]-3,3- dimethylbutyramide, N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)- pyrimidin-5-yl]-2-(4- fluorophenyl)-acetamide, Hexanoic acid [4-amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]- amide, N-[4-Amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]-2-(3- chlorophenyl)-acetamide, 2- Cyclopentyl-N-(4,6-dimethyl-2-moφholin-4-yl-pyrimidin-5-yl) -acetamide, N-(4,6- Dimethyl-2-moφholin-4-yl-pyrimidin-5-yl)-3,3-dimethylbutyra mide, N-(4,6-Dimethyl-2- moφholin-4-ylpyrimidin-5-yl)-2-(4-fluorophenyl)-acetamide, 2-(3,4-Difluorophenyl)-N- (4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)-acetamide, N-(4,6-Dimethyl-2-moφholin-4- ylpyrimidin-5-yl)-2-(3-fluorophenyl)-acetamide and Hexanoic acid (4,6-dimethyl-2- moφholin-4-ylpyrimidin-5-yl)-amide; as the free base or a salt thereof. Formula 18 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 18. Such compounds are described in International Publication No. WO2004096767A1, published November 11, 2004 and corresponding to International Application No. PCT/DK2004/000283 filed April 23, 2004; US Publication No. US20060264496A1, published November 23, 2006 and corresponding to US Application No.10/551,783 filed April 23, 2004; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 18, these references incorporated by reference herein control. [0292] In an embodiment, the Kv7 channel activator is a compound according to formula 18: mula 18 wherein, the dotted line represents an optional bond; R ¹ and R ^1′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 - cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano- C _3-8 -cycloalk(en)yl and cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; or R ¹ and R ^1′ together with the carbon atom to which they are attached form a 3-8 membered saturated or unsaturated ring which optionally contains 1 or 2 heteroatoms; s is 0 or 1; U is O, NR ¹¹ , S, SO ₂ , SO ₂ NR ¹¹ , CO—O or CO—NR ¹¹ ; wherein R ¹¹ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; or R ² and R ¹¹ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms; R ² is selected from the group consisting of hydrogen, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 - alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, halogen, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 - cycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, —NO ₂ , NR ¹⁰ R ^10′ —C _1-6 - alk(en/yn)yl, NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl and NR ¹⁰ R ^10′ —C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl; wherein R ¹⁰ and R ^10′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _{1- 6} -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 -cycloalk(en)yl and cyano-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, or R ¹⁰ and R ^10′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms; with the proviso that when R ² is NO ₂ , halogen or cyano then s is 0; and with the proviso that when R ² is a hydrogen atom or acyl and s is 1 then U is NR ¹¹ , O or S; wherein the group —(U)s—R ² is linked to position 4 or 6 of the indole or indoline; q is 0 or 1; Z is O or S; X is CO or SO ₂ ; with the proviso that q is 0 when X is SO ₂ ; R ³ is selected from the group consisting of C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, heterocycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, C _1-6 - alk(en/yn)yl-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, Ar, Ar—C _1-6 - alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar-heterocycloalk(en)yl, Ar—C _3-8 -cycloalk(en)yl-C _{1- 6} -alk(en/yn)yl, Ar—C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, Ar—C _1-6 -alk(en/yn)yl- heterocycloalk(en)yl, C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-C _1-6 - alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-C _3-8 -cycloalk(en)yl, C _1-6 -alk(en/yn)yloxy- heterocycloalk(en)yl, Ar-oxy-C _1-6 -alk(en/yn)yl, Ar—C _1-6 -alk(en/yn)yloxy-C _1-6 -alk(en/yn)yl, C _1-6 -alk(en/yn)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yloxy-carbonyl-C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yloxy-carbonyl-C _1-6 -alk(en/yn)yl, hydroxy- C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 -cycloalk(en)yl, hydroxy-heterocycloalk(en)yl, hydroxy-C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, hydroxy- C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-heterocycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 - alk(en/yn)yl-C _3-8 -cycloalk(en)yl, halo-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, halo-C _1-6 - alk(en/yn)yl-Ar, halo-C _3-8 -cycloalk(en)yl-Ar, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl-Ar, halo-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl-Ar, cyano-C _1-6 -alk(en/yn)yl, cyano-C _3-8 - cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, cyano-C _1-6 -alk(en/yn)yl-heterocycloalk(en)yl, acyl-C _1-6 -alk(en/yn)yl, acyl-C _3-8 -cycloalk(en)yl, acyl-heterocycloalk(en)yl, acyl-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, acyl-C _1-6 -alk(en/yn)yl-C _3-8 -cycloalk(en)yl, acyl-C _1-6 - alk(en/yn)yl-heterocycloalk(en)yl and —NR ¹² R ^12′ , optionally substituted NR ¹² R ^12′ —C _1-6 - alk(en/yn)yl, optionally substituted NR ¹² R ^12′ —C _3-8 -cycloalk(en)yl, optionally substituted NR ¹² R ^12′ —C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; wherein R ¹² and R ^12′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _{3- 8} -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar, Ar—C _1-6 -alk(en/yn)yl, Ar—C _3-8 -cycloalk(en)yl, Ar— C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, hydroxy-C _1-6 -alk(en/yn)yl, hydroxy-C _3-8 - cycloalk(en)yl, hydroxy-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, halo-C _1-6 -alk(en/yn)yl, halo- C _3-8 -cycloalk(en)yl, halo-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, cyano-C _1-6 -alk(en/yn)yl, cyano-C3-8-cycloalk(en)yl and cyano-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, or R ¹² and R ^12′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms; with the proviso that when R ³ is NR ¹² R ^12′ then q is 0; and Y is selected from the groups according to the following formulas:

, wherein, W is O or S; T is N, NH or O; L is N, C or CH; a is 0, 1, 2 or 3; b is 0, 1, 2, 3 or 4; c is 0 or 1; d is 0, 1, 2 or 3; e is 0, 1 or 2; f is 0, 1, 2, 3, 4 or 5; g is 0, 1, 2, 3 or 4; h is 0, 1, 2 or 3; j is 0, 1, 2 or 3; with the proviso that when T is a nitrogen atom then j is 0, 1, 2 or 3; and when T is NH or an oxygen atom then j is 0, 1 or 2; k is 0, 1, 2, 3 or 4; and each R ⁵ is independently selected from the group consisting of a C _1-6 -alk(en/yn)yl, C _3-8 - cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, Ar, Ar—C1-6-alk(en/yn)yl, Ar-thio, Ar- oxy, acyl, C _1-6 -alk(en/yn)yloxy, C _3-8 -cycloalk(en)yloxy, C _3-8 -cycloalk(en)yl-C _1-6 - alk(en/yn)yloxy, halogen, halo-C _1-6 -alk(en/yn)yl, halo-C _3-8 -cycloalk(en)yl, halo-C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, —CO—NR ⁶ R ^6′ , cyano, cyano-C _1-6 -alk(en/yn)yl, cyano- C _3-8 -cycloalk(en)yl, cyano-C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, —NR ⁷ R ^7′ , —S—R ⁸ and —SO ₂ R ⁸ , or two adjacent R ⁵ together with the aromatic group to which they are attached form a 4-8 membered ring which optionally contains one or two heteroatoms; R ⁶ and R ^6′ are independently selected from the group consisting of hydrogen, C _1-6 - alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl and Ar; R ⁷ and R ^7′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar and acyl; and R ⁸ is selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl, C _3-8 - cycloalk(en)yl-C _1-6 -alk(en/yn)yl, Ar and —NR ⁹ R ^9′ ; wherein R ⁹ and R ^9′ are independently selected from the group consisting of hydrogen, C _1-6 -alk(en/yn)yl, C _3-8 -cycloalk(en)yl and C _3-8 -cycloalk(en)yl-C _1-6 -alk(en/yn)yl; provided that when R ⁸ is —NR ⁹ R ^9′ then R ⁵ is not —S—R ⁸ ; or salts thereof. Formula 19 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 19. Such compounds are described in US Patent No. 9,248,122, issued February 2, 2016 and corresponding to US Application No. 14/091,395 filed November 27, 2013; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 19, this reference incorporated by reference herein controls. [0293] In an embodiment, the Kv7 channel activator is a compound according to formula 19: Formula 19 wherein, A ¹ , A ² and A ³ independently of each other represent CR ⁴ , N, O, S or N(CH ₃ ), A ⁴ represents CR ⁴ or N, and n denotes 0 or 1, with the proviso, that at least one of A ¹ , A ² , A ³ and A ⁴ does not represent CR ⁴ , and with the proviso, that if n denotes 0, then precisely one of A ¹ , A ² and A ³ represents O, S or N(CH ₃ ), or if n denotes 1, then A ¹ , A ² and A ³ independently of each other represent CR ⁴ or N, R ¹ represents C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C1-8-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-8 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents F; Cl; Br; I; CN; CF ₃ ; C(═O)H; NO ₂ ; OCF ₃ ; SCF ₃ ; C _1-4 -aliphatic residue, C(═O)—C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue, C(═O)—NH—C _1-4 - aliphatic residue, C(═O)—N(C _1-4 -aliphatic residue) ₂ , O—C _1-4 -aliphatic residue, O— C(═O)—C _1-4 -aliphatic residue, S—C _1-4 -aliphatic residue, S(═O) ₂ —C _1-4 -aliphatic residue, S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ represents C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-8 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, or denotes S—R ⁵ , O—R ⁶ or N(R ⁷ R ⁸ ), wherein R ⁵ and R ⁶ in each case represent C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-8 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso, that if R ⁵ or R ⁶ denote a 3 to 10 membered heterocycloaliphatic residue, than the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, R ⁷ represents C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-8 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso that if R ⁷ denotes 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom; and R ⁸ denotes C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; or R ⁷ and R ⁸ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; and each R ⁴ independently represents H, F; Cl; Br; I; CN; CF ₃ ; CHF ₂ ; CH ₂ F; OCF ₃ ; OCHF ₂ ; OCH ₂ F; SCF ₃ ; O—C _1-4 -aliphatic residue, C _1-4 -aliphatic residue or S(═O) ₂ —C _1-4 -aliphatic residue; in which an “aliphatic group” and “aliphatic residue” may in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” may in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group”, an “aliphatic residue”, a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , NH—C(═O)—C _{1- 4} aliphatic residue, N(C _1-4 aliphatic residue)-C(═O)—C _1-4 aliphatic residue, NH—S(═O) ₂ — C _1-4 aliphatic residue, N(C _1-4 aliphatic residue)-S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF3, O—C1-4-aliphatic residue, O—C(═O)—C1-4-aliphatic residue, SH, SCF3, S—C1-4- aliphatic residue, S(═O) ₂ OH, S(═O) ₂ —C _1-4 -aliphatic residue, S(═O) ₂ —O—C _1-4 -aliphatic residue, S(═O) ₂ —NH(C _1-4 -aliphatic residue), S(═O) ₂ —N(C _1-4 -aliphatic residue) ₂ , CN, CF ₃ , CHO, COOH, C _1-4 -aliphatic residue, C(═O)—C _1-4 -aliphatic residue, C(═O)—O— C _1-4 -aliphatic residue, C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, C(═O)NH ₂ , a C(═O)—NH(C _1-4 -aliphatic residue) and C(═O)—N(C _1-4 -aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , 1-4-aliphatic residue), N(C1-4-aliphatic residue) ₂ , NH—C(═O)—C _1-4 -aliphatic residue, N(C _1-4 aliphatic residue)-C(═O)—C _{1- 4} aliphatic residue, NH—S(═O) ₂ —C _1-4 aliphatic residue, N(C _1-4 aliphatic residue)- S(═O) ₂ —C _1-4 aliphatic residue, OH, OCF ₃ , O—C _1-4 -aliphatic residue, O—C(═O)—C _1-4 - aliphatic residue, SH, SCF ₃ , S—C _1-4 -aliphatic residue, S(═O) ₂ OH, S(═O) ₂ —C _1-4 - aliphatic residue, S(═O) ₂ —O—C _1-4 -aliphatic residue, S(═O) ₂ —NH(C _1-4 -aliphatic residue), S(═O) ₂ —N(C _1-4 -aliphatic residue) ₂ , CN, CF ₃ , C(═O)H, C(═O)OH, C _1-4 -aliphatic residue, C(═O)—C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue, C _3-6 - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH ₂ , C(═O)—NH(C _1-4 -aliphatic residue) and C(═O)—N(C _1-4 -aliphatic residue) ₂ ; in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a free compound, a solvate and/or a physiologically acceptable salt. [0294] In further embodiments, A ¹ , A ² and A ³ independently of each other represent CR ⁴ , N, O, S or N(CH ₃ ), A ⁴ represents CR ⁴ or N, and n denotes 0 or 1, with the proviso, that at least one of A ¹ , A ² , A ³ and A ⁴ does not represent CR ⁴ , and with the proviso, that if n denotes 0, then precisely one of A ¹ , A ² and A ³ represents O, S or N(CH ₃ ), or if n denotes 1, then A ¹ , A ² and A ³ independently of each other represent CR ⁴ or N, R ¹ denotes C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, or denotes C _3-10 - cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)—OH, C _3-8 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-8 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-8 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , O _3-8 - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 - aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a C _1-8 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN and C(═O)OH, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; C _1-4 -aliphatic residue, S—C _1-4 -aliphatic residue, O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, Or C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, NH(C1-4-aliphatic residue), N(C1-4-aliphatic residue)2, OH, ═O, O—C1-4- aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN and C(═O)OH, R ³ denotes C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, Or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-8 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O— C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 - aliphatic residue and C(═O)OH, Or denotes S—R ⁵ , O—R ⁶ or N(R ⁷ R ⁸ ), wherein R ⁵ and R ⁶ in each case represent C _{1- 10} -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, or in each case represent C _3-10 - cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)—OH, C _3-8 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-8 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-8 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, on the condition that if R ⁵ or R ⁶ denote a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)—O—C _1-4 -aliphatic residue, C _3-6 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a O _1-0 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, and/or R ⁸ denotes C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, Or R ⁷ and R ⁸ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)— OH, C _3-6 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue,wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, And/or wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁷ and R ⁸ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _{1- 4} -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 - aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)—OH, and each R ⁴ independently represents H, F, Cl, Br, I, CN, CF ₃ , CHF ₂ , CH ₂ F, OCF ₃ , OCHF ₂ , OCH ₂ F, SCF ₃ , O—C _1-4 -aliphatic residue, C _1-4 -aliphatic residue or S(═O) ₂ —C _1-4 -aliphatic residue. In further embodiments, n denotes 1 and A ¹ represents N, A ² represents CR ⁴ , A ³ represents CR ⁴ and A ⁴ represents CR ⁴ ; or n denotes 1 and A ¹ represents CR ⁴ , A ² represents N, A ³ represents CR ⁴ and A ⁴ represents CR ⁴ ; or n denotes 1 and A ¹ represents CR ⁴ , A ² represents CR ⁴ , A ³ represents N and A ⁴ represents CR ⁴ ; or n denotes 1 and A ¹ represents CR ⁴ , A ² represents CR ⁴ , A ³ represents CR ⁴ and A ⁴ represents N; or n denotes 1 and A ¹ represents N, A ² represents N, A ³ represents CR ⁴ and A ⁴ represents CR ⁴ ; or n denotes 1 and A ¹ represents N, A ² represents CR ⁴ , A ³ represents N and A ⁴ represents CR ⁴ ; or n denotes 1 and A ¹ represents N, A ² represents CR ⁴ , A ³ represents CR ⁴ and A ⁴ represents N; or n denotes 1 and A ¹ represents CR ⁴ , A ² represents N, A ³ represents N and A ⁴ represents CR ⁴ ; or n denotes 1 and A ¹ represents CR ⁴ , A ² represents N, A ³ represents CR ⁴ and A ⁴ represents N; or n denotes 1 and A ¹ represents CR ⁴ , A ² represents CR ⁴ , A ³ represents N and A ⁴ represents N; or n denotes 0 and A ¹ represents CR ⁴ , A ² represents CR ⁴ , and A ³ represents S; or n denotes 0 and A ¹ represents N, A ² represents CR ⁴ , and A ³ represents S; or n denotes 0 and A ¹ represents S, A ² represents CR ⁴ and A ³ represents CR ⁴ ; or n denotes 0 and A ¹ represents S, A ² represents CR ⁴ and A ³ represents N. [0295] In further embodiments, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; C _1-4 -aliphatic residue, S—C _1-4 -aliphatic residue or O—C _1-4 -aliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH and O—C _1-4 -aliphatic residue. [0296] In further embodiments, R ² represents C _1-4 -aliphatic residue. [0297] In further embodiments, each R ⁴ independently represents H; F; Cl; Br; CN; CF ₃ ; OCF ₃ ; CH ₃ , OCH ₃ or S(═O) ₂ CH ₃ . [0298] In further embodiments, R ¹ represents the partial structure: wherein, m denotes 0, 1, or 2, R ^1a and R ^1b each independently of one another represent H, F, Cl, Br, I, O—C _1-4 -aliphatic residue or C _1-4 -aliphatic residue, R ^1c denotes C _1-4 - aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _{1- 4} -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and O—C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and O—C _1-4 -aliphatic residue, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 - aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 - aliphatic residue, C(═O)CH3, C(═O)C2H5, C(═O)OCH3 and C(═O)OC2H5, and wherein the C _3-6 cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ C _1-4 -aliphatic residue and C(═O)OH. [0299] In further embodiments, m denotes 1 or 2, R ^1a and R ^1b represent H, R ^1c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or m denotes 0 and R ^1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O— C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O— C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , C _1-4 -aliphatic residue and C(═O)OH. [0300] In further embodiments, R ³ denotes a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 - aliphatic residue, CF ₃ , CN and C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and O—C _1-4 - aliphatic residue, or denotes C3-6-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , (═O)—O—C _1-4 -aliphatic residue, S—C _1-4 - aliphatic residue, CF ₃ , CN and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _{1- 4} -aliphatic residue, and wherein the C _3-7 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, or R ³ denotes S—R ⁵ or O— R ⁶ , wherein R ⁵ and R ⁶ in each case denote C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 - aliphatic residue, NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , CF ₃ and C _1-4 - aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and O—C _1-4 -aliphatic residue, or in each case denote C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may be linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, on the condition that if R ⁵ or R ⁶ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, or R ³ denotes N(R ⁷ R ⁸ ), wherein R ⁷ denotes C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, or denotes C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case be linked, via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, on the condition that if R ⁷ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, and R ⁸ denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, or R ⁷ and R ⁸ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and O—C _1-4 - aliphatic residue, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁷ and R ⁸ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C _1-4 - aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , ON, C _1-4 -aliphatic residue, C(═O)OH, C _{3- 6} cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, and pyridyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C1-4-aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH. [0301] In further embodiments, R ³ denotes C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 - aliphatic residue, or denotes C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O— C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 - aliphatic group, or R ³ denotes S—R ⁵ or O—R ⁶ , wherein R ⁵ and R ⁶ in each case denote C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, or in each case denote C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O— C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue in each case may be linked via an unsubstituted C _1-4 -aliphatic group, on the condition that if R ⁵ or R ⁶ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, or R ³ denotes N(R ⁷ R ⁸ ), wherein R ⁷ denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, or denotes C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-6 - cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue is in each case linked via a unsubstituted C _1-4 -aliphatic group, on the condition that if R ⁷ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, and R ⁸ denotes unsubstituted C _1-4 -aliphatic residue, or R ⁷ and R ⁸ form together with the nitrogen atom connecting them a 3 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, and wherein the 3 to 7 membered heterocycloaliphatic residue formed by R ⁷ and R ⁸ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C _1-4 - aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, benzyl, phenyl, and pyridyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH and O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OCH ₃ , OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ CH ₂ OCH ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue. [0302] In further embodiments, A ¹ , A ² and A ³ independently of each other represent CR ⁴ , N, O, S or N(CH ₃ ), A ⁴ represents CR ⁴ or N, and n denotes 0 or 1, with the proviso, that at least one of A ¹ , A ² , A ³ and A ⁴ does not represent CR ⁴ , and with the proviso, that if n denotes 0, then precisely one of A ¹ , A ² and A ³ represents O, S or N(CH ₃ ), or if n denotes 1, then A ¹ , A ² and A ³ independently of each other represent CR ⁴ or N, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2, R ^1a and R ^1b each independently of one another represent H, F, Cl, O—C _1-4 -aliphatic residue or C _1-4 -aliphatic residue, R ^1c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, C _1-10 —C _1-4 aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and O—C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, C _{1- 10} —C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and O—C _1-4 -aliphatic residue, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O— C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ C _1-4 -aliphatic residue and C(═O)OH, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; C _1-4 - aliphatic residue, S—C _1-4 -aliphatic residue or O—C _1-4 -aliphatic residue, wherein the C _{1- 4} -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, ═O, OH and O—C _{1- 4} -aliphatic residue, R ³ denotes C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C1-4-aliphatic residue, OCF3, SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 -aliphatic group, or R ³ denotes S—R ⁵ or O—R ⁶ , wherein R ⁵ and R ⁶ in each case denote C _1-8 - aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, or in each case denote C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and O—C _1-4 - aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue in each case may be linked via an unsubstituted C _1-4 - aliphatic group, on the condition that if R ⁵ or R ⁶ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, or R ³ denotes N(R ⁷ R ⁸ ), wherein R ⁷ denotes C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ and C _1-4 - aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, or denotes C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , C(═O)—O—C _1-4 - aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and O—C _1-4 - aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue is in each case linked via an unsubstituted C _1-4 -aliphatic group, on the condition that if R ⁷ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, and R ⁸ denotes unsubstituted C _1-4 -aliphatic residue, or R ⁷ and R ⁸ form together with the nitrogen atom connecting them a 3 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF ₃ and O—C _1-4 -aliphatic residue, and wherein the 3 to 7 membered heterocycloaliphatic residue formed by R ⁷ and R ⁸ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, C _1-4 - aliphatic residue, C(═O)OH, benzyl, phenyl, and pyridyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, and O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OCH ₃ , OCF ₃ , OCH ₂ CH ₂ OH, O CH ₂ CH ₂ OCH ₃ , SH, SCF ₃ , CF ₃ and C _1-4 -aliphatic residue; and each R ⁴ independently represents H, F, Cl, Br, CN, CF ₃ , OCF ₃ , CH ₃ , OCH ₃ or S(═O) ₂ CH ₃ . [0303] In further embodiments, the Kv7 channel activator is selected from the group consisting of:12-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1, 5]naphthyridine- 3-carboxylic acid amide; 22-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl- [1,5]naphthyridine-3-carboxylic acid amide; 3-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 4-methyl-[1,6]naphthyridine-3-carboxylic acid amide; 42-Ethylsulfanyl-N-[(4- fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxyl ic acid amide; 52- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,7]naph thyridine-3-carboxylic acid amide; 6-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,7]na phthyridine-3- carboxylic acid amide; 72-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl- [1,8]naphthyridine-3-carboxylic acid amide; 82-Ethylsulfanyl-N-[(4-fluorophenyl)- methyl]-4-methyl-[1,8]naphthyridine-3-carboxylic acid amide; 92-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,8]naph thyridine-3-carboxylic acid amide; 102-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(tr ifluoromethyl)- [1,8]naphthyridine-3-carboxylic acid amide; 112-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-4-methyl-7-(trifluoromethyl)-[1,6]naphthyridine-3-ca rboxylic acid amide; 122- Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(triflu oromethyl)-[1,6]naphthyridine- 3-carboxylic acid amide; 132-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7- (trifluoromethyl)-[1,5]naphthyridine-3-carboxylic acid amide; 142-Ethylsulfanyl-N-[(4- fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naph thyridine-3-carboxylic acid amide; 155-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-7-methyl-thien o[3,2-b]pyridine-6- carboxylic acid amide; 166-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl- thieno[2,3-b]pyridine-5-carboxylic acid amide; 175-Ethoxy-N-[(3-fluorophenyl)-methyl]- 7-methyl-2-(trifluoromethyl)-thieno[3,2-b]pyridine-6-carboxy lic acid amide; 186-Ethoxy- N-[(3-fluorophenyl)-methyl]-4-methyl-2-(trifluoromethyl)-thi eno[2,3-b]pyridine-5- carboxylic acid amide; in the form of a free compound, a solvate and/or a physiologically acceptable salt. Formula 20 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 20. Such compounds are described in US Patent No. 9,284,286 issued March 15, 2016 and corresponding to US Application No.14/091.373 filed November 27, 2013; International Publication No. WO2014082737A1, published June 5, 2014 and corresponding to International Application No. PCT/EP2013/003572 filed November 27, 2013; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 20, these references incorporated by reference herein control. [0304] In an embodiment, the Kv7 channel activator is a compound according to formula 20: Formula 20 wherein: A ¹ represents CR ¹⁰ R ¹¹ or S; A ² represents CR ¹² R ¹³ , C(═O), O, S, S(═O) or S(═O) ₂ ; A ³ , A ⁴ and A ⁵ independently of each other represent CR ⁷ , N, O, S or NR ⁸ , A ⁶ represents CR ⁷ or N, and n denotes 0 or 1, with the proviso, that if n denotes 0, then precisely one of A ³ , A ⁴ and A ⁵ represents O, S or NR ⁸ , or if n denotes 1, then A ³ , A ⁴ and A ⁵ independently of each other represent CR ⁷ or N; and with the proviso, that if n denotes 1 and A ³ , A ⁴ and A ⁵ each represent CR ⁷ , then A ⁶ does not represent N; R ¹ represents C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; C3-10- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² , R ³ ; R ⁴ , R ⁵ , R ¹⁰ , R ¹¹ , R ¹² and R ¹³ each independently of another represent H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OH; OCF ₃ ; SH; SCF ₃ ; C _1-10 -aliphatic residue, O—C _1-10 -aliphatic residue or S—C _1-10 -aliphatic residue, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; or C _3-10 -cycloaliphatic residue, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; or R ² and R ³ or R ⁴ and R ⁵ or R ¹⁰ and R ¹¹ or R ¹² and R ¹³ or R ² and R ¹¹ or R ² and R ⁴ or R ² and R ¹³ or R ⁴ and R ¹³ or R ⁴ and R ¹¹ or R ¹² and R ¹³ , together with the carbon atom(s) joining them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; wherein the remaining substituents R ² , R ³ ; R ⁴ ; R ⁵ ; R ¹⁰ , R ¹¹ , R ¹² and R ¹³ in each case have the meaning given above; R ⁶ represents a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; or represents an aryl or a heteroaryl, in each case unsubstituted or mono- or poly-substituted; each R ⁷ independently of each other represents H, F; Cl; CN; CF ₃ ; CHF ₂ ; CH ₂ F; OCF ₃ ; OCHF ₂ ; OCH ₂ F; SCF ₃ ; O—C _1-4 - aliphatic residue, C _1-4 -aliphatic residue or S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; and R ⁸ represents H or a C _1-4 - aliphatic residue, wherein the aliphatic residue may be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; in which an “aliphatic group” and “aliphatic residue” may in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” may in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group”, an “aliphatic residue”, a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , NH—C(═O)—C _1-4 aliphatic residue, N(C _1-4 -aliphatic residue)-C(═O)—C _1-4 -aliphatic residue, NH—S(═O) ₂ —C _1-4 -aliphatic residue, N(C _1-4 -aliphatic residue)-S(═O) ₂ —C _1-4 - aliphatic residue, ═O, OH, OCF ₃ , O—C _1-4 -aliphatic residue, O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , S—C _1-4 -aliphatic residue, S(═O) ₂ OH, S(═O) ₂ —C _1-4 -aliphatic residue, S(═O) ₂ —O—C _1-4 -aliphatic residue, S(═O) ₂ —NH(C _1-4 -aliphatic residue), S(═O) ₂ —N(C _1-4 -aliphatic residue) ₂ , CN, CF ₃ , CHO, COOH, C _1-4 -aliphatic residue, C(═O)—C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue, C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH ₂ , a C(═O)—NH(C _1-4 -aliphatic residue) and C(═O)—N(C _1-4 -aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , NH—C(═O)—C _1-4 -aliphatic residue, N(C _1-4 aliphatic residue)-C(═O)—C _1-4 aliphatic residue, NH—S(═O) ₂ —C _{1- 4} aliphatic residue, N(C _1-4 aliphatic residue)-S(═O) ₂ —C _1-4 aliphatic residue, OH, OCF ₃ , O—C _1-4 -aliphatic residue, O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , S—C _1-4 - aliphatic residue, S(═O) ₂ OH, S(═O) ₂ —C _1-4 -aliphatic residue, S(═O) ₂ —O—C _1-4 -aliphatic residue, S(═O) ₂ —NH(C _1-4 -aliphatic residue), S(═O) ₂ —N(C _1-4 -aliphatic residue) ₂ , CN, CF ₃ , C(═O)H, C(═O)OH, C _1-4 -aliphatic residue, C(═O)—C _1-4 -aliphatic residue, C(═O)— O—C _1-4 -aliphatic residue, C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH ₂ , C(═O)—NH(C _1-4 - aliphatic residue) and C(═O)—N(C _1-4 -aliphatic residue) ₂ ; in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a free compound, a solvate and/or a physiologically acceptable salt. [0305] In further embodiments, A ¹ represents CR ¹⁰ R ¹¹ or S; A ² represents CR ¹² R ¹³ , C(═O), O, S, S(═O) or S(═O) ₂ ; A ³ , A ⁴ and A ⁵ independently of each other represent CR ⁷ , N, O, S or NR ⁸ , A ⁶ represents CR ⁷ or N, and n denotes 0 or 1, with the proviso, that if n denotes 0, then precisely one of A ³ , A ⁴ and A ⁵ represents O, S or NR ⁸ , or if n denotes 1, then A ³ , A ⁴ and A ⁵ independently of each other represent CR ⁷ or N; and with the proviso, that if n denotes 1 and A ³ , A ⁴ and A ⁵ each represent CR ⁷ , then A ⁶ does not represent N; R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C _3-6 - cycloaliphatic residue and a 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-10 - cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case be optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 cycloaliphatic residue, 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , and wherein the C _3-6 - cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN and C(═O)OH, R ² , R ³ , R ⁵ , R ¹⁰ , R ¹¹ , R ¹² and R ¹³ each independently of the others represents H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OH; OCF ₃ ; SH; SCF ₃ ; C _1-4 -aliphatic residue, O—C _1-4 -aliphatic residue or S—C _1-4 - aliphatic residue, in each case saturated or unsaturated, branched or unbranched, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, or a C _3-10 -cycloaliphatic residue, saturated or unsaturated, branched or unbranched, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue may in each case optionally linked via a C _1- 4-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, or R ² and R ³ or R ⁴ and R ⁵ or R ¹⁰ and R ¹¹ or R ¹² and R ¹³ or R ² and R ¹¹ or R ² and R ⁴ or R ² and R ¹³ or R ⁴ and R ¹³ or R ⁴ and R ¹¹ or R ¹² and R ¹³ , together with the carbon atom(s) joining them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated and in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _{1- 4} -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the remaining substituents R ² , R ³ , R ⁴ , R ⁵ , R ¹⁰ , R ¹¹ , R ¹² and R ¹³ in each case have the meaning given above; R ⁶ represents a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated and in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C _3-6 - cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-10 - cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, or represents an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, be y, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, NH(C1-4- aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O— C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN and C(═O)OH, each R ⁷ independently of each other represents H, F; Cl; CN; CF ₃ ; CHF ₂ ; CH ₂ F; OCF ₃ ; OCHF ₂ ; OCH ₂ F; SCF ₃ ; a O—C _1-4 -aliphatic residue, a C _1-4 -aliphatic residue or a S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue. and R ⁸ represents H or C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and O—C _1-4 -aliphatic residue. [0306] In further embodiments, A ¹ represents S; and A ² represents S, S(═O) ₂ or CR ¹² R ¹³ , wherein R ¹² and R ¹³ both represent H or both represent F. [0307] In further embodiments, n denotes 1 and A ³ represents CR ⁷ , A ⁴ represents CR ⁷ , A ⁵ represents CR ⁷ and A ⁶ represents CR ⁷ ; or n denotes 1 and A ³ represents N, A ⁴ represents CR ⁷ , A ⁵ represents CR ⁷ and A ⁶ represents CR ⁷ ; or n denotes 1 and A ³ represents CR ⁷ , A ⁴ represents N, A ⁵ represents CR ⁷ and A ⁶ represents CR ⁷ ; or n denotes 1 and A ³ represents CR ⁷ , A ⁴ represents CR ⁷ , A ⁵ represents N and A ⁶ represents CR ⁷ ; or n denotes 1 and A ³ represents N, A ⁴ represents N, A ⁵ represents CR ⁷ and A ⁶ represents CR ⁷ ; or n denotes 1 and A ³ represents N, A ⁴ represents CR ⁷ , A ⁵ represents N and A ⁶ represents CR ⁷ ; or n denotes 1 and A ³ represents N, A ⁴ represents CR ⁷ , A ⁵ represents CR ⁷ and A ⁶ represents N; or n denotes 1 and A ³ represents CR ⁷ , A ⁴ represents N, A ⁵ represents CR ⁷ and A ⁶ represents N; or n denotes 1 and A ³ represents CR ⁷ , A ⁴ represents N, A ⁵ represents N and A ⁶ represents CR ⁷ ; or n denotes 1 and A ³ represents CR ⁷ , A ⁴ represents CR ⁷ , A ⁵ represents N and A ⁶ represents N; or n denotes 0 and A ³ represents S, A ⁴ represents CR ⁷ and A ⁵ represents CR ⁷ ; or n denotes 0 and A ³ represents S, A ⁴ represents CR ⁷ and A ⁵ represents N; or n denotes 0 and A ³ represents O, A ⁴ represents CR ⁷ and A ⁵ represents CR ⁷ , or n denotes 0 and A ³ represents O, A ⁴ represents CR ⁷ and A ⁵ represents N; or n denotes 0 and A ³ represents CR ⁷ , A ⁴ represents CR ⁷ and A ⁵ represents S; or n denotes 0 and A ³ represents N, A ⁴ represents CR ⁷ and A ⁵ represents S; or n denotes 0 and A ³ represents CR ⁷ , A ⁴ represents CR ⁷ and A ⁵ represents O; or n denotes 0 and A ³ represents N, A ⁴ represents CR ⁷ and A ⁵ represents O. [0308] In further embodiments, R ¹ represents the partial structure: wherein: R ^14a and R ^14b each independently of the other represent H; F; Cl; Br; CF ₃ ; CN; OH; OCF ₃ ; NH ₂ ; C _1-4 -aliphatic residue, O—C _1-4 -aliphatic residue, NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, OH and OCF ₃ ; or independently represent C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, C _1-4 - aliphatic residue, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue) and N(C _1-4 -aliphatic residue) ₂ ; m represents 0, 1, 2 or 3; Y represents O or NR ¹⁵ , wherein R ¹⁵ represents H or C _1-4 -aliphatic residue, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, C _1-4 -aliphatic residue, OH, O—C _1-4 -aliphatic residue, OCF ₃ , NH ₂ , NH(C _1-4 - aliphatic residue) and N(C _1-4 -aliphatic residue) ₂ ; or C _3-10 -cycloaliphatic residue, saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, C _1-4 -aliphatic residue, OH, O—C _1-4 -aliphatic residue, OCF ₃ , NH ₂ , NH(C _1-4 - aliphatic residue) and N(C _1-4 -aliphatic residue) ₂ ; o represents 0 or 1, B represents C _1-8 - aliphatic residue, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, CN, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , C(═O)OH, CF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue) and N(C _1-4 -aliphatic residue) ₂ ; or C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated, unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, CN, OH, O—C _1-4 -aliphatic residue, OCF ₃ , C _1-4 - aliphatic residue, C(═O)—OH, CF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ and SCF ₃ ; or aryl or heteroaryl, in each case unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, NO ₂ , CN, OH, O—C _1-4 -aliphatic residue, OCF ₃ , C _1-4 -aliphatic residue, C(═O)OH, CF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , S—C _1-4 -aliphatic residue, SCF ₃ , benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly- substituted by one or more substituents selected independently of one another from the group consisting of F, Cl, Br, NO ₂ , CN, OH, O—C _1-4 -aliphatic residue, OCF ₃ , C _1-4 - aliphatic residue, C(═O)—OH, CF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , S—C _1-4 -aliphatic residue and SCF ₃ . [0309] In further embodiments, R ^14a and R ^14b each independently of the other represents H; F; Cl; CH ₃ ; CH ₂ CH ₃ ; (CH ₂ ) ₂ CH ₃ ; CH(CH ₃ ) ₂ ; (CH ₂ ) ₃ CH ₃ ; CH(CH) ₃ CH ₂ CH ₃ ; C(CH ₃ ) ₃ ; OH; OCH ₃ ; OCH ₂ CH ₃ ; O(CH ₂ ) ₂ OCH ₃ or O(CH ₂ ) ₂ OH; m represents 0, 1 or 2 and represents 0 and B represents CH ₃ ; CH ₂ CH ₃ ; (CH ₂ ) ₂ CH ₃ ; CH(CH ₃ ) ₂ ; (CH ₂ ) ₃ CH ₃ ; CH(CH ₃ )CH ₂ CH ₃ ; C(CH ₃ ) ₃ ; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl; phenyl, pyridyl or thienyl, in each case unsubstituted or mono-, di- or tri-substituted by one, two or three substituents each selected independently of one another from the group consisting of F, Cl, CN, OH, O— C _1-4 -aliphatic residue, OCF ₃ , C _1-4 -aliphatic residue, CF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue) and N(C _1-4 -aliphatic residue) ₂ . [0310] In further embodiments, R ² ; R ³ ; R ⁴ ; R ⁵ ; R ¹⁰ , R ¹¹ , R ¹² and R ¹³ each independently of the others represents H; F; Cl; CF ₃ ; CN; OH; OCF ₃ ; SCF ₃ ; CH ₃ ; CH ₂ CH ₃ ; (CH ₂ ) ₂ CH ₃ ; CH(CH ₃ ) ₂ ; (CH ₂ ) ₃ CH ₃ ; CH(CH) ₃ CH ₂ CH ₃ ; C(CH ₃ ) ₃ ; OCH ₃ ; OCH ₂ CH ₃ ; O(CH ₂ ) ₂ OCH ₃ ; O(CH ₂ ) ₂ OH; SCH ₃ ; SCH ₂ CH ₃ ; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; or R ² and R ³ or R ⁴ and R ⁵ or R ¹⁰ and R ¹¹ or R ¹² and R ¹³ or R ² and R ¹¹ or R ² and R ⁴ or R ² and R ¹³ or R ⁴ and R ¹³ or R ⁴ and R ¹¹ or R ¹² and R ¹³ , together with the carbon atom(s) joining them, form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted; wherein the remaining substituents R ² , R ³ ; R ⁴ ; R ⁵ ; R ¹⁰ , R ¹¹ , R ¹² and R ¹³ in each case have the meaning given above. [0311] In further embodiments, each R ⁷ represents H, F; Cl; CN; CF ₃ ; CHF ₂ ; CH ₂ F; OCF ₃ ; OCHF ₂ ; OCH ₂ F; SCF ₃ ; CH ₃ ; CH ₂ CH ₃ ; CH ₂ CH ₂ CH ₃ ; CH(CH ₃ ) ₂ ; OH ₂ CH ₂ CH ₂ CH ₃ ; CH(CH) ₃ CH ₂ CH ₃ ; CH ₂ CH(CH ₃ ) ₂ ; O(CH ₃ ) ₃ ; OCH ₃ ; OCH ₂ CH ₃ ; O(CH ₂ ) ₂ OCH ₃ ; O(CH ₂ ) ₂ OH; S(═O) ₂ CH ₃ S(═O) ₂ CH ₂ CH ₃ S(═O) ₂ CH(CH ₃ ) ₂ or S(═O) ₂ CH ₂ CH ₂ CH ₃ ; and R ⁸ represents H or CH ₃ or CH ₂ CH ₃ or CH(CH ₃ ) ₂ . [0312] In further embodiments, R ⁶ represents a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO ₂ , CN, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , C _1-4 -aliphatic residue, CF ₃ , SH, S—C _1-4 -aliphatic residue and SCF ₃ ; or an aryl or a heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO ₂ , CN, OH, O—C _1-4 -aliphatic residue, OCF ₃ , C _1-4 -aliphatic residue, CF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 - aliphatic residue) ₂ , SH, S—C _1-4 -aliphatic residue and SCF ₃ . [0313] In further embodiments, R ⁶ represents phenyl, pyridyl or thienyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, CN, OH, O—C _1-4 - aliphatic residue, OCF ₃ , C _1-4 -aliphatic residue, CF ₃ and SCF ₃ . [0314] In further embodiments, A ¹ represents S; and A ² represents S, S(═O) ₂ or CR ¹² R ¹³ , wherein R ¹² and R ¹³ both represent H or both represent F; and R ¹ represents the partial structure: wherein: R ^14a and R ^14b each independently of the other represents H; F; Cl; CH ₃ ; CH ₂ CH ₃ ; (CH ₂ ) ₂ CH ₃ ; CH(CH ₃ ) ₂ ; (OH ₂ ) ₃ CH ₃ ; CH(CH) ₃ CH ₂ CH ₃ ; C(CH ₃ ) ₃ ; OH; OCH ₃ ; OCH2CH3; O(CH2)2OCH3; or O(CH2)2OH; m represents 0, 1 or 2 and B represents phenyl or naphthyl or pyridyl or thienyl, in each case unsubstituted or mono- or di- or tri- substituted by one, two or three substituents each selected independently of one another from the group consisting of F, Cl, CN, OH, O- _1-4 -aliphatic residue, OCF ₃ , C _1-4 - aliphatic residue, C(═O)—OH, CF ₃ , NH ₂ , NH(C _1-4 -aliphatic residue) and N(C _1-4 -aliphatic residue) ₂ ; R ² , R ³ , R ⁴ ; R ⁵ , R ¹⁰ , R ¹¹ , R ¹² and R ¹³ each independently of the others represent H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OH; OCF ₃ ; SH; SCF ₃ ; CH ₃ ; CH ₂ CH ₃ ; CH ₂ CH ₂ CH ₃ ; CH(CH ₃ ) ₂ ; CH ₂ CH ₂ CH ₂ CH ₃ ; CH(CH) ₃ CH ₂ CH ₃ ; CH ₂ CH(CH ₃ ) ₂ ; C(CH ₃ ) ₃ ; OCH ₃ ; OCH ₂ CH ₃ ; O(CH ₂ ) ₂ OCH ₃ ; O(CH ₂ ) ₂ OH; SCH ₃ ; SCH ₂ CH ₃ ; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; or R ² and R ³ or R ⁴ and R ⁵ or R ¹⁰ and R ¹¹ or R ¹² and R ¹³ or R ² and R ¹¹ or R ² and R ⁴ or R ² and R ¹³ or R ⁴ and R ¹³ or R ⁴ and R ¹¹ or R ¹² and R ¹³ , together with the carbon atom(s) joining them, form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted; wherein the remaining substituents R ² , R ³ ; R ⁴ ; R ⁵ ; R ¹⁰ , R ¹¹ , R ¹² and R ¹³ in each case have the meaning given above; R ⁶ represents phenyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, OCH ₃ , OCH ₂ CH ₃ , OCF ₃ , CH ₃ , CH ₂ CH ₃ , CH(CH ₃ ) ₂ and CF ₃ ; each R ⁷ represents H, F; CI; CN; CF3; CHF2; CH2F; OCF3; OCHF2; OCH2F; SCF3; CH3; CH ₂ CH ₃ ; CH ₂ CH ₂ CH ₃ ; CH(CH ₃ ) ₂ ; CH ₂ CH ₂ CH ₂ CH ₃ ; CH(CH) ₃ CH ₂ CH ₃ ; CH ₂ CH(CH ₃ ) ₂ ; C(CH ₃ ) ₃ ; OCH ₃ ; OCH ₂ CH ₃ ; O(CH ₂ ) ₂ OCH ₃ ; O(CH ₂ ) ₂ OH; S(═O) ₂ CH ₃ S(═O) ₂ CH ₂ CH ₃ , S(═O) ₂ CH(CH ₃ ) ₂ or S(═O) ₂ CH ₂ CH ₂ CH ₃ ; and R ⁸ represents H or CH ₃ or CH ₂ CH ₃ or CH(CH ₃ ) ₂ . [0315] In further embodiments, the Kv7 channel activator is selected from the group consisting of: 12-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-m ethyl-butyl)- benzamide; 2 N-(3,3-Dimethyl-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl] -benzamide; 3 3-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-me thyl-butyl)-pyridine-2- carboxylic acid amide; 43-[2-(Benzenesulfonyl)-ethylsulfanyl]-N-(thiophen-2-yl-meth yl)- pyridine-2-carboxylic acid amide; 54-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N- (3-methyl-butyl)-pyridine-3-carboxylic acid amide; 64-[[3,3-Difluoro-3-(4-fluorophenyl)- propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carb oxylic acid amide; 73-[[3,3- Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-methyl-but yl)-pyridine-4-carboxylic acid amide; 83-[2-(Benzenesulfonyl)-ethylsulfanyl]-N-(thiophen-2-yl-meth yl)-pyridine-4- carboxylic acid amide; 93-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-m ethyl- butyl)-pyrazine-2-carboxylic acid amide; 104-[[3,3-Difluoro-3-(4-fluorophenyl)- propyl]sulfanyl]-N-(3-methyl-butyl)-pyrimidine-5-carboxylic acid amide; 114-[[3,3- Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(4-fluorophe nyl)-methyl]-pyrimidine-5- carboxylic acid amide; 123-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3- methyl-butyl)-pyridazine-4-carboxylic acid amide; 133-[[3,3-Difluoro-3-(4-fluorophenyl)- propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridazine-4-ca rboxylic acid amide; 144- [[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(4-flu orophenyl)-methyl]-thiazole-5- carboxylic acid amide; 154-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(4 - fluorophenyl)-methyl]-2-methyl-thiazole-5-carboxylic acid amide; in the form of a free compound, a solvate and/or a physiologically acceptable salt. Formula 21 [0316] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in US Publication No. US20140148454A1, published May 29, 2014 and corresponding to US Application No. 14/091,378 filed November 27, 2013; International Publication No. WO2014082739A1, published June 5, 2014 and corresponding to International Application No. PCT/EP2013/003574 filed November 27, 2013; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 21, these references incorporated by reference herein control. [0317] In an embodiment, the Kv7 channel activator is a compound according to formula 21: Formula 21 wherein, A ¹ represents CR ⁵ or N; A ² represents CR ⁶ , N, O, S or NR ⁷ ; A ³ represents CR ⁸ or N, and n denotes 0 or 1, on the condition, that if n denotes 0, then A ² represents O, S or NR ⁷ , or if n denotes 1, then A ² represents CR ⁶ or N, wherein R ⁵ is selected from F, Cl, Br, CN, CH3, CF3, CHF2, CH2F, OCH3, C2H5, SCH3, OCF3, OCHF2 or OCH2F; R ⁶ is selected from H, F, Cl, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; R ⁷ represents C _1-4 -aliphatic residue or C _3-5 -cycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted; R ⁸ is selected from H, F, Cl, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; with the proviso, that, if n denotes 1, then at least one of A ¹ , A ² and A ³ denotes N, with the proviso, that if n denotes 1 and A ³ denotes N, then A ¹ and/or A ² denotes N, and with the proviso, that if n denotes 1 and A ² denotes N and A ¹ denotes CR ⁵ and A ³ denotes CR ⁸ , then R ⁵ denotes F, Cl, CH ₃ , CF ₃ , CHF ₂ or CH ₂ F; R ¹³ represents H or C _1-4 -aliphatic residue, R ¹ represents C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; or C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; or aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C1-4-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted, or denotes S—R ⁹ , O—R ¹⁰ or N(R ¹¹ R ¹² ), wherein R ⁹ and R ¹⁰ in each case represent C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted; C _3-6 - cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso, that if R ⁹ or R ¹⁰ denote a 3 to 7 membered heterocycloaliphatic residue, than the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, R ¹¹ represents C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted; C _3-6 - cycloaliphatic residue or a 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso that if R ¹¹ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom; and R ¹² denotes C _{1- 6} -aliphatic residue, unsubstituted or mono- or polysubstituted; or R ¹¹ and R ¹² form together with the nitrogen atom connecting them a 3 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; R ³ represents C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; or C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; or aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ³ denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom; and R ⁴ denotes H or C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; or R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; in which an “aliphatic group” and “aliphatic residue” may in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” may in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group”, an “aliphatic residue”, a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , NH—C(═O)—C _1-4 - aliphatic residue, N(C _1-4 aliphatic residue)-C(═O)—C _1-4 aliphatic residue, NH—S(═O) ₂ — C _1-4 aliphatic residue, N(C _1-4 aliphatic residue)-S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , O—C _1-4 -aliphatic residue, O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , S—C _1-4 - aliphatic residue, S(═O) ₂ OH, S(═O) ₂ —C _1-4 -aliphatic residue, S(═O) ₂ —O—C _1-4 -aliphatic residue, S(═O) ₂ —NH(C _1-4 -aliphatic residue), S(═O) ₂ —N(C _1-4 -aliphatic residue) ₂ , CN, CF ₃ , CHO, COOH, C _1-4 -aliphatic residue, C(═O)—C _1-4 -aliphatic residue, C(═O)—O— C _1-4 -aliphatic residue, C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, C(═O)NH ₂ , a C(═O)—NH(C _1-4 -aliphatic residue) and C(═O)—N(C _1-4 -aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , NH—C(═O)—C _1-4 -aliphatic residue, N(C _1-4 aliphatic residue)-O(═O)—C _{1- 4} aliphatic residue, NH—S(═O) ₂ —C _1-4 aliphatic residue, N(C _1-4 aliphatic residue)- S(═O)2—C1-4 aliphatic residue, OH, OCF3, O—C1-4-aliphatic residue, O—C(═O)—C1-4- aliphatic residue, SH, SCF ₃ , S—C _1-4 -aliphatic residue, S(═O) ₂ OH, S(═O) ₂ —C _1-4 - aliphatic residue, S(═O) ₂ —O—C _1-4 -aliphatic residue, S(═O) ₂ —NH(C _1-4 -aliphatic residue), S(═O) ₂ —N(C _1-4 -aliphatic residue) ₂ , CN, CF ₃ , C(═O)H, C(═O)OH, C _1-4 -aliphatic residue, C(═O)—C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue, C _3-6 - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH ₂ , C(═O)—NH(C _1-4 -aliphatic residue) and C(═O)—N(C _1-4 -aliphatic residue) ₂ ; in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a free compound, a solvate and/or a physiologically acceptable salt. [0318] In further embodiments, A ¹ represents CR ⁵ or N; A ² represents CR ⁶ , N, O, S or NR ⁷ ; A ³ represents CR ⁸ or N, and n denotes 0 or 1, on the condition, that if n denotes 0, then A ² represents O, S or NR ⁷ , or if n denotes 1, then A ² represents CR ⁶ or N, wherein R ⁵ is selected from F, Cl, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; R ⁶ is selected from H, F, Cl, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; R ⁷ represents C _1-4 -aliphatic residue or C _3-5 - cycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, R ⁸ is selected from H, F, Cl, Br, CN, CH ₃ , CF ₃ , CHF ₂ , CH ₂ F, OCH ₃ , C ₂ H ₅ , SCH ₃ , OCF ₃ , OCHF ₂ or OCH ₂ F; with the proviso, that, if n denotes 1, then at least one of A ¹ , A ² and A ³ denotes N, with the proviso, that if n denotes 1 and A ³ denotes N, then A ¹ and/or A ² denotes N, and with the proviso, that if n denotes 1 and A ² denotes N and A ¹ denotes CR ⁵ and A ³ denotes CR ⁸ , then R ⁵ denotes F, Cl, CH ₃ , CF ₃ , CHF ₂ or CH ₂ F; R ¹³ represents H or C _1-4 -aliphatic residue, R ¹ denotes C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C _3-6 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, zyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)—OCH ₃ and C(═O)—OC ₂ H ₅ , and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 - aliphatic residue), an N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O— C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN and C(═O)OH, R ² denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, or denotes C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 - aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O— C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 - aliphatic residue and C(═O)OH, or denotes S—R ⁹ , O—R ¹⁰ or N(R ¹¹ R ¹² ); wherein R ⁹ and R ¹⁰ in each case represent C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, or in each case represent C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocyclo-aliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C _3-6 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 - cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), an N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C1-4-aliphatic residue)2, OH, ═O, O—C1-4-aliphatic residue, OCF3, SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, on the condition that if R ⁹ or R ¹⁰ denote a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, R ¹¹ denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)— O—C _1-4 -aliphatic residue, and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O— C _1-4 -aliphatic residue, or denotes C _3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)—O—C _1-4 -aliphatic residue, C _3-6 -cycloaliphatic residue, and a 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C1-4-aliphatic residue and C(═O)OH, on the condition that if R ¹¹ denotes a 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, and R ¹² denotes C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 aliphatic residue, or R ¹¹ and R ¹² form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)—OH, C _3-6 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 - aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ¹¹ and R ¹² together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)— OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—OCH ₃ and C(═O)—OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _{3- 6} -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, R ³ denotes C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)— O—C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 - aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)—O—C _1-4 -aliphatic residue, C _3-6 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C _1-4 - aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, on the condition that if R ³ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , OCH ₂ CH ₂ OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _{3- 6} -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), an N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a C _1-4 -aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O— C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN and C(═O)OH, R ⁴ denotes H or C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, or R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C _3-6 -cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 - cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, NH(C1-4- aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, , phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , ═O, OH, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 -aliphatic residue), N(C1-4-aliphatic residue)2, OH, O—C1-4-aliphatic residue, OCF3, OCH2CH2OH, OCH ₂ OCH ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _{3- 6} -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 - aliphatic residue), N(C _1-4 -aliphatic residue) ₂ , OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , CN, C _1-4 -aliphatic residue and C(═O)OH. [0319] In further embodiments, the compound is according to formula 21 wherein n denotes 0 and is according to the formula:

wherein, A ² represents O and A ³ represents CR ⁸ ; or A ² represents S and A ³ represents CR ⁸ ; or A ² represents NR ⁷ and A ³ represents CR ⁸ ; or A ² represents O and A ³ represents N; or A ² represents S and A ³ represents N; or A ² represents NR ⁷ and A ³ represents N. [0320] In further embodiments, the compound is according to formula 21 wherein n denotes 1 and is according to the formula: wherein: A ¹ represents N and A ² represents CR ⁶ and A ³ represents CR ⁸ ; or A ¹ represents CR ⁵ and A ² represents N and A ³ represents CR ⁸ ; or A ¹ represents N and A ² represents N and A ³ represents CR ⁸ ; or A ¹ represents N and A ² represents CR ⁶ and A ³ represents N; or A ¹ represents CR ⁵ and A ² represents N and A ³ represents N; or A ¹ represents N and A ² represents N and A ³ represents N. [0321] In further embodiments, R ⁵ denotes F, Cl, CH ₃ , OCH ₃ or CH ₂ CH ₃ ; and/or R ⁶ denotes H; and/or R ⁷ denotes CH ₃ , CH ₂ CH ₃ or cyclopropyl; and/or R ⁸ denotes H. [0322] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2, R ^1a and R ^1b each independently of one another represent H, F, Cl, Br, I, O—C _1-4 -aliphatic residue or C _1-4 -aliphatic residue, R ^1c denotes C _1-4 - aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _{1- 4} -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and O—C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 - cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 - aliphatic residue, C(═O)CH3, C(═O)C2H5, C(═O)OCH3 and C(═O)OC2H5, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ C _1-4 -aliphatic residue and C(═O)OH. [0323] In further embodiments, m denotes 1 or 2, R ^1a and R ^1b represent H, R ^1c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or m denotes 0 and R ^1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O— C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O— C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ C _1-4 -aliphatic residue and C(═O)OH. [0324] In further embodiments, R ² is selected from the group consisting of CH ₃ , C ₂ H ₅ , CH ₂ CH ₂ CH ₃ , CH(CH ₃ ) ₂ , CH ₂ CH ₂ CH ₂ CH ₃ , CH ₂ CH(CH ₃ ) ₂ , CH(CH ₃ )CH ₂ CH ₃ , C(CH ₃ ) ₃ , CH ₂ -cyclopropyl, OCH ₃ , OC ₂ H ₅ , OCH ₂ CH ₂ CH ₃ , OCH(CH ₃ ) ₂ , O-cyclopropyl, SCH ₃ , SC ₂ H ₅ , SCH ₂ CH ₂ CH ₃ , SCH(CH ₃ ) ₂ , S-cyclopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N(CH ₃ ) ₂ , N(CH ₃ )C ₂ H ₅ , N(CH ₃ )CH ₂ CH ₂ CH ₃ , N(CH ₃ )CH(CH ₃ ) ₂ , N(CH ₃ )- cyclopropyl, N(C ₂ H ₅ ) ₂ , N(C ₂ H ₅ )CH ₂ CH ₂ CH ₃ , N(C ₂ H ₅ )CH(CH ₃ ) ₂ , N(C ₂ H ₅ )-cyclopropyl, N- aziridinyl, N-azetidinyl, N-pyrrolidinyl, N-piperidinyl or N-morpholinyl, in each case unsubstituted or mono- or polysubstituted with F, OH and/or OCH ₃ . [0325] In further embodiments, R ³ represents the partial structure: wherein: o denotes 0, 1, 2 or 3, R ^3a and R ^3b each independently of one another represent H, F, Cl, Br, I, O—C1-4-aliphatic residue or C1-4-aliphatic residue or together denote ═O, and R ^3c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and O—C _1-4 - aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 - aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and unsubstituted O—C _1-4 - aliphatic residue, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , C _1-4 -aliphatic residue and C(═O)— OH, and R ⁴ denotes H or unsubstituted C _1-4 -aliphatic residue or C _1-4 -aliphatic residue, monosubstituted with OCH ₃ , or R ³ and R ⁴ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, C(═O)OH, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , C _1-4 -aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl, wherein the C _1-4 -aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, CF ₃ and O—C _1-4 -aliphatic residue, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , S—C _1-4 - aliphatic residue, CF ₃ , C _1-4 -aliphatic residue, C(═O)OH and C _3-6 -cycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 - cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , S—C _1-4 -aliphatic residue, CF ₃ , C _1-4 -aliphatic residue and C(═O)OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ³ and R ⁴ together with the nitrogen atom connecting them may optionally be condensed with a C _3-6 -cycloaliphatic residue, or a 3 to 7 membered heterocycloaliphatic residue, wherein the C _3-6 -cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, O—C _1-4 -aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)OH, C(═O)CH ₃ , C(═O)C ₂ H ₆ , C(═O)OCH ₃ and C(═O)OC ₂ H ₆ . [0326] In further embodiments, R ³ represents the partial structure: Wherein, o denotes 0, 1, 2 or 3, R ^3a and R ^3b each independently of one another represent H, F, CH3 or OCH3, or together denote ═O, R ^3c denotes C1-4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, O—C _1-4 -aliphatic residue, and CF ₃ , or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 - aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, and C _1-4 -aliphatic residue, and R ⁴ denotes H, CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ OCH ₃ or CH ₂ CH ₂ CH ₂ OCH ₃ , or R ³ and R ⁴ form together with the nitrogen atom connecting them a heteroaliphatic residue, selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl, tetrahydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2- a]pyrazinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, C(═O)OH, OCH ₃ , OCH ₂ CH ₃ , OCF ₃ , SCF ₃ , CF ₃ , C(═O)CH ₃ , C(═O)OCH ₃ , CH ₂ CF ₃ , CH ₂ OH, CH ₂ OCH ₃ , CH ₂ CH ₂ OCH ₃ , CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ CH ₃ , CH(CH ₃ ) ₂ and cyclopropyl. [0327] In further embodiments, A ¹ represents CR ⁵ , N; A ² represents CR ⁶ , N, O, S or NR ⁷ ; A ³ represents CR ⁸ or N, and n denotes 0 or 1, on the condition, that if n denotes 0, then A ² represents O, S or NR ⁷ , or if n denotes 1, then A ² represents CR ⁶ or N, wherein R ⁵ denotes F, Cl, CH ₃ , OCH ₃ or CH ₂ CH ₃ ; and/or R ⁶ denotes H; and/or R ⁷ denotes CH ₃ , CH ₂ CH ₃ or cyclopropyl; and/or R ⁸ denotes H; with the proviso, that, if n denotes 1, then at least one of A ¹ , A ² and A ³ denotes N, with the proviso, that if n denotes 1 and A ³ denotes N, then A ¹ and/or A ² denotes N, and with the proviso, that if n denotes 1 and A ² denotes N and A ¹ denotes CR ⁵ and A ³ denotes CR ⁸ , then R ⁵ denotes F, Cl, CH ₃ , CF ₃ , CHF ₂ or CH ₂ F; R ¹³ represents H or CH ₃ ; R ¹ represents the partial structure: wherein, m denotes 1 or 2, R ^1a and R ^1b represent H and R ^1c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 -aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or denotes C _3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 - aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or wherein m denotes 0 and R ^1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O— C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ , C(═O)OC ₂ H ₅ , C _3-6 -cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O— C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, C _1-4 -aliphatic residue, C(═O)CH ₃ , C(═O)C ₂ H ₅ , C(═O)OCH ₃ and C(═O)OC ₂ H ₅ , and wherein the C _3-6 -cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ C _1-4 -aliphatic residue and C(═O)OH; R ² is selected from the group consisting of CH ₃ , C ₂ H ₅ , CH ₂ CH ₂ CH ₃ , CH(CH ₃ ) ₂ , CH ₂ CH ₂ CH ₂ CH ₃ , CH ₂ CH(CH ₃ ) ₂ , CH(CH ₃ )CH ₂ CH ₃ , C(CH ₃ ) ₃ , CH ₂ -cyclopropyl, OCH ₃ , OC ₂ H ₅ , OCH ₂ CH ₂ CH ₃ , OCH(CH ₃ ) ₂ , O-cyclopropyl, SCH ₃ , SC ₂ H ₅ , SCH ₂ CH ₂ CH ₃ , SCH(CH ₃ ) ₂ , S-cyclopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N(CH ₃ ) ₂ , N(CH ₃ )C ₂ H ₅ , N(CH ₃ )CH ₂ CH ₂ CH ₃ , N(CH ₃ )CH(CH ₃ ) ₂ , N(CH ₃ )- cyclopropyl, N(C ₂ H ₅ ) ₂ , N(C ₂ H ₅ )CH ₂ CH ₂ CH ₃ , N(C ₂ H ₅ )CH(CH ₃ ) ₂ , N(C ₂ H ₅ )-cyclopropyl, N- aziridinyl, N-azetidinyl, N-pyrrolidinyl, N-piperidinyl or N-morpholinyl, in each case unsubstituted or mono- or polysubstituted with F, OH and/or OCH ₃ ; R ³ represents the partial structure: wherein: denotes 0, 1, 2 or 3, R ^3a and R ^3b each independently of one another represent H, F, CH ₃ or OCH ₃ , or together denote ═O, R ^3c denotes C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, O—C _1-4 -aliphatic residue, and CF ₃ , or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C _1-4 - aliphatic residue, CF ₃ and C _1-4 -aliphatic residue, or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, OH, O—C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , CN, and C _1-4 -aliphatic residue, and R ⁴ denotes H, CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ OCH ₃ or CH ₂ CH ₂ CH ₂ OCH ₃ , or R ³ and R ⁴ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl, tetrahydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]-pyrazinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, C(═O)OH, OCH ₃ , OCH ₂ CH ₃ , OCF ₃ , SCF ₃ , CF ₃ , C(═O)CH ₃ , C(═O)OCH ₃ , CH ₂ CF ₃ , CH ₂ OH, CH ₂ OCH ₃ , CH ₂ CH ₂ OCH ₃ , CH ₃ , CH ₂ CH ₃ , CH ₂ CH ₂ CH ₃ , CH(CH ₃ ) ₂ and cyclopropyl. [0328] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-6-methyl-2-morph olin-4-yl- pyrimidine-5-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4,6-dimethoxy-2- morpholin-4-yl-pyrimidine-5-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4- ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; N-[(4- Chlorophenyl)-methyl]-2-methyl-6-morpholin-4-yl-4-propyl-pyr idine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-ethoxy-2-methyl-6-morpholin-4-yl-p yridine-3- carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-[(3R)-3-fluoro-pyrrolidin-1-yl]-2- methyl- 6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-3- isopropyl-5-morpholin-4-yl-pyrazine-2-carboxylic acid amide; N-[(4-Chlorophenyl)- methyl]-3-isopropyl-5-morpholin-4-yl-pyridine-2-carboxylic acid amide; 4-Isopropyl-2- (methyl-tetrahydro-pyran-4-yl-amino)-N-[1-[3-(trifluoromethy loxy)-phenyl]-ethyl]-thiazole- 5-carboxylic acid amide; 4-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-methyl-2- morpholin-4-yl-pyrimidine-5-carboxylic acid amide; 4-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 4-Ethylsulfanyl-N- [(4-fluorophenyl)-methyl]-2-methyl-6-morpholin-4-yl-pyridine -3-carboxylic acid amide; N- (4,4-Dimethyl-pentyl)-4-ethylsulfanyl-2-methyl-6-morpholin-4 -yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-2-methyl-6-[(3R) -3-methyl- morpholin-4-yl]-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4- ethylsulfanyl-2-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyri dine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-cyclopropyl-2-methyl-6-morphol in-4-yl-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-methyl-6-morpholin -4- yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-ethoxy-2-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4- dimethylamino-2-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; N-[(4- Chlorophenyl)-methyl]-3-(1-methyl-propyl)-5-morpholin-4-yl-p yrazine-2-carboxylic acid amide; N-(2-Cyclopentyl-ethyl)-3-(1-methyl-propyl)-5-morpholin-4-yl -pyrazine-2- carboxylic acid amide; 4-Isopropyl-2-[methyl-(tetrahydro-pyran-4-yl-methyl)-amino]- N-[1- [3-(trifluoromethyloxy)-phenyl]-ethyl]-thiazole-5-carboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-4-isopropyl-2-(methyl-tetrahydro-pyran -4-yl-amino)-thiazole-5- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-[methyl-(tetrahydr o- pyran-4-yl-methyl)-amino]-thiazole-5-carboxylic acid amide; N-[(4-Chlorophenyl)- methyl]-4-isopropyl-2-morpholin-4-yl-thiazole-5-carboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-4-isopropyl-2-piperidin-1-yl-thiazole- 5-carboxylic acid amide; N- (4,4-Dimethyl-pentyl)-4-isopropyl-2-piperidin-1-yl-thiazole- 5-carboxylic acid amide; N- [(4-Chlorophenyl)-methyl]-4-isopropyl-2-([1,4]oxazepan-4-yl) -thiazole-5-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-([1,4]oxazepan-4-yl)-t hiazole-5-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2-morpholin-4-yl-4-propyl-t hiazole-5- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-isopropyl-2-morpholin-4-yl- oxazole-5-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-isopropyl-2-morpholin-4-yl- oxazole-5-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-5-isopropyl-3-methyl-2- morpholin-4-yl-3H-imidazole-4-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-5- isopropyl-3-methyl-2-morpholin-4-yl-3H-imidazole-4-carboxyli c acid amide; 2-(Methyl- tetrahydro-pyran-4-yl-amino)-4-(trifluoromethyl)-N-[1-[3-(tr ifluoromethyloxy)-phenyl]- ethyl]-thiazole-5-carboxylic acid amide; 2-(Methyl-tetrahydro-pyran-4-yl-amino)-4- (trifluoromethyl)-N-[[3-(trifluoromethyloxy)-phenyl]-methyl] -thiazole-5-carboxylic acid amide; N-[1-(4-Chlorophenyl)-ethyl]-2-(methyl-tetrahydro-pyran-4-yl -amino)-4- (trifluoromethyl)-thiazole-5-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2- (methyl-tetrahydro-pyran-4-yl-amino)-4-(trifluoromethyl)-thi azole-5-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-[methyl-(tetrahydro-pyran-4-yl -methyl)-amino]-4- (trifluoromethyl)-thiazole-5-carboxylic acid amide; 2-Morpholin-4-yl-4-(trifluoromethyl)-N- [[3-(trifluoromethyloxy)-phenyl]-ethyl]-thiazole-5-carboxyli c acid amide; 2-Morpholin-4-yl- 4-(trifluoromethyl)-N-[1-[3-(trifluoromethyloxy)-phenyl]-eth yl]-thiazole-5-carboxylic acid amide; N-[1-(4-Chlorophenyl)-ethyl]-2-morpholin-4-yl-4-(trifluorome thyl)-thiazole-5- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-morpholin-4-yl-4-(trifluoromet hyl)- thiazole-5-carboxylic acid amide; 2-Morpholin-4-yl-4-(trifluoromethyl)-N-[1-[3- (trifluoromethyl)phenyl]-ethyl]-thiazole-5-carboxylic acid amide; in the form of a free compound, a solvate and/or a physiologically acceptable salt. Formula 22 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 22. Such compounds are described in Patent No. 9,278,103 issued March 8, 2016 and corresponding to US Application No.14/230,572 filed March 31, 2014; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 22, this reference incorporated by reference herein controls. [0329] In an embodiment, the Kv7 channel activator is a compound according to formula 22: Formula 22 , wherein, R ¹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents F; Cl; Br; I; CN; CF ₃ ; C(═O)H; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ⁶ represents a C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes, O—R ⁸ , wherein R ⁸ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3- 10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an “aliphatic group” and an “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH— S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O— C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH— C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 - aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C1-4 aliphatic residue)2; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , an NH—C(═O)—C _1-4 aliphatic residue, an NH—S(═O) ₂ —C _1-4 aliphatic residue, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , C(═O)H, C(═O)OH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)— O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH ₂ , a C(═O)—NH(C _{1- 4} aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; said compound being in the form of a free compound, the racemate, a mixture of enantiomers, diastereomers, or of enantiomers and diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of a salt of physiologically acceptable acids or bases. [0330] In further embodiments, R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH)C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue, OH, an O—C _{1- 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)— C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ — O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent sleeted from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN and C(═O)—OH, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, or a O—C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue; a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and an O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 - cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue, R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO2; OCF3; a C1-4-aliphatic residue, a O—C1-4-aliphatic residue, a S—C1-4-aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue; a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 - cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue, R ⁶ denotes a C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue, or R ⁶ denotes O—R ⁸ , wherein R ⁸ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or represent a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1- 4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue. [0331] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R ^12a and R ^12b each independently of one another represent H, F, Cl, Br, I, NO ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(═O)—OH, or together denote ═O, and R ^12c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a S(═O) ₂ —C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1- ₄ aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a S(═O) ₂ —C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, nzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH. [0332] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2 or 3, R ^12a and R ^12b each independently of one another represent H, F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue or together denote ═O, and R ^12c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, CN, a S(═O) ₂ —C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , OCF ₂ H, CF ₃ , CN, a C _1-4 -aliphatic residue, CH ₂ —OH, CH ₂ —OCH ₃ , S(═O) ₂ —CH ₃ , SCF ₃ , NO ₂ , N(C _1-4 aliphatic residue) ₂ , C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _{3- 6} cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, Cl, CH ₃ , O—CH ₃ , CF ₃ and OCF ₃ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH. [0333] In further embodiments, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, or a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue, and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue. [0334] In further embodiments, R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, or a S—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 aliphatic residue. [0335] In further embodiments, R ⁶ denotes a C _2-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(═O)—O—C _1-4 -aliphatic residue, a S—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R ⁶ denotes O—R ⁸ wherein R ⁸ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , CF ₃ , a C(═O)—O—C _1-4 -aliphatic residue, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may be bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C1-4 aliphatic residue, OCF3, SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, on the condition that if R ⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0336] In further embodiments, R ⁶ denotes a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , a S aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case is unsubstituted, or denotes a C _3-10 -cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C _1-4 aliphatic group, on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R ⁶ denotes O—R ⁸ wherein R ⁸ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a C(═O)—O—C _1-4 - aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 aliphatic residue, or in each case denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1- 4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged via an unsubstituted C _1-8 aliphatic group, on the condition that if R ⁷ or R ⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0337] In further embodiments, R ¹ represents the partial structure: wherein: m is 0, 1 or 2, and R ^12a and R ^12b each independently of one another represent H, F, OH, CH ₃ or OCH ₃ , or together denote ═O, R ^12c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, S(═O) ₂ —CH ₃ , an unsubstituted O—C _{1- 4} aliphatic residue, and CF ₃ , or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or wherein m is 0 or 2, and R ^12a and R ^12b each independently of one another represent H, F, OH, CH ₃ or OCH ₃ ; and R ^12c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , OCF ₂ H, CH ₂ — OH, CH ₂ —OCH ₃ , S(═O) ₂ —CH ₃ , SCF ₃ , NO ₂ , N(CH ₃ ) ₂ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH, C(═O)—O— C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)— O—C ₂ H ₅ , R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; CH ₂ —OH; CH ₂ —O—CH ₃ ; CH ₂ —CH ₂ —OH; CH ₂ —CH ₂ —OCH ₃ ; O-methyl; O-ethyl; O—(CH ₂ ) ₂ —O—CH ₃ ; O—(CH ₂ ) ₂ —OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO ₂ ; OCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.- butyl; O-methyl; O-ethyl; O—(CH ₂ ) ₂ —O—CH ₃ ; O—(CH ₂ ) ₂ —OH; S-Methyl; or S-Ethyl, R ⁶ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ —CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), CH ₂ —OCH ₃ , C ₂ H ₄ —OCH ₃ , C ₃ H ₆ —OCH ₃ , cyclopropyl, cyclobutyl, or tetrahydropyranyl, ethenyl or propenyl (—CH ₂ CH═CH ₂ , —CH═CH—CH ₃ , —C((═CH ₂ )—CH ₃ ), in each case unsubstituted, or R ⁶ denotes O—R ⁸ wherein R ⁸ denotes methyl, ethyl, n-propyl, 2- propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, N(C _1-4 aliphatic residue) and an O—C _{1- 4} -aliphatic residue, or in each case denote CH ₂ -cyclopropyl or oxetanyl, wherein the C _{1- 4} -aliphatic residue in each case is unsubstituted. [0338] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpho lin-4-yl- pyridine-3-carboxylic acid amide; 9 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4- yl-2-[(E)-prop-1-enyl]-pyridine-3-carboxylic acid amide; 10 N-[(3-Fluorophenyl)-methyl]- 4-methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide; 19 N-[(3- Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-py ridine-3-carboxylic acid amide; N-[3-Fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-6-m orpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2- isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4- Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-[(E)-prop- 1-enyl]-pyridine-3- carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-prop yl- pyridine-3-carboxylic acid amide 2-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-2- methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethoxy-N-[(4- fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; N- (4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-6-morpholin-4-yl-py ridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpho lin-4-yl-pyridine- 3-carboxylic acid amide; 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)- methyl]-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-2- ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro- phenyl)-methyl]-2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine- 3-carboxylic acid amide; 2- Ethoxy-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl ]-pyridine-3-carboxylic acid amide; 2-Butoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4- yl-pyridine-3- carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2- propoxy-pyridine-3-carboxylic acid amide; 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[[4- (trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide; 2-Ethoxy-4-methyl-6- morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyrid ine-3-carboxylic acid amide; 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl) -pyridine-3-carboxylic acid amide; 2-Methoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl )-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4 - yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-ethoxy-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-2- isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine -3-carboxylic acid amide; N- [(4-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methy l-morpholin-4-yl]- pyridine-3-carboxylic acid amide; 2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)- 3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2- isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine -3-carboxylic acid amide; N- (4,4-Dimethyl-pentyl)-2-methoxy-4-methyl-6-[(3R)-3-methyl-mo rpholin-4-yl]-pyridine-3- carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-[(3R)-3-methyl- morpholin-4-yl]-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-4-methyl- 6-[(3R)-3-methyl-morpholin-4-yl]-2-(1-methyl-propyl)-pyridin e-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin- 4-yl]-2-(1-methyl-propyl)- pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6- [(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)- methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-p yridine-3-carboxylic acid amide; 2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-[(3R)-3-met hyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl- morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]- 2-methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine -3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-met hyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4-methyl-2-(1-methyl- propyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-tert-Butyl-N-(4,4-dimethyl- pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl- pentyl)-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridi ne-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)- 3-methyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl- 6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; 2-Methoxy-4-methyl- 6-[(3R)-3-methyl-morpholin-4-yl]-N-(4,4,4-trifluoro-butyl)-p yridine-3-carboxylic acid amide; 2-Methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-[[4-(t rifluoromethyl)- phenyl]-methyl]-pyridine-3-carboxylic acid amide; 2-tert-Butyl-N-[(3-fluorophenyl)- methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-methyl- morpholin-4-yl]-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl- morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]- 2-(2-fluoro-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-car boxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2-(2,2-difluoro-ethoxy)-4-methyl-6-mor pholin-4-yl-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-(cyclopropyl-methoxy)-4-methyl -6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-(2,2-Difluoro-ethoxy)-N-[(4- fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2-ethoxy-4-methyl-6-[(3R)-3-methyl-mor pholin-4-yl]-pyridine-3- carboxylic acid amide; 2-(Cyclopropyl-methoxy)-N-[(4-fluorophenyl)-methyl]-4-methyl -6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2- isopropyl-6-[(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl -pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-methyl-2-(2-methyl-butyl)-6-morpho lin-4-yl-pyridine-3- carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-(1,1-dimethyl-propyl)-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2- cyclopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridi ne-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-(2-dimethylaminoethyloxy)-4-me thyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-isopropyl-6-[(2S)-2- (methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxyl ic acid amide; N-[(4- Chlorophenyl)-methyl]-2-cyclopropyl-6-[(2S)-2-(methoxymethyl )-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)- methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-car boxylic acid amide; 2- Isopropyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)- phenyl]-methyl]-pyridine-3- carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-2-propyl- pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Isopropyl-4-methyl-6-morpholin-4-yl- N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)- methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-car boxylic acid amide; N-[(3- Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(oxetan-3- yloxy)-pyridine-3- carboxylic acid amide; 4-Methyl-6-morpholin-4-yl-2-propyl-N-(4,4,4-trifluoro-butyl) - pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-4-methyl-6-morpholin- 4-yl-2-propyl-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-4- methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide; 4-Methyl-6- morpholin-4-yl-2-propyl-N-[[4-(trifluoromethyl)-phenyl]-meth yl]-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-prop yl-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin -4- yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-4-methyl-6-morpholin-4- yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[(3- fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; 2- Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin -4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[(3,4-difluoro-phenyl)-methyl]-4-methyl-6-mo rpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[(3,5-difluoro-phenyl)-methyl]-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-4-methyl-6- morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyrid ine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-methyl-6-morphol in-4-yl-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-methyl-2-(1-methyl-propyl)-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-(2-methoxy- ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N- [[4-fluoro-3-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morp holin-4-yl-pyridine-3- carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-(3-methoxy-propyl)-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[[3-fluoro-4- (methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholin-4-yl-py ridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2-(methoxymethyl)-4-methyl-6-mor pholin-4-yl- pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2,4-diisopropyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-(2-methoxy- ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)- methyl]-2,4-diethyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; and N-(4,4- Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-2-tetrahydro-pyra n-4-yl-pyridine-3-carboxylic acid amide, respectively in the form of free compounds; racemic mixtures; mixtures of the enantiomers, diastereomers, or enantiomers and diastereomers in any mixing ratio, or an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases. Formula 23 [0339] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 23. Such compounds are described in US Patent No.9,168,259 issued March 8, 2016 and corresponding to US Application No. 13/449,472 filed April 18, 2012; US Patent No.8,552,200 issued December 12, 2013 and corresponding to US Application No.13/276,464 filed October 19, 2011; International Publication No. WO2012052167A1, published April 26, 2012 and corresponding to International Application No. PCT/EP2011/005265 filed April 26, 2012; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 23, these references incorporated by reference herein control. [0340] In an embodiment, the Kv7 channel activator is a compound according to formula 23: Formula 23 wherein, R ¹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents F; Cl; Br; I; CN; CF ₃ ; C(═O)H; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ⁴ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _{1- 8} aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁴ denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom; R ⁵ denotes H or a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; or R ⁴ and R ⁵ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; R ⁶ represents a C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes S—R ⁷ , O—R ⁸ or N(R ⁹ R ¹⁰ ), wherein R ⁷ and R ⁸ in each case represent a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁷ or R ⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, R ⁹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom; R ¹⁰ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; or R ⁹ and R ¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; in which an “aliphatic group” and an “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O— C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O— C1-4-aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , an NH—C(═O)—C _1-4 aliphatic residue, an NH—S(═O) ₂ —C _{1- 4} aliphatic residue, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , C(═O)H, C(═O)OH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH ₂ , a C(═O)—NH(C _{1- 4} aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; said compound being in the form of a free compound, the racemate, a mixture of enantiomers, diastereomers, or of enantiomers and diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of a salt of physiologically acceptable acids or bases. [0341] In further embodiments, R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1- ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)— C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ — O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN and C(═O)—OH, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, or a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and an O—C _{1- 4} -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C1-4-aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue, R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, a S—C _1-4 - aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue, R ⁴ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1- 4 aliphatic residue), an N(C1-4 aliphatic residue)2, OH, ═O, an O—C1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, a C(═O)—O—C _1-4 -aliphatic residue a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁴ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _{3- 6} cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O— CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN and C(═O)—OH, R ⁵ denotes H or a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or R ⁴ and R ⁵ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _{3- 6} cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with a C _3-10 cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C _3-10 cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , ═O, OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3- 6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, R ⁶ denotes a C _{2- 10} -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue, or R ⁶ denotes S—R ⁷ , O—R ⁸ or N(R ⁹ R ¹⁰ ), wherein R ⁷ and R ⁸ in each case represent a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or in each case represent a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1- 4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁷ or R ⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue, R ⁹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, a C(═O)—O—C _1-4 -aliphatic residue a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue, R ¹⁰ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or R ⁹ and R ¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁹ and R ¹⁰ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _{3- 6} cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, enzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O— CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH. [0342] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R ^12a and R ^12b each independently of one another represent H, F, Cl, Br, I, NO ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF3, CN, a C1-4 aliphatic residue or C(═O)—OH, or together denote ═O, and R ^12c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a S(═O) ₂ —C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a S(═O) ₂ —C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O) —OH. [0343] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2 or 3, R ^12a and R ^12b each independently of one another represent H, F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue or together denote ═O, and R ^12c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, CN, a S(═O) ₂ —C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF3, and a C1-4-aliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , OCF ₂ H, CF ₃ , CN, a C _1-4 -aliphatic residue, CH ₂ —OH, CH ₂ —OCH ₃ , S(═O) ₂ —CH ₃ , SCF ₃ , NO ₂ , N(C _1-4 aliphatic residue) ₂ , C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _{3- 6} cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, Cl, CH ₃ , O—CH ₃ , CF ₃ and OCF ₃ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH. [0344] In further embodiments, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, or a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted aliphatic residue, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue, and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted aliphatic residue. [0345] In further embodiments, R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, or a S—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue. [0346] In further embodiments, R ⁴ represents the partial structure: wherein: n denotes 0, 1, 2, or 3, R ^13a and R ^13b each independently of one another represent H, F, Cl, Br, I, NO ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(═O)—OH, or together denote ═O, and R ^13c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, R ⁵ denotes H or a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or R ⁴ and R ⁵ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, C(═O)—OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _{3- 6} cycloaliphatic residue a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, and pyridyl, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with a C _3-10 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cycclopentyl, or a 3 to 10 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C _{3- 10} cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , ═O, OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ — OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, and C(═O)—OH, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH. [0347] In further embodiments, R ⁴ represents the partial structure: wherein: n denotes 0, 1, 2 or 3, R ^13a and R ^13b each independently of one another represent H, F, Cl, Br, I, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue or together denote ═O, and R ^13c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _{1- 4} -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, Cl, CH ₃ , O—CH ₃ , CF ₃ and OCF ₃ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH, R ⁵ denotes H or an unsubstituted C _1-4 -aliphatic residue or a C _1-4 -aliphatic residue monosubstituted with O-methyl, or R ⁴ and R ⁵ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, C(═O)—OH, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl, wherein the C _1-4 -aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, CF3 and an unsubstituted O—C1-4-aliphatic residue, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , a C _1-4 -aliphatic residue, C(═O)— OH, and a C _3-6 cycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, and wherein the C _3-6 cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with a C _3-6 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl, or a 4 to 7 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C _{3- 6} cycloaliphatic residue or the 4 to 7 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ . [0348] In further embodiments, R ⁶ denotes a C _2-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(═O)—O—C _1-4 -aliphatic residue, a S—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue. on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R ⁶ denotes S—R ⁷ or O—R ⁸ wherein R ⁷ and R ⁸ in each case denote a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , CF ₃ , a C(═O)—O—C _1-4 -aliphatic residue, and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or in each case denote a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _{1- 4} -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may be bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, on the condition that if R ⁷ or R ⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R ⁶ denotes N(R ⁹ R ¹⁰ ), wherein R ⁹ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 -aliphatic residue, CF ₃ , a C(═O)—O—C _1-4 -aliphatic residue, and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case be bridged, preferably is bridged, via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, on the condition that if R ⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, and R ¹⁰ denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or R ⁹ and R ¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _{1- 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁹ and R ¹⁰ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, residue, benzyl, phenyl, thienyl, and pyridyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, and C(═O)—OH. [0349] In further embodiments, R ⁶ denotes a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case is unsubstituted, or denotes a C _3-10 -cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O—C _1-4 -aliphatic residue. and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C _1-4 aliphatic group, on the condition that if R ⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R ⁶ denotes S—R ⁷ or O—R ⁸ wherein R ⁷ and R ⁸ in each case denote a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C1-4-aliphatic residue, an NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or in each case denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged via an unsubstituted C _1-8 aliphatic group, on the condition that if R ⁷ or R ⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R ⁶ denotes N(R ⁹ R ¹⁰ ), wherein R ⁹ denotes a C1-8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted C _1-8 aliphatic group, preferably an unsubstituted C _1-4 aliphatic group, on the condition that if R ⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, and R ¹⁰ denotes an unsubstituted C _1-4 -aliphatic residue, or R ⁹ and R ¹⁰ form together with the nitrogen atom connecting them a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the 3 to 6 membered heterocycloaliphatic residue formed by R ⁹ and R ¹⁰ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue, C(═O)—OH, residue, benzyl, phenyl, and pyridyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, and an unsubstituted O— C _1-4 -aliphatic residue, and wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OCH ₃ , OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , CF ₃ , and a C _1-4 -aliphatic residue. [0350] In further embodiments, R ¹ represents the partial structure: wherein: m is 0, 1 or 2, and R ^12a and R ^12b each independently of one another represent H, F, OH, CH ₃ or OCH ₃ , or together denote ═O, R ^12c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, S(═O) ₂ —CH ₃ , an unsubstituted O—C _{1- 4} aliphatic residue, and CF ₃ , or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or wherein m is 0 or 2, and R ^12a and R ^12b each independently of one another represent H, F, OH, CH ₃ or OCH ₃ ; and R ^12c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , OCF ₂ H, CH ₂ — OH, CH2—OCH3, S(═O)2—CH3, SCF3, NO2, N(CH3)2, CF3, CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ , C(═O)—O— C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)— O—C ₂ H ₅ , R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl; CH ₂ —OH; CH ₂ —O—CH ₃ ; CH ₂ —CH ₂ —OH; CH ₂ —CH ₂ —OCH ₃ ; O-methyl; O-ethyl; O—(CH ₂ ) ₂ —O—CH ₃ ; O—(CH ₂ ) ₂ —OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, R ³ represents H; F; Cl; Br; I; CN; CF ₃ ; SCF ₃ ; NO ₂ ; OCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.- butyl; O-methyl; O-ethyl; O—(CH ₂ ) ₂ —O—CH ₃ O (CH ) OH SM thyl; or S-Ethyl, R ⁴ represents the partial structure (T2) wherein n denotes 0, 1, 2 or 3, R ^13a and R ^13b each independently of one another represent H, F, CH ₃ or OCH ₃ , or together denote ═O, R ^13c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, an unsubstituted O—C _1-4 aliphatic residue, and CF ₃ , or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, and a C _1-4 -aliphatic residue, R ⁵ denotes H, methyl or ethyl, C ₂ H ₄ OCH ₃ or C ₃ H ₆ OCH ₃ , or R ⁴ and R ⁵ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl, ydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl, y dolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, C(═O)—OH, O- methyl, O-ethyl, OCF ₃ , SCF ₃ , CF ₃ , C(═O)—CH ₃ , C(═O)—OCH ₃ , CH ₂ CF ₃ , CH ₂ OH, CH ₂ —OCH ₃ , CH ₂ CH ₂ —OCH ₃ , methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl, R ⁶ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ —CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), CH ₂ — OCH ₃ , C ₂ H ₄ —OCH ₃ , C ₃ H ₆ —OCH ₃ , cyclopropyl, cyclobutyl, or tetrahydropyranyl, ethenyl or propenyl (—CH ₂ CH═CH ₂ , —CH═CH—CH ₃ , —C((═CH ₂ )—CH ₃ ), in each case unsubstituted, or R ⁶ denotes S—R ⁷ or O—R ⁸ wherein R ⁷ and R ⁸ in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, N(C _{1- 4} aliphatic residue) and an O—C _1-4 -aliphatic residue, or in each case denote CH ₂ - cyclopropyl or oxetanyl, wherein the C1-4-aliphatic residue in each case is unsubstituted, or R ⁶ denotes N(R ⁹ R ¹⁰ ), wherein R ⁹ denotes methyl, C(═O)—CH ₃ , ethyl, n-propyl, 2- propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, R ¹⁰ denotes methyl or ethyl, or R ⁹ and R ¹⁰ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted. [0351] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-[(3,5-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6- morpholin-4-yl- pyridine-3-carboxylic acid amide; Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-2- methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N- [(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine -3-carboxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl -(tetrahydro-pyran-2-yl- methyl)-amino]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-6-(3-methoxy-azetidin-1-yl)-4-methyl-pyridine-3-carb oxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-hydroxy-azeti din-1-yl)-4-methyl-pyridine- 3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophen yl)- methylamino]-4-methyl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4- methyl-6-morpholin-4-yl-2-[(E)-prop-1-enyl]-pyridine-3-carbo xylic acid amide; N-[(3- Fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propyl-pyri dine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-morpholin-4-yl -4-(trifluoromethyl)- pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)methyl]-4-methyl-2,6-dimorpholin- 4-yl-pyridine-3-carboxylic acid amide; 1-[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl- carbamoyl]-4-methyl-pyridin-2-yl]-piperidine-4-carboxylic acid methyl ester; 1-[6- Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4-methyl -pyridin-2-yl]-piperidine-4- carboxylic acid; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(4-hydroxy-pip eridin-1-yl)- 4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-6-(4-oxo-piperidin-1-yl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(4- fluoro-2-methoxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(4-fluoro-2-hydroxy-phenyl)-methyl]-4-met hyl-6-morpholin-4- yl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)methyl]-2-methoxy-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2-(2- methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxy lic acid amide; 2-Ethyl-N- [(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine -3-carboxylic acid amide; N- [(3-Fluorophenyl)methyl]-2-isopropyl-4-methyl-6-morpholin-4- yl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-pyrro lidin-1-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- pyrrolidin-1-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-4-methyl-6-(1,2,3,4-tetrahydro-isoquinolin-2-yl)-pyr idine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[6-(t rifluoromethyl)- 1,2,3,4-tetrahydro-isoquinolin-2-yl]-pyridine-3-carboxylic acid amide; N-[(4- Fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-[(E)-prop-1 -enyl]-pyridine-3- carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-prop yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3- methoxy-pyrrolidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N- [(3-fluorophenyl)-methyl]-4-methyl-6-(4-methyl-piperazin-1-y l)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-piper idin-1-yl-pyridine-3- carboxylic acid amide; 6-Dimethylamino-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-6-methylamino-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-6-(2-methoxy-ethyl-methyl-amino)-4-met hyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(2-methoxy-eth ylamino)-4- methyl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2- (isopropylsulfanyl)-4-methyl-6-morpholin-4-yl-pyridine-3-car boxylic acid amide; 2- Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl -pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4 -yl-pyridine-3- carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2- ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; 2- Ethylsulfanyl-4-methyl-N-(3-methyl-butyl)-6-morpholin-4-yl-p yridine-3-carboxylic acid amide; N-(Cyclopentyl-methyl)-2-ethylsulfanyl-4-methyl-6-morpholin- 4-yl-pyridine-3- carboxylic acid amide; N-(2-Cyclopentyl-ethyl)-2-ethylsulfanyl-4-methyl-6-morpholin -4- yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(6-fluoro-pyridin-2-yl)-methyl]-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(5-fluoro- pyridin-2-yl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; N-(2,2- Dimethyl-propyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(2-me thyl-morpholin-4-yl)- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(4- methoxy-piperidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4- methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl]-pyridin e-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[2-(trifluorome thyl)-phenyl]-methyl]- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4- fluorophenyl)-methyl-methyl-amino]-4-methyl-pyridine-3-carbo xylic acid amide; 2- Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(3-phenyl-propyl)- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-phenethyl-pyridi ne-3-carboxylic acid amide; N-Benzyl-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine- 3-carboxylic acid amide N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(pro pylsulfanyl)- pyridine-3-carboxylic acid amide; 2-(Butylsulfanyl)-N-[(3-fluorophenyl)-methyl]-4-methyl- 6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-5-fluoro-N-[(3- fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; 2- Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[3-(trifluorometh yl)phenyl]-methyl]-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluorome thyl)- phenyl]-methyl]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-4-methyl-6-[methyl-(tetrahydro-pyran-4-yl-methyl)-am ino]-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4-methyl-2-(2-methyl-propylsulfa nyl)-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2-(2- methoxy-ethylsulfanyl)-4-methyl-6-morpholin-4-yl-pyridine-3- carboxylic acid amide; 2- Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl -pyridine-3-carboxylic acid amide; 2-Dimethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morph olin-4-yl-pyridine- 3-carboxylic acid amide; 6-(2,6-Dimethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl- pentyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3 -carboxylic acid amide; 2- Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(2-tetrahydro-pyra n-2-yl-ethyl)-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(tetrahydro-pyra n-2- yl-methyl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 4-methyl-6-(4-methyl-piperidin-1-yl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N- [[2-(4-fluorophenyl)-phenyl]methyl]-4-methyl-6-morpholin-4-y l-pyridine-3-carboxylic acid amide; 2-[[6-Ethylsulfanyl-5-[(3-fluorophenyl)-methyl-carbamoyl]-4- methyl-pyridin-2-yl]- methyl-amino]-acetic acid ethyl ester; 6-(4-Cyclopropyl-piperazin-1-yl)-2-ethylsulfanyl-N- [(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide; 6-(4,4-Dimethyl- piperidin-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluorome thylsulfanyl)- phenyl]-methyl]pyridine-3-carboxylic acid amide; N-(Cyclohexyl-methyl)-2-ethylsulfanyl- 4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-(2- methoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyl ic acid amide; 2- Ethylsulfanyl-N-(3-methoxy-propyl)-4-methyl-6-morpholin-4-yl -pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-N-(4-methyl-pentyl)-6-morpholin-4-y l-pyridine-3- carboxylic acid amide; N-Butyl-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3 - carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-pentyl-pyridine- 3- carboxylic acid amide; 2-Ethylsulfanyl-N-[[4-fluoro-3-(trifluoromethyl)-phenyl]meth yl]-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(2-tert-Butoxy-ethyl)-2- ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; 2- Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-b utyl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[4-fluoro-2-(4-fluorophenyl)-phenyl]methy l]-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-methoxy-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)- methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carbo xylic acid amide; 2- Methoxy-4-methyl-6-morpholin-4-yl-N-[(2-phenyl-phenyl)-methy l]-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-morpholin-4-yl-p yridine-3- carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-2-ethoxy-4-methyl-6-morphol in- 4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2-ethoxy-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethoxy-4-methyl-6- morpholin-4-yl-N-[(2-phenyl-phenyl)-methyl]-pyridine-3-carbo xylic acid amide; 2- Ethylsulfanyl-N-[[3-fluoro-5-(trifluoromethyl)-phenyl]methyl ]-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[2-fluoro-3-(trifluoromethyl)- phenyl]methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyl ic acid amide; 2- Ethylsulfanyl-N-[[2-fluoro-5-(trifluoromethyl)-phenyl]methyl ]-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- ([1,4]oxazepan-4-yl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6- morpholin-4-yl-N-[[4-(trifluoromethyloxy)-phenyl]-methyl]pyr idine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-([1,4]oxaze pan-4-yl)-pyridine- 3-carboxylic acid amide; 2-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-6- ([1,4]oxazepan-4-yl)-pyridine-3-carboxylic acid amide; N-[(2,3-Difluoro-phenyl)-methyl]- 2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxy lic acid amide; N-[(2,5- Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholi n-4-yl-pyridine-3-carboxylic acid amide; N-[(3-Cyano-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morph olin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-(2-isopropoxy-ethyl)-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(3,3-Dimethyl-butyl)-2-ethylsulfanyl- 4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(3-Cyclopentyl-propyl)-2- ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; N-(2- Cyclohexyl-ethyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; N-[(2,4-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6- morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[3-(4-fluorophenyl)-propyl]-4-methyl- 6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6- morpholin-4-yl-N-(3-pyridin-2-yl-propyl)-pyridine-3-carboxyl ic acid amide; 2-Butoxy-N- [(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine -3-carboxylic acid amide; N- [(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-propox y-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-ox o-azetidin-1-yl)- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[3-(3-fluorophenyl)-propyl]-4-methyl- 6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6- morpholin-4-yl-N-(3-pyridin-3-yl-propyl)-pyridine-3-carboxyl ic acid amide; 2- Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(3-pyridin-4-yl-pr opyl)-pyridine-3-carboxylic acid amide; N-(5,5-Dimethyl-hexyl)-2-ethylsulfanyl-4-methyl-6-morpholin- 4-yl-pyridine-3- carboxylic acid amide; 2-Methoxy-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)- phenyl]-methyl]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-4-methyl-6-[methyl-(pyridin-4-yl-methyl)-amino]-pyri dine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[meth yl-(pyridin-3-yl- methyl)-amino]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-6-[(4-fluoro-benzoyl)- methyl-amino]-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine- 3-carboxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl -(pyridin-2-yl-methyl)- amino]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-6-(pyridin-3-yl-methylamino)-pyridine-3-carboxylic acid amide; 6-(Acetyl-methyl- amino)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl- pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morph olin-4-yl-pyridine- 3-carboxylic acid amide; N-[(3-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 6-[Bis(2-methoxy-ethyl)-amino]-2- ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine- 3-carboxylic acid amide; 2- (Ethyl-methyl-amino)-N-[(3-fluorophenyl)-methyl]-4-methyl-6- morpholin-4-yl-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-methoxy-pro pyl- methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[3-(2- fluorophenyl)-propyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; 2- Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[[3-(trifluorometh yloxy)-phenyl]- methyl]pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[3-(methoxymethyl)- phenyl]methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyl ic acid amide; 2-Ethoxy-4- methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-meth yl]-pyridine-3-carboxylic acid amide; 2-Ethoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-butyl) -pyridine-3- carboxylic acid amide; N-(1,3-Benzodioxol-5-yl-methyl)-2-ethylsulfanyl-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[2-fluoro-4- (trifluoromethyl)-phenyl]methyl]-4-methyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide; 6-(Azepan-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 4-methyl-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-N-[(4-methoxyphenyl)-methyl]-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; (2S)-2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-6-(2-methyl-morpholin-4-yl)-p yridine-3-carboxylic acid amide; (2R)-2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- (2-methyl-morpholin- 4-yl)-pyridine-3-carboxylic acid amide; 2-Methoxy-4-methyl-6-morpholin-4-yl-N-(4,4,4- trifluoro-butyl)-pyridine-3-carboxylic acid amide; N-(3-Cyclopropyl-propyl)-2- ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; 2- Ethylsulfanyl-N-[[3-fluoro-4-(trifluoromethyl)-phenyl]methyl ]-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- (3-oxo-piperazin-1-yl)-pyridine-3-carboxylic acid amide; 6-(4-Acetyl-piperazin-1-yl)-2- ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine- 3-carboxylic acid amide; N- [(4-Cyano-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morphol in-4-yl-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-N-[[4-(methoxymethyl)-phenyl]methyl]-4-methy l- 6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[3-fluoro-4- (methoxymethyl)-phenyl]methyl]-4-methyl-6-morpholin-4-yl-pyr idine-3-carboxylic acid amide; N-[(4-Dimethylaminophenyl)-methyl]-2-ethylsulfanyl-4-methyl- 6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[4-fluoro-3-(methoxymethyl)- phenyl]methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyl ic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(4-meth yl-3-oxo-piperazin-1-yl)- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- (6-oxa-2-azaspiro[3.3]heptan-2-yl)-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl- pentyl)-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-pyridine- 3-carboxylic acid amide; 4- Methyl-2-methylsulfanyl-6-morpholin-4-yl-N-(4,4,4-trifluoro- butyl)-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morp holin-4-yl- pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-4-methyl-2- methylsulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro- phenyl)-methyl]-4-methyl-2-methylsulfanyl-6-morpholin-4-yl-p yridine-3-carboxylic acid amide; 4-Methyl-2-methylsulfanyl-6-morpholin-4-yl-N-[[4-(trifluorom ethyl)-phenyl]- methyl]pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-6-(6-oxo-2,3,4,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyra zin-2-yl)-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-ox a-6- azabicyclo[2.2.1]heptan-6-yl)-pyridine-3-carboxylic acid amide; N-(3-Cyano-propyl)-2- ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; 2- Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(p-tolyl-methyl)-p yridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-N-(3-methylsulfonyl-propyl)-6-morph olin-4-yl-pyridine-3- carboxylic acid amide; N-(4-Cyano-butyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-(m-tolyl- methyl)-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-methoxy-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]- 2-ethoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 6-(2-Ethyl- morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 4-methyl-pyridine-3- carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-methyl-2-methylsulfanyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-2- isopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine -3-carboxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl -pyridin-2-yl-amino)- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- (methyl-pyridin-3-yl-amino)-pyridine-3-carboxylic acid amide; 2-Dimethylamino-N-[(4- fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4- yl]-pyridine-3-carboxylic acid amide; 2-(Ethyl-methyl-amino)-N-[(4-fluorophenyl)-methyl]-4-methyl- 6-[(3R)-3- methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; 2-(Ethyl-methyl-amino)-N-[(4- fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl -(tetrahydro-pyran-3-yl- methyl)-amino]-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-4-methyl- 6-[(3R)-3-methyl-morpholin-4-yl]-2-methylsulfanyl-pyridine-3 -carboxylic acid amide; 2- Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3 -methyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; 6-(3-Ethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-6-[(3R)-3-(methoxymethyl)-morpholin-4- yl]-4-methyl-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3- (methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxyl ic acid amide; N-[(4- Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-methyl-mo rpholin-4-yl]-pyridine-3- carboxylic acid amide; 2-Ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3-meth yl- morpholin-4-yl]-pyridine-3-carboxylic acid amide; 2-Dimethylamino-N-(4,4-dimethyl- pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3 -carboxylic acid amide; N- (4,4-Dimethyl-pentyl)-2-(ethyl-methyl-amino)-4-methyl-6-[(3R )-3-methyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl-6-[(3R)- 3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2- methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3 -carboxylic acid amide; N- (4,4-Dimethyl-pentyl)-2-ethoxy-4-methyl-6-[(3R)-3-methyl-mor pholin-4-yl]-pyridine-3- carboxylic acid amide; 2-(Ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-N-[[4- (trifluoromethyl)-phenyl]-methyl]pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl- pentyl)-2-(ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-pyr idine-3-carboxylic acid amide; 2-(Ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-N-(4,4,4-tr ifluoro-butyl)- pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-(ethyl-methyl-amino)-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4- methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-methylsulfanyl-pyr idine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-[(3R)-3-m ethyl-morpholin-4- yl]-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-4-methyl-6-[(3R)-3- methyl-morpholin-4-yl]-2-(1-methyl-propyl)-pyridine-3-carbox ylic acid amide; N-(4,4- Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2 -(1-methyl-propyl)-pyridine- 3-carboxylic acid amide; 2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-[(3R)-3 - methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-4- methyl-6-[(3R)-3-methyl-morpholin-4-yl]-2-propyl-pyridine-3- carboxylic acid amide; 2- Cyclopropyl-N-(4,4-dimethyl-pentyl)-4-methyl-6-[(3R)-3-methy l-morpholin-4-yl]-pyridine- 3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-methyl-6-[(3R)-3-methyl-morpholin- 4-yl]-2-propyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-4-methyl-6-(methyl-pyridin-4-yl-amino)-pyridine-3-ca rboxylic acid amide; 2- Ethylsulfanyl-N-[(4-fluoro-3-methyl-phenyl)-methyl]-4-methyl -6-morpholin-4-yl-pyridine- 3-carboxylic acid amide; 2-Ethylsulfanyl-N-(2-hydroxy-3-phenyl-propyl)-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2- (ethyl-methyl-amino)-4-methyl-6-morpholin-4-yl-pyridine-3-ca rboxylic acid amide; N- [(3,5-Difluoro-phenyl)-methyl]-2-(ethyl-methyl-amino)-4-meth yl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Dimethylamino-N-[(4-fluorophenyl)-methyl]-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)- methyl]-2-dimethylamino-4-methyl-6-morpholin-4-yl-pyridine-3 -carboxylic acid amide; N- [(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-[(3R)-3 -methyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; N-[(3,5-Dimethyl-phenyl)-methyl]-2-ethylsulfanyl-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-heptyl-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 6-Dimethylamino-N-(4,4- dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-pyridine-3-carboxy lic acid amide; N-(4,4- Dimethyl-pentyl)-2-ethylsulfanyl-6-(2-methoxy-ethyl-methyl-a mino)-4-methyl-pyridine-3- carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-6-(3-methoxy-propyl- methyl-amino)-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-6-(3-propyl-morpholin-4-yl)-p yridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)-3-met hyl-morpholin-4- yl]-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6- [(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; N-[(3-Fluorophenyl)- methyl]-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridi ne-3-carboxylic acid amide; 2-Ethylsulfanyl-N-hexyl-4-methyl-6-morpholin-4-yl-pyridine-3 -carboxylic acid amide; N- (4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-(methyl-tet rahydro-furan-3-yl-amino)- pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-(2- methyl-morpholin-4-yl)-pyridine-3-carboxylic acid amide; 2-tert-Butyl-N-(4,4-dimethyl- pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl- pentyl)-4-methyl-2-(1-methyl-propyl)-6-morpholin-4-yl-pyridi ne-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(2-ox a-6-azaspiro[3.4]octan-6-yl)- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(2R)-2- (methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxyl ic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(2S)-2-(methoxy methyl)-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2- ethylsulfanyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyri dine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-[(3R)- 3-methyl- morpholin-4-yl]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-(3-hydroxy-3-phenyl- propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N- (2-hydroxy-4-methyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridi ne-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[2-(2-methoxy- ethyl)-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-(5-hydroxy-4,4-dimethyl- pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4- methyl-N-[(3-methylsulfonyl-phenyl)-methyl]-6-morpholin-4-yl -pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[2-(t rifluoromethyl)- 5,6,7,8-tetrahydro-[1,6]naphthyridin-6-yl]pyridine-3-carboxy lic acid amide; N-[(3,5- Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-[(3R)-3- methyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl- 6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4- methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-(4,4,4-trifluoro-b utyl)-pyridine-3-carboxylic acid amide; 2-Methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-(4,4,4 -trifluoro- butyl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-[(3R)-3-methyl- morpholin-4-yl]-N-[[4-(trifluoromethyl)-phenyl]-methyl]pyrid ine-3-carboxylic acid amide; 2-Methoxy-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-N-[[4-(t rifluoromethyl)-phenyl]- methyl]pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6- [3-(methoxymethyl)-azetidin-1-yl]-4-methyl-pyridine-3-carbox ylic acid amide; 6-(2,5- Dimethyl-morpholin-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl) -methyl]-4-methyl-pyridine- 3-carboxylic acid amide; 2-Dimethylamino-4-methyl-6-morpholin-4-yl-N-[[4- (trifluoromethyl)-phenyl]-methyl]pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro- phenyl)-methyl]-2-dimethylamino-4-methyl-6-morpholin-4-yl-py ridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[2-(t rifluoromethyl)- 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazin-7-yl]-pyridine-3-ca rboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2-dimethylamino-4-methyl-6-morpholin-4 -yl-pyridine-3-carboxylic acid amide; 2-Dimethylamino-N-(4,4-dimethyl-pentyl)-4-methyl-6-morpholin -4-yl- pyridine-3-carboxylic acid amide; 2-Dimethylamino-4-methyl-6-morpholin-4-yl-N-(4,4,4- trifluoro-butyl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-N-[(4- methylsulfonyl-phenyl)-methyl]-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; 2- Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-6-[(3R)-3-(methoxy methyl)-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-6- [(3S)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3- carboxylic acid amide; 2- tert-Butyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin- 4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[4-(2 ,2,2-trifluoro- ethyl)-piperazin-1-yl]-pyridine-3-carboxylic acid amide; 6-(2,2-Dimethyl-morpholin-4-yl)- 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridin e-3-carboxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[methyl -(2-oxo-propyl)-amino]- pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-[(2R)-2- (methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxyl ic acid amide; N-[(4- Chlorophenyl)-methyl]-2-ethylsulfanyl-6-[(2S)-2-(methoxymeth yl)-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6- [(3R)-3-(methoxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3- carboxylic acid amide; N- [(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-6-[(3S)-3-(methoxy methyl)-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-6-(methyl-tetrahydro-pyran-4-yl-amino)-pyridine-3-car boxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-methoxy-cycl ohexyl)-methyl-amino]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-6-[2-(trifluoromethyl)-morpholin-4-yl]-pyridine-3-car boxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl -tetrahydro-pyran-3-yl- amino)-pyridine-3-carboxylic acid amide; 6-(3,5-Dimethyl-morpholin-4-yl)-2- ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine- 3-carboxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3-(hydroxy methyl)-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6- [(3R)-3-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3- carboxylic acid amide; N- [(4-Chlorophenyl)-methyl]-2-isopropyl-4-methyl-6-[(3R)-3-met hyl-morpholin-4-yl]- pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-methyl-6-[(3R)-3- methyl-morpholin-4-yl]-2-propyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-(3- hydroxy-4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyrid ine-3-carboxylic acid amide; N-[(4-Cyano-3-fluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methy l-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-(2-fluoro-ethoxy)-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]- 2-(2,2-difluoro-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3 -carboxylic acid amide; N- [(4-Chlorophenyl)-methyl]-2-(cyclopropyl-methoxy)-4-methyl-6 -morpholin-4-yl-pyridine- 3-carboxylic acid amide; 2-(2,2-Difluoro-ethoxy)-N-[(4-fluorophenyl)-methyl]-4-methyl -6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-ethoxy- 4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridine-3-carboxy lic acid amide; N-(4,4- Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-[(2S)-2-methyl-m orpholin-4-yl]-pyridine-3- carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-[(2R)-2- methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; 2-(Cyclopropyl-methoxy)-N-[(4- fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2-isopropyl-6-[(3S)-3-(methoxymethyl)- morpholin-4-yl]-4-methyl- pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-methyl-2-(2-methyl-butyl)-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-(1,1- dimethyl-propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carbox ylic acid amide; N-(4,4- Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6-(methyl-tetrahyd ro-pyran-3-yl-amino)- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N-[(4- nitrophenyl)-methyl]-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2- cyclopropyl-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyridi ne-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2-(2-dimethylaminoethyloxy)-4-me thyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(4-fluoro-3-methoxy-phenyl)- methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2-isopropyl-6-[(2S)-2-(methoxymethyl)- morpholin-4-yl]-4-methyl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-(3-hydroxy-4-methyl-pentyl)-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluoro-4- methoxy-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3 -carboxylic acid amide; N- [[4-(Difluoro-methoxy)-phenyl]-methyl]-2-ethylsulfanyl-4-met hyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; N-(1,3-Dihydro-isobenzofuran-5-yl-methyl)-2- ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; N-[(4- Chlorophenyl)-methyl]-2-cyclopropyl-6-[(2S)-2-(methoxymethyl )-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6- [(2S)-2-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3- carboxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(2R)-2-(hydroxy methyl)-morpholin-4-yl]-4- methyl-pyridine-3-carboxylic acid amide; 6-(Benzyl-methyl-amino)-2-ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-6-[methyl-(tetrahydro-furan-2 -yl-methyl)-amino]-pyridine- 3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[(3R) -3- methyl-morpholin-4-yl]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-6-[(3S)-3-methyl-morpholin-4- yl]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-[meth yl-[[4- (trifluoromethyl)-phenyl]-methyl]-amino]-pyridine-3-carboxyl ic acid amide; 6-(1,1-Dioxo- [1,4]thiazinan-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-met hyl]-4-methyl-pyridine-3- carboxylic acid amide; 6-(Azetidin-1-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl ]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-6-(methyl-tetrahydro-furan-3-yl-amino)-pyridine-3-car boxylic acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(N-meth yl-anilino)-pyridine-3- carboxylic acid amide; 6-(2,3-Dihydro-1H-isoindol-2-yl)-2-ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-4-methyl-6-(1,2,3,4-tetrahydro-quinoli n-1-yl)-pyridine-3-carboxylic acid amide; 6-(2,3-Dihydro-1H-indol-1-yl)-2-ethylsulfanyl-N-[(3-fluoroph enyl)-methyl]-4- methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin-4-yl-N- (2,4,4-trimethyl-pentyl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-6-[(3-methoxy-cyclohexyl)-methyl-amino ]-4-methyl-pyridine-3- carboxylic acid amide; N-(4,4-Difluoro-pentyl)-2-ethylsulfanyl-4-methyl-6-morpholin -4-yl- pyridine-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,4-Difluoro-phenyl)-methyl]-2- isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Isopropyl-4- methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl)-phenyl]-meth yl]-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-ox o-morpholin-4- yl)-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl- 2-propyl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-isopropyl-4-methyl- 6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Isopropyl-4-methyl-6-morpholin-4- yl-N-(4,4,4-trifluoro-butyl)-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)- methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-car boxylic acid amide; N-[(3- Fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-(oxetan-3- yloxy)-pyridine-3- carboxylic acid amide; 2-Ethylsulfanyl-N-(4-methoxy-4-methyl-pentyl)-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-(4-fluoro-4-methyl- pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 4-Methyl-6- morpholin-4-yl-2-propyl-N-(4,4,4-trifluoro-butyl)-pyridine-3 -carboxylic acid amide; N- [(3,4-Difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-2-p ropyl-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-2 -propyl- pyridine-3-carboxylic acid amide; 4-Methyl-6-morpholin-4-yl-2-propyl-N-[[4- (trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-2- oxo-pentyl)-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridi ne-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(8-ox a-3-azabicyclo[3.2.1]octan- 3-yl)-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4-methyl-6- morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]- 2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl- N-(4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3 -carboxylic acid amide; 2- Cyclopropyl-4-methyl-6-morpholin-4-yl-N-(4,4,4-trifluoro-but yl)-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morphol in-4-yl-pyridine-3- carboxylic acid amide; 2-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6-morphol in- 4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[(3,4-difluoro-phenyl)-methyl]-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[(3,5- difluoro-phenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine- 3-carboxylic acid amide; 2- Cyclopropyl-4-methyl-6-morpholin-4-yl-N-[[4-(trifluoromethyl )-phenyl]methyl]-pyridine-3- carboxylic acid amide;N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-methyl-6-m orpholin- 4-yl-pyridine-3-carboxylic acid amide;2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methoxy-6-morpholin-4-yl-pyridine-3-carboxylic acid amide;N-(4,4-Dimethyl-pentyl)-2- (2-methoxy-ethylsulfanyl)-4-methyl-6-morpholin-4-yl-pyridine -3-carboxylic acid amide;2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl )-methyl-(3-methoxy-propyl)- amino]-4-methyl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-6-morpholin- 4-yl-N-(3,4,4-trimethyl-pentyl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3- fluorophenyl)-methyl]-6-[3-(2-methoxy-ethyl)-morpholin-4-yl] -4-methyl-pyridine-3- carboxylic acid amide; 2-(Acetyl-methyl-amino)-N-[(3-fluorophenyl)-methyl]-4-methyl -6- morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)- methyl]-6-[(4-fluorophenyl)-methyl-(2-methoxy-ethyl)-amino]- 4-methyl-pyridine-3- carboxylic acid amide;2-Ethylsulfanyl-4-methyl-N-[3-(3-methyl-oxetan-3-yl)-p ropyl]-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pent-2-ynyl)-2- ethylsulfanyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxyli c acid amide; 2- Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxa- 8-azabicyclo[3.2.1]octan-8- yl)-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- (methoxymethyl)-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-4-methyl-2-(1-methyl-propyl)-6-morphol in-4-yl-pyridine-3- carboxylic acid amide; N-(4,4-Dimethyl-hexyl)-2-ethylsulfanyl-4-methyl-6-morpholin- 4-yl- pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-(2-methoxy-ethoxy)-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-4-methyl-N-[3- (1-methyl-cyclopropyl)-propyl]-6-morpholin-4-yl-pyridine-3-c arboxylic acid amide; 2- Cyclopropyl-N-[[4-fluoro-3-(methoxymethyl)-phenyl]-methyl]-4 -methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[4-fluoro-3-(methoxymethyl)- phenyl]methyl]-4-methyl-6-[(3R)-3-methyl-morpholin-4-yl]-pyr idine-3-carboxylic acid amide; 2-Ethylsulfanyl-N-[[4-fluoro-3-(hydroxymethyl)-phenyl]methyl ]-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-2-(3-methoxy- propyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[[3- fluoro-4-(methoxymethyl)-phenyl]-methyl]-4-methyl-6-morpholi n-4-yl-pyridine-3- carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-2-(methoxymethyl)-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-2,4- diisopropyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)- 2-(2-methoxy-ethyl)-4-methyl-6-morpholin-4-yl-pyridine-3-car boxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2,4-diethyl-6-morpholin-4-yl-pyridine- 3-carboxylic acid amide; and N-(4,4-Dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-2-tetrahyd ro-pyran-4-yl-pyridine- 3-carboxylic acid amide, respectively in the form of free compounds; racemic mixtures; mixtures of the enantiomers, diastereomers, or enantiomers and diastereomers in any mixing ratio, or an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases. Formula 24 [0352] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 24. Such compounds are described in US Patent No.9,168,259 issued March 8, 2016 and corresponding to US Application No. 13/449,472 filed April 18, 2012; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 24, this reference incorporated by reference herein controls. [0353] In an embodiment, the Kv7 channel activator is a compound according to formula 24: Formula 24 wherein, X ¹ represents a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted; or a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted, and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; or represents OX ⁶ , wherein X ⁶ represents a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted; or a C _3-6 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted; X ² and X ³ independently of one another represent H; F; Cl; Br; I; CN; CH2F; CHF2; CF3; OH; OCH2F; OCHF2; OCF3; SCF ₃ ; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; or a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted; with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, X ⁴ and X ⁵ independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be unsubstituted or mono- or polysubstituted; or a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted; on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, or X ² and X ³ and/or X ⁴ and X ⁵ in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted, and the respective remaining substituents of X ² and X ³ each independently of one another represent H; F; Cl; Br; I; CN; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; or a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, and the respective remaining substituents of X ⁴ and X ⁵ each independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be unsubstituted or mono- or polysubstituted; or a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted; on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, or X ² and X ⁴ together with the carbon atoms connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted, and X ³ represents H; F; Cl; Br; I; CN; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF2; OCF3; SCF3; a C1-4-aliphatic residue, or an O—C1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; or a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted; and X ⁵ represents H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 -aliphatic residue, wherein the C _{1- 4} aliphatic residue may be unsubstituted or mono- or polysubstituted; or a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted; on the condition that if X ⁵ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, in which an “aliphatic group” and an “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a N(C _1-4 -aliphatic residue)-C(═O)—C _{1- 4} aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, a N(C _1-4 -aliphatic residue)- S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, a S(═O) ₂ — N(C _1-4 -aliphatic residue) ₂ , CN, CH ₂ F, CHF ₂ , CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, CH ₂ OH, CH ₂ —OCH ₃ , C ₂ H ₄ —OH, C ₂ H ₄ —OCH ₃ CH ₂ —CF ₃ , a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1-4 aliphatic residue), an N(C1- ₄ aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a N(C _1-4 -aliphatic residue)- C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, a N(C _1-4 -aliphatic residue)-S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , a O—C _1-4 - aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, a S(═O) ₂ — N(C _1-4 -aliphatic residue) ₂ , CN, CH ₂ F, CHF ₂ , CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, CH ₂ OH, CH ₂ —OCH ₃ , C ₂ H ₄ —OH, C ₂ H ₄ —OCH ₃ CH ₂ —CF ₃ , a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; said compound being in the form of a free compound, the racemate, a mixture of enantiomers, diastereomers, or of enantiomers and diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of a salt of physiologically acceptable acids or bases. [0354] In further embodiments, X ¹ represents a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represents a C _3-6 - cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH2F, OCHF2, OCF3, CH2F, CHF2, CF3 and an unsubstituted O—C1-4-aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue may optionally be bridged via a C _{1- 4} aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represents OX ⁶ , wherein X ⁶ represents a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue; wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, X ² and X ³ independently of one another represent H; F; Cl; Br; I; CN; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF ₂ ; OCF ₃ ; SCF ₃ ; a C _{1- 4} -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, X ⁴ and X ⁵ independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; or a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 - aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or X ² and X ³ and/or X ⁴ and X ⁵ in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and the respective remaining substituents of X ² and X ³ each independently of one another represent H; F; Cl; Br; I; CN; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, and the respective remaining substituents of X ⁴ and X ⁵ each independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 - aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or X ² and X ⁴ together with the carbon atoms connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and the remaining substituent X ³ represents H; F; Cl; Br; I; CN; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represents a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 - aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, and the remaining substituent X ⁵ represents H; CH ₂ F; CHF ₂ ; CF ₃ ; OCH ₂ F; OCHF ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represents a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, on the condition that if X ⁵ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH2F, OCHF2, OCF3, CH2F, CHF2, CF3 and an unsubstituted O—C _1-4 -aliphatic residue. [0355] In further embodiments, X ¹ represents a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represents a C _3-6 - cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or represents OX ⁶ , wherein X ⁶ represents a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCH ₂ F, OCHF ₂ , OCF ₃ , CH ₂ F, CHF ₂ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue. [0356] In further embodiments, X ¹ represents a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCH2F, OCHF2, OCF3, SH, SCF3, a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue is in each case unsubstituted, or represents a C _3-6 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue is in each case unsubstituted, or represents OX ⁶ , wherein X ⁶ represents a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCH ₂ F, OCHF ₂ , OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a S(═O)—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, CN, and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue is in each case unsubstituted. [0357] In further embodiments, X ¹ represents a C _2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or represents a C _3-6 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or represents OX ⁶ , wherein X ⁶ represents a C _{1- 4} -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue. [0358] In further embodiments, X ¹ represents ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ —CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), ethenyl or propenyl (—CH ₂ CH═CH ₂ , —CH═CH—CH ₃ , —C(═CH ₂ )— CH ₃ ), cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or represents OX ⁶ , wherein X ⁶ represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, CH ₂ OH, CH ₂ OCH ₃ , CH ₂ CH ₂ OH, CH ₂ CH ₂ OCH ₃ , and CH(OH)CH ₂ OH. [0359] In further embodiments, X ² and X ³ independently of one another represent H; F; Cl; Br; I; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , OCH ₂ F, OCHF ₂ , OCF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, X ⁴ and X ⁵ independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 - aliphatic residue, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , OCH ₂ F, OCHF ₂ , OCF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, or X ² and X ³ and/or X ⁴ and X ⁵ in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , OCH ₂ F, OCHF ₂ , OCF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and the respective remaining substituents of X ² and X ³ each independently of one another represent H; F; Cl; Br; I; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , OCH ₂ F, OCHF ₂ , OCF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, and the respective remaining substituents of X ⁴ and X ⁵ each independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or represent a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , OCH ₂ F, OCHF ₂ , OCF ₃ , and a C _1-4 -aliphatic residue, on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or X ² and X ⁴ together with the carbon atoms connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH2F, CHF2, CF3, OCH2F, OCHF2, OCF3, and a C1-4-aliphatic residue, wherein the C1-4- aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and the remaining substituent X ³ represents H; F; Cl; Br; I; CH ₂ F; CHF ₂ ; CF ₃ ; OH; OCH ₂ F; OCHF ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or represents a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , OCH ₂ F, OCHF ₂ , OCF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and the remaining substituent X ⁵ represents H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue, or represents a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , OCH ₂ F, OCHF ₂ , OCF ₃ , and a C _1-4 -aliphatic residue, on the condition that if X ⁵ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C _1-4 -aliphatic residue. [0360] In further embodiments, X ² and X ³ independently of one another represent H; F; Cl; Br; I; CH ₂ F; CHF ₂ ; CF ₃ ; OH; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue is in each case unsubstituted, or represent a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, X ⁴ and X ⁵ independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue is unsubstituted, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted, on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, or X ² and X ³ and/or X ⁴ and X ⁵ in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , and a C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue is in each case unsubstituted, and the respective remaining substituents of X ² and X ³ each independently of one another represent H; F; Cl; Br; I; CH ₂ F; CHF ₂ ; CF ₃ ; OH; a C _1-4 -aliphatic residue, or an O—C _{1- 4} aliphatic residue, wherein the C _1-4 -aliphatic residue is in each unsubstituted, or represent a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, and the respective remaining substituents of X ⁴ and X ⁵ each independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 - aliphatic residue, wherein the C _1-4 -aliphatic residue is unsubstituted, or represent a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted, on the condition that if X ⁴ and/or X ⁵ denote(s) a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom, or X ² and X ⁴ together with the carbon atoms connecting them, form a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue is in each case unsubstituted, and the remaining substituent X ³ represents H; F; Cl; Br; I; CH ₂ F; CHF ₂ ; CF ₃ ; OH; a C _1-4 -aliphatic residue, or an O—C _1-4 aliphatic residue, wherein the C _1-4 - aliphatic residue is in each case unsubstituted, or represents a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted, and the remaining substituent X ⁵ represents H; CH ₂ F; CHF ₂ ; CF ₃ ; a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue is unsubstituted, or represents a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted, on the condition that if X ⁵ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom. [0361] In further embodiments, X ² and X ³ independently of one another represent H; OH; an unsubstituted C _1-4 -aliphatic residue, or an unsubstituted O—C _1-4 aliphatic residue, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, X ⁴ and X ⁵ independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; an unsubstituted C _1-4 -aliphatic residue, or X ² and X ³ or X ⁴ and X ⁵ in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C _3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CH ₂ F, CHF ₂ , CF ₃ , an unsubstituted O—C _1-4 -aliphatic residue, and an unsubstituted C _1-4 -aliphatic residue, and the respective remaining substituents of X ² and X ³ each independently of one another represent H; OH; an unsubstituted C _1-4 -aliphatic residue, or an unsubstituted O—C _{1- 4} aliphatic residue, with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, and the respective remaining substituents of X ⁴ and X ⁵ each independently of one another represent H; CH ₂ F; CHF ₂ ; CF ₃ ; an unsubstituted C _1-4 - aliphatic residue, or X ² and X ⁴ together with the carbon atoms connecting them, form a C _3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an unsubstituted aliphatic residue, CH ₂ F, CHF ₂ , CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, and the remaining substituent X ³ represents H; F; Cl; Br; I; OH; an unsubstituted C _1-4 -aliphatic residue, or an unsubstituted O—C _1-4 aliphatic residue, and the remaining substituent X ⁵ represents H; CH ₂ F; CHF ₂ ; CF ₃ ; an unsubstituted C _1-4 -aliphatic residue. [0362] In further embodiments, X ² and X ³ independently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ —CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), OCH ₃ or OCH ₂ CH ₃ , with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, X ⁴ and X ⁵ independently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n- butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ — CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), CH ₂ F; CHF ₂ ; CF ₃ ; or X ² and X ³ or X ⁴ and X ⁵ in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C _3-6 -cycloaliphatic residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, CH ₂ F, CHF ₂ , CF ₃ , OCH ₃ and OCH ₂ CH ₃ , and the respective remaining substituents of X ² and X ³ each independently of one another represents H; methyl; ethyl, n-propyl, 2-propyl, n- butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ — CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), OCH ₃ or OCH ₂ CH ₃ , with the proviso that at least one of X ² and X ³ denotes H or is linked via a carbon atom, and the respective remaining substituents of X ⁴ and X ⁵ each independently of one another represents H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ —CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), CH ₂ F; CHF ₂ ; CF ₃ ; or X ² and X ⁴ together with the carbon atoms connecting them, form a C _3-6 -cycloaliphatic residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, CH ₂ F, CHF ₂ , CF ₃ , OCH ₃ and OCH ₂ CH ₃ , and the respective remaining substituent of X ³ represents H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ — CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), OCH ₃ or OCH ₂ CH ₃ , and the respective remaining substituent X ⁵ represents H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.- butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ —CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), CH ₂ F; CHF ₂ ; CF ₃ . [0363] In further embodiments, X ¹ represents ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or represents OX ⁶ , wherein X ⁶ represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, X ² and X ³ in dependently of one another represent H; methyl; ethyl, n- propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, X ⁴ and X ⁵ independently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, CH ₂ F, CHF ₂ , or CF ₃ ; or X ² and X ³ or X ⁴ and X ⁵ in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C _3-6 -cycloaliphatic residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of OH, methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, CH ₂ F, CHF ₂ , CF ₃ , OCH ₃ and OCH ₂ CH ₃ , and the respective remaining substituents of X ² and X ³ in dependently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, and the respective remaining substituents of X ⁴ and X ⁵ independently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, CH ₂ F, CHF ₂ , or CF ₃ ; or X ² and X ⁴ together with the carbon atoms connecting them, form a C _3-6 -cycloaliphatic residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of OH, methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, CH ₂ F, CHF ₂ , CF ₃ , OCH ₃ and OCH ₂ CH ₃ , and X ³ represents H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.- butyl, and X ⁵ represents H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, CH ₂ F, CHF ₂ , or CF ₃ . [0364] In further embodiments, the Kv7 cannel activator is selected from the group consisting of: 2-Cyclopropyl-N-(3-hydroxy-4,4-dimethyl-pentyl)-4-methyl-6-m orpholin-4- yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[[(1S,2R)-2-hydroxy-cyclohexyl]- methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N- [[(1R,2S)-2-hydroxy-cyclohexyl]-methyl]-4-methyl-6-morpholin -4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-([2-hydroxy-cyclopentyl]-methyl)-4-methyl-6- morpholin-4- yl-pyridine-3-carboxylic acid amide; N-(3-Hydroxy-4,4-dimethyl-pentyl)-2-isopropyl-4- methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Isopropyl-4-methyl-6- morpholin-4-yl-N-(4,4,4-trifluoro-3-hydroxy-butyl)-pyridine- 3-carboxylic acid amide; and N-[[(1S,2R)-2-Hydroxy-cyclohexyl]-methyl]-2-isopropyl-4-meth yl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; optionally in the form of a single stereoisomer or a mixture of stereoisomers, in the form of the free compound and/or a physiologically acceptable salt thereof. Formula 25 [0365] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 25. Such compounds are described in US Patent No.8,653,101 issued February 18, 2014 and corresponding to US Application No.10/992,118 filed November 18, 2005; International Publication No. WO2012025236A1, published March 1, 2012 and corresponding to International Application No. PCT/EP2011/004277 filed August 26, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 25, these references incorporated by reference herein control. [0366] In an embodiment, the Kv7 channel activator is a compound according to formula 25. Formula 25 wherein, R ¹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-8 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; SCF ₃ ; S(═O) ₂ —OH; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _{1- 4} aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 - aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _{1- 4} aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 -aliphatic residue, a N(C _1-4 aliphatic residue)-C(═O)—C _{1- 4} aliphatic residue, or a N(C _1-4 aliphatic residue)-S(═O) ₂ —C _1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ⁷ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an “aliphatic group” and “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O— C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O— C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , an NH—C(═O)—C _1-4 aliphatic residue, an NH—S(═O) ₂ —C _1-4 aliphatic residue, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , C(═O)H, C(═O)OH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)— O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH ₂ , a C(═O)—NH(C _{1- 4} aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases. [0367] In further embodiments, R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O— CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN and C(═O)—OH, R ² represents H; F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , a O—C _1-4 -aliphatic residue, a O—C(═O)— C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, and a NH—S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 - aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1- 4 aliphatic residue)2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4- aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0368] In further embodiments, R ² represents H; F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted aliphatic residue, a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _{1- 4} aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue. [0369] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 aliphatic residue, a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group. [0370] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C═O)—C _1-4 aliphatic residue, a C _1-4 aliphatic residue, O—C _1-4 aliphatic residue, a S— C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH ₃ . [0371] In further embodiments, at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H. [0372] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, NO ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(═O)—OH, or together denote ═O, R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes a C3-10-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH3, C(═O)—C2H5, C(═O)—O—CH3 and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, yl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH. [0373] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue, R ^8c denotes a C _{1- 4} aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _{1- 4} aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _{1- 4} -aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)— O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH. [0374] In further embodiments, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1- ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, and wherein the C _3-10 - cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue. on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0375] In further embodiments, R ⁷ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted C _1-4 -aliphatic residue, and wherein the C _{3- 10} -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is bridged via a unsubstituted C _1-8 aliphatic group. [0376] In further embodiments, R ¹ represents the partial structure: wherein: m is 0, 1 or 2 and R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 - aliphatic residue, or wherein m is 0, R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; and R ^8c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _{1- 4} aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ , C(═O)—O—C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , R ² is selected from the group consisting of H; F; Cl; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O—CH ₃ ; R ³ , R ⁴ , R ⁵ and R ⁶ are each independently of one another selected from the group consisting of H; F; Cl; Br; CF ₃ ; CN; OCF ₃ and NO ₂ ; R ⁷ denotes a C1-6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 - aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 - aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case is unsubstituted. [0377] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-(3,3-dimethyl-butyl)-2-methoxy-4-methyl-7-(trifluoromethyl )-quinoline-3- carboxylic acid amide; 2-ethoxy-4-methyl-N-(thiophene-2-yl-methyl)-7-(trifluorometh yl)- quinoline-3-carboxylic acid amide; 2-ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2- methoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(4- fluorophenyl)-methyl]-2-methoxy-4-methyl-7-(trifluoromethyl) -quinoline-3-carboxylic acid amide; 2-ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluorome thyl)-quinoline-3- carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2-(2- methoxy-ethoxy)-4-methyl-7-(trifluoromethyl)-quinoline-3-car boxylic acid amide; N-[(3- fluorophenyl)-methyl]-2-(2-hydroxy-ethoxy)-4-methyl-7-(trifl uoromethyl)-quinoline-3- carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-isopropoxy-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2- isopropoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxyl ic acid amide; 2-ethoxy-N- [(3-fluorophenyl)-methyl]-4-methoxy-7-(trifluoremethyl)-quin oline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2,4-dimethoxy-7-(trifluoromethyl )-quinoline-3- carboxylic acid amide; 2-ethoxy-N-[(4-fluorophenyl)-methyl]-4-methoxy-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethoxy-6,7-difluoro-N-[(3- fluorophenyl)-methyl]-4-methoxy-quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)- methyl]-2,4-dimethoxy-7-(trifluoromethyl)-quinoline-3-carbox ylic acid amide; 6,7- difluoro-N-[(3-fluorophenyl)-methyl]-2,4-dimethoxy-quinoline -3-carboxylic acid amide; 7- fluoro-N-[(3-fluorophenyl)-methyl]-2-methoxy-4-methyl-quinol ine-3-carboxylic acid amide; N-[(3-fluoro-4-methyl-phenyl)-methyl]-2-methoxy-4-methyl-7-( trifluoromethyl)- quinoline-3-carboxylic acid amide; 2-ethoxy-N-[(3-fluoro-4-methyl-phenyl)-methyl]-4- methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-methoxy-4-methyl-N-(m- tolyl-methyl)-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethoxy-4-methyl-N- (m-tolyl-methyl)-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(4-fluoro-3- methyl-phenyl)-methyl]-2-methoxy-4-methyl-7-(trifluoromethyl )-quinoline-3-carboxylic acid amide; 2-ethoxy-N-[(4-fluoro-3-methyl-phenyl)-methyl]-4-methyl-7-(t rifluoromethyl)- quinoline-3-carboxylic acid amide; 2-methoxy-4-methyl-N-(p-tolyl-methyl)-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethoxy-4-methyl-N-(p-tolyl-methyl)- 7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethoxy-4-methyl-N-(4-methyl- pentyl)-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-methoxy-4-methyl-N-(4- methyl-pentyl)-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-(4,4-dimethyl- pentyl)-2-methoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-c arboxylic acid amide; N- (4,4-dimethyl-pentyl)-2-ethoxy-4-methyl-7-(trifluoromethyl)- quinoline-3-carboxylic acid amide; 7-bromo-2-ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-quinol ine-3-carboxylic acid amide; 7-bromo-2-ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-quinol ine-3- carboxylic acid amide; 7-bromo-N-[(3-fluorophenyl)-methyl]-2-methoxy-4-methyl- quinoline-3-carboxylic acid amide; 7-bromo-N-[(4-fluorophenyl)-methyl]-2-methoxy-4- methyl-quinoline-3-carboxylic acid amide; 7-cyano-2-ethoxy-N-[(4-fluorophenyl)-methyl]- 4-methyl-quinoline-3-carboxylic acid amide; 7-cyano-2-ethoxy-N-[(3-fluorophenyl)- methyl]-4-methyl-quinoline-3-carboxylic acid amide; 7-cyano-N-[(3-fluorophenyl)- methyl]-2-methoxy-4-methyl-quinoline-3-carboxylic acid amide; 7-cyano-N-[(4- fluorophenyl)-methyl]-2-methoxy-4-methyl-quinoline-3-carboxy lic acid amide; N-[(3- fluoro-2-methoxy-phenyl)-methyl]-2-methoxy-4-methyl-7-(trifl uoromethyl)-quinoline-3- carboxylic acid amide; N-[(3-fluoro-5-methoxy-phenyl)-methyl]-2-methoxy-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(5-fluoro-2-methoxy-phenyl)- methyl]-2-methoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-c arboxylic acid amide; N-[(3- fluoro-2-hydroxy-phenyl)-methyl]-2-methoxy-4-methyl-7-(trifl uoromethyl)-quinoline-3- carboxylic acid amide; N-[(3-fluoro-5-hydroxy-phenyl)-methyl]-2-methoxy-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(5-fluoro-2-hydroxy-phenyl)- methyl]-2-methoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-c arboxylic acid amide; N-[(3- fluoro-4-hydroxy-phenyl)-methyl]-2-methoxy-4-methyl-7-(trifl uoromethyl)-quinoline-3- carboxylic acid amide; 7-fluoro-N-[(4-fluorophenyl)-methyl]-2-methoxy-4-methyl- quinoline-3-carboxylic acid amide: 5,7-difluoro-N-[(3-fluorophenyl)-methyl]-2-methoxy-4- methyl-quinoline-3-carboxylic acid amide; 6,7-difluoro-N-[(3-fluorophenyl)-methyl]-2- methoxy-4-methyl-quinoline-3-carboxylic acid amide; 7,8-difluoro-N-[(3-fluorophenyl)- methyl]-2-methoxy-4-methyl-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)- methyl]-4-methyl-2-(2,2,2-trifluoro-ethoxy)-7-(trifluorometh yl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-methoxy-4-(trifluoromethyl)-qu inoline-3-carboxylic acid amide; 2-ethoxy-N-[(3-fluorophenyl)-methyl]-4-(trifluoromethyl)-qui noline-3- carboxylic acid amide; and N-[(3-fluorophenyl)-methyl]-2-isopropoxy-4-(trifluoromethyl) - quinoline-3-carboxylic acid amide; respectively in the form of the free compounds; the racemate; the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio or of an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases. Formula 26 [0378] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 26. Such compounds are described in International Publication No. WO2012025236A1, published March 1, 2012 and corresponding to International Application No. PCT/EP2011/004277 filed August 26, 2011; US Patent No.9,073,862 issued July 7, 2015 and corresponding to US Application No.14/098,842 filed November 26, 2013; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 26, these references incorporated by reference herein control. [0379] In an embodiment, the Kv7 channel activator is a compound according to formula 26: Formula 26 wherein, R ¹ represents a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; SCF ₃ ; S(═O) ₂ —OH; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _{1- 4} aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 - aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _{1- 4} aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 -aliphatic residue, a N(C _1-4 aliphatic residue)-C(═O)—C _{1- 4} aliphatic residue, or a N(C _1-4 aliphatic residue)-S(═O) ₂ —C _1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ⁷ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁷ represents an unsubstituted aliphatic residue, then R ⁷ does not represent methyl or ethyl, and on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an “aliphatic group” and “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _{1- 4} aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 - aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O)2—O—C1-4-aliphatic residue, a S(═O)2—NH—C1-4-aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , an NH—C(═O)—C _1-4 aliphatic residue, an NH—S(═O) ₂ —C _{1- 4} aliphatic residue, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , C(═O)H, C(═O)OH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH ₂ , a C(═O)—NH(C _{1- 4} aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases. [0380] In further embodiments, R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, nzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O— CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN and C(═O)—OH, R ² represents H; F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , a O—C _1-4 -aliphatic residue, a O—C(═O)— C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, and a NH—S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 - aliphatic residue; a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1- 4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH, on the condition that if R ⁷ represents an unsubstituted aliphatic residue, then R ⁷ does not represent methyl or ethyl, and on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0381] In further embodiments, R ² represents H; F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 - aliphatic residue. [0382] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 aliphatic residue, a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and a O—C1-4-aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group. [0383] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C═O)—C _1-4 aliphatic residue, a C _1-4 aliphatic residue, O—C _1-4 aliphatic residue, a S— C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH ₃ . [0384] In further embodiments, at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H. [0385] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, NO ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(═O)—OH, or together denote ═O, R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, enzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH. [0386] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue, R ^8c denotes a C _{1- 4} aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _{1- 4} aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _{1- 4} -aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)— O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH. [0387] In further embodiments, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _{1- 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, and wherein the C _3-10 - cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, on the condition that if R ⁷ represents an unsubstituted aliphatic residue, then R ⁷ does not represent methyl or ethyl, and on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0388] In further embodiments, R ⁷ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is bridged via a unsubstituted C _1-8 aliphatic group, on the condition that if R ⁷ represents an unsubstituted aliphatic residue, then R ⁷ does not represent methyl or ethyl. [0389] In further embodiments, R ¹ represents the partial structure: wherein: m is 0, 1 or 2 and R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 - aliphatic residue, or wherein m is 0, R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; and R ^8c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _{1- 4} aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ , C(═O)—O—C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , R ² is selected from the group consisting of H; F; Cl; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O—CH ₃ ; R ³ , R ⁴ , R ⁵ and R ⁶ are each independently of one another selected from the group consisting of H; F; Cl; Br; CF ₃ ; CN; OCF ₃ and NO ₂ ; R ⁷ denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 - aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 - aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case is unsubstituted, and on the condition that if R ⁷ represents an unsubstituted aliphatic residue, then R ⁷ does not represent methyl or ethyl. [0390] In further embodiments, the Kv7 channel activator may be selected from the group consisting of: [0391] N-[(3-fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-7- (trifluoromethyl)- quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4- methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)- methyl]-2-(2-hydroxy-ethoxy)-4-methyl-7-(trifluoromethyl)-qu inoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-isopropoxy-4-methyl-7-(trifluo romethyl)-quinoline- 3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2-isopropoxy-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-4- methyl-2-(2,2,2-trifluoro-ethoxy)-7-(trifluoromethyl)-quinol ine-3-carboxylic acid amide; and N-[(3-fluorophenyl)-methyl]-2-isopropoxy-4-(trifluoromethyl) -quinoline-3-carboxylic acid amide; respectively in the form of the free compounds; the racemate; the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio or of an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases. Formula 27 [0392] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 27. Such compounds are described in International Publication No. WO2012025238A1, published March 1, 2012 and corresponding to International Application No. PCT/EP2011/004279 filed August 26, 2011; US Patent No.8,445,512 issued May 21, 2013 and corresponding to US Application No.13/218,556 filed August 26, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 27, these references incorporated by reference herein control. [0393] In an embodiment, the Kv7 channel activator is a compound according to formula 27:

wherein: R ¹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-8 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; SCF ₃ ; S(═O) ₂ —OH; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _{1- 4} aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 - aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _{1- 4} aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 -aliphatic residue, a N(C _1-4 aliphatic residue)-C(═O)—C _{1- 4} aliphatic residue, or a N(C _1-4 aliphatic residue)-S(═O) ₂ —C _1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H, R ⁷ represents a C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _{3- 10} -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue, in which an “aliphatic group” and “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)— NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH— S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O— C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH— C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 - aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , an NH—C(═O)—C _1-4 aliphatic residue, OH, OCF ₃ , a O— C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 - aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 - aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , C(═O)H, C(═O)OH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C3-6-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases. [0394] In further embodiments, R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—O ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—O ₂ H ₅ , C(═O)—O— CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN and C(═O)—OH, R ² represents H; F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , a O—C _1-4 -aliphatic residue, a O—C(═O)— C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, and a NH—S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 - aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C1-4-aliphatic residue and a O—C1-4-aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group, on the condition that at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H, R ⁷ denotes a C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0395] In further embodiments, R ² represents H; F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted aliphatic residue, a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _{1- 4} aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue. [0396] In further embodiments, R ² is ≠H. [0397] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 aliphatic residue, a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group, on the condition that at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H. [0398] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C═O)—C _1-4 aliphatic residue, a C _1-4 aliphatic residue, O—C _1-4 aliphatic residue, a S— C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH ₃ , on the condition that at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H. [0399] In further embodiments, R ¹ represents the partial structure: [0400] Wherein, m denotes 0, 1, 2, 3 or 4, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, NO ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(═O)—OH, or together denote ═O, R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1- ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—O ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—O ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, C(═O)—CH ₃ , C(═O)—O ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—O ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH. [0401] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue, R ^8c denotes a C _{1- 4} aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _{1- 4} aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _{1- 4} -aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—O ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—O ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—O ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH. [0402] In further embodiments, R ⁷ denotes a C _2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _{1- 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue. on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0403] In further embodiments, R ⁷ denotes a C _2-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, and a C1-4-aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C _1-8 aliphatic group, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0404] In further embodiments, R ¹ represents the partial structure: wherein: m is 0, 1 or 2 and R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 - aliphatic residue, or wherein m is 0, R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; and R ^8c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _{1- 4} aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ , C(═O)—O—C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , R ² is selected from the group consisting of H; F; Cl; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O—CH3; R ³ , R ⁴ , R ⁵ and R ⁶ are each independently of one another selected from the group consisting of H; F; Cl; Br; CH ₃ ; CF ₃ ; CN; OCF ₃ and NO ₂ ; on the condition that at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H, R ⁷ denotes ethyl, n-propyl, 2- propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl or propenyl (—CH ₂ CH═CH ₂ , —CH═CH—CH ₃ , —C(═CH ₂ )—CH ₃ ), in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—CH ₃ , CF ₃ , and N(CH ₃ ) ₂ , or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl tetrahydrofuranyl, or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, an O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case is unsubstituted, and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl tetrahydrofuranyl, or tetrahydropyranyl may in each case be optionally bridged, via an unsubstituted C _1-4 aliphatic group, on the condition that if R ⁷ denotes piperidinyl tetrahydrofuranyl, or tetrahydropyranyl, each of these residues is linked via a carbon atom. [0405] In further embodiments, the Kv7 channel activator is selected from the group consisting of: 4-methyl-2-propyl-N-(thiophene-2-yl-methyl)-7-(trifluorometh yl)-quinoline- 3-carboxylic acid amide; N-(cycloheptyl-methyl)-4-methyl-2-propyl-7-(trifluoromethyl) - quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-4-methyl-2-propyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-4- methyl-2-propyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethyl-N-[(4- fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-quinoline -3-carboxylic acid amide; 2- ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethy l)-quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2-isopropyl-4-methyl-7-(trifluor omethyl)-quinoline-3- carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-isopropyl-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-cyclopropyl-N-[(4-fluorophenyl)- methyl]-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-cyclopropyl-N- [(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-quino line-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-isopropyl-7-(trifluoromethyl)- quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2-isopropyl-7-(trifluoromethyl)- quinoline-3-carboxylic acid amide; 2-tert-butyl-N-[(3-fluorophenyl)-methyl]-7-(trifluoromethyl) -quinoline-3- carboxylic acid amide; 2-tert-butyl-N-[(4-fluorophenyl)-methyl]-7-(trifluoromethyl) - quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-(methoxymethyl)-4- methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)- methyl]-2-(methoxymethyl)-4-methyl-7-(trifluoromethyl)-quino line-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2-(hydroxymethyl)-4-methyl-7-(tr ifluoromethyl)- quinoline-3-carboxylic acid amide; 2-(2,2-dimethyl-propyl)-N-[(3-fluorophenyl)-methyl]-4- methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-(2,2-dimethyl-propyl)-N- [(4-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-quino line-3-carboxylic acid amide; 2-cyclopentyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(triflu oromethyl)-quinoline-3- carboxylic acid amide; 2-cyclopentyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-(4,4-dimethyl-pentyl)-4-methyl-2- propyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]- 4-methyl-2-[(E)-prop-1-enyl]-7-(trifluoromethyl)-quinoline-3 -carboxylic acid amide; N-[(3- fluorophenyl)-methyl]-4-methyl-2-(2-methyl-prop-1-enyl)-7-(t rifluoromethyl)-quinoline-3- carboxylic acid amide; 7-bromo-2-ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-quinoli ne- 3-carboxylic acid amide; 7-bromo-2-ethyl-N-[(4-fluorophenyl)-methyl]-4-methyl- quinoline-3-carboxylic acid amide; 7-bromo-2-cyclopropyl-N-[(3-fluorophenyl)-methyl]-4- methyl-quinoline-3-carboxylic acid amide; 7-bromo-2-cyclopropyl-N-[(4-fluorophenyl)- methyl]-4-methyl-quinoline-3-carboxylic acid amide; 7-bromo-N-[(3-fluorophenyl)- methyl]-2-isopropyl-4-methyl-quinoline-3-carboxylic acid amide; 7-bromo-N-[(4- fluorophenyl)-methyl]-2-isopropyl-4-methyl-quinoline-3-carbo xylic acid amide; 2- (dimethylaminomethyl)-N-[(3-fluorophenyl)-methyl]-4-methyl-7 -(trifluoromethyl)- quinoline-3-carboxylic acid amide; 2-ethyl-N-[(4-fluoro-3-methyl-phenyl)-methyl]-4- methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 7-cyano-2-ethyl-N-[(3- fluorophenyl)-methyl]-4-methyl-quinoline-3-carboxylic acid amide; 2-ethyl-N-[(3-fluoro-4- methyl-phenyl)-methyl]-4-methyl-7-(trifluoromethyl)-quinolin e-3-carboxylic acid amide; 7-cyano-2-ethyl-N-[(4-fluorophenyl)-methyl]-4-methyl-quinoli ne-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-4-methyl-2-(2-methyl-propyl)-7-( trifluoromethyl)-quinoline-3- carboxylic acid amide; 7-cyano-2-cyclopropyl-N-[(3-fluorophenyl)-methyl]-4-methyl- quinoline-3-carboxylic acid amide; 7-cyano-2-cyclopropyl-N-[(4-fluorophenyl)-methyl]-4- methyl-quinoline-3-carboxylic acid amide; 7-cyano-N-[(3-fluorophenyl)-methyl]-2- isopropyl-4-methyl-quinoline-3-carboxylic acid amide; and 7-cyano-N-[(4-fluorophenyl)- methyl]-2-isopropyl-4-methyl-quinoline-3-carboxylic acid amide; respectively in the form of the free compounds; the racemate; the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio or of an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases. Formula 28 [0406] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 28. Such compounds are described in International Publication No. WO2012028300A1, published March 8,2012 and corresponding to International Application No. PCT/EP2011/004369 filed August 31, 2011; US Patent No.8,618,129 issued December 31, 2013 and corresponding to US Application No.13/222,023 filed August 31, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 28, these references incorporated by reference herein control. [0407] In an embodiment, the Kv7 channel activator is a compound according to formula 28:

wherein, R ¹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted and optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents F; Cl; Br; I; CN; CF3; C(═O)H; NO2; OCF3; SCF3; a C1-4-aliphatic residue, a C(═O)—C1-4 aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O— C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; SCF ₃ ; S(═O) ₂ —OH; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH— S(═O) ₂ —C _1-4 -aliphatic residue, a N(C _1-4 aliphatic residue)-C(═O)—C _1-4 aliphatic residue, or a N(C _1-4 aliphatic residue)S(═O) ₂ —C _1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _{1- 4} aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ⁷ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _{3- 10} -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an “aliphatic group” and “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, OH, ═O, OCF ₃ , a O—C _1-4 -aliphatic residue, a O— C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH— C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 - aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, ═O, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)— NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , NH(C1-4 aliphatic residue), an N(C1-4 aliphatic residue)2, an NH—C(═O)—C1-4 aliphatic residue, an NH—S(═O) ₂ —C _1-4 aliphatic residue, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH— C _1-4 -aliphatic residue, CN, CF ₃ , C(═O)H, C(═O)OH, a C _1-4 -aliphatic residue, a C(═O)— C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases. [0408] In further embodiments, R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF3, SH, SCF3, a S—C1-4 aliphatic residue, CF3, CN, a C1-4-aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue may optionally be bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _{1- 4} aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _{3- 6} cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN and C(═O)—OH, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _{1- 4} aliphatic residue) ₂ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, and a NH—S(═O) ₂ — C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 -aliphatic residue; a C _3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4-aliphatic residue, CF3, CN, a C1-4- aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 - aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , ═O, OH, an O—C _{1- 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0409] In further embodiments, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue. [0410] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 aliphatic residue, a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, and a O—C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group. [0411] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C═O)—C _1-4 aliphatic residue, a C _1-4 aliphatic residue, O—C _1-4 aliphatic residue, a S— C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH ₃ . [0412] In further embodiments, at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H. [0413] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, NO ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(═O)—OH, or together denote ═O, R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , ═O, OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes a C _3-10 - cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO2, NH2, an NH(C1- 4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _{3- 6} cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH. [0414] In further embodiments, R ¹ represents the partial structure wherein, m denotes 0, 1, or 2, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue, R ^8c denotes a C _{1- 4} aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF3 and an unsubstituted O—C1-4-aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, Cl, CH ₃ , O—CH ₃ , CF ₃ and OCF ₃ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH. [0415] In further embodiments, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , ═O, OH, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, CF3, CN, a C1-4-aliphatic residue, a C3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, and wherein the C _3-10 - cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue. on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0416] In further embodiments, R ⁷ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged via an unsubstituted C _1-8 aliphatic group, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0417] In further embodiments, R ¹ represents the partial structure: wherein: m is 0, 1 or 2 and R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or wherein m is 0, R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; R ^8c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ , C(═O)—O—C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O— CH ₃ and C(═O)—O—C ₂ H ₅ , R ² is selected from the group consisting of F; Cl; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O—CH ₃ ; R ³ , R ⁴ , R ⁵ and R ⁶ are each independently of one another selected from the group consisting of H; F; Cl; CF ₃ ; CN; OCF ₃ and NO ₂ ; R ⁷ denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 - aliphatic residue, a C(═O)—O—C1-4-aliphatic residue, OCF3, SH, SCF3, a S—C1-4- aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of OH, and an unsubstituted O—C _1-4 - aliphatic residue. [0418] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-(3-fluorobenzyl)-2,4-dimethyl-1-oxo-7-(trifluoromethyl)-1, 2- dihydroisoquinoline-3-carboxamide; N-(3-fluorobenzyl)-4-methyl-1-oxo-2-propyl-7- (trifluoromethyl)-1,2-dihydroisoquinoline-3-carboxamide; 2-ethyl-N-(3-fluorobenzyl)-4- methyl-1-oxo-7-(trifluoromethyl)-1,2-dihydroisoquinoline-3-c arboxamide; N-(3- fluorobenzyl)-2-isopropyl-4-methyl-1-oxo-7-(trifluoromethyl) -1,2 dihydroisoquinoline-3- carboxamide; andN-(3-fluorobenzyl)-2-(2-methoxyethyl)-4-methyl-1-oxo-7- (trifluoromethyl)-1,2-dihydroisoquinoline-3-carboxamide; respectively in the form of the free compounds; the racemate; the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio or of an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases. Formula 29 [0419] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 29. Such compounds are described in US Patent No.8,653,102 issued February 18, 2014and corresponding to US Application No.13/218,579 filed August 26, 2011; International Publication No. PCT/EP2011/004280, published March 1, 2012, and corresponding to International Application No. WO2012025239A1filed August 25, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 29, these references incorporated by reference herein control. [0420] In an embodiment, the Kv7 channel activator is a compound according to formula 29: wherein: X denotes O or S, R ¹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ² represents F; Cl; Br; I; CN; CF ₃ ; C(═O)H; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; SCF ₃ ; S(═O) ₂ —OH; NO ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _{1- 4} aliphatic residue, a C(═O)—N(C _1-4 aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O—C _1-4 - aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, wherein the C _{1- 4} aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH—S(═O) ₂ —C _1-4 -aliphatic residue, a N(C _1-4 aliphatic residue)-C(═O)—C _1- 4 aliphatic residue, or a N(C1-4 aliphatic residue)-S(═O)2—C1-4 aliphatic residue, wherein the C _1-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R ⁷ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an “aliphatic group” and “aliphatic residue” can in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” can in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group” and an “aliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), a NH—C(═O)—C _{1- 4} aliphatic residue, a NH—S(═O) ₂ —C _1-4 aliphatic residue, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)— NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, a NH— S(═O)2—C1-4 aliphatic residue, ═O, OH, OCF3, a O—C1-4-aliphatic residue, a O— C(═O)—C _1-4 -aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 -aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH— C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 - aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , (C ₁ aliphatic residue), _-4 an N(C _1-4 aliphatic residue) ₂ , an NH—C(═O)—C _1-4 aliphatic residue, an NH—S(═O) ₂ — C _1-4 aliphatic residue, OH, OCF ₃ , a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 - aliphatic residue, SH, SCF ₃ , a S—C _1-4 -aliphatic residue, S(═O) ₂ OH, a S(═O) ₂ —C _1-4 - aliphatic residue, a S(═O) ₂ —O—C _1-4 -aliphatic residue, a S(═O) ₂ —NH—C _1-4 -aliphatic residue, CN, CF ₃ , C(═O)H, C(═O)OH, a C _1-4 -aliphatic residue, a C(═O)—C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, a C _3-6 -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)—NH ₂ , a C(═O)—NH(C _1-4 aliphatic residue), and a C(═O)—N(C _1-4 aliphatic residue) ₂ ; with the exception of the following compound: 1-ethyl-N-(4-methoxybenzyl)-4-methyl-2-oxo-1,2- dihydroquinoline-3-carboxamide, in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases. [0421] In further embodiments, R ¹ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), OH, an O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, wherein the C1-4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , O—CH ₂ —OH, O—CH ₂ —O—CH ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O— CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _{1- 4} aliphatic residue, CF ₃ , CN and C(═O)—OH, X represents O or S; R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _{1- 4} aliphatic residue, a C(═O)—O—C _1-4 aliphatic residue, a C(═O)—NH—C _1-4 aliphatic residue, a C(═O)—N(C1-4 aliphatic residue)2, a O—C1-4-aliphatic residue, a O—C(═O)— C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH—C(═O)—C _1-4 aliphatic residue, and a NH—S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and a O—C _1-4 - aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, a C _{1- 4} -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), OH, an O—C _1-4 - aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue and C(═O)—OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(═O)—OH, and wherein the C3-10-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0422] In further embodiments, R ² represents F; Cl; Br; I; CN; CF ₃ ; NO ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted aliphatic residue, a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted aliphatic residue, and wherein the C _3-6 -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an unsubstituted C _1-4 - aliphatic residue and an unsubstituted O—C _1-4 -aliphatic residue. [0423] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another represent H; F; Cl; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; C(═O)H; C(═O)—OH; C(═O)—NH ₂ ; S(═O) ₂ —OH; NO ₂ ; a C _1-4 -aliphatic residue, a C(═O)—C _1-4 aliphatic residue, a C(═O)— O—C _1-4 aliphatic residue, a O—C _1-4 -aliphatic residue, a O—C(═O)—C _1-4 -aliphatic residue, a S—C _1-4 -aliphatic residue, a S(═O) ₂ —C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and a O— C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH, a C _1-4 -aliphatic residue and a O—C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group. [0424] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C═O)—C _1-4 aliphatic residue, a C _1-4 aliphatic residue, O—C _1-4 aliphatic residue, a S— C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH ₃ . [0425] In further embodiments, at least one of R ³ , R ⁴ , R ⁵ and R ⁶ is ≠H. [0426] In further embodiments, R ¹ represents the partial structure: wherein, m denotes 0, 1, 2, 3 or 4, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, NO2, NH2, a NH(C1-4 aliphatic residue), OH, an O—C1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(═O)—OH, R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)— OH, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—OH, a C _3-6 cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF3, CF3 and an unsubstituted O—C1-4-aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O— C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)— OH, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , NH ₂ , an NH(C _{1- 4} aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(═O)—OH. [0427] In further embodiments, R ¹ represents the partial structure: wherein: m denotes 0, 1, or 2, R ^8a and R ^8b each independently of one another represent H, F, Cl, Br, I, an O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue, R ^8c denotes a C _{1- 4} aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C _{1- 4} aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF ₃ and an unsubstituted O—C _{1- 4} -aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , a C _3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)— O—C ₂ H ₅ , and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(═O)—OH. [0428] In further embodiments, R ⁷ denotes a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, an O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 -aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, COOH, CF ₃ , CN, and a C _1-4 - aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _{1- 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 - aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C _3-6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O—C _1-4 -aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, and wherein the C _3-10 - cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO ₂ , OH, an O—C _1-4 aliphatic residue, a C(═O)—O—C _{1- 4} -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue. on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0429] In further embodiments, R ⁷ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C1-4-aliphatic residue, COOH, a C(═O)—O—C1-4- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF ₃ and an unsubstituted aliphatic residue, or denotes a C _3-10 - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, an O—C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S—C _1-4 aliphatic residue, a C(═O)—O—C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted C _1-4 -aliphatic residue, and wherein the C _3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged via an unsubstituted C _1-8 aliphatic group, on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. [0430] In further embodiments, R ¹ represents the partial structure: wherein: m is 0, 1 or 2 and R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; R ^8c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C1-4 aliphatic residue, CF3, and an unsubstituted C1-4- aliphatic residue, or wherein m is 0, R ^8a and R ^8b each independently of one another represent H, F, a O—C _1-4 aliphatic residue or a C _1-4 aliphatic residue; and R ^8c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _{1- 4} aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ , C(═O)—O—C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(═O)—CH ₃ , C(═O)—C ₂ H ₅ , C(═O)—O—CH ₃ and C(═O)—O—C ₂ H ₅ , X represents O or S; R ² is selected from the group consisting of F; Cl; Br; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O—CH ₃ ; R ³ , R ⁴ , R ⁵ and R ⁶ are each independently of one another selected from the group consisting of H; F; Cl; Br; CF ₃ ; CN; OCF ₃ and NO ₂ ; R ⁷ denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C _1-4 - aliphatic residue, COOH, a C(═O)—O—C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S— C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of OH, and an unsubstituted O—C _1-4 - aliphatic residue, or denotes an unsubstituted C _3-6 -cycloaliphatic residue or an unsubstituted 3 to 6 membered heterocycloaliphatic residue, on the condition that if R ⁷ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom. [0431] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-[(3-Fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-7-(trifluorom ethyl)-1H- quinoline-3-carboxylic acid amide; 1-Butyl-N-[(3-fluorophenyl)-methyl]-4-methyl-2-oxo-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1,4- dimethyl-2-thioxo-7-(trifluoromethyl)-1H-quinoline-3-carboxy lic acid amide; N-[(3- Fluorophenyl)-methyl]-1-(2-methoxy-ethyl)-4-methyl-2-oxo-7-( trifluoromethyl)-1H- quinoline-3-carboxylic acid amide; 1-Ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-2-oxo-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(4-Fluorophenyl)-methyl]-1,4- dimethyl-2-oxo-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(4- Fluorophenyl)-methyl]-1-(2-methoxy-ethyl)-4-methyl-2-oxo-7-( trifluoromethyl)-1H- quinoline-3-carboxylic acid amide; 1-Ethyl-N-[(4-fluorophenyl)-methyl]-4-methyl-2-oxo-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1,4- dimethyl-2-oxo-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-(2- methoxy-ethyl)-4-methyl-2-oxo-1H-quinoline-3-carboxylic acid amide; N-[(3- Fluorophenyl)-methyl]-4-methyl-2-oxo-1-propyl-7-(trifluorome thyl)-1H-quinoline-3- carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4-methyl-1-(3-methyl-butyl)-2-ox o-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4- methyl-1-(4-methyl-pentyl)-2-oxo-7-(trifluoromethyl)-1H-quin oline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-(3-methoxy-propyl)-4-methyl-2- oxo-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-[2- (2-methoxy-ethoxy)-ethyl]-4-methyl-2-oxo-7-(trifluoromethyl) -1H-quinoline-3-carboxylic acid amide; 7-Bromo-N-[(3-fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-1H-qu inoline-3- carboxylic acid amide; 7-Bromo-N-[(4-fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-1H- quinoline-3-carboxylic acid amide; 7-Bromo-N-[(3-fluorophenyl)-methyl]-1-(2-methoxy- ethyl)-4-methyl-2-oxo-1H-quinoline-3-carboxylic acid amide; 7-Bromo-N-[(4- fluorophenyl)-methyl]-1-(2-methoxy-ethyl)-4-methyl-2-oxo-1H- quinoline-3-carboxylic acid amide; 7-Cyano-N-[(3-fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-1H-qu inoline-3- carboxylic acid amide; 7-Cyano-N-[(4-fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-1H- quinoline-3-carboxylic acid amide; 7-Cyano-N-[(3-fluorophenyl)-methyl]-1-(2-methoxy- ethyl)-4-methyl-2-oxo-1H-quinoline-3-carboxylic acid amide; 7-Cyano-N-[(4- fluorophenyl)-methyl]-1-(2-methoxy-ethyl)-4-methyl-2-oxo-1H- quinoline-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-1-(2-methoxy-ethyl)-4-methyl-2-oxo-7 - (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-1,4- dimethyl-2-oxo-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; 2-[3-[(3- Fluorophenyl)-methyl-carbamoyl]-4-methyl-2-oxo-7-(trifluorom ethyl)-1H-quinolin-1-yl]- acetic acid methyl ester; 3-[3-[(3-Fluorophenyl)-methyl-carbamoyl]-4-methyl-2-oxo-7- (trifluoromethyl)-1H-quinolin-1-yl]-propionic acid methyl ester; 2-[3-[(3-Fluorophenyl)- methyl-carbamoyl]-4-methyl-2-oxo-7-(trifluoromethyl)-1H-quin olin-1-yl]-acetic acid; 3-[3- [(3-Fluorophenyl)-methyl-carbamoyl]-4-methyl-2-oxo-7-(triflu oromethyl)-1H-quinolin-1- yl]-propionic acid; N-[(3-Fluorophenyl)-methyl]-1-[1-(methoxymethyl)-propyl]-4-m ethyl-2- oxo-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)- methyl]-1-[2-methoxy-1-(methoxymethyl)-ethyl]-4-methyl-2-oxo -7-(trifluoromethyl)-1H- quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-(2-methoxy-butyl)-4- methyl-2-oxo-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3- Fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-7-(trifluoromethylo xy)-1H-quinoline-3- carboxylic acid amide; 7-Fluoro-N-[(3-fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-1H- quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-(2-methoxy-1-methyl- ethyl)-4-methyl-2-oxo-7-(trifluoromethyl)-1H-quinoline-3-car boxylic acid amide; N-[(4- Fluorophenyl)-methyl]-1,4-dimethyl-2-thioxo-7-(trifluorometh yl)-1H-quinoline-3- carboxylic acid amide; 7-Chloro-N-[(3-fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-1H- quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-(2-hydroxy-ethyl)-4- methyl-2-oxo-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; 1-(2-Ethoxy- ethyl)-N-[(3-fluorophenyl)-methyl]-4-methyl-2-oxo-7-(trifluo romethyl)-1H-quinoline-3- carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-isopropyl-4-methyl-2-oxo-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4- methyl-2-oxo-1-pentyl-7-(trifluoromethyl)-1H-quinoline-3-car boxylic acid amide; N-[(3- Fluorophenyl)-methyl]-1-methyl-2-oxo-4-(trifluoromethyl)-1H- quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1-(2-methoxy-propyl)-4-methyl-2- oxo-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-4- methyl-2-oxo-1-tetrahydro-pyran-4-yl-7-(trifluoromethyl)-1H- quinoline-3-carboxylic acid amide; and N-[(3-Fluorophenyl)-methyl]-4-methoxy-1-methyl-2-oxo-7-(trif luoromethyl)- 1H-quinoline-3-carboxylic acid amide; respectively in the form of the free compounds; the racemate; the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio or of an individual enantiomer or diastereomer; or in the form of the salts of physiologically acceptable acids or bases. Formula 30 [0432] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 30. Such compounds are described in International Publication No. WO2010075973A1, published July 8, 2010, and corresponding to International Application No. PCT/EP2009/009040 filed December 16, 2009; US Patent No.8,367,700 issued February 5, 2013 and corresponding to US Application No.12/635,800 filed December 11, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 30, these references incorporated by reference herein control. [0433] In an embodiment, the Kv7 channel activator is a compound according to formula 30: , wherein, R ⁰ stands for C _1-10 alkyl or C _2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, each unsubstituted or mono- or polysubstituted; C _1-8 alkyl-bridged C _{3- 7} cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or C _1-8 alkyl-bridged aryl or heteroaryl, each unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; R ¹ stands for F; Cl; Br; CN; C _1-10 alkyl or C _{2- 10} heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, each unsubstituted or mono- or polysubstituted; C _1-8 alkyl-bridged C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; C _1-8 alkyl-bridged heteroaryl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or C _1-8 alkyl-bridged aryl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be unbranched, saturated or unsaturated, unsubstituted; R ² stands for H; F; Cl; Br; or C _{1- 10} alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; or R ¹ and R ² together with the carbon atom binding them as ring member form a C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, each optionally fused to (hetero)aryl, unsubstituted or mono- or polysubstituted; R ³ , R ⁴ , R ⁵ and R ⁶ each mutually independently denote H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; R ⁰ ; C(═O)H; C(═O)R ⁰ ; CO ₂ H; C(═O)OR ⁰ ; CONH ₂ ; C(═O)NHR ⁰ ; C(═O)N(R ⁰ ) ₂ ; OH; OR ⁰ ; —O—(C _1-8 alkyl)-O—; O— C(═O)—R ⁰ ; O—C(═O)—O—R ⁰ ; O—(C═O)—NH—R ⁰ ; O—C(═O)—N(R ⁰ ) ₂ ; O— S(═O) ₂ —R ⁰ ; O—S(═O) ₂ OH; O—S(═O) ₂ OR ⁰ ; O—S(═O) ₂ NH ₂ ; O—S(═O) ₂ NHR ⁰ ; O— S(═O) ₂ N(R ⁰ ) ₂ ; NH ₂ ; NH—R ⁰ ; N(R ⁰ ) ₂ ; NH—C(═O)—R ⁰ ; NH—C(═O)—O—R ⁰ ; NH— C(═O)—NH ₂ ; NH—C(═O)—NH—R ⁰ ; NH—C(═O)—N(R ⁰ ) ₂ ; NR ⁰ —C(═O)—R ⁰ ; NR ⁰ — C(═O)—O—R ⁰ ; NR ⁰ —C(═O)—NH ₂ ; NR ⁰ —C(═O)—NH—R ⁰ ; NR ⁰ —C(═O)—)—N(R ⁰ ) ₂ ; NH—S(═O) ₂ OH; NH—S(═O) ₂ R ⁰ ; NH—S(═O) ₂ OR ⁰ ; NH—S(═O) ₂ NH ₂ ; NH— S(═O) ₂ NHR ⁰ ; NH—S(═O) ₂ N(R ⁰ ) ₂ ; NR ⁰ —S(═O) ₂ OH; NR ⁰ —S(═O) ₂ R ⁰ ; NR ⁰ — S(═O) ₂ OR ⁰ ; NR ⁰ —S(═O) ₂ NH ₂ ; NR ⁰ —S(═O) ₂ NHR ⁰ ; NR ⁰ —S(═O) ₂ N(R ⁰ ) ₂ ; SH; SR ⁰ ; S(═O)R ⁰ ; S(═O) ₂ R ⁰ ; S(═O) ₂ OH; S(═O) ₂ OR ⁰ ; S(═O) ₂ NH ₂ ; S(═O) ₂ NHR ⁰ ; or S(═O) ₂ N(R) ₂ ; R ⁷ , R ⁸ , R ⁹ , R ¹⁰ each mutually independently stand for H; F; Cl; Br; or C _{1- 10} alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; R ¹¹ stands for H; F; Cl; Br; CN; or R ⁰ ; R ¹² stands for H; F; Cl; Br; CN; or C _1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; R ¹³ stands for H; F; Cl; Br; CN; C _1-10 alkyl or C _2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, each unsubstituted or mono- or polysubstituted; C _1-8 alkyl-bridged C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or C _2-8 alkyl-bridged aryl or heteroaryl, each unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; R ¹⁴ stands for H; F; Cl; Br; CN; or C _1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; or R ¹¹ and R ¹³ together with the carbon atoms binding them as ring members form a C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, optionally fused to (hetero)aryl, unsubstituted or mono- or polysubstituted; or R ¹¹ and R ¹² ; or R ¹³ and R ¹⁴ , together with the carbon atoms binding them as ring members form a C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, each optionally fused to (hetero)aryl, unsubstituted or mono- or polysubstituted; R ¹⁵ stands for R ⁰ ; wherein “alkyl- substituted”, “heteroalkyl-substituted”, “heterocyclyl-substituted” and “cycloalkyl- substituted” stand for the substitution of one or more hydrogen atoms, each mutually independently, with F; Cl; Br; I; CN; CF ₃ ; ═O; ═NH; ═C(NH ₂ ) ₂ ; NO ₂ ; R ⁰ ; C(═O)H; C(═O)R ⁰ ; CO ₂ H; C(═O)OR ⁰ ; CONH ₂ ; C(═O)NHR ⁰ ; C(═O)N(R ⁰ ) ₂ ; OH; OR ⁰ ; O—(C _{1- 8} alkyl)-O; O—C(═O)—R ⁰ ; O—C(═O)—O—R ⁰ ; O—(C═O)—NH—R ⁰ ; O—C(═O)— N(R ⁰ ) ₂ ; O—S(═O) ₂ —R ⁰ ; O—S(═O) ₂ OH; O—S(═O) ₂ OR ⁰ ; O—S(═O) ₂ NH ₂ ; O— S(═O) ₂ NHR ⁰ ; O—S(═O) ₂ N(R ⁰ ) ₂ ; NH ₂ ; NH—R ⁰ ; N(R ⁰ ) ₂ ; NH—C(═O)—R ⁰ ; NH—C(═O)— O—R ⁰ ; NH—C(═O)—NH ₂ ; NH—C(═O)—NH—R ⁰ ; NH—C(═O)—N(R ⁰ ) ₂ ; NR ⁰ —C(═O)— R ⁰ ; NR ⁰ —C(═O)—O—R ⁰ ; NR ⁰ —C(═O)—NH ₂ ; NR ⁰ —C(═O)—NH—R ⁰ ; NR ⁰ —C(═O)— N(R ⁰ ) ₂ ; NH—S(═O) ₂ OH; NH—S(═O) ₂ R ⁰ ; NH—S(═O) ₂ OR ⁰ ; NH—S(═O) ₂ NH ₂ ; NH— S(═O) ₂ NHR ⁰ ; NH—S(═O) ₂ N(R) ₂ ; NR ⁰ —S(═O) ₂ OH; NR ⁰ —S(═O) ₂ R ⁰ ; NR ⁰ —S(═O) ₂ OR ⁰ ; NR ⁰ —S(═O) ₂ NH ₂ ; NR ⁰ —S(═O) ₂ NHR ⁰ ; NR ⁰ —S(═O) ₂ N(R ⁰ ) ₂ ; SH; SR ⁰ ; S(═O)R ⁰ ; S(═O) ₂ R ⁰ ; S(═O) ₂ OH; S(═O) ₂ OR ⁰ ; S(═O) ₂ NH ₂ ; S(═O) ₂ NHR ⁰ ; or S(═O) ₂ N(R) ₂ ; wherein “aryl-substituted” and “heteroaryl-substituted” stand for the substitution of one or more hydrogen atoms, each mutually independently, with F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; R ⁰ ; C(═O)H; C(═O)R ⁰ ; CO ₂ H; C(═O)OR ⁰ ; CONH ₂ ; C(═O)NHR ⁰ ; C(═O)N(R ⁰ ) ₂ ; OH; OR ⁰ ; O—(C _1-8 alkyl)-O; O—C(═O)—R ⁰ ; O—C(═O)—O—R ⁰ ; O—(C═O)—NH—R ⁰ ; O— C(═O)—N(R ⁰ ) ₂ ; O—S(═O) ₂ —R ⁰ ; O—S(═O) ₂ OH; O—S(═O) ₂ OR ⁰ ; O—S(═O) ₂ NH ₂ ; O— S(═O) ₂ NHR ⁰ ; O—S(═O) ₂ N(R ⁰ ) ₂ ; NH ₂ ; NH—R ⁰ ; N(R ⁰ ) ₂ ; NH—C(═O)—R ⁰ ; NH—C(═O)— O—R ⁰ ; NH—C(═O)—NH ₂ ; NH—C(═O)—NH—R ⁰ ; NH—C(═O)—N(R ⁰ ) ₂ ; NR ⁰ —C(═O)— R ⁰ ; NR ⁰ —C(═O)—O—R ⁰ ; NR ⁰ —C(═O)—NH ₂ ; NR ⁰ —C(═O)—NH—R ⁰ ; NR ⁰ —C(═O)— N(R ⁰ )2; NH—S(═O)2OH; NH—S(═O)2R ⁰ ; NH—S(═O)2OR ⁰ ; NH—S(═O)2NH2; NH— S(═O) ₂ NHR ⁰ ; NH—S(═O) ₂ N(R ⁰ ) ₂ ; NR ⁰ —S(═O) ₂ OH; NR ⁰ —S(═O) ₂ R ⁰ ; NR ⁰ — S(═O) ₂ OR ⁰ ; NR ⁰ —S(═O) ₂ NH ₂ ; NR ⁰ —S(═O) ₂ NHR ⁰ ; NR ⁰ —S(═O) ₂ N(R ⁰ ) ₂ ; SH; SR ⁰ ; S(═O)R ⁰ ; S(═O) ₂ R ⁰ ; S(═O) ₂ OH; S(═O) ₂ OR ⁰ ; S(═O) ₂ NH ₂ ; S(═O) ₂ NHR ⁰ ; or S(═O) ₂ N(R) ₂ ; in the form of a free compound or salt of a physiologically compatible acid or base. [0434] In further embodiments, R ¹ stands for C _1-10 alkyl or C _2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C _3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, each unsubstituted or mono- or polysubstituted; C _{1- 8} alkyl-bridged C _3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; C _1-8 alkyl-bridged heteroaryl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or C _{1- 8} alkyl-bridged aryl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be unbranched, saturated or unsaturated, unsubstituted; R ² stands for H; or C _{1- 10} alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted. [0435] In further embodiments, R ³ , R ⁴ , R ⁵ and R ⁶ each mutually independently denote H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; R ⁰ ; C(═O)(R ⁰ or H); C(═O)O(R ⁰ or H); C(═O)N(R ⁰ or H) ₂ ; OH; OR ⁰ ; —O—(C _1-8 alkyl)-O—; O—(C _1-8 alkyl)-O—C _1-8 alkyl; OCF ₃ ; N(R ⁰ or H) ₂ ; N(R ⁰ or H)—C(═O)—R ⁰ ; N(R ⁰ or H)—C(═O)—N(R ⁰ or H) ₂ ; SH; SCF ₃ ; SR ⁰ ; S(═O) ₂ R ⁰ ; S(═O) ₂ O(R ⁰ or H); S(═O) ₂ —N(R ⁰ or H) ₂ . [0436] In further embodiments, R ⁷ , R ⁸ , R ⁹ , R ¹⁰ mutually independently stand for H; or C _{1- 10} alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted. [0437] In further embodiments, R ¹¹ stands for H; F; Cl; Br; CN; C _1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; phenyl or heteroaryl, each unsubstituted or mono- or polysubstituted; or C _1-4 alkyl- bridged phenyl or heteroaryl, each unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; R ¹³ stands for H; F; Cl; Br; CN; C _1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; phenyl or heteroaryl, each unsubstituted or mono- or polysubstituted; or C _2-4 alkyl-bridged phenyl or heteroaryl, each unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; or R ¹¹ and R ¹³ together with the carbon atoms binding them as ring members form a C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, optionally fused to phenyl, unsubstituted or mono- or polysubstituted. [0438] In further embodiments, R ¹² and R ¹⁴ each mutually independently stand for H; or C _1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted. [0439] In further embodiments, R ¹⁵ stands for C _3-10 alkyl or C _2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C _3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, unsubstituted or mono- or polysubstituted; C _1-8 alkyl- bridged C _3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or C _1-8 alkyl-bridged aryl or heteroaryl, each unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Formula 31 [0440] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 31. Such compounds are described in International Publication No. WO2010075973A1, published July 8, 2010, and corresponding to International Application No. PCT/EP2009/009040 filed December 16, 2009; US Patent No.8,367,700 issued February 5, 2013, and corresponding to US Application No.12/635,800 filed December 11, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 31, these references incorporated by reference herein control. [0441] In an embodiment, the Kv7 channel activator is a compound according to formula 31: wherein, R ¹ stands for C _1-10 alkyl or C _2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C _3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl or thienyl, each unsubstituted or mono- or polysubstituted; C _1-8 alkyl-bridged C _3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; C _1-8 alkyl-bridged phenyl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted; or C _1-8 alkyl-bridged thienyl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; R ³ , R ⁴ , R ⁵ and R ⁶ each mutually independently denote H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; R ⁰ ; C(═O)(R ⁰ or H); C(═O)O(R ⁰ or H); C(═O)N(R ⁰ or H) ₂ ; OH; OR ⁰ ; O— (C _1-8 alkyl)-O; O—(C _1-8 alkyl)-O—C _1-8 alkyl; N(R ⁰ or H) ₂ ; N(R ⁰ or H)—C(═O)—R ⁰ ; N(R ⁰ or H)—C(═O)—N(R ⁰ or H) ₂ ; SH; SR ⁰ ; S(═O) ₂ R ⁰ ; S(═O) ₂ O(R ⁰ or H); or S(═O) ₂ —N(R ⁰ or H) ₂ ; R ⁷ , R ⁸ , R ⁹ , R ¹⁰ each mutually independently stand for H; or C _1-4 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; R ¹¹ and R ¹³ each independently stand for H; or C _1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; or R ¹¹ and R ¹³ together with the carbon atoms binding them as ring members form a C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted; R ¹⁵ stands for C _3-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, unsubstituted or mono- or polysubstituted; C _1-8 alkyl-bridged C _3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or C _1-8 alkyl-bridged aryl or heteroaryl, each unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. [0442] In further embodiments, R ¹⁵ stands for C _3-10 alkyl, saturated or unsaturated; branched or unbranched, unsubstituted or mono- or polysubstituted; or is selected from the following substructures:

wherein: n=0, 1, 2, 3, 4, 5, 6, 7 or 8; m=0, 1, 2 or 3; ring X can contain one or two N atoms as ring member(s); ring Y contains at least 1 heteroatom selected from N, O or S and can contain up to 3 heteroatoms mutually independently selected from N, O or S; and/or can contain one or two double bonds; R ¹⁸ and R ¹⁹ mutually independently denote H; F; Cl; Br; I; NO ₂ ; CF ₃ ; CN; R ⁰ ; C(═O)(R ⁰ or H); C(═O)O(R ⁰ or H); C(═O)N(R ⁰ or H) ₂ ; OH; OR ⁰ ; O—(C _1-8 alkyl)-O; O—(C _1-8 alkyl)-O—C _1-8 alkyl; N(R ⁰ or H) ₂ ; N(R ⁰ or H)— C(═O)—R ⁰ ; N(R ⁰ or H)—C(═O)—N(R ⁰ or H) ₂ ; SH; SR ⁰ ; S(═O) ₂ R ⁰ ; S(═O) ₂ O(R ⁰ or H); or S(═O) ₂ —N(R ⁰ or H) ₂ H; or R ¹⁸ and R ¹⁹ together with the carbon or nitrogen atoms binding them as ring members form an aryl or heteroaryl fused to the phenyl or heteroaryl ring, each unsubstituted or mono- or polysubstituted; or a C _3-7 cycloalkyl or heterocyclyl fused to the phenyl or heteroaryl ring, each saturated or unsaturated, unsubstituted or mono- or polysubstituted; R ²⁰ and R ²¹ mutually independently denote H or C _1-10 alkyl, saturated or unsaturated; branched or unbranched, unsubstituted or mono- or polysubstituted; or C _3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted; or R ²⁰ and R ²¹ together with the carbon atoms or heteroatoms binding them as ring members form an aryl or heteroaryl fused to ring Y, each unsubstituted or mono- or polysubstituted; R ²² and R ²³ mutually independently denote H; or C _1-10 alkyl, saturated or unsaturated; branched or unbranched, unsubstituted. [0443] In further embodiments, the Kv7 channel activator is selected from the group consisting of: 4-Oxo-4-(1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl)-N-(3- (trifluoromethyl)benzyl)butyric acid amide; 4-(1-Methyl-3,4-dihydro-1H-isoquinolin-2-yl)- 4-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]butyric acid amide; 4-Oxo-4-(1-thien-2-yl-3,4- dihydroisoquinolin-2(1H)-yl)-N-(3-(trifluoromethyl)benzyl)bu tyric acid amide; 4-Oxo-4-[1- (4-pyridyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-[[3-(trifluor omethyl)phenyl]methyl]butyric acid amide; 4-(7-Fluoro-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxo- N-(3- (trifluoromethyl)benzyl)butyric acid amide; 4-(5-Fluoro-1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-4-oxo-N-[[3-(trifluoromethyl)phenyl]methyl ]butyric acid amide; 4-Oxo-4- (1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-[[2-(trifluorom ethyl)phenyl]methyl]butyric acid amide; 4-Oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-[[4- (trifluoromethyl)phenyl]methyl]butyric acid amide; 4-(4-Methyl-1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-4-oxo-N-[[3-(trifluoromethyl)phenyl]methyl ]butyric acid amide; 4-(4,4- Dimethyl-1-phenyl-1,3-dihydroisoquinolin-2-yl)-4-oxo-N-[[3- (trifluoromethyl)phenyl]methyl]butyric acid amide; 4-(7-Methoxy-1-phenyl-3,4-dihydro- 1H-isoquinolin-2-yl)-4-oxo-N-[[3-(trifluoromethyl)phenyl]met hyl]butyric acid amide; 4-(5- Methoxy-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxo-N-[[ 3- (trifluoromethyl)phenyl]methyl]butyric acid amide; 4-(3-Methyl-1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-4-oxo-N-[[3-(trifluoromethyl)phenyl]methyl ]butyric acid amide; N-(2- Chlorophenyl)-4-oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2 -yl)butyric acid amide; N- (2,1,3-Benzothiadiazol-4-yl)-4-oxo-4-(1-phenyl-3,4-dihydro-1 H-isoquinolin-2-yl)butyric acid amide; N-(1-Methyl-6-indazolyl)-4-oxo-4-(1-phenyl-3,4-dihydro-1H-is oquinolin-2- yl)butyric acid amide; N-(2-Furylmethyl)-4-oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinol in-2- yl)butyric acid amide; N-Benzyl-4-oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2- yl)butyric acid amide; 4-Oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-(2- pyridylmethyl)butyric acid amide; N-[(4-Methoxyphenyl)methyl]-4-oxo-4-(1-phenyl-3,4- dihydro-1H-isoquinolin-2-yl)butyric acid amide; 4-Oxo-N-phenethyl-4-(1-phenyl-3,4- dihydro-1H-isoquinolin-2-yl)butyric acid amide; 4-Oxo-4-(1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-N-(4-pyridylmethyl)butyric acid amide; 4-Oxo-4-(1-phenyl-3,4-dihydro- 1H-isoquinolin-2-yl)-N-(3-phenylpropyl)butyric acid amide; N-[2-(1H-Indol-3-yl)ethyl]-4- oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)butyric acid amide; 4-(5,7-Dimethyl-1- phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-(4-methoxyphenyl)- 4-oxobutyric acid amide; N-(2-Chlorophenyl)-4-(5,7-dimethyl-1-phenyl-3,4-dihydro-1H-i soquinolin-2-yl)-4- oxobutyric acid amide; -(5,7-Dimethyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-( 1- methyl-6-indazolyl)-4-oxobutyric acid amide; 4-(5,7-Dimethyl-1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-N-(2-furylmethyl)-4-oxobutyric acid amide; N-Benzyl-4-(5,7-dimethyl-1- phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxobutyric acid amide;4 -(5,7-Dimethyl-1- phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxo-N-(2-pyridylme thyl)butyric acid amide; 4- (5,7-Dimethyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-[( 4-methoxyphenyl)methyl]-4- oxobutyric acid amide; 4-(5,7-Dimethyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4- oxo- N-phenethylbutyric acid amide; 4-(5,7-Dimethyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2- yl)-4-oxo-N-(3-phenylpropyl)butyric acid amide; N-(4-Methoxyphenyl)-4-(5-methyl-1- phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxobutyric acid amide; N-(2-Chlorophenyl)-4- (5-methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxobut yric acid amide; N-(1- Methyl-6-indazolyl)-4-(5-methyl-1-phenyl-3,4-dihydro-1H-isoq uinolin-2-yl)-4-oxobutyric acid amide; N-(2-Furylmethyl)-4-(5-methyl-1-phenyl-3,4-dihydro-1H-isoqui nolin-2-yl)-4- oxobutyric acid amide; N-Benzyl-4-(5-methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-y l)- 4-oxobutyric acid amide; 4-(5-Methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxo- N- (2-pyridylmethyl)butyric acid amide; N-[(4-Methoxyphenyl)methyl]-4-(5-methyl-1-phenyl- 3,4-dihydro-1H-isoquinolin-2-yl)-4-oxobutyric acid amide; 4-(5-Methyl-1-phenyl-3,4- dihydro-1H-isoquinolin-2-yl)-4-oxo-N-phenethylbutyric acid amide; 4-(5-Methyl-1-phenyl- 3,4-dihydro-1H-isoquinolin-2-yl)-4-oxo-N-(3-phenylpropyl)but yric acid amide; N-(4- Methoxyphenyl)-4-(7-methyl-1-phenyl-3,4-dihydro-1H-isoquinol in-2-yl)-4-oxobutyric acid amide; N-(2-Chlorophenyl)-4-(7-methyl-1-phenyl-3,4-dihydro-1H-isoqu inolin-2-yl)-4- oxobutyric acid amide; N-(1-Methyl-6-indazolyl)-4-(7-methyl-1-phenyl-3,4-dihydro-1H - isoquinolin-2-yl)-4-oxobutyric acid amide; N-(2-Furylmethyl)-4-(7-methyl-1-phenyl-3,4- dihydro-1H-isoquinolin-2-yl)-4-oxobutyric acid amide; N-Benzyl-4-(7-methyl-1-phenyl- 3,4-dihydro-1H-isoquinolin-2-yl)-4-oxobutyric acid amide; 4-(7-Methyl-1-phenyl-3,4- dihydro-1H-isoquinolin-2-yl)-4-oxo-N-(2-pyridylmethyl)butyri c acid amide; N-[(4- Methoxyphenyl)methyl]-4-(7-methyl-1-phenyl-3,4-dihydro-1H-is oquinolin-2-yl)-4- oxobutyric acid amide; 4-(7-Methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxo- N- phenethylbutyric acid amide; 4-(7-Methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4- oxo-N-(4-pyridylmethyl)butyric acid amide; 4-Oxo-4-(1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-N-(2-thienylmethyl)butyric acid amide; N-[(2-Chlorophenyl)methyl]-4- oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)butyric acid amide; N-[(2,4- Dichlorophenyl)methyl]-4-oxo-4-(1-phenyl-3,4-dihydro-1H-isoq uinolin-2-yl)butyric acid amide; N-[(3,4-Dichlorophenyl)methyl]-4-oxo-4-(1-phenyl-3,4-dihydro -1H-isoquinolin-2- yl)butyric acid amide; 4-Oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-(p- tolylmethyl)butyric acid amide; N-(1,3-Benzodioxol-5-ylmethyl)-4-oxo-4-(1-phenyl-3,4- dihydro-1H-isoquinolin-2-yl)butyric acid amide; N-[(3-Fluorophenyl)methyl]-4-oxo-4-(1- phenyl-3,4-dihydro-1H-isoquinolin-2-yl)butyric acid amide; N-[(2-Fluorophenyl)methyl]-4- oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)butyric acid amide; N-[(4- Fluorophenyl)methyl]-4-oxo-4-(1-phenyl-3,4-dihydro-1H-isoqui nolin-2-yl)butyric acid amide; N-[(2,5-Difluorophenyl)methyl]-4-oxo-4-(1-phenyl-3,4-dihydro -1H-isoquinolin-2- yl)butyric acid amide; N-(1-Naphthylmethyl)-4-oxo-4-(1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)butyric acid amide; 4-(7-Methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2- yl)-4-oxo-N-propylbutyric acid amide; 4-(5-Methyl-1-phenyl-3,4-dihydro-1H-isoquinolin- 2-yl)-4-oxo-N-propylbutyric acid amide; 4-(5,7-Dimethyl-1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-4-oxo-N-propylbutyric acid amide; 4-Oxo-4-(1-phenyl-3,4-dihydro-1H- isoquinolin-2-yl)-N-propylbutyric acid amide; 4-Oxo-4-(1-(2-tolyl)-3,4-dihydro-1H- isoquinolin-2-yl)-N-[[3-(trifluoromethyl)-phenyl]methyl]buty ric acid amide;4-Oxo-4-(1-(2- tolyl)-3,4-dihydro-1H-isoquinolin-2-yl)-N-[[4-(trifluorometh yl)-phenyl]methyl]butyric acid amide; 4-Oxo-4-(1-(2-tolyl)-3,4-dihydro-1H-isoquinolin-2-yl)-N-[[2- (trifluoromethyl)- phenyl]methyl]butyric acid amide; 4-Oxo-4-(1-(2-tolyl)-6-methyl-3,4-dihydro-1H- isoquinolin-2-yl)-N-[[3-(trifluoromethyl)-phenyl]methyl]buty ric acid amide; 4-(1-(2-Methyl- prop-2-yl)-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxo-N-[[3- (trifluoromethyl)phenyl]methyl]butyric acid amide; 4-(1-Cyclohexyl-3,4-dihydro-1H- isoquinolin-2-yl)-4-oxo-N-[[3-(trifluoromethyl)-phenyl]methy l]butyric acid amide; and 4- Oxo-4-(1-(2-fluorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl)-N -[[3- (trifluoromethyl)phenyl]methyl]butyric acid amide. Formula 32 [0444] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 32. Such compounds are described in International Publication No. WO2010037863A1, published April 8, 2010, and corresponding to International Application No. PCT/EP2009/062859 filed October 2, 2009; US Publication No. US20120238547A1, published September 20, 2012 and corresponding to US Application No.13/394,345 filed September 2, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 32, these references incorporated by reference herein control. [0445] In an embodiment, the Kv7 channel activator is a compound according to formula 32: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, azetidinyl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo and trifluoromethyl; R ³ represents a heterocyclic ring selected from furanyl and pyrrolyl which furanyl and pyrrolyl is optionally substituted one or more times with substituents selected from C _1-6 -alkyl, C _1-6 -alkoxy, halo and trifluoromethyl; R ⁴ represents C _1-6 -alkyl; and R ⁵ and R ⁶ , together with the nitrogen to which they are attached, form a heterocyclic ring selected from morpholinyl and 1,4-oxazepanyl. [0446] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is pyrrolidinyl which is optionally substituted one or more times with halo. [0447] In further embodiments, R ³ represents furanyl which is optionally substituted with C _1-6 -alkyl. [0448] In further embodiments, R ⁴ represents C _1-6 -alkyl. [0449] In further embodiments, R ⁵ and R ⁶ , together with the nitrogen to which they are attached, represents morpholinyl. [0450] In further embodiments, the compound is 3-Methyl-furan-2-carboxylic acid [2- ((R)-3-fluoro-pyrrolidin-1-yl)-4-methyl-6-[1,4]oxazepan-4-yl -pyridin-3-yl]-amide. [0451] In further embodiments, the compound is 3-Methyl-furan-2-carboxylic acid [2- ((R)-3-fluoro-pyrrolidin-1-yl)-4-methyl-6-morpholin-4-yl-pyr idin-3-yl]-amide; Formula 33 [0452] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 33. Such compounds are described in US Publication No. US20120232058A1, published September 13, 2012, and corresponding to US Application No.13/394,468 filed September 2, 2010; International Publication No. WO2011026891A1, published March 10, 2011 and corresponding to International Application No. PCT/EP2010/062860 filed September 2, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 33, these references incorporated by reference herein control. [0453] In an embodiment, the Kv7 channel activator is a compound according to formula 33: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ represents C _1-6 -alkyl; R ³ represents a heterocyclic ring selected from furanyl and pyrrolyl which furanyl and pyrrolyl is optionally substituted one or more times with substituents selected from C _1-6 - alkyl, C _{1 -6} -alkoxy, halo and trifluoromethyl; R ⁴ represents C _1-6 -alkyl; and R ⁵ and R ⁶ , together with the nitrogen to which they are attached, form a heterocyclic ring selected from morpholinyl and 1,4-oxazepanyl. [0454] In further embodiments, R ¹ represents metyl or iso-propyl. [0455] In further embodiments, R ³ represents furanyl which is optionally substituted with C _1-6 -alkyl. [0456] In further embodiments, R ⁴ represents C _1-6 -alkyl. [0457] In further embodiments, R ⁵ and R ⁶ , together with the nitrogen to which they are attached, represents 1,4-oxazepanyl. [0458] In further embodiments, the compound is 3-Methyl-furan-2-carboxylic acid(2- isopropyl-4-methyl-6-[1,4]oxazepan-4-yl-pyridin-3-yl)-amide; or 3-Methyl-furan-2- carboxylic acid(2,4-dimethyl-6-[1,4]oxazepan-4-yl-pyridin-3-yl)-amide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof. Formula 34 [0459] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 34. Such compounds are described in International Publication No. WO2010122064A1, published October 28, 2010, and corresponding to International Application No. PCT/EP2010/055284 filed April 21, 2010; US Publication No. US20120115900A1, published May 10, 2012 and corresponding to US Application No.13/265,273 filed April 21, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 34, these references incorporated by reference herein control. [0460] In an embodiment, the Kv7 channel activator is a compound according to formula 34:

a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo, hydroxy, amino, C _{1- 6} -alkyl, trifluoromethyl, C _1-6 -alkoxy, hydroxy-C _1-6 -alkyl and C _1-6 -alkoxy-C ₁ -C ₆ -alkyl; L represents a linker selected from —CR′R″—, —CH2—CR′R″—, —CR′R″-CH2—, and — O—, wherein R′ and R″, independently of each other, represent hydrogen, C _1-6 -alkyl or halo; n is 0 or 1; R ³ represents C _1-6 -alkyl, phenyl, pyridyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, or C _3-6 -cycloalkyl, which phenyl, pyridyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl is optionally substituted one or more times with substituents selected from C _1-6 -alkyl, C _3-6 -cycloalkyl, phenyl, C _1-6 - alkoxy, halo and trifluoromethyl; R ⁴ represents hydrogen, halo or C _1-6 -alkyl; and R ⁵ represents hydrogen or halo. [0461] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is pyrrolidinyl or piperidinyl, which pyrrolidinyl and piperidinyl is optionally substituted one or more times with halo. [0462] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halo. [0463] In further embodiments, L represents —CH ₂ —. [0464] In further embodiments, R ³ represents C _1-6 -alkyl. [0465] In further embodiments, R ³ represents phenyl, pyridyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, or C _3-6 -cycloalkyl, which phenyl, pyridyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl is optionally substituted one or more times with substituents selected from C _1-6 -alkyl and halo. [0466] In further embodiments, R ⁴ represents C _1-6 -alkyl. [0467] In further embodiments, R ⁵ represents hydrogen. [0468] In further embodiments, the Kv7 channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N-[6-(7,8-dihydro-5H-[1,6]naphthyrid in-6-yl)-4- methyl-2-pyrrolidin-1-yl-pyridin-3-yl]-acetamide N-[6-(7,8-Dihydro-5H-[1,6]naphthyridin- 6-yl)-4-methyl-2-pyrrolidin-1-yl-pyridin-3-yl]-3,3-dimethyl- butyramide; N-[6-(7,8-Dihydro- 5H-[1,6]naphthyridin-6-yl)-4-methyl-2-pyrrolidin-1-yl-pyridi n-3-yl]-3-fluoro-benzamide; N- [6-(7,8-dihydro-5H-1,6-naphthyridin-6-yl)-2-[(3R)-3-fluoropy rrolidin-1-yl]-4-methyl-3- pyridyl]-3-methyl-furan-2-carboxamide; 2-(3,5-difluorophenyl)-N-[6-(7,8-dihydro-5H-1,6- naphthyridin-6-yl)-2-[(3R)-3-fluoropyrrolidin-1-yl]-4-methyl -3-pyridyl]acetamide; N-[2- (4,4-difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6-naphthyridi n-6-yl)-4-methyl-3-pyridyl]-3- methyl-furan-2-carboxamide; 2-(3,5-difluorophenyl)-N-[2-(4,4-difluoro-1-piperidyl)-6- (7,8-dihydro-5H-1,6-naphthyridin-6-yl)-4-methyl-3-pyridyl]ac etamide; N-[2-(4,4-difluoro- 1-piperidyl)-6-(7,8-dihydro-5H-1,6-naphthyridin-6-yl)-4-meth yl-3-pyridyl]-1-methyl- imidazole-2-carboxamide; N-[2-(4,4-difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6- naphthyridin-6-yl)-4-methyl-3-pyridyl]-5-methyl-oxazole-4-ca rboxamide; N-[2-(4,4- difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6-naphthyridin-6-y l)-4-methyl-3-pyridyl]-4- methyl-thiazole-5-carboxamide; N-[2-(4,4-difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6- naphthyridin-6-yl)-4-methyl-3-pyridyl]-3-methyl-isoxazole-4- carboxamide; N-[2-(4,4- difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6-naphthyridin-6-y l)-4-methyl-3-pyridyl]-4- methyl-oxazole-5-carboxamide; 2-cyclopropyl-N-[2-(4,4-difluoro-1-pipridyl)-6-(7,8- dihydro-5H-1,6-naphthyridin-6-yl)-4-methyl-3-pyridyl]acetami de; N-[2-(4,4-difluoro-1- piperidyl)-6-(7,8-dihydro-5H-1,6-naphthyridin-6-yl)-4-methyl -3-pyridyl]-5-ethyl-oxazole-4- carboxamide; N-[2-(4,4-difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6-naphth yridin-6-yl)-4- methyl-3-pyridyl]-3-methyl-pyridine-2-carboxamide; N-[2-(4,4-difluoro-1-piperidyl)-6-(7,8- dihydro-5H-1,6-naphthyridin-6-yl)-4-methyl-3-pyridyl]-2,5-di methyl-oxazole-4- carboxamide; N-[2-(4,4-difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6-naphth yridin-6-yl)-4- methyl-3-pyridyl]-5-phenyl-oxazole-4-carboxamide; 5-cyclopropyl-N-[2-(4,4-difluoro-1- piperidyl)-6-(7,8-dihydro-5H-1,6-naphthyridin-6-yl)-4-methyl -3-pyridyl]oxazole-4-carb oxamide; N-[2-(4,4-difluoro-1-piperidyl)-6-(7,8-dihydro-5H-1,6-naphth yridin-6-yl)-4- methyl-3-pyridyl]-5-methyl-isothiazole-4-carboxamide; ethyl N-[2-(4,4-difluoro-1- piperidyl)-6-(7,8-dihydro-5H-1,6-naphthyridin-6-yl)-4-methyl -3-pyridyl]carbamate; N-[6- (3-chloro-7,8-dihydro-5H-1,6-naphthyridin-6-yl)-2-[(3R)-3-fl uoropyrrolidin-1-yl]-4,6- dimethyl-1H-pyridin-3-yl]-3,3-dimethyl-butanamide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof. Formula 35 [0469] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 35. Such compounds are described in US Publication No. US20120059037A1, published March 8, 2012, and corresponding to US Application No.13/256,893 filed March 11, 2010; International Publication No. WO2010105960A1, published September 23, 2010 and corresponding to International Application No. PCT/EP2010/053072 filed March 11, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 35, these references incorporated by reference herein control. [0470] In an embodiment, the Kv7 channel activator is a compound according to formula 35: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , independently of each other, represent hydrogen, C _1-6 -alkyl, hydroxy-C _1-6 -alkyl or C _1-6 -alkoxy-C _1-6 -alkyl; or R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, C _1-6 -alkyl, trifluoromethyl, C _1-6 -alkoxy, hydroxy- C _1-6 -alkyl and C _1-6 -alkoxy-C _1-6 -alkyl; L represents a linker selected from —CR′R″—, — CH ₂ —CR′R″— and —CR′R″—CH ₂ —, wherein R′ and R″, independently of each other, represent hydrogen, C _1-6 -alkyl or halogen; n is 0, 1; R ³ represents C _1-6 -alkyl, phenyl or furanyl, which phenyl and furanyl is optionally substituted one or more times with substituents selected from C _1-6 -alkyl, C _1-6 -alkoxy, halogen and trifluoromethyl; and R ⁴ represents hydrogen, halogen or C _1-6 -alkyl. [0471] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halogen. [0472] In further embodiments, L represents —CH ₂ —, and n is 1. [0473] In further embodiments, R ³ represents phenyl, which phenyl is optionally substituted one or more times with halogen. [0474] In further embodiments, R ³ represents C _1-6 -alkyl. [0475] In further embodiments, R ⁴ represents halogen. [0476] In further embodiments, R ⁴ represents hydrogen. [0477] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-pyrrolidin-1-yl -pyridin-3-yl}-2- (3,5-difluoro-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-{6-[(pyridin-3-ylmethyl)- amino]-2-pyrrolidin-1-yl-pyridin-3-yl}-acetamide; N-{6-[(6-Chloro-pyridin-3-ylmethyl)- amino]-2-pyrrolidin-1yl-pyridin-3-yl}-3,3-dimethyl-butyramid e; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof. Formula 36 [0478] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 36. Such compounds are described in Patent Cooperation Treaty application No. EP2010/052257 published September 2, 2010, which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 36, these references incorporated by reference herein control. [0479] In an embodiment, the Kv7 channel activator is a compound according to formula 36: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , independently of each other, represent hydrogen, Ci-6-alkyl, hydroxy- C-ι-6-alkyl or Ci-6-alkoxy-Ci-6-alkyl; or R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1 H-pyrrol-1-yl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, Ci _-6 -alkyl, trifluoro- methyl, Ci _-6 -alkoxy, hydroxy- d- ₆ -alkyl and d- ₆ -alkoxy- d- ₆ -alkyl; L represents a linker selected from -CR ¹ R"-, -CH ₂ - CR ¹ R"- and -CR'R"-CH ₂ -, wherein R' and R", independently of each other, represent hydrogen, d- ₆ -alkyl or halogen; R ³ represents Ci-6-alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from C _1-6 -alkyl, Ci-6- alkoxy, halogen and trifluoromethyl; and R ⁴ represents H or Ci- ₆ -alkyl. [0480] In further embodiments, R ¹ and R ² , independently of each other, represent Ci- ₆ - alkyl. [0481] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached, is morpholinyl. [0482] In further embodiments, L represents -CH ₂ -. [0483] In further embodiments, R ³ represents phenyl, which phenyl is optionally substituted one or more times with halogen. [0484] In further embodiments, R ⁴ represents methyl. [0485] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N-{4-methyl-6-morpholin-4-yl-2-[(tet rahydro-pyran- 4- ylmethyl)-amino]-pyrimidin-5-yl}-acetamide; 2-(3,5-Difluoro-phenyl)-N-{4- dimethylamino-6-methyl-2-[(tetrahydro-pyran-4- ylmethyl)-amino]-pyrimidin-5-yl}- acetamide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically- acceptable addition salt thereof, or an /V-oxide thereof. Formula 37 [0486] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 37. Such compounds are described in International Publication No. WO2010094644A1, published August 26, 2010, and corresponding to International Application No. PCT/EP2010/051839 filed February 15, 2010; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 37, the reference incorporated by reference herein controls. [0487] In an embodiment, the Kv7 channel activator is a compound according to formula 37: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , independently of each other, represent Ci _-6 -alkyl; or R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1 H-pyrrol-1 -yl, piperidinyl and morpholinyl, which pyrrolidinyl and piperidinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, C _1-6 -alkyl, trifluoromethyl, Ci- ₆ -alkoxy, hydroxy-d- ₆ -alkyl and Ci- ₆ -alkoxy- Ci- ₆ -alkyl; L represents a linker selected from -CR ¹ R"- and -O-CR'R"-, wherein R' and R", independently of each other, represent hydrogen, d- ₆ -alkyl or halogen; n is 0 or 1 ; R ³ represents d- ₆ -alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from d-6-alkyl, Ci-6-alkoxy, halogen and trifluoromethyl; and R ⁴ represents Ci-6-alkyl. [0488] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halogen. [0489] In further embodiments, R' and R", independently of each other, represents hydrogen or methyl. [0490] In further embodiments, R ³ represents phenyl, which phenyl is optionally substituted one or more times with halogen. [0491] In further embodiments, R ³ represents d-e-alkyl. [0492] In further embodiments, R ⁴ represents methyl. [0493] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 3,3-Dimethyl-N-(5-methyl-6-morpholin-4-yl-2-pyrrolidin-1-yl- pyridin-3-yl)- butyramide; 2-(3,5-Difluoro-phenyl)-N-(5-methyl-6-morpholin-4-yl-2-pyrro lidin-1-yl- pyridin-3-yl)-acetamide; N-[2-((R)-3-Fluoro-pyrrolidin-1-yl)-5-methyl-6-morpholin-4-y l- pyridin-3-yl]-3,3-dimethylbutyramide; (S)-N-[2-((R)-3-Fluoro-pyrrolidin-1-yl)-5-methyl-6- morpholin-4-yl-pyridin-3-yl]-2-phenylpropionamide;[2-((R)-3- Fluoro-pyrrolidin-1-yl)-5- methyl-6-morpholin-4-yl-pyridin-3-yl]-carbamic acid ethyl ester; (S)-N-[2-((R)-3-Fluoro- pyrrolidin-1-yl)-5-methyl-6-morpholin-4-yl-pyridin-3-yl]-2-m ethyl-butyramide;or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an /V-oxide thereof. Formula 38 [0494] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 38. Such compounds are described in International Publication No. WO2010094645A1, published August 26, 2010, and corresponding to International Application No. PCT/EP2010/051840 filed February 15, 2010; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 38, the reference incorporated by reference herein controls. [0495] In an embodiment, the Kv7 channel activator is a compound according to Formula 38: , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , independently of each other, represent d-e-alkyl; or R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1 H-pyrrol-1-yl, piperidinyl, mor-pholinyl and 1 ,4-oxazepanyl, which pyrrolidinyl and piperidinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, d _-6 -alkyl, trifluoromethyl, d- ₆ -alkoxy, hydroxy-Ci _-6 - alkyl and Ci- ₆ -alkoxy-Ci- ₆ -alkyl; L represents a linker selected from -CR ¹ R"- and -O- CR'R"-, wherein R' and R", independently of each other, represent hydrogen, Ci _-6 -alkyl or halogen; n is 0 or 1 ; R ³ represents C _1-6 -alkyl, phenyl or furanyl, which phenyl and furanyl is optionally substituted one or more times with substituents selected from d _-6 - alkyl, Ci _-6 - alkoxy, halogen and trifluoromethyl; and R ⁴ represents d _-6 -alkyl. [0496] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halogen. [0497] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is 1 ,4-oxazepanyl. [0498] In further embodiments, L is -CH ₂ - and n is 1. [0499] In further embodiments, n is 0. [0500] In further embodiments, R ³ represents phenyl, which phenyl is optionally substituted one or more times with halogen. [0501] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(3,4-Difluoro-phenyl)-N-[2-((R)-3-fluoro-pyrrolidin-1-yl)- 5-methyl-6- [1 ,4]oxazepan-4-yl-pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-/V-(5-methyl-2,6-bis-[1 ,4]oxazepan-4-yl-pyridin-3-yl)- acetamide; 3-Fluoro-/V-(5-methyl-6-[1 ,4]oxazepan-4-yl- 2-pyrrolidin-1-yl-pyridin-3-yl)- benzamide; 3-methyl-N-[5-methyl-6-(1 ,4-oxazepan-4-yl)- 2-pyrrolidin-1-yl-3-pyridyl]furan-2-carboxamide; 2-(3-fluorophenyl)-N-[2-[(3R)-3- fluoropyrrolidin-1-yl]-5-methyl-6-(1 ,4-oxazepan-4- yl)-3-pyridyl]acetamide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically- acceptable addition salt thereof, or an /V-oxide thereof. Formula 39 [0502] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 1. Such compounds are described in International Publication No. WO2008142140A2, published November 27, 2008, and corresponding to International Application No. PCT/EP2008/056322 filed May 22, 2008; US Patent No.8,178,544 published May 15, 2012 and corresponding to US Application No.12/601,124 filed May 22, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 39, the reference incorporated by reference herein controls. [0503] In an embodiment, the Kv7 channel activator is a compound according to Formula 39: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ represents hydrogen, alkyl or halo; and R ² represents hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, phenyl-alkyl, amino, alkyl-carbonyl-amino, cyano or nitro; or R ¹ and R ² together with the carbon atom to which they are attached form a cycloalkyl (spiro) group; or R ¹ represents hydrogen; and R ² together with one of R ³ , R ⁴ and R ⁵ , attached in ortho-position on the aromatic ring, form a —(CH ₂ ) _n — bridge, wherein n is 1, 2 or 3; R ³ , R ⁴ and R ⁵ , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino, alkyl-sulfanyl, alkyl-sulfonyl, phenyl, phenoxy, benzoyl, cyano or nitro; or two of R ³ , R ⁴ and R ⁵ , together form a methylenedioxy group; and the remaining of R ³ , R ⁴ and R ⁵ is as defined above; or two of R ³ , R ⁴ and R ⁵ , together with the phenyl ring to which they are attached, form a naphthyl group; and the remaining of R ³ , R ⁴ and R ⁵ is as defined above; or one of R ³ , R ⁴ and R ⁵ , attached in ortho-position on the aromatic ring, and together with R ² form a —(CH ₂ ) _n — bridge, wherein n is 1, 2 or 3; and the remaining of R ³ , R ⁴ and R ⁵ , are as defined above; R ⁶ and R ⁷ , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino, nitro, cyano or phenyl; and R′ and R″, independently of each other, represent alkyl, hydroxy-alkyl, amino-alkyl, cycloalkyl, phenyl-alkyl, phenyl-hydroxyalkyl, N-alkyl-amino- alkyl, N,N-dialkyl-amino-alkyl, alkoxy-alkyl, piperidinyl, N-alkyl-piperidinyl, furanyl-alkyl, pyridinyl-alkyl, pyrazolyl-alkyl, imidazolyl-alkyl, pyrimidinyl, pyrimidinyl substituted with one or two substituents selected from N-alkyl-amino, N,N-dialkyl-amino and phenyl; or R′ and R″, together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, thiazolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl and homomorpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl and homomorpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of alkyl, alkoxy, alkoxy-alkyl, alkyl-carbonyl-amino, cycloalkyl-carbonyl-amino, hydroxy- alkyl, hydroxy, amino, N-alkyl-amino, N,N-dialkyl-amino, amino-alkyl, N-alkyl-amino- alkyl, N,N-dialkyl-amino-alkyl, carbamoyl-alkyl, N-alkyl-carbamoyl-alkyl, N,N-dialkyl- carbamoyl-alkyl, N-hydroxy-alkyl-carbamoyl, N,N-dialkyl-amino-alkyl-carbamoyl, alkoxy- carbonyl, cyano-alkyl, pyrrolidinyl, pyrrolidinyl-alkyl, piperidinyl, piperidinyl-carbonyl, hydroxy-piperidinyl, hydroxy-piperidinyl-alkyl, hydroxy-piperidinyl-carbonyl, N-alkyl- piperidinyl, piperidinyl-alkyl, N-alkyl-piperidinyl-alkyl, morpholino-alkyl, morpholino-alkyl- carbamoyl, morpholino-carbonyl-alkyl, triazolyl-alkyl, piperazinyl, piperazinyl-alkyl, piperazinyl-carbonyl, N-alkyl-piperazinyl, N-alkyl-piperazinyl-alkyl, N-alkyl-piperazinyl- carbonyl, pyridinyl, pyridinyl-alkyl, and pyridinyl substituted once or twice with alkyl, trifluoromethyl and/or cyano. [0504] In further embodiments, R ¹ represents hydrogen or alkyl; and R ² represents hydrogen or alkyl. [0505] In further embodiments, R ³ , R ⁴ and R ⁵ , independently of each other, represent hydrogen, alkyl, halo, haloalkyl, hydroxy, alkoxy, alkyl-sulfanyl, alkyl-sulfonyl, phenyl or phenoxy. [0506] In further embodiments, R ⁶ and R ⁷ , independently of each other, represent hydrogen, halo, haloalkyl, hydroxy, alkoxy, or amino. [0507] In further embodiments, R′ and R″, independently of each other, represent alkyl, hydroxy-alkyl, cycloalkyl, or phenyl-alkyl. [0508] In further embodiments, R′ and R″, together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, thiazolidinyl, piperidinyl, piperazinyl, homopiperazinyl and morpholinyl, which piperazinyl is optionally substituted one or more times with alkyl. [0509] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H-quinaz olin-3-yl)- acetamide; 2-(3,5-Difluoro-phenyl)-N-(2-dimethylamino-4-oxo-4H-quinazol in-3-yl)- acetamide; 2-(4-Chloro-phenyl)-N-(2-diethylamino-4-oxo-4H-quinazolin-3- yl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-[2-(ethyl-methyl-amino)-4-oxo-4H-q uinazolin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N-(2-dimethylamino-4-oxo-7-trifluoro methyl-4H-quinazolin-3-yl)- propionamide; N-(2-Diethylamino-4-oxo-4H-quinazolin-3-yl)-2-(4-methanesulf onyl- phenyl)-acetamide; N-{2-[(2-Methoxy-ethyl)-methyl-amino]-4-oxo-4H-quinazolin-3- yl}-2- (4-trifluoromethyl-phenyl)-acetamide; 2-(4-Butoxy-phenyl)-N-{2-[(2-methoxy-ethyl)- methyl-amino]-4-oxo-4H-quinazolin-3-yl}-acetamide; N-[2-(Benzyl-methyl-amino)-4-oxo- 4H-quinazolin-3-yl]-2-(4-methanesulfonyl-phenyl)-acetamide; 2-(4-Butoxy-phenyl)-N-(4- oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-(4-oxo-2- thiazolidin-3-yl-4H-quinazolin-3-yl)-acetamide; N-(2-Diethylamino-4-oxo-4H-quinazolin- 3-yl)-2-(3,5-difluoro-phenyl)-acetamide; 2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-oxo-2- thiazolidin-3-yl-4H-quinazolin-3-yl)-acetamide; 2-Benzo[1,3]dioxol-5-yl-N-(2- diethylamino-4-oxo-4H-quinazolin-3-yl)-acetamide; N-(2-Diethylamino-4-oxo-4H- quinazolin-3-yl)-2-phenyl-acetamide; or N-[2-(Ethyl-methyl-amino)-4-oxo-4H-quinazolin- 3-yl]-2-phenyl-acetamide; or a stereoisomer or a mixture of its stereoisomers, a pharmaceutically-acceptable addition salt thereof. [0510] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(3-Fluoro-4-trifluoromethyl-phenyl)-N-(4-oxo-2-pyrrolidin- 1-yl-4H- quinazolin-3-yl)-acetamide; 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{2-[(2-methoxy-ethyl)- methyl-amino]-4-oxo-4H-quinazolin-3-yl}-acetamide; N-[2-(Benzyl-methyl-amino)-4-oxo- 4H-quinazolin-3-yl]-2-(3,4-difluoro-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-(2- morpholin-4-yl-4-oxo-4H-quinazolin-3-yl)-acetamide; 2-(4-Chloro-phenyl)-N-{7-fluoro-2- [(2-methoxy-ethyl)-methyl-amino]-4-oxo-4H-quinazolin-3-yl}-a cetamide; 2-(4-Chloro- phenyl)-N-(2-morpholin-4-yl-4-oxo-4H-quinazolin-3-yl)-acetam ide; 2-(3,5-Difluoro- phenyl)-N-{7-fluoro-2-[(2-methoxy-ethyl)-methyl-amino]-4-oxo -4H-quinazolin-3-yl}- acetamide; 2-(4-Chloro-phenyl)-N-(2-dimethylamino-4-oxo-4H-quinazolin-3 -yl)- acetamide; N-(2-Diethylamino-6-fluoro-4-oxo-4H-quinazolin-3-yl)-2-(3,5- difluoro- phenyl)-acetamide; 2-(4-Chloro-phenyl)-N-(2-diethylamino-6-fluoro-4-oxo-4H- quinazolin-3-yl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-[2-(4-methyl-piperazin-1-yl)-4oxo- 4H-quinazolin-3-yl]-acetamide; N-(2-Diethylamino-6-fluoro-4-oxo-4H-quinazolin-3-yl)-2- (3-fluoro-5-trifluoromethyl-phenyl)-acetamide; N-[2-(Benzyl-methyl-amino)-4-oxo-4H- quinazolin-3-yl]-2-(3,5-difluoro-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-{2-[(2- methoxy-ethyl)-methyl-amino]-4-oxo-4H-quinazolin-3-yl}-aceta mide; 2-(3-Fluoro-5- trifluoromethyl-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-7-trifluo romethyl-4H-quinazolin-3-yl)- acetamide; 2-(3,5-Difluoro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-7-trifluo romethyl-4H- quinazolin-3-yl)-acetamide; 2-(3-Fluoro-5-trifluoromethyl-phenyl)-N-{2-[(2-methoxy- ethyl)-methyl-amino]-4-oxo-7-trifluoromethyl-4H-quinazolin-3 -yl}-acetamide; 2-(3,5- Difluoro-phenyl)-N-{2-[(2-methoxy-ethyl)-methyl-amino]-4-oxo -7-trifluoromethyl-4H- quinazolin-3-yl}-acetamide; N-(6-Butoxy-2-morpholin-4-yl-4-oxo-4H-quinazolin-3-yl)-2- (3,5-difluoro-phenyl)-acetamide; N-(5-Chloro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)- 2-(3,5-difluoro-phenyl)-acetamide; N-(5-Chloro-2-diethylamino-4-oxo-4H-quinazolin-3- yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(2-Diethylamino-7-fluoro-4-oxo-4H-quinazolin- 3-yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(2-Diethylamino-5-fluoro-4-oxo-4H- quinazolin-3-yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(2-Diethylamino-4-oxo-7- trifluoromethyl-4H-quinazolin-3-yl)-2-(3,5-difluoro-phenyl)- acetamide; N-(7-Chloro-2- diethylamino-4-oxo-4H-quinazolin-3-yl)-2-(3,5-difluoro-pheny l)-acetamide; N-(7-Chloro- 4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-2-(3,5-difluoro- phenyl)-acetamide; N-(6- Chloro-2-diethylamino-7-fluoro-4-oxo-4H-quinazolin-3yl)-2-(3 ,5-difluoro-phenyl)- acetamide; N-(2-Diethylamino-5,7-difluoro-4-oxo-4H-quinazolin-3-yl)-2-( 3,5-difluoro- phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-(7-fluoro-4-oxo-2-pyrrolidin-1-yl- 4H- quinazolin-3-yl)-acetamide; N-(6-Chloro-7-fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3 - yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(5,7-Difluoro-4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(5,7-Dichloro-2-diethylamino-4- oxo-4H-quinazolin-3-yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(2-Diethylamino-6,7- difluoro-4-oxo-4H-quinazolin-3-yl)-2-(3,5-difluoro-phenyl)-a cetamide; N-(6,7-Difluoro-4- oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-2-(3,5-difluoro-ph enyl)-acetamide; 2-(3-Fluoro- 4-trifluoromethyl-phenyl)-N-(2-morpholin-4-yl-4-oxo-4H-quina zolin-3-yl)-acetamide; N- (2-Dimethylamino-4-oxo-4H-quinazolin-3-yl)-2-(3-fluoro-4-tri fluoromethyl-phenyl)- acetamide; N-(6-Chloro-2-diethylamino-4-oxo-4H-quinazolin-3-yl)-2-(3,5- difluoro- phenyl)-acetamide; N-(2-Dimethylamino-6-fluoro-4-oxo-4H-quinazolin-3-yl)-2-(3-f luoro- 4-trifluoromethyl-phenyl)-acetamide; N-(6-Fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin- 3-yl)-2-(3-fluoro-4-trifluoromethyl-phenyl)-acetamide; 2-(4-Chloro-3-fluoro-phenyl)-N-(6- fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetamide ; 2-(3,5-Difluoro-phenyl)-N- (6-fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetam ide; 2-(4-Chloro-3-fluoro- phenyl)-N-(2-dimethylamino-6-fluoro-4-oxo-4H-quinazolin-3-yl )-acetamide; 2-(3,5- Difluoro-phenyl)-N-(2-dimethylamino-6-fluoro-4-oxo-4H-quinaz olin-3-yl)-acetamide; N- (5,7-Dichloro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-2- (3,5-difluoro-phenyl)- acetamide; 2-(3,5-Difluoro-phenyl)-N-(2-dimethylamino-5-fluoro-4-oxo-4H -quinazolin-3- yl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-(2-dimethylamino-7-fluoro-4-oxo-4H -quinazolin- 3-yl)-acetamide; N-(2-Dimethylamino-5-fluoro-4-oxo-4H-quinazolin-3-yl)-2-(3-f luoro-5- trifluoromethyl-phenyl)-acetamide; N-(2-Dimethylamino-7-fluoro-4-oxo-4H-quinazolin-3- yl)-2-(3-fluoro-4-trifluoromethyl-phenyl)-acetamide; 2-(4-Chloro-phenyl)-N-(2- diethylamino-5,7-difluoro-4-oxo-4-quinazolin-3-yl)-acetamide ; 2-(4-Chloro-phenyl)-N-(7- fluoro-4-oxo-2-pyrrolidin-1yl-4H-quinazolin-3-yl)-acetamide; 2-(3,5-Difluoro-phenyl)-N- [5-fluoro-2-(isopropyl-methyl-amino)-4-oxo-4H-quinazolin-3-y l]-acetamide; 2-(3,5- Difluoro-phenyl)-N-[2-(ethyl-methyl-amino)-5-fluoro-4-oxo-4H -quinazolin-3-yl]- acetamide; 2-(3,5-Difluoro-phenyl)-N-[7-fluoro-2-(isopropyl-methyl-amin o)-4-oxo-4H- quinazolin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N-[2-(ethyl-methyl-amino)-7-fluoro-4 - oxo-4H-quinazolin-3-yl]-acetamide; 2-(4-Chloro-phenyl)-N-(7-fluoro-4-oxo-2-pyrrolidin-1- yl-4H-quinazolin-3-yl)-propionamide; 2-(4-Chloro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-propionamide; N-(2-Diethylamino-8-fluoro-4-oxo-4H-quinazolin-3-yl)-2- (3,5-difluoro-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-(8-fluoro-4-oxo-2-pyrrolidin-1- yl-4H-quinazolin-3-yl)-acetamide; 2-Naphthalen-2-yl-N-(4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-acetamide; N-(5,7-Difluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)- 2- (3,4-difluoro-phenyl)-acetamide; 2-(3,4-Difluoro-phenyl)-N-[2-(ethyl-methyl-amino)-7- fluoro-4-oxo-4H-quinazolin-3-yl]-acetamide; 2-(4-Chloro-phenyl)-N-[2-(ethyl-methyl- amino)-7-fluoro-4-oxo-4H-quinazolin-3-yl]-acetamide; 2-Naphthalen-1-yl-N-(4-oxo-2- pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetamide; 2-(4-Chloro-phenyl)-N-(5,7-difluoro-4-oxo- 2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-[2-(ethyl- methyl-amino)-5,7-difluoro-4-oxo-4H-quinazolin-3-yl]-acetami de; N-[5,7-Difluoro-2- (isopropyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-2-(3,4-di fluoro-phenyl)-acetamide; N-[5,7-Difluoro-2-(isopropyl-methyl-amino)-4-oxo-4H-quinazol in-3-yl]-2-(3,5-difluoro- phenyl)-acetamide; N-[2-(Ethyl-methyl-amino)-7-fluoro-4-oxo-4H-quinazolin-3-yl] -2-(4- methylsulfanyl-phenyl)-acetamide; 2-(4-Isobutyl-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-propionamide; N-[2-(Ethyl-methyl-amino)-7-fluoro-4-oxo-4H-quinazolin- 3-yl]-2-(4-methoxy-phenyl)-acetamide; N-(7-Fluoro-4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-2-(4-phenoxy-phenyl)-acetamide; 2-Biphenyl-4-yl-N-(7-fluoro-4-oxo-2- pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetamide; 2-(4-Chloro-phenyl)-N-(4-oxo-2-pyrrolidin- 1-yl-4H-quinazolin-3-yl)-acetamide; 2-(3,4-Difluoro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl- 4H-quinazolin-3-yl)-acetamide; N-[2-(Ethyl-methyl-amino)-7-fluoro-4-oxo-4H-quinazolin- 3-yl]-2-(4-isopropyl-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-[2-(isopropyl-methyl- amino)-4-oxo-4-quinazolin-3-yl]-acetamide; 2-(3,4-Difluoro-phenyl)-N-[2-(isopropyl- methyl-amino)-4-oxo-4H-quinazolin-3-yl]-acetamide; 2-(3,4-Difluoro-phenyl)-N-(7-fluoro- 4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetamide; 2-(3,4-Difluoro-phenyl)-N-(8- fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-acetamide ; 2-(3,4-Difluoro-phenyl)-N- [2-(isobutyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-acetami de; 2-(3,5-Difluoro-phenyl)- N-[2-(isobutyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-aceta mide; 2-(3,4-Difluoro- phenyl)-N-[7-fluoro-2-(isopropyl-methyl-amino)-4-oxo-4H-quin azolin-3-yl]-acetamide; N- (7-Chloro-6-fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-y l)-2-(3,5-difluoro-phenyl)- acetamide; 2-(3,5-Difluoro-phenyl)-N-(2-diisopropylamino-4-oxo-4H-quina zolin-3-yl)- acetamide; N-[2-(Cyclopentyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-2- (3,5-difluoro- phenyl)-acetamide; N-[2-(Cyclopentyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-2- (3,4- difluoro-phenyl)-acetamide; 2-(3,4-Difluoro-phenyl)-N-(2-diisopropylamino-4-oxo-4H- quinazolin-3-yl)-acetamide; 2-(3,4-Difluoro-phenyl)-N-(4-oxo-2-piperidin-1-yl-4H- quinazolin-3-yl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-(4-oxo-2-piperidin-1-yl-4H- quinazolin-3-yl)-acetamide; N-(8-Chloro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-2- (3,5-difluoro-phenyl)-acetamide; N-(2-Diethylamino-6-hydroxy-4-oxo-4H-quinazolin-3- yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(6,8-Dichloro-2-diethylamino-4-oxo-4H- quinazolin-3-yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(6-Amino-2-diethylamino-4-oxo- 4H-quinazolin-3-yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(7-Amino-2-diethylamino-4- oxo-4H-quinazolin-3-yl)-2-(3,5-difluoro-phenyl)-acetamide; N-(7-Amino-4-oxo-2- pyrrolidin-1-yl-4H-quinazolin-3-yl)-2-(3,5-difluoro-phenyl)- acetamide; or a stereoisomer or a mixture of its stereoisomers, a pharmaceutically-acceptable addition salt thereof. [0511] In further embodiments, 2-(3,5-difluorophenyl)-N-(2-dimethylamino-4-oxo-7- trifluoromethyl-4H-quinazolin-3-yl )-propionamide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof. Formula 40 [0512] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 40. Such compounds are described in International Publication No. WO2010060955A1, published June 3, 2010 and corresponding to International Application No. PCT/EP2009/065890 filed November 26, 2009; US Publication No. US20110312962A1, published December 22, 2011 and corresponding to US Application No.13/131,218 filed November 26, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 40, these references incorporated by reference herein control. [0513] In an embodiment, the Kv7 channel activator is a compound according to Formula 40: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein Y represents —(CH ₂ ) _n —, — (CH ₂ ) _n —O— or —(CH ₂ ) _n —S— wherein n is 0 or 1; R ¹ represents C _1-6 -alkyl, benzo[1,3]dioxolyl, phenyl or pyridyl, which phenyl and pyridyl are optionally substituted one or more times with substituents selected from the group consisting of C _1-6 -alkyl, halogen, trifluoromethyl, hydroxy, C _1-6 -alkoxy and trifluoromethoxy; R ² and R ³ , independently of each other, represent hydrogen or C _1-6 -alkyl; and R ⁴ and R ⁵ , independently of each other, represent hydrogen, C _1-6 -alkyl, halogen, trifluoromethyl, hydroxy, C _1-6 -alkoxy or trifluoromethoxy. [0514] In further embodiments, Y represents —(CH ₂ ) _n —, wherein n is 0 or 1; R ¹ represents C _1-6 -alkyl, benzo[1,3]dioxolyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from the group consisting of C _1-6 -alkyl, halogen, trifluoromethyl, hydroxy, C _1-6 -alkoxy and trifluoromethoxy; R ² and R ³ , independently of each other, represent hydrogen or C _1-6 -alkyl; and R ⁴ and R ⁵ , independently of each other, represent hydrogen, C _1-6 -alkyl, halogen, trifluoromethyl, hydroxy, C _1-6 -alkoxy or trifluoromethoxy. [0515] In further embodiments, n is 1. [0516] In further embodiments, R ¹ represents phenyl optionally substituted one or more times with substituents selected from the group consisting of C _1-6 -alkyl, halogen, trifluoromethyl and C _1-6 -alkoxy. [0517] In further embodiments, R ² and R ³ represent hydrogen. [0518] In further embodiments, R ² and R ³ represent C _1-6 -alkyl. [0519] In further embodiments, R ⁴ and R ⁵ , independently of each other, represent hydrogen or halogen. [0520] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N-[6-(4-fluoro-benzylamino)-2-morpho lin-4-yl- pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N-{6-[1-(4-fluoro-phenyl)-1-methyl- ethylamino]-2-morpholin-4-yl-pyridin-3-yl}-acetamide; N-[6-(4-Fluoro-benzylamino)-2- morpholin-4-yl-pyridin-3-yl]-2-methyl-benzamide; 2-Benzo[1,3]dioxol-5-yl-N-[6-(4-fluoro- benzylamino)-2-morpholin-4-yl-pyridin-3-yl]-acetamide; N-[6-(4-Fluoro-benzylamino)-2- morpholin-4-yl-pyridin-3-yl]-2-(4-methoxy-phenyl)-acetamide; N-[6-(4-Fluoro- benzylamino)-2-morpholin-4-yl-pyridin-3-yl]-2-(3-methoxy-phe nyl)-acetamide; 2-(2,4- Dichloro-phenyl)-N-[6-(4-fluoro-benzylamino)-2-morpholin-4-y l-pyridin-3-yl]-acetamide; N-[6-(4-Fluoro-benzylamino)-2-morpholin-4-yl-pyridin-3-yl]-2 -(3-trifluoromethyl-phenyl)- acetamide; N-[6-(4-Fluoro-benzylamino)-2-morpholin-4-yl-pyridin-3-yl]-2 -(2-fluoro- phenyl)-acetamide; N-[6-(4-Fluoro-benzylamino)-2-morpholin-4-yl-pyridin-3-yl]-2 -(3- fluoro-phenyl)-acetamide; or 2-(4-Chloro-phenyl)-N-[6-(4-fluoro-benzylamino)-2- morpholin-4-yl-pyridin-3-yl]-acetamide, N-[6-[(4-Fluorophenyl)-methylamino]-2- morpholino-3-pyridyl]-2-(4-fluorophenyl)-sulfanyl-acetamide; 2-(3-fluorophenoxy)-N-[6- [(4-fluorophenyl)-methyl amino]-2-morpholino-3-pyridyl]acetamide; 2-(6-chloro-3- pyridyl)-N-[6-[(4-fluorophenyl)-methylamino]-2-morpholino-3- pyridyl]acetamide; 2-fluoro- N-[6-[(4-fluorophenyl)-methylamino]-2-morpholino-3-pyridyl]p yridine-3-carboxamide; a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof. Formula 41 [0521] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 41. Such compounds are described in US Publication No. US20110269783A1, published November 3, 2011, and corresponding to US Application No.13/128,015 filed November 6, 2009; International Publication No. WO2010051819A1, published May 14, 2010, and corresponding to International Application No. PCT/DK2009/050293 filed November 6, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 41, these references incorporated by reference herein control. [0522] In an embodiment, the Kv7 channel activator is a compound according to Formula 41: A stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein L represents a linker selected from —(CR′R″) ₂ —, —CR′R″—S—, —CR′R″—O— or wherein R′ and R″, independently of each other, represent hydrogen, C _1-6 -alkyl or halogen; R ¹ and R ² , independently of each other, represent C _1-6 -alkyl, hydroxy-C _1-6 -alkyl-, C _1-6 -alkoxy-C _1-6 - alkyl-, phenyl, phenyl-C _1-6 -alkyl-, which phenyl is optionally substituted with one or two times with a substituent selected from the group consisting of C _1-6 -alkoxy, halogen and cyano; or R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, C _1-6 -alkyl, trifluoromethyl, C _1-6 -alkoxy, hydroxy-C _1-6 -alkyl- and C _1-6 -alkoxy-C _1-6 -alkyl-; R ³ , R ⁴ and R ⁵ , independently of each other, represent hydrogen, C _1-6 -alkyl, halogen, trihalomethyl, hydroxy, C _1-6 -alkoxy, trifluoromethoxy, amino, cyano or nitro; and R ⁶ and R ⁷ , independently of each other, represent hydrogen, C _1-6 -alkyl, halogen, trihalomethyl, hydroxy, C _1-6 -alkoxy, trifluoromethoxy, amino, nitro, cyano or phenyl. [0523] In further embodiments, R ¹ and R ² , independently of each other, represent C _1-6 - alkyl, alkoxy-C _1-6 -alkyl- or phenyl-C _1-6 -alkyl-. [0524] In further embodiments, R ¹ and R ² , together with the nitrogen to which they are attached, form a pyrrolidinyl ring. [0525] In further embodiments, R ³ , R ⁴ and R ⁵ , independently of each other, represent hydrogen, C _1-6 -alkyl or halogen. [0526] In further embodiments, R ⁶ and R ⁷ , independently of each other, represent hydrogen or halogen. [0527] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-(7-Fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-3-(3 -fluoro-phenyl)- propionamide; 3-(3-Fluoro-phenyl)-N-{2-[(2-methoxy-ethyl)-methyl-amino]-4- oxo-4H- quinazolin-3-yl}-propionamide; N-[2-(Benzyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-3- (3-fluoro-phenyl)-propionamide; N-[2-(Benzyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]- 3-(3,5-difluoro-phenyl)-propionamide; 3-(3-Fluoro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-propionamide; N-(4-Oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-3-phenyl- propionamide; N-(2-Dimethylamino-7-fluoro-4-oxo-4H-quinazolin-3-yl)-3-(3-f luoro- phenyl)-propionamide; N-(4-Oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-2-phenylsulfa nyl- acetamide; N-(4-Oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-2-phenoxy-ace tamide; N-(5- Fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-3-(3-fluo ro-phenyl)-propionamide; 2- (4-Fluoro-phenylsulfanyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H-quin azolin-3-yl)-acetamide; N- (5,7-Difluoro-4-oxo-2-pynolidin-1-yl-4H-quinazolin-3-yl)-3-( 3-fluoro-phenyl)- propionamide; 2-(4-tert-Butyl-phenylsulfanyl)-N-(4-oxo-2-pyrrolidin-1-yl-4 H-quinazolin-3- yl)-acetamide; N-[5,7-Difluoro-2-(isopropyl-methyl-amino)-4-oxo-4H-quinazol in-3-yl]-3- (3-fluoro-phenyl)-propionamide; N-(5,7-Difluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3- yl)-3-(3,5-difluoro-phenyl)-propionamide; (S)-N-(5,7-Difluoro-4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-3-phenyl-butyramide; 3-(4-Chloro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-butyramide; 3-(3-Fluoro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-butyramide; cis-2-(4-Chloro-phenyl)-cyclopropanecarboxylic acid(2- dimethylamino-7-fluoro-4-oxo-4H-quinazolin-3-yl)-amide; cis-2-(4-Chloro-phenyl)- cyclopropanecarboxylic acid[5,7-difluoro-2-(isopropyl-methyl-amino)-4-oxo-4H- quinazolin-3-yl]-amide; cis-2-(4-Chloro-phenyl)-cyclopropanecarboxylic acid(5,7- difluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-amide; cis-2-(4-Chloro-phenyl)- cyclopropanecarboxylic acid[2-(ethyl-methyl-amino)-7-fluoro-4-oxo-4H-quinazolin-3-y l]- amide; cis-2-(4-Chloro-phenyl)-cyclopropanecarboxylic acid[7-fluoro-2-(isopropyl- methyl-amino)-4-oxo-4H-quinazolin-3-yl]-amide; cis-2-(4-Chloro-phenyl)- cyclopropanecarboxylic acid[2-(ethyl-methyl-amino)-5,7-difluoro-4-oxo-4H-quinazolin -3- yl]-amide; cis-2-(4-Chloro-phenyl)-cyclopropanecarboxylic acid(8-fluoro-4-oxo-2- pyrrolidin-1-yl-4H-quinazolin-3-yl)-amide; or a stereoisomer or a mixture of its stereoisomers, a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof. [0528] In further embodiments, the compound is of formula: wherein: X represents —CR′R″—, —S—, or —O—, wherein R′ and R″, independently of each other, represent hydrogen, C _1-6 -alkyl or halogen, and R′, R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ⁷ are as defined above. [0529] In further embodiments, the compound is of formula: wherein: R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ and R ⁷ are as defined above. Formula 42 [0530] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in International Publication No. WO2011026890A1, published March 10, 2011, and corresponding to International Application No. PCT/EP2010/062859 filed September 2, 2010; US Publication No. US20120238547A1, published September 20, 2012, and corresponding to US Application No.13/394,345 filed September 2, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 42, these references incorporated by reference herein control. [0531] In an embodiment, the Kv7 channel activator is a compound according to Formula 42: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, azetidinyl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo and trifluoromethyl; R ³ represents a heterocyclic ring selected from furanyl and pyrrolyl which furanyl and pyrrolyl is optionally substituted one or more times with substituents selected from C _1-6 -alkyl, C _1-6 -alkoxy, halo and trifluoromethyl; R ⁴ represents C _1-6 -alkyl; and R ⁵ and R ⁶ , together with the nitrogen to which they are attached, form a heterocyclic ring selected from morpholinyl and 1,4-oxazepanyl. [0532] In further embodiments, R ¹ and R ² together with the nitrogen to which they are attached is pyrrolidinyl which is optionally substituted one or more times with halo. [0533] In further embodiments, R ³ represents furanyl which is optionally substituted with C _1-6 -alkyl. [0534] In further embodiments, R ⁴ represents C _1-6 -alkyl. [0535] In further embodiments, R ⁵ and R ⁶ , together with the nitrogen to which they are attached, represents morpholinyl. [0536] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 3-Methyl-furan-2-carboxylic acid [2-((R)-3-fluoro-pyrrolidin-1-yl)-4-methyl- 6-[1,4]oxazepan-4-yl-pyridin-3-yl]-amide; 3-Methyl-furan-2-carboxylic acid [2-((R)-3- fluoro-pyrrolidin-1-yl)-4-methyl-6-morpholin-4-yl-pyridin-3- yl]-amide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof. Formula 43 [0537] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 43. Such compounds are described in International Publication No. WO2010026104A1, published March 11, 2010, and corresponding to International Application No. PCT/EP2009/061125 filed August 28, 2009; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 43, the reference incorporated by reference herein controls. [0538] In an embodiment, the Kv7 channel activator is a compound according to Formula 43: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , independently of each other, represent Ci _-6 -alkyl, hydroxy-d-e-alkyl or Ci _-6 - alkoxy-Ci- ₆ -alkyl; or R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1 H-pyrrol-1 -yl, azetidinyl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo, hydroxy, amino, Ci _-6 -alkyl, trifluoromethyl, Ci _-6 -alkoxy, hydroxy-Ci _-6 -alkyl and Ci- ₆ -alkoxy-Ci- ₆ -alkyl; R ³ represents Ci _-6 -alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from Ci _-6 - alkyl, Ci _-6 -alkoxy, halo and trifluoromethyl; and L represents a linker selected from - CR ¹ R"-, -CH ₂ -CR ¹ R"- and -CR ¹ R ¹ ^CH ₂ -, wherein R ¹ and R", independently of each other, represent hydrogen, Ci _-6 -alkyl or halo. [0539] In further embodiments, R ¹ and R ² , independently of each other, represent Ci-6- alkyl. [0540] In further embodiments, R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, azetidinyl, piperidinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo, d-e-alkyl and trifluoromethyl. [0541] In further embodiments, R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring which is pyrrolidinyl optionally substituted one or more times with a substituent selected from the group consisting of halo, d-e-alkyl and trifluoromethyl. [0542] In further embodiments, R ¹ and R ² , together with the nitrogen to which they are attached, form a heterocyclic ring which is piperidinyl optionally substituted one or more times with a substituent selected from the group consisting of halo, d-e-alkyl and trifluoromethyl. [0543] In further embodiments, R ³ represents te/t-butyl. [0544] In further embodiments, R ³ represents phenyl, which is optionally substituted one or more times with substituents selected from Ci _-6 -alkyl, Ci _-6 -alkoxy, halo and trifluoromethyl. [0545] In further embodiments, L represents -CH ₂ -. [0546] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluorophenyl)-N-{2-pyrrolidin-1-yl-6-[(tetrahydro-p yran-4- ylmethyl)-amino]- pyridin-3-yll-acetamide; 3,3-Dimethyl-N-{2-pyrrolidin-1-yl-6- [(tetrahydro-pyran-4-ylmethyl)-amino]-pyridin-3-yllbutyramid e; 2-(3,5-Difluoro-phenyl)-N- {2-morpholin-4-yl-6-[(tetrahydro-pyran-4-ylmethyl)-amino]- pyridin-3-yll-acetamide; 2- (3,5-Difluoro-phenyl)-N-{2-dimethylamino-6-[(tetrahydro-pyra n-4-ylmethyl)-amino]- pyridin-3-yll-acetamide; N-{2-Dimethylamino-6-[(tetrahydro-pyran-4-ylmethyl)-amino]- pyridin-3-yll-3,3-dimethyl-butyramide; 2-(3,5-Difluoro-phenyl)-N-{2-((S)-3-fluoro- pyrrolidin-1-yl)-6-[(tetrahydro-pyran-4-ylmethyl)-amino]-pyr idin-3-yll-acetamide; N-{2- ((S)-3-Fluoro-pyrrolidin-1-yl)-6-[(tetrahydro-pyran-4-ylmeth yl)-amino]-pyridin-3-yll-3,3- dimethyl-butyramide; 2-(3,5-Difluoro-phenyl)-N-{2-(3,3-dimethyl-pyrrolidin-1-yl)- 6- [(tetrahydro-pyran-4-ylmethyl)-amino]-pyridin-3-yll-acetamid e; N-{2-(3,3-Dimethyl- pyrrolidin-1-yl)-6-[(tetrahydro-pyran-4-ylmethyl)-amino]-pyr idin-3-yll-3,3-dimethyl- butyramide; N-{2-((R)-3-Fluoro-pyrrolidin-1-yl)-6-[(tetrahydro-pyran-4-y lmethyl)-amino]- pyridin-3-yll-3,3-dimethyl-butyramide; 2-(3,5-Difluoro-phenyl)-N-{2-((R)-3-fluoro- pyrrolidin-1-yl)-6-[(tetrahydro-pyran-4-ylmethyl)-amino]-pyr idin-3-yll-acetamide; 2-(3,5- Difluoro-phenyl)-N-[6-[(tetrahydro-pyran-4-ylmethyl)-amino]- 2-((S)-2-trifluoromethyl- pyrrolidin-1-yl)-pyridin-3-yl]-acetamide; 3,3-Dimethyl-N-[6-[(tetrahydro-pyran-4- ylmethyl)-amino]-2-((S)-2-trifluoromethylpyrrolidin-1-yl)-py ridin-3-yl]-butyramide; or a pharmaceutically-acceptable addition salt thereof. Formula 44 [0547] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 44. Such compounds are described in International Publication No. WO2010105960A1, published September 23, 2010, and corresponding to International Application No. PCT/EP2010/053072 filed March 11, 2010; US Publication No. US20110003865A1, published January 6, 2011, and corresponding to US Application No.12/747,394 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 44, these references incorporated by reference herein control. [0548] In an embodiment, the Kv7 channel activator is a compound according to Formula 44: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; R ² represents hydrogen; R ³ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R″—, — CH ₂ —CR′R″—, —CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen, alkyl or halo. [0549] In further embodiments, R ¹ represents alkyl. [0550] In further embodiments, R ¹ represents phenyl optionally substituted one or more times with substituents selected from alkyl and halo. [0551] In further embodiments, R ³ represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl. [0552] In further embodiments, R ³ represents alkyl. [0553] In further embodiments, L represents a linker selected from —CR′R″—, —CH ₂ — CR′R″—, —CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen or alkyl. [0554] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-( 3,5-difluoro- phenyl)-acetamide; N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-( 3,4- difluoro-phenyl)-acetamide; N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2- (3-fluoro-4-trifluoromethyl-phenyl)-acetamide; (S)—N-[2-Diethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-2-phenyl-propionamide; N-[2-Diethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-3-(3-fluoro-phenyl)-propionamide; (R)—N-[2-Diethylamino-6- (4-fluoro-benzylamino)-pyridin-3-yl]-3-phenyl-butyramide; trans-2-Phenyl- cyclopropanecarboxylic acid [2-diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]- amide; N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-( 3-fluoro-phenyl)- acetamide; N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-3,3 -dimethyl- butyramide; N-[2-Diethylamino-6-(2,4,6-trimethyl-benzylamino)-pyridin-3- yl]-2-(3,5- difluoro-phenyl)-acetamide; N-(2-Diethylamino-6-isobutylamino-pyridin-3-yl)-2-(3,5- difluoro-phenyl)-acetamide; N-[2-Diethylamino dimethyl-benzylamino)-pyridin-3-yl]-2- (3,5-difluoro-phenyl)-acetamide; N-[2-Diethylamino-6-(2,2-dimethyl-propylamino)- pyridin-3-yl]-2-(3,5-difluoro-phenyl)-acetamide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof. Formula 45 [0555] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 45. Such compounds are described in US Publication No. US20110039896A1, published February 17, 2011, and corresponding to US Application No.12/747,346 filed December 10, 2008; International Publication No. WO2009074593A1, published June 18, 2009, and corresponding to International Application No. PCT/EP2008/067164 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 45, these references incorporated by reference herein control. [0556] In an embodiment, the Kv7 channel activator is a compound according to Formula 45:

a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ represents alkyl, phenyl, benzo[1,3]dioxolyl or benzo[1,4]dioxinyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, trifluoromethyl, alkoxy, cyano and difluoromethoxy; R ² represents hydrogen; R ³ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R″—, — CH ₂ —CR′R″—, —CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen, alkyl or halo. [0557] In further embodiments, R ¹ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; R ² represents hydrogen; R ³ represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; and L represents a linker selected from —CR′R″—, —CH ₂ —CR′R″—, — CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen, alkyl or halo. [0558] In further embodiments, R ¹ represents alkyl. [0559] In further embodiments, R ¹ represents phenyl, benzo[1,3]dioxolyl or benzo[1,4]dioxinyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, trifluoromethyl, alkoxy, cyano and difluoromethoxy. [0560] In further embodiments, R ³ represents alkyl. [0561] In further embodiments, R ³ represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl. [0562] In further embodiments, L represents a linker selected from —CR′R″—, —CH ₂ — CR′R″—, —CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen or alkyl. [0563] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-[6-(4-Fluoro-benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]- 2-(3-fluoro-4- trifluoromethyl-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-[6-(4-fluoro-benzylamino)- 2-pyrrolidin-1-yl-pyridin-3-yl]-acetamide; 2-(3,4-Difluoro-phenyl)-N-[6-(4-fluoro- benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]-acetamide; (S)-N-[6-(4-Fluoro-benzylamino)- 2-pyrrolidin-1-yl-pyridin-3-yl]-2-phenyl-propionamide; N-[6-(4-Fluoro-benzylamino)-2- pyrrolidin-1-yl-pyridin-3-yl]-3-(3-fluoro-phenyl)-propionami de; (R)-N-[6-(4-Fluoro- benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]-3-phenyl-butyra mide; (R)-2-Phenyl- cyclopropanecarboxylic acid [6-(4-fluoro-benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]- amide; N-[6-(4-Fluoro-benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]- 2-(3-fluoro-phenyl)- acetamide; N-[6-(4-Fluoro-benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]- 3,3-dimethyl- butyramide; 2-(3,5-Difluoro-phenyl)-N-(6-isobutylamino-2-pyrrolidin-1-yl -pyridin-3-yl)- acetamide; 2-(3,5-Difluoro-phenyl)-N-[6-(5-fluoro-2-methyl-benzylamino) -2-pyrrolidin-1- yl-pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N-[6-(2,6-dimethyl-benzylamino)-2- pyrrolidin-1-yl-pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N-[2-pyrrolidin-1-yl-6-(4- trifluoromethyl-benzylamino)-pyridin-3-yl]-acetamide; N-{6-[(Benzo[1,3]dioxol-5- ylmethyl)-amino]-2-pyrrolidin-1-yl-pyridin-3-yl}-3,3-dimethy l-butyramide; N-[6-(3,4- Difluoro-benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]-2-(3,5 -difluoro-phenyl)-acetamide; N-{6-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-2-pyrrolidin-1-yl -pyridin-3-yl}-2-(3,5-difluoro- phenyl)-acetamide; N-[6-(4-Cyano-benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]-2 -(3,5- difluoro-phenyl)-acetamide; N-[6-(3,4-Difluoro-benzylamino)-2-pyrrolidin-1-yl-pyridin-3- yl]-3,3-dimethyl-butyramide; 2-(3,5-Difluoro-phenyl)-N-[6-(4-methoxy-benzylamino)-2- pyrrolidin-1-yl-pyridin-3-yl]-acetamide; N-[6-(4-Difluoromethoxy-benzylamino)-2- pyrrolidin-1-yl-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-acetam ide; N-[6-(4-Difluoromethoxy- benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]-3,3-dimethyl-bu tyramide; 2-(3,5-Difluoro- phenyl)-N-{6-[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amin o]-2-pyrrolidin-1-yl-pyridin- 3-yl}-acetamide; N-{6-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-2-pyr rolidin-1- yl-pyridin-3-yl}-3,3-dimethyl-butyramide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof. Formula 46 [0564] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 46. Such compounds are described in International Publication No. WO2009074591A1, published June 18, 2009, and corresponding to International Application No. PCT/EP2008/067161 filed December 10, 2008; US Publication No. US20110003866A1, published December 10, 2008, and corresponding to US Application No.12/747,414 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 46, these references incorporated by reference herein control. [0565] In an embodiment, the Kv7 channel activator is a compound according to Formula 46: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; R ² represents hydrogen; R ³ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R″—, — CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen, alkyl or halo. [0566] In further embodiments, R ¹ represents alkyl. [0567] In further embodiments, R ¹ represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl. [0568] In further embodiments, R ³ represents alkyl. [0569] In further embodiments, R ³ represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl. [0570] In further embodiments, L represents a linker selected from —CR′R″—, — CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen, alkyl or halo. [0571] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2- (3,4-difluoro- phenyl)-acetamide; N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2- (3,5- difluoro-phenyl)-acetamide; N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]- 2-(3-fluoro-4-trifluoromethyl-phenyl)-acetamide; (S)—N-[2-Dimethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-2-phenyl-propionamide; N-[2-Dimethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-3-(3-fluoro-phenyl)-propionamide; trans-2-Phenyl- cyclopropanecarboxylic acid[2-dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]- amide; N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2- (3-fluoro-phenyl)- acetamide; N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-3, 3-dimethyl- butyramide; 2-(3,5-Difluoro-phenyl)-N-[2-dimethylamino-6-(2,4,6-trimethy l- benzylamino)-pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N-[2-dimethylamino-6- (2,6-dimethyl-benzylamino)-pyridin-3-yl]-acetamide; N-[2-Dimethylamino-6-(5-fluoro-2- methyl-benzylamino)-pyridin-3-yl]-3,3-dimethyl-butyramide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof. Formula 47 [0572] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 47. Such compounds are described in US Publication No. US20110003867A1, published January 6, 2011, and corresponding to US Application No.12/747,422 filed December 10, 2008; International Publication No. WO2009074594A1, published June 18, 2009, and corresponding to International Application No. PCT/EP2008/067165 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 47, these references incorporated by reference herein control. [0573] In an embodiment, the Kv7 channel activator is a compound according to Formula 47: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; R ² represents hydrogen; R ³ represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R″—, — CH ₂ —CR′R″—, —CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen, alkyl or halo. [0574] In further embodiments, R ¹ represents alkyl. [0575] In further embodiments, R ¹ represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl. [0576] In further embodiments, R ³ represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl. [0577] In further embodiments, R ³ represents alkyl. [0578] In further embodiments, L represents a linker selected from —CR′R″—, —CH ₂ — CR′R″—, —CR′R″—CH ₂ — and cycloalkyl, wherein R′ and R″, independently of each other, represent hydrogen, alkyl or halo. [0579] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2- (3,5-difluoro- phenyl)-acetamide; N-[2-Ethylmethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl] -2-(3,4- difluoro-phenyl)-acetamide; N-[2-Ethylmethylamino-6-(4-fluoro-benzylamino)-pyridin-3- yl]-2-(3-fluoro-4-trifluoromethyl-phenyl)-acetamide; N-[2-Ethylmethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-3-(3-fluoro-phenyl)-propionamide; (R)—N-[2-(Ethyl-methyl- amino)-6-(4-fluoro-benzylamino)-pyridin-3-yl]-3-phenyl-butyr amide; trans-2-Phenyl- cyclopropanecarboxylic acid [2-Ethylmethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]- amide; N-[2-Ethylmethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl] -2-(3-fluoro- phenyl)-acetamide; N-[2-Ethylmethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl] -3,3- dimethyl-butyramide; pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N-[6-(2,2-dimethyl- propylamino)-2-(ethyl-methyl-amino)-pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N- [2-(ethyl-methyl-amino)-6-isobutylamino-pyridin-3-yl]-acetam ide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof. Formula 48 [0580] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 48. Such compounds are described in International Publication No. WO2007104717A1, published September 20, 2007, and corresponding to International Application No. PCT/EP2007/052239 filed March 9, 2007; US Publication No. US20090036473A1, published February 5, 2009, and corresponding to US Application No.12/278,091 filed March 9, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 48, these references incorporated by reference herein control. [0581] In an embodiment, the Kv7 channel activator is a compound according to Formula 48: including any of its stereoisomers, or any mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ and R ² , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, baloalkoxy, amino, alkyl-carbonyl-amino, alkyl-sulfonyl, cyano or nitro; R ³ represents alkyl, cycloalkyl or alkoxy; and R ⁴ and R ⁵ , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino, nitro or cyano. [0582] In further embodiments, R ¹ and R ² , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl- carbonyl-amino, alkyl-sulfonyl, cyano or nitro. [0583] In further embodiments, R ³ represents alkyl, cycloalkyl or alkoxy. [0584] In further embodiments, R ⁴ and R ⁵ , independently of each other, represent hydrogen, alkyd, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl- carbonyl-amino, nitro or cyano. [0585] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H- quinazolin-3-yl)-amide; 2-(4-Fluoro-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4- oxo-4H-quinazolin-3-yl)-amide; 2-(3-Fluoro-4-methyl-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)- amide; 2-Phenyl-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)-amide; 2-(4-Chloro-phenyl)- cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)-amide; 2-( ⁴ -Fluoro- phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)-amide; 2-p- Tolyl-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)-amide; 2-(3- Fluoro-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)- amide; or 2-p-Tolyl-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)- amide; or a pharmaceutically-acceptable addition salt thereof. Formula 49 [0586] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 49. Such compounds are described in International Publication No. WO2007057447A1, published May 24, 2007, and corresponding to International Application No. PCT/EP2006/068627 filed November 17, 2006; US Publication No. US20090291973A1, published November 26, 2009, and corresponding to US Application No.12/085,188 filed November 17, 2006; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 49, these references incorporated by reference herein control. [0587] In an embodiment, the Kv7 channel activator is a compound according to Formula 49: , including any of its stereoenantiomers or any mixture of its stereoenantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R ¹ represents hydrogen or alkyl; and R ² represents alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, phenylalkyl, amino, alkyl-carbonyl-amino, cyano or nitro; or R ¹ and R ² together with the carbon atom to which they are attached form a cycloalkyl group; or R ¹ represents hydrogen; and R ² together with R ³ attached in ortho- position on the aromatic ring form a —(CH ₂ ) _n — bridge, wherein n is 1, 2 or 3; R ³ and R ⁴ , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino, alkyl-sulfonyl, phenyl, benzoyl, cyano or nitro; or R ³ and R ⁴ together form a methylenedioxy group; or R ³ attached in ortho-position on the aromatic ring and together with R ² form a — (CH ₂ ) _n — bridge, wherein n is 1, 2 or 3; and R ⁴ is as defined above; R ⁵ represents alkyl, cycloalkyl, alkoxy, alkylthio or phenyl; and R ⁶ and R ⁷ , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino(acetamido), nitro, cyano or phenyl; provided, however, that if R ¹ is hydrogen, R ² is methyl, R ³ and R ⁴ represent hydrogen, R ⁵ is isopropyl, and R ⁶ and R ⁷ represent hydrogen, then the compound it is not a quinazoline derivative racemate but the R- or S-enantiomer of the quinazoline derivative. [0588] In further embodiments, R ¹ represents hydrogen or alkyl. [0589] In further embodiments, R ² represents alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, phenylalkyl, amino, alkyl-carbonyl-amino, cyano or nitro. [0590] In further embodiments, R ¹ represents hydrogen or methyl; and R ² represents methyl, ethyl, isopropyl, cyclohexyl, fluoro or benzyl. [0591] In further embodiments, R ¹ and R ² together with the carbon atom to which they are attached form a cycloalkyl group. [0592] In further embodiments, R ¹ represents hydrogen; and R ² together with R ³ attached in ortho-position on the aromatic ring form a —(CH ₂ ) _n — bridge, wherein n is 1, 2 or 3. [0593] In further embodiments, R ³ and R ⁴ , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl- carbonyl-amino, alkyl-sulfonyl, phenyl, benzoyl, cyano or nitro; or R ³ and R ⁴ together form a methylenedioxy group. [0594] In further embodiments, R ³ attached in ortho-position on the aromatic ring and together with R ² form a —(CH ₂ ) _n — bridge, wherein n is 1, 2 or 3; and R ⁴ is as defined in claim 7. [0595] In further embodiments, R ⁵ represents alkyl, cycloalkyl, alkoxy, alkylthio or phenyl. [0596] In further embodiments, R ⁶ and R ⁷ , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl- carbonyl-amino(acetamido), nitro, cyano or phenyl. [0597] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-3-methyl-2-phenyl-b utyramide; 2-(4-Chloro-phenyl)-N-(2-isopropylsulfanyl-4-oxo-4H-quinazol in-3-yl)-butyramide; 2- (3,5-Difluoro-phenyl)-N-(2-isopropylsulfanyl-4-oxo-7-trifluo romethyl-4H-quinazolin-3-yl)- propionamide; N-(2-Ethyl-7-fluoro-4-oxo-4H-quinazolin-3-yl)-2-phenyl-propi onamide; (S)-N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-2-phenyl-propio namide; N-(2-Isopropyl-4- oxo-4H-quinazolin-3-yl)-2,3-diphenyl-propionamide; Bicyclo[4.2.0]octa-1,3,5-triene-7- carboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)-amide; N-(2-Isopropyl-4-oxo-4H- quinazolin-3-yl)-2-p-tolyl-propionamide; 2-Cyclohexyl-N-(2-isopropyl-4-oxo-4H- quinazolin-3-yl)-2-phenyl-acetamide; 2-(3-Benzoyl-phenyl)-N-(2-isopropyl-4-oxo-4H- quinazolin-3-yl)-propionamide; 1-Phenyl-cyclopropanecarboxylic acid (2-isopropyl-4- oxo-4H-quinazolin-3-yl)-amide; 2-(3,4-Dimethoxy-phenyl)-N-(2-isopropyl-4-oxo-4H- quinazolin-3-yl)-propionamide; (R)-N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-2-phenyl- propionamide; N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-2-phenyl-isobutyram ide; 2-(4- Chloro-phenyl)-N-(2-isopropyl-4-oxo-7-trifluoromethyl-4H-qui nazolin-3-yl)-propionamide; N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-2-(4-trifluoromethy l-phenyl)-propionamide; 2- (3,4-Dichloro-phenyl)-N-(2-isopropyl-4-oxo-7-trifluoromethyl -4H-quinazolin-3-yl)- propionamide; 2-(3-Fluoro-phenyl)-N-(2-isopropyl-4-oxo-4H-quinazolin-3-yl) - propionamide; 2-(4-Chloro-phenyl)-N-(2-isopropyl-4-oxo-4H-quinazolin-3-yl) - propionamide; N-(2-Isopropyl-4-oxo-7-trifluoromethyl-4H-quinazolin-3-yl)-2 -(4- trifluoromethyl-phenyl)-propionamide; N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-2-(4- methoxy-phenyl)-propionamide; N-(2-Isopropyl-4-oxo-7-trifluoromethyl-4H-quinazolin-3- yl)-2-(4-methoxy-phenyl)-propionamide; 2-(3,4-Dichloro-phenyl)-N-(2-isopropyl-4-oxo- 4H-quinazolin-3-yl)-propionamide; 2-(3-Fluoro-4-methyl-phenyl)-N-(2-isopropyl-4-oxo-7- trifluoromethyl-4H-quinazolin-3-yl)-propionamide; 2-(3-Fluoro-4-methyl-phenyl)-N-(2- isopropyl-4-oxo-4H-quinazolin-3-yl)-propionamide; 2-(4-Isobutyl-phenyl)-N-(2-isopropyl- 4-oxo-4H-quinazolin-3-yl)-propionamide; N-(7-Chloro-2-isopropyl-4-oxo-4H-quinazolin- 3-yl)-2-(3-fluoro-phenyl)-propionamide; N-(6-Chloro-2-isopropyl-4-oxo-4H-quinazolin-3- yl)-2-(3-fluoro-phenyl)-propionamide; 2-(4-Fluoro-phenyl)-N-(2-isopropyl-4-oxo-4H- quinazolin-3-yl)-propionamide; N-(5-Chloro-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-2-(3- fluoro-phenyl)-propionamide; N-(8-Chloro-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-2-(3- fluoro-phenyl)-propionamide; N-(8-Cyano-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-2-(3- fluoro-phenyl)-propionamide; 7-Methyl-bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)-amide; N-(2-Isopropylsulfanyl-4-oxo-4H- quinazolin-3-yl)-2-phenyl-propionamide; 2-(4-Chloro-phenyl)-N-(2-isopropylsulfanyl-4- oxo-4H-quinazolin-3-yl)-propionamide; 2-(4-Chloro-phenyl)-N-(2-ethoxy-4-oxo-4H- quinazolin-3-yl)-propionamide; 2-(3,5-Difluoro-phenyl)-N-(2-methylsulfanyl-4-oxo-7- trifluoromethyl-4H-quinazolin-3-yl)-propionamide; 2-Fluoro-N-(2-isopropyl-4-oxo-4H- quinazolin-3-yl)-2-phenyl-propionamide; (S)-2-Fluoro-N-(2-isopropyl-4-oxo-4H- quinazolin-3-yl)-2-phenyl-propionamide; (R)-2-Fluoro-N-(2-isopropyl-4-oxo-4H- quinazolin-3-yl)-2-phenyl-propionamide; (S)-2-Fluoro-N-(2-isopropyl-4-oxo-7- trifluoromethyl-4H-quinazolin-3-yl)-2-phenyl-propionamide; or (R)-2-Fluoro-N-(2- isopropyl-4-oxo-7-trifluoromethyl-4H-quinazolin-3-yl)-2-phen yl-propionamide; or an N- oxide thereof, any of its stereoenantiomers or any mixture of its stereoenantiomers, or a pharmaceutically-acceptable addition salt thereof. Formula 50 [0598] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 50. Such compounds are described in US Patent No.7,741,352, issued June 22, 2010, and corresponding to US Application No. 10/546,533 filed March 11, 2004; International Publication No. WO2004080377A2, published September 23, 2004, and corresponding to International Application No. PCT/EP2004/050290 filed March 11, 2004; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 50, these references incorporated by reference herein control. [0599] In an embodiment, the Kv7 channel activator is a compound according to Formula 50: any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein R ¹ represents —CN; R ² represents halo, haloalkyl, hydroxyl or alkoxy; X represents, NR″ or NR″CH ₂ (read in the stated direction); wherein R″ represents hydrogen; R ⁴ represents aryl-alkyl, which is substituted one or more times with substituents selected from the group consisting of halo, or methylenedioxy; or R ⁴ represents a group of formula -Z′-L″-Z″; wherein Z′ and Z″, independently of one another, represent an aryl group, which aryl may be optionally substituted one or more times with halo; and L″ represents a single (covalent) bond, or a linker selected from O or OCH ₂ , with the proviso that when X represents NR″, then R ⁴ represents aryl-alkyl and when X represents NR″CH ₂ , then R ⁴ represents a group of formula -Z′-L″-Z″. [0600] In further embodiments, R ⁴ represents benzyl which is substituted one or two times with halo or one time with methylenedioxy. [0601] In further embodiments, R ⁴ represents 4-fluoro-benzyl, 3,4-dichloro-benzyl or benzo[1,3]dioxol-5-ylmethyl. [0602] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 4-(4-Fluoro-benzylamino)-2-hydroxy-benzonitrile 4-(3,4-Dichloro- benzylamino)-2-hydroxy-benzonitrile or 4-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-2- hydroxy-benzonitrile; or a pharmaceutically-acceptable addition salt thereof. [0603] In further embodiments, R ⁴ represents a group of formula -Z′-L″-Z″; wherein Z′ represents phenyl, or phen-4-yl; which phenyl may optionally be substituted one or two times with halo; and Z″ represent phenyl; which may optionally be substituted one or two times with halo; and L″ represents a single (covalent) bond, or a linker selected from alkyl, O, or OCH ₂ . [0604] In further embodiments, R ⁴ represents 3-phenoxy-phenyl, 3-benzyloxy-phenyl, or biphenyl-4-yl. [0605] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-Hydroxy-4-(3-phenoxy-benzylamino)-benzonitrile; 4-(3-Benzyloxy- benzylamino)-2-hydroxy-benzonitrile; or 4-[(Biphenyl-4-ylmethyl)-amino]-2-hydroxy- benzonitrile; or a pharmaceutically-acceptable addition salt thereof. Formula 51 [0606] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 51. Such compounds are described in US Patent No.7,741,352, issued June 22, 2010, and corresponding to US Application No. 10/546,533 filed March 11, 2004; International Publication No. WO2004080377A2, published September 23, 2004 and corresponding to International Application No. PCT/EP2004/050290 filed March 11, 2004; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 51, these references incorporated by reference herein control. [0607] In an embodiment, the Kv7 channel activator is a compound according to Formula 51: wherein, R represents hydrogen, halogen or hydroxy. R ¹ , R ² , R ³ and R ⁴ independently of each another represent hydrogen, halogen, alkyl, trihalogenmethyl, phenyl, p-methyl- phenyl or p-trihalogenmethyl-phenyl, or R ¹ and R ² , R ² and R ³ , or R ³ and R ⁴ are joined together to form a benzo fused ring, R ⁵ represents hydrogen or alkyl, and R ⁶ represents halogen or trihalogenmethyl, or a pharmaceutically-acceptable addition salt thereof. [0608] In further embodiments, R represents hydrogen, halogen or hydroxy, R ¹ , R ² , R ³ and R ⁴ independently of each another represent hydrogen, halogen, alkyl, trihalogenmethyl, phenyl, p-methyl-phenyl or p-trihalogenmethyl-phenyl, and when R ¹ and R ⁴ are hydrogen, then R ² or R ³ is phenyl, p-methyl-phenyl or p-trihalogenmethyl- phenyl; or R ¹ and R ² , R ² and R ³ , or R ³ and R ⁴ are joined together to form a benzo fused ring, R ⁵ represents hydrogen or alkyl, and R ⁶ represents halogen or trihalogenmethyl. [0609] In further embodiments, R ¹ , R ³ and R ⁴ represent hydrogen, and R ² represents halogen, trihalogenmethyl or phenyl. [0610] In further embodiments, R ¹ and R ² , R ² and R ³ , or R ³ and R ⁴ are joined together to form a benzo fused ring. [0611] In further embodiments, R ⁵ is hydrogen or methyl. [0612] In further embodiments, R ⁶ is chlorine. [0613] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: (+)-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluoromet hyl)-2H-indol- 2-one; (−)-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluorom ethyl)-2H-indol-2-one; (±)-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-6(4-methylphen yl)-2H-indol-2-one; (±)-3- (5-chloro-2-hydroxyphenyl)-1,3-dihydro-2H-indol-one; (±)-3-(5-chloro-2-hydroxyphenyl)- 4,6-dichloro-1,3-dihydro-2H-indol-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-6- phenyl-2H-indol-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-6-iodo-2H-indo l-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-6-trifluoromet hyl)-2H-indol-2-one; (±)-3-(5- chloro-2-hydroxyphenyl)-1,3-dihydro-6-[4-(trifluoromethyl)-p henyl]-2H-indol-2-one; (±)-3- (5-chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[e]indol-2-one ; (±)-3-(5-chloro-2- hydroxyphenyl)-1,3-dihydro-2H-benz[f]indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)- 1,3-dihydro-2H-benx[g]indol-2-one; (±)-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3- hydroxy-6-(trifluoromethyl)-2H-indol-2-one; (±)-3-(5-chloro-2-methoxyphenyl)-1,3- dihydro-3-hydroxy-4-(trifluoromethyl)-2H-indol-2-one; (±)-3-(5-chloro-2-methoxyphenyl)- 1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; (−)-3-(5-chloro-2- methoxyphenyl)-1,3-dihydro-hydroxy-6-(trifluoromethyl)-2H-in dol--2-one; (±)-3-(5-chloro- 2-methoxyphenyl)-1,3-dihydro-3-hydroxy-7-(trifluoromethyl)-2 H-indol-2-one; (±)-3-(5- chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-5-bromo-2H-ind ol-2-one; (±)-3-(5- chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-iodo-2H-indo l-2-one; (±)-3-(5-chloro- 2-methoxyphenyl)-4,6-dichloro-1,3-dihydro-3-hydroxy-2H-indol -2-one; (±)-3-(5-chloro-2- methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[f]indol-2-one; (±)-3-(5-chloro-2- hydroxyphenyl)-1,3-dihydro-3-hydroxy-4,6-bis-(trifluoromethy l)-2H-indol-2-one; (±)-3-(5- chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4-(trifluorome thyl)-2H-indol-2-one; (±)-3- (5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluor omethyl)-2H-indol-2-one; (+)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(tr ifluoromethyl)-2H-indol-2- one; (−)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-( trifluoromethyl)-2H- indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-7-(t rifluoromethyl)- 2H-indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-3 -hydroxy- 2H-indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-5-br omo-2H- indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-io do-2H-indol-2- one; (±)-1,3-dihydro-3-hydroxy-3-[2-hydroxy-5-(trifluoromethyl)- phenyl]-6- (trifluoromethyl)-2H-indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3- hydroxy-2H-benz[g]indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3- hydroxy-2H-benz[f]indol-2-one; (±)-3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-fluoro-6- (trifluoromethyl)-2H-indol-2-one; (3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3- fluoro-6-(trifluoromethyl)-2H-indol-2-one; (3R)-(−)-(5-chloro-2-methoxyphenyl)-1,3- dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol2-one; (±)-3-(5-chloro-2-methoxyphenyl)- 1,3-dihydro-3-fluoro-7-(trifluoromethyl)2H-indol-2-one; (±)-3-(5-chloro-2- methoxyphenyl)-1,3-dihydro-3-fluoro-6-phenyl-2H-indol-2-one; (±)-3-(5-chloro-2- methoxyphenyl)-1,3-dihydro-3-fluoro-6-iodo-2H-indol-2-one; (±)-3-(5-chloro-2- methoxyphenyl)-1,3-dihydro-3-fluoro-5-methyl-2H-indol-2-one; (±)-3-(5-chloro-2- methoxyphenyl)-1,3-dihydro-3-fluoro-5-bromo-2H-indol-2-one; (±)-3-(5-chloro-2- methoxyphenyl)-1,3-dihydro-3-fluoro-4,6-bis-(trifluoromethyl )-2H-indol-2-one; or (±)-3- (5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-7-(trifluoro methyl)-2H-indol-2-one; or a pharmaceutically-acceptable addition salt thereof. [0614] In further embodiments, R represents hydrogen, halogen or hydroxy, R ¹ , R ² , R ³ and R ⁴ independently of each another represent hydrogen, halogen, alkyl, trihalogenmethyl, phenyl, p-methyl-phenyl or p-trihalogenmethyl-phenyl, or R ¹ and R ² , R ² and R ³ , or R ³ and R ⁴ are joined together to form a bezo fused ring, R ⁵ represents hydrogen or alkyl, and R ⁶ represents halogen or trihalogenmethyl, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent. Formula 52 [0615] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 52. Such compounds are described in International Publication No. CN114380731A, published April 22, 2022, and corresponding to International Application No. CN202210226122.7A filed March 9, 2022; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 52, this reference incorporated by reference herein controls. [0616] In an embodiment, the Kv7 channel activator is a compound according to Formula 52: wherein, R ₁ is selected from H, halogen, substituted or unsubstituted phenyl, or a substituted or unsubstituted phenylalkyl group, the substituents of said phenyl and phenylalkyl groups each being independently selected from halogen or haloalkyl; X is selected from S or C; R ₂ is optionally selected from H, alkyl, alkenyl or alkynyl; R ₃ and R ₄ each independently selected from H or alkyl; y is selected from O or S; R ₅ is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, alkoxy or furyl, the substituent of the alkyl is selected from alkoxy, dialkylamino or alkoxycarbonyl, and the substituent of the cycloalkyl is selected from halogen. [0617] In further embodiments, R ₂ is selected from H, C ₁ -C ₃ Alkyl radical, C ₁ -C ₃ Alkenyl or C ₁ -C ₃ Alkynyl. [0618] In further embodiments, R ₃ and R ₄ are each independently selected from H or C ₁ -C ₆ An alkyl group. [0619] In further embodiments, R ₅ is selected from substituted or unsubstituted C ₁ - C ₆ Alkyl, substituted or unsubstituted C ₃ -C ₆ Cycloalkyl radical, C ₁ -C ₆ Alkoxy or furyl, the substituents of the alkyl or the alkoxy being selected from C ₁ -C ₆ Alkoxy, di (C) ₁ -C ₄ Alkyl) amino or C ₁ -C ₆ Alkoxycarbonyl, the substituents of cycloalkyl being selected from halogen. [0620] In further embodiments, the formula is one of formulas II – IV: wherein, n is more than or equal to 0;R ₁₁ and R ₁₂ each independently selected from H, halogen or halomethyl; R ₂ is selected from H, C ₁ -C ₃ Alkyl radical, C ₂ -C ₃ Alkenyl or C ₂ - C ₃ An alkynyl group; R ₃ and R ₄ are independently selected from H or C ₁ -C ₆ alkyl group; y is selected from O or S; R ₅ is selected from substituted or unsubstituted C ₁ -C ₆ Alkyl, substituted or unsubstituted C3-C6Cycloalkyl radical, C1-C6Alkoxy or furyl, the substituents of the alkyl being selected from C ₁ -C ₆ Alkoxy, di (C) ₁ -C ₄ Alkyl) amino or C ₁ - C ₆ Alkoxycarbonyl, the substituents of cycloalkyl being selected from halogen. [0621] In further embodiments, n is 0 to 3, R ₁₁ is selected from H, F or trifluoromethyl, and R ₁₂ is selected from H, F, Cl or methyl. [0622] In further embodiments, R ₃ is one of H or methyl, and R ₄ is other of H or methyl. [0623] In further embodiments, R ₅ is selected from methyl, ethyl, isopropyl, isobutyl, neopentyl, cyclobutyl, ethoxy, isopropoxy, tert-butoxy or tetrahydrofuranyl. Formula 53 [0624] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 53. Such compounds are described in International Publication No. WO2021260090A1, published December 30, 2021, and corresponding to International Application No. PCT/EP2021/067288 filed June 24, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 53, this reference incorporated by reference herein controls. [0625] In an embodiment, the Kv7 channel activator is a compound according to Formula 53:

, wherein, X ¹ represents nitrogen or CR ^X1 ; wherein R ^X1 represents hydrogen, halogen, (C _1-4 )alkyl, or (C _1-4 )alkoxy; X ² represents nitrogen or CR ^X2 ; wherein R ^X2 represents hydrogen, halogen, (C _1-4 )alkyl, or (C _1-4 )alkoxy; X ³ represents nitrogen or CR ^X3 ; wherein R ^X3 represents hydrogen, halogen, (C _1-4 )alkyl, (C _{1- 4} )alkoxy, or hydroxy; R ¹ represents hydrogen or methyl; R ^X4 represents hydrogen, halogen, or (C _1-4 )alkyl; • R ^2A represents hydrogen; (C1-4)alkyl; (C2-4)alkenyl; (C2-4)alkynyl; (C3-6)cycloalkyl; (C1- 4)fluoroalkyl; (C1- 4)hydroxyalkyl; (C _1-4 )alkoxy-(C _1-2 )alkyl; (C _1-2 )alkoxy-(C _1-2 )alkoxy-(C _{1- 2} )alkyl; (C _1-2 )alkyl- S-(C _1-2 )alkyl; (C _1-2 )alkyl-(SO ₂ )-(C _1-2 )alkyl; cyano; (C _1-2 )cyanoalkyl; H ₂ N- C(O)-(C _1-2 )alkyl; (R ^N1 ) ₂ N-(C _1-2 )alkyl or (R ^N1 ) ₂ N-C(O)-, wherein R ^N1 independently represents hydrogen or (C _1-2 )alkyl; or a 5-membered heteroaryl group containing one to four nitrogen atoms, wherein said 5-membered heteroaryl group is independently unsubstituted or mono- substituted with (C _1-4 )alkyl; and R ^2B represents hydrogen or methyl; or • R ^2A and R ^2B form, together with the carbon atom to which they are attached, a ring of 3- to 6 members, wherein the members needed to complete said ring are each independently selected from -CH ₂ - and -O- and wherein said ring does not contain more than one -O- member; L represents a direct bond, cycloprop-1,1-diyl, -CHR ^L -O-*, -O-CH ₂ -*, -CH ₂ -NH- *, -CH ₂ - N(CH ₃ )-*, -O-, or –(SO ₂ )-; wherein R ^L represents hydrogen, (C _1-4 )alkyl, CH ₃ -O- CH ₂ -, or (CH ₃ ) ₂ NCH ₂ -; wherein the asterisks indicate the bond which is linked to the aromatic carbon atom; R ³ represents hydrogen or fluoro; • R ⁴ represents hydrogen or (C _1-4 )alkyl; R ⁵ represents hydrogen, fluoro, or hydroxy; and R ⁶ represents fluoro or (C ₁ )fluoroalkyl; or • R ⁴ and R ⁵ together represent a bridge selected from -CH ₂ - and - CH ₂ CH ₂ -; and R ⁶ represents hydrogen, fluoro, (C ₁ )fluoroalkyl, or (C _1-4 )alkyl; or a salt thereof. [0626] In further embodiments, X ¹ represents CR ^X1 ; wherein R ^X1 represents hydrogen or halogen; X ² represents nitrogen or CH; X ³ represents nitrogen or CH; R ¹ represents hydrogen; R ^X4 represents hydrogen, halogen, or (C _1-4 )alkyl; R ^2A represents hydrogen; (C _1-4 )alkyl; (C _1-4 )fluoroalkyl; (C _1-4 )hydroxyalkyl; or (C _1-4 )alkoxy-(C _{1- 2} )alkyl; R ^2B represents hydrogen; L represents a direct bond, -CH ₂ -O-*, or-O-; wherein the asterisk indicates the bond which is linked to the aromatic carbon atom; R ³ represents hydrogen or fluoro; • R ⁴ represents hydrogen or (C _1-4 )alkyl; R ⁵ represents hydrogen, fluoro, or hydroxy; and R ⁶ represents fluoro or (C ₁ )fluoroalkyl; or • R ⁴ and R ⁵ together represent a bridge selected from -CH ₂ - and -CH ₂ CH ₂ -; and R ⁶ represents hydrogen, fluoro, (C ₁ )fluoroalkyl, or (C _1-4 )alkyl; or a salt thereof (meaning a salt of the compound of Formula 53). [0627] In further embodiments, R ^2A represents hydrogen, (C _1-4 )alkyl, (C _1-4 )fluoroalkyl, (C _1-4 )hydroxyalkyl, or methoxymethyl; and R ^2B represents hydrogen; or a salt thereof. [0628] In further embodiments, L represents a direct bond; or a salt thereof. [0629] In further embodiments, R ³ represents fluoro; or a salt thereof. [0630] In further embodiments, R ^X4 represents hydrogen; or a salt thereof. [0631] In further embodiments, each of X ¹ , X ² , and X ³ represents CH; or a salt thereof. [0632] In further embodiments, the fragment represents: ; wherein R ^X4 represents hydrogen or halogen; R ³ represents hydrogen or fluoro; and L represents a direct bond, -CH ₂ -O-*, or-O-; wherein the asterisk indicates the bond which is linked to the aromatic carbon atom; or • ; wherein X ³ represents nitrogen or CH; R ^X4 represents hydrogen or (C _1-4 )alkyl; R ³ represents hydrogen or fluoro; and L represents -CH ₂ -O-*, or-O-; wherein the asterisk indicates the bond which is linked to the aromatic carbon atom; or a salt thereof. [0633] In further embodiments, R ⁴ represents hydrogen; R ⁵ represents hydrogen or fluoro; and R ⁶ represents fluoro, difluoromethyl or trifluoromethyl; or a salt thereof. [0634] In further embodiments, R ⁴ and R ⁵ together represent a -CH ₂ - bridge; and R ⁶ represents hydrogen, fluoro, difluoromethyl, or trifluoromethyl; or a salt thereof. [0635] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 1-(3,3-Difluoro-cyclobutyl)-3-(3-trifluoromethyl-benzyl)-ure a; 1- Bicyclo[1.1.1]pent-1-yl-3-[1-(3-trifluoromethyl-phenyl)-ethy l]-urea; 1-(3-Difluoromethyl- cyclobutyl)-3-[1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-(3-Fluoro-bicyclo[1.1.1]pent-1- yl)-3-[1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-(3-Difluoromethyl-bicyclo[1.1.1]pent-1- yl)-3-[1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-Bicyclo[1.1.1]pent-1-yl-3-[1-(3- trifluoromethoxy-phenyl)-ethyl]-urea; 1-(3-Difluoromethyl-cyclobutyl)-3-[1-(3- trifluoromethoxy-phenyl)-ethyl]-urea; 1-(3-Fluoro-bicyclo[1.1.1]pent-1-yl)-3-[1-(3- trifluoromethoxy-phenyl)-ethyl]-urea; 1-[2,2-Difluoro-1-(3-trifluoromethyl-phenyl)-ethyl]-3- (3-hydroxy-3-trifluoromethyl-cyclobutyl)-urea; 1-(3,3-Difluoro-1-methyl-cyclobutyl)-3- [2,2-difluoro-1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-Bicyclo[1.1.1]pent-1-yl-3-[1-(3- difluoromethoxy-phenyl)-ethyl]-urea; 1-(3-Difluoromethyl-bicyclo[1.1.1]pent-1-yl)-3-[2- hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-(3-Difluoromethyl-bicyclo[1.1.1]pent- 1-yl)-3-[2,2-difluoro-1-(3-trifluoromethyl-phenyl)-ethyl]-ur ea; 1-(3-Difluoromethyl- bicyclo[1.1.1]pent-1-yl)-3-[2-methoxy-1-(3-trifluoromethyl-p henyl)-ethyl]-urea; 1-(3- Difluoromethyl-bicyclo[1.1.1]pent-1-yl)-3-(2-fluoro-3-triflu oromethyl-benzyl)-urea; 1-(3- Difluoromethyl-bicyclo[1.1.1]pent-1-yl)-3-(3-fluoro-5-triflu oromethyl-benzyl)-urea; 1-(3- Fluoro-bicyclo[1.1.1]pent-1-yl)-3-[3-(2,2,2-trifluoro-ethoxy )-benzyl]-urea; 1-(3- Difluoromethyl-cyclobutyl)-3-[3-(2,2,2-trifluoro-ethoxy)-ben zyl]-urea; 1-[3-(2,2,2- Trifluoro-ethoxy)-benzyl]-3-(3-trifluoromethyl-bicyclo[1.1.1 ]pent-1-yl)-urea; 1-(3- Difluoromethoxy-benzyl)-3-(3-fluoro-bicyclo[1.1.1]pent-1-yl) -urea; 1-(3-Difluoromethoxy- benzyl)-3-(3-difluoromethyl-cyclobutyl)-urea; 1-(3-Difluoromethoxy-benzyl)-3-(3- trifluoromethyl-bicyclo[1.1.1]pent-1-yl)-urea; 1-(3-Trifluoromethoxy-benzyl)-3-(3- trifluoromethyl-bicyclo[1.1.1]pent-1-yl)-urea; 1-(3-Fluoro-bicyclo[1.1.1]pent-1-yl)-3-(3- trifluoromethoxy-benzyl)-urea; 1-(3-Difluoromethyl-cyclobutyl)-3-(3-trifluoromethoxy- benzyl)-urea; 1-Bicyclo[1.1.1]pent-1-yl-3-(3-trifluoromethoxy-benzyl)-urea ; 1-(3- Difluoromethyl-benzyl)-3-(3-difluoromethyl-cyclobutyl)-urea; 1-(3-Difluoromethyl-benzyl)- 3-(3-trifluoromethyl-bicyclo[1.1.1]pent-1-yl)-urea; 1-(3-Difluoromethyl-cyclobutyl)-3-(2- trifluoromethoxy-pyridin-4-ylmethyl)-urea; 1-(2-Trifluoromethoxy-pyridin-4-ylmethyl)-3- (3-trifluoromethyl-bicyclo[1.1.1]pent-1-yl)-urea; 1-(3-Difluoromethyl-cyclobutyl)-3-{2- methoxy-1-[2-(2,2,2-trifluoro-ethoxy)-pyridin-4-yl]-ethyl}-u rea; 1-{2-Methoxy-1-[2-(2,2,2- trifluoro-ethoxy)-pyridin-4-yl]-ethyl}-3-(3-trifluoromethyl- cyclobutyl)-urea; 1-[1-(2- Difluoromethoxy-pyridin-4-yl)-ethyl]-3-(3-difluoromethyl-cyc lobutyl)-urea; 1-{1-[2-Methyl- 6-(2,2,2-trifluoro-ethoxy)-pyrimidin-4-yl]-ethyl}-3-(3-trifl uoromethyl-bicyclo[1.1.1]pent-1- yl)-urea; 1-Bicyclo[1.1.1]pent-1-yl-3-(3-trifluoromethyl-benzyl)-urea; 1-(3-Fluoro- bicyclo[1.1.1]pent-1-yl)-3-(3-trifluoromethyl-benzyl)-urea; 1-(3-Trifluoromethyl-benzyl)-3- (3-trifluoromethyl-bicyclo[1.1.1]pent-1-yl)-urea; 1-(3-Difluoromethyl-cyclobutyl)-3-(3- trifluoromethyl-benzyl)-urea; 1-(3-Methyl-bicyclo[1.1.1]pent-1-yl)-3-(3-trifluoromethyl- benzyl)-urea; 1-(3-Fluoromethyl-bicyclo[1.1.1]pent-1-yl)-3-(3-trifluoromet hyl-benzyl)- urea; 1-(3-Trifluoromethyl-benzyl)-3-(3-trifluoromethyl-cyclobutyl )-urea; 1-(3-Hydroxy-3- trifluoromethyl-cyclobutyl)-3-(3-trifluoromethyl-benzyl)-ure a; 1-Bicyclo[1.1.1]pent-1-yl-3- [2-(2,2,2-trifluoro-ethoxy)-pyridin-4-ylmethyl]-urea; 1-(3-Fluoro-bicyclo[1.1.1]pent-1-yl)-3- [2-(2,2,2-trifluoro-ethoxy)-pyridin-4-ylmethyl]-urea; 1-[2-(2,2,2-Trifluoro-ethoxy)-pyridin- 4-ylmethyl]-3-(3-trifluoromethyl-bicyclo[1.1.1]pent-1-yl)-ur ea; 1-(3-Difluoromethyl- cyclobutyl)-3-[2-(2,2,2-trifluoro-ethoxy)-pyridin-4-ylmethyl ]-urea; 1-(3-Difluoromethyl- bicyclo[1.1.1]pent-1-yl)-3-(3-trifluoromethyl-benzyl)-urea; 1-Bicyclo[2.1.1]hex-1-yl-3-(3- trifluoromethyl-benzyl)-urea; 1-(3,3-Difluoro-1-methyl-cyclobutyl)-3-(3-trifluoromethyl- benzyl)-urea; 1-(3-(trifluoromethyl)benzyl)-3-((1s,3s)-3-(trifluoromethyl) cyclobutyl)urea; 1-(3-(trifluoromethyl)benzyl)-3-((1r,3r)-3-(trifluoromethyl) cyclobutyl)urea; 1-((1s,3s)-3- (difluoromethyl)cyclobutyl)-3-(3-(trifluoromethyl)benzyl)ure a; 1-((1r,3r)-3- (difluoromethyl)cyclobutyl)-3-(3-(trifluoromethyl)benzyl)ure a; 1-{(S)-1-[2-Methyl-6-(2,2,2- trifluoro-ethoxy)-pyrimidin-4-yl]-ethyl}-3-(3-trifluoromethy l-bicyclo[1.1.1]pent-1-yl)- urea; 1-((1r,3r)-3-(difluoromethyl)cyclobutyl)-3-((2-(2,2,2-triflu oroethoxy)pyridin-4- yl)methyl)urea; 1-((1s,3s)-3-(difluoromethyl)cyclobutyl)-3-((2-(2,2,2- trifluoroethoxy)pyridin-4-yl)methyl)urea; 1-((1s,3R)-3-(difluoromethyl)cyclobutyl)-3-((S)- 1-(3-(trifluoromethoxy)phenyl)ethyl)urea; and 1-((1r,3S)-3-(difluoromethyl)cyclobutyl)-3- ((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)urea; or a salt thereof. Formula 54 [0636] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 54. Such compounds are described in International Publication No. WO2021219594A1, published November 4, 2021 and corresponding to International Application No. PCT/EP2021/060918 filed April 27, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 54, this reference incorporated by reference herein controls. [0637] In an embodiment, the Kv7 channel activator is a compound according to Formula 54: wherein, X ¹ represents nitrogen or CR ^x1 ; wherein R ^X1 represents hydrogen, halogen, (C _1-4 )alkyl, or (C _{1- 4} )alkoxy;X ² represents nitrogen or CR ^X2 ; wherein R ^X2 represents hydrogen, halogen, (C _1-4 )alkyl, or (C _{1- 4} )alkoxy; X ³ represents nitrogen or CR ^X3 ; wherein R ^X3 represents hydrogen, halogen, (C _1-4 )alkyl, (C _{1- 4} )alkoxy, or hydroxy;• R ¹ represents hydrogen, or methyl; or• R ¹ and R ^X1 together represent a -CH ₂ CH ₂ - bridge; Y represents -C(R ^Y1 )(R ^Y2 )-, or *-CH ₂ -C(R ^Y3 )(R ^Y4 )-, wherein the asterisk indicates the bond which is linked to the cyclobutyl ring;R ^Y1 represents hydrogen, or fluoro;R ^Y2 represents hydrogen or fluoro;R ^Y3 represents hydrogen, fluoro or iodo;R ^Y4 represents hydrogen or fluoro; R ^2A represents hydrogen; (C _1-4 )alkyl; (C _2-4 )alkenyl; (C _2-4 )alkynyl; (C _3-6 )cycloalkyl; (C _{1- 4} )fluoroalkyl; (C _1-4 )hydroxyalkyl; (C _1-4 )alkoxy-(C _1-2 )alkyl; (C _1-2 )alkoxy-(C _1-2 )alkoxy- (C _{1- 2} )alkyl; (C _1-2 )alkyl-S-(C _1-2 )alkyl; (C _1-2 )alkyl-(SO ₂ )-(C _1-2 )alkyl; cyano; (C _1-2 )cyanoalkyl; H ₂ N- C(O)-(C _1-2 )alkyl; (R ^N1 ) ₂ N-(C _1-2 )alkyl or (R ^N1 ) ₂ N-C(O)-, wherein R ^N1 independently represents hydrogen or (C _1-2 )alkyl; or a 5-membered heteroaryl group containing one to four nitrogen atoms, wherein said 5-membered heteroaryl group is independently unsubstituted or mono-substituted with(C _1-4 )alkyl; and R ^2B represents hydrogen, or methyl; or R ^2A and R ^2B form, together with the carbon atom to which they are attached, a ring of 3- to 6 members, wherein the members needed to complete said ring are each independently selected from -CH ₂ - and -O- and wherein said ring does not contain more than one -O- member; or R ^2A and R ^X3 together represent a -CH ₂ -O-* bridge, wherein the asterisk indicates the bond which is linked to the aromatic carbon atom, andR ^2B represents hydrogen;R ³ represents -SFs; (C _1-2 )alkyi-S(O) ₂ -; or a fragment R ³¹ represents hydrogen, or fluoro; and L represents a direct bond, cycloprop-1 ,1-diyl, -CHR ^L -O-*, -O-CH ₂ -*, -CH ₂ -NH-*, - CH ₂ -N(CH ₃ )-*, -O-, or -(SO ₂ )-; wherein R ^L represents hydrogen, (C _1- )alkyl, CH ₃ -0-CH ₂ -, or (CH ₃ ) ₂ NCH ₂ -; wherein the asterisks indicate the bond which is linked to the aromatic carbon atom; orR ³ and R ^X1 together represent a -O-CF ₂ -O- bridge; orR ³ and R ^X2 together represent a -O-CF ₂ - O- bridge; and R ⁴ represents hydrogen, halogen, or (C _1-4 )alkyl; or a salt thereof. [0638] In further embodiments, R ¹ represents hydrogen; or a salt thereof (meaning a salt of compound of Formula 54). [0639] In further embodiments, R ^Y1 , R ^Y2 , R ^Y3 and R ^Y4 all represent hydrogen; or a salt thereof. [0640] In further embodiments, R ^2A represents hydrogen, (C _1-4 )alkyl, (C _3-6 )cycloalkyl, (C _1-4 )fluoroalkyl, (C _1-4 )hydroxyalkyl, (C _1-4 )alkoxy-(C _1-2 )alkyl, (C _1-2 )alkyl-S-(C _1-2 )alkyl, (C _{1- 2} )alkyl-(SO ₂ )-(C _1-2 )alkyl, cyano, (C _{1- 2} )cyanoalkyl, H ₂ N-C(O)-(C _1-2 )alkyl, (R ^N1 ) ₂ N-(C _1- 2)alkyl, or (R ^N1 )2N-C(O)-, wherein R ^N1 independently represents hydrogen or (C1-2)alkyl; and R ^2B represents hydrogen; or R ^2A and R ^2B form, together with the carbon atom to which they are attached, a ring of 3- to 6 members selected from cycloprop-1 ,1-diyl, cyclobut-1 ,1-diyl, oxetane-3,3-diyl and tetrahydropyran-4,4-diyl; or a salt thereof. [0641] In further embodiments, R ^2A represents hydrogen, methyl, or hydroxymethyl; and R ^2B represents hydrogen; or a salt thereof. [0642] In further embodiments, R ³ represents a fragment whereinR ³¹ represents hydrogen, or fluoro; and L represents a direct bond, -CHR ^L -O- ^* , - O-CH ₂ - ^* , -CH ₂ -NH- ^* , -CH ₂ -N(CH ₃ )- ^* , or -O-; wherein R ^L represents hydrogen, methyl, CH ₃ -O-CH ₂ -, or (CH ₃ ) ₂ NCH ₂ -; wherein the asterisks indicate the bond which is linked to the aromatic carbon atom; or a salt thereof. [0643] In further embodiments, R ⁴ represents hydrogen; or a salt thereof. [0644] In further embodiments, the fragment ents: or wherein X ³ represents nitrogen and X ¹ represents CR ^X1 ; X ¹ represents nitrogen and X ³ represents CR ^X3 ; or X ¹ represents CR ^X1 and X ³ represents CR ^X3 ; or a salt thereof. [0645] In further embodiments, the fragment represents wherein R ^X1 represents hydrogen, fluoro, chloro, methyl, or methoxy; R ^X2 represents hydrogen; R ^X3 represents hydrogen, fluoro, or chloro; R ⁴ represents hydrogen, fluoro, chloro, or methyl; R ³¹ represents hydrogen, or fluoro; and L represents a direct bond, - CHR ^L -O- ^* , -CH ₂ -NH- ^* , -CH ₂ -N(CH ₃ )- ^* , -O-, or ; wherein R ^L represents hydrogen, or methyl; wherein the asterisks indicate the bond which is linked to the aromatic carbon atom; or wherein X ³ represents nitrogen and X ¹ represents CR ^X1 ; X ¹ represents nitrogen and X ³ represents CR ^X3 ; or X ¹ represents CR ^X1 and X ³ represents CR ^X3 ; wherein R ^X1 represents hydrogen, or methoxy; R ^X3 represents hydrogen; R ⁴ represents hydrogen, or methyl; and L represents -CHR ^L -O-*, -CH ₂ -NH-*, or -CH ₂ -N(CH ₃ )-*; wherein R ^L represents hydrogen, methyl, CH ₃ -O-CH ₂ -, or (CH ₃ ) ₂ NCH ₂ -; wherein the asterisks indicate the bond which is linked to the aromatic carbon atom; or a salt thereof. [0646] In further embodiments, X ¹ represents CR ^X1 ; wherein R ^X1 represents hydrogen; X ² represents nitrogen or CR ^X2 ; wherein R ^X2 represents hydrogen; X ³ represents nitrogen or CR ^X3 ; wherein R ^X3 represents hydrogen; R ¹ represents hydrogen; Y represents -CH ₂ -, or -CH ₂ -CH ₂ -; R ^2A represents hydrogen, or hydroxymethyl;R ^2B represents hydrogen; R ³ represents trifluoromethyl or 2,2,2- trifluoroethoxy; and R ⁴ represents hydrogen; or a salt thereof. [0647] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 1-Spiro[3.3]hept-2-yl-3-(3-trifluoromethyl-benzyl)-urea;1-Sp iro[2.3]hex-5- yl-3-(3-trifluoromethyl-benzyl)-urea;1 -(1 , 1 -Difluoro-spiro[2.3]hex-5-yl)-3-(3- trifluoromethyl-benzyl)-urea; 1-((3r,5r)-1,1-Difluoro-spiro[2.3]hex-5-yl)-3-(3- trifluoromethyl-benzyl)-urea; 1-((3s,5s)-1 , 1 -Difluoro-spiro[2.3]hex-5-yl)-3-(3- trifluoromethyl-benzyl)-urea; 1-(6,6-Difluoro-spiro[3.3]hept-2-yl)-3-(3-trifluoromethyl- benzyl)-urea;1-[1-(3-Difluoromethoxy-phenyl)-cyclopropyl]-3- spiro[3.3]hept-2-yl-urea;1- (2-Fluoro-3-trifluoromethoxy-benzyl)-3-spiro[3.3]hept-2-yl-u rea;1-[2-Methoxy-1-(3- trifluoromethyl-phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea;1- [1-(2-Difluoromethoxy-pyridin- 4-yl)-2-methoxy-ethyl]-3-spiro[3.3]hept-2-yl-urea;1-Spiro[3. 3]hept-2-yl-3-(5- trifluoromethoxy-2,3-dihydro-benzofuran-3-yl)-urea;1-(2-Fluo ro-3-trifluoromethyl- benzyl)-3-spiro[3.3]hept-2-yl-urea;1-(3-Difluoromethoxy-benz yl)-3-spiro[3.3]hept-2-yl- urea;1-Spiro[3.3]hept-2-yl-3-[3-(2,2,2-trifluoro-ethoxy)-ben zyl]-urea;1-(3-Difluoromethyl- benzyl)-3-spiro[3.3]hept-2-yl-urea;1-(2-Fluoro-5-trifluorome thyl-benzyl)-3-spiro[3.3]hept- 2-yl-urea;1-(4-Fluoro-3-trifluoromethyl-benzyl)-3-spiro[3.3] hept-2-yl-urea;1-(3-Fluoro-5- trifluoromethyl-benzyl)-3-spiro[3.3]hept-2-yl-urea;1-[1-(2-B romo-5-trifluoromethyl- phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea;1-[1-(2-Methoxy-5- trifluoromethyl-phenyl)- ethyl]-3-spiro[3.3]hept-2-yl-urea;1-[1-(2-Methoxy-3-trifluor omethyl-phenyl)-ethyl]-3- spiro[3.3]hept-2-yl-urea;1-(2-Methoxy-3-trifluoromethyl-benz yl)-3-spiro[3.3]hept-2-yl- urea;1-Spiro[3.3]hept-2-yl-3-[1-(3-trifluoromethyl-phenyl)-e thyl]-urea;1-[Cyclopropyl-(3- trifluoromethyl-phenyl)-methyl]-3-spiro[3.3]hept-2-yl-urea;1 -[Cyclopropyl-(3- difluoromethoxy-phenyl)-methyl]-3-spiro[3.3]hept-2-yl-urea;1 -{1-[4-Methyl-3-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-{1-[4-Chloro-3-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-{1-[4-Methoxy-3-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-{1-[2-Methyl-3-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-{1-[2-Chloro-3-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-{1-[2-Methoxy-3-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-{1-[3-Methyl-5-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-{1-[3-Chloro-5-(2,2,2- trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea; 1-(1-(3-(pentafluoro-l6- sulfaneyl)phenyl)ethyl)-3-(spiro[3.3]heptan-2-yl)urea;1-(3-( pentafluoro-l6- sulfaneyl)benzyl)-3-(spiro[3.3]heptan-2-yl)urea;1-[1-(3-Meth anesulfonyl-phenyl)-ethyl]-3- spiro[3.3]hept-2-yl-urea; 1-Spiro[3.3]hept-2-yl-3-[3-(1-trifluoromethyl-cyclopropyl)- benzyl]-urea;1-(2-Hydroxy-5-trifluoromethyl-benzyl)-3-spiro[ 3.3]hept-2-yl-urea;1-{1-[2- Chloro-5-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3.3 ]hept-2-yl-urea;1-{1-[2- Methoxy-5-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[3. 3]hept-2-yl-urea;1- Spiro[3.3]hept-2-yl-3-(3-trifluoromethoxy-benzyl)-urea;1-Spi ro[3.3]hept-2-yl-3-(3- trifluoromethanesulfonyl-benzyl)-urea;1-Spiro[3.3]hept-2-yl- 3-(3-trifluoromethoxymethyl- benzyl)-urea;1-Spiro[3.3]hept-2-yl-3-[3-(3-trifluoromethyl-p henyl)-oxetan-3-yl]-urea;1-[2- Hydroxy-2-methyl-1-(3-trifluoromethyl-phenyl)-propyl]-3-spir o[3.3]hept-2-yl-urea;1-(2,2- Difluoro-benzo[1,3]dioxol-4-ylmethyl)-3-spiro[3.3]hept-2-yl- urea;1-[1-(2,2-Difluoro- benzo[1,3]dioxol-4-yl)-ethyl]-3-spiro[3.3]hept-2-yl-urea;1-{ 2-Dimethylamino-1-[6-(2,2,2- trifluoro-ethoxy)-pyridin-2-yl]-ethyl}-3-spiro[3.3]hept-2-yl -urea;1-Spiro[3.3]hept-2-yl-3-{4- [2-(2,2,2-trifluoro-ethoxy)-pyridin-4-yl]-tetrahydro-pyran-4 -yl}-urea;1-{2-Methoxy-1-[2- (2,2,2-trifluoro-ethoxy)-pyridin-4-yl]-ethyl}-1-methyl-3-spi ro[3.3]hept-2-yl-urea;1-[1-(2- Difluoromethoxy-pyridin-4-yl)-cyclobutyl]-3-spiro[3.3]hept-2 -yl-urea;1-[1-(2- Difluoromethoxy-pyridin-4-yl)-1 -methyl-ethyl]-3-spiro[3.3]hept-2-yl-urea; 5-(2,2,2- Trifluoro-ethoxy)-3,4-dihydro-1H-[2,6]naphthyridine-2-carbox ylic acid spiro[3.3]hept-2- ylamide; 1-Methoxymethyl-5-(2,2,2-trifluoro-ethoxy)-3,4-dihydro-1 H-isoquinoline-2- carboxylic acid spiro[3.3]hept-2- ylamide;1-[Cyano-(3-trifluoromethyl-phenyl)-methyl]-3- spiro[3.3]hept-2-yl-urea;1-Spiro[3.3]hept-2-yl-3-[(1 H-[1 ,2,4]triazol-3-yl)-(3- trifluoromethyl-phenyl)-methyl]-urea;1-[2,2-Difluoro-1-(3-tr ifluoromethyl-phenyl)-ethyl]-3- spiro[3.3]hept-2-yl-urea;1-Spiro[3.3]hept-2-yl-3-[2,2,2-trif luoro-1-(3-trifluoromethyl- phenyl)-ethyl]-urea;1-Spiro[3.3]hept-2-yl-3-[6-(2,2,2-triflu oro-ethoxy)-pyrimidin-4- ylmethyl]-urea;1-[2-Methyl-6-(2,2,2-trifluoro-ethoxy)-pyrimi din-4-ylmethyl]-3- spiro[3.3]hept-2-yl-urea;1-Spiro[3.3]hept-2-yl-3-{1-[6-(2,2, 2-trifluoro-ethoxy)-pyrimidin-4- yl]-ethyl}-urea;2-(3-Spiro[3.3]hept-2-yl-ureido)-2-(3-triflu oromethyl-phenyl)-acetamide; N-Methyl-2-(3-spiro[3.3]hept-2-yl-ureido)-2-(3-trifluorometh yl-phenyl)-acetamide; 1-[2- Methanesulfonyl-1-(3-trifluoromethoxy-phenyl)-ethyl]-3-spiro [3.3]hept-2-yl-urea; 1-[1- (2,2-Difluoro-benzo[1,3]dioxol-5-yl)-ethyl]-3-spiro[3.3]hept -2-yl-urea; 1-[2-Cyano-1-(3- trifluoromethoxy-phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea; 1-[2-Cyano-1-(3- trifluoromethyl-phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea;1- {1-[2-Methyl-6-(2,2,2-trifluoro- ethoxy)-pyrimidin-4-yl]-ethyl}-3-spiro[3.3]hept-2-yl-urea;1- [2-Methanesulfonyl-1-(3- trifluoromethyl-phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea;1- Spiro[3.3]hept-2-yl-3-[2-(2,2,2- trifluoro-ethoxy)-pyrimidin-4-ylmethyl]-urea;1-[2-(2-Methoxy -ethoxy)-1-(3-trifluoromethyl- phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea;1-[2-lsopropoxy-1- (3-trifluoromethyl-phenyl)- ethyl]-3-spiro[3.3]hept-2-yl-urea;1-[3-Ethoxy-1-(3-trifluoro methyl-phenyl)-propyl]-3- spiro[3.3]hept-2-yl-urea;1-[3-Hydroxy-1-(3-trifluoromethyl-p henyl)-propyl]-3- spiro[3.3]hept-2-yl-urea;1-[3-Methylsulfanyl-1-(3-trifluorom ethyl-phenyl)-propyl]-3- spiro[3.3]hept-2-yl-urea;1-[2-Hydroxy-1-(3-trifluoromethyl-p henyl)-ethyl]-3- spiro[3.3]hept-2-yl-urea;1-{3-Ethoxy-1 -[2-(2,2,2-trifluoro-ethoxy)-pyridin-4-yl]-propyl)-3- spiro[3.3]hept-2-yl-urea;1-{2-Methoxy-1-[6-(2,2,2-trifluoro- ethoxy)-pyrimidin-4-yl]-ethyl}- 3-spiro[3.3]hept-2-yl-urea;4-(3-Spiro[3.3]hept-2-yl-ureido)- 4-(3-trifluoromethyl-phenyl)- butyramide;1-Spiro[3.3]hept-2-yl-3-[1 -(3-trifluoromethyl-phenyl)-but-3-enyl]-urea;1-[3- Methanesulfonyl-1-(3-trifluoromethyl-phenyl)-propyl]-3-spiro [3.3]hept-2-yl-urea;1-{2- Hydroxy-1-[2-methyl-6-(2,2,2-trifluoro-ethoxy)-pyrimidin-4-y l]-ethyl}-3-spiro[3.3]hept-2-yl- urea;1-{2-Hydroxy-1-[6-(2,2,2-trifluoro-ethoxy)-pyrimidin-4- yl]-ethyl}-3-spiro[3.3]hept-2- yl-urea;1-[3,3-Difluoro-1-(3-trifluoromethyl-phenyl)-propyl] -3-spiro[3.3]hept-2-yl-urea;1- {3-Hydroxy-1-[6-(2,2,2-trifluoro-ethoxy)-pyrimidin-4-yl]-pro pyl}-3-spiro[3.3]hept-2-yl- urea;1-[1-(3-Methanesulfonyl-phenyl)-2-methoxy-ethyl]-3-spir o[3.3]hept-2-yl-urea;1-{2- Hydroxy-1-[3-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro [3.3]hept-2-yl-urea;1-{3- Hydroxy-1-[3-(2,2,2-trifluoro-ethoxy)-phenyl]-propyl)-3-spir o[3.3]hept-2-yl-urea;1- [Cyano-(3-trifluoromethyl-phenyl)-methyl]-3-spiro[3.3]hept-2 -yl-urea;1-Spiro[3.3]hept-2- yl-3-{1-[3-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-urea;1-{2 -Methoxy-1-[3-(2,2,2-trifluoro- ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea;1-{2-Metho xy-1-[2-(2,2,2-trifluoro- ethoxy)-pyridin-4-yl]-ethyl}-3-spiro[3.3]hept-2-yl-urea;1-Sp iro[3.3]hept-2-yl-3-{1-[2-(2,2,2- trifluoro-ethoxy)-pyridin-4-yl]-ethyl}-urea;1-{2-Dimethylami no-1-[2-(2,2,2-trifluoro- ethoxy)-pyridin-4-yl]-ethyl}-3-spiro[3.3]hept-2-yl-urea;1-{1 -[3-Fluoro-5-(2,2,2-trifluoro- ethoxy)-phenyl]-ethyl}-3-spiro[3.3]hept-2-yl-urea;1-Spiro[3. 3]hept-2-yl-3-(2- trifluoromethoxy-pyridin-4-ylmethyl)-urea;1-Spiro[3.3]hept-2 -yl-3-[1-(2-trifluoromethoxy- pyridin-4-yl)-ethyl]-urea; 1-{1-[2-Fluoro-3-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-3- spiro[3.3]hept-2-yl-urea;1-{1-[2-Huoro-5-(2,2,2-trifluoro- ethoxy)-phenyl]-ethyl}-3- spiro[3.3]hept-2-yl-urea;1-[1-(2-Difluoromethoxy-pyridin-4-y l)-ethyl]-3-spiro[3.3]hept-2-yl- urea;1-(Spiro[3.3]heptan-2-yl)-3-(1-(2-((1,1,1-trifluoroprop an-2-yl)oxy)pyridin-4- yl)ethyl)urea;1-(Spiro[3.3]heptan-2-yl)-3-(1-(3-((1,1,1-trif luoropropan-2- yl)oxy)phenyl)ethyl)urea;1-Spiro[3.3]hept-2-yl-3-[2-(2,2,2-t rifluoro-ethoxy)-pyridin-4- ylmethyl]-urea;1-Spiro[3.3]hept-2-yl-3-[6-(2,2,2-trifluoro-1 -methoxymethyl-ethoxy)- pyridin-2-ylmethyl]-urea;1-[6-(1-Dimethylaminomethyl-2,2,2-t rifluoro-ethoxy)-pyridin-2- ylmethyl]-3-spiro[3.3]hept-2-yl-urea;1-[2-(1-Dimethylaminome thyl-2,2,2-trifluoro-ethoxy)- pyridin-4-ylmethyl]-3-spiro[3.3]hept-2-yl-urea;1-Spiro[3.3]h ept-2-yl-3-[2-(2,2,2-trifluoro-1- methoxymethyl-ethoxy)-pyridin-4-ylmethyl]-urea;1-[5-Methyl-6 -(2,2,2-trifluoro-ethoxy)- pyridin-2-ylmethyl]-3-spiro[3.3]hept-2-yl-urea;1-[4-Methyl-3 -(2,2,2-trifluoro-ethoxy)- benzyl]-3-spiro[3.3]hept-2-yl-urea;1-[3-Huoro-5-(2,2,2-trifl uoro-1-methyl-ethoxy)-benzyl]- 3-spiro[3.3]hept-2-yl-urea;1-Spiro[3.3]hept-2-yl-3-{1-[3-(2, 2,2-trifluoro-1-methyl-ethoxy)- phenyl]-cyclopropyl}-urea;1-Spiro[3.3]hept-2-yl-3-[4-(2,2,2- trifluoro-ethoxy)-pyrimidin-2- ylmethyl]-urea;1-{1-[4-Huoro-3-(2,2,2-trifluoro-ethoxy)-phen yl]-ethyl}-3-spiro[3.3]hept-2- yl-urea;1-[4-Huoro-3-(2,2,2-trifluoro-ethoxy)-benzyl]-3-spir o[3.3]hept-2-yl-urea;1-{2- [Methyl-(2,2,2-trifluoro-ethyl)-amino]-pyridin-4-ylmethyl}-3 -spiro[3.3]hept-2-yl-urea;1- Spiro[3.3]hept-2-yl-3-[2-(2,2,2-trifluoro-ethylamino)-pyridi n-4-ylmethyl]-urea;1- Spiro[3.3]hept-2-yl-3-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-p yridin-2-ylmethyl]-urea;1- Spiro[3.3]hept-2-yl-3-[2-(2,2,2-trifluoro-1-methyl-ethoxy)-p yrimidin-4-ylmethyl]-urea;1- Spiro[3.3]hept-2-yl-3-[1-(3-trifluoromethoxy-phenyl)-ethyl]- urea;1-Spiro[2.3]hex-5-yl-3-[6- (2,2,2-trifluoro-1-methyl-ethoxy)-pyrimidin-4-ylmethyl]-urea ;1-[1-(2,2-Difluoro-benzo[1 ,3]dioxol-4-yl)-ethyl]-3-spiro[2.3]hex-5-yl-urea; 1-{2-Hydroxy-1-[6-(2,2,2-trifluoro-ethoxy)- pyrimidin-4-yl]-ethyl}-3-spiro[2.3]hex-5-yl-urea;1-{2-Hydrox y-1 -[2-methyl-6-(2,2,2- trifluoro-ethoxy)-pyrimidin-4-yl]-ethyl}-3-spiro[2.3]hex-5-y l-urea;1-[1-(3-Difluoromethoxy- phenyl)-ethyl]-3-spiro[2.3]hex-5-yl-urea;1-(2-Methoxy-5-trif luoromethyl-benzyl)-3- spiro[2.3]hex-5-yl-urea;1-Spiro[2.3]hex-5-yl-3-[4-(2,2,2-tri fluoro-ethoxy)-pyrimidin-2- ylmethyl]-urea;1-(1-(3-(pentafluoro-l6-sulfaneyl)phenyl)ethy l)-3-(spiro[2.3]hexan-5- yl)urea;1-(2-Methoxy-3-trifluoromethyl-benzyl)-3-spiro[2.3]h ex-5-yl-urea; 1-{1-[2-Huoro- 5-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-3-spiro[2.3]hex-5- yl-urea;1-(3-(pentafluoro-l6- sulfaneyl)benzyl)-3-(spiro[2.3]hexan-5-yl)urea;1-{1-[2-Huoro -3-(2,2,2-trifluoro-ethoxy)- phenyl]-ethyl}-3-spiro[2.3]hex-5-yl-urea;1-{1-[3-Huoro-5-(2, 2,2-trifluoro-ethoxy)-phenyl]- ethyl}-3-spiro[2.3]hex-5-yl-urea;1-[1-(2-Methoxy-3-trifluoro methyl-phenyl)-ethyl]-3- spiro[2.3]hex-5-yl-urea;1-(2-Huoro-3-trifluoromethoxy-benzyl )-3-spiro[2.3]hex-5-yl- urea;1-Spiro[2.3]hex-5-yl-3-{1-[3-(2,2,2-trifluoro-1-methyl- ethoxy)-phenyl]-cyclopropyl}- urea;1-[1-(3-Difluoromethoxy-phenyl)-cyclopropyl]-3-spiro[2. 3]hex-5-yl-urea;1-[1-(2- Methoxy-5-trifluoromethyl-phenyl)-ethyl]-3-spiro[2.3]hex-5-y l-urea;1-[3-Hydroxy-1-(3- trifluoromethoxy-phenyl)-propyl]-3-spiro[2.3]hex-5-yl-urea;1 -[1-(2-Difluoromethoxy- pyridin-4-yl)-ethyl]-3-spiro[2.3]hex-5-yl-urea;1-Spiro[2.3]h ex-5-yl-3-[1-(3-trifluoromethyl- phenyl)-ethyl]-urea;1-Spiro[2.3]hex-5-yl-3-[1-(3-trifluorome thoxy-phenyl)-ethyl]-urea;1- (3-Huoro-5-trifluoromethyl-benzyl)-3-spiro[2.3]hex-5-yl-urea ;1-[2-Hydroxy-1-(3- trifluoromethyl-phenyl)-ethyl]-3-spiro[2.3]hex-5-yl-urea;1-S piro[2.3]hex-5-yl-3-{1-[6- (2,2,2-trifluoro-ethoxy)-pyrimidin-4-yl]-ethyl}-urea;1-{1-[2 -Methyl-6-(2,2,2-trifluoro- ethoxy)-pyrimidin-4-yl]-ethyl}-3-spiro[2.3]hex-5-yl-urea;1-[ 2,2-Difluoro-1 -(3- trifluoromethyl-phenyl)-ethyl]-3-spiro[2.3]hex-5-yl-urea;1-[ 2-Methoxy-1-(3- trifluoromethyl-phenyl)-ethyl]-3-spiro[2.3]hex-5-yl-urea;1-( 4-Huoro-3-trifluoromethyl- benzyl)-3-spiro[2.3]hex-5-yl-urea;1-(2-Huoro-3-trifluorometh yl-benzyl)-3-spiro[2.3]hex-5- yl-urea;1-(2-Chloro-3-trifluoromethyl-benzyl)-3-spiro[2.3]he x-5-yl-urea;1-(2-Huoro-5- trifluoromethyl-benzyl)-3-spiro[2.3]hex-5-yl-urea;1-{1-[5-Me thoxy-6-(2,2,2-trifluoro- ethoxy)-pyrimidin-4-yl]-ethyl}-3-spiro[2.3]hex-5-yl-urea;1-S piro[2.3]hex-5-yl-3-(2- trifluoromethoxy-pyridin-4-ylmethyl)-urea;1-{2-Methoxy-1-[2- (2,2,2-trifluoro-ethoxy)- pyridin-4-yl]-ethyl}-3-spiro[2.3]hex-5-yl-urea;1-(3-Difluoro methoxy-benzyl)-3- spiro[2.3]hex-5-yl-urea;1 -Spiro [2.3] h ex-5-y I -3-(3-trifIuoromethoxy-benzyI )-urea; 1- Spiro[2.3]hex-5-yl-3-[3-(2,2,2-trifluoro-ethoxy)-benzyl]-ure a; 1-(3-Difluoromethyl-benzyl)- 3-spiro[2.3]hex-5-yl-urea; 1-Spiro[2.3]hex-5-yl-3-[2-(2,2,2-trifluoro-ethoxy)-pyridin-4 - ylmethyl]-urea; 1-(6,6-Difluoro-spiro[3.3]hept-2-yl)-3-[2-(2,2,2-trifluoro-e thoxy)-pyridin-4- ylmethyl]-urea;1-(6,6-Difluoro-spiro[3.3]hept-2-yl)-3-[1-(3- trifluoromethyl-phenyl)-ethyl]- urea;1-Spiro[3.3]hept-2-yl-3-[(1 H-[1 ,2,3]triazol-4-yl)-(3-trifluoromethyl-phenyl)-methyl]- urea;1-[(1-Methyl-1 H-tetrazol-5-yl)-(3-trifluoromethyl-phenyl)-methyl]-3-spiro[ 3.3]hept-2- yl-urea;1-[(2-Methyl-2H-tetrazol-5-yl)-(3-trifluoromethyl-ph enyl)-methyl]-3-spiro[3.3]hept- 2-yl-urea;1-[(3-Methyl-3H-[1,2,3]triazol-4-yl)-(3-trifluorom ethyl-phenyl)-methyl]-3- spiro[3.3]hept-2-yl-urea;1-[1-(2-Difluoromethoxy-pyridin-4-y l)-ethyl]-3-(6-iodo- spiro[3.3]hept-2-yl)-urea;1-[(R)-1-(2-Difluoromethoxy-pyridi n-4-yl)-ethyl]-3- spiro[3.3]hept-2-yl-urea;1-[(S)-1-(2-Difluoromethoxy-pyridin -4-yl)-ethyl]-3-spiro[3.3]hept- 2-yl-urea;1-Spiro[3.3]hept-2-yl-3-{1-[3-((R)-2,2,2-trifluoro -1-methyl-ethoxy)-phenyl]- cyclopropyl}-urea;1-Spiro[3.3]hept-2-yl-3-{1-[3-((S)-2,2,2-t rifluoro-1-methyl-ethoxy)- phenyl]-cyclopropyl}-urea;1-Spiro[3.3]hept-2-yl-3-[2-((R)-2, 2,2-trifluoro-1- methoxymethyl-ethoxy)-pyridin-4-ylmethyl]-urea;1-Spiro[3.3]h ept-2-yl-3-[2-((S)-2,2,2- trifluoro-1-methoxymethyl-ethoxy)-pyridin-4-ylmethyl]-urea;1 -[(S)-1-(3-Difluoromethoxy- phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea;1-[(R)-1-(3-Difluo romethoxy-phenyl)-ethyl]-3- spiro[3.3]hept-2-yl-urea;1-Spiro[3.3]hept-2-yl-3-[(S)-1-(3-t rifluoromethyl-phenyl)-ethyl]- urea;1-Spiro[3.3]hept-2-yl-3-{(S)-1-[3-(2,2,2-trifluoro-etho xy)-phenyl]-ethyl}-urea;1-{(S)- 1-[4-Fluoro-3-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-3-spir o[3.3]hept-2-yl-urea;1- Spiro[3.3]hept-2-yl-3-[(R)-2,2,2-trifluoro-1-(3-trifluoromet hyl-phenyl)-ethyl]-urea;1- Spiro[3.3]hept-2-yl-3-[(R)-(1H-[1,2,4]triazol-3-yl)-(3-trifl uoromethyl-phenyl)-methyl]- urea;1-Spiro[3.3]hept-2-yl-3-[2-((R)-2,2,2-trifluoro-1-methy l-ethoxy)-pyrimidin-4- ylmethyl]-urea;1-Spiro[3.3]hept-2-yl-3-[2-((S)-2,2,2-trifluo ro-1-methyl-ethoxy)-pyrimidin- 4-ylmethyl]-urea;1-Spiro[3.3]hept-2-yl-3-{(S)-1-[6-(2,2,2-tr ifluoro-ethoxy)-pyrimidin-4-yl]- ethyl}-urea;1-Spiro[3.3]hept-2-yl-3-{(R)-1-[6-(2,2,2-trifluo ro-ethoxy)-pyrimidin-4-yl]-ethyl}- urea;1-[(R)-2-Hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-3- spiro[3.3]hept-2-yl-urea;1- [(S)-2-Hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-3-spiro[3 .3]hept-2-yl-urea;1-[(R)-2- Hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-3-spiro[2.3]hex- 5-yl-urea;1-[(R)-1-(2- Difluoromethoxy-pyridin-4-yl)-2-methoxy-ethyl]-3-spiro[3.3]h ept-2-yl-urea;1-{(R)-2- Methoxy-1-[2-(2,2,2-trifluoro-ethoxy)-pyridin-4-yl]-ethyl}-3 -spiro[2.3]hex-5-yl-urea;1-[(S)- 1-(2-Difluoromethoxy-pyridin-4-yl)-ethyl]-3-spiro[2.3]hex-5- yl-urea; or 1-[(S)-1-(2-Bromo- 5-trifluoromethyl-phenyl)-ethyl]-3-spiro[3.3]hept-2-yl-urea; or a salt thereof. Formula 55 [0648] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds of Formula 55. Such compounds are described in International Publication No. WO2020157126A1, published August 6, 2020, and corresponding to International Application No. PCT/EP2020/052156 filed January 29, 2020; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 55, this reference incorporated by reference herein controls. [0649] In an embodiment, the Kv7 channel activator is a compound according to Formula 55: or a tautomer, salt, solvate, stereoisomer or isotope thereof, wherein: Y is selected from: C1-C10 alkylamino, C1-C10 alkyl, C1-C10 alkoxy, C3-C8 cycloalkyl, Cl- C10 alkylcarbonyl, Cl -CIO alkylaminocarbonyl, Cl -CIO alkylthio, aryl, heterocycle, Cl -CIO carbonyl, C1-C10 amide and C1-C10 carboxyl and it is optionally mono-substituted or bi- substituted with a first substituent independently selected from: hydroxyl, amino, thiol, carboxylic acid, amide, carbonyl, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy carbonyl, C1-C6 alkylamino, C1-C6 alkylaminocarbonyl, C1-C6 alkyloxy, C1-C6 alkylthio, C2-C8 alkenyl, C5-C7 cycloalkenyl, C2-C8 alkynyl and C5-C10 aryl, any of said first substituents being optionally substituted by one or more second substituents independently selected from: hydroxyl, amino, thiol, carboxylic acid, amide, carbonyl, halogen, C1-C6 alkyl, C3- C6 cycloalkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy carbonyl, C1-C6 alkylamino, C1-C6 alkylaminocarbonyl, C1-C6 alkyloxy, C1-C6 alkylthio, C2-C8 alkenyl, C5-C7 cycloalkenyl, C2- C8 alkynyl and C5-C10 aryl; b is an integer comprised between 1 and 3;or Y is NH or O and b is 1;R.2 is selected from: an aromatic ring, a cycloalkyl, a heterocycle, a linear or branched saturated alkyl and a linear or branched unsaturated alkyl, any of which optionally bearing in one or more positions at least one substituent independently selected from the group consisting of: OH, NO2, CN, halogen, NH2, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy carbonyl, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkylaminocarbonyl, acetamidyl, C1-C6 alkyloxy, C1-C6 alkylthio, C2-C8 alkenyl, C5-C7 cycloalkenyl, C2-C8 alkynyl, C5-C10 aryl, thiol and thiol ether; Ri, R3, R4 and R5 are each independently selected from the group consisting of: H, N¾, OH, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy carbonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C1-C6 alkylaminocarbonyl, C1-C6 alkyloxy, C1-C6 alkylthio, C2-C8 alkenyl, C5-C7 cycloalkenyl, heterocycle, C2-C8 alkynyl and C5-C10 aryl, any of which being optionally substituted by one or more substituents independently selected from: hydroxyl, amine, thiol, carboxyl, carboxylic acid, and halogen; Q is selected from the group consisting of: C=0, SO2, SO, SO2NH, CONH, CSNH, C=NH, CNHNH, and C=S; when Q is C=0 or C=S, R ₆ is selected from: linear or branched C3-C30 alkyl, linear or branched C5-C30 arylalkyl, C3-C8 cycloalkyl, linear or branched C2-C4 alkyl substituted by C3-C8 cycloalkyl, linear or branched C3- C10 cycloalkylamino, linear or branched Cl -CIO alkylamino, linear or branched C2-C10 alkenylamino, linear or branched C2-C10 alkynylamino, C5-C10 aryl, linear or branched C7-C15 arylalkylamino, linear or branched C7-C15 arylalkenylamino, linear or branched C7-C15 arylalkynylamino, C2-C30 alkenyl, C2-C30 alkynyl and C1-C30 alkoxyl, any of which being optionally substituted with one or more substituents independently selected from: linear or branched alkyl group, halogen, hydroxyl group, amine group, alkylamine, dialkylamine, thiol, thioether and cycloalkyl; when Q is SO2, SO, SO2NH, CONH, CSNH, C=NH, or CNHNH, R ₆ is selected from: linear or branched C1-C30 alkyl, C3-C8 cycloalkyl, linear or branched C1-C30 alkylcarbonyl, linear or branched C1-C30 alkoxycarbonyl, linear or branched C1-C30 alkylamino, linear or branched Cl- C30 alkylaminocarbonyl, linear or branched C1-C30 alkyloxy, linear or branched C1-C30 alkylthio, linear or branched C2-C30 alkenyl, C5-C8 cycloalkenyl, linear or branched C2- C30 alkynyl, heterocycle and aryl, any of which being optionally substituted with one or more substituents independently selected from: halogen, C1-C6 alkyl, oxo and C3-C7 cycloalkyl. [0650] In further embodiments, b is 1. [0651] In further embodiments, Q is C=0 or SO2. [0652] In further embodiments, Y is Cl -CIO alkylamino, Cl -CIO alkyl or Cl -CIO alkoxy. [0653] In further embodiments, R2 is an aromatic ring optionally substituted with one or more substituents independently selected from the group consisting of: OH, NO2, halogen, NH2, C1-C3 haloalkyl, acetamidyl, C1-C6 alkyloxy, C1-C3 haloalkoxy, and C1- C6 alkylcarbonyl. [0654] In further embodiments, Ri, R3, R4 and R5 are each independently: H, C1-C6 alkyl, C3- C6 cycloalkyl, NH ₂ , NH(C1-C6 alkyl), N(C1-C6 alkyl)2 , azepane, pirrolidine, piperidine, aziridine or halogen. [0655] In further embodiments, when Q is C=0 or C=S, R ₆ is selected from: linear or branched C3-C30 alkyl, linear or branched C5-C30 arylalkyl, C3-C8 cycloalkyl, linear or branched C2-C4 alkyl substituted by C3-C8 cycloalkyl, linear or branched C1-C10 alkylamino, linear or branched C7-C15 arylalkylamino, C2- C30 alkenyl, C2-C30 alkynyl and C1-C30 alkoxyl, any of which being optionally substituted with one or more substituents independently selected from: halogen and cycloalkyl; and where Q is S02, SO, SO2NH, CONH, CSNH, C=NH, or CNHNH, Re is C3-C8 cycloalkyl or aryl and is optionally substituted with one or more C1-C6 alkyl. [0656] In further embodiments, the Kv7 Channel activator is selected from the group consisting of those listed in the following table

Formula 56 [0657] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 56. Such compounds are described in International Publication No. WO2020016297A1, published January 23, 2020, and corresponding to International Application No. PCT/EP2019/069240 filed July 17, 2019; Patent Cooperation Treaty application No. PCT/EP2019/069240 published January 23, 2020, which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 56, this reference incorporated by reference herein controls. [0658] In an embodiment, the Kv7 channel activator is a compound according to Formula 56: wherein, R ₁ is selected from a branched or unbranched C1 to C5 alkyl group and – NR _1a R _1b group, where R _1a and R _1b are selected independently of one another from hydrogen atom and branched or unbranched C1 to C5 alkyl group or with one another and with the nitrogen atom the NR _1a R _1b group form a C3 to C9 heterocycloalkyl group, the C3 to C9 heterocycloalkyl group each having at least one substituent selected from the hydrogen atom and C1 to C3 alkyl group and optionally in addition to the nitrogen atom of the NR _1a R _1b - Group has at least one further heteroatom in the cycle; R _{2 is} selected from the group consisting of branched or unbranched C1 to C10 alkyl group, C3 to C10 cycloalkyl group, C3 to C10 heterocycloalkyl group, at least one hetero atom being selected from nitrogen and oxygen atom, C6 to C12 aryl group; and C5 to C11 heteroaryl group, the C1 to C10 alkyl group, C3 to C10 cycloalkyl group, C3 to C10 heterocycloalkyl group, C6 to C12 aryl group, or C5 to C11 heteroaryl group in each case at least one further Substituents R _2a , wherein R _{2a is} selected from the group consisting of hydrogen atom, halogen atom, branched or unbranched C1 to C3 alkyl group, branched or unbranched (per) halogenated C1 to C3 alkyl group and branched or unbranched C1 to C3 Alkoxy group, and wherein the C3 to C10 cycloalkyl group, C3 to C10 heterocycloalkyl group, C6 to C12 aryl group or C5 to C11 heteroaryl group comprises one or more ring systems which are condensed or separated; R _{3 is} selected from the group consisting of branched or unbranched C1 to C10 alkoxy group; branched or unbranched C1-C10 alkyl group and - (CH ₂ ) _P -C6 to C12 aryl group, which has at least one substituent selected from hydrogen atom, halogen atom and C1 to C3 alkoxy group and wherein the C6 to C12 aryl group has one or comprises several ring systems which are condensed or separated; R _{4 is} selected from hydrogen, halogen atom and branched or unbranched C1 -C5 alkyl group; X is a nitrogen atom or a -CH group; n is zero or an integer ranging from 1 to 3; m is zero or an integer ranging from 1 to 5; and p is zero or an integer ranging from 1 to 5. [0659] In further embodiments, n is zero and / or m is 1 and / or X is a nitrogen atom. [0660] In further embodiments, R ₁ is selected from the group consisting of branched or unbranched C1- to C3-alkyl group and - NR _1a R _1b group, wherein R _1a and R _1b are independently selected from hydrogen atom and branched or unbranched C1- to C3-alkyl group or with one another and form a C4 to C6 heterocycloalkyl group with the nitrogen atom of the NR _1a R _1b group, the C4 to C6 heterocycloalkyl group each having at least one substituent selected from the hydrogen atom and C1 to C3 alkyl group and optionally in addition to the nitrogen atom of the NR _1a R _1b group has at least one further oxygen atom in the cycle; and or R _{2 is} selected from the group consisting of mono- or difluorophenyl group; CF ₃ phenyl group; F ₅ S-phenyl group; C4 to C8 cycloalkyl group; branched or unbranched C1 to C5 alkyl group; Biphenyl group; Pyridine group; Piperidine group; Tetrahydropyran group; Dioxolane group and phenyl group, the phenyl group having at least one substituent R _2a selected from hydrogen atom and methoxy group; and or R _{3 is} selected from the group consisting of ethoxy group, propyl group, tert-butyl group, - (CH ₂ ) _P -phenyl group, which has at least one substituent selected from hydrogen atom, halogen atom and methoxy group and where p is zero or is 1 or 2; and or R _{4 is} a hydrogen atom _, a bromine atom or a methyl group. [0661] In further embodiments, the Kv7 channel activator is selected from the group consisting of: Formulas 57 – 139 [0662] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds of formulas 57 - 139. Such compounds are described in International Publication No. WO2018204765A1, published November 8, 2018, and corresponding to International Application No. PCT/US2018/031057 filed May 4, 2018; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of any of Formulas 57 - 139, this reference incorporated by reference herein controls. [0663] In an embodiment, the Kv7 channel activator is a compound according to any one of formulas 57 – 139:

wherein (for any of compounds 57 – 139), each and any of R ^1, R ^2, and R ³ independently = H, CI, Br, F, I, OH, OAc, CF3, NH2, CN, OC _1-6 saturated, unsaturated alkyl, cycloalkyl, cycloheteroalkyl, or aryl, SC _1-6 saturated, unsaturated alkyl, cycloalkyl, cycloheteroalkyl, or aryl, C _1-6 saturated alkyl, unsaturated alkyl, cycloalkyl, cycloheteroalkyl, CO2H, COC1-8 alkyl unsaturated alkyl, or aryl, C02C _1-6 saturated, unsaturated alkyl, or aryl, CONH2, C02NHC _1-6 saturated, unsaturated alkyl or aryl, C02N(C _1-6 saturated, unsaturated alkyl or aryl)2, NHC _1-6 saturated, unsaturated alkyl, or cycloalkyl, N(C _1- 6 saturated, unsaturated alkyl, or cycloalkyl)2, or C5-7aryl or heteroaryl; and wherein each X = independently C, CH, CH2, S, SO, SO2, NH, NC _1-6 saturated, unsaturated alkyl, or cycloalkyl, or O, and wherein each n, where present, is independently = 0-6. Formula 140 [0664] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 140. Such compounds are described in International Publication No. WO2016077724A1, published May 19, 2016, and corresponding to International Application No. PCT/US2015/060627 filed November 13, 2015; US Patent No.10,526,280, issued January 7, 2020 and corresponding to US Application No. US10526280B2 filed November 11, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 140, this reference incorporated by reference herein controls. [0665] In an embodiment, the Kv7 channel activator is a compound according to Formula 140:

wherein, R ¹ is H or optionally-substituted alkyl;R ² is optionally-substituted alkyl;R ³ and R ⁴ are each independently H or optionally-substituted alkyl;R ⁵ is H, optionally- substituted alkyl, acyl, or alkoxycarbonyl;R ⁶ and R ⁷ are each independently H, deuterium, optionally- substituted alkyl, or R ⁶ and R ⁷ together form a carbocycle;R ⁸ is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R ⁸ is 4-halophenyl, then R ² is substituted alkyl or branched alkyl or at least one of R ⁶ or R ⁷ is not H; andR ³⁰ , R ³¹ and R ³² are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy. [0666] In further embodiments, R ¹ is H. [0667] In further embodiments, R ² is C ₁ -C ₆ alkyl. [0668] In further embodiments, R ² is carbocyclic-substituted alkyl or heterocyclic- substituted alkyl. [0669] In further embodiments, R ³ and R ⁴ are each H. [0670] In further embodiments, R ⁵ is H. [0671] In further embodiments, R ⁶ and R ⁷ are both H; R ⁶ and R ⁷ are both deuterium; R ⁶ and R ⁷ together form a cycloalkyl; or at least one of R ⁶ or R ⁷ is a substituted alkyl. [0672] In further embodiments, R ⁸ is selected from: w erein R ⁹ -R ²⁵ are each independently H, halogen, optionally-substituted sulfanyl, or optionally-substituted alkyl. [0673] In further embodiments, R ⁸ is: eein at least one of R ⁹ or R ¹⁰ is halogen. [0674] In further embodiments, R ⁸ is: wherein at least one of R ¹⁹ or R ²⁰ is halogen. [0675] In further embodiments, R ⁸ is: wherein at least one of R ¹⁴ -R ¹⁸ is substituted sulfanyl or haloalkyl; or wherein R ¹⁶ is F. [0676] In further embodiments, at least one of R ¹⁴ -R ¹⁸ is —SF ₅ or CF ₃ . [0677] In further embodiments, R ⁸ is: wherein at least one of R ¹¹ -R ¹³ or R ²³ -R ²⁵ is substituted sulfanyl. [0678] In further embodiments, R ⁸ is: wherein at least one of R ¹⁴ -R ¹⁸ is halo-substituted sulfanyl, haloalkyl or halogen. [0679] In further embodiments, at least one of R ¹⁴ -R ¹⁸ is —SF5 or —CF3. [0680] In further embodiments, R ¹⁵ , R ¹⁶ , or R ¹⁷ is —SF ₅ or —CF ₃ . [0681] In further embodiments, R ³² is —F, and R ³⁰ and R ³¹ are each H. [0682] In further embodiments, the Kv7 Channel activator is selected from the group consisting of:

[0683] In further embodiments, the compound is according to formula 141 wherein: R ¹ is H or optionally-substituted alkyl; R ² is substituted alkyl having one or more hydrogen atoms substituted with a substituent selected from halogen, cycloalkyl, alkoxy, amino, hydroxyl, aryl, alkenyl, or carboxyl; R ³ and R ⁴ are each independently H or optionally- substituted alkyl; R ⁵ is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R ⁶ and R ⁷ are each independently H, deuterium, optionally-substituted alkyl, or R ⁶ and R ⁷ together form a carbocycle; R ⁸ is optionally-substituted thiazolyl, optionally- substituted thiophenyl, or substituted phenyl; andR ³⁰ , R ³¹ and R ³² are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy. [0684] In further embodiments, the compound is according to formula 141 wherein: R ¹ is H or optionally-substituted alkyl; R ² is optionally-substituted alkyl; R ³ and R ⁴ are each independently H or optionally-substituted alkyl; R ⁵ is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R ⁶ and R ⁷ are each independently H, deuterium, optionally- substituted alkyl, or R ⁶ and R ⁷ together form a carbocycle, provided at least one R ⁶ or R ⁷ is not H; R ⁸ is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R ⁸ is 4-halophenyl, then R ² is substituted alkyl or branched alkyl or at least one of R ⁶ or R ⁷ is not H; andR ³⁰ , R ³¹ and R ³² are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy. [0685] In further embodiments, the compound is according to formula 141 wherein: R ¹ is H or optionally-substituted alkyl;R ² is optionally-substituted alkyl;R ³ and R ⁴ are each independently H or optionally-substituted alkyl;R ⁵ is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;R ⁶ and R ⁷ are each independently H, deuterium, optionally-substituted alkyl, or R ⁶ and R ⁷ together form a carbocycle;R ⁸ is in at least one of R ¹⁴ -R ¹⁸ is substituted sulfanyl or haloalkyl; andR ³ and R ³¹ are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy; andR ³² is deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy. [0686] In further embodiments, R ³² is halogen. [0687] In further embodiments, R ³² is —F. [0688] In further embodiments, at least one of R ¹⁴ -R ¹⁸ is halo-substituted sulfanyl. [0689] In further embodiments, at least one of R ¹⁴ -R ¹⁸ is haloalkyl. [0690] In further embodiments, at least one of R ¹⁴ -R ¹⁸ is —SF ₅ . [0691] In further embodiments, at least one of R ¹⁴ -R ¹⁸ is —CF ₃ . [0692] In further embodiments, R ¹⁶ is —SF ₅ . [0693] In further embodiments, R ¹⁶ is —CF ₃ . [0694] In further embodiments, R ² is alkyl. [0695] In further embodiments, R ² is C ₁ -C ₆ alkyl. [0696] In further embodiments, R ² is ethyl. [0697] In further embodiments, R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are each H. [0698] In further embodiments, R ³² is —F and R ¹⁶ is —CF ₃ . [0699] In further embodiments, R ² is alkyl. [0700] In further embodiments, R ³ and R ³¹ are each H. [0701] In further embodiments, R ¹⁵ , R ¹⁶ , or R ¹⁷ is —SF ₅ or —CF ₃ . [0702] In further embodiments, R ¹ , R ¹ , R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ are each H; R ² is alkyl; and R ³² is —F. Formula 141 [0703] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 141. Such compounds are described in International Publication No. WO2016077724A1, published May 19, 2016, and corresponding to International Application No. PCT/US2015/060627 filed November 13, 2015; US Patent No.10,526,280, issued January 7, 2020, and corresponding to US Application No. US10526280B2 filed November 11, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 141, these references incorporated by reference herein control. [0704] In an embodiment, the Kv7 channel activator is a compound according to Formula 141: wherein, R ¹ is H or optionally-substituted alkyl; R ² is optionally-substituted alkyl; R ³ and R ⁴ are each independently H or optionally-substituted alkyl; R ⁵ is H, optionally- substituted alkyl, acyl, or alkoxycarbonyl; R ⁶ and R ⁷ are each independently H, deuterium, optionally-substituted alkyl, or R ⁶ and R ⁷ together form a carbocycle; andR ⁸ is optionally-substituted thiazolyl. [0705] In further embodiments, the compound is according to formula 142 wherein: R ¹ is H or optionally-substituted alkyl; R ² is optionally-substituted alkyl; R ³ and R ⁴ are each independently H or optionally-substituted alkyl; R ⁵ is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R ⁶ and R ⁷ are each independently H, deuterium, optionally- substituted alkyl, or R ⁶ and R ⁷ together form a carbocycle; and R ⁸ is substituted thiophenyl, wherein at least one substituent on the thiophenyl is halo-substituted sulfanyl. Formula 142 [0706] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 142. Such compounds are described in US Patent No.10,077,245, issued September 18, 2018, and corresponding to US Application No.15/306,971 filed April 22, 2015; US Patent No.10,316,008, issued June 11, 2019 and corresponding to US Application No.15/870,276 filed January 12, 2018; international Publication No. WO2015165352A1, published November 5, 2015 and corresponding to International Application No. PCT/CN2015/077216 filed April 22, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 142, these references incorporated by reference herein control. [0707] In an embodiment, the Kv7 channel activator is a compound according to Formula 142: wherein, X is selected from a group consisting of oxygen and sulfur; n is 1, 2 or 3;R ₁ is H or halogen;R ₂ and R ₃ are each independently selected from a group consisting of H, D and C ₁ -C ₃ alkyl; or R ₂ and R ₃ together with the carbon atom to which they attached form C ₃ -C ₆ saturated ring;R ₄ and R ₅ are each independently selected from a group consisting of H; halogen; C ₁ -C ₆ alkyl; C ₃ -C ₆ cycloalkyl; cyano; alkoxyl; C ₁ -C ₆ alkyl substituted by hydroxy, amino, C ₁ -C ₄ alkoxy, C ₁ -C ₄ alkylcarbonyl, or halogen; C ₁ -C ₄ alkoxy substituted by halogen; C ₁ -C ₆ alkylcarbonyl; C ₁ -C ₆ alkoxycarbonyl; C ₁ -C ₆ alkylaminocarbonyl; C ₂ - C ₆ alkenyl; and C ₂ -C ₆ alkynyl; provided that R ₄ and R ₅ are not simultaneously hydrogen; R ₆ is selected from a group consisting of C ₁ -C ₆ alkoxy; C ₁ -C ₆ alkylamino; C ₁ -C ₆ alkyl; C ₃ - C ₆ cycloalkyl; C ₂ -C ₆ alkenyl; C ₂ -C ₆ alkynyl; C ₆ -C ₁₀ aryl; C ₁ -C ₆ alkyl substituted by halogen, cyano, hydroxy, C ₁ -C ₆ alkoxyl, di(C ₁ -C ₄ alkyl) amino, C ₁ -C ₆ alkylcarbonyl, C ₁ - C ₆ alkylcarbonylamino, or C ₁ -C ₆ alkoxycarbonyl; C ₃ -C ₆ cycloalkyl substituted by halogen; C ₂ -C ₆ alkenyl substituted by halogen; C ₂ -C ₆ alkynyl substituted by halogen; tetrahydrofuranyl; and wherein, R ₇ and R ₈ are each independently selected from a group consisting of C ₁ -C ₄ alkyl. [0708] In further embodiments, R ₁ is H or fluorine; R ₂ and R ₃ are each independently selected from a group consisting of H and D, or R ₂ and R ₃ together with the carbon atom to which they attached form cyclopropyl; one of R4 and R5 is C1-C4 alkyl, and the other is H or C ₁ -C ₄ alkyl. [0709] In further embodiments, one of R ₄ and R ₅ is methyl, and the other is H or methyl. Formula 143 [0710] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 143. Such compounds are described in US Patent No.10,077,245, issued September 18, 2018, and corresponding to US Application No.15/306,971 filed April 22, 2015; US Patent No.10,316,008, issued June 11, 2019 and corresponding to US Application No.15/870,276 filed January 12, 2018; international Publication No. WO2015165352A1, published November 5, 2015, and corresponding to International Application No. PCT/CN2015/077216 filed April 22, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 143, these references incorporated by reference herein control. [0711] In an embodiment, the Kv7 channel activator is a compound according to Formula 143: wherein, X: is selected from a group consisting of oxygen and sulfur;R ₁ is H or halogen;R ₂ and R ₃ are each independently selected from a group consisting of H, D and C ₁ -C ₃ alkyl; or R ₂ and R ₃ together with the carbon atom to which they attached form C ₃ - C ₆ saturated ring;R ₄ and R ₅ are each independently selected from a group consisting of H; halogen; C ₁ -C ₆ alkyl; C ₃ -C ₆ cycloalkyl; cyano; C ₁ -C ₄ alkoxyl; C ₁ -C ₆ alkyl substituted by hydroxy, amino, C ₁ -C ₄ alkoxy, C ₁ -C ₄ alkylcarbonyl, or halogen; C ₁ -C ₄ alkoxy substituted by halogen; C ₁ -C ₆ alkylcarbonyl; C ₁ -C ₆ alkoxycarbonyl; C ₁ -C ₆ alkylaminocarbonyl; C ₂ - C ₆ alkenyl; and C ₂ -C ₆ alkynyl; provided that R ₄ and R ₅ are not simultaneously hydrogen;R ₆ is selected from a group consisting of C ₁ -C ₆ alkoxy; C ₁ -C ₆ alkylamino; C ₁ - C ₆ alkyl; C ₃ -C ₆ cycloalkyl; C ₂ -C ₆ alkenyl; C ₂ -C ₆ alkynyl; C ₆ -C ₁₀ aryl; C ₁ -C ₆ alkyl substituted by halogen, cyano, hydroxy, C ₁ -C ₆ alkoxyl, di(C ₁ -C ₄ alkyl) amino, C ₁ - C ₆ alkylcarbonyl, C ₁ -C ₆ alkylcarbonylamino, or C ₁ -C ₆ alkoxycarbonyl; C ₃ -C ₆ cycloalkyl substituted by halogen; C ₂ -C ₆ alkenyl substituted by halogen; C ₂ -C ₆ alkynyl substituted by halogen; tetrahydrofuranyl; and wherein, R ₇ and R ₈ are each independently selected from a group consisting of C ₁ -C ₄ alkyl. [0712] In further embodiments, R ₁ is H or fluorine; R ₂ and R ₃ are each independently selected from a group consisting of H and D, or R ₂ and R ₃ together with the carbon atom to which they attached form cyclopropyl; one of R ₄ and R ₅ is C ₁ -C ₄ alkyl, and the other is H or C ₁ -C ₄ alkyl. Formula 144 - 146 [0713] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to any one of Formulas 144 - 146. Such compounds are described in US Patent No.10,077,245, issued September 18, 2018, and corresponding to US Application No.15/306,971 filed April 22, 2015; US Patent No.10,316,008, issued June 11, 2019, and corresponding to US Application No.15/870,276 filed January 12, 2018; international Publication No. WO2015165352A1, published November 5, 2015, and corresponding to International Application No. PCT/CN2015/077216 filed April 22, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formulas 144 - 146, these references incorporated by reference herein control. [0714] In an embodiment, the Kv7 channel activator is a compound according to a formula from the group consisting of 144, 145, and 146:

, wherein, R ₂ and R ₃ are each independently selected from a group consisting of H, D and C1-C3 alkyl; or R2 and R3 together with the carbon atom to which they attached form C3- C ₆ saturated ring;R ₄ and R ₅ are each independently selected from a group consisting of H; C ₁ -C ₆ alkyl; C ₁ -C ₄ alkoxyl; C ₁ -C ₆ alkyl substituted by halogen; C ₁ -C ₄ alkoxy substituted by halogen; provided that R ₄ and R ₅ are not simultaneously hydrogen;R ₉ is selected from a group consisting of C ₁ -C ₆ alkyl and C ₃ -C ₆ cycloalkyl;R ₁₀ is selected from a group consisting of C ₁ -C ₆ alkyl; C ₁ -C ₆ alkyl substituted by halogen, cyano, hydroxy, C ₁ -C ₆ alkoxyl, di(C ₁ -C ₄ alkyl)amino, C ₁ -C ₆ alkylcarbonyl, C ₁ -C ₆ alkylamido, or C ₁ - C ₆ alkoxycarbonyl; C ₃ -C ₆ cycloalkyl; and C ₃ -C ₆ cycloalkyl substituted by halogen; tetrahydrofuranyl; and wherein, R ₇ and R ₈ are each independently selected from a group consisting of C ₁ -C ₄ alkyl. [0715] In further embodiments, R ₂ and R ₃ are each independently selected from a group consisting of H and D, or R ₂ and R ₃ together with the carbon atom to which they attached form cyclopropyl; one of R ₄ and R ₅ is C ₁ -C ₁ alkyl, and the other is H or C ₁ - C ₄ alkyl;R ₉ is selected from a group consisting of C ₁ -C ₆ alkyl and C ₃ -C ₆ cycloalkyl;R ₁₀ is selected from a group consisting of C ₁ -C ₆ alkyl; C ₁ -C ₆ alkyl substituted by halogen, cyano, hydroxy, C ₁ -C ₆ alkoxyl, di(C ₁ -C ₄ alkyl)amino, C ₁ -C ₆ alkylcarbonyl, C ₁ - C ₆ alkylamido, or C ₁ -C ₆ alkoxycarbonyl; C ₃ -C ₆ cycloalkyl; C ₃ -C ₆ cycloalkyl substituted by halogen; tetrahydrofuranyl; and wherein, R ₇ and R ₈ are each independently selected from a group consisting of C ₁ -C ₄ alkyl. [0716] In further embodiments, R ₉ is selected from a group consisting of methyl, ethyl and propyl;R ₁₀ is selected from a group consisting of C ₁ -C ₃ alkyl; C ₁ -C ₃ alkyl substituted by halogen, cyano, hydroxy, C ₁ -C ₃ alkoxyl, di(C ₁ -C ₃ alkyl)amino, C ₁ -C ₃ alkylcarbonyl, C ₁ - C ₃ alkylamido, or C ₁ -C ₃ alkoxycarbonyl; C ₃ -C ₆ cycloakyl; C ₃ -C ₆ cycloakyl substituted by halogen; tetrahydrofuranyl; and wherein, R ₇ and R ₈ are each independently selected from a group consisting of C ₁ -C ₃ alkyl. [0717] In further embodiments, the Kv7 Channel activator is selected from the group consisting of:

Formula 147 [0718] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 147. Such compounds are described in International Publication No. WO2013165575A1, published November 7, 2013, and corresponding to International Application No. PCT/US2013/030984 filed March 13, 2013; US Patent No.9,556,114 issued January 31, 2017, and corresponding to US Application No.14/566,167 filed December 10, 2014; US Publication No. US20170096390A1, published April 6, 2017, and corresponding to US Application No. 15/380,216 filed December 15, 2016; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 147, these references incorporated by reference herein control. [0719] In an embodiment, the Kv7 channel activator is a compound according to Formula 147: or a pharmaceutically acceptable salt or solvate thereof, wherein: X ₁ , X ₂ , X ₃ , X ₄ , X ₅ , X ₆ , X7, and X8 are each independently selected from hydrogen, deuterium, and F; X9 and X ₁₀ are each independently selected from hydrogen and deuterium; and n is 1, 2, or 3, wherein at least one of X ₁ , X ₂ , and X ₃ is F. [0720] In further embodiments, the Kv7 channel activator is: wherein, A is N or C—X ₃ ; X ₁ , X ₂ , X ₃ , X ₄ , X ₅ , X ₆ , X ₇ , and X ₈ are each independently selected from hydrogen, 19F and 18F; and n is 2 or 3, provided that one of X ₁ , X ₂ , X ₃ , X ₄ , X ₅ , X ₆ , X ₇ , and X ₈ is 18F. [0721] In further embodiments, two of X ₁ , X ₂ , X ₃ , X ₄ , X ₅ , X ₆ , X ₇ and X ₈ are F. [0722] In further embodiments, three of X ₁ , X ₂ , X ₃ , X ₄ , X ₅ , X ₆ , X ₇ and X ₈ are F. [0723] In further embodiments, the Kv7 channel activator is: wherein, X ₁ , X ₂ , X ₃ , and X ₆ are each independently selected from hydrogen, 18F, and 19F, provided that one of X ₁ , X ₂ , X ₃ , and X ₆ is 18F. [0724] In further embodiments, X ₆ is fluorine and one of X ₁ , X ₂ , and X ₃ is fluorine. [0725] In further embodiments, one of X ₁ , X ₂ , X ₃ , and X ₆ is 18F. [0726] In further embodiments, at least one of X ₁ , X ₂ , and X ₃ is 19F. [0727] In further embodiments, X6 is 19F or 18F. [0728] In further embodiments, the compound is selected from the group consisting of: Formula 148 [0729] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 148. Such compounds are described in US Publication No. US20130184294A1, published July 18, 2013, and corresponding to US Application No.13/822,669 filed September 7, 2011; International Publication No. WO2012038850A1, published March 29, 2012, and corresponding to International Application No. PCT/IB2011/053917 filed September 7, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 148, these references incorporated by reference herein control. [0730] In an embodiment, the Kv7 channel activator is a compound according to Formula 148: wherein, R ¹ is alkyl, cycloalkyl, wherein alkyl or cycloalkyl may be substituted with one or more halogen, alkoxy, aryl, or aryloxy; R ² is cycloalkyl or NR ⁴ R ⁵ ; R ³ is H, halogen, alkyl, or alkoxy, wherein any alkyl may be substituted with one or more halogen atoms; R ⁴ and R ⁵ are independently selected from H, C _1-6 alkyl, C _3-6 cycloalkyl, or —C _1-6 alkyl-C _{3- 6} cycloalkyl, wherein each alkyl or each cycloalkyl may be substituted with one or more halogen, provided that both R ⁴ and R ⁵ are not H simultaneously; or R ⁴ and R ⁵ , together with the N atom to which they are attached, form a heterocycloalkyl;—X—Y— is ═CH— CH═, —CH ₂ —CH ₂ —, or —CH ₂ —; or a pharmaceutically acceptable salt thereof. [0731] In further embodiments, R ¹ is C _5-6 alkyl; R ² is NR ⁴ R ⁵ , wherein one of R ⁴ or R ⁵ is H and the other is C _3-6 alkyl, C _3-6 cycloalkyl, or —C _1-3 alkyl-C _3-6 cycloalkyl; R ³ is halogen, alkyl, or alkoxy, wherein any alkyl may be substituted with one or more halogen atoms; —X—Y— is ═CH—CH═ or —CH ₂ —CH ₂ —; or a pharmaceutically acceptable salt thereof. [0732] In further embodiments, R ¹ is —CH ₂ C(CH ₃ ) ₃ ; R ³ is chloro, methyl, trifluoromethyl or 1,1-difluoroethoxy; R ⁴ is H and R ⁵ is isopropyl, isobutyl, 1-cyclopropylethyl, cyclobutyl or cyclopentyl; —X—Y— is ═CH—CH═ or —CH ₂ —CH ₂ —; or a pharmaceutically acceptable salt thereof. [0733] In further embodiments, R ¹ is C _5-6 alkyl; R ² is C _3-6 cycloalkyl; R ³ is halogen, or alkyl, wherein alkyl may be substituted with one or more halogen atoms; —X—Y— is ═CH—CH═ or —CH ₂ —CH ₂ —; or a pharmaceutically acceptable salt thereof. [0734] In further embodiments, R ¹ is —CH ₂ C(CH ₃ ) ₃ ; R ² is cyclopropyl; R ³ is chloro, methyl, trifluoromethyl or 1,1-difluoroethoxy; —X—Y— is ═CH—CH═ or —CH ₂ —CH ₂ — ; or a pharmaceutically acceptable salt thereof. Formula 149 [0735] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 149. Such compounds are described in US Patent No.8,466,201, issued June 18, 2013, and corresponding to US Application No. 12/746,524 filed December 5, 2008; US Patent No.9,464,052, issued October 11, 2016, and corresponding to US Application No.13/054,960 filed July 20, 2009; US Patent No.9,675,567 issued June 13,2017, and corresponding to US Application No. 15/259,064 filed September 8, 2016; US Patent No.8,466,201 issued June 18, 2013, and corresponding to US Application No.12/746,524 filed December 5, 2008; International Publication No. WO2009071947A2, published June 11, 2009, and corresponding to International Application No. PCT/GB2008/051158 filed December 5, 2008; International Publication No. WO2010010380A1, published January 28, 2010, and corresponding to International Application No. PCT/GB2009/050887 filed July 20, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 149, these references incorporated by reference herein control. [0736] In an embodiment, the Kv7 channel activator is a compound according to Formula 149: wherein, Ar ¹ and Ar ² are each phenyl; are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5;R ¹ is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups, dialkylamino groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 5;R ² is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and where b is greater than 1, each substituent R ² may be the same or different; V is selected from the group consisting of (CR ^3a R ^3b )pSO2N(R ³ b)X;W is NR ^4a ; X is a substituent selected from the group consisting of hydroxyalkyl groups, and polyalkylene glycol residues; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 , wherein each n1 is 0; and p is an integer of from 0 to 2,and wherein V is substituting said Ar ¹ at an ortho position with respect to said Z or said W. [0737] In further embodiments, a is an integer of from 0 to 3. [0738] In further embodiments, R ¹ is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different. [0739] In further embodiments, b is an integer of from 0 to 4. [0740] In further embodiments, R ² is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups. [0741] In further embodiments, R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups. [0742] In further embodiments, V is selected from the group consisting of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of from 0 to 2, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO—[(CR (CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 0 to 4, c3 is an integer of from 1 to 20 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different from each other and each is a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms. [0743] In further embodiments, V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms and polyalkylene glycol residues of general formula HO—[(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R ^6a , R ^6b , R ^6c , R ^6d may be the same or different and each is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms. [0744] In further embodiments, V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, each of R ^3a and R ^3b is a hydrogen atom, and X is a hydroxylalkyl group having from 1 to 4 carbon atoms or a polyalkylene glycol residue of general formula HO—-[CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is 1 or 2, c3 is an integer of from 1 to 6 and each of R ^6a , R ^6b , R ^6c and R ^6d is a hydrogen atom. [0745] In further embodiments, Ar ¹ and Ar ² are each phenyl; a is an integer of from 0 to 3;R ¹ is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 4;R ² is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, nitro groups, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where b is greater than 1, each substituent R ² may be the same or different; W is NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 , wherein each n1 is 0; and V is selected from the group consisting of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X and, wherein p is an integer of from 0 to 2,R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms which may optionally be substituted with at least one substituent selected from alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, carbonyl groups, hydroxyl groups and cyano groups, and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO-[(CR ^6a R ^6b ) _c1 —O— (CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 0 to 4, c3 is an integer of from 1 to 20 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different from each other and each is a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms. [0746] In further embodiments, Ar ¹ and Ar ² are each phenyl; a is 0 or 1;R ¹ is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 3;R ² is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, nitro groups, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where b is greater than 1, each substituent R ² may be the same or different; W is NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms and 5- or 6-membered aromatic heterocyclic groups containing 1 or 2 sulfur atoms, oxygen atoms and/or nitrogen atoms; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 , wherein each n1 is 0; and V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms and polyalkylene glycol residues of general formula HO—[(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R ^6a , R ^6b , R ^bc and R ^6d may be the same or different and each is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms. [0747] In further embodiments, Ar ¹ and Ar ² are each phenyl; a is 0 or 1;R ¹ is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is 0 to 3;R ² is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups; W is a group of formula NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 wherein each n1 is 0; and V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, each of R ^3a and R ^3b is a hydrogen atom, and X is a hydroxylalkyl group having from 1 to 4 carbon atoms or a polyalkylene glycol residue of general formula HO—[(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is 1 or 2, c3 is an integer of from 1 to 6 and each of R ^6a , R ^6b , R ^6c and R ^6d is a hydrogen atom. [0748] In further embodiments, Ar ¹ and Ar ² are each phenyl; a is an integer of from 0 to 3;R ¹ is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 4;R ² is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, nitro groups, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where b is greater than 1, each substituent R ² may be the same or different; W is NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms; and V is selected from the group consisting of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X wherein p is an integer of from 0 to 2, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO—[(CR ^6a R ^6c ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 0 to 4, c3 is an integer of from 1 to 20 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different from each other and each is a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms. [0749] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 1-[2-(2,6-Dichlorophenylamino)phenyl]-N-[2-(2-hydroxyethoxy) ethyl]- methanesulfonamide,N-[2-(2-hydroxyethoxy)ethyl]-C-[2-(2,4,6- trichlorophenylamino)phenyl]-methanesulfonamide,1-[2-(2,6-di chloro-4- trifluoromethylphenylamino)phenyl]-N-{2-(2-hydroxyethoxy)eth yl]methanesulfonamide,1- [2-(2,6-dichloro-3-methylphenylamino)phenyl]-N-{2-(2-hydroxy ethoxy)- ethyl]methanesulfonamide,N-(2-hydroxyethyl)-1-[3-(2,4,6- trichlorophenylamino)phenyl]methane sulphonamide,N-(2-hydroxyethyl)-2-(2,4,6- trichlorophenylamino)benzenesulfonamide,N-(2-hydroxyethyl)-2 -(2,6- dichlorophenylamino)benzene sulfonamide,2-(2,6-dichloro-4- trifluoromethylphenylamino)-N-(2-hydroxyethyl)-benzenesulfon amide,2-(2,6-dichloro-3- methylphenylamino)-N-(2-hydroxyethyl)-benzenesulfonamide,2-( 2,6-dichloro-4- trifluoromethylphenylamino)-N-[2-(2-hydroxyethoxy)ethyl]-ben zenesulfonamide,2-(2,6- dichloro-3-methylphenylamino)-N-[2-(2-hydroxyethoxy)ethyl]-b enzenesulfonamide,2- (3,5-dichlorophenylamino)-N-[2-(2-hydroxyethoxy)ethyl]-benze nesulfonamide, andN-[2- (2-hydroxyethoxy)ethyl]-2-(2,4,6-trichlorophenylamino)-benze nesulfonamide, or a pharmacologically acceptable salt or pro-drug thereof. [0750] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5; R ¹ is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, haloalkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 5;R ² is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, haloalkoxy groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and where b is greater than 1, each substituent R ² may be the same or different; V is selected from the group consisting of (CR ^3a R ^3b ) _p CON(R ^3b )X and (CR ^3a R ^3b ) _p N(R ^3b )CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z;W is selected from the group consisting of NR ^4a , O, S, S═O, SO ₂ and C(R ^4a R ^4b ) ₂ ;X is a substituent selected from the group consisting of hydroxyalkyl groups, alkoxyalkyl groups, haloalkoxyalkyl groups, aryloxyalkyl groups, polyalkylene glycol residues, carboxyalkyl groups, alkoxycarbonylalkyl groups, haloalkoxycarbonylalkyl groups and aralkyloxycarbonylalkyl groups; Y and Z are the same or different and each is a substituent selected from the group consisting of (CR ^5a R ^5b ) _n1 , C═O, SO ₂ , C(═O)NR ^5a ; C(═O)NR ^5a SO ₂ and C═O(R ^5a R ^5b ) _n2 ;R ^3a , R ^3b , R ^4a , R ^4b , R ^5a and R ^5b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups, cycloalkyl groups, aryl groups and heteroaryl groups;n1 and n2 are the same or different and each is an integer of from 0 to 2; and p is an integer of from 0 to 2. [0751] In further embodiments, Ar ¹ and Ar ² are the same or different and each is an aryl group having from 5 to 14 carbon atoms or a 5- to 7-membered aromatic heterocyclic group containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms. [0752] In further embodiments, Ar ¹ and Ar ² are the same or different and each is an aryl group having from 6 to 10 carbon atoms or a 5- or 6-membered aromatic heterocyclic group containing 1 or 2 sulfur atoms, oxygen atoms and/or nitrogen atoms. [0753] In further embodiments, Ar ¹ and Ar ² are each phenyl. [0754] In further embodiments, R ² is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, haloalkoxy groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups. [0755] In further embodiments, W is a group of formula NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups. [0756] In further embodiments, Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 wherein each n1 is 0. [0757] In further embodiments, V is selected from the group consisting of (CR ^3a R ^3b ) _p CON(R ^3b )X and (CR ^3a R ^3b ) _p N(R ^3b CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z, wherein p is an integer of from 0 to 2, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, alkoxyalkyl groups comprising alkyl groups having from 1 to 6 carbon atoms which are substituted by at least one alkoxy group having from 1 to 6 carbon atoms, haloalkoxyalkyl groups comprising alkyl groups having from 1 to 6 carbon atoms which are substituted by at least one haloalkoxy group having from 1 to 6 carbon atoms, aryloxy groups having from 5 to 14 carbon atoms, polyalkylene glycol residues of general formula HO— [(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 0 to 4, c3 is an integer of from 1 to 20 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different from each other and each is a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms, carboxyalkyl groups comprising alkyl groups having from 1 to 6 carbon atoms which are substituted with at least one carboxy group, alkoxycarbonylalkyl groups comprising alkyl groups having from 1 to 6 carbon atoms which are substituted with at least one alkoxycarbonyl group having from 2 to 7 carbon atoms, haloalkoxycarbonylalkyl groups comprising carbonylalkyl groups having from 2 to 7 carbon atoms that are substituted with haloalkoxy groups having from 1 to 6 carbon atoms and aralkyloxycarbonylalkyl groups comprising carbonylalkyl groups having from 2 to 7 carbon atoms which are substituted with at least one aralkyloxy group that comprises an alkyl group having from 1 to 6 carbon atoms that is substituted with an aryl group having from 5 to 14 carbon atoms. [0758] In further embodiments, V is selected from the group consisting of (CR ^3a R ^3b ) _p CON(R ^3b )X and (CR ^3a R ^3b ) _p N(R ^3b )CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms, polyalkylene glycol residues of general formula HO—[(CR ^6a R ^6b ) _c1 — O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different and each is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, alkoxyalkyl groups comprising an alkyl group having from 1 to 4 carbon atoms that is substituted with at least one alkoxy group having from 1 to 4 carbon atoms, carboxyalkyl groups comprising an alkyl group having from 1 to 4 carbon atoms that is substituted with at least one carboxy group, carboxyalkyl groups comprising alkyl groups having from 1 to 4 carbon atoms which are substituted with at least one carboxy group and alkoxycarbonylalkyl groups comprising alkyl groups having from 1 to 4 carbon atoms which are substituted with at least one alkoxycarbonyl group having from 2 to 5 carbon atoms. [0759] In further embodiments, V is selected from the group consisting of (CR ^3a R ^3b ) _p CON(R ^3b )X and (CR ^3a R ^3b ) _p N(R ^3b )CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, each of R ^3a and R ^3b is a hydrogen atom, and X is selected from the group consisting of alkyl groups having 1 or 2 carbon atoms which are substituted with a group selected from hydroxyl groups, methoxy groups, ethoxy groups, carboxy groups, methoxycarbonyl groups and ethoxycarbonyl groups. [0760] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are each phenyl; a is 0 or 1;R ¹ is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, haloalkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, nitro groups, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is 0 to 3; R ² is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, haloalkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups; W is a group of formula NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 wherein each n1 is 0; and V is selected from the group consisting of (CR ^3a R ^3b ) _p CON(R ^3b )X and (CR ^3a R ^3b ) _p N(R ^3b )CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, each of R ^3a and R ^3b is a hydrogen atom, and X is selected from the group consisting of alkyl groups having 1 or 2 carbon atoms which are substituted with a group selected from hydroxyl groups, methoxy groups, ethoxy groups, carboxy groups, methoxycarbonyl groups and ethoxycarbonyl groups. [0761] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-(2-hydroxyethyl)-2-[3-(2,4,6-trichlorophenylamino)phenyl]a cetamide;{2- [5-(3,5-dichlorophenylamino)-2-fluorophenyl]-acetylamino}ace tic acid; 2-[4-(2,6-dichloro- 4-trifluoromethyl-phenylamino)-phenyl]-N-(2-hydroxyethyl)-ac etamide; {2-[4-(3,5- dichlorophenylamino)-phenyl]-acetylamino}acetic acid;N-(2-hydroxy-ethyl)-2-[4-(2,4,6- trichloro-phenylamino)-phenyl]acetamide; 3-(2,6-dichloro-4-trifluoromethyl- phenylamino)-N-(2-hydroxy-ethyl)benzamide; 2-[2-fluoro-5-(2,4,6-trichloro- phenylamino)-phenyl]-N-(2-hydroxy-ethyl)acetamide; 2-[5-(2,6-dichloro-4- trifluoromethyl-phenylamino)-2-fluoro-phenyl]-N-(2-hydroxy-e thyl)acetamide; 2-[5-(2,6- dichloro-4-trifluoromethoxy-phenylamino)-2-fluoro-phenyl]-N- (2-hydroxy- ethyl)acetamide; 2-[4-(2,6-dichloro-4-trifluoromethoxy-phenylamino)-phenyl]-N -(2- hydroxy-ethyl)-acetamide; 5-(2,6-dichloro-4-trifluoromethyl-phenylamino)-2-fluoro-N-(2 - hydroxy-ethyl)-benzamide; 2-[4-(2,6-dichloro-4-trifluoromethyl-phenylamino)-phenyl]-N- (2-hydroxy-2-methyl-propyl)acetamide; 2-[5-(2,6-dichloro-4-trifluoromethyl- phenylamino)-2-fluoro-phenyl]-N-(2-hydroxy-2-methyl-propyl)a cetamide; and 2-[4-(2,6- dichloro-4-trifluoromethoxy-phenylamino)-2-fluoro-phenyl]-N- (2-hydroxy- ethyl)propionamide. [0762] In further embodiments, the compound is according to formula 150 wherein: Ar ¹ and Ar ² are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5; R ¹ is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, haloalkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 5; R ² is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, haloalkoxy groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and where b is greater than 1, each substituent R ² may be the same or different; V is selected from the group consisting of (CR ^3a R ^3b ) _p CON(R ^3b )X and (CR ^3a R ^3b ) _p N(R ^3b )CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z; W is selected from the group consisting of NR ^4a , O, S, S═O, SO ₂ and C(R ^4a R ^4b ) ₂ ; X is a substituent selected from the group consisting of hydrogen atoms, alkyl groups, hydroxyalkyl groups, alkoxyalkyl groups, haloalkoxyalkyl groups, aryloxyalkyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, polyalkylene glycol residues, aminoalkyl groups, monoalkylaminoalkyl groups, dialkylaminoalkyl groups; alkyl groups that are substituted with groups of formula NR8R9 wherein R8 and R9 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated heterocyclic group which optionally contains at least one more heteroatom selected from nitrogen, oxygen and sulphur atoms (said saturated or partially unsaturated heterocyclic group optionally further being substituted by one or more substituents selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, nitro groups, amino groups, monoalkylamino groups, dialkylamino groups and hydroxyl groups), carboxyalkyl groups, alkoxycarbonylalkyl groups, haloalkoxycarbonylalkyl groups and aralkyloxycarbonylalkyl groups; Y and Z are the same or different and each is a substituent selected from the group consisting of (CR ^5a R ^5b ) _n1 , C═O, SO ₂ , C(═O)NR ^5a ; C(═O)NR ^5a SO ₂ and C═O(R ^5a R ^5b ) _n2 ;R ^3a , R ^3b , R ^4a , R ^4b , R ^5a and R ^5b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups, cycloalkyl groups, aryl groups and heteroaryl groups; n1 and n2 are the same or different and each is an integer of from 0 to 2; and p is an integer of from 0 to 2. [0763] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are each phenyl; a is 1; R ¹ is halogen; b is an integer of from 0 to 3; R ² is selected from the group consisting of alkyl having from 1 to 3 carbon atoms, halogen, haloalkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, haloalkoxy having from 1 to 3 carbon atoms, carboxyl, amino, hydroxyl and cyano, and where b is greater than 1, each substituent R ² may be the same or different; V is (CR ^3a R ^3b ) _p CON(R ^3b )X, wherein said group is in the 3-(meta) or 4-(para) position with respect to the substituent Z;W is NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen, alkyl having from 1 to 3 carbon atoms and phenyl; X is a substituent selected from the group consisting of hydroxyalkyl having from 1 to 4 carbon atoms, polyalkylene glycol residue of general formula: HO—[(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 —wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different and each is a hydrogen or an alkyl having from 1 to 4 carbon atoms, alkoxyalkyl comprising an alkyl having from 1 to 4 carbon atoms that is substituted with at least one alkoxy having from 1 to 4 carbon atoms, carboxyalkyl comprising an alkyl having from 1 to 4 carbon atoms that is substituted with at least one carboxy, carboxyalkyl comprising alkyl having from 1 to 4 carbon atoms which are substituted with at least one carboxy and alkoxycarbonylalkyl comprising alkyl having from 1 to 4 carbon atoms which are substituted with at least one alkoxycarbonyl having from 2 to 5 carbon atoms; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 wherein each n1 is 0;R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen and alkyl; and p is an integer of from 0 to 2. [0764] In further embodiments, V is (CR ^3a R ^3b ) _p CON(R ^3b )X, wherein said groups is in the 3-(meta) or 4-(para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, each of R ^3a and R ^3b is hydrogen, and X is selected from the group consisting of alkyl having 1 or 2 carbon atoms which are substituted with a group selected from hydroxyl groups, methoxy groups, ethoxy groups, carboxy groups, methoxycarbonyl groups and ethoxycarbonyl groups. [0765] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: {2-[5-(3,5-dichlorophenylamino)-2-fluorophenyl]-acetylamino} acetic acid; 2-[5-(2,6-dichloro-4-trifluoromethoxy-phenylamino)-2-fluoro- phenyl]-N-(2-hydroxy- ethyl)acetamide; 5-(2,6-dichloro-4-trifluoromethyl-phenylamino)-2-fluoro-N-(2 -hydroxy- ethyl)-benzamide; 2-[5-(2,6-dichloro-4-trifluoromethyl-phenylamino)-2-fluoro-p henyl]-N- (2-hydroxy-2-methyl-propyl)acetamide; and 2-[4-(2,6-dichloro-4-trifluoromethoxy- phenylamino)-2-fluoro-phenyl]-N-(2-hydroxy-ethyl)propionamid e. [0766] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are each phenyl; are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5; R ¹ is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups, dialkylamino groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 5; R ² is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and where b is greater than 1, each substituent R ² may be the same or different; V is selected from the group consisting of (CR ^3a R ^3b ) _p SO ₂ N(R ³ b)X;W is NR ^4a ;X is a substituent selected from the group consisting of hydroxyalkyl groups, and polyalkylene glycol residues; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 , wherein each n1 is 0; and p is an integer of from 0 to 2,and wherein V is substituting said Ar ¹ at an ortho position with respect to said Z or said W. In further embodiments, [0767] In further embodiments, a is an integer of from 0 to 3. [0768] In further embodiments, R ¹ is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different. [0769] In further embodiments, b is an integer of from 0 to 4. [0770] In further embodiments, R ² is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups. [0771] In further embodiments, R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups. [0772] In further embodiments, V is selected from the group consisting of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of from 0 to 2, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO—[(CR (CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 0 to 4, c3 is an integer of from 1 to 20 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different from each other and each is a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms. [0773] In further embodiments, V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms and polyalkylene glycol residues of general formula HO—[(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R ^6a , R ^6b , R ^6c , R ^6d may be the same or different and each is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms. [0774] In further embodiments, V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, each of R ^3a and R ^3b is a hydrogen atom, and X is a hydroxylalkyl group having from 1 to 4 carbon atoms or a polyalkylene glycol residue of general formula HO—-[CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is 1 or 2, c3 is an integer of from 1 to 6 and each of R ^6a , R ^6b , R ^6c and R ^6d is a hydrogen atom. [0775] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are each phenyl; a is an integer of from 0 to 3;R ¹ is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 4;R ² is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, nitro groups, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where b is greater than 1, each substituent R ² may be the same or different; W is NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 , wherein each n1 is 0; and V is selected from the group consisting of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X and, wherein p is an integer of from 0 to 2,R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms which may optionally be substituted with at least one substituent selected from alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, carbonyl groups, hydroxyl groups and cyano groups, and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO-[(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 0 to 4, c3 is an integer of from 1 to 20 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different from each other and each is a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms. [0776] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are each phenyl; a is 0 or 1;R ¹ is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 3;R ² is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, nitro groups, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where b is greater than 1, each substituent R ² may be the same or different; W is NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms and 5- or 6-membered aromatic heterocyclic groups containing 1 or 2 sulfur atoms, oxygen atoms and/or nitrogen atoms; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 , wherein each n1 is 0; and V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms and polyalkylene glycol residues of general formula HO— [(CR ^6a R ^6b ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R ^6a , R ^6b , R ^bc and R ^6d may be the same or different and each is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms. [0777] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are each phenyl; a is 0 or 1; R ¹ is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is 0 to 3; R ² is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups; W is a group of formula NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups; Y and Z are each a group of formula (CR ^5a R ^5b ) _n1 wherein each n1 is 0; and V is a group of formula of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X, wherein p is an integer of 0 or 1, each of R ^3a and R ^3b is a hydrogen atom, and X is a hydroxylalkyl group having from 1 to 4 carbon atoms or a polyalkylene glycol residue of general formula HO—[(CR ^6a R ^6b ) _c1 — O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is 1 or 2, c3 is an integer of from 1 to 6 and each of R ^6a , R ^6b , R ^6c and R ^6d is a hydrogen atom. [0778] In further embodiments, the compound is according to Formula 149 wherein: Ar ¹ and Ar ² are each phenyl; a is an integer of from 0 to 3; R ¹ is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where a is greater than 1, each substituent R ¹ may be the same or different; b is an integer of from 0 to 4; R ² is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, nitro groups, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphonylamino groups having from 1 to 6 carbon atoms and cyano groups and, where b is greater than 1, each substituent R ² may be the same or different; W is NR ^4a , wherein R ^4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms; and V is selected from the group consisting of (CR ^3a R ^3b ) _p SO ₂ N(R ^3b )X wherein p is an integer of from 0 to 2, R ^3a and R ^3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO—[(CR ^6a R ^6c ) _c1 —O—(CR ^6c R ^6d ) _c2 ] _c3 — wherein c1 and c2 are the same or different and each is an integer of from 0 to 4, c3 is an integer of from 1 to 20 and R ^6a , R ^6b , R ^6c and R ^6d may be the same or different from each other and each is a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms. Formula 150 [0779] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 150. Such compounds are described in International Publication No. WO2012004698A1, published January 12, 2012, and corresponding to International Application No. PCT/IB2011/052686 filed June 20, 2011; US Patent No.8,883,812, issued November 11, 2014 and corresponding to US Application No.13/808,355 filed June 20, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 150, these references incorporated by reference herein control. [0780] In an embodiment, the Kv7 channel activator is a compound according to Formula 150: wherein, n is an integer of 1 or 2; t is 0 or 1; each R ¹ is independently selected from C _{1- 3} alkoxy, C _1-3 alkyl, C _1-3 alkyl-O—C _1-3 alkyl; R ² and R ³ are independently C _1-3 alkyl, C _{1- 3} alkoxy, or C _3-6 cyloalkyl provided that at least one is C _1-3 alkoxy; R ⁴ is C _1-6 alkyl, C _{1- 3} alkyl-C _3-6 cyloalkyl, C _3-6 heterocycloalkyl; or a pharmaceutically acceptable salt thereof. [0781] In further embodiments, R ¹ , R ² , and R ³ are each C _1-3 alkoxy; wherein R ⁴ is C _{4- 6} alkyl, and wherein n and t are each 1, or a pharmaceutically acceptable salt thereof. [0782] In further embodiments, R ¹ , R ² , and R ³ are each methoxy; R ⁴ is —CH ₂ -t-butyl, and n and t are each 1, or a pharmaceutically acceptable salt thereof. [0783] In further embodiments, the compound is N-(4,6-dimethoxy-2-(4- methoxypiperidin-1-yl)pyrimidin-5-yl)-3,3-dimethylbutanamide , or a pharmaceutically acceptable salt thereof. Formula 151 [0784] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 151. Such compounds are described in US Patent No.9,353,048 issued May 31, 2016, and corresponding to US Application No. 14/353,842 filed October 23, 2012; International Publication No. WO2013060097A1, published May 2, 2013, and corresponding to International Application No. PCT/CN2012/001423 filed October 23, 2012; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 152, these references incorporated by reference herein control. [0785] In an embodiment, the Kv7 channel activator is a compound according to Formula 151: , wherein, R ₁ is a radical selected from the group consisting of C ₂ -C ₈ alkenyl, C ₅ - C ₇ cycloalkenyl and C ₂ -C ₈ alkynyl; wherein, the C ₂ -C ₈ alkenyl is unsubstituted or optionally substituted by hydroxyl, amino, halogen atom, phenyl or halogenated phenyl; the C ₂ -C ₈ alkynyl is unsubstituted or optionally substituted by hydroxyl, amino, halogen atom, phenyl or halogenated phenyl; R ₂ is a radical selected from the group consisting of F, Cl and methoxyl;R ₃ is a radical selected from the group consisting of H, halogen atom and trifluoromethyl; Y is not present or Y is O;R ₄ is a radical selected from the group consisting of C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl and C ₆ -C ₁₀ aryl;R ₅ is a radical selected from the group consisting of H, halogen atom, amino and or R ₅ , together with adjacent a fused-ring structure of R ₆ is H or C ₁ -C ₆ alkyl. [0786] In further embodiments, the Kv7 Channel activator is selected from the group consisting of:

Formula 152 [0787] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 152. In another embodiment, the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in International Publication No. US20100057224A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; US Patent No.8,629,143 published January 14, 2014, and corresponding to US Application No.12/949,435 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 152, these references incorporated by reference herein control. [0788] In an embodiment, the Kv7 channel activator is a compound according to Formula 152: , or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein Z is a ring fused with the pyridazine ring, selected from the group consisting of benzo, cycloalkyl, cycloalkenyl, heterocycle, and heteroaryl;R ¹ is an optional substituent wherein each occurrence of R ¹ is independently G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , -OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , - SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , - N(R ^a )CONR ^a R ^b , -N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , -(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m -OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m - C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -NR ^a R ^b ,-(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , - (CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b , or -(CR ^za R ^zb ) _m -G ^a ; p is 0, 1, 2, 3, or 4;R ³ is hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, -(CR ^3a R ^3b ) _m -G ^3a , or G ^3a ; G ^3a , at each occurrence, is independently aryl, cycloalkyl, or cycloalkenyl; each of which is optionally substituted;R ⁴ is alkenyl, alkynyl, haloalkyl, G ^4a , -(CR ^4a R ^4b ) _n -G ^4a , or alkyl which is optionally substituted with one or two groups independently selected from the group consisting of S(R ^1a ), 0(R ^1a ) and N(R ^1a ) ₂ ;each occurrence of R ^1a is independently hydrogen, G ^a , -(CR ^za R ^zb ) _m -G ^a , alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl;G ^4a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is optionally substituted; G ^3a and G ^4a , at each occurrence, are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , -OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , - SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , - N(R ^a )CONR ^a R ^b , -N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -G ^a , -(CR ^za R ^zb ) _m -CN, -(CR ^za R ^zb ) _m -NO ₂ , - (CR ^za R ^zb ) _m -OR ^a , -(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m -OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , - (CR ^za R ^zb ) _m -S(O)R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m - N(R ^a )COOR ^b , -(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and -(CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;G ^a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , -OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , - S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -N(R ^a )COOR ^b , - N(R ^a )CONR ^a R ^b ,-N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a ,- (CR ^za R ^zb )m-OC(O)R ^a , -(CR ^za R ^zb )m-OC(O)NR ^a R ^b , -(CR ^za R ^zb )m-SR ^a , -(CR ^za R ^zb )m-S(O)R ^a ,- (CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m - C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b ,- (CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and -(CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;R ^za , R ^zb , R ^3a , R ^3b , R ^4a , and R ^4b , at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl; R ^a and R ^b , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; and m and n, at each occurrence, are each independently 1, 2, 3, or 4;with the proviso that when Z ¹ is benzo, p is 0 or 4, R ¹ is halogen, R ³ is G ^3a , and G ^3a is aryl, substituted with 1 or 2 substituents selected from the group consisting of alkyl and unsubstituted aryl, then R ⁴ is other than unsubstituted aryl, unsubstituted alkyl, or haloalkyl. [0789] In further embodiments, Z ¹ is benzo, heteroaryl, or cycloalkyl. [0790] In further embodiments, R ³ is alkyl, halogen, haloalkyl, G ^3a , or -(CR ^3a R ^3b ) _m -G ^3a . [0791] In further embodiments, R ⁴ is unsubstituted alkyl, haloalkyl, -C(R ^4a R ^4b ) _n -G ^4a , or alkyl substituted with a -S(R ^la ) group. [0792] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; and R ⁴ is unsubstituted alkyl, haloalkyl, -C(R ^4a R ^4b ) _n -G ^4a , or alkyl substituted with a -S(R ^la ) group. In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; and R ⁴ is -C(R ^4a R ^4b ) _n -G ^4a . [0793] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; R ⁴ is -C(R ^4a R ^4b ) _n - G ^4a ; and R ³ is alkyl, halogen, haloalkyl, G ^3a , or -(CR ^3a R ^3b ) _m -G ^3a . [0794] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; R ⁴ is -C(R ^4a R ^4b ) _n - G ^4a ;R ³ is alkyl, halogen, haloalkyl, G ^3a , or -(CR ^3a R ^3b ) _m -G ^3a ; andG ^3a is aryl or cycloalkyl. [0795] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; andR ⁴ is unsubstituted alkyl or haloalkyl. [0796] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; R ⁴ is unsubstituted alkyl or haloalkyl; and R ³ is alkyl, halogen, haloalkyl, G ^3a , or -(CR ^3a R ^3b ) _m -G ^3a . [0797] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; R ⁴ is unsubstituted alkyl or haloalkyl; R ³ is alkyl, halogen, haloalkyl, G ^3a , or -(CR ^3a R ^3b ) _m -G ^3a ; and G ^3a is aryl or cycloalkyl. [0798] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; and R ⁴ is alkyl substituted with a -S(R ^la ) group. [0799] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; R ⁴ is alkyl substituted with a -S(R ^la ) group; and R ³ is alkyl, halogen, haloalkyl, G ^3a , or -(CR ^3a R ^3b ) _m - G ^3a . [0800] In further embodiments, Z ¹ is benzo, cycloalkyl, or heteroaryl; R ⁴ is alkyl substituted with a -S(R ^la ) group; R ³ is alkyl, halogen, haloalkyl, G ^3a , or -(CR ^3a R ^3b ) _m -G ^3a ; and G ^3a is aryl or cycloalkyl. [0801] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(4-chlorophenyl)-N-(4-isopropyl-l-oxophthalazin-2(lH)-yl)a cetamide; 2-( 1 -adamantyl)-N- [4-(4-bromophenyl)- 1 -oxophthalazin-2( 1 H)-yl]acetamide; N-[4-(4- bromophenyl)-l-oxophthalazin-2(lH)-yl]-2-(4-chlorophenyl)ace tamide; 2-(4- chlorophenyl)-N-( 1 -oxo-4-phenylphthalazin-2( 1 H)-yl)acetamide; 2-(3,5- difluorophenyl)-N-(4-isopropyl-l-oxophthalazin-2(lH)-yl)acet amide; 2-( 1 -adamantyl)-N- (4-isopropyl- 1 -oxophthalazin-2( 1 H)-yl)acetamide; 2-(l-adamantyl)-N-(8-oxo-5- phenylpyrido[2,3-d]pyridazin-7(8H)-yl)acetamide; 2-(l-adamantyl)-N-(4-isopropyl-l-oxo- 5,6,7,8-tetrahydro-5,8-ethanophthalazin- 2(1 H)-yl)acetamide; 2-(l-adamantyl)-N-(4-oxo- 7-phenylthieno[2,3-d]pyridazin-5(4H)-yl)acetamide; 2-(3,5-difluorophenyl)-N-(4-oxo-7- phenylthieno[2,3-d]pyridazin-5(4H)-yl)acetamide; 2-(3,5-difluorophenyl)-N-[l-oxo-4- (trifluoromethyl)phthalazin-2(lH)-yl]acetamide; 2-( 1 -adamantyl)-N-[ 1 -oxo-4- (trifluoromethyl)phthalazin-2(l H)-yl]acetamide; 2-(4-chlorophenyl)-N- [ 1 -oxo-4- (trifluoromethyl)phthalazin-2( 1 H)-yl] acetamide; N-(5,8-difluoro-l-oxo-4- phenylphthalazin-2(lH)-yl)-2-(4-fluorophenyl)acetamide; 2-(l-adamantyl)-N-(5,8-difluoro- l-oxo-4-phenylphthalazin-2(lH)-yl)acetamide; 2-(4-chlorophenyl)-N-(5,8-difluoro-l-oxo-4- phenylphthalazin-2(lH)-yl)acetamide; 2-(l-adamantyl)-N-(l-oxo-4-phenylphthalazin-2(lH)- yl)acetamide; 2-(3,5-difluorophenyl)-N-(l-oxo-4-phenylphthalazin-2(lH)-yl) acetamide; N- (4-chloro-l-oxophthalazin-2(lH)-yl)-2-(3,5-difluorophenyl)ac etamide; 2-( 1 -adamantyl)-N- (4-chloro- 1 -oxophthalazin-2( 1 H)-yl)acetamide; N-(4-chloro-l-oxophthalazin-2(lH)-yl)- 2-(4-chlorophenyl)acetamide; 2-(4-chlorophenyl)-N-(4-cyclopropyl-l-oxophthalazin-2(lH)- yl)acetamide; N-(4-cyclopropyl-l-oxophthalazin-2(lH)-yl)-2-(3,5- difluorophenyl)acetamide; 2-( 1 -adamantyl)-N-(4-cyclopropyl- 1 -oxophthalazin-2( 1 H)- yl)acetamide; 2-(2,3-difluorophenyl)-N-(l-oxo-4-phenylphthalazin-2(lH)-yl) acetamide; 2- (4-fluorophenyl)-N-( 1 -oxo-4-phenylphthalazin-2( 1 H)-yl)acetamide; 2-(2,5- difluorophenyl)-N-(l-oxo-4-phenylphthalazin-2(lH)-yl)acetami de; 2-(4-chlorophenyl)-N-(4- methyl- 1 -oxophthalazin-2( 1 H)-yl)acetamide; 2-(l-adamantyl)-N-(7-oxo-4- phenylthieno[2,3-d]pyridazin-6(7H)-yl)acetamide; 2-[(l S,2S,5S)-6,6- dimethylbicyclo[3.1.1]hept-2-yl]-N-(7-oxo-4-phenylthieno[2,3 - d]pyridazin-6(7H)- yl)acetamide; 2-(4-chlorophenyl)-N-(7-oxo-4-phenylthieno[2,3-d]pyridazin-6 (7H)- yl)acetamide; 2-(4-fluorophenyl)-N-(7-oxo-4-phenylthieno[2,3-d]pyridazin-6 (7H)- yl)acetamide; 2-(3,5-difluorophenyl)-N-(7-oxo-4-phenylthieno[2,3-d]pyridaz in-6(7H)- yl)acetamide; 2-[3,5-dimethyl-l-adamantyl]-N-(4-isopropyl-l-oxophthalazin- 2(lH)- yl)acetamide; 2-(3,5-difluorophenyl)-N-(6-fluoro-l-oxo-4-phenylphthalazin- 2(lH)- yl)acetamide; 2-(4-chlorophenyl)-N-(6-fluoro-l-oxo-4-phenylphthalazin-2(lH )- yl)acetamide; 2-( 1 -adamantyl)-N-(6-fluoro- 1 -oxo-4-phenylphthalazin-2( 1 H)- yl)acetamide; 2-(3,5-difluorophenyl)-N-(4-methyl-l-oxophthalazin-2(lH)-yl) acetamide; 2- [l-(4-chlorophenyl)cyclopropyl]-N-[l-oxo-4-(trifluoromethyl) phthalazin-2(lH)-yl]acetamide; 2- [ 1 -(4-chlorophenyl)cyclobutyl] -N-[ 1 -oxo-4-(trifluoromethyl)phthalazin-2( 1 H)- yl]acetamide; 2-(2-naphthyl)-N-[l-oxo-4-(trifluoromethyl)phthalazin-2(lH)- yl]acetamide; 3- (4-chlorophenyl)-3-methyl-N-[l-oxo-4-(trifluoromethyl)phthal azin-2(lH)-yl]butanamide; 2- cyclopentyl-N- [ 1 -oxo-4-(trifluoromethyl)phthalazin-2( 1 H)-yl] acetamide; 2.2- difluoro- N-[l-oxo-4-(trifluoromethyl)phthalazin-2(lH)-yl]-2-phenylace tamide; 2-cyclobutyl-N-[l-oxo- 4-(trifluoromethyl)phthalazin-2(lH)-yl]acetamide; N-[ 1 -oxo-4-(trifluoromethyl)phthalazin- 2(lH)-yl]-2-[4- (trifluoromethyl)phenyl]acetamide; 2- [4-(dimethylamino)phenyl]-N-[l-oxo- 4-(trifluoromethyl)phthalazin-2(lH)-yl] acetamide; 3.3- dimethyl-N-[l-oxo-4- (trifluoromethyl)phthalazin-2(lH)-yl]butanamide; 2-[4-(methylsulfonyl)phenyl]-N-[l-oxo-4- (trifluoromethyl)phthalazin-2(lH)-yl] acetamide; N- [ 1 -oxo-4-(trifluoromethyl)phthalazin- 2( 1 H)-yl] -3-phenylpropanamide; N-[l-oxo-4-(trifluoromethyl)phthalazin-2(lH)-yl]-2-(l- phenylcyclopropyl)acetamide; 3- methyl-N-[l-oxo-4-(trifluoromethyl)phthalazin-2(lH)-yl]- 3-phenylbutanamide; N-[l-oxo-4-(trifluoromethyl)phthalazin-2(lH)-yl]-2-(3- thienyl)acetamide; N- [ 1 -oxo-4-(trifluoromethyl)phthalazin-2( 1 H)-yl] -2-(2- thienyl)acetamide; 2-(5-chloro-2-thienyl)-N-[l-oxo-4-(trifluoromethyl)phthalazi n-2(lH)- yl]acetamide; 2-(5-methyl-2-thienyl)-N-[l-oxo-4-(trifluoromethyl)phthalazi n-2(lH)- yl]acetamide; N- [ 1 -oxo-4-(trifluoromethyl)phthalazin-2( 1 H)-yl] -2-phenylacetamide; (±)-2-(e o-bicyclo[2.2.1]heptan-2-yl)-N-[l-oxo-4-(trifluoromethyl)pht halazin-2(lH)-yl] acetamide; 2-(4-chloro-3-fluorophenyl)-N-[l-oxo-4-(trifluoromethyl)phth alazin-2(lH)-yl] acetamide; 2-(3-fluoroadamantan- 1-yl)-N-(4-isopropyl- 1 -oxophthalazin-2( lH)- yl)acetamide; 2-(3-hydroxyadamantan-l-yl)-N-(4-isopropyl-l-oxophthalazin-2 (lH)- yl)acetamide; N-(4-tert-butyl-l-oxophthalazin-2(lH)-yl)-2-cyclopentylaceta mide; (±)-2-(e o-bicyclo[2.2.1]heptan-2-yl)-N-(4-tert-butyl-l-oxophthalazin -2(lH)-yl)acetamide; N-(4-tert- butyl- 1 -oxophthalazin-2( 1 H)-yl)-3 -methyl-3-phenylbutanamide; N-(4-tert-butyl-l- oxophthalazin-2(lH)-yl)-2-(4-chlorophenyl)acetamide; 2-[(l S,2S,4R)-bicyclo[2.2.1]hept- 2-yl]-N-(4-cyclobutyl-l-oxophthalazin-2(lH)- yl)acetamide; 2-[(l S,2S,4S)- bicyclo[2.2.1]hept-5-en-2-yl]-N-(4-cyclobutyl-l-oxophthalazi n-2(lH)- yl)acetamide; (±)-2- (e o-bicyclo[2.2.1]heptan-2-yl)-N-(4-cyclobutyl-l-oxophthalazin -2(lH)- yl)acetamide; N-(4- cyclobutyl-l-oxophthalazin-2(lH)-yl)-2-(3,5-difluorophenyl)a cetamide; 2-(4-chlorophenyl)- N-(4-cyclobutyl-l-oxophthalazin-2(lH)-yl)acetamide; (±)-2-(e o-bicyclo[2.2.1]heptan-2-yl)- N-(4-cyclopentyl-l-oxophthalazin-2(lH)-yl)acetamide; 2-(4-chlorophenyl)-N-(4- cyclopentyl-l-oxophthalazin-2(lH)-yl)acetamide; N-(4-cyclopentyl-l-oxophthalazin-2(lH)- yl)-2-(3,5-difluorophenyl)acetamide; (±)-2-(e o-bicyclo[2.2.1]heptan-2-yl)-N-(4- cyclohexyl-l-oxophthalazin-2(lH)- yl)acetamide; 2-(adamantan- 1 -yl)-N-(4-cyclohexyl- 1 -oxophthalazin-2( 1 H)-yl)acetamide; 2- (4-chlorophenyl)-N-(4-cyclohexyl-l- oxophthalazin-2(lH)-yl)acetamide; N-(4-cyclohexyl-l-oxophthalazin-2(lH)-yl)-2-(3,5- difluorophenyl)acetamide; (±)-4-(3- { [(ero-bicyclo[2.2.1 ]heptan-2-yl)acetyl]amino} -4- oxo-3,4- dihydrophthalazin- 1-yl)benzoic acid; (±)-methyl 4-(3 - { [ero-bicyclo [2.2.1 ]hept-2-ylacetyl] amino } -4-oxo-3 ,4- dihydrophthalazin- 1 -yl)benzoate; methyl 4-(3- {[(4-chlorophenyl)acetyl]amino}-4-oxo-3,4-dihydrophthalazin- l- yl)benzoate; (±)-4-(3- {[e o-bicyclo[2.2.1]hept-2-ylacetyl]amino}-4-oxo-3,4-dihydrophth alazin-l- yl)-N,N- dimethylbenzamide; 3- methyl-N-(l-oxo-4-phenylphthalazin-2(lH)-yl)-3- phenylbutanamide; 2-(2,4-dichlorophenyl)-N-(l-oxo-4-phenylphthalazin-2(lH)- yl)acetamide; (±)-2-(e o-bicyclo[2.2.1]heptan-2-yl)-N-[4-(4-bromophenyl)-l- oxophthalazin-2(lH)- yl]acetamide; N-[4-(4-bromophenyl)-l-oxophthalazin-2(lH)-yl]-3- methyl-3-phenylbutanamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(l- methylcyclopentyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-[l- (trifluoromethyl)cyclopentyl]acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2- [(l S,2S,5R)-3,3-difluoro-6,6- dimethylbicyclo[3.1. l]hept-2-yl]acetamide; N- [4-(4- chlorophenyl)- 1 -oxophthalazin-2( 1 H)-yl]-3 -methyl-3 -phenylbutanamide; N-[4-(4- chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-fluoro-2-phenylace tamide; N-[4-(4- chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-phenylacetamide; N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)-yl]-2-(morpholin-4-yl)acetamide; N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)-yl]-2-(pyridin-3-yl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin- 2(lH)-yl]-2-(pyridin-2-yl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2- (3,4-dichlorophenyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(3,5- dimethoxyphenyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(3,5- dimethylphenyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-[3- (trifluoromethoxy)phenyl]acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-[4- (trifluoromethyl)phenyl]acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-[3- (trifluoromethyl)phenyl]acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-[4- (dimethylamino)phenyl]acetamide; 2-(4-bromophenyl)-N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)-yl]acetamide; 2-(3-chlorophenyl)-N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)-yl]acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(4- methoxyphenyl)acetamide; N- [4-(4-chlorophenyl)- 1 -oxophthalazin-2( 1 H)-yl] -2-(3 - methoxyphenyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(4- hydroxyphenyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(4- methylphenyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(3- methylphenyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2- cyclopentylacetamide; N- [4-(4-chlorophenyl)- 1 -oxophthalazin-2( 1 H)-yl] -4- methylpentanamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-[4- (methylsulfonyl)phenyl]acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-(5- chloro-2-thienyl)acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2-yl)-N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)- yl]acetamide; 2-(4-chloro-3-fluorophenyl)-N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)- yl]acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-2-[(l S,2S,5S)-6,6- dimethylbicyclo[3.1. l]hept-2-yl]acetamide; 2-(adamantan- 1 -yl)-N- [4-(4- chlorophenyl)- 1 -oxophthalazin-2( 1 H)-yl] acetamide; 2-(4-chlorophenyl)-N- [4-(4- chlorophenyl)- 1 -oxophthalazin-2( 1 H)-yl] acetamide; N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)-yl]-2-(3,5-difluorophenyl)acetamide; N-[4-(4-chlorophenyl)- 1 - oxophthalazin-2(l H)-yl]-2-( 1 -phenylcyclopentyl)acetamide; N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)-yl]-2- phenylcyclopropanecarboxamide; N-[4-(4-chlorophenyl)-l- oxophthalazin-2(lH)-yl]-2-(2-naphthyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin- 2(lH)-yl]-2-(l-naphthyl)acetamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-4,4,4- trifluorobutanamide; N-[4-(4-chlorophenyl)-l-oxophthalazin-2(lH)-yl]-3,3,3- trifluoropropanamide; (±)-2-(e o-bicyclo[2.2.1]hept-2-yl)-N-[4-(3-chlorophenyl)-l- oxophthalazin-2(lH)- yl] acetamide; 2-(adamantan- 1 -yl)-N- [4-(3 -chlorophenyl)- 1 - oxophthalazin-2( 1 H)-yl] acetamide; 2-(4-chlorophenyl)-N- [4-(3 -chlorophenyl)- 1 - oxophthalazin-2( 1 H)-yl] acetamide; N- [4-(3 -chlorophenyl)- 1 -oxophthalazin-2( 1 H)- yl]-2-(3 ,5 -difluorophenyl)acetamide; 2-[(l S,2S,4R)-bicyclo[2.2.1]hept-2-yl]-N-[4-(4- fluorophenyl)-l-oxophthalazin- 2(1 H)-yl]acetamide; 2-[(l S,2S,4S)-bicyclo[2.2.1]hept-5- en-2-yl]-N-[4-(4-fluorophenyl)-l-oxophthalazin- 2(1 H)-yl]acetamide; (±)-2-(e o- bicyclo[2.2.1]hept-2-yl)-N-[4-(4-fluorophenyl)-l-oxophthalaz in-2(lH)- yl] acetamide; 2-(4- chlorophenyl)-N-[4-(4-fluorophenyl)-l-oxophthalazin-2(lH)-yl ] acetamide; 2-(3,5- difluorophenyl)-N-[4-(4-fluorophenyl)-l-oxophthalazin-2(lH)- yl]acetamide; (±)-2-(e o- bicyclo[2.2.1]hept-2-yl)-N-[4-(2,4-difluorophenyl)-l-oxophth alazin- 2(1 H)-yl]acetamide; 2-(4-chlorophenyl)-N-[4-(4-methylphenyl)-l-oxophthalazin-2(l H)-yl]acetamide; 2-(3,5- difluorophenyl)-N-[4-(4-methylphenyl)-l-oxophthalazin-2(lH)- yl]acetamide; 2-[(l S,2S,5S)- 6,6-dimethylbicyclo[3.1.1]hept-2-yl]-N-[4-(4-methylphenyl)-l - oxophthalazin-2(lH)- yl]acetamide; 2-(adamantan- 1 -yl)-N- [4-(4-methylphenyl)- 1 -oxophthalazin-2( 1 H)-yl] acetamide; N-(4-benzyl- 1 -oxophthalazin-2( 1 H)-yl)-2- [ 1 -(trifluoromethyl)cyclopentyl] acetamide; N-(4-benzyl- 1 -oxophthalazin-2( 1 H)-yl)-3-methyl-3 -phenylbutanamide; (±)-N-(4-benzyl-l-oxophthalazin-2(lH)-yl)-2-(e o-bicyclo[2.2.1]hept-2-yl)acetamide; N-(4- benzyl-l-oxophthalazin-2(lH)-yl)-2-(4-chlorophenyl)acetamide ; N-(4-benzyl-l- oxophthalazin-2(lH)-yl)-2-(3,5-difluorophenyl)acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2- yl)-N-[4-(4-chlorobenzyl)-l-oxophthalazin-2(lH)- yl] acetamide; N-[4-(4-chlorobenzyl)-l- oxophthalazin-2(lH)-yl]-2-(4-chlorophenyl)acetamide; N-[4-(4-chlorobenzyl)-l- oxophthalazin-2(lH)-yl]-2-(3,5-difluorophenyl)acetamide; 2- [(l S,2S,4R)- bicyclo[2.2.1]hept-2-yl]-N-{ l-oxo-4-[4- (trifluoromethyl)phenyl]phthalazin-2(lH)-yl} acetamide; 3- methyl-N- { l-oxo-4-[4-(trifluoromethyl)phenyl]phthalazin-2(lH)-yl}-3- phenylbutanamide; 2-(adamantan-l-yl)-N- { l-oxo-4-[4-(trifluoromethyl)phenyl]phthalazin- 2(lH)- yl} acetamide; (±)-2-(exo-bicyclo[2.2.1 ]hept-2-yl)-N- { 1 -oxo-4-[4- (trifluoromethyl)phenyl]phthalazin-2(lH)-yl} acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2-yl)- N-[4-(4-methoxyphenyl)-l-oxophthalazin-2(lH)- yl] acetamide; N-[4-(4-methoxyphenyl)-l- oxophthalazin-2(lH)-yl]-2-(4- methylcyclohexyl)acetamide; 2-(3,5-difluorophenyl)-N-[4- (4-methoxyphenyl)-l-oxophthalazin-2(lH)- yl] acetamide; 2-(adamantan- 1 -yl)-N- [4-(4- methoxyphenyl)- 1 -oxophthalazin-2( 1 H)-yl] acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2- yl)-N-[4-(2,5-dimethylphenyl)-l-oxophthalazin- 2(1 H)-yl]acetamide; 2-(adamantan-l-yl)- N-[4-(2,5-dimethylphenyl)-l-oxophthalazin-2(lH)-yl]acetamide ; 2-(4-chlorophenyl)-N-[4- (2,5-dimethylphenyl)-l-oxophthalazin-2(lH)-yl]acetamide; 2-(3,5-difluorophenyl)-N-[4- (2,5-dimethylphenyl)-l-oxophthalazin-2(lH)- yl] acetamide; 2-[(l S,2S,4S)- bicyclo[2.2.1]hept-5-en-2-yl]-N-[4-(2,4-dimethylphenyl)-l- oxophthalazin-2(lH)- yl]acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2-yl)-N-[4-(2,4-dimethylphenyl)-l- oxophthalazin- 2(1 H)-yl]acetamide; 2-(4-chlorophenyl)-N-[4-(2,4-dimethylphenyl)-l- oxophthalazin-2(lH)-yl]acetamide; 2-(3,5-difluorophenyl)-N-[4-(2,4-dimethylphenyl)-l- oxophthalazin-2(lH)- yl]acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2-yl)-N-[4-(3,4- dimethylphenyl)-l-oxophthalazin- 2(1 H)-yl]acetamide; 2-(adamantan-l-yl)-N-[4-(3,4- dimethylphenyl)-l-oxophthalazin-2(lH)-yl]acetamide; 2-(4-chlorophenyl)-N-[4-(3,4- dimethylphenyl)-l-oxophthalazin-2(lH)-yl]acetamide; 2-(3,5-difluorophenyl)-N-[4-(3,4- dimethylphenyl)-l-oxophthalazin-2(lH)- yl]acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2-yl)- N-[l-oxo-4-(2-phenylethyl)phthalazin-2(lH)- yl]acetamide; (±)-2-(e o-bicyclo[2.2.1]hept-2- yl)-N-[4-(4-isopropylphenyl)-l-oxophthalazin-2(lH)- yl]acetamide; 2-(adamantan-l-yl)-N- [4-(4-isopropylphenyl)-l-oxophthalazin-2(lH)-yl]acetamide; 2-(4-chlorophenyl)-N- [4-(4- isopropylphenyl)- 1 -oxophthalazin-2( 1 H)-yl] acetamide; 2-(3,5-difluorophenyl)-N-[4-(4- isopropylphenyl)-l-oxophthalazin-2(lH)- yl] acetamide; (±)-2-(ero-bicyclo[2.2.1 ]hept-2- yl)-N-[ 1 -oxo-4-(l -phenylcyclopropyl)phthalazin- 2(1 H)-yl]acetamide; 2-(adamantan- 1 - yl)-N- [4-isopropyl- 1 -oxo-7-(trifluoromethyl)phthalazin-2( 1 H)- yl] acetamide; 2- (adamantan- 1 -yl)-N- [7-bromo-4-(4-methoxyphenyl)- 1 -oxophthalazin-2( 1 H)- yl] acetamide; 2-(adamantan- 1 -yl)-N- [6-bromo-4-(4-methoxyphenyl)- 1 -oxophthalazin-2( 1 H)- yl] acetamide; N-[6-bromo-4-(4-methoxyphenyl)-l-oxophthalazin-2(lH)-yl]-2-( 3,5- difluorophenyl)acetamide; N-[7-bromo-4-(4-methoxyphenyl)-l-oxophthalazin-2(lH)-yl]-2- (3,5- difluorophenyl)acetamide; 2-(3-bromoadamantan-l-yl)-N-(7-oxo-4- phenylthieno[2,3-d]pyridazin-6(7H)- yl)acetamide; 2-(3-fluoroadamantan-l-yl)-N-(7-oxo- 4-phenylthieno[2,3-d]pyridazin-6(7H)- yl)acetamide; 2-(3-hydroxyadamantan-l-yl)-N-(7- oxo-4-phenylthieno[2,3-d]pyridazin-6(7H)- yl)acetamide; N-[4-(4-chlorophenyl)-5,8- difluoro-l-oxophthalazin-2(lH)-yl]-2-(3,5- difluorophenyl)acetamide; 2-(4-chlorophenyl)-N- [4-(4-chlorophenyl)-5 , 8-difluoro- 1 -oxophthalazin-2( 1 H)- yl]acetamide; 2-(adamantan- l-yl)-N-[4-(4-chlorophenyl)-5,8-difluoro- 1 -oxophthalazin-2(lH)- yl]acetamide; (±)-2-(e o- bicyclo[2.2.1]hept-2-yl)-N-[4-(4-chlorophenyl)-5,8-difluoro- l- oxophthalazin-2(lH)- yl]acetamide; 2-(adamantan-l-yl)-N-(l-oxo-4-phenyl-5,6,7,8-tetrahydrophtha lazin-2(lH)- yl)acetamide; 2-(3,5-difluorophenyl)-N-(l-oxo-4-phenyl-5,6,7,8-tetrahydrop hthalazin- 2(lH)- yl)acetamide; 2-(4-chlorophenyl)-N-(l-oxo-4-phenyl-5,6,7,8-tetrahydrophtha lazin- 2(lH)- yl)acetamide; 2-(3,5-difluorophenyl)-N-(l-oxo-4-phenyl-l,5,6,7-tetrahydro- 2H- cyclopenta[d]pyridazin-2-yl)acetamide; 2-(adamantan-l-yl)-N-(l-oxo-4-phenyl-l,5,6,7- tetrahydro-2H- cyclopenta[d]pyridazin-2-yl)acetamide; 2-(4-chlorophenyl)-N-(l-oxo-4- phenyl-l,5,6,7-tetrahydro-2H-cyclopenta[d]pyridazin- 2-yl)acetamide; 2-(methylthio)-N-[l- oxo-4-(trifluoromethyl)phthalazin-2(lH)-yl]acetamide; 2-(adamantan- 1 -ylthio)-N- [ 1 - oxo-4-(trifluoromethyl)phthalazin-2( 1 H)-yl] acetamide; 2-(adamantan-l-ylthio)-N-(l-oxo- 4-phenylphthalazin-2(lH)-yl)acetamide; and 2-( 1 ,3 -benzodioxol-5 -yl)-N- [4-(4- chlorophenyl)- 1 -oxophthalazin-2( 1 H)-yl]acetamide. Formula 153 [0802] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 153. Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 153, these references incorporated by reference herein control. [0803] In an embodiment, the Kv7 channel activator is a compound according to Formula 153: or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein, R ¹ is an optional substituent wherein each occurrence of R ¹ is independently G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , -N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , -(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m - OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m - S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b ,-(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , -(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , -(CR ^za R ^zb ) _m - N(R ^a )SO ₂ NR ^a R ^b , or -(CR ^za R ^zb ) _m -G ^a ; p is 0, 1, 2, 3, or 4;R ³ is hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, -(CR ^3a R ^3b ) _m -G ^3a , or G ^3a ; G ^3a , at each occurrence, is independently aryl, cycloalkyl, or cycloalkenyl; each of which is optionally substituted;R ⁴ is alkenyl, alkynyl, haloalkyl, G ^4a , -(CR ^4a R ^4b ) _n -G ^4a , or alkyl which is optionally substituted with one or two groups independently selected from the group consisting of S(R ^1a ), 0(R ^1a ) and N(R ^1a ) ₂ ;each occurrence of R ^1a is independently hydrogen, G ^a , -(CR ^za R ^zb ) _m -G ^a , alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl;G ^4a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is optionally substituted; G ^3a and G ^4a , at each occurrence, are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , -OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , - S(O) ₂ NR ^a R ^b , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , - N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -G ^a , -(CR ^za R ^zb ) _m -CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , - (CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m -OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , - (CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m - C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , - (CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and -(CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;G ^a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b , -N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b ,-N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a ,-(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m - OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a ,-(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m - S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b ,-(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and - (CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;R ^za , R ^zb , R ^3a , R ^3b , R ^4a , and R ^4b , at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl; R ^a and R ^b , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; and m and n, at each occurrence, are each independently 1, 2, 3, or 4. Formula 154 [0804] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 154. Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 154, these references incorporated by reference herein control. [0805] In an embodiment, the Kv7 channel activator is a compound according to Formula 154: or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, whereinR ¹ is an optional substituent wherein each occurrence of R ¹ is independently G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO2, -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , -N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , -(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m - OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m - S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b ,-(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , -(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , -(CR ^za R ^zb ) _m - N(R ^a )SO ₂ NR ^a R ^b , or -(CR ^za R ^zb ) _m -G ^a ; p is 0, 1, 2, 3, or 4;R ³ is hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, -(CR ^3a R ^3b ) _m -G ^3a , or G ^3a ; G ^3a , at each occurrence, is independently aryl, cycloalkyl, or cycloalkenyl; each of which is optionally substituted;R ⁴ is alkenyl, alkynyl, haloalkyl, G ^4a , -(CR ^4a R ^4b ) _n -G ^4a , or alkyl which is optionally substituted with one or two groups independently selected from the group consisting of S(R ^1a ), 0(R ^1a ) and N(R ^1a ) ₂ ;each occurrence of R ^1a is independently hydrogen, G ^a , -(CR ^za R ^zb ) _m -G ^a , alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl;G ^4a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is optionally substituted; G ^3a and G ^4a , at each occurrence, are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , -OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , - S(O) ₂ NR ^a R ^b , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , - N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -G ^a , -(CR ^za R ^zb ) _m -CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , - (CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m -OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , - (CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m - C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , - (CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and -(CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;G ^a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b , -N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b ,-N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a ,-(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m - OC(O)NR ^a R ^b , -(CR ^za R ^zb )m-SR ^a , -(CR ^za R ^zb )m-S(O)R ^a ,-(CR ^za R ^zb )m-S(O)2R ^a , -(CR ^za R ^zb )m- S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b ,-(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and - (CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;R ^za , R ^zb , R ^3a , R ^3b , R ^4a , and R ^4b , at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl; R ^a and R ^b , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; and m and n, at each occurrence, are each independently 1, 2, 3, or 4 ; and q is 0, 1, or 2. Formula 155 [0806] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 155. Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 155, these references incorporated by reference herein control. [0807] In an embodiment, the Kv7 channel activator is a compound according to Formula 155: or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein R ¹ is an optional substituent wherein each occurrence of R ¹ is independently G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , -N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb )m-NO2, -(CR ^za R ^zb )m-OR ^a , -(CR ^za R ^zb )m-OC(O)R ^a , -(CR ^za R ^zb )m- OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m - S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b ,-(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , -(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , -(CR ^za R ^zb ) _m - N(R ^a )SO ₂ NR ^a R ^b , or -(CR ^za R ^zb ) _m -G ^a ; p is 0, 1, 2, 3, or 4;R ³ is hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, -(CR ^3a R ^3b ) _m -G ^3a , or G ^3a ; G ^3a , at each occurrence, is independently aryl, cycloalkyl, or cycloalkenyl; each of which is optionally substituted;R ⁴ is alkenyl, alkynyl, haloalkyl, G ^4a , -(CR ^4a R ^4b ) _n -G ^4a , or alkyl which is optionally substituted with one or two groups independently selected from the group consisting of S(R ^1a ), 0(R ^1a ) and N(R ^1a ) ₂ ;each occurrence of R ^1a is independently hydrogen, G ^a , -(CR ^za R ^zb ) _m -G ^a , alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl;G ^4a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is optionally substituted; G ^3a and G ^4a , at each occurrence, are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , -OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , - S(O) ₂ NR ^a R ^b , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , - N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -G ^a , -(CR ^za R ^zb ) _m -CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , - (CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m -OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , - (CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m - C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , - (CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and -(CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;G ^a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b , -N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b ,-N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a ,-(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m - OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a ,-(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m - S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b ,-(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and - (CR ^za R ^zb )m-N(R ^a )SO2NR ^a R ^b ;R ^za , R ^zb , R ^3a , R ^3b , R ^4a , and R ^4b , at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl; R ^a and R ^b , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; and m and n, at each occurrence, are each independently 1, 2, 3, or 4 ; and u is 0, 1, 2, or 3. Formula 156 [0808] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 156. Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 156, these references incorporated by reference herein control. [0809] In an embodiment, the Kv7 channel activator is a compound according to Formula 156:

or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein R ¹ is an optional substituent wherein each occurrence of R ¹ is independently G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , -N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , -(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m - OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m - S(O)2NR ^a R ^b , -(CR ^za R ^zb )m-C(O)R ^a , -(CR ^za R ^zb )m-C(O)OR ^a , -(CR ^za R ^zb )m-C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b ,-(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , -(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , -(CR ^za R ^zb ) _m - N(R ^a )SO ₂ NR ^a R ^b , or -(CR ^za R ^zb ) _m -G ^a ; p is 0, 1, 2, 3, or 4;R ³ is hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, -(CR ^3a R ^3b ) _m -G ^3a , or G ^3a ; G ^3a , at each occurrence, is independently aryl, cycloalkyl, or cycloalkenyl; each of which is optionally substituted;R ⁴ is alkenyl, alkynyl, haloalkyl, G ^4a , -(CR ^4a R ^4b ) _n -G ^4a , or alkyl which is optionally substituted with one or two groups independently selected from the group consisting of S(R ^1a ), 0(R ^1a ) and N(R ^1a ) ₂ ;each occurrence of R ^1a is independently hydrogen, G ^a , -(CR ^za R ^zb ) _m -G ^a , alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl;G ^4a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is optionally substituted; G ^3a and G ^4a , at each occurrence, are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of G ^a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , -OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , - S(O) ₂ NR ^a R ^b , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b ,-N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b , - N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -G ^a , -(CR ^za R ^zb ) _m -CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a , - (CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m -OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a , - (CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m -S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m - C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b , - (CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and -(CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;G ^a , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; each of which is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO ₂ , -OR ^a , - OC(O)R ^a , -OC(O)NR ^a R ^b , -NR ^a R ^b , -SR ^a , -S(O)R ^a , -S(O) ₂ R ^a , -S(O) ₂ NR ^a R ^b , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b , -N(R ^a )COOR ^b , -N(R ^a )CONR ^a R ^b ,-N(R ^a )SO ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m - CN, -(CR ^za R ^zb ) _m -NO ₂ , -(CR ^za R ^zb ) _m -OR ^a ,-(CR ^za R ^zb ) _m -OC(O)R ^a , -(CR ^za R ^zb ) _m - OC(O)NR ^a R ^b , -(CR ^za R ^zb ) _m -SR ^a , -(CR ^za R ^zb ) _m -S(O)R ^a ,-(CR ^za R ^zb ) _m -S(O) ₂ R ^a , -(CR ^za R ^zb ) _m - S(O) ₂ NR ^a R ^b , -(CR ^za R ^zb ) _m -C(O)R ^a , -(CR ^za R ^zb ) _m -C(O)OR ^a , -(CR ^za R ^zb ) _m -C(O)NR ^a R ^b , - (CR ^za R ^zb ) _m -NR ^a R ^b , -(CR ^za R ^zb ) _m -N(R ^a )COOR ^b ,-(CR ^za R ^zb ) _m -N(R ^a )CONR ^a R ^b , and - (CR ^za R ^zb ) _m -N(R ^a )SO ₂ NR ^a R ^b ;R ^za , R ^zb , R ^3a , R ^3b , R ^4a , and R ^4b , at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl; R ^a and R ^b , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl; and m and n, at each occurrence, are each independently 1, 2, 3, or 4 ; v is 1, 2, or 3; and y is absent, a bond, -CH ₂ -, or -CH ₂ CH ₂ -. Formula 157 [0810] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 157. Such compounds are described in US Publication No. US20110257146A1, published October 20, 2011, and corresponding to US Application No.12/223,136 filed January 25, 2007; International Publication No. WO2007087424A2, published August 2, 2007, and corresponding to International Application No. PCT/US2007/002116 filed January 26, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 157, these references incorporated by reference herein control. [0811] In an embodiment, the Kv7 channel activator is a compound according to Formula 157: [0812] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: zinc-5,7-Diiodo-8-hydroxyquinoline and zinc-8-Hydroxyquinoline. [0813] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: zinc-pyrrolidine dithiocarbamate, zinc-diethyldithiocarbamate, zinc- disulfiram and zinc-dimethyldithiocarbamate. [0814] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: zinc-vitamin E and zinc-vitamin A. Formula 158 [0815] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 158. Such compounds are described in US Publication No. US20110257146A1, published October 20, 2011, and corresponding to US Application No.12/223,136 filed January 25, 2007; International Publication No. WO2007087424A2, published August 2, 2007, and corresponding to International Application No. PCT/US2007/002116 filed January 26, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 158, these references incorporated by reference herein control. [0816] In an embodiment, the Kv7 channel activator is a compound according to Formula 158: wherein, A is a bond, CH ₂ , CHR _b , CH ₂ S, CHR _b S, CH ₂ O, CH ₂ NR _c , or NH; Rb is alkyl; R _c is H or S(O) _m -aryl; R ₁ is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted cycloalkyl, or an optionally substituted heteroaryl; R ₂ is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted cycloalkyl, an optionally substituted heteroaryl, an optionally substituted heterocyclic, an optionally substituted aralkyl, R ₃ is H or alkyl; each R _d and R _e is independently an optionally substituted alkyl, an optionally substituted aryl, or R _d and R _e together form an optionally substituted cycloalkyl; and m is 0, 1, or 2. Formula 159 [0817] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 159. Such compounds are described in US Publication No. US20110257146A1, published October 20, 2011, and corresponding to US Application No.12/223,136 filed January 25, 2007; International Publication No. WO2007087424A2, published August 2, 2007, and corresponding to International Application No. PCT/US2007/002116 filed January 26, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 159, these references incorporated by reference herein control. [0818] In an embodiment, the Kv7 channel activator is a compound according to Formula 159: wherein, R ₄ is H, an optionally substituted alkyl, an optionally substituted alkenyl, alkynyl, allyl, or an optionally substituted aryl; R ₅ is H, hal, or hydroxyl; R ₆ is H, hal, hydroxyl, NH ₂ , a mono- or di-substituted amine, or an optionally substituted alkoxy; R ₇ is H, hal, hydroxyl, an optionally substituted alkoxy, or nitro; X is S or NR _a ; Y is O, S, or NR _a ; and each R _a is independently H or an optionally substituted aryl. [0819] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: N-Benzo[g]quinolin-4-yl-N′-(2-diethylamino-ethyl)-benzene- 1,4-diamine; 2- [2-(3,4-Dihydroxy-phenyl)-2-oxo-ethylsulfanyl]-4,6-dimethyl- nicotinonitrile; 2-[2-(4- Methoxy-phenyl)-2-oxo-ethylsulfanyl]-4-(5-methyl-furan-2-yl) -5,6,7,8-tetrahydro- quinoline-3-carbonitrile; 6-Methyl-4-(5-methyl-furan-2-yl)-2-(2-oxo-2-phenyl- ethylsulfanyl)-nicotinonitrile; 2-(2-Oxo-2-thiophen-2-yl-ethylsulfanyl)-4-pyridin-4-yl- 5,6,7,8-tetrahydro-quinoline-3-carbonitrile; 2-(3,5-Diiodo-2-methoxy-phenyl)-2,3,5,6,7,8- hexahydro-1H-benzo[4,5]thieno[2,3-d]pyrimidin-4-one; 2,2,2-Trifluoro-1-[1-(2,2,2- trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-1H-pyrrol-2-yl] -ethanone; 1,5-Diphenyl-1H- pyrazole-3-carboxylic acid tert-butylamide; 3-(4-Bromo-phenyl)-5-(3-phenyl-allylidene)- dihydro-pyrimidine-2,4-dione; 2-Amino-7-hydroxy-6-[(2-iodo-phenylimino)-methyl]-4- phenyl-4H-chromene-3-carbonitrile; 3-(1H-Benzoimidazol-2-yl)-6-nitro-chromen-2- ylideneamine; 6-Methoxy-3-(4-nitro-phenyl)-chroman-2-one; 2-(Benzo[1,2,5]thiadiazol- 4-yliminomethyl)-benzo[b]thiophen-3-ol; 4-[3-(4-Bromo-phenyl)-3-oxo-propenylamino]- N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; 2-[(5-Nitro-furan-2-ylmethylene)- amino]-benzamide; 2-Benzo[4,5]imidazo[1,2-c]quinazolin-6-yl-phenylamine; Dimethyl- phenyl)-5-(3-phenyl-allylidene)-pyrimidine-2,4,6-trione; 4-(4-Cyclohexyl-phenyl)-thiazol- 2-ylamine; or 4-(4-Cyclohexyl-phenyl)-thiazol-2-ylamine. Formula 160 [0820] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 160. Such compounds are described in International Publication No. WO2004060880A1, published July 22, 2004, and corresponding to International Application No. PCT/US2003/039352 filed December 11, 2003; US Patent No.6,933,308, issued August 23, 2005, and corresponding to US Application No.10/730,781 filed December 9, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 160, these references incorporated by reference herein control. [0821] In an embodiment, the Kv7 channel activator is a compound according to Formula 160: wherein, R ₁ is C _1-6 alkyl, C _3-7 cycloalkyl, —(CH ₂ ) _1-4 C _3-7 cycloalkyl, —(CH ₂ ) _2-4 N(C _1-6 alkyl) ₂ , —(CH ₂ ) _2-4 OC _1-6 alkyl, hydrogen, C _1-6 alkyl, or — (CH ₂ ) _2-4 OC _1-6 alkyl; or where R ¹ and R ² taken together are —CH ₂ CH ₂ XCH ₂ CH ₂ —, where X is a chemical bond, CH ₂ , CHOH, NH, NCH ₃ , NCOCH ₃ , O, or S; R ³ is hydrogen or hydroxy, provided that where R ³ is hydroxy, m is not 0; R ⁴ is hydrogen, C _1-6 alkyl, hydroxymethyl, or trifluoromethyl; R ⁵ is halogen, C _1-6 alkyl, C _1-2 perfluoroalkyl, C _1-6 alkoxy, C _1-2 perfluoroalkoxy, —N(R ⁴ ) ₂ , N-morpholinyl, or pyridyl; R ⁶ is hydrogen, halogen, or C _{1- 6} alkoxy; m is 0 or 1. [0822] In further embodiments, R ³ is hydrogen and m is 1. [0823] In further embodiments, R ⁴ is methyl. [0824] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-[2-(4-morpholinyl)ethyl]-N-[1-[3-(3-pyridinyl)phenyl]ethyl ]-4- (trifluoromethyl)-5-thiazolecarboxamide; N-[1-[3-(dimethylamino)phenyl]ethyl]-2-[2-(1- pyrrolidinyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamid e; 2-[2-(1-pyrrolidinyl)ethyl]-4- (trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-t hiazolecarboxamide; 2-[2-[(2- furanylmethyl)methylamino]ethyl]-N-[(1S)-1-[3-(4-morpholinyl )phenyl]ethyl]-4- (trifluoromethyl)-5-thiazolecarboxamide; 2-[2-[(2-furanylmethyl)methylamino]ethyl]-N-[1- [3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazole carboxamide; 2-[2-(1- pyrrolidinyl)ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]- 4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-[(2-furanylmethyl)methylamino]ethyl]-N-[1-[3- (trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazo lecarboxamide; 2-[2- (diethylamino)ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl] -4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-(diethylamino)ethyl]-N-[1-[3-(dimethylamino)phenyl]ethy l]-4- (trifluoromethyl)-5-thiazolecarboxamide; 2-[2-[ethyl(4-pyridinylmethyl)amino]ethyl]-4- (trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-t hiazolecarboxamide; 2-[2-(4- thiomorpholinyl)ethyl]-4-(trifluoromethyl)-N-[1-[3-(trifluor omethyl)phenyl]ethyl]-5- thiazolecarboxamide; 2-[2-[[2-(dimethylamino)ethyl]methylamino]ethyl]-N-[1-[3- (trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazo lecarboxamide; 2-[2-[[2- (dimethylamino)ethyl]methylamino]ethyl]-4-(trifluoromethyl)- N-[1-[3- (trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; 2-[2-(4-methyl-1-piperazinyl)ethyl]- N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)- 5-thiazolecarboxamide; 2-[2- (1-piperidinyl)ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl ]-4-(trifluoromethyl)-5- thiazolecarboxamide; N-[1-[3-(dimethylamino)phenyl]ethyl]-2-[2-(1-piperidinyl)eth yl]-4- (trifluoromethyl)-5-thiazolecarboxamide; 2-[2-(1-piperidinyl)ethyl]-4-(trifluoromethyl)-N- [1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; N-[(1S)-1-[3-(4- morpholinyl)phenyl]ethyl]-2-[2-(1-piperidinyl)ethyl]-4-(trif luoromethyl)-5- thiazolecarboxamide; 2-[2-(4-hydroxy-1-piperidinyl)ethyl]-N-[1-[3- (trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazo lecarboxamide; 2-[2-(4- hydroxy-1-piperidinyl)ethyl]-4-(trifluoromethyl)-N-[1-[3-(tr ifluoromethyl)phenyl]ethyl]-5- thiazolecarboxamide; 2-[2-[(cyclopropylmethyl)propylamino]ethyl]-N-[1-[3- (trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazo lecarboxamide; 2-[2- [(cyclopropylmethyl)propylamino]ethyl]-N-[1-[3-(dimethylamin o)phenyl]ethyl]-4- (trifluoromethyl)-5-thiazolecarboxamide; 2-[2-[(cyclopropylmethyl)propylamino]ethyl]-4- (trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-t hiazolecarboxamide; 2-[2- (diethylamino)ethyl]-N-[(1S)-1-[3-(3-pyridinyl)phenyl]ethyl] -4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-(1-piperidinyl)ethyl]-N-[(1S)-1-[3-(3-pyridinyl)phenyl] ethyl]-4- (trifluoromethyl)-5-thiazolecarboxamide; 2-[2-[(1-ethylpropyl)amino]ethyl]-N-[1-[3- (trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazo lecarboxamide; 2-[2-[(1- ethylpropyl)amino]ethyl]-4-(trifluoromethyl)-N-[1-[3-(triflu oromethyl)phenyl]ethyl]-5- thiazolecarboxamide; 2-[2-[(2-furanylmethyl)amino]ethyl]-N-[(1S)-1-[3-(3- pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarbox amide; 2-[2- (cyclopentylamino)ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]et hyl]-4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-(cyclopentylamino)ethyl]-N-[(1S)-1-[3-(3- pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarbox amide; 2-[2-[bis(2- methoxyethyl)amino]ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]e thyl]-4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-[bis(2-methoxyethyl)amino]ethyl]-4-(trifluoromethyl)-N- [1-[3- (trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; 2-[2-[bis(2- methoxyethyl)amino]ethyl]-N-[(1S)-1-[3-(3-pyridinyl)phenyl]e thyl]-4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-(4-morpholinyl)ethyl]-N-[(1S)-1-[3-(4- morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarb oxamide; N-[1-[3- (dimethylamino)phenyl]ethyl]-2-[2-(4-thiomorpholinyl)ethyl]- 4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-[[2-(dimethylamino)ethyl]methylamino]ethyl]-N-[1-[3- (dimethylamino)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolec arboxamide; and 2-[2-(4- methyl-1-piperazinyl)ethyl]-N-[(1S)-1-[3-(4-morpholinyl)phen yl]ethyl]-4-(trifluoromethyl)- 5-thiazolecarboxamide. [0825] In further embodiments, R ³ is hydroxy and m is 1. [0826] In further embodiments, R ⁴ is methyl. [0827] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-[1-hydroxy-2-(1-piperidinyl)ethyl]-N-[1-[3-(trifluorometho xy)phenyl]ethyl]- 4-(trifluoromethyl)-5-thiazolecarboxamide; 2-[1-hydroxy-2-(1-pyrrolidinyl)ethyl]-4- (trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-t hiazolecarboxamide; 2-[2-[(2- furanylmethyl)methylamino]-1-hydroxyethyl]-4-(trifluoromethy l)-N-[1-[3- (trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; 2-[2- [(cyclopropylmethyl)propylamino]-1-hydroxyethyl]-N-[1-[3- (trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazo lecarboxamide; 2-[2- (diethylamino)-1-hydroxyethyl]-N-[(1S)-1-[3-(4-morpholinyl)p henyl]ethyl]-4- (trifluoromethyl)-5-thiazolecarboxamide; 2-[2-(diethylamino)-1-hydroxyethyl]-N-[(1S)-1- [3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazole carboxamide; 2-[1-hydroxy-2- (4-morpholinyl)ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl ]-4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[1-hydroxy-2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)-N-[ 1-[3- (trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; 2-[1-hydroxy-2-(4-methyl-1- piperazinyl)ethyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromet hyl)phenyl]ethyl]-5- thiazolecarboxamide; 2-[1-hydroxy-2-(4-methyl-1-piperazinyl)ethyl]-N-[(1S)-1-[3-( 4- morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-5-thiazolecarb oxamide; 2-[1-hydroxy-2-(4- methyl-1-piperazinyl)ethyl]-N-[(1S)-1-[3-(3-pyridinyl)phenyl ]ethyl]-4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[1-hydroxy-2-(1-piperidinyl)ethyl]-4-(trifluoromethyl)-N-[ 1-[3- (trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; 2-[1-hydroxy-2-(1- pyrrolidinyl)ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]- 4-(trifluoromethyl)-5- thiazolecarboxamide; N-[1-[3-(dimethylamino)phenyl]ethyl]-2-[1-hydroxy-2-(1- pyrrolidinyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamid e; 2-[1-hydroxy-2-(1- pyrrolidinyl)ethyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl ]-4-(trifluoromethyl)-5- thiazolecarboxamide; 2-[2-[(cyclopropylmethyl)propylamino]-1-hydroxyethyl]-4- (trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-t hiazolecarboxamide; and 2-[2- (4-acetyl-1-piperazinyl)-1-hydroxyethyl]-4-(trifluoromethyl) -N-[1-[3- (trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide. [0828] In further embodiments, the compound has a stereochemical configuration according to the formula: [0829] In further embodiments, the compound is according to the formula: [0830] Wherein, R ¹ is C _1-6 alkyl, C _3-7 cycloalkyl, —(CH ₂ ) _1-4 C _3-7 cycloalkyl, —(CH ₂ ) _2-4 N(C _{1- 6} alkyl) ₂ , —(CH ₂ ) _2-4 OC _1-6 alkyl, s hydrogen C _1-6 alkyl, or —(CH ₂ ) _2-4 OC _1-6 alkyl; or where R ¹ and R ² taken together are —CH ₂ CH ₂ XCH ₂ CH ₂ —, where X is a chemical bond, CH ₂ , CHOH, NH, NCH ₃ , NCOCH ₃ , O, or S; R ³ is hydrogen or hydroxy, provided that where R ³ is hydroxy, m is not 0; R ⁴ is hydrogen, C _1-6 alkyl, hydroxymethyl, or trifluoromethyl; R ⁵ is halogen, C _1-6 alkyl, C _1-2 perfluoroalkyl, C _1-6 alkoxy, C1-2perfluoroalkoxy, —N(R ⁴ )2, N-morpholinyl, or pyridyl; and m is 0 or 1; or a pharmaceutically acceptable salt thereof. Formula 161 [0831] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 161. Such compounds are described in US Patent No.7,144,881 issued December 5, 2006, and corresponding to US Application No.10/919,184 filed November 21, 2003; International Publication No. WO2004047738A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037305 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 161, these references incorporated by reference herein control. [0832] In an embodiment, the Kv7 channel activator is a compound according to Formula 161: wherein, R is C _1-4 alkyl, CF ₃ or hydroxymethyl; R ¹ and R ² are each independently hydrogen, C _1-4 alkyl, halogen or morpholin-4-yl; R ⁴ is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C _{1- 4} alkyl, dimethylamino, hydroxymethyl, chloro and fluoro; R ⁵ is hydrogen or fluoro; or R ⁴ and R ⁵ taken together are —CH═CH—CH═CH— or —CH ₂ CH ₂ O—; and R ³ , R ⁶ and R ⁷ are each independently selected from hydrogen or fluoro. Formula 162 [0833] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 162. Such compounds are described in US Patent No.7,144,881 issued December 5, 2006, and corresponding to US Application No.10/919,184 filed November 21, 2003; International Publication No. WO2004047738A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037305 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 162, these references incorporated by reference herein control. [0834] In an embodiment, the Kv7 channel activator is a compound according to Formula 162: , wherein, R is methyl or hydroxymethyl; R ¹ and R ² are each independently hydrogen, C _{1- 4} alkyl, halogen or morpholin-4-yl; R ⁴ is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C1-4alkyl, dimethylamino, hydroxymethyl, chloro and fluoro; R ⁵ is hydrogen or fluoro; or R ⁴ and R ⁵ taken together are —CH═CH—CH═CH— or —CH ₂ CH ₂ O—; and R ³ , R ⁶ and R ⁷ are each independently selected from hydrogen or fluoro. [0835] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro- benzofuran-5-yl)-ethyl]-amide; 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3- dihydro-benzofuran-5-yl)-ethyl]-amide; 2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide; 2-(2-fluoro-phenyl)- cyclopropanecarboxylic acid(2-hydroxy-1-naphthalen-2-yl-ethyl)-amide; 2-(3-fluoro- phenyl)-cyclopropanecarboxylic acid(2-hydroxy-1-naphthalen-2-yl-ethyl)-amide; 2-(4- fluoro-phenyl)-cyclopropanecarboxylic acid(2-hydroxy-1-naphthalen-2-yl-ethyl)-amide; 2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid(2-hydroxy-1-naphthalen-2-yl-ethyl)- amide; 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(4-fluoro-3-morpholin-4-yl- phenyl)-2-hydroxy-ethyl]-amide; 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(4- fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide; 2-(4-fluoro-phenyl)- cyclopropanecarboxylic acid[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]- amide; 2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid[1-(4-fluoro-3-morpholin-4-yl- phenyl)-2-hydroxy-ethyl]-amide; 2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid(1- naphthalen-2-yl-ethyl)-amide; 2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid(1- naphthalen-2-yl-ethyl)-amide; 2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid{1-[3-(3- dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyll}-amide; 2-(2,5-difluoro-phenyl)- cyclopropanecarboxylic acid{1-[3-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyl}-a mide; 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(3-pyridin-3-yl-phenyl)-ethyl]-amide; 2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid[1-(3-pyridin-3-yl-phenyl)-ethyl]- amide; (S)-2-phenyl-cyclopropanecarboxylic acid[1-(3-pyridin-3-yl-phenyl)-ethyl]-amide; (S)-2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid{1-[3-(6-fluoro-pyridin-3-yl)-phenyl]- ethyl}-amide; (S)-2-phenyl-cyclopropanecarboxylic acid{1-[3-(2-fluoro-pyridin-3-yl)- phenyl]-ethyl}-amide; and (S)-2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid{1-[3-(2- fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide; or a pharmaceutically acceptable salt thereof. Formula 163 [0836] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 163. Such compounds are described in International Publication No. WO2004047743A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037348 filed November 21, 2003; US Patent No.7,045,551 issued May 16, 2006, and corresponding to US Application No.10/719,465 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 163, these references incorporated by reference herein control. [0837] In an embodiment, the Kv7 channel activator is a compound according to Formula 163: wherein, R ¹ is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, furanyl, C _3-6 cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; A is —CH═CH— or —(CH ₂ ) _n —; R ² is hydrogen or hydroxymethyl; n is an integer of 0, 1 or 2; R ⁴ is selected from the group consisting of di(C _1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, morpholin-4-ylmethyl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C _1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R ₅ is hydrogen or fluoro; or R ⁴ and R ⁵ taken together is —CH═CH—CH═CH— optionally substituted with a substituent independently selected from the group consisting of C _1-4 alkyl, C _1-4 alkoxy, trifluoromethyl and trifluoromethoxy; and R ³ , R ⁶ , and R ⁷ are each independently hydrogen or fluoro. Formula 164 [0838] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 164. Such compounds are described in International Publication No. WO2004047743A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037348 filed November 21, 2003; US Patent No.7,045,551 issued May 16, 2006, and corresponding to US Application No.10/719,465 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 164, these references incorporated by reference herein control. [0839] In an embodiment, the Kv7 channel activator is a compound according to Formula 164:

wherein, R ¹ is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, furanyl, C _3-6 cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; A is —CH═CH— or —(CH ₂ ) _n —; R ² is hydrogen; n is an integer of 0, 1 or 2; R ⁴ is selected from the group consisting of di(C _1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, morpholin-4-ylmethyl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C _1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R ⁵ hydrogen or fluoro; or R ⁴ and R ⁵ taken together is —CH═CH—CH═CH— optionally substituted with a substituent independently selected from the group consisting of C _1-4 alkyl, C _1-4 alkoxy, trifluoromethyl and trifluoromethoxy; and R ³ , R ⁶ , and R ⁷ are each independently hydrogen or fluoro. [0840] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: (R)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl - propionamide; (R)-3-(2-fluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phe nyl)-ethyl]- acrylamide; (R)-3-(3-fluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phe nyl)-ethyl]- acrylamide; (R)-3-(2,4-difluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl -phenyl)-ethyl]- acrylamide; (R)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl] -3-(2-fluoro- phenyl)-acrylamide (R)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl] -3-(3- fluoro-phenyl)-acrylamide (R)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl] - 3-(4-fluoro-phenyl)-acrylamide (R)-3-(2,4-difluoro-phenyl)-N-[1-(4-fluoro-3-morpholin-4- yl-phenyl)-2-hydroxy-ethyl]-acrylamide (R)-3-(3-fluoro-phenyl)-N-(2-hydroxy-1- naphthalen-2-yl-ethyl)-acrylamide; (R)-3-(4-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2- yl-ethyl)-acrylamide; (R)-3-(2,4-difluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-e thyl)- acrylamide; (R)-3-(3,4-difluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-e thyl)- acrylamide; (R)-4-fluoro-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-benzamide ; (R)-2,3- difluoro-N-(2-hydroxy-1-naphthalen-2-yl-ethyl)-benzamide; (R)-2,4-difluoro-N-(2- hydroxy-1-naphthalen-2-yl-ethyl)-benzamide; (R)-3,4-difluoro-N-(2-hydroxy-1- naphthalen-2-yl-ethyl)-benzamide; (R)-2-(2,4-difluoro-phenyl)-N-(2-hydroxy-1- naphthalen-2-yl-ethyl)-acetamide; (R)-3-(2-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2- yl-ethyl)-propionamide; (R)-3-(3-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl )- propionamide; (R)-3-(4-fluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-ethyl )- propionamide; (R)-3-(2,4-difluoro-phenyl)-N-(2-hydroxy-1-naphthalen-2-yl-e thyl)- propionamide; (R)-3-(2-fluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphthalen -2-yl)- ethyl]-acrylamide; (R)-3-(3-fluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphthalen -2-yl)- ethyl]-acrylamide; (R)-3-(4-fluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphthalen -2-yl)- ethyl]-acrylamide; (R)-3-(2,4-difluoro-phenyl)-N-[2-hydroxy-1-(7-methoxy-naphth alen-2- yl)-ethyl]-acrylamide; (1R, 2S)-N-(2,3-dihydroxy-1-naphthalen-2-yl-propyl)-3-(2-fluoro- phenyl)-acrylamide; (1R, 2S)-3-(2,4-difluoro-phenyl)-N-(2,3-dihydroxy-1-naphthalen-2- yl-propyl)-acrylamide; (1R, 2S)-3-(3,4-difluoro-phenyl)-N-(2,3-dihydroxy-1-naphthalen-2- yl-propyl)-acrylamide; and (1R, 2S)-3-(3,5-difluoro-phenyl)-N-(2,3-dihydroxy-1- naphthalen-2-yl-propyl)-acrylamide; or a pharmaceutically acceptable salt thereof. Formula 165 [0841] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 165. Such compounds are described in US Patent No.7,135,472 issued November 14, 2006, and corresponding to US Application No.10/719,187 filed November 21, 2003; International Publication No. WO2004047744A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037349 filed November 21, 2003; US Patent No. 7,135,472 issued November 14, 2006, and Patent Cooperation Treaty application No. US2003/037349 published June 10, 2004, which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 165, these references incorporated by reference herein control. [0842] In an embodiment, the Kv7 channel activator is a compound according to Formula 165: , wherein, R ¹ is selected from the group consisting of straight or branched chain C _x _ ₆ alkyl optionally substituted with amino, C alkylamino or di(C _1.4 alkyl) amino, pyridinyl, pyrrodidinyl, piperidinyl, 2-thienyl, furanyl, imidazolyl, indenyl, benzofuran, C _3.6 cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, CM alkyl, C alkoxy, trifluoromethyl, and trifiuoromethoxy; A is -CH=CH-, 1,1 -cyclopropyl, or-(CH ₂ ) _n -; R ² is C _M alkyl, CF ₃ or hydroxymethyl; R ³ , R ⁴ , R ⁵ and R ⁶ each are independently hydrogen or fluoro; n is an integer of 0 to 4, inclusive; Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl and triazolyl optionally substituted with substituents independently selected from the group consisting of C _M alkyl, halogen, amino and dimethylaminomethyl; provided that when Het is pyridinyl, pyrimidinyl or pyrazinyl, then A is not -CH=CH-. Formula 166 [0843] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 166. Such compounds are described in US Patent No.7,135,472, issued November 14, 2006, and corresponding to US Application No.10/719,187 filed November 21, 2003; International Publication No. WO2004047744A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037349 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 166, these references incorporated by reference herein control. [0844] In an embodiment, the Kv7 channel activator is a compound according to Formula 166: wherein, R ¹ is selected from the group consisting of straight or branched chain C _1-6 alkyl optionally substituted with amino, C _1-4 alkylamino or di(C _1-4 alkyl) amino, pyridinyl, pyrrodidinyl, piperidinyl, 2-thienyl, furanyl, imidazolyl, indenyl, benzofuran, C _3-6 cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl, and trifluoromethoxy; A is —CH═CH—, 1,1-cyclopropyl, or —(CH ₂ ) _n —; R ² is methyl or hydroxymethyl; R ³ , R ⁴ , R ⁵ and R ⁶ each are independently hydrogen or fluoro; n is an integer of 0 to 4, inclusive; Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl and triazolyl optionally substituted with substituents independently selected from the group consisting of C _1-4 alkyl, halogen, amino and dimethylaminomethyl; provided that when Het is pyridinyl, pyrimidinyl or pyrazinyl, then A is not —CH═CH—. [0845] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: (S)-3-(2-fluoro-phenyl)-N-[1-(3-[1,2,4]triazol-1-yl-phenyl)- ethyl]-acrylamide; (S)-3-(2-fluoro-phenyl)-N-[1-(3-thiazol-2-yl-phenyl)-ethyl]- acrylamide; (S)-3-(2-fluoro- phenyl)-N-[1-(3-pyrazol-1-yl-phenyl)-ethyl]-acrylamide; (S)-3-(2-fluoro-phenyl)-N-[1-(3- imidazol-1-yl-phenyl)-ethyl]-acrylamide; (S)-4-phenyl-N-[1-(3-pyridin-3-yl-phenyl)-ethyl]- butyramide; (S)-N-[1-(3-pyridin-3-yl-phenyl)-ethyl]-benzamide; (S)-1H-imidazole-4- carboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide; (S)-N-[1-(3-imidazol-1-yl-phenyl)- ethyl]-3-phenyl-acrylamide; (S)-N-[1-(3-oxazol-5-yl-phenyl)-ethyl]-3-phenyl-acrylamide; (S)-3-phenyl-N-[1-(3-thiazol-2-yl-phenyl)-ethyl]-acrylamide; (S)-3-phenyl-N-[1-(3- pyrazol-1-yl-phenyl)-ethyl]-acrylamide; and (S)-benzofuran-2-carboxylic acid {1-[3-(6- fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide; or a pharmaceutically acceptable salt thereof. Formula 167 [0846] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 167. Such compounds are described in International Publication No. WO2002096858A1, published December 5, 2002, and corresponding to International Application No. PCT/US2002/017049 filed May 31, 2002; US Patent No.6,831,080, issued December 14, 2004, and corresponding to US Application No.10/160,582 filed May 31, 2002; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 167, these references incorporated by reference herein control. [0847] In an embodiment, the Kv7 channel activator is a compound according to Formula 167: , wherein, R is C _1-4 alkyl or trifluoromethyl; R ¹ is selected from the group consisting of pyridinyl, quinolinyl, thienyl, furanyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, chromanyl, indanyl, biphenylyl, phenyl and substituted phenyl, in which said substituted phenyl is substituted with substituent independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R ² and R ³ are each independently selected from the group consisting of hydrogen, C _1-4 alkyl and halogen; R ⁴ is selected from the group consisting of di(C _1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C _1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R ⁵ is hydrogen, chloro or fluoro; or R ⁴ and R ⁵ taken together are —CH═CH— CH═CH— or —X(CH ₂ ) _m Y— in which X and Y are each independently selected from the group consisting of CH ₂ , (CH ₂ ) _n N(R ⁹ )— and O, wherein m is 1 or 2; n is 0 or 1; R ⁶ , R ⁷ , and R ⁸ are each independently selected from hydrogen, chloro and fluoro; and R ⁹ is selected from the group consisting of hydrogen, C _1-4 alkyl, hydroxyethyl, C _{1- 4} alkoxyethyl, cyclopropylmethyl, —CO ₂ (C _1-4 alkyl), and —CH ₂ CH ₂ NR ¹⁰ R ¹¹ in which R ¹⁰ and R ¹¹ are each independently hydrogen or C _1-4 alkyl. Formula 168 [0848] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 168. Such compounds are described in International Publication No. WO2002096858A1, published December 5, 2002, and corresponding to International Application No. PCT/US2002/017049 filed May 31, 2002; US Patent No.6,831,080 issued December 14, 2004, and corresponding to US Application No.10/160,582 filed May 31, 2002; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 168, these references incorporated by reference herein control. [0849] In an embodiment, the Kv7 channel activator is a compound according to Formula 168: , wherein, R ¹ is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, benzodioxanyl, 1,3-benzodioxol-5-yl, chroman-5-yl, indan-5-yl, 4-biphenylyl, phenyl and substituted phenyl, in which said substituted phenyl is substituted with substituent independently selected from the group consisting of halogen, C _1-4 alkyl, C -4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R ⁴ is selected from the group consisting of optionally substituted di(C _1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C _1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R ⁵ is hydrogen or fluoro; or R ⁴ and R ⁵ taken together are —CH═CH—CH═CH— or —X(CH ₂ ) _m Y—, in which X and Y are each independently selected from the group consisting of CH ₂ , (CH ₂ ) _n N(R ⁹ )— and O, wherein m is 1 or 2; n is 0 or 1; R ⁶ , R ⁷ , and R ⁸ are each independently selected from hydrogen, chloro and fluoro; and R ⁹ is selected from the group consisting of hydrogen, C _1-4 alkyl, hydroxyethyl, C _1-4 alkoxyethyl, cyclopropylmethyl, —CO ₂ (C _1-4 alkyl), and —CH ₂ CH ₂ NR ¹⁰ R ¹¹ in which R ¹⁰ and R ¹¹ are each independently hydrogen or C _1-4 alkyl. [0850] In further embodiments, R ¹ is substituted phenyl or 1,3-benzodioxol-5-yl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C1-4 alkyl, and C1-4 alkoxy; and R ⁴ and R ⁵ taken together are —X(CH ₂ ) _m Y— in which X and Y are each O, and m is 1. [0851] In further embodiments, R ¹ is selected from the group consisting of substituted phenyl, 1,3-benzodioxol-5-yl, and indan-5-yl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethoxy and trifluoromethyl; and R ⁴ and R ⁵ taken together are —X(CH ₂ ) _m Y— in which X is CH ₂ , Y is O, and m is 1. [0852] In further embodiments, R ¹ is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethoxy, trifluoromethyl and nitro; R ⁴ is optionally substituted morpholin-4-yl with one or two substituents each independently selected from the group consisting of C _1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; and R ⁵ is hydrogen or fluoro. [0853] In further embodiments, R ¹ is phenyl, fluorophenyl or difluorophenyl. [0854] In further embodiments, R ¹ is substituted phenyl or 1,3-benzodioxol-5-yl in which said substituted phenyl is substituted with one or two substituents each independently selected from halogen or C _1-4 alkyl; and R ⁴ and R ⁵ taken together are —X(CH ₂ ) _m Y— in which X and Y are O, and m is 2. [0855] In further embodiments, R ¹ is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from halogen or C _1-4 alkyl; R ⁴ and R ⁵ taken together are —X(CH ₂ ) _m Y— in which X is (CH ₂ ) _n N(R ⁹ )—; Y is CH ₂ , and m and n are 1; and R ⁹ is CO ₂ (C _1-4 alkyl). [0856] In further embodiments, R ¹ is substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from halogen; R ⁴ and R ⁵ taken together are —X(CH ₂ ) _m Y— in which X is (CH ₂ ) _n N(R ⁹ )— and Y is O wherein m is 2 and n is 0; and R ⁹ is hydrogen, cyclopropylmethyl or C _1-4 alkyl. [0857] In further embodiments, R ¹ is 3-quinolinyl or pyridinyl; R ⁴ is trifluoromethoxy; and R ⁵ is hydrogen. [0858] In further embodiments, R ¹ is substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen or C _1-4 alkyl; R ⁴ and R ⁵ taken together are —X(CH ₂ ) _m Y—, in which X is CH ₂ and Y is (CH ₂ ) _n N(R ⁹ )— wherein m is 1 and n is 0; and R ⁹ is CO2(C1-4alkyl). [0859] In further embodiments, R ¹ is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R ⁴ and R ⁵ taken together are —X(CH ₂ ) _m Y—, in which X is (CH ₂ ) _n N(R ⁹ )— and Y is CH ₂ wherein m is 2 and n is 0; and R ⁹ is hydrogen, C _1-4 alkyl, acetyl, hydroxyethyl or methoxyethyl. [0860] In further embodiments, R ¹ is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R ⁴ and R ⁵ taken together are —X(CH ₂ ) _n Y—, in which X is CH ₂ and Y is (CH ₂ ) _n N(R ⁹ )— wherein m is 2 and n is 0; and R ⁹ is hydrogen, C _1-4 alkyl, acetyl, hydroxyethyl or methoxyethyl. [0861] In further embodiments, R ¹ is pyridinyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R ⁴ is optionally substituted pyridinyl with one or two substituents each independently selected from C _1-4 alkyl and halogen; and R ⁵ is hydrogen or fluoro. [0862] In further embodiments, R ¹ is 1,3-benzodioxol-5-yl; R ⁴ is di(C _1-4 alkyl)amino; and R ⁵ is hydrogen or fluoro. [0863] In further embodiments, R ¹ is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R ⁴ is pyrimidinyl; and R ⁵ is hydrogen or fluoro. [0864] In further embodiments, R ¹ is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R ⁴ is pyrazinyl; and R ⁵ is hydrogen or fluoro. [0865] In further embodiments, R ¹ is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from C _1-4 alkyl and halogen; R ⁴ is piperazinyl or 4-methylpiperazinyl; and R ⁵ is hydrogen or fluoro. [0866] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: 2-Methyl-3-phenyl-but-2-enoic acid (1-naphthalen-2-ylethyl)-amide; N-(1- Benzo[1,3]dioxol-5-yl-ethyl)-3-(3-methoxy-phenyl)-acrylamide ; N-[1-(2,3- Dihydrobenzofuran-5-yl)ethyl]-3-(3-methoxyphenyl)-acrylamide ; (S)-3-Phenyl-N-[1-(3- morpholin-4-yl-phenyl)ethyl]acrylamide; 3-(3-Fluorophenyl)-N-[1-(2,3- dihydrobenzo[1,4]dioxin-6-yl)-ethyl]acrylamide; (±)-7-{1-[3-(4- Fluorophenyl)acryloylamino]ethyl}-3,4-dihydro-1H-isoquinolin e-2-carboxylic acid methyl ester; 3-(2-Fluorophenyl)-N-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]o xazin-6-yl)ethyl]- acrylamide; (S)-N-(1-Naphthalen-2-yl-ethyl)-3-phenyl-acrylamide; (S)-3-(4-Fluoro- phenyl)-N-(1-naphthalen-2-yl-ethyl)-acrylamide; (±)-N-(1-Benzo[1,3]dioxol-5-yl-ethyl)-3- (2,4-difluoro-phenyl)-acrylamide; (±)-N-[1-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-3-(2- fluoro-phenyl)-acrylamide; (±)-3-(2,4-Difluoro-phenyl)-N-[1-(2,3-dihydro-benzofuran-5- yl)-ethyl]-acrylamide; (S)-3-(2,4-Difluoro-phenyl)-N-[1-(3-morpholin-4-yl-phenyl)-e thyl]- acrylamide; (S)-N-[1-(3-(2,6-Dimethyl-morpholin)-4-yl-phenyl)-ethyl]-3-p henyl- acrylamide; (S)-3-(2-Fluoro-phenyl)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl ]-acrylamide; (S)-N-[1-(3-Morpholin-4-yl-phenyl)-ethyl]-3-thiophen-3-yl-ac rylamide; (S)-3-(4-Fluoro- phenyl)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (S)-N-{1-[3-(cis-2,6-Dimethyl- morpholin-4-yl)-phenyl]-ethyl}-3-(4-fluoro-phenyl)-acrylamid e; (S)-3-(2,4-Difluoro- phenyl)-N-{1-[3-(cis-2,6-dimethyl-morpholin-4-yl)-phenyl]-et hyl}-acrylamide; (S)-3-(3,4- Difluoro-phenyl)-N-{1-[3-(cis-2,6-dimethyl-morpholin-4-yl)-p henyl]-ethyl}-acrylamide; (S)- 3-(2,5-Difluoro-phenyl)-N-{1-[3-(cis-2,6-dimethyl-morpholin- 4-yl)-phenyl]-ethyl}- acrylamide; (S)-3-(2-Fluoro-phenyl)-N-{1-[3-(2-methyl-morpholin-4-yl)-ph enyl]-ethyl}- acrylamide; (S)-3-(3-Fluoro-phenyl)-N-{1-[3-(2-methyl-morpholin-4-yl)-ph enyl]-ethyl}- acrylamide; (S)-3-(4-Fluoro-phenyl)-N-{1-[3-(2-methyl-morpholin-4-yl)-ph enyl]-ethyl}- acrylamide; (S)-3-(2,4-Difluoro-phenyl)-N-{1-[3-(2-methyl-morpholin-4-yl )-phenyl]-ethyl}- acrylamide; (S)-N-{1-[3-(2-Oxa-5-aza-bicyclo[2.2.1]hept-5-yl)phenyl]ethy l}-3-phenyl- acrylamide; (S)-N-{1-[3-(2-Hydroxymethyl-morpholin-4-yl)-phenyl]-ethyl}- 3-phenyl- acrylamide; (±)-N-[1-(3-Morpholin-4-yl-phenyl)-propyl]-3-phenyl-acrylam ide; (±)-3-(2,4- Difluoro-phenyl)-N-[1-(3-morpholin-4-yl-phenyl)-propyl]-acry lamide; (±)-3-(2-Fluoro- phenyl)-N-[1-(3-morpholin-4-yl-phenyl)-propyl]-acrylamide; (±)-3-(3-Fluoro-phenyl)-N-[1- (3-morpholin-4-yl-phenyl)-propyl]-acrylamide; (±)-N-[1-(4-Fluoro-3-morpholin-4-yl- phenyl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide; (±)-N-[1-(4-Fluoro-3-morpholin-4-yl- phenyl)-ethyl]-3-(4-fluoro-phenyl)-acrylamide; (±)-3-(2,4-Difluoro-phenyl)-N-[1-(4-fluoro- 3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (±)-N-[1-(4-Fluoro-3-morpholin-4-yl-phenyl)- ethyl]-3-(4-fluoro-phenyl)-acrylamide; (±)-3-(3,4-Difluoro-phenyl)-N-[1-(4-fluoro-3- morpholin-4-yl-phenyl)-ethyl]-acrylamide; (±)-3-(2,5-Difluoro-phenyl)-N-[1-(4-fluoro-3- morpholin-4-yl-phenyl)-ethyl]-acrylamide; (±)-N-[1-(4-Fluoro-3-morpholin-4-yl-phenyl)- ethyl]-3-(3-fluoro-phenyl)-acrylamide; (±)-N-[1-(4-Fluoro-3-morpholin-4-yl-phenyl)-ethyl]- 3-(2-fluoro-phenyl)-acrylamide; (±)-3-(3-Fluoro-phenyl)-N-[1-(1,2,3,4-tetrahydro-quinolin- 7-yl)-ethyl]-acrylamide; (±)-3-(4-Fluoro-phenyl)-N-[1-(1,2,3,4-tetrahydro-quinolin-7 - yl)ethyl]-acrylamide; (±)-3-(2-Fluoro-phenyl)-N-[1-(1-methyl-1,2,3,4-tetrahydro-q uinolin- 7-yl)ethyl]acrylamide; (±)-N-{1-[1-(2-Hydroxy-ethyl)-1,2,3,4-tetrahydro-quinolin-7 -yl]- ethyl}-3-phenyl-acrylamide; (±)-3-(2,5-Difluoro-phenyl)-N-{1-[1-(2-hydroxy-ethyl)-1,2,3 ,4- tetrahydro-quinolin-7-yl]-ethyl}-acrylamide; (±)-3-(3,5-Difluoro-phenyl)-N-{1-[1-(2- hydroxy-ethyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-ethyl}-acry lamide; (S)-3-Phenyl-N-[1-(3- pyridyl-phenyl)-ethyl]acrylamide; (S)-(2,4-Difluoro-phenyl)-N-[1-(3-pyridin-3-yl-phenyl)- ethyl]-acrylamide; (S)-3-Phenyl-N-[1-(3-pyridin-4-yl-phenyl)-ethyl]-acrylamide; (S)-N-{1- [3-(6-Chloro-pyridin-3-yl)-phenyl]-ethyl}-3-(2-fluoro-phenyl )-acrylamide; (S)-3-Phenyl-N- [1-(3-pyrimidin-5-yl-phenyl)-ethyl]-acrylamide; (S)-3-Phenyl-N-[1-(3-pyridin-2-yl-phenyl)- ethyl]-acrylamide; (S)-3-(2-Fluoro-phenyl)-N-[1-(3-pyridin-2-yl-phenyl)-ethyl]- acrylamide; (S)-3-(2-Fluoro-phenyl)-N-{1-[3-(6-fluoro-pyridin-3-yl)-phen yl]ethyl}-acrylamide; (S)-3-(4- Fluoro-phenyl)-N-{1-[3-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl }-acrylamide; (S)-N-{1-[3-(6- Fluoro-pyridin-3-yl)-phenyl]-ethyl}-3-pyridin-3-yl-acrylamid e; (S)-N-{1-[3-(6-Fluoro- pyridin-3-yl)-phenyl]-ethyl}-3-pyridin-4-yl-acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)- phenyl]-ethyl}-3-(3-fluoro-phenyl)-acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)- phenyl]-ethyl}-3-pyridin-3-yl-acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)-phenyl]- ethyl}-3-pyridin-2-yl-acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)-phenyl]-ethyl}-3- pyridin-4-yl-acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)-phenyl]-ethyl}-3-(2-fluo ro- phenyl)-acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)-phenyl]-ethyl}-3-(2,4-di fluoro- phenyl)-acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)-phenyl]-ethyl}-3-(4-fluo ro- phenyl)-acrylamide; (S)-3-(2-Fluoro-phenyl)-N-[1-(3-pyridin-3-yl- phenyl)ethyl]acrylamide; (S)-N-{1-[3-(6-Fluoro-pyridin-3-yl)-phenyl]-ethyl}-3-phenyl- acrylamide; (S)-N-{1-[3-(6-Chloro-pyridin-3-yl)-phenyl]-ethyl}-3-phenyl- acrylamide; (S)- 3-(2-Fluoro-phenyl)-N-[1-(3-pyridin-4-yl-phenyl)ethyl]acryla mide; (S)-3-(2-Fluoro- phenyl)-N-[1-(3-pyrazin-2-yl-phenyl)ethyl]acrylamide; (S)-3-(2-Fluoro-phenyl)-N-[1-(3- pyrimidin-5-yl-phenyl)ethyl]acrylamide; (S)-3-(2-Fluoro-phenyl)-N-{1-[3-(4-methyl- pyridin-3-yl)phenyl]ethyl}acrylamide; (S)-3-(4-Fluorophenyl)-N-{1-[3-(4-methylpiperazin- 1-yl)phenyl]ethyl}acrylamide; and (S)-3-(2,3-Difluoro-phenyl)-N-{1-[3-(4-methyl- piperazin-1-yl)-phenyl]-ethyl}-acrylamide; or a pharmaceutically acceptable salt thereof. Formula 169 [0867] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 169. Such compounds are described in International Publication No. WO2002096858A1, published December 5, 2002, and corresponding to International Application No. PCT/US2002/017049 filed May 31, 2002; US Patent No.6,831,080, issued December 14, 2004, and corresponding to US Application No.10/160,582 filed May 31, 2002; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 169, these references incorporated by reference herein control. [0868] In an embodiment, the Kv7 channel activator is a compound according to Formula 169: wherein, R ¹ is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, benzodioxanyl, 1,3-benzodioxol-5-yl, chroman-5-yl, indan-5-yl, 4-biphenylyl, phenyl and substituted phenyl, in which said substituted phenyl is substituted with substituent independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R ⁴ is selected from the group consisting of optionally substituted di(C _1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C _1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R ⁵ is hydrogen or fluoro; or R ⁴ and R ⁵ taken together are —CH═CH—CH═CH— or —X(CH ₂ ) _m Y—, in which X and Y are each independently selected from the group consisting of CH ₂ , (CH ₂ ) _n N(R ⁹ )— and O, wherein m is 1 or 2; n is 0 or 1; R ⁶ , R ⁷ , and R ⁸ are each independently selected from hydrogen, chloro and fluoro; and R ⁹ is selected from the group consisting of hydrogen, C ₄ alkyl, hydroxyethyl, C _1-4 alkoxyethyl, cyclopropylmethyl, —CO ₂ (C _1-4 alkyl), and —CH ₂ CH ₂ NR ¹⁰ R ¹¹ in which R ¹⁰ and R ¹¹ are each independently hydrogen or C _1-4 alkyl. [0869] In further embodiments, R ¹ is selected from the group consisting of 2-thienyl, chroman-5-yl, 4-biphenylyl, phenyl and substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethoxy and nitro; and R ⁴ and R ⁵ taken together are —CH═CH—CH═CH—. [0870] In further embodiments, R ¹ is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C _1-4 alkyl, C _1-4 alkoxy, trifluoromethoxy, trifluoromethyl and nitro; R ⁴ is optionally substituted morpholin-4-yl with one or two substituents each independently selected from the group consisting of C _1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; and R ⁵ is hydrogen or fluoro. [0871] In further embodiments, R ¹ is phenyl, fluorophenyl or difluorophenyl. [0872] In further embodiments, R ¹ is pyridinyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R ⁴ is optionally substituted pyridinyl with one or two substituents each independently selected from C _1-4 alkyl and halogen; and R ⁵ is hydrogen or fluoro. [0873] In further embodiments, R ¹ is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from C _1-4 alkyl and halogen; R ⁴ is piperazinyl or 4-methylpiperazinyl; and R ⁵ is hydrogen or fluoro. Formula 170 [0874] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 170. Such compounds are described in US Patent No.6,326,385, issued December 4, 2001, and corresponding to US Application No.09/361,747 filed August 4, 2000; International Publication No. WO2001010381A2, published February 15, 2001, and corresponding to International Application No. PCT/US2000/021309 filed August 4, 2000; US Patent No.6,326,385 issued December 4, 2001, and Patent Cooperation Treaty application No. US2000/021309 published February 15, 2001, which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 170, these references incorporated by reference herein control. [0875] In an embodiment, the Kv7 channel activator is a compound according to Formula 170: wherein, Ar ¹ and Ar ² are each members independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl; and X is a member selected from the group consisting of O, S and N—R ¹ , wherein R ¹ is a member selected from the group consisting of H, (C ₁ -C ₈ )alkyl, substituted (C ₁ -C ₈ )alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C ₁ -C ₄ )alkyl, substituted aryl(C ₁ - C ₄ )alkyl, CN, —C(O)R ² , —OR ³ , —C(O)NR ³ R ⁴ , and —S(O) ₂ NR ³ R ⁴ ; wherein R ² is a member selected from the group consisting of (C ₁ -C ₈ )alkyl, substituted (C ₁ -C ₈ )alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C ₁ -C ₄ )alkyl and substituted aryl(C ₁ -C ₄ )alkyl; and R ³ and R ⁴ are each members independently selected from the group consisting of hydrogen, (C ₁ -C ₈ )alkyl, substituted (C ₁ -C ₈ )alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C ₁ -C ₄ )alkyl and substituted aryl(C ₁ -C ₄ )alkyl, or R ³ and R ⁴ can be combined with the nitrogen to which each is attached to form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices. [0876] In further embodiments, Ar ¹ is a member selected from the group consisting of phenyl, substituted phenyl, indolyl, substituted indolyl, benzofuranyl, substituted benzofuranyl, furanyl, substituted furanyl, thienyl, substituted thienyl, isothiazolyl, substituted isothiazolyl, pyrazolyl and substituted pyrazolyl. [0877] In further embodiments, Ar ¹ is substituted phenyl, substituted or unsubstituted 2- indolyl and substituted or unsubstituted 2-thienyl. [0878] In further embodiments, X is O. [0879] In further embodiments, the Ar ¹ substituents are selected from the group consisting of halogen, alkyl, halo(C ₁ -C ₄ )alkyl, (C ₁ -C ₄ )alkoxy, halo(C ₁ -C ₄ )alkoxy, nitro, cyano, —NHC(O)R ⁷ , —NHR ⁷ , phenyl and substituted phenyl, wherein R ⁷ is a member selected from hydrogen, (C ₁ -C ₈ )alkyl, substituted (C ₁ -C ₈ )alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted hcterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C ₁ -C ₄ )alkyl and substituted aryl(C ₁ -C ₄ )alkyl, or R ⁷ can be combined with the nitrogen to which it is attached to form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices. [0880] In further embodiments, Ar ² is selected from the group consisting of heteroaryl and substituted heteroaryl. [0881] In further embodiments, Ar ¹ is substituted aryl; Ar ² is heteroaryl or substituted heteroaryl; and X is O. [0882] In further embodiments, Ar ² is pyridyl or substituted pyridyl. [0883] In further embodiments, Ar ² is selected from the group consisting of 6-methyl-3- pyridyl and 2-chloro-5-pyridyl. [0884] In further embodiments, Ar ¹ is substituted phenyl. [0885] In further embodiments, the compound is according to the formula: [0886] wherein, Y is a member selected from the group consisting of halogen, C1- C ₄ alkyl, C ₁ -C ₄ substituted alkyl, —OCH ₃ and —OCF ₃ , and R ⁵ and R ⁶ are members independently selected from the group consisting of H, halogen, alkyl, halo(C ₁ -C ₄ )alkyl, nitro, cyano and phenyl, with the proviso that both R ⁵ and R ⁶ are not H. [0887] In further embodiments, R ⁵ and R ⁶ are members independently selected from the group consisting of H, F, and Cl, with the optional proviso that both R ⁵ and R ⁶ are not H. Further embodiments (Collectively referred to as “Formula 171” for ease of reference in the appended claims. “Formula 171”, as recited in the claims, captures any of the below compounds preceding the TDP-43 Modulators section.) [0888] In another embodiment, the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in International Publication No. WO2021055538A1, published March 25, 2021, and corresponding to International Application No. PCT/US2020/051171 filed September 17, 2020; International Publication No. WO2017075222A1, published May 4, 2017, and corresponding to International Application No. PCT/US2016/059128 filed October 27, 2016; International Publication No. WO2021211867A1, published October 21, 2021, and corresponding to International Application No. PCT/US2021/027518 filed April 15, 2021; International Publication No. WO2020092577A1, published May 7, 2020, and corresponding to International Application No. PCT/US2019/058878 filed October 30, 2019; International Publication No. WO2021119018A1, published June 17, 2021, and corresponding to International Application No. PCT/US2020/063,822 filed December 8, 2020; International Publication No. WO2011085351A2, published July 14, 2011, and corresponding to International Application No. PCT/US2011/020784 filed January 11, 2011; US Publication No. US20100286138A1, published November 11, 2010, and corresponding to US Application No.12/777,935 filed May 11, 2010; US Publication No. US20210262029A1, published August 26, 2021, and corresponding to US Application No.17/245734 filed April 30, 2021; US Patent No.11,221,329, issued on January 11, 2022, and corresponding to US Application No.15/771,857 filed October 27, 2016; which are incorporated by reference in their entirety herein. [0889] In further embodiments, the compound is selected from the group consisting of N-(l-cyclobutyl-4-fluoro-6-(l- hydroxycyclobutyl)-lH-benzo[d]imidazol-2-yl)-4,4,4-trifluoro - 3,3- dimethylbutanamide; N-(l -(tert-butyl)-6-(difluoromethoxy)- 1H- benzo[d]imidazol-2- yl)-3,3-dimethylbutanamide; N-(6-cyano-l-(l,l,l- trifluoro-2-methylpropan-2-yl)-lH- benzo[d]imidazol-2-yl)-3,3- dimethylbutanamide; N-(l -cyclobutyl -4-fluoro-6-(2- hydroxypropan-2-yl)- 1H- benzo[d]imidazol-2-yl)-2-(l -methyl cyclopropyljacetamide; N- (6-cyano-l- cyclobutyl-4-fluoro-lH-benzo[d]imidazol-2-yl)-3,3-dimethylbu tanamide; N- (l- cyclobutyl-6-fluoro-lH-benzo[d]imidazol-2-yl)-3,3-dimethylbu tanamide; N-(l-(tert-butyl)-6- cyano-4-fluoro-lH-benzo[d]imidazol-2-yl)-3,3- dimethylbutanamide; N-(7-cyano-l-(l- methylcyclobutyl)-lH- benzo[d]imidazol -2 -yl)-3 -cyclopropyl-3 -methylbutanamide; N-(6- chloro-7- cyano-l-cyclobutyl-lH-benzo[d]imidazol-2-yl)-3,3-dimethylbut anamide; N- (l- cyclobutyl-5-fluoro-lH-benzo[d]imidazol-2-yl)-3,3-dimethylbu tanamide; N-(l-(tert-butyl)-6- cyano-4,7-difluoro-lH-benzo[d]imidazol-2-yl)-3,3- dimethylbutanamide; N-(6-cyano- 1 - cyclobutyl-7-(trifluoromethyl)-lH- benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide; N-(6- cyano-4,7-difluoro-l- (l-methylcyclobutyl)-lH-benzo[d]imidazol-2-yl)-3,3- dimethylbutanamide; N- (l-(tert-butyl)-5,7-difluoro-lH-benzo[d]imidazol-2-yl)-4,4,4 - trifluoro-3,3- dimethylbutanamide; and N-(l-(tert-butyl)-5,6-difluoro-lH-benzo[d]imidazol- 2-yl)-2-(2,2,3,3-tetrafluorocyclobutyl)acetamide. [0890] In another embodiment, the Kv7 channel activator is selected from the group consisting of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyra mide in a crystalline form with XRPD reflections at 10.36, 12.67, 28.64 and 29.98 (°2θ) using CuK _α1 radiation.; N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyra mide in a crystalline form with XRPD reflections at 8.68, 18.09, 22.60 and 30.62 (°2θ) using CuK _α1 radiation.; N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyra mide in a crystalline form with XRPD reflections at 8.63, 22.26, 23.40 and 30.49 (°2θ) using CuK _α1 radiation. [0891] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: Chromanol 293B, MIR-1556, UCL2077, JNJ303, L-735821 (L-7), fenofibrate; and a salt or hydrate thereof. [0892] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: a Triaminopyridine or one of its derivatives, an Acrylamide, a Benzamide, a Fenamate, a Dimethoxypyrimidine or one of its derivatives, Oxindole, Celecoxib, zinc pyrithione, ML213, QO58, QO58 lysine, NS1643, Benzbromarone, ZG1732 and ZG2083. [0893] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: NS15370, P-Retigabine, SF0034 or RL648_81 or any combination thereof. [0894] In further embodiments, the Kv7 channel activator is selected from the group consisting of: linopirdine, (1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-indol-2- one) XE991 (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE991)), DMP-543 (10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone (DMP-543)), ML252 ((S)-2- phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252)) and UCL2077. [0895] In further embodiments, the Kv7 channel activator is an analog of flupirtine. [0896] In further embodiments, the Kv7 channel activator is selected from the group consisting of: N-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-3-carboxamide ; N- (2,6- dimethylphenyl)bicyclo[2.2.1]heptane-3-carboxamide; N-(2,5- dimethylphenyl)bicyclo[2.2.1]heptane-3-carboxamide; N-(2-chloro-4,6- dimethylphenyl)pentanamide; N-(2-chloro-4,6-dimethylphenyl)-3,3-dimethylbutanamide; 2-(l -adamantyl)-N-(2,6-difluorophenyl)acetamide; N-(2-bromo-4-methylphenyl)-2- cyclopentylacetamide; N-(2,3-dimethylphenyl)-2-phenylcyclopropane-l-carboxamide; N- (4-methylphenyl)-2-phenylcyclopropane-l -carboxamide; N-(2,4- dimethoxyphenyl)bicyclo[2.2.1]heptane-3-carboxamide; 7-ethyl-l,3-dimethyl-5-(2-oxo-2- piperidin-1 -ylethyl)sulfanylpyrimido[4,5-d]pyrimidine-2,4-dione; 1 ,3-dimethyl-7-(2- methylpropyl)-5-(2-oxo-2-piperidin-l -ylethyl)sulfanylpyrimido[4,5-d]pyrimidine-2,4- dione; l,3-dimethyl-5-[2-(4-methylpiperidin-l-yl)-2-oxoethyl]sulfan yl-7- propylpyrimido[4,5-d]pyrimidine-2,4-dione; 7-ethyl-l ,3-dimethyl-5-[2-(4- methylpiperidin- l-yl)-2-oxoethyl]sulfanylpyriinido[4,5-d]pyrimidine-2,4-dion e; 2-(4- chloro-2-methyl-5- pyrrolidin-l -ylsulfonylphenoxy)-N-cyclohexylacetamide; 2-(4-chloro- 2-methyl-5-thiomo holin-4-ylsulfonylphenoxy)-N-cyclohexylacetamide; 1-[1-(1,3- benzodioxol-5-yl)ethyl]-3- cyclohexylurea; l-(l -adamantyl)-3-[l-(l,3-benzodioxol-5- yl)ethyl]urea; 3-(5-bromo-2- hydroxyphenyl)-N-(furan-2-ylmethyl)-3-phenylpropanamide; ethyl 2-benzamido-2-(2,6- dimethylpyran-4-ylidene)acetate; (2,4-dichlorophenyl)methyl 1- benzamido-5- oxopyrrolidine-3-carboxylate; N-[2-cyano-5-(cyanomethylsulfanyl)-4- phenylthiophen-3- yl]-2-phenylacetamide; N-(6-bromo-l,3-diethyl-2-oxobenzimidazol-5- yl)-2- phenylpropanamide; N-(2,5-diethoxy-4-mo holin-4-ylphenyl)-2-phenylacetamide _; N-[4- [(5-methylthiophen-2-yl)methylamino]phenyl]butanamide; N-[(2-methylsulfanyl-6- propan-2-ylpyridin-3-yl)methyl]-3-phenylbutanamide; 4-bromo-N-(thiophen-2- ylmethylideneamino)-lH-pyrazole-5-carboxamide; S-[2-[(6-fiuoro-3-prop-2-ynyl-l ,3- benzothiazol-2-ylidene)amino]-2-oxoethyl] ethanethioate; 1 -cyclohexyl-3-[l -(3,4- dimethylphenyl)ethyl]thiourea; N-[4-methyl-l -oxo-l-(l -phenylethylamino)pentan-2- yljcyclohexanecarboxamide; 5-chloro-2-[(3-methylphenyl)methylsulfonyl]-N-(5-propyl-I , 3,4-thiadiazol-2-yl)pyrimidine-4-carboxamide; 2-benzylsulfonyl-5-chloro-N-(5-propan- 2- yl-l ,3,4-thiadiazol-2-yl)pyrimidine-4-carboxamide; and 4-bromo-N-(furan-2- ylmethylideneamino)-lH-pyrazole-5-carboxamide. [0897] In further embodiments, the metal channel activator is QRA-244 as described in Dan Elbaum et al. “TST-20: QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients”; 31 ^st International symposium on ALS/MND; Live Poster Session C, December 11, 2020. TDP-43 MODULATORS [0899] Amyotrophic lateral sclerosis (ALS) is a neurological disorder in which the upper and lower motor neurons progressively degenerate (Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat Commun.2020 Feb 21;11(1):1004. doi: 10.1038/s41467-020-14815-x. PMID: 32081878; PMCID: PMC7035286.). The degradation of motor neurons leads to muscular atrophy and eventually paralysis. In many individuals afflicted with ALS, Trans-activation response element (TAR) DNA- binding protein 43 (TDP-43), a heterogeneous nuclear ribonucleoprotein, is incorrectly localized to the cytoplasm. In the cytoplasm is forms aggregates associated with degenerating motor neurons. TDP-43 aggregates are present in nearly all cases of sporadic ALS. Moreover, a proportion of familial ALS is associated with mutations in the TARDBP gene encoding TDP-43. Modulation of TDP-43 in combination with the metal channel activator may therefore provide a promising approach to treat neurodegenerative disease, such as ALS. [0900] Examples of TDP-43 modulators are disclosed in Formulas 200 – 220, and in the corresponding references applications. Such TDP-43 modulators are advantageously useful in combination therapies with Kv7 modulators as described herein. Formula 200 [0901] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 200. Such compounds are described in International Publication No. WO2021035101A1, published February 25, 2021, and corresponding to International Application No. PCT/US2020/047287 filed August 21, 2020; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 200, these references incorporated by reference herein control. [0902] In an embodiment, the TDP-43 modulator is a compound according to Formula 200:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein: X ¹ is selected from the group consisting of nitrogen and CH; R ^1a is selected from the group consisting of hydrogen, halogen, C _1-20 linear alkyl, C _3-20 branched alkyl, C _1-20 linear heteroalkyl, C _3-20 branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted; R ^1b is selected from the group consisting of hydrogen, halogen, C _1-20 linear alkyl, C _3-20 branched alkyl, C _1-20 linear heteroalkyl, C _3-20 branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted; R ^1c is selected from the group consisting of hydrogen, halogen, C1-20 linear alkyl, C3-20 branched alkyl, C _1-20 linear heteroalkyl, C _3-20 branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted; and R ^1d is selected from the group consisting of hydrogen, halogen, C _1-20 linear alkyl, C _3-20 branched alkyl, C _1-20 linear heteroalkyl, C _3-20 branched heteroalkyl, each of which except hydrogen and halogen are optionally substituted; R ² is a substituted or unsubstituted C ₁ -C ₂₀ linear, branched, or cyclic organic group including at least one nitrogen; and R ⁴ is a hydrogen, halogen, a hydroxyl group, a cyano group, a nitro group, a substituted or unsubstituted C ₀ -C ₁₀ amino group, a substituted or unsubstituted C ₁ -C ₁₀ alkyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkynyl group, and a substituted or unsubstituted C ₁ -C ₁₀ alkoxy group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkyl group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkenyl group, a substituted or unsubstituted C ₆ -C ₂₀ aryl group, a substituted or unsubstituted C ₆ -C ₂₀ aryloxy group, a substituted or unsubstituted C ₆ -C ₂₀ arylthio group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryl group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryloxy group, or a substituted or unsubstituted C ₂ -C ₂₀ heteroarylthio group. [0903] In further embodiments, X ¹ is selected from the group consisting of nitrogen and CH; R ^la is selected from the group consisting of hydrogen, halogen, CF ₃ , OCF ₃ , C _{1- 4} linear alkyl, C3-4 branched alkyl, (C2-8 dialkylamino)(C2-4 alkyl), (C3-6 alkyleneamino)(C2-4 alkyl), C _1-4 linear alkoxy, and C _3-4 branched alkoxy; R ^lb is selected from the group consisting of hydrogen, halogen, CF ₃ , OCF ₃ , C _1-4 linear alkyl, C3-4 branched alkyl, (C2-8 dialkylamino)(C2-4 alkyl), (C3-6 alkyleneamino)(C2-4 alkyl), C _{1- 4} linear alkoxy, and C _3-4 branched alkoxy; R ^lc is selected from the group consisting of hydrogen, halogen, CF ₃ , OCF ₃ , C _1-4 linear alkyl, C3-4 branched alkyl, (C2-8 dialkylamino)(C2-4 alkyl), (C3-6 alkyleneamino)(C2-4 alkyl), C _1-4 linear alkoxy, and C _{3- 4} branched alkoxy; R ^ld is selected from the group consisting of hydrogen, halogen, CF ₃ , OCF ₃ , C _1-4 linear alkyl, C3-4 branched alkyl, (C2-8 dialkylamino)(C2-4 alkyl), (C3-6 alkyleneamino)(C2-4 alkyl), C _1-4 linear alkoxy, and C _3-4 branched alkoxy; wherein any two selected from the group consisting of R ^la , R ^lb , R ^lc , and R ^ld are optionally connected to form a ring; R ² is selected from the group consisting of-(CH2)n-NR ⁵ R ⁶ , -(CH2)nC(0)- NR ⁵ R ⁶ , n ¹ is 1 or 2; R ⁴ is hydrogen; CF3; a five-membered monocyclic heteroaryl ring comprising at least one heteroatom selected from the group consisting from O, N, and S that is optionally substituted with up to 2 groups selected from C _1-4 linear alkyl, C3-4 branched alkyl, C _1-4 linear alkoxy, C3-4 branched alkoxy, CF3, CF3O, halogen, e-membered monocyclic heteroaryl ring comprising at least one heteroatom selected from the group consisting from O, N, and S; a phenyl ring that is optionally substituted with up to 2 groups selected from C _1-4 linear alkyl, C _3-4 branched alkyl, C _1-4 linear alkoxy, C _{3- 4} branched alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, CF ₃ , CF ₃ O, halogen,

wherein, R ^3a is at each occurrence independently selected from the group consisting of C _1-4 linear alkyl and C _3-4 branched alkyl; R ^3b is at each occurrence independently selected from the group consisting of C _1-4 linear alkyl and C _3-4 branched alkyl; R ⁵ is selected from the group consisting of hydrogen, C _1-4 linear alkyl, C3-4 branched alkyl, - CH2-(C1-6 cycloalkyl), C(0)C 1-6 linear alkyl, C(0)C ₃ - ₆ branched alkyl, R ⁶ is selected from the group consisting of C _1-4 linear alkyl, C3-4 branched alkyl, and an optionally substituted benzyl group wherein the optionally substituted benzyl group is substituted with 0 to 2 groups selected from the group consisting of halogen, - CN, -NO ₂ , -OH, -NH ₂ , Ci-6 alkyl, C _3-7 branched alkyl, Ci-6 linear haloalkyl, C _3-7 branched haloalkyl, Ci-6 linear alkoxy, C _3-7 branched alkoxy, C1-6 linear haloalkoxy, C _{3- 7} branched haloalkoxy, C _3-7 cycloalkyl, aryl, heterocycle, and heteroaryl, provided that when R ² is ⁶ , R is not hydrogen, C _1-4 linear alkyl, C3-4 branched alkyl, or benzyl; n ² is 1 or 2; n ³ is 0 or 1; n ⁴ is 0 or 1; n ⁵ is 0, 1, or 2; n ⁶ is 0 or 1; R ⁷ is selected from the group consisting of hydrogen and C(0)0R ⁸ ; R ⁸ is selected from the group consisting of C _1-4 linear alkyl and C _3-4 branched alkyl; X ² is selected from the group consisting of a single bond, oxygen, CH ₂ , CHOH, and NR ⁹ ; R ⁹ is C _1-4 linear alkyl that is optionally substituted with an NH2; R ¹⁰ is selected from the group consisting of OH, OR ¹¹ , NR ¹² R ¹³ , NHSO2R ²² , and R ¹¹ is selected from the group consisting of C _1-4 linear alkyl and C _3-4 branched alkyl; R ¹² is selected from the group consisting of hydrogen, C _1-4 linear alkyl, C _3-4 branched alkyl, C _1-4 linear fluoroalkyl, C(O)R ¹⁴ ; R ¹³ is selected from the group consisting of hydrogen, C _1-4 linear alkyl, C _3-4 branched alkyl, and heteroaryl; R ¹² and R ¹³ are optionally taken together with the atoms to which they are connected to form a ring with 3 to 6 atoms; R ¹⁴ is selected from the group consisting of C _1-4 linear alkyl C _3-4 branched alkyl, and R ¹⁵ is selected from the group consisting of C _1-4 linear alkyl and C _3-4 branched alkyl; R ¹⁶ is selected from the group consisting of hydrogen, C _1-4 linear alkyl, C _3-4 branched alkyl, CH ₂ -(C _I-6 cycloalkyl), and C(0)R ¹⁸ ; R ¹⁷ is selected from the group consisting of hydrogen, benzyl and C(0)R ¹⁸ ; R ¹⁸ is selected from the group consisting of C _1-4 linear alkyl and C _3-4 branched alkyl; R ¹⁹ is selected from the group consisting of hydrogen and C(0)R ²⁰ ; R ²⁰ is selected from the group consisting of C _1-4 linear alkyl and C _3-4 branched alkyl; R ²¹ is a benzene ring that is optionally substituted with 0 to 2 groups selected from the group consisting of halogen, -CN, -NO ₂ , -OH, -NH ₂ , C1- ₆ alkyl, C _3-7 branched alkyl, C1- ₆ linear haloalkyl, C _{3- 7} branched haloalkyl, C1- ₆ linear alkoxy, C _3-7 branched alkoxy, C1- ₆ linear haloalkoxy, C _3-7 branched haloalkoxy, C _3-7 cycloalkyl, aryl, heterocycle, and heteroaryl; R ²² is selected from the group consisting of C1-4 linear alkyl, C3-4 branched alkyl, n is 2, 3, or 4; m is 2, 3, or 4; q is 2, 3, or 4; y is 2, 3, or 4; u is 2, 3, or 4; v is 2, 3, or 4; w is 2, 3, or 4; z is 1, 2 or 3; r is 2, 3, or 4; and x is 2, 3, or 4. [0904] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁵ , and R ⁶ are defined as above. [0905] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁵ , and R ⁶ are defined as above. [0906] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁶ , and R ⁷ are defined as above. [0907] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein m, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁶ , and R ⁷ are defined as above. [0908] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein q, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁶ , and R ⁷ are defined as above. [0909] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein q, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁶ , and R ⁷ are defined as above. [0910] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein y, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁶ , and R ⁷ are defined as above. [0911] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein y, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁶ , and R ⁷ are defined as above. [0912] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein z, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and R ⁶ are defined as above. [0913] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein z, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and R ⁶ are defined as above. [0914] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein r, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and R ⁷ are defined as above. [0915] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein r, R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and R ⁷ are defined as above. [0916] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and R ⁶ are defined as above. [0917] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and R ⁶ are defined as above. [0918] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁵ , and R ⁶ are defined as above. [0919] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁵ , and R ⁶ are defined as above. [0920] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , R ⁵ , and R ⁶ are defined as above. [0921] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and R ⁶ are defined as above. [0922] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and u are defined as above. [0923] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and u are defined as above. [0924] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and x are defined as above. [0925] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and x are defined as above. [0926] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , v, X ² , and n ¹ are defined as above. [0927] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , v, X ² , and n ¹ are defined as above. [0928] In further embodiments, the compound is:

an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and w are defined as above. [0929] In further embodiments, the compound is: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof, wherein R ^1a , R ^1b , R ^1c , R ^1d , R ⁴ , and w are defined as above. [0930] In further embodiments, the TDP-43 modulator is selected from the group consisting of: N ¹ -(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-N ¹ ,N ³ ,N ³ - trimethylpropane-1,3-diamine; 2-(4-Methoxyphenyl)-N-(3-{methyl[3- (methylamino)propyl]-amino}propyl)quinolin-4-amine; N ¹ -(3-Aminopropyl)-N ³ -(2-(4- methoxyphenyl)quinolin-4-yl)-N ¹ -methylpropane-l,3-diamine; N ¹ -(2-(4- Methoxyphenyl)quinolin-4-yl)-N ³ -(3-(piperidin-1-yl)propyl)propane-1,3-diamine; N ¹ -(2-(4- methoxyphenyl)quinolin-4-yl)-N ³ -methyl-N ³ -(3-(piperidin-l-yl)propyl)propane-1,3- diamine; tert-ButylN-{3-[(3-{[2-(4-methoxyphenyl)quinolin- 4yl]amino}propyl)amino]propyl}carbamate; N ¹ -(3-aminopropyl)-N ³ -(5-fluoro-2-(4- methoxyphenyl)quinolin-4-yl)-N ¹ -methylpropane-1,3-diamine:N-{3-[(3- Aminopropyl)amino]propyl}-2-(4-methoxyphenyl)quinolin-4-amin e; N ¹ -(3-Aminopropyl)- N ³ -(6-methoxy-2-(4-methoxyphenyl)quinolin-4-yl)-N ¹ -methylpropane-1,3-diamine; N ¹ -(3- Aminopropyl)-N ³ -(2-(2-methyl-4-methoxyphenyl)quinolin-4-yl)-N ¹ -methylpropane-1,3- diamine; N ¹ -(3-Aminopropyl)-N ³ -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)-N ¹ - methylpropane-1,3-diamine; N ¹ -(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)- N ¹ ,N ⁴ -dimethylbutane-1,4-diamine; N ¹ -(2-fluoroethyl)-N ³ -(3-((2-(4- methoxyphenyl)quinolin-4-yl)amino)propyl)-N ¹ ,N ³ -dimethylpropane-1,3-diamine; 3-((3- ((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)amino)-propa n-l-ol; N-(3-(3- methoxypropylamino)propyl)-2-(4-methoxyphenyl)quinolin-4-ami ne; N-(3-(2-(4- Methoxyphenyl)quinolin-4-ylamino)propyl)-N-(3-aminopropyl)ac etamide; N ¹ - (Cyclopropylmethyl)-N ¹ -(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N ³ ,N ³ - dimethylpropane-1,3-diamine:tert-Butyl3-(((3-(dimethylamino) propyl)(3-((2-(4- methoxyphenyl)quinolin-4-yl)amino)propyl)amino)methyl)azetid ine-1-carboxylate; tert- Butyl4-(((3-(dimethylamino)propyl)(3-((2-(4-methoxyphenyl)qu inolin-4- yl)amino)propyl)amino)methyl)piperidine-l-carboxylate:N ¹ -(Azetidin-3-ylmethyl)-N ¹ -(3- ((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N ³ ,N ³ -dimethylpropane-1,3-diamine; N ^1- (3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-N ³ ,N ³ -dimethyl-N ¹ -(piperidin-4- ylmethyl)propane-1,3-diamine; N ¹ -(2-(4-Methoxyphenyl)quinolin-4-yl)-N ³ -((l-methyl-lH- imidazol-5-yl)methyl)propane-1,3-diamine; N-(3-(Hexahydropyrrolo[3,4-c]pyrrol-2(lH)- yl)propyl)-2-(4-methoxyphenyl)quinolin-4-amine; N ¹ -((6-Aminopyridin-3-yl)methyl)-N ³ -(2- (4-methoxyphenyl)-quinolin-4-yl)-N ¹ -methylpropane-1,3-diamine; l-(Dimethylamino)-3- ((3-((2-(4-methoxyphenyl)quinolin-4-yl)-amino)propyl)(methyl )amino)propan-2-ol; 1-(3- ((3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)-methyla mino)propyl)piperidin-4-ol; tert-butyl5-(3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)prop yl)hexahydro-pyrrolo[3,4- c]pyrrole-2(lH)-carboxylate; N ¹ -((6-(dimethylamino)pyridin-3-yl)methyl)-N ³ -(2-(4- methoxyphenyl)quinolin-4-yl)-N^methylpropane-1,3-diamine; N ¹ -(3-aminopropyl)-N ¹ - methyl-N ³ -(2-(4-(piperazin-l-yl)phenyl)quinolin-4-yl)propane-1, 3-diamine; N ¹ -(2-(4- methoxyphenyl)quinolin-4-yl)-N ³ -methyl-N ³ -((l-methylpiperidin-4-yl)methyl)propane-l,3- diamine:N ¹ -(2-(4-methoxyphenyl)quinolin-4-yl)-N ³ -methyl-N ³ -(2-(piperidin-2- yl)ethyl)propane-1,3-diamine; tert-Butyl(2-(3-((2-(4-methoxyphenyl)quinolin-4- yl)amino)propyl)octahydrocyclopenta[c]pyrrol-4-yl)carbamate: N ¹ -(2-(4- Methoxyphenyl)quinolin-4-yl)-N ³ -(octahydrocyclopenta[c]pyrrol-4-yl)propane-1,3- diamine; N-(3-(4-Aminohexahydrocyclopenta[c]pyrrol-2(lH)-yl)propyl)-2 -(4- methoxyphenyl)quinolin-4-amine; tert-Butyl2-(3-((2-(4-methoxyphenyl)quinolin-4- yl)amino)propyl)hexahydro-lH-pyrrolo[3,4-c]pyridine-5(6H)-ca rboxylate; N-(3- (Hexahydro-lH-pyrrolo[3,4-c]pyridin-2(3H)-yl)propyl)-2-(4-me thoxyphenyl)quinolin-4- amine; tert-Butyl4-((3-((2-(4-methoxyphenyl)quinolin-4- yl)amino)propyl)amino)hexahydrocyclopenta[c]pyrrole-2(lH)-ca rboxylate; N ¹ -((l- (Cyclopropylmethyl)piperidin-4-yl)methyl)-N ³ -(2-(4-methoxypheny^quinolin-d-y^- N^methylpropane-1,3-diamine; N-(2-(l-(3-Aminopropyl)piperidin-2-yl)ethyl)-2-(4- methoxyphenyl)quinolin-4-amine:N ¹ -(l-(4-Fluorobenzyl)piperidin-4-yl)-N ³ -(2-(4- methoxyphenyl)quinolin-4-yl)propane-1,3-diamine:tert-Butyl6- (3-((2-(4- methoxyphenyl)quinolin-4-yl)amino)propyl)-2,6-diazaspiro[3.4 ]octane-2-carboxylate; N- (3-(2,6-Diazaspiro[3.4]octan-6-yl)propyl)-2-(4-methoxyphenyl )quinolin-4-amine:2-(4- Methoxyphenyl)-N-(3-(4-methyl-l,4-diazepan-l-yl)propyl)quino lin-4-amine:tert-Butyl2-(2- ((3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)amino)et hyl)piperidine-l- carboxylate; N ¹ -(2-(4-methoxyphenyl)quinolin-4-yl)-N ³ -(2-(piperidin-2-yl)ethyl)propane- l,3-diamine; N-(3-(4-(3-Aminopropyl)piperazin-1-yl)propyl)-2-(4-methoxyph enyl)quinolin- 4-amine; tert-Butyl4-{[(3-{[2-(4-methoxyphenyl)quinolin-4- yl]amino}propyl)(methyl)amino]methyl}piperidine-1-carboxylat e; N-(3-(N-Methyl-N- ((piperidin-4-yl)methyl)amino)propyl)-2-(4-methoxyphenyl)qui nolin-4-amine; N-(3-((2-(4- Methoxyphenyl)quinolin-4-yl)amino)propyl)-4-(2H-tetrazol-5-y l)benzenesulfonamide; N ¹ - (4-(2H-Tetrazol-5-yl)phenyl)-N ³ -(2-(4-methoxyphenyl)quinolin-4-yl)propane-l,3-diamine ; (1-(3-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)propyl)piperi din-4-yl)methanol; l- (Diethylamino)-3-((3-((2-(4-methoxyphenyl)quinolin-4-yl)amin o)propyl)amino)propan-2- ol; N ¹ -(2-(4-Methoxyphenyl)quinolin-4-yl)-N ³ -((l-methyl-lH-pyrazol-5-yl)methyl)propane- 1,3-diamine; N ¹ -(2-(4-methoxyphenyl)quinolin-4-yl)-N ³ -(2-(pyridin-2-yl)ethyl)propane-l,3- diamine; N ¹ -(2-(4-Methoxyphenyl)quinolin-4-yl)-N ³ -(4-(piperidin-l-yl)phenyl)propane-l,3- diamine; N-((l-(3-Aminopropyl)piperidin-3-yl)methyl)-2-(4-methoxyphen yl)quinolin-4- amine; N-(3-(2-(6-Methoxy-lH-indol-3-yl)ethylamino)propyl)-2-(4- methoxyphenyl)quinolin-4-amine:tert-Butyl4-{[({l-[(tert-buto xy)carbonyl]piperidin-4- yl}methyl)(3-{[2-(4-methoxyphenyl)-quinolin-4-yl]amino}propy l)amino]methyl}piperidine-l- carboxylate; N-(3-(Bis((piperidin-4-yl)methyl)amino)propyl)-2-(4- methoxyphenyl)quinolin-4-amine; N ¹ -(4-Methoxybenzyl)-N ³ -(2-(4- methoxyphenyl)quinolin-4-yl)-N ¹ -methylpropane-1,3-diamine; tert-Butyl(3-((4-((2-(4- methoxyphenyl)quinolin-4-yl)amino)cyclohexyl)amino)propyl)ca rbamate; tert-Butyl4-{[(3- {[2-(4-methoxyphenyl)quinolin-4-yl]amino}propyl)amino]methyl }piperidine-1-carboxylate; N ¹ -(2-(4-methoxyphenyl)quinolin-4-yl)-N ³ -(3-(pyridin-4-ylamino)propyl)propane-1,3- diamine; 2-(3-(4-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)piperidin-l - yl)propyl)isoindoline-1,3-dione; 2-(3-(3-(((2-(4-Methoxyphenyl)quinolin-4- yl)amino)methyl)piperidin-1-yl)propyl)isoindoline-1,3-dione; N-(3-((3-((2-(4- Methoxyphenyl)quinolin-4-yl)amino)propyl)amino)propyl)methan esulfonamide; 2-(3-(2- (2-((2-(4-Methoxyphenyl)quinolin-4-yl)amino)ethyl)piperidin- l-yl)propyl)isoindoline-1,3- dione; N-(3-(Hexahydropyrrolo[l,2-a]pyrazin-2(lH)-yl)propyl)-2-(4- methoxyphenyl)quinolin-4-amine; 2-(4-Methoxyphenyl)-N-(l'-methyl-[l,4'-bipiperidine]-4- yl)quinolin-4-amine; N ¹ -(2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl)-N ³ -(2-(4- methoxyphenyl)quinolin-4-yl)propane-1,3-diamine; N ¹ -((l-(Cyclopropylmethyl)piperidin- 4-yl)methyl)-N ³ -(2-(4-methoxyphenyl)\quinolin-4-yl)propane-l,3-diamin e; 1-(3-((2-(4- Methoxyphenyl)quinolin-4-yl)amino)propyl)piperidine-4-carbox amide; 2-(4- Methoxyphenyl)-N-(3-(4-methylpiperazin-l-yl)propyl)quinolin- 4-amine; 2-(4- Methoxyphenyl)-N-(2-(4-methylpiperazin-l-yl)ethyl)quinolin-4 -amine; 2-(4- Methoxyphenyl)-N-(3-morpholinopropyl)quinolin-4-amine; 2-(7-Amino-4-methyl-2-oxo- 2H-chromen-3-yl)-N-(3-((3-((2-(4-methoxyphenyl)quinolin-4- yl)amino)propyl)(methyl)amino)propyl)acetamide; 5-(dimethylamino)-N-{3-[(3-{[2-(4- methoxyphenyl)quinolin-4yl]amino}propyl)(methyl)amino]propyl }naphthalene-l- sulfonamide; cis-N ¹ -(6,7-dimethoxy-2-(4-(piperazin-l-yl)phenyl)quinolin-4 -yl)cyclobutane- l,3-diamine; trans-/V ¹ -(6,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4 - yl)cyclobutane-1,3-diamine; trans-N ¹ -(6,7-dimethoxy-2-(4-(piperazin-1- yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine; N ¹ -(6,7-dimethoxy-2-(4-(piperazin-1- yl)phenyl)quinolin-4-yl)propane-1,3-diamine; cis-N ¹ -(2-(4-(piperazin-1-yl)phenyl)quinolin- 4-yl)cyclobutane-1,3-diamine; N ¹ -(2-(4-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)- yl)phenyl)quinolin-4-yl)propane-1,3-diamine; cis-N ¹ -(6,7-dimethoxy-2-(4-(piperazin-1- yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine; N ¹ -(2-(4-(piperazin-1- yl)phenyl)quinolin-4-yl)propane-1,3-diamine; N ¹ -(6,7-dimethoxy-2-(4-(piperazin-1- yl)phenyl)quinolin-4-yl)-N ³ ,N ³ -dimethylpropane-1,3-diamine; N ¹ -(3-aminopropyl)-N ¹ - methyl-N ³ -(2-(3-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1, 3-diamine; N ¹ -(6,7- dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-d iamine; N ¹ -(2-(4- (piperazin-1-yl)phenyl)quinolin-4-yl)cyclohexane-1,4-diamine ; 2-amino-1-(4-(4-(4-((3- (dimethylamino)propyl)amino)quinolin-2-yl)phenyl)piperazin-1 -yl)-3-methylbutan-1-one; 2-amino-1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin- 2-yl)phenyl)piperazin-1- yl)propan-1-one; N ¹ -(2-(l-(1-methylpiperidin-4-yl)-lH-pyrazol-4-yl)quinol in-4-yl)propane- 1,3-diamine; N ¹ -(3-aminopropyl)-N ³ -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)- N ¹ -methylpropane-1,3-diamine; N ¹ -(2-(4-(piperidin-4-yl)phenyl)quinolin-4-yl)propane- 1,3-diamine; N ¹ -(2-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)quinolin-4-yl) propane-1,3-diamine; trans-N ¹ -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclo butane-1,3-diamine; - dimethyl-N ³ -(2-(3-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1, 3-diamine; -dimethyl- N ³ -(2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)propane-1, 3-diamine; -(2-(l-(2-(pyrrolidin-1- yl)ethyl)-lH-pyrazol-4-yl)quinolin-4-yl)propane-1,3-diamine; trans-N ¹ -(6,7-dimethoxy-2- (4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine; N-(l-(4- aminocyclohexyl)piperidin-4-yl)-2-(4-methoxyphenyl)quinolin- 4-amine; -(6-fluoro-2-(4- (piperazin-1-yl)phenyl)quinolin-4-yl)-N ³ -dimethylpropane-1,3-diamine; N-(1-(3- aminopropyl)piperidin-4-yl)-2-(4-methoxyphenyl)quinolin-4-am ine; cis-N ¹ -(6,7- dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-d iamine; 2-amino-N-(1- ((1-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)p henyl)piperazin-1-yl)-3- methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3-me thylbutanamide; - dimethyl-N ³ -(2-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)quinol in-4-yl)propane-1,3- diamine; -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)-N ³ -dimethylpropane-1,3- diamine; -(6,7-dimethoxy-2-(4-methoxyphenyl)quinolin-4-yl)propane-1,3 -diamine; - dimethyl-N ³ -(2-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-yl)pr opane-1,3-diamine; 2- amino-N-(l-(4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin -2-yl)phenyl)piperazin-1- yl)-3-methyl-1-oxobutan-2-yl)-3-methylbutanamide; cis-N ¹ -(2-(4- methoxyphenyl)quinolin-4-yl)cyclobutane-1,3-diamine; -([2,6'-biquinolin]-4-yl)propane- 1,3-diamine; 4-(4-(4-((3-(dimethylamino)propyl)amino)quinolin-2-yl)phenyl )-1- methylpiperazin-2-one; N1-(2-(piperidin-4-yl)quinolin-4-yl)propane-1,3-diamine; N ¹ -(2- (2,3-dihydrobenzofiiran-5-yl)quinolin-4-yl)propane-l,3-diami ne; N1-(2-(4-(methoxy- d3)phenyl)quinolin-4-yl)propane-1,3-diamine; N1-([2,6'-biquinolin]-4-yl)-N ³ - dimethylpropane-1,3-diamine; N1-(2-(4-methoxyphenyl)quinolin-4-yl)cyclobutane-1,3- diamine; N ¹ -(2-(l,2,3,6-tetrahydropyridin-4-yl)quinolin-4-yl)prop ane-l,3-diamine; N1-(2- (4-methoxyphenyl)quinolin-4-yl)cyclohexane-1,4-diamine; 2-(4-methoxyphenyl)-N- (piperidin-4-yl)quinolin-4-amine; N1-(2-(4-(methoxy-d3)phenyl)quinolin-4-yl)-N ³ - dimethylpropane-1,3-diamine; N1-(2-(benzofiiran-5-yl)quinolin-4-yl)-N ³ - dimethylpropane-1,3-diamine; N1-(2-(l-methyl-lH-pyrazol-4-yl)quinolin-4-yl)propane-1,3- diamine; N1-(2-(1-(azetidin-3-y1)-1H-pyrazol-4-yl)quinolin-4-y1)-N ³ ,N ³ -dimethylpropane- 1,3-diamine; N1-(2-(l-cyclopropyl-1H-pyrazol-4-yl)quinolin-4-yl)-N ³ -dimethylpropane-1,3- diamine; N1-(2-(cyclohex-1-en-1-yl)quinolin-4-yl)propane-1,3-diamine; (S)-2-amino-N- (3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propyl)-N-methyl propanamide; N1-(2-(4- methoxyphenyl)quinolin-4-yl)-N ³ -bis(methyl-d3)propane-1,3-diamine; N1-(2-(furan-2- yl)quinolin-4-yl)propane-1,3-diamine; N1-(5-fluoro-2-(4-methoxyphenyl)quinolin-4-yl)-N ³ - dimethylpropane-1,3-diamine; N1-(2-(l-(2-morpholinoethyl)-lH-pyrazol-4-yl)quinolin-4- yl)propane-1,3-diamine; 3-((2-(4-methoxyphenyl)quinolin-4-yl)amino)propan-l-ol; N1-(2- (2-methoxypyrimidin-5-yl)quinolin-4-yl)-N ³ ,N ³ -dimethylpropane-1,3-diamine; N3,N3- dimethyl-N ³ -(2-methylquinolin-4-yl)propane-1,3-diamine; 3-((2-(4- methoxyphenyl)quinolin-4-yl)amino)-N,N-dimethylpropanamide; N1-(2-(6- methoxypyridin-3-yl)quinolin-4-yl)-N ³ -dimethylpropane-1,3-diamine; N1-(2,2-difluoro-6- (4-methoxyphenyl)-[1,3]dioxolo[4,5-g]quinolin-8-yl)-N ³ -dimethylpropane-1,3-diamine; N- (4,4-difluorocyclohexyl)-2-(4-methoxyphenyl)quinolin-4-amine ; tert-butyl3-((2-(4- methoxyphenyl)quinolin-4-yl)amino)propanoate; N1-(6-methoxy-2- (trifluoromethyl)quinolin-4-yl)-N ³ -dimethylpropane-1,3-diamine; N ¹ -(6-methoxy-7-(3- (pyrrolidin-l-yl)propoxy)quinolin-4-yl)-N ³ ,N ³ -dimethylpropane-1,3-diamine; 2-cyclohexyl- N-(l-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-l-y l)propoxy)quinolin-4-amine; N1-(3-aminopropy1)-N ³ -(6,7-dimethoxyquinolin-4-y-methylpropane-1,3-diamine; 6- methoxy--N-(l-methylpiperidin-4-yl)-7-(3-(pyrrolidin-1-yl)pr opoxy)quinolin-4-amine; N1- (6,7-dimethoxyquinolin-4-yl)-N ³ ,N ³ -diethylpropane-1,3-diamine; 6,7-dimethoxy-N-(l'- methyl-[1,4'-bipiperidin]-4-yl)quinolin-4-amine; N1-(3-aminopropy1)-N ³ .(7-chloroquinolin- 4-yl)-N ¹ -methylpropane-1,3-diamine; N1-(3-aminopropyl)-N ³ -(2-(4- (dimethylamino)phenyl)quinolin-4-yl)-N ¹ -methylpropane-1,3-diamine,an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug, or a complex thereof. Formula 201 [0931] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 201. Such compounds are described in International Publication No. WO2022178338A2, published August 25, 2022, and corresponding to International Application No. PCT/US2022/017116 filed February 20, 2022; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 201, these references incorporated by reference herein control. [0932] In an embodiment, the TDP-43 modulator is a compound according to Formula 201: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein, X, Y, and Z are each independently N or CH; R ² is an amino(C ₃ -Cv)cycloalkyl group or a (Ci- C ₅ alkyl) ₂ amino(C ₃ -Cv)cycloalkyl group, wherein the (C i-C alkyl) attached to “amino” are optionally connected to form a ring; R ³ is a substituted or unsubstituted phenyl group; and R ⁴ is an amino(C ₃ -Cv)cycloalkyl group, a (Ci-C ₅ alkyl) ₂ amino(C ₃ -Cv)cycloalkyl group wherein the (C i-C alkyl) are optionally connected to form a ring, a heterocyclyl(C ₂ - C ₅ )alkyloxy group, or a heteroaryl(C ₂ -C ₅ )alkyloxy group, wherein “heterocyclyl” is a substituted or unsubstituted nitrogen-containing non-aromatic mono-heterocycle and wherein “heteroaryl” is a substituted or substituted nitrogen-containing aromatic mono- heterocycle. [0933] In further embodiments, X is CH, Y is CH, and Z is CH. [0934] In further embodiments, X is N, Y is CH, and Z is CH. [0935] In further embodiments, X is CH, Y is N, and Z is CH. [0936] In further embodiments, X is CH, Y is CH, and Z is N. [0937] In further embodiments, X is N, Y is N, and Z is CH. [0938] In further embodiments, X is CH, Y is N, and Z is N. [0939] In further embodiments, X is N, Y is CH, and Z is N. [0940] In further embodiments, X is N, Y is N, and Z is N. [0941] In further embodiments, R ² is an amino(C ₃ -C ₇ )cycloalkyl group selected from an aminocyclopropyl group, an aminocyclobutyl group, an aminocyclopentyl group, an aminocyclohexyl group, or an aminocycloheptyl group, each of which has either cis- configuration or trans-configuration. [0942] In further embodiments, R ² is a (C ₁ -C ₅ alkyl)2amino(C ₃ -C ₇ )cycloalkyl group selected from a (C ₁ -C ₅ alkyl) ₂ aminocyclopropyl group, a (C ₁ -C ₅ alkyl) ₂ aminocyclobutyl group, a (C ₁ -C ₅ alkyl)2aminocyclopentyl group, a (C ₁ -C ₅ alkyl) ₂ aminocyclohexyl group, or a (C ₁ - C ₅ alkyl)2aminocycloheptyl group, each of which has either cis-configuration or trans configuration. [0943] In further embodiments, R ³ is a substituted or unsubstituted phenyl group. [0944] In further embodiments, R ³ is a phenyl group, a chlorophenyl group, or a methoxyphenyl group. [0945] In further embodiments, R ⁴ is a (C ₀ -C ₅ alkyl)2amino(C ₂ -C ₅ )alkyloxy group selected from a (C ₁ -C ₅ alkyl)2 _a minoethyloxy group, a (C ₁ -C ₅ alkyl) ₂ aminopropyloxy group, a (C ₁ - C ₅ alkyl)2aminobutyloxy group, and a (C ₁ -C ₅ alkyl) ₂ aminopentyloxy group, wherein two “(C ₁ - C ₅ alkyl)” are optionally connected to form a ring. [0946] In further embodiments, the ring is a substituted or unsubstituted azetidine, a substituted or unsubstituted pyrrolidine, or a substituted or unsubstituted piperidine. [0947] In further embodiments, R ⁴ is a (C ₀ -C ₅ alkyl)2amino(C ₂ -C ₅ )alkyl group selected from a (C ₁ -C ₅ alkyl) ₂ aminoethyl group, a (C ₁ -C ₅ alkyl) ₂ aminopentyl group, a (C ₁ - C ₅ alkyl) ₂ aminobutyl group, and a (C ₁ -C ₅ alkyl) ₂ aminopentyl group, wherein two “(Ci- Csalkyl)” are optionally connected to form a ring. [0948] In further embodiments, the ring is a substituted or unsubstituted azetidine, a substituted or unsubstituted pyrrolidine, or a substituted or unsubstituted piperidine. [0949] In further embodiments, R ⁴ is a heterocyclyl(C2-C5)alkyloxy group or a heteroaryl(C ₂ -C ₅ )alkyloxy group, wherein “heterocyclyl” is a substituted or unsubstituted nitrogen-containing non-aromatic mono-heterocycle and wherein “heteroaryl” is a substituted or substituted nitrogen-containing aromatic mono-heterocycle. [0950] In further embodiments, “heterocyclyl” and the “heteroaryl” are connected to the “(C ₂ -C ₅ )alkyloxy” through a nitrogen atom. [0951] In further embodiments, R ⁴ is a substituted or unsubstituted pyrrolidinoethyloxy group or substituted or unsubstituted pyrrolidinopropyloxy group. [0952] In further embodiments, the compound is according to formula 201, an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein, X, Y, and Z are each independently N or CH; R ² is a substituted or unsubstituted C ₁ -C ₂₀ linear, branched, or cyclic organic group including at least one nitrogen; and R ³ and R ⁴ are each independently hydrogen, halogen, a hydroxyl group, a cyano group, a nitro group, a substituted or unsubstituted C ₀ -C ₁₀ amino group, a substituted or unsubstituted Ci- C10 alkyl group, a substituted or unsubstituted C2-C10 alkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkynyl group, and a substituted or unsubstituted C ₁ -C ₁₀ alkoxy group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkyl group, a substituted or unsubstituted C ₃ - C ₁₀ cycloalkenyl group, a substituted or unsubstituted C ₂ - C ₁₀ heterocycloalkenyl group, a substituted or unsubstituted C ₆ -C ₂₀ aryl group, a substituted or unsubstituted C ₆ - C ₂₀ aryloxy group, a substituted or unsubstituted C ₆ -C ₂₀ arylthio group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryl group, a substituted or unsubstituted C ₂ - C ₂₀ heteroaryloxy group, or a substituted or unsubstituted C ₂ -C ₂₀ heteroarylthio group. [0953] In further embodiments, Formula 202 [0954] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 202. Such compounds are described in International Publication No. WO2022178338A2, published August 25, 2022 and corresponding to International Application No. PCT/US2022/017116 filed February 20, 2022; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 202, these references incorporated by reference herein control. [0955] In an embodiment, the TDP-43 modulator is a compound according to Formula 202: , an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein, X is N or CH; R ¹ and R ² are the same or different and are each independently H, halogen, C ₁ -C ₄ alkyl, C ₁ - C4 alkoxy, CF3, or CF3O, wherein C1-C4 alkyl and C1-C4 alkoxy are optionally substituted with at least one fluorine; R ³ is H, C ₁ -C ₇ alkyl, C ₄ -C ₇ carbocyclic, aryl, heteroaryl, heterocyclic, heterocyclic alkyl, wherein R ³ is optionally taken together with either A or B to form a ring consisting of 4-7 ring members; R ⁴ = phenyl or phenyl substituted with C ₁ - C ₄ alkyl, C ₁ -C ₄ alkoxy, CF ₃ , CF ₃ O, halogen, amino, or sulfonamide; A = (CH2) _n , wherein n is 2-4, wherein A and R ³ are optionally taken together to form a ring consisting of 4-7 ring members; B = (CH2) _n , wherein n is 2-6, wherein B and R ³ are optionally taken together to form a ring consisting of 4-7 members, and wherein B is optionally substituted with one or more substituents selected from C ₁ -C ₄ alkyl, hydroxy, C ₁ - C ₄ alkoxy, CF ₃ , and CF ₃ O; and Z is OH, C ₁ -C ₄ alkoxy, OCF ₃ , or N with one or more of H, C ₁ -C ₄ alkyl, heteroaryl, substituted heteroaryl, C ₁ -C ₄ sulfonamido, substituted amido. [0956] In further embodiments, X = CH; R ¹ and R ² are each H, R ³ is H or Me, R ⁴ is 4- methoxyphenyl, A is (CH2) ₃ , B is (CH ₂ ) _n , wherein n is 2-4 and Z = N(R ⁶ ) ₂ , wherein each R ⁶ is independently H, C ₁ -C ₄ alkyl, heteroaryl, substituted heteroaryl, C ₁ - C ₄ sulfonamido, or substituted amido. Formula 203 - 204 [0957] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to any one of Formula 203 - 204. Such compounds are described in International Publication No. WO2022178338A2, published August 25, 2022, and corresponding to International Application No. PCT/US2022/017116 filed February 20, 2022; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 203 - 204, these references incorporated by reference herein control. [0958] In an embodiment, the TDP-43 modulator is a compound according to any one of Formula 203 - 204: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein, R ² is a substituted or unsubstituted C ₁ -C ₂₀ linear, branched, or cyclic organic group including at least one nitrogen; and R ³ , R ⁴ , R ⁵ , and R ⁶ are each independently hydrogen, halogen, a hydroxyl group, a cyano group, a nitro group, a substituted or unsubstituted C ₀ -C ₁₀ amino group, a substituted or unsubstituted Ci- C ₁₀ alkyl group, a substituted or unsubstituted C ₂ - C ₁₀ alkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkynyl group, and a substituted or unsubstituted C ₁ -C ₁₀ alkoxy group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkyl group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkenyl group, a substituted or unsubstituted C ₂ - C ₁₀ heterocycloalkenyl group, a substituted or unsubstituted C ₆ -C ₂ o aryl group, a substituted or unsubstituted C ₆ -C ₂₀ aryloxy group, a substituted or unsubstituted C ₆ - C ₂₀ arylthio group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryl group, a substituted or unsubstituted C ₂ - C ₂₀ heteroaryloxy group, or a substituted or unsubstituted C ₂ - C ₂₀ heteroarylthio group. Formula 205 [0959] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 205. Such compounds are described in International Publication No. WO2022178338A2, published August 25, 2022, and corresponding to International Application No. PCT/US2022/017116 filed February 20, 2022; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 205, these references incorporated by reference herein control. [0960] In an embodiment, the TDP-43 modulator is a compound according to Formula 205: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein, R ² is a substituted or unsubstituted C ₁ -C ₂₀ linear, branched, or cyclic organic group including at least one nitrogen; and R ^1a , R ^1b , R ^1c , and R ^ld are each independently hydrogen, halogen, a hydroxyl group, a cyano group, a nitro group, a substituted or unsubstituted C ₀ - C ₁₀ amino group, a substituted or unsubstituted C ₁ -C ₁₀ alkyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkynyl group, and a substituted or unsubstituted C ₁ -C ₁₀ alkoxy group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkyl group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkenyl group, a substituted or unsubstituted C ₆ -C ₂₀ aryl group, a substituted or unsubstituted C ₆ -C ₂₀ aryloxy group, a substituted or unsubstituted C ₆ - C ₂₀ arylthio group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryl group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryloxy group, or a substituted or unsubstituted C ₂ - C ₂₀ heteroarylthio group. Formula 206 [0961] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 206. Such compounds are described in International Publication No. WO2022178338A2, published August 25, 2022, and corresponding to International Application No. PCT/US2022/017116 filed February 20, 2022; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 206, these references incorporated by reference herein control. [0962] In an embodiment, the TDP-43 modulator is a compound according to Formula 206: an enantiomer, a diastereomer, a hydrate, a solvate, a pharmaceutically acceptable salt, an isotopic analog, a prodrug or a complex thereof, wherein, R ² is a substituted or unsubstituted C ₁ -C ₂₀ linear, branched, or cyclic organic group including at least one nitrogen; and R ^1a , R ^1b , 1 ^lc , R ^1d , and R ^1e are each independently hydrogen, halogen, a hydroxyl group, a cyano group, a nitro group, a substituted or unsubstituted Co-Cio amino group, a substituted or unsubstituted Ci-Cio alkyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ alkynyl group, and a substituted or unsubstituted C ₁ -C ₁₀ alkoxy group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkyl group, a substituted or unsubstituted C ₃ -C ₁₀ cycloalkenyl group, a substituted or unsubstituted C ₂ -C ₁₀ heterocycloalkenyl group, a substituted or unsubstituted C ₆ -C ₂₀ aryl group, a substituted or unsubstituted C ₆ -C ₂₀ aryloxy group, a substituted or unsubstituted C ₆ - C ₂₀ arylthio group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryl group, a substituted or unsubstituted C ₂ -C ₂₀ heteroaryloxy group, or a substituted or unsubstituted C ₂ - C ₂₀ heteroarylthio group. Formula 207 - 210 [0963] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to any one of Formulas 207 - 210. Such compounds are described in International Publication No. WO2022015997A2, published January 20, 2022, and corresponding to International Application No. PCT/US2021/041852 filed July 15, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of any one of Formulas 207 - 210, this reference incorporated by reference herein control. [0964] In an embodiment, the TDP-43 modulator is a compound according to Formula 207: N-(2-(3-hydroxypiperidin-1-yl)ethyl)-5-((3-(trifluoromethyl) phenoxy)methyl)isoxazole-3- carboxamide, or a pharmaceutically acceptable salt thereof and/or a structurally similar compound. [0965] In an embodiment, the TDP-43 modulator is a compound according to Formula 208:

1-(9-hydroxy-7-(p-tolyl)-2,3-dihydrobenzo[ ^][1,4]oxazepin-4(5H)-yl)-3-(5-methyl-1H- 1,2,4-triazol-3-yl)propan-1-one or a pharmaceutically acceptable salt thereof and/or a structurally similar compound. [0966] In an embodiment, the TDP-43 modulator is a compound according to Formula 209: , 6-(benzo[d][1,3]dioxol-5-yl)-N-((1-isobutylpyrrolidin-3-yl)m ethyl)nicotinamide or a pharmaceutically acceptable salt thereof and/or a structurally similar compound. [0967] In an embodiment, the TDP-43 modulator is a compound according to Formula 210: 3-(5-(1H-indol-3-yl)-1,3,4-oxadiazol-2-yl)-N-(1,2,3,4-tetrah ydronaphthalen-1- yl)propenamide or a pharmaceutically acceptable salt thereof and/or a structurally similar compound. Formula 211 - 212 [0968] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to one of Formulas 211 - 212. Such compounds are described in US Patent No.11,147,795, issued October 19, 2021, and corresponding to US Application No.16/515,743 filed July 18, 2019; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of one of Formulas 211 - 212, this reference incorporated by reference herein control. [0969] In an embodiment, the TDP-43 modulator is a compound according to one of Formulas 211 - 212:

or a pharmaceutically acceptable salt thereof, or a combination thereof, wherein * denotes a chiral center; each of R and R ^3a is independently hydrogen or alkyl; R ^a is — CF ₃ , —OR ^a1 , or —NR ^b1 R ^b2 ; R ^a1 is H or alkyl; each of R ^b1 and R ^b2 is independently H or alkyl; R ^1a is hydrogen, alkyl, or a nitrogen protecting group; each of R ¹ , R ² and R ³ is independently hydrogen, alkyl, haloalkyl, halide, vinyl, alkynyl, —CHO, — C(═O)R ^1b (ketone), —CO ₂ R ^1c (ester), —OR ^1d , OSO ₂ R ^1e , aryl and heteroaryl, wherein each of R ^1b , R ^1c , R ^1d , and R ^1e is independently alkyl or aryl; R ^2a is hydrogen, alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, heteroaryl or ester functional group; R ^2b is alkyl, cycloalkyl, aralkyl, alkenyl, aralkenyl, heteroalkyl, or heteroaryl; and Z is a conjugated electron withdrawing group. [0970] In further embodiments, R ^1a , R ¹ , and R ³ are H, R ² is halide, and R is alkyl. [0971] In further embodiments, * is an (R)- or (S)-configuration and R ^2b is alkyl, Z is an ester, and R ^2a is alkenyl or heteroaryl. [0972] In further embodiments, diastereomeric excess of said compound is at least 90% d.e. [0973] In further embodiments, the TDP-43 modulator of formula 212 is selected from the group consisting of:

wherein R ^2a is alkenyl; and wherein R ^2a is heteroaryl. [0974] In further embodiments, the TDP-43 modulator is selected from the group consisting of: or a pharmacologically acceptable salt thereof. Formula 213 [0975] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 213. Such compounds are described in International Publication No. WO2021025723A1, published February 11, 2021, and corresponding to International Application No. PCT/US2020/000030 filed July 312020; US Publication No. US20210052519A1, published February 25, 2021, and corresponding to US Application No.16/873,866 filed July 31, 2020; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 213, these references incorporated by reference herein control. [0976] In an embodiment, the TDP-43 modulator is a compound according to Formula 213: , wherein, R ₁ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₃ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₄ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₅ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₆ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₀ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₁ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₂ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₃ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₄ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₅ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₆ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₇ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₈ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; and R ₂₉ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon. [0977] In further embodiments, R ₁ is hydrogen, alkyl or acyl. [0978] In further embodiments, R ₃ -R ₆ are independently hydrogen or alkyl. [0979] In further embodiments, R ₂₀ -R ₂₄ are independently hydrogen, alkyl or halogen. [0980] In further embodiments, R ₂₅ -R ₂₉ are independently hydrogen, alkyl or halogen. Formula 214 [0981] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 214. Such compounds are described in International Publication No. WO2021025723A1, published February 11, 2021, and corresponding to International Application No. PCT/US2020/000030 filed July 312020; US Publication No. US20210052519A1, published February 25, 2021, and corresponding to US Application No.16/873,866 filed July 31, 2020; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 214, these references incorporated by reference herein control. [0982] In an embodiment, the TDP-43 modulator is a compound according to Formula 214: wherein, R ₁ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₃ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₄ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₅ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₆ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₇ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₈ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₀ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₁ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₂ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₃ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₄ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₅ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₆ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₇ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; R ₂₈ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon; and R ₂₉ is hydrogen, acyl, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, arylalkyl, aryloxy, aryloxyalkyl, electron withdrawing group, halogen, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclicalkyl, hydroxy, mercapto, saturated cyclic hydrocarbon, substituted alkenyl, substituted alkyl, substituted alkynyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic, or unsaturated cyclic hydrocarbon. [0983] In further embodiments, R ₁ is hydrogen, alkyl or acyl. [0984] In further embodiments, R ₃ -R ₆ are independently hydrogen or alkyl. [0985] In further embodiments, R ₂₀ -R ₂₄ are independently hydrogen, alkyl or halogen. [0986] In further embodiments, R ₂₅ -R ₂₉ are independently hydrogen, alkyl or halogen. Formula 215 [0987] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 215. Such compounds are described in US Publication No. US20170369474A1, published December 28, 2017, and corresponding to US Application No.15/533,339 filed December 4, 2015; International Publication No. WO2016090313A1, published June 9, 2016, and corresponding to International Application No. PCT/US2015/064103 filed December 4, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 215, these references incorporated by reference herein control. [0988] In an embodiment, the TDP-43 modulator is a compound according to Formula 215: , wherein, Ring A is heteroaryl; R ¹ is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1- C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —OR ^A , —NR ^B R ^C , —NR ^B C(O)R ^D , or —SR ^E , each of which is optionally substituted with 1-5 R ⁷ ; R ² is H, C ₁ - C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ - C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —OR ^A , or — SR ^E , each of which is optionally substituted with 1-5 R ⁸ ; each of R ³ and R ⁴ is independently H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cyano, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —NR ^B C(O)R ^D , —NR ^B C(O)NR ^B R ^C , —SR ^E , — S(O)R ^E , —S(O) ₂ R ^E , —NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ ; R ⁵ is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ - C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, —OR ^A , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , or —SR ^E , each of which is optionally substituted with 1-5 R ⁹ ; or R ⁵ , together with the nitrogen atom to which it is attached, forms a heterocyclyl or heteroaryl ring with Ring A, optionally substituted with 1-3 R ⁹ ; each R ⁶ is independently C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cyano, hydroxy, halo, — OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —SR ^E , —S(O)R ^E , —S(O) ₂ R ^E , — NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ ; each R ^A , R ^B , R ^C , R ^D , or R ^E is independently H, C ₁ -C ₆ alkyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, each of which is optionally substituted with 1-4 occurrences of R ⁷ ; or R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ ; each R ⁷ , R ⁸ , or R ⁹ is independently C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, nitro, —OR ^a , —NR ^b R ^c , —C(O)R ^d , —C(O)OR ^a , —C(O)NR ^b R ^c , —NR ^b C(O)R ^d , — NR ^b C(O)NR ^b R ^c , —SR ^e , —S(O)R ^e , —S(O)2R ^e , —NR ^b S(O)2R ^e , or —S(O)2NR ^b R ^c , each of which is optionally substituted with 1-5 R ¹⁰ ; each R ¹⁰ is C ₁ -C ₆ alkyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, hydroxy, cyano, or nitro, each of which is optionally substituted with 1-4 R ¹¹ ; each R ^a , R ^b , R ^c , R ^d , or R ^e is H, C ₁ -C ₆ alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with R ¹¹ ; or R ^B and R ^C , together with the atoms to which each is attached, form a cycloalkyl or heterocyclyl ring optionally substituted with 1-4 R ¹¹ ; each R ¹¹ is independently C ₁ - C ₆ alkyl, halo, hydroxy, cycloalkyl, alkoxy, keto, cyano, or nitro; and n is 0, 1, 2, 3, 4, or 5. [0989] In further embodiments, R ¹ is C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, cycloalkyl, —OR ^A , or — NR ^B R ^C , and R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ . [0990] In further embodiments, R ¹ is —NR ^B R ^C , and R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ . [0991] In further embodiments, R ¹ is selected from the group consisting of [0992] In further embodiments, R ² is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R ⁸ . [0993] In further embodiments, each of R ³ and R ⁴ is independently H, C ₁ -C ₆ alkyl, C ₂ - C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , or —NR ^B C(O)R ^D , each of which is optionally substituted with 1-5 R ⁹ . [0994] In further embodiments, R ⁵ is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R ⁹ . [0995] In further embodiments, Ring A is a monocyclic or bicyclic heteroaryl. [0996] In further embodiments, Ring A is a 5- or 6-membered monocyclic heteroaryl. [0997] In further embodiments, R ⁶ is C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cyano, hydroxy, halo, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —S(O) ₂ R ^E , — NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ . [0998] In further embodiments, R ⁶ is C ₁ -C ₆ alkyl, cyano, hydroxy, halo, —OR ^A , or — NR ^B R ^C . [0999] In further embodiments, n is 0, 1, or 2. [1000] In further embodiments, the TDP-43 modulator is a compound of formula 215 or a pharmaceutically acceptable salt thereof, wherein, Ring A is aryl; R ¹ is C ₁ -C ₆ alkyl, C ₂ - C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —OR ^A , —NR ^B R ^C , —NR ^B C(O)R ^D , or —SR ^E , each of which is optionally substituted with 1-5 R ⁷ ; R ² is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ - C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —C(O)R ^D , — C(O)OR ^A , —C(O)NR ^B R ^C , —OR ^A , or —SR ^E , each of which is optionally substituted with 1-5 R ⁸ ; each of R ³ and R ⁴ is independently H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cyano, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —NR ^B C(O)R ^D , — NR ^B C(O)NR ^B R ^C , —SR ^E , —S(O)R ^E , —S(O) ₂ R ^E , —NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ ; R ⁵ is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ - C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, —OR ^A , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , or —SR ^E , each of which is optionally substituted with 1-5 R ⁹ ; or R ⁵ , together with the nitrogen atom to which it is attached, forms a heterocyclyl or heteroaryl ring with Ring A, optionally substituted with 1-3 R ⁹ ; each R ⁶ is independently C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cyano, hydroxy, halo, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —SR ^E , — S(O)R ^E , —S(O) ₂ R ^E , —NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ ; each R ^A , R ^B , R ^C , R ^D , or R ^E is independently H, C ₁ -C ₆ alkyl, C ₁ - C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, each of which is optionally substituted with 1-4 occurrences of R ⁷ ; or R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ ; each R ⁷ , R ⁸ , or R ⁹ is independently C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ - C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, nitro, —OR ^a , —NR ^b R ^c , —C(O)R ^d , —C(O)OR ^a , —C(O)NR ^b R ^c , —NR ^b C(O)R ^d , —NR ^b C(O)NR ^b R ^c , —SR ^e , —S(O)R ^e , —S(O) ₂ R ^e , —NR ^b S(O) ₂ R ^e , or — S(O) ₂ NR ^b R ^c , each of which is optionally substituted with 1-5 R ¹⁰ ; each R ¹⁰ is C ₁ -C ₆ alkyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, hydroxy, cyano, or nitro, each of which is optionally substituted with 1-4 R ¹¹ ; each R ^a , R ^b , R ^c , R ^d , or R ^e is H, C ₁ -C ₆ alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with R ¹¹ ; or R ^B and R ^C , together with the atoms to which each is attached, form a cycloalkyl or heterocyclyl ring optionally substituted with 1-4 R ¹¹ ; each R ¹¹ is independently C ₁ - C ₆ alkyl, halo, hydroxy, cycloalkyl, alkoxy, keto, cyano, or nitro; and n is 0, 1, 2, 3, 4, or 5; provided that when R ² is CH ₃ , Ring A is not [1001] In further embodiments, R ¹ is C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, cycloalkyl, —OR ^A , or — NR ^B R ^C and R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ . [1002] In further embodiments, R ¹ is —NR ^B R ^C , and R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ . [1003] In further embodiments, R ¹ is selected from the group consisting of [1004] In further embodiments, R ² is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R ⁸ . [1005] In further embodiments, each of R ³ and R ⁴ is independently H, C ₁ -C ₆ alkyl, C ₂ - C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , or —NR ^B C(O)R ^D , each of which is optionally substituted with 1-5 R ⁹ . [1006] In further embodiments, R ⁵ is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R ⁹ . [1007] In further embodiments, Ring A is a monocyclic fused aryl. [1008] In further embodiments, R ⁶ is C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cyano, hydroxy, halo, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —S(O)2R ^E , — NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ . [1009] In further embodiments, R ⁶ is C ₁ -C ₆ alkyl, cyano, hydroxy, halo, —OR ^A , or — NR ^B R ^C . [1010] In further embodiments, n is 0, 1, or 2. [1011] In further embodiments, Ring A is selected from the group consisting of: [1012] In further embodiments, Ring A is [1013] In further embodiments, the compound is or a pharmaceutically acceptable salt thereof. [1014] In further embodiments, the compound is or a pharmaceutically acceptable salt thereof. Formula 216 [1015] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 216. Such compounds are described in US Publication No. US20170360726A1, published December 21, 2017 and corresponding to US Application No.15/533,354 filed December 4, 2015; International Publication No. WO2016090317A1, published June 9, 2016 and corresponding to International Application No. PCT/US2015/064107 filed December 4, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 216, these references incorporated by reference herein control. [1016] In an embodiment, the TDP-43 modulator is a compound according to Formula 216: or a pharmaceutically acceptable salt thereof, wherein, Ring A is aryl or heteroaryl; Ring B is 6-membered aryl or 5- or 6-membered heteroaryl; R″ is H or C(O)R ¹ ; R ¹ is C ₁ - C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ - C ₆ hydroxyalkyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —OR ^A , —NR ^B R ^C , —NR ^B C(O)R ^D , or —SR ^E , each of which is optionally substituted with 1-5 R ⁷ ; each R is independently H, C ₁ -C ₆ alkyl, C ₂ - C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cyano, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocyclylalkyl, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , — C(O)NR ^B R ^C , —NR ^B C(O)R ^D , —NR ^B C(O)NR ^B R ^C , —SR ^E , —S(O)R ^E , —S(O) ₂ R ^E , — NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁸ ; R ⁵ is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ - C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, — C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —OR ^A , or —SR ^E , each of which is optionally substituted with 1-5 R ⁹ ; or R ⁵ , together with the nitrogen atom to which it is attached, forms a heterocyclyl or heteroaryl ring with Ring A, optionally substituted with 1-3 R ⁹ ; each R ⁶ is independently C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cyano, hydroxy, halo, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , — C(O)NR ^B R ^C , —SR ^E , —S(O)R ^E , —S(O) ₂ R ^E , —NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ ; each R ^A , R ^B , R ^C , R ^D , or R ^E is independently H, C ₁ -C ₆ alkyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, each of which is optionally substituted with 1-4 occurrences of R ⁷ ; or R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ ; each R ⁷ , R ⁸ , or R ⁹ is independently C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, nitro, —OR ^a , —NR ^b R ^c , —C(O)R ^d , — C(O)OR ^a , —C(O)NR ^b R ^c , —NR ^b C(O)R ^d , —NR ^b C(O)NR ^b R ^c , —SR ^e , —S(O)R ^e , — S(O) ₂ R ^e , —NR ^b S(O) ₂ R ^e , or —S(O) ₂ NR ^b R ^c , each of which is optionally substituted with 1-5 R ¹⁰ ; each R ¹⁰ is C ₁ -C ₆ alkyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, hydroxy, cyano, or nitro, each of which is optionally substituted with 1-4 R ¹¹ ; each R ^a , R ^b , R ^c , R ^d , or R ^e is H, C ₁ -C ₆ alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with R ¹¹ ; or R ^B and R ^C , together with the atoms to which each is attached, form a cycloalkyl or heterocyclyl ring optionally substituted with 1-4 R ¹¹ ; each R ¹¹ is independently C ₁ -C ₆ alkyl, halo, hydroxy, cycloalkyl, alkoxy, keto, cyano, or nitro; n is 0, 1, 2, 3, 4, or 5; and p is 0, 1, or 2; provided that Ring B is not wherein the connection to C(O)R ¹ and N(R ⁵ )S(O) ₂ — is as shown. [1017] In further embodiments, R″ is H or C(O)R ¹ . [1018] In further embodiments, R ¹ is C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, cycloalkyl, —OR ^A , or — NR ^B R ^C , and R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4R ⁷ . [1019] In further embodiments, R ¹ is —NR ^B R ^C , and R ^B and R ^C , together with the atoms to which each is attached, form a heterocyclyl ring optionally substituted with 1-4 R ⁷ . [1020] In further embodiments, R ¹ is selected from the group consisting of [1021] In further embodiments, each R is independently H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ -C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , or — NR ^B C(O)R ^D , each of which is optionally substituted with 1-5 R ⁸ . [1022] In further embodiments, each R is independently H, C ₁ -C ₆ alkyl, C ₁ -C ₆ haloalkyl, or halo, each of which is optionally substituted with 1-5 R ⁸ . [1023] In further embodiments, R is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R ⁸ . [1024] In further embodiments, R ⁵ is H, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R ⁹ . [1025] In further embodiments, Ring A is a monocyclic or bicyclic aryl or heteroaryl. [1026] In further embodiments, Ring A is phenyl or a 5- or 6-membered heteroaryl. [1027] In further embodiments, R ⁶ is C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₁ -C ₆ heteroalkyl, C ₁ - C ₆ haloalkyl, C ₁ -C ₆ hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cyano, hydroxy, halo, —OR ^A , —NR ^B R ^C , —C(O)R ^D , —C(O)OR ^A , —C(O)NR ^B R ^C , —S(O) ₂ R ^E , — NR ^B S(O) ₂ R ^E , or —S(O) ₂ NR ^B R ^C , each of which is optionally substituted with 1-5 R ⁹ . [1028] In further embodiments, Ring A is selected from the group consisting of: [1029] In further embodiments, Ring A is and R ⁶ is C ₁ -C ₆ alkyl or halo. [1030] In further embodiments, Ring B is phenyl. [1031] In further embodiments, Ring B is selected from: [1032] In further embodiments, Ring B is a 5- or 6-membered heteroaryl. [1033] In further embodiments, Ring B is selected from: wherein the connectivity to —S(O) ₂ is indicated by a wavy line and the connectivity to R″ is as shown. [1034] In further embodiments, n is 0, 1, or 2 and p is 0 or 1. Formula 217 [1035] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 217. Such compounds are described in US Publication No. US20170360726A1, published December 21, 2017, and corresponding to US Application No.15/533,354 filed December 4, 2015; International Publication No. WO2016090317A1, published June 9, 2016, and corresponding to International Application No. PCT/US2015/064107 filed December 4, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 217, these references incorporated by reference herein control. [1036] In an embodiment, the TDP-43 modulator is a compound according to Formula 217: , or a pharmaceutically acceptable salt thereof, wherein each of X, Y, and Z is independently N or C(R ^D )2, and Ring A, R, R″, R ⁵ , R ⁶ , R ^D , n, p and subvariables thereof are defined as for Formula 216. [1037] In further embodiments, the TDP-43 modulator is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. Formula 218 [1038] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 218. Such compounds are described in International Publication No. WO2012162249A1, published November 29, 2012, and corresponding to International Application No. PCT/US2012/038861 filed May 21, 2012; US Patent No.9,359,363, issued June 7, 2016, and corresponding to US Application No.14/118,628 filed May 21, 2012; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 218, these references incorporated by reference herein control. [1039] In an embodiment, the TDP-43 modulator is a compound according to Formula 218: and analogs, derivatives, isomers, prodrugs, and pharmaceutically acceptable salts thereof wherein, R ¹¹ and R ¹² are independently H, alkyl, alkenyl, alkynyl, cyclyl, heterocyclyl, aryl, heteroaryl, C(O)R ¹⁷ , or C(O)OR ¹⁷ , each of which can be optionally substituted. In some embodiments, R ¹¹ is an optionally substituted aryl or heteroaryl; R ¹³ and R ¹⁴ are independently H, alkyl, alkenyl, alkynyl, cyclyl, heterocyclyl, aryl, heteroaryl, OR ¹⁷ , C(O)R ¹⁷ , or C(O)OR ¹⁷ , N(R ¹⁷ )2, each of which can be optionally substituted; R15 is independently, halo, alkyl, alkenyl, cyclyl, heterocyclyl, aryl, heteroaryl, NO ₂ , OR ¹⁷ , OC(O)R ¹⁷ , OC(O)OR ¹⁷ , N(R ¹⁷ ) ₂ , NHC(O)R ¹⁷ , NHC(O)OR ¹⁷ , C(O)R ¹⁷ , C(O)OR ¹⁷ , SR ¹⁷ , or SO ₂ R ¹⁷ , each of which can be optionally substituted; b is 0, 1, 2, 3, or 4; c is 0, 1, 2, 3, 4, or 5; and when present a R ¹⁶ substituent can be located at the 2, 3, 4, 5, or 6 position of the phenyl group. [1040] In further embodiments, the TDP-43 modulator is selected from the group consisting of:

Formula 219 [1041] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 219. Such compounds are described in US Publication No. US20220160699A1, published May 26, 2022 and corresponding to US Application No.17/310,971 filed March 16, 2020; International Publication No. WO2020190866A1, published September 24, 2020 and corresponding to International Application No. PCT/US2020/022972 filed March, 16, 2020; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 219, these references incorporated by reference herein control. [1042] In an embodiment, the TDP-43 modulator is a compound according to Formula 219: wherein, R ₁ is H, OH, or lower alkyl; R ₂ is an optionally substituted aromatic ring of four, five, or six carbons, wherein the aromatic ring is carbocyclic or heterocyclic, and wherein each position on the aromatic ring is independently H, halo, lower alkyl, OH, lower alkoxy, NH ₂ , lower alkylamino, di(lower alkyl)amino, SH, lower alkylthio, NO ₂ , or two residues together form a heterocyclic ring; R ₃ and R ₈ are each independently H, lower alkyl, ═O, ═S, OH, NH ₂ , aryl, or aralkyl, where aryl and aralkyl are substituted with 0-3 moieties selected from the group consisting of halo, OH, NH ₂ , lower alkyl, lower alkoxy, SH, lower alkylthio, and lower alkylamino R ₄ , R ₅ , R ₆ , and R ₇ are each independently H, lower alkyl, OH, NH ₂ , aryl, or aralkyl, where aryl and aralkyl are substituted with 0-3 moieties selected from the group consisting of halo, OH, NH ₂ , lower alkyl, lower alkoxy, SH, lower alkylthio, and lower alkylamino; at least one of R ₉ and R ₁₀ , R ₁₀ and R ₁₁ , or R ₁₁ and R ₁₂ , together form an optionally substituted benzene ring, wherein the benzene ring is optionally substituted with H, halo, lower alkyl, OH, lower alkoxy, or NO ₂ ; and wherein any one of the carbon atoms on any one of fused rings of Formula 219 is optionally replaced with a nitrogen atom. [1043] In further embodiments, the TDP-43 modulator is selected from the group consisting of:

, or a pharmaceutically acceptable salt thereof. [1044] In further embodiments, the compound is according to Formula 219 wherein the compound is according to any one of the subformulas: , wherein, R ₁ is H, OH, or lower alkyl; R ₂ , is an optionally substituted aromatic ring of four, five, or six carbons, wherein the aromatic ring is carbocyclic or heterocyclic, and wherein each position on the aromatic ring is independently H, halo, lower alkyl, OH, lower alkoxy, NH ₂ , lower alkylamino, di(lower alkyl)amino, SH, lower alkylthio, NO ₂ , or two residues together form a heterocyclic ring; R ₃ and R ₈ are each independently H, lower alkyl, ═O, ═S, OH, NH ₂ , aryl, or aralkyl, where aryl and aralkyl are substituted with 0-3 moieties selected from the group consisting of halo, OH, NH ₂ , lower alkyl, lower alkoxy, SH, lower alkylthio, and lower alkylamino; R ₄ , R ₅ , R ₆ , and R ₇ are each independently H, lower alkyl, OH, NH ₂ , aryl, or aralkyl, where aryl and aralkyl are substituted with 0-3 moieties selected from the group consisting of halo, OH, NH ₂ , lower alkyl, lower alkoxy, SH, lower alkylthio, and lower alkylamino; R ₈ , R ₉ , R ₁₀ , R ₁₁ , R ₁₂ , R ₁₃ , R ₁₄ are each independently H, halo, lower alkyl, OH, lower alkoxy, or NO ₂ ; and wherein any one of the carbon atoms on any one of fused rings is optionally replaced with a nitrogen atom. [1045] In further embodiments, the compound is according to Formula 219 wherein the compound is according to the subformulas: wherein, R ₁ is H, OH, or lower alkyl; R ₂ is an optionally substituted aromatic ring of four, five, or six carbons, wherein the aromatic ring is carbocyclic or heterocyclic, and wherein each position on the aromatic ring is independently H, halo, lower alkyl, OH, lower alkoxy, NH ₂ , lower alkylamino, di(lower alkyl)amino, SH, lower alkylthio, NO ₂ , or two residues together form a heterocyclic ring; R ₃ , R ₄ , R ₅ , R ₆ , and R ₇ are each independently H, lower alkyl, OH, NH ₂ , aryl, or aralkyl, where aryl and aralkyl are substituted with 0-3 moieties selected from the group consisting of halo, OH, NH ₂ , lower alkyl, lower alkoxy, SH, lower alkylthio, and lower alkylamino; at least one of R ₈ and R ₉ , R ₉ and R ₁₀ , or R ₁₀ and R ₁₁ together form an optionally substituted benzene ring, wherein the benzene ring is optionally substituted with H, halo, lower alkyl, OH, lower alkoxy, or NO ₂ ; and wherein any one of the carbon atoms on any one of fused rings is optionally replaced with a nitrogen atom. [1046] In further embodiments, the compound is according to Formula 219 wherein the compound is according to any one of the subformulas: wherein, R ₁ is H, OH, or lower alkyl; R ₂ is an optionally substituted aromatic ring of four, five, or six carbons, wherein the aromatic ring is carbocyclic or heterocyclic, and wherein each position on the aromatic ring is independently H, halo, lower alkyl, OH, lower alkoxy, NH ₂ , lower alkylamino, di(lower alkyl)amino, SH, lower alkylthio, NO ₂ , or two residues together form a heterocyclic ring; R ₃ , R ₄ , R ₅ , R ₆ , and R ₇ are each independently H, lower alkyl, OH, NH ₂ , aryl, or aralkyl, where aryl and aralkyl are substituted with 0-3 moieties selected from the group consisting of halo, OH, NH ₂ , lower alkyl, lower alkoxy, SH, lower alkylthio, and lower alkylamino; R ₈ , R ₉ , R ₁₀ , R ₁₁ , R ₁₂ , and R13 are each independently H, halo, lower alkyl, OH, lower alkoxy, or NO2; and wherein any one of the carbon atoms on any one of fused rings is optionally replaced with a nitrogen atom. Formula 220 [1047] In an embodiment, the TDP-43 modulator is AIM4, a compound according to formula 220 described in Prasad, A., Raju, G., Sivalingam, V. et al. An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models. Sci Rep 6, 39490 (2016), which is incorporated by reference in its entirety herein: Formula 221 [1048] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 221. Such compounds are described in International Publication No. WO2022049377A1, published March 10, 2022, and corresponding to International Application No. PCT/GB2021/052262 filed September 1, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 221, this reference incorporated by reference herein control. [1049] In an embodiment, the TDP-43 modulator is a compound according to Formula 221: wherein, R _1a is H or methyl; R _1b is H or fluoro; A is group (Aa), (Ab), (Ac) or (Ad): wherein group (Aa) is: Aa); wherein: R ₂ is H, C _1-4 alkyl, C _{1- 4} alkylene(aryl), C _1-4 alkylene(OH), C _1-4 alkylene(C _3-6 cycloalkyl), C _{1- 4} alkylene(4-7 membered heterocycloalkyl), C _1-4 alkoxy, OC _1-4 alkylene(aryl), C _{1- 4} alkyleneOC _1-4 alkyl, C _1-4 alkyleneOC _3-6 cycloalkyl, C _1-4 alkyleneO(4-7 membered heterocycloalkyl), C _{1- 4} alkyleneO(aryl), C _3-6 alkynyl and C _1-4 alkyleneO(C _3-6 alkynyl); wherein said aryl, heterocycloalkyl or cycloalkyl are optionally substituted by 1, 2 or 3 substituents each independently selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _{1- 4} haloalkyl, halo, CN, OH, NR _2a R _2b , SO ₂ R _2c and NHSO ₂ R _2c ; R _2a is selected from H and C _1-4 alkyl; R _2b is selected from H, C _1-4 alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _1-4 haloalkyl, aryl and 4-7 membered heterocycloalkyl; R _2c is selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _{1- 4} haloalkyl, aryl and 4-7 membered heterocycloalkyl; each R ₃ is independently halo, methyl, ethyl or n-propyl; m is 0, 1, 2, 3 or 4; wherein group (Ab) is: wherein: R ₄ is H, C _1-4 alkyl or C _1-4 alkylene(aryl); wherein said aryl is optionally substituted by 1, 2 or 3 substituents each independently selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _1-4 haloalkyl, halo, CN, OH, NR _4a R _4b , SO ₂ R _4c and NHSO ₂ R _4c ; R _4a is selected from H and C _1-4 alkyl; R _4b is selected from H, C _1-4 alkyl, C _{3- 6} cycloalkyl, C _1-4 alkoxy, C _1-4 haloalkyl, aryl and 4-7 membered heterocycloalkyl; R _4c is selected from C1-4alkyl, C3-6cycloalkyl, C1-4alkoxy, C1-4haloalkyl, aryl and 4-7 membered heterocycloalkyl; R ₅ is H or C _1-4 alkyl; each R ₆ is independently C _1-4 alkyl or halo; n is 0, 1, 2 or 3; wherein group (Ac) is: (Ac); wherein: R ₇ is C _1-4 alkyl, C _{1- 4} alkylene(OH) or C _1-4 alkyleneOC _1-4 alkyl; o is 1 or 2; wherein group (Ad) is: (Ad); wherein: X is a bond, O or CH ₂ ; each R ₈ is independently halo, C _1-4 alkyl, C _1-4 alkoxy OC _1-4 haloalkyl, OC _1-4 alkylene(C _{3- 6} cycloalkyl), OC _1-4 alkylene(4-7 membered heterocycloalkyl) or OH; wherein said heterocycloalkyl and cycloalkyl are optionally substituted by 1, 2 or 3 substituents independently selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _1-4 haloalkyl, halo, CN, OH, NR _8a R _8b , SO ₂ R _8c and NHSO ₂ R _8c ; R _8a is selected from H and C _1-4 alkyl; R _8b is selected from H, C _{1- 4} alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _1-4 haloalkyl, aryl and 4-7 membered heterocycloalkyl; R _8c is selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _1-4 haloalkyl, aryl and 4-7 membered heterocycloalkyl; each R ₉ is independently halo or C _1-4 alkyl; p is 0, 1 or 2; q is 0, 1, 2, 3 or 4; wherein B is: erein: R ₁₀ is H, halo or C _1-4 alkyl; D, E and F are each independently C(R ₁₀ ); or one of D, E and F is N and the two remaining D, E and F groups are independently C(R ₁₀ ); and provided that the compound of formula (I) is not (E)-N-(3-fluoro-2-methylphenyl)-3-(1H- indazol-6-yl)acrylamide; or a pharmaceutically acceptable salt and/or solvate thereof. [1050] In further embodiments, R _1a is H or methyl; R _1b is H or fluoro; A is group (Aa), (Ab), (Ac) or (Ad): wherein group (Aa) is: (Aa); wherein: R ₂ is H, C _{1- 4} alkyl, C _1-4 alkylene(aryl), C _1-4 alkylene(OH), C _1-4 alkylene(C _3-6 cycloalkyl), C _{1- 4} alkylene(4- 7 membered heterocycloalkyl), C _1-4 alkoxy, OC _1-4 alkylene(aryl), C _{1- 4} alkyleneOC _1-4 alkyl, C _1-4 alkyleneOC _3-6 cycloalkyl, C _1-4 alkyleneO(4-7 membered heterocycloalkyl), C _{1- 4} alkyleneO(aryl), C _3-6 alkynyl or C _1-4 alkyleneO(C _3-6 alkynyl); wherein said aryl, heterocycloalkyl or cycloalkyl may be optionally substituted by up to 3 substituents each independently selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _1-4 alkoxy, C _{1- 4} haloalkyl, halo and CN; each R ₃ is independently halo, methyl, ethyl or n-propyl; m is 0, 1, 2, 3 or 4; wherein group (Ab) is: (Ab); wherein: R ₄ is H, C _1-4 alkyl or C _{1- 4} alkylene(aryl); wherein said aryl may be optionally substituted by up to 3 substituents each independently selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _{1- 4} alkoxy, C _1-4 haloalkyl, halo and CN; R ₅ is H or C _1-4 alkyl; each R ₆ is independently C _1-4 alkyl or halo; n is 0, 1, 2 or 3; wherein group (Ac) is: (Ac); wherein: R ₇ is C _1-4 alkyl, C _{1- 4} alkylene(OH) or C _1-4 alkyleneOC _1-4 alkyl; o is 1 or 2; wherein group (Ad) is: (Ad); wherein: X is a bond, O or CH ₂ ; each R ₈ is independently halo, C _1-4 alkyl, C _1-4 alkoxy or OH; each R ₉ is independently halo or C _{1- 4} alkyl; p is 0, 1 or 2; q is 0, 1, 2, 3 or 4; wherein B is: ein: R ₁₀ is H, halo or C _1-4 alkyl; and D, E and F are each independently C(R ₁₀ ); or one of D, E and F is N and the two remaining D, E and F groups are independently C(R ₁₀ ); provided that the compound of formula (I) is not (E)-N-(3-fluoro-2-methylphenyl)-3-(1H- indazol-6- yl)acrylamide; or a pharmaceutically acceptable salt and/or solvate thereof. [1051] In further embodiments, R ₂ is C _1-4 alkyl, C _{1- 4} alkylene(aryl), C _1-4 alkylene(OH), C _{1- 4} alkyleneOC _1-4 alkyl, C _1-4 alkyleneOC _3-6 cycloalkyl, C _{1- 4} alkyleneO(aryl), C _1-4 alkylene(4-7 membered heterocycloalkyl), C _1-4 alkyleneO(4-7 membered heterocycloalkyl) and C _{1- 4} alkyleneO(C _3-6 alkynyl); wherein said aryl, heterocycloalkyl or cycloalkyl may be optionally substituted by up to 3 substituents each independently selected from C _{1- 4} alkyl, C _3-6 cycloalkyl; C _1-4 alkoxy, C _1-4 haloalkyl, halo and CN. [1052] In further embodiments, the aryl is unsubstituted. [1053] In further embodiments, the aryl is substituted by 1, 2 or 3 substituents independently selected from methyl, chloro and fluoro. [1054] In further embodiments, the heterocycloalkyl is unsubstituted. [1055] In further embodiments, the heterocycloalkyl is substituted by 1, 2 or 3 substituents independently selected from CH ₂ CH ₂ F and fluoro. [1056] In further embodiments, each R ₃ is independently fluoro or methyl. [1057] In further embodiments, m is 1 or 2. [1058] In further embodiments, m is 1 and R ₃ is in the 3- position. [1059] In further embodiments, m is 1 and R ₃ is in the 6- position. [1060] In further embodiments, m is 2, one R ₃ is in the 3-position, and the other R ₃ is in the 6-position. [1061] In further embodiments, R ₄ is H, methyl or benzyl. [1062] In further embodiments, R ⁵ is H. [1063] In further embodiments, each R ₆ is independently fluoro or methyl. [1064] In further embodiments, n is 0. [1065] In further embodiments, R ₇ is methyl, CH ₂ OH or CH ₂ OMe. [1066] In further embodiments, o is 2. [1067] In further embodiments, X is a bond or O. [1068] In further embodiments, R ₈ is independently methyl, OMe or fluoro. [1069] In further embodiments, p is 0 or 1. [1070] In further embodiments, each R ₉ is independently fluoro. [1071] In further embodiments, q is 1 or 2. [1072] In further embodiments, D, E and F are C(R ₁₀ ). [1073] In further embodiments, D is N, and E and F are C(R ₁₀ ). [1074] In further embodiments, E is N, and D and F are C(R ₁₀ ). [1075] In further embodiments, F is N, and D and E are C(R ₁₀ ). [1076] In further embodiments, each R ₁₀ is independently H, fluoro, chloro or methyl. [1077] In further embodiments, the TDP-43 modulator is selected from the group consisting of: (E)-N-(3-fluoro-2-methylphenyl)-3-(7-methyl-1H-indazol-6-yl) acrylamide; (E)-N-(2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylam ide; (R,E)-N-(2,3-dihydro- 1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-((1R,2R)-2- methylcyclohexyl) acrylamide (racemic mixture); (E) 3 (1H indazol 6 yl) N ((1R2R) 2 methylcyclohexyl) acrylamide (enantiomer 1); (E)-3-(1H-indazol-6-yl)-N-((1R,2R)-2- methylcyclohexyl) acrylamide (enantiomer 2); (E)-N-(7-fluoro-2,3-dihydro-1H-inden-1- yl)-3-(1H-indazol-6-yl)acrylamide; (E)-N-(6-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol-6-yl)acrylamide; (E)-N-(5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6- yl)acrylamide; (E)-N-(4-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-y l)acrylamide; (E)-N-(2,3-dihydro-1H-inden-1-yl)-3-(7-fluoro-1H-indazol-6-y l)acrylamide; (E)-N-(2,3- dihydro-1H-inden-1-yl)-3-(5-fluoro-1H-indazol-6-yl)acrylamid e; (E)-N-(2,3-dihydro-1H- inden-1-yl)-3-(4-fluoro-1H-indazol-6-yl)acrylamide; (E)-3-(5-chloro-1H-indazol-6-yl)-N- (2,3-dihydro-1H-inden-1-yl)acrylamide; (E)-3-(4-chloro-1H-indazol-6-yl)-N-(2,3-dihydro- 1H-inden-1-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-(2-methyl-2,3-dihydro-1H-inden-1- yl)acrylamide (mixture of stereoisomers); (E)-3-(1H-indazol-6-yl)-N-(2-methyl-2,3- dihydro-1H-inden-1-yl)acrylamide (stereoisomer 1); (E)-3-(1H-indazol-6-yl)-N-(2-methyl- 2,3-dihydro-1H-inden-1-yl)acrylamide (stereoisomer 2); (E)-3-(1H-indazol-6-yl)-N-(2- methyl-2,3-dihydro-1H-inden-1-yl)acrylamide (stereoisomer 3); (E)-3-(1H-indazol-6-yl)- N-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide (stereoisomer 4); (E)-3-(1H-indazol- 6-yl)-N-(3-methylchroman-4-yl)acrylamide (mixture of stereoisomers); (E)-3-(1H-indazol- 6-yl)-N-(3-methylchroman-4-yl)acrylamide (stereoisomer 1); (E)-3-(1H-indazol-6-yl)-N- (3-methylchroman-4-yl)acrylamide (stereoisomer 2); (E)-3-(1H-indazol-6-yl)-N-(3- methylchroman-4-yl)acrylamide (stereoisomer 3); (E)-3-(1H-indazol-6-yl)-N-(3- methylchroman-4-yl)acrylamide (stereoisomer 4); (E)-N-(2-(benzyloxy)phenyl)-3-(1H- indazol-6-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-(2- (phenoxymethyl)phenyl)acrylamide; (E)-N-(2-(cyclobutoxymethyl)phenyl)-3-(1H-indazol- 6-yl)acrylamide; (E)-N-(1-benzyl-1H-indazol-7-yl)-3-(1H-indazol-6-yl)acrylami de; (E)-3- (1H-indazol-6-yl)-N-(1-methyl-1H-indazol-7-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-(m- tolyl)acrylamide; (E)-N-(3-chlorophenyl)-3-(1H-indazol-6-yl)acrylamide; (E)-N-(3- fluorophenyl)-3-(1H-indazol-6-yl)acrylamide; (E)-N-(2,6-dimethylphenyl)-3-(1H-indazol- 6-yl)acrylamide; (E)-N-((1R,3R)-3-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-ind azol-6- yl)acrylamide (mixture of stereoisomers); (E)-N-((1R,3R)-3-fluoro-2,3-dihydro-1H-inden- 1-yl)-3-(1H-indazol-6-yl)acrylamide (stereoisomer 1); (E)-N-((1R,3S)-3-fluoro-2,3- dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide (stereoisomer 2); (E)-N-(2- (hydroxymethyl)phenyl)-3-(1H-indazol-6-yl)acrylamide; (E)-N-(3-fluoro-2,6- dimethylphenyl)-3-(1H-indazol-6-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-(2- (methoxymethyl)phenyl)acrylamide; (E)-N-(2-(((1-(2-fluoroethyl)azetidin-3- yl)oxy)methyl)phenyl)-3-(1H-indazol-6-yl)acrylamide hydrochloride; (E)-N-(2-((3- fluoroazetidin-1-yl)methyl)phenyl)-3-(1H-indazol-6-yl)acryla mide; (E)-N-(2-(2-(3- fluoroazetidin-1-yl)ethyl)phenyl)-3-(1H-indazol-6-yl)acrylam ide; (E)-N-(2-fluoro-6- methylphenyl)-3-(1H-indazol-6-yl)acrylamide; (E)-N-(3-fluoro-2-methylphenyl)-3-(1H- pyrazolo[4,3-b]pyridin-6-yl)acrylamide; (E)-N-(2,3-dihydro-1H-inden-1-yl)-3-(1H- pyrazolo[4,3-c]pyridin-6-yl)acrylamide; (E)-N-(2,3-dihydro-1H-inden-1-yl)-3-(1H- pyrazolo[3,4-b]pyridin-6-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-((1S,2S)-2-methoxy- 2,3-dihydro-1H-inden-1-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-(7-methyl-2,3-dihydro- 1H-inden-1-yl)acrylamide; (E)-3-(1H-indazol-6-yl)-N-(3-methyl-2,3-dihydro-1H-inden-1- yl)acrylamide; and (E)-3-(1H-indazol-6-yl)-N-(2-((prop-2-yn-1- yloxy)methyl)phenyl)acrylamide; or a pharmaceutically acceptable salt and/or solvate of any one thereof. Formula 222 [1078] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 222. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 222, this reference incorporated by reference herein control. [1079] In an embodiment, the TDP-43 modulator is a compound according to Formula 222: or a pharmaceutically acceptable salt or solvate thereof, wherein R ¹ is hydrogen, halo, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C _1-9 heteroaryl, optionally substituted C _3-8 cycloalkyl, and optionally substituted C _{1- 9} heterocyclyl; each of X ¹ and X ² is independently selected from O, S, N, and C; W is a bond; O; S; (CH2)n; S(O); SO2; NRa; C(O); C(O)NRa; NRaC(O); SO2NRa; NRaSO2; CRa=CRb; C=NRa; or NRa=CRb, wherein n is 1-5 and each of Ra and Rb is independently H, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; each of R ² and R ³ is optionally present depending on the valence of the atom to which each is attached, and if present, each of R ² and R ³ is independently hydrogen, halo, hydroxyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, and optionally substituted C1-9 heterocyclyl; R ⁴ is hydrogen, optionally substituted C1-6 alkyl, C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, and optionally substituted C1-9 heterocyclyl; U is hydrogen, wherein m is 0-3, a ^{5 6 7 8} nd each of R , R , R, R , and R ⁹ is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, and optionally substituted C1-9 heterocyclyl; or R3 and U, together with the nitrogen atom to which they are attached, form 4- to 6- membered heterocyclyl or heteroaryl optionally substituted by one or more substituents selected from hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, and optionally substituted C1-9 heterocyclyl; one of the two is a single bond, and the other is a double bond; or each of the two are aromatic bonds; each of V and Z is independently N or CH; and A is optionally substituted C3-8 carbocyclyl, optionally substituted C1-9 heterocyclyl, and optionally substituted C1-9 heteroaryl. [1080] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of:

Formula 223 [1081] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 223. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 223, this reference incorporated by reference herein control. [1082] In an embodiment, the TDP-43 modulator is a compound according to Formula 223:

or a pharmaceutically acceptable salt or solvate thereof, wherein R ¹ is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; each of Q ¹ , Q ² , Q ³ , and Q ⁴ is independently C or N, and at least one of Q ¹ , Q ² , Q ³ , and Q ⁴ is N; W is a bond; O; S; (CH ₂ ) _n ; S(O); SO ₂ ; NR _a ; C(O); C(O)NR _a ; NR _a C(O); SO ₂ NR _a ; NR _a SO ₂ ; CRa=CRb; C=NRa; or NRa=CRb, wherein n is 1-5, and each of Ra and Rb is independently H, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3- 8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; each of R ² and R ³ is optionally present depending on the valence of the atom to which each is attached, and if present, each of R ² and R ³ is independently hydrogen, halo, hydroxyl, optionally substituted C6- 10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; R ⁴ is hydrogen, optionally substituted C1-6 alkyl, C3-8 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, or optionally substituted C1-9 heterocyclyl; U is hydrogen, wherein m is 0-3, and each of R ⁵ , R ⁶ , R ⁷ , R ⁸ , and R ⁹ is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; or R ³ and U, together with the nitrogen atom to which they are attached, form 4- to 6- membered heterocyclyl or heteroaryl optionally substituted by one or more substituents selected from hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C _3-8 cycloalkyl, or optionally substituted C _1-9 heterocyclyl; wherein each is a single bond or a double bond and at least one is a double bond; or each is an aromatic bond; each of V and Z is independently N or CH; and A is optionally substituted C _3-8 carbocyclyl, optionally substituted C _1-9 heterocyclyl, or optionally substituted C1-9 heteroaryl. [1083] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of:

Formula 224 [1084] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 224. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 224, this reference incorporated by reference herein control. [1085] In an embodiment, the TDP-43 modulator is a compound according to Formula 224:

or a pharmaceutically acceptable salt thereof, wherein R ¹ is optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C1-9 heterocyclyl, optionally substituted C6-10 aryl, or optionally substituted C1-9 heteroaryl; R ² is optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, -N=CHRa, or -N=CHRbRc, wherein Ra is optionally substituted C1-6 alkyl or optionally substituted C1-9 heteroaryl; Rb is optionally substituted C6-10 arylene; and Rc is hydrogen or NHSO2Me; and each of R ³ and R ⁴ is independently H, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; or R3 and R4, together with the nitrogen to which they are attached, form optionally substituted C1-9 heterocyclyl. [1086] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of:

Formula 225 [1087] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 225. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 225, this reference incorporated by reference herein control. [1088] In an embodiment, the TDP-43 modulator is a compound according to Formula 225: or a pharmaceutically acceptable salt thereof, wherein each bond denoted as is either a single bond or a double bond, provided that the bonds denoted as are not both simultaneously double bonds; X ¹ is selected from N and CR ^A ; X ² is selected from N and CR ^A ; X ³ is selected from N and CR ^A ; each R ^A is independently selected from H, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy; Ar is selected from C6-10 aryl and 5-10 membered heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R ⁷ ; each R ⁷ is independently selected from halo, CN, NO2, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, OR ^a1 , SR ^a1 , C(O)R ^b1 , C(O)NR ^c2 R ^d1 , C(O)OR ^a1 , OC(O)R ^b1 , OC(O)NR ^c1 R ^d1 , NR ^c1 R ^d1 , NR ^c1 C(O)R ^b1 , NR ^c1 C(O)OR ^a1 , NR ^c1 C(O)NR ^c1 R ^d1 , NR ^c1 S(O) ₂ R ^b1 , NR ^c1 S(O) ₂ NR ^c1 R ^d1 , S(O) ₂ R ^b1 , and S(O) ₂ NR ^c1 R ^d1 ; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, NO2, OR ^a1 , SR ^a1 , C(O)R ^b1 , C(O)NR ^c1 R ^d1 , C(O)OR ^a1 , OC(O)R ^b1 , OC(O)NR ^c1 R ^d1 , NR ^c1 R ^d1 , NR ^c1 C(O)R ^b1 , NR ^c1 C(O)OR ^a1 , NR ^c1 C(O)NR ^c1 R ^d1 , NR ^c1 S(O)2R ^b1 , NR ^c1 S(O) ₂ NR ^c1 R ^d1 , S(O) ₂ R ^b1 and S(O) ₂ NR ^c1 R ^d1 ; R ¹ is selected from the group consisting of H and C1-6 alkyl, wherein said C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, OR ^a2 , C(O)R ^b2 , C(O)NR ^c2 R ^d2 , C(O)OR ^a2 , NR ^c2 R ^d2 , NR ^c2 C(O)R ^b2 , NR ^c2 C(O)OR ^a2 , NR ^c2 C(O)NR ^c2 R ^d2 , NR ^c2 S(O)2R ^b2 , NR ^c2 S(O)2NR ^c2 R ^d2 , S(O)2R ^b2 , and S(O)2NR ^c2 R ^d2 ; R ² is C1-6 alkyl, which is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, OR ^a2 , C(O)R ^b2 , C(O)NR ^c2 R ^d2 , C(O)OR ^a2 , NR ^c2 R ^d2 , NR ^c2 C(O)R ^b2 , NR ^c2 C(O)OR ^a2 , NR ^c2 C(O)NR ^c2 R ^d2 , NR ^c2 S(O)2R ^b2 , NR ^c2 S(O)2NR ^c2 R ^d2 , S(O)2R ^b2 , and S(O)2NR ^c2 R ^d2 ; or R ¹ and R ² together with the N to which they are attached form a 4-7 membered non-aromatic heterocyclyl, which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected R ⁸ ; each R ⁸ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR ^a2 , C(O)R ^b2 , C(O)NR ^c2 R ^d2 , C(O)OR ^a2 , NR ^c2 R ^d2 , NR ^c2 C(O)R ^b2 , NR ^c2 C(O)OR ^a2 , NR ^c2 C(O)NR ^c2 R ^d2 , NR ^c2 S(O)2R ^b2 , NR ^c2 S(O)2NR ^c2 R ^d2 , S(O)2R ^b2 , and S(O)2NR ^c2 R ^d2 ; R ³ is selected from H, C1-6 alkyl, and C1-6 haloalkyl; R ⁴ is selected from H, C1-6 alkyl, and C1-6 haloalkyl; Y is selected from N, C, and CR ^A ; when the bond between R ⁵ and Y is a single bond, R ⁵ is 5-10 membered heteroaryl, which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, OR ^a3 , SR ^a3 , C(O)R ^b3 , C(O)NR ^c3 R ^d3 , C(O)OR ^a3 , OC(O)R ^b3 , OC(O)NR ^c3 R ^d3 , NR ^c3 R ^d3 , NR ^c3 C(O)R ^b3 , NR ^c3 C(O)OR ^a3 , NR ^c3 C(O)NR ^c3 R ^d3 , NR ^c3 S(O)2R ^b3 , NR ^c3 S(O)2NR ^c3 R ^d3 , S(O)2R ^b3 , and S(O)2NR ^c3 R ^d3 ; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, NO2, OR ^a3 , SR ^a3 , C(O)R ^b3 , C(O)NR ^c3 R ^d3 , C(O)OR ^a3 , OC(O)R ^b3 , OC(O)NR ^c3 R ^d3 , NR ^c3 R ^d3 , NR ^c3 C(O)R ^b3 , NR ^c3 C(O)OR ^a3 , R ^c3 C(O)NR ^c3 R ^d3 , NR ^c3 S(O)2R ^b3 , NR ^c3 S(O)2NR ^c3 R ^d3 , S(O)2R ^b3 and S(O)2NR ^c3 R ^d3 ; when the bond between R ⁵ and Y is a double bond, R ⁵ is CR ^B R ^c ; R ^B is selected from H, C1-6 alkyl, and C1-6 haloalkyl; R ^c is selected from C6-10 aryl and 5-10 membered heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, OR ^a3 , SR ^a3 , C(O)R ^b3 , C(O)NR ^c3 R ^d3 , C(O)OR ^a3 , OC(O)R ^b3 , OC(O)NR ^c3 R ^d3 , NR ^c3 R ^d3 , NR ^c3 C(O)R ^b3 , NR ^c3 C(O)OR ^a3 , NR ^c3 C(O)NR ^c3 R ^d3 , NR ^c3 S(O)2R ^b3 , NR ^c3 S(O)2NR ^c3 R ^d3 , S(O)2R ^b3 , and S(O)2NR ^c3 R ^d3 ; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, NO2, OR ^a3 , SR ^a3 , C(O)R ^b3 , C(O)NR ^c3 R ^d3 , C(O)OR ^a3 , OC(O)R ^b3 , OC(O)NR ^c3 R ^d3 , NR ^c3 R ^d3 , NR ^c3 C(O)R ^b3 , NR ^c3 C(O)OR ^a3 , NR ^c3 C(O)NR ^c3 R ^d3 , NR ^c3 S(O)2R ^b3 , NR ^c3 S(O)2NR ^c3 R ^d3 , S(O)2R ^b3 and S(O)2NR ^c3 R ^d3 ; or R ⁴ and R ⁵ together with Y and N to which R ⁴ is attached form a 5-14 membered heteroaryl, which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R ⁹ ; each R ⁹ is independently selected from halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, OR ^a3 , SR ^a3 , C(O)R ^b3 , C(O)NR ^c3 R ^d3 , C(O)OR ^a3 , OC(O)R ^b3 , OC(O)NR ^c3 R ^d3 , NR ^c3 R ^d3 , NR ^c3 C(O)R ^b3 , NR ^c3 C(O)OR ^a3 , NR ^c3 C(O)NR ^c3 R ^d3 , NR ^c3 S(O)2R ^b3 , NR ^c3 S(O)2NR ^c3 R ^d3 , S(O)2R ^b3 , and S(O)2NR ^c3 R ^d3 ; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, NO2, OR ^a3 , SR ^a3 , C(O)R ^b3 , C(O)NR ^c3 R ^d3 , C(O)OR ^a3 , OC(O)R ^b3 , OC(O)NR ^c3 R ^d3 , NR ^c3 R ^d3 , NR ^c3 C(O)R ^b3 , NR ^c3 C(O)OR ^a3 , NR ^c3 C(O)NR ^c3 R ^d3 , NR ^c3 S(O)2R ^b3 , NR ^c3 S(O)2NR ^c3 R ^d3 , S(O)2R ^b3 and S(O)2NR ^c3 R ^d3 ; R ⁶ is selected from H, C1-6 alkyl, and C1-6 haloalkyl; or R ⁶ is absent; each R ^a1 , R ^b1 , R ^a2 , R ^b2 , R ^a3 , and R ^b3 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R ^g ; each R ^c1 , R ^d1 , R ^c2 , R ^d2 , R ^c3 , and R ^d3 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(O)R ^b7 , C(O)NR ^c7 R ^d7 , C(O)OR ^a7 , NR ^c7 R ^d7 , S(O)R ^b7 , S(O)NR ^c7 R ^d7 , S(O)2R ^b7 , and S(O)2NR ^c7 R ^d7 ; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R ^g ; each R ^a7 , R ^b7 , R ^c7 , and R ^d7 is in dependently selected from H, C1-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and R ^g , wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R ^g ; or any R ^cl and R ^dl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7- membered non-aromatic heterocyclyl group optionally substituted with 1, 2, or 3 substituents independently selected from R ^g ; or any R ^c2 and R ^d2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7- membered non-aromatic heterocyclyl group optionally substituted with 1, 2, or 3 substituents independently selected from R ^g ; or any R ^c3 and R ^d3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7- membered non-aromatic heterocyclyl group optionally substituted with 1, 2, or 3 substituents independently selected from R ^g ; each R ^g is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano-C1-3 alkylene, HO-C1-3 alkylene, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfamyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 acyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino. [1089] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of:

Formula 226 [1090] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 226. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 226, this reference incorporated by reference herein control. [1091] In an embodiment, the TDP-43 modulator is a compound according to Formula 226: or a pharmaceutically acceptable salt thereof, wherein R ¹ is hydroxy, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; each occurrence of R ² is independently optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; R ³ is a nitrogen- or oxygen-containing moiety; Ring A is (i) a 5 or 6-membered heteroaryl or 5-6 or 6-5 membered bicyclic heteroaryl, each having at least one nitrogen or oxygen ring atom, or (ii) phenyl; L ¹ is absent, C1-C2 alkylene, -NR ^C -, -O-, -S-, -C(O)-, -NHC(O)-, or - C(O)NH-; L ² is -O-(CR ^a R ^b )m-, -(CR ^a R ^b )m-, -NR ^c -(CR ^a R ^b )m-, or -S-(CR ^a R ^b )m-; X ¹ is CH, N, or CR ^C ; each occurrence of R ^a and R ^b are independently hydrogen, hydroxy, hydroxy(Ci-4)alkyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3- 8 cycloalkyl, or optionally substituted C1-9 heterocyclyl, halogen, nitro, NR ^c C(O)R ^d , - NOR ^d , -SR ^d , -NR ^d R ^e , -C(O)R ^d , -C(S)R ^d , -OC(O)R ^d , -SC(O)R ^d , OC(S)R ^d , SC(S)R ^d , - NR ^c C(S)R ^d , -SO ₂ R ^c , -S(O)R ^c , -NR ^c SO ₂ R ^d , -OS(O) ₂ R ^d , -OP(O)R ^d R ^e , or -P(O)R ^d R ^e ; R ^c is a hydrogen or C1-6 alkyl; each occurrence of R ^d and R ^e are independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C1-9 heteroaryl, optionally substituted C3-8 cycloalkyl, or optionally substituted C1-9 heterocyclyl; m is 1-4; and p is 1 or 2. [1092] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of:

Formula 227 [1093] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 227. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 227, this reference incorporated by reference herein control. [1094] In an embodiment, the TDP-43 modulator is a compound according to Formula 227 , or a pharmaceutically acceptable salt thereof, wherein Q ¹ and Q ² are each independently CH or N, wherein Q ¹ and Q ² are not both N; each R ¹ is independently hydroxy, C1-4 alkyl, or C1-4 alkoxy; n is 0, 1, or 2; each R ² is independently C1-4 alkyl or C1-4 alkoxy; and m is 0 or 1. [1095] In further embodiments, the TDP-43 modulator compound is or a pharmaceutically acceptable salt thereof. Formula 228 [1096] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 228. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 228, this reference incorporated by reference herein control. [1097] In an embodiment, the TDP-43 modulator is a compound according to Formula 228: or a pharmaceutically acceptable salt thereof, wherein Ar ¹ is phenyl or pyridyl, with each optionally independently substituted with 1 or 2 C1-4 alkoxy; Ar ² is phenyl, pyridyl, or pyrimidyl with each optionally independently substituted with halo, C1-4 alkyl, C1-4 alkoxy, or C(O)NR ^2a R ^2b ; and R ^2a and R ² are each independently H or C1-4 alkyl. [1098] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of:

Formula 229 [1099] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 229. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 229, this reference incorporated by reference herein control. [1100] In an embodiment, the TDP-43 modulator is a compound according to Formula 229:

or a pharmaceutically acceptable salt thereof, wherein R ¹ is hydroxy, C1-4 alkoxy, or H(CO)R ^1a ; and R ^1a is phenyl or pyridyl, optionally substituted with amino, alkylamino, or dialkylamino. [1101] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of: Formula 230 [1102] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 230. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 230, this reference incorporated by reference herein control. [1103] In an embodiment, the TDP-43 modulator is a compound according to Formula 230:

or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl or pyridyl, with each optionally independently substituted with 1 or 2 alkyl, aminoalkyl, (alkylamino)alkyl, or (dialkylamino)alkyl; R ¹ is hydrogen or alkyl; and R ² is hydrogen or halo. [1104] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of: Formula 231 [1105] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 231. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 231, this reference incorporated by reference herein control. [1106] In an embodiment, the TDP-43 modulator is a compound according to Formula 231: or a pharmaceutically acceptable salt thereof, wherein R ¹ and R ² are each independently hydrogen or C1-4 alkyl; R ³ is hydrogen or C1-3 alkyl substituted with morpholinyl. [1107] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of:

Formula 232 [1108] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 232. Such compounds are described in International Publication No. WO2021252895A2, published December 16, 2021, and corresponding to International Application No. PCT/US2021/037008 filed June 11, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 232, this reference incorporated by reference herein control. [1109] In an embodiment, the TDP-43 modulator is a compound according to Formula 232:

or a pharmaceutically acceptable salt thereof, wherein X is selected from: [1110] In further embodiments, the TDP-43 modulator compound is Formulas 233 - 237 [1111] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to any one of Formulas 233 - 237. Such compounds are described in International Publication No. WO2021247921A1, published December 9, 2021, and corresponding to International Application No. PCT/US2021/035778 filed June 3, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of any one of Formulas 233 - 237, this reference incorporated by reference herein control. [1112] In an embodiment, the TDP-43 modulator is a compound according to any one of Formulas 233 - 237: wherein n is 0, 1, 2, 3, or 4; X is S or O; each R ¹ is, independently, halo, cyano, hydroxy, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, - SO2-optionally substituted C1-C6 alkyl, or -CO2-optionally substituted C1-C6 alkyl; R ² is optionally substituted C2-C9 heteroaryl; and R ³ is optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C9 heterocyclyl, optionally substituted C1-C6 alkyl C3-C8 cycloalkyl, optionally substituted C1-C6 heteroalkyl C3-C8 cycloalkyl, optionally substituted C1-C6 alkyl C2-C9 heteroaryl, optionally substituted C1-C6 heteroalkyl C2-C9 heteroaryl, optionally substituted C1-C6 alkyl C2-C9 heterocyclyl, optionally substituted C1-C6 heteroalkyl C2-C9 heterocyclyl, optionally substituted C1-C6 alkyl C6-C10 aryl, or optionally substituted C1-C6 heteroalkyl C6-C10 aryl. [1113] In further embodiments, X is S. [1114] In further embodiments, X is O. [1115] In further embodiments, n is 0. [1116] In further embodiments, n is 1. [1117] In further embodiments, R ¹ is halo. [1118] In further embodiments, halo is fluoro. [1119] In further embodiments, R ¹ is cyano. [1120] In further embodiments, R ¹ is hydroxy. [1121] In further embodiments, R ¹ is optionally substituted C1-C6 alkyl. [1122] In further embodiments, optionally substituted C1-C6 alkyl is methyl, ethyl, trifluoromethyl, or hydroxymethyl. [1123] In further embodiments, R ¹ is optionally substituted C1-C6 heteroalkyl. [1124] In further embodiments, optionally substituted C1-C6 heteroalkyl is ethoxy or trifluoromethoxy. [1125] In further embodiments, R ¹ is -SO2-optionally substituted C1-C6 alkyl. [1126] In further embodiments, -SO2-optionally substituted C1-C6 alkyl is -SO2-methyl. [1127] In further embodiments, R ¹ is -CO2-optionally substituted C1-C6 alkyl. [1128] In further embodiments, -CO2-optionally substituted C1-C6 alkyl is -CO2-methyl or -CO2-ethyl. [1129] In further embodiments, R ² is a 5-membered optionally substituted C2-C9 heteroaryl. [1130] In further embodiments, R ² is [1131] In further embodiments, R ² is a 6-membered optionally substituted C2-C9 heteroaryl.25. The compound of claim 24, wherein R ² is [1132] In further embodiments, R ³ is optionally substituted C3-C8 cycloalkyl. [1133] In further embodiments, R ³ is cyclohexyl. [1134] In further embodiments, R ³ is optionally substituted C2-C9 heterocyclyl. [1135] In further embodiments, R ³ is wherein R ⁴ is -C(O)R ⁵ ; R ⁵ is optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C1-C6 alkyl C3-C8 cycloalkyl, or optionally substituted C1-C6 heteroalkyl C3-C8 cycloalkyl. [1136] In further embodiments, R ³ is optionally substituted C6-C10 aryl. [1137] In further embodiments, R ³ is phenyl, 4-cyano-phenyl, or 4-fluoro-phenyl. [1138] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of (where the structure numbers are independent from the Formula numbers utilized herein):

Formula 238 [1139] In an embodiment, the TDP-43 modulator may be selected from one of the following compounds according to Formula 238. Such compounds are described in International Publication No. WO2021239915A1, published December 2, 2021, and corresponding to International Application No. PCT/EP2021/064274 filed May 27, 2021; US Patent No.8,133,882, issued March 13, 2012 and corresponding to US Application No.12/293,055 filed March 14, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 238, these references incorporated by reference herein control. [1140] In an embodiment, the TDP-43 modulator is a compound according to Formula 238: Formula 238 or a pharmaceutically acceptable salt thereof: wherein R ¹ : a cycloalkyl or lower alkylene-cycloalkyl, wherein the cycloalkyl in R ¹ may be substituted; R ² : — H or a halogen; R ³ : — H, a halogen, — OR ⁰ or — O-lower alkylene-aryl; R°: the same or different from each other and each represents — H or a lower alkyl R ⁴ : a lower alkyl, halogeno-lower alkyl, lower alkylene-cycloalkyl, cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic group in R ⁴ may respectively be substituted; R ⁵ : — NO2, — CN, a lower alkyl, lower alkenyl, halogeno-lower alkenyl, -L-R ^a , — C(0)R°, — O — R ^b , — N(R ⁶ ) ₂ , lower alkylene-N(R ⁶ )(R ^c ), — N(R ⁶ )C(0) — R ^d , lower alkylene- N(R ⁶ )C(0) — R ^d , lower) alkylene-N(R ⁰ )C(O)O-lower alkyl, — N(R°)C(0)N(R°) — R ^e , lower alkylene-N(R°)C(0)N(R°)— R ^e , — N(R ⁰ )S(O) ₂ N(R°)C(O)— R ^d , — CH=NOH, cycloalkyl, heterocyclic group, (2,4-dioxo-l,3-thiazolidin-5-ylidene)methyl or (4-oxo-2- thioxo-l,3- thiazolidin-5-ylidene)methyl, wherein the cycloalkyl and heterocyclic group in R ⁵ may respectively be substituted; R ⁶ : H, a lower alkyl, lower alkylene-C0 ₂ R° or lower alkylene-P(0)(OR ^p ) ₂ , wherein the lower alkylene in R ⁶ may be substituted; L: a lower alkylene or lower alkenylene which may respectively be substituted; R ^a : — OR ⁰ , — CN, — O-lower alkylene-aryl, — O-lower alkylene-C0 ₂ R°, — C(0)R°, — C0 ₂ R°, — C(0)NH0H, — C(0)N(R ⁶ ) ₂ , — C(0)N(R°)-aryl, — C(0)N(R°)— S(0) ₂ -lower alkyl, — C(0)N(R°) — S(0) ₂ -aryl, — C(0)N(R°) — S(0) ₂ -heterocyclic group, — NH ₂ OH, — 0C(0)R°, — OC(0)-halogeno-lower alkyl, — P(0)(0R ^p ) ₂ , an aryl or heterocyclic group, wherein the aryl and heterocyclic group in R ^a may be substituted; R ^p : R°, a lower alkylene-OC(0)-lower alkyl, lower alkylene-OC(0)-cycloalkyl, lower alkylene-OC(0)0- lower alkyl, lower alkylene-OC(0)0-cycloalkyl, or lower alkylene- heterocyclic group, wherein the heterocyclic group in R ^p may be substituted; R ^b : H, a cycloalkyl, aryl, heterocyclic group, lower alkylene-R ^ba or lower alkenylene-R ^ba , wherein the lower alkylene, lower alkenylene, cycloalkyl, aryl and heterocyclic group in R ^b may be substituted; R ^ba : —OR ⁰ , — O— Si(lower alkyl) ₃ , — C0 ₂ R°, — C(0)NH0H, — C(0)N(R°) ₂ , — C(0)N(R°) — S(0) ₂ -lower alkyl, — C(0)N(R°)— S(0) ₂ -aryl, =C(NH ₂ )=NOH, — C(NH ₂ )=N0— C(0)R°, — C(NH ₂ )=N0— C(0)-lower alkylene-C(O)R ⁰ , — C0 ₂ -lower alkylene-aryl, — P(0)(0R ^p ) ₂ , — C(0)R°, — C(0)-aryl, a cycloalkyl, aryl or heterocyclic group, wherein the aryl and heterocyclic group in R ^ba may be substituted; R ^c : H, a lower alkyl, lower alkylene-OR ⁰ , lower alkylene-C0 ₂ R°, lower alkylene- C(0)NH0H, lower)alkylene-C(0)N(R°) ₂ , lower alkylene-P(0)(OR ^p ) ₂ , lower alkylene-aryl, lower alkylene-heterocyclic group, aryl or heterocyclic group, wherein the lower alkylene, aryl and heterocyclic group in R ^c may be substituted; R ^d : a Ci - ₇ alkyl, lower alkenyl, halogeno-lower alkyl, lower alkylene-R ^da , lower alkenylene- R ^da , cycloalkyl, aryl or heterocyclic group, wherein the lower alkylene, lower alkenylene, cycloalkyl, aryl and heterocyclic group in R ^d may be substituted; R ^da : — CN, —OR ⁰ , — 0C(0)R°, -O-lower alkylene-C0 ₂ R°, -O-aryl, — C0 ₂ R°, — C(0)NH0H, — C(0)N(R°) ₂ , — C0 ₂ -lower alkylene- N(R°) ₂ , — P(0)(0R ^p ) ₂ , — N(R ⁶ ) ₂ , — N(R°)C(0)R°, — C(0)N(R°)-aryl, — C(0)N(R°)-(lower alkylene which may be substituted with — C0 ₂ R°)-aryl, — N(R°)C(0)-aryl, — N(R°)C(0)— OR ⁰ , —N(R°)C(0)— O-lower alkylene-aryl, — N(R°)S(0) ₂ -aryl, — S- heterocyclic group, — C(O)N(R ⁰ )-heterocyclic group, — N(R°)C(0)-heterocyclic group, a cycloalkyl, aryl or heterocyclic group, wherein the cycloalkyl, aryl and heterocyclic group in R ^da may be substituted; R ^e : lower alkylene-C0 ₂ R°, lower alkylene-C(0)NHOH, lower)alkylene-C(0)N(R°) ₂ , a lower alkylene-heterocyclic group, aryl, heterocyclic group, — S(0) ₂ -aryl or — S(0) ₂ -heterocyclic group, wherein the aryl and heterocyclic group in R ^e may be substituted; X: CH; A: C(R ⁷ ); R ⁷ : — H or a lower alkyl, or R ⁴ and R' may together form a lower alkylene which may be substituted. [1141] In further embodiments, the TDP-43 modulator compound is selected from the group consisting of: Further TDP-43 modulator embodiments [1142] The TDP-43 modulator may be present as isotopically labeled forms of compounds detailed herein. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure at levels higher than natural abundance include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to ² H (deuterium, D), ³ H (tritium), ⁿ C, ¹³ C, ¹⁴ C, ¹⁵ N, ¹⁸ F, ³¹ P, ³² P, ³⁵ S, CI and I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as ³ H, ¹³ C and ¹⁴ C are incorporated, are provided. Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of subjects (e.g., humans). Also provided for isotopically labeled compounds described herein are any pharmaceutically acceptable salts, or hydrates, as the case may be. [1143] In some variations, the compounds disclosed herein may be varied such that from 1 to “n” hydrogens attached to a carbon atom is/are replaced by deuterium, in which “n” is the number of hydrogens in the molecule. Such compounds may exhibit increased resistance to metabolism and are thus useful for increasing the half-life of the compound when administered to a subject. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci.5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium. [1144] Deuterium labeled or substituted therapeutic compounds of the disclosure may have improved drug metabolism and pharmacokinetics (DMPK) properties, relating to absorption, distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index. An ¹⁸ F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure can generally be prepared by carrying out the procedures known to those skilled in the art by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compounds provided herein. [1145] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as Ή" or "hydrogen", the position is understood to have hydrogen at its natural abundance isotopic composition. PHARMACEUTICAL COMPOSITIONS [1146] In an embodiment, provided is a pharmaceutical composition comprising a metal channel activator and a TDP-43 modulator. [1147] In another embodiment, the metal channel activator in said pharmaceutical composition is a potassium channel activator. [1148] In another embodiment, the potassium channel activator in said pharmaceutical composition is a Kv7 channel activator. [1149] In another embodiment, the Kv7 channel activator in said pharmaceutical composition is selected from the group consisting of a Kv7.1 channel activator, a Kv7.2 channel activator, a Kv7.3 channel activator, a Kv7.4 channel activator, a Kv7.5 channel activator, or any combination thereof. [1150] In another embodiment, the Kv7 channel activator in said pharmaceutical composition is a Kv7.2/7.3 channel activator. [1151] In another embodiment, the metal channel activator in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 1 to 170 and the compounds disclosed in the “further embodiments” under the “METAL CHANNEL ACTIVATORS” subheading. [1152] In another embodiment, the TDP-43 modulator in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 200 to 238. [1153] In another embodiment, the TDP-43 modulator in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 200 to 238, and the metal channel activator in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 1 to 170 and the compounds disclosed in the “further embodiments” under the “METAL CHANNEL ACTIVATORS” subheading. [1154] In another embodiment, the TDP-43 modulator or a pharmaceutically acceptable salt thereof in said pharmaceutical composition is in a form of a prodrug. METHODS OF TREATING DISEASES [1155] The combination therapies disclosed herein are useful for treating or preventing various neurological and neurodegenerative disorders. In an embodiment, disclosed is a method for treating or preventing a disease that involves TDP-43, including administering to a subject any of the above pharmaceutical compositions. The disease may be selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), chronic traumatic encephalopathy (CTE), hippocampal sclerosis of aging (CARTS), inclusion body myositis (IBM), Alzheimer’s disease (AD), Alzheimer’s disease (AD) related disorders, or any combination thereof. [1156] In another embodiment, disclosed is a method for treating or preventing a disease associated with TDP-43 proteinopathies, including administering to a subject any of the above pharmaceutical compositions. [1157] In another embodiment, disclosed is a method for treating or preventing a disease associated with TDP-43 proteinopathies and/or that can benefit from Kv7 channel activation, including administering to a subject any of the above pharmaceutical compositions. [1158] In another embodiment, disclosed is a method for treating or preventing a disease that can benefit from Kv7 channel activation, including administering to a subject any of the above pharmaceutical compositions. [1159] In another embodiment, disclosed is a method for treating or preventing diseases that involve excess amounts of TDP-43 in the cytosol, including administering to a subject any of the above pharmaceutical compositions. [1160] In another embodiment, disclosed is a method of use of the TDP-43 modulators of the present invention as positron emission tomography (PET) imaging agents, including administering to a subject any of the pharmaceutical compositions. [1161] In another embodiment, disclosed is a method of use of the TDP-43 modulators of the present invention as single-photon emission computed tomography (SPECT) imaging agents, wherein the method includes administering to a subject any of the above pharmaceutical compositions including an isotopically labeled metal channel activator, an isotopically labeled TDP-43 modulator, or any combination thereof. The pharmaceutical composition may be administered in a combination with at least one other agent known to treat amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), chronic traumatic encephalopathy (CTE), hippocampal sclerosis of aging (CARTS), inclusion body myositis (IBM), Alzheimer’s disease (AD), Alzheimer’s disease (AD) related disorders, or any combination thereof. [1162] In another embodiment, the combination of Kv7 opener and TDP-43 modulator further includes at least one other agent. In some embodiments, the at least one other agent is riluzole, troriluzole, and/or edavarone. [1163] In further embodiments, a kit is provided for treating a patient afflicted with a disorder involving metal channel dysfunction and TDP-43, said kit comprising: (a) the metal channel activator; and (b) instructions for administering said metal channel activator in combination with [1164] In further embodiments, a kit is provided for treating a patient wherein the patient is afflicted with a disorder involving metal channel dysfunction and TDP-43, said kit comprising: (a) the metal channel activator; and (b) instructions for administering said metal channel activator in combination with a TDP-43 modulator by one of the aforementioned methods. [1165] In further embodiments, a kit is provided for treating a patient wherein the patient is afflicted with a disorder involving metal channel dysfunction and TDP-43, said kit comprising: (a) the TDP-43 modulator; and (b) instructions for administering said TDP-43 modulator with a metal channel activator by one of the aforementioned methods. [1166] Throughout this application, various publications are referenced by author name and date, or by patent number or patent publication number. The disclosures of these publications are hereby incorporated in their entireties by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention. [1167] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims. For example, pharmaceutically acceptable salts other than those specifically disclosed in the description and Examples herein can be employed. Furthermore, it is intended that specific items within lists of items, or subset groups of items within larger groups of items, can be combined with other specific items, subset groups of items or larger groups of items whether or not there is a specific disclosure herein identifying such a combination. PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT [1168] Compounds are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of one or more of a compound of any one of Formulas 1 – 180, Formulas 200 – 238, those listed in “Further Embodiments” under the “METAL CHANNEL ACTIVATORS” subsection, or pharmaceutically acceptable salt(s) thereof, and a pharmaceutically acceptable carrier, further optionally containing conventional excipients. A therapeutically effective amount is the amount needed to provide a meaningful patient benefit as determined by practitioners in that art. Pharmaceutically acceptable carriers are those having acceptable safety profiles which are conventionally known. Compositions encompass common solid and liquid forms including but not limited to capsules, tablets, lozenges, liquid suspensions, syrups, elixirs, and solutions. Solid compositions may by formulated to timed or sustained release. Compositions are made using common formulation techniques, such as the aforementioned solid and liquid forms, conventional excipients, such as binding and wetting agents, and vehicles, such as water and alcohols. [1169] The TDP-43 modulators of the present invention may be given orally, sublingually, intranasally, buccally, subcutaneously or in any other suitable means of delivery in table 1. The TDP-43 modulators may be in the form of a prodrug, which releases the agent in the body, a sustained release vehicle, a delayed release vehicle, or any other suitable delivery form. The TDP-43 modulator and the metal channel activator may be delivered simultaneously or sequentially. If the agents are delivered sequentially, either agent may be dosed first, and the separation of time may include finishing the dosing of one agent completely before commencing the dosage of the other or they may be intermingled in time. Typically, the TDP-43 modulator is administered at a time proximate to the administration of the metal channel activator, e.g., within 1 week, 1 day, 1 hour, 1 minute before or after the metal channel activator or simultaneously with the metal channel activator. [1170] The metal channel activators of the present invention may be given orally, sublingually, intranasally, buccally, subcutaneously or in any other suitable means of delivery in table 1. Metal channel activators may be given in the form of a prodrug, which will release the active compound in the body, a delayed release formulation, which will release the active compound after a time delay, a sustained release formulation, which will release the active compound slowly over time, or any other suitable formulation to deliver the active ingredient. The metal channel activator may be delivered simultaneously or sequentially with the TDP-43 modulator. If the agents are delivered sequentially, either agent may be dosed first, and the separation of time may include finishing the dosing of one agent completely before commencing the dosage of the other or they may be intermingled in time. Typically, the metal channel activator will be administered at a time nearing the administration of the TDP-43 modulator e.g., within 1 week, 1 day, 1 hour, 1 minute before or after the TDP-43 modulator or simultaneously with the metal channel activator. [1171] The dose of the TDP-43 modulator and metal channel activator for use together may depend on the subject to be treated inclusive of the age, sex, weight, and general health condition thereof. In this regard, precise amounts of the agent(s) for administration will depend on the judgment of the practitioner. In determining the effective amount of the TDP-43 modulator and metal channel activator to be administered in the treatment or reducing of the conditions associated with the symptoms and disorders, the physician may evaluate clinical factors including symptoms severity or progression of the disorder. In some conditions, a rapid absorption of the TDP-43 modulator or metal channel activator may be desirable. The effective amount of the treatment will vary depending on the subject and disease state being treated, the severity of the affliction and the manner of administration, and may be determined routinely by one of ordinary skill in the art. [1172] Some of the TDP-43 modulators and metal channel activators can be administered sublingually. The sublingual formulation may be administered in an effective amount to a subject in need thereof. The subject may be an animal or human. When the TDP-43 modulator or metal channel activator is prepared as a sublingual formulation, the sublingually administered chemical agent or the drug can diffuse into capillaries through mucous membrane under the tongue, and then enter venous circulation of the subject. As such, sublingual administration may have advantages over oral administration as allowing for direct or faster entry to venous circulation, without risks of degradation in gastrointestinal tract, alteration by drug metabolism in liver and the like. [1173] A sublingual formulation useful in the present invention comprises an effective amount of a TDP-43 modulator, metal channel activator, or pharmaceutically acceptable salts, solvates, anomers, enantiomers, hydrates, or prodrugs thereof. The formulation provides sufficient solubility for a TDP-43 modulator and/or metal channel activator to be incorporated into the sublingual formulation at relatively large doses and sublingually delivered. The formulation is preferably a modified oral disintegrating formulation of a TDP-43 modulator and/or metal channel activator. The excipients, including mannitol and gelatin, are blended, solubilized with water and deaerated before being mixed with the active pharmaceutical ingredient (or “API”), a TDP-43 modulator and/or a metal channel activator, which have been milled separately. Particle size of the API (D50) is less than about 2 microns. The mixture is lyophilized by flash freezing and then freeze- dried. The formulation has good oral palatability. The effective amount of a TDP-43 modulator and/or metal channel activator for the sublingual formulation useful in the present invention to achieve a lower therapeutic dose may be less than that of orally administered agent. Moreover, effective dose of the sublingual formulation of the TDP- 43 modulator and/or metal channel activator may be about 1 to 95 % of that of the orally administered agent. Sublingual formulations of the metal channel activator and/or TDP- 43 modulator may also have improved properties. [1174] In one aspect of the invention, the TDP-43 modulator and/or metal channel activator is provided in a sublingual formulation in a form of an orally dissolving or disintegrating tablet (ODT). The ODT as used herein may be prepared by mixing the TDP-43 modulator and/or the metal channel activator with water-soluble diluents and compressed in a tablet. A suspension comprising the active product may be prepared with appropriate excipients and the suspension may be dispensed into blister packs and freeze-dried. An exemplary freeze-dried preparation platform that could be used for the ODT is the ZYDIS® (Catalent, Somerset, NJ, USA) formulation. In particular, the excipients, including water, are blended and the TDP-43 modulator and/or metal channel activator are separately milled to size and mixed with the excipients. The suspension then undergoes lyophilization by flash freezing and freeze drying. Other methods of preparing ODTs may be used without limitation, and detailed description of general methods thereof have been disclosed, for example, in US Patent Nos 5,631,023; 5,837,287; 6,149,938; 6,212,791; 6,284,270; 6,316,029; 6,465,010; 6,471,992; 6,471,992; 6,509,040; 6,814,978; 6,908,626; 6,908,626; 6,982,25l; 7,282,217; 7,425,341; 7,939,105; 7,993,674; 8,048,449; 8,127,516; 8,158,152; 8,221,480; 8,256,233; and 8,313,768, each of which is incorporated herein by reference in its entirety. [1175] The clinical or therapeutic effect of the sublingually formulated TDP-43 modulator may have an improved pharmacokinetic profile for the pharmaceutical agent as measured by standard testing parameters. When the TDP-43 modulator is administered sublingually, the T _max , C _max and AUC of the drug may be improved compared to the same dose of the orally administered version of the same compound. For example, the sublingual formulation of the TDP-43 modulator may have a greater C _max than the orally administered TDP-43 modulator to provide a therapeutically beneficial effect. The sublingual formulation of the TDP-43 modulator may have an earlier or lesser T _max than the orally administered TDP-43 modulator to provide a therapeutically beneficial effect and in some instances, a more rapid therapeutic effect. Alternatively, the sublingual formulation of the TDP-43 modulator may have a greater AUC per milligram of the agent than the orally administered TDP-43 modulator. In addition, as the TDP-43 modulator may make the metal channel activator more effective, lesser amounts of the metal channel activator may be needed to achieve the same results lessening of the inherent side effects. [1176] The clinical or therapeutic effect of the sublingually formulated metal channel activator may have an improved pharmacokinetic profile for the pharmaceutical agent as measured by standard testing parameters. When the metal channel activator is administered sublingually, the T _max , C _max and AUC of the drug may be improved compared to the same dose of the orally administered version of the same compound. For example, the sublingual formulation of the metal channel activator may have a greater C _max than the orally administered metal channel activator to provide a therapeutically beneficial effect. The sublingual formulation of the metal modulator may have an earlier or lesser T _max than the orally administered metal channel activator to provide a therapeutically beneficial effect and in some instances, a more rapid therapeutic effect. Alternatively, the sublingual formulation of the metal channel activator may have a greater AUC per milligram of the agent than the orally administered metal channel activator. In addition, as the metal channel activator may make the TDP-43 modulator more effective, lesser amounts of the TDP-43 modulator may be needed to achieve the same results lessening of the inherent side effects. [1177] The disclosure and methods encompass all conventional modes of administration including oral, parenteral, intranasal, sublingual, topical, and transdermal methods. Among other routes of administration, the standard routes of administration described by the FDA are contemplated herein as shown in Table 1 below (FDA Routes of Administration; retrieved from www.fda.gov; content current as of 11/1/2022). Table 1: FDA Routes of Administration

[1178] In some embodiments, the route of administration may be oral, intranasal, inhalation, intravenous, sublingual, topical, injectable and/or transdermal. [1179] The pharmaceutical compositions of the present invention comprising the TDP- 43 modulator and/or metal channel activator may also include other pharmaceutically acceptable carriers and/or excipients such as binders, lubricants, diluents, coatings, disintegrants, barrier layer components, glidants, coloring agents, solubility enhancers, gelling agents, fillers, proteins, co-factors, emulsifiers, solubilizing agents, suspending agents and mixtures thereof. A skilled artisan in the art would know what other pharmaceutically acceptable carriers and/or excipients could be included in the formulations according to the invention. The choice of excipients would depend on the characteristics of the compositions and on the nature of other pharmacologically active compounds in the formulation. [1180] The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical. Excipients may also serve as part of the overall vehicle for delivery. Excipients may also be used to achieve effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating. Excipients herein may also serve an antimicrobial function or improve pharmaceutical composition characteristics such as lubricity, flowability, disintegration and taste. [1181] Pharmaceutical compositions may comprise one or more pharmaceutically acceptable carriers, excipients, or diluents. Examples of such carriers are well known to those skilled in the art and can be prepared in accordance with acceptable pharmaceutical procedures, such as, for example, those described in Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, Pa. (1985), the entire disclosure of which is incorporated by reference herein for all purposes. As used herein, “pharmaceutically acceptable” refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient. Pharmaceutically acceptable carriers are biologically acceptable and compatible with the other ingredients in the formulation. Appropriate excipients are known to those skilled in the art (see Handbook of Pharmaceutical Excipients, fifth edition, 2005 edited by Rowe et al., McGraw Hill) and have been utilized to yield a novel sublingual formulation with unexpected properties. Pharmaceutical compositions herein are not limited to a single active ingredient, and supplementary active ingredients can also be incorporated. [1182] Examples of pharmaceutically acceptable carriers that may be used in preparing the pharmaceutical compositions of the present invention may include, but are not limited to, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropyl methyl-cellulose, sodium carboxymethylcellulose; other carriers such as, polyvinylpyrrolidone (PVP), talc, calcium sulphate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, pyrogen-free water and combinations thereof. If desired, disintegrating agents may be combined as well, and exemplary disintegrating agents may be, but not limited to, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. The compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association one or more chemical agents as described above with the carrier which constitutes one or more necessary ingredients. In general, the pharmaceutical compositions of the present invention may be manufactured in conventional methods known in the art, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes, and the like. TDP-43 modulators, metal channel activator, and/or the pharmaceutically acceptable salts thereof can be formulated using pharmaceutically acceptable carriers well known in the art into dosages suitable for sublingual, intranasal or buccal administration. Such carriers enable the TDP-43 modulators and/or metal channel activator to be formulated in dosage forms such as tablets, powders, pills, capsules, liquids, gels, films, syrups, slurries, suspensions, and the like. [1183] The TDP-43 modulator and/or metal channel activator compounds disclosed can be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents, or encapsulating materials. Oral formulations containing a compound disclosed can be any conventionally used oral form, including but not limited to tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions, or solutions. In powders, the carrier can be a finely divided solid, which is an admixture with a finely divided compound. In tablets, a compound disclosed herein can be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets can contain up to 99% of the compound. [1184] Capsules can contain mixtures of one or more compound(s) disclosed herein with inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato, or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like. [1185] Useful tablet formulations can be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes, ion exchange resins, benzyl alcohol, eucalyptol, gelatin, limonene, mannitol, menthol, menthone, methyl acetate, sucralose, and vanillin. Surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecyl sulfate, magnesium aluminum silicate, and triethanolamine. Oral formulations herein can utilize standard delay or time-release formulations to alter the absorption of the compound(s). The oral formulation can also consist of administering a compound disclosed herein in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed. [1186] Liquid carriers can be used in preparing solutions for oral, parenteral (such as intravenous, intramuscular, or other injections), or inhalation administration including but not limited to suspensions, emulsions, syrups, and elixirs. A TDP-43 modulator and/or metal channel activator compound of the present teachings can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a mixture of both, or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-regulators. Examples of liquid carriers for oral and parenteral administration include, but are not limited to, water (particularly containing additives as described herein, e.g., cellulose derivatives such as a sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration, the carrier can be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellants. [1187] Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal, or subcutaneous injection. Sterile injectable solutions can also be administered intravenously. Compositions for oral administration can be in either liquid or solid form. [1188] Preferably the pharmaceutical composition is in unit dosage form, for example, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the pharmaceutical composition can be further sub-divided to contain appropriate quantities of the compound. The unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes, or sachets containing liquids. Alternatively, the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. Such doses can be administered in any manner useful in directing the compound(s) to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal, and subcutaneous injections), rectally, vaginally, and transdermally. [1189] When administered for the treatment or inhibition of a particular disease state or disorder, it is understood that an effective dosage can vary depending upon the particular compound utilized, the pharmaceutical composition formulated, the mode of administration, physical factors related to the individual being treated, and severity of the condition being treated. In therapeutic applications, a compound of the present teachings can be provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications. The dosage to be used in the treatment of a specific individual typically must be subjectively determined by the attending physician. The variables involved include the specific condition, stage of said condition, and the characteristics of the patient including their size, age and response pattern to the compound utilized. [1190] In some cases, it may be desirable to administer a compound directly to the airways of the patient, using devices such as, but not limited to, metered dose inhalers, breath-operated inhalers, multidose dry-powder inhalers, pumps, squeeze-actuated nebulized spray dispensers, aerosol dispensers, and aerosol nebulizers. For administration by intranasal or intrabronchial inhalation, the compounds of the present teachings can be formulated into a liquid composition, a solid composition, or an aerosol composition. The liquid composition can include, by way of illustration, one or more compounds of the present teachings dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents and can be administered by, for example, a pump or a squeeze-actuated nebulized spray dispenser. The solvents can be, for example, isotonic saline or bacteriostatic water. The solid composition can be, by way of illustration, a powder preparation including one or more compounds of the present teachings intermixed with lactose or other inert powders that are acceptable for intrabronchial use, and can be administered by, for example, an aerosol dispenser or a device that breaks or punctures a capsule encasing the solid composition and delivers the solid composition for inhalation. The aerosol composition can include, by way of illustration, one or more compounds of the present teachings, propellants, surfactants, and co-solvents, and can be administered by, for example, a metered device. The propellants can be a chlorofluorocarbon (CFC), a hydrofluoroalkane (HFA), or other propellants that are physiologically and environmentally acceptable. [1191] Compounds described herein can be administered parenterally or intraperitoneally. Solutions or suspensions of these compounds or a pharmaceutically acceptable salts, hydrates, or esters thereof can be prepared in water suitably mixed with a surfactant such as hydroxyl-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations typically contain a preservative to inhibit the growth of microorganisms. [1192] The pharmaceutical forms suitable for injection can include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In some embodiments, the form can be sterile and its viscosity permits it to flow through a syringe. The form preferably is stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. [1193] Compounds described herein can be administered transdermally, i.e., administered across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administration can be carried out using the compounds of the present teachings including pharmaceutically acceptable salts, hydrates, or esters thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal). [1194] Transdermal administration can be accomplished through the use of a transdermal patch containing a compound, such as a compound disclosed herein, and a carrier that can be inert to the compound, can be non-toxic to the skin, and can allow delivery of the compound for systemic absorption into the blood stream via the skin. The carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments can be viscous liquid or semisolid emulsions of either the oil- in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the compound can also be suitable. A variety of occlusive devices can be used to release the compound into the blood stream, such as a semi-permeable membrane covering a reservoir containing the compound with or without a carrier, or a matrix containing the compound. Other occlusive devices are known in the literature. [1195] Compounds described herein can be administered rectally or vaginally in the form of a conventional suppository. Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water-soluble suppository bases, such as polyethylene glycols of various molecular weights, can also be used. [1196] Lipid formulations or nanocapsules can be used to introduce compounds of the present teachings into host cells either in vitro or in vivo. Lipid formulations and nanocapsules can be prepared by methods known in the art. Pharmacokinetics and Dosing [1197] In some embodiments, a method of treating a neurological disease may be characterized by one or more pharmacokinetic parameters such as AUC, C _max , T _max , and others known and understood to persons of skill in the art. The term “pharmacokinetic” (PK) as used herein is used in its ordinary sense to mean the pharmacokinetic aspects of drug delivery. By definition pharmacokinetics (PK) is the study of how an organism affect a drug, e.g., how, and how fast it metabolizes the drug. The pharmacokinetics typically vary based upon the dosage amount of one or more of the disclosed TDP-43 modulators and/or metal channel activators. The pharmacokinetics may or may not vary as a function of administration route, and, if any, the binders, excipients, and dilutants in the pharmaceutical composition. [1198] In some embodiments, a method of treating a neurological disease may be characterized by an AUC for a TDP-43 and/or metal channel activator compound according to Formulas 1 – 180, Formulas 200 – 238, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof. In some embodiments, the AUC _0-t and/or AUC _0-inf (collectively referred to in the alternative as, simply, AUC) may be from about 80 – 125% of a given AUC value. In some embodiments, the AUC may be within 80 – 125 % of about 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1300, 1600, 1900, 2500, 3500, 5000, 7500, 10,000, 15,000, 20,000, 30,000, 50,000, and/or 100,000 hr*ng/mL. In some embodiments, a systemic treatment may have a larger AUC than a localized (such as topical or subdermal) treatment. [1199] In some embodiments, a method of treating a neurological disease may be characterized by a C _max for a TDP-43 and/or metal channel activator compound according to Formulas 1 – 180, Formulas 200 – 238, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof. In some embodiments, the C _max may be from about 80 – 125% of a given C _max value. In some embodiments, the C _max may be within 80 – 125 % of about 1, 2, 3, 4, 5, 8, 10, 20, 35, 50, 80,100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1300, 1600, 1900, 2500, 3500, 5000, 7500, 10,000, 15,000, 20,000, 30,000, 50,000, and/or 100,000 ng/mL. In some embodiments, a systemic treatment may have a larger C _max than a localized (such as topical or subdermal) treatment. [1200] In some embodiments, a ratio C _max /AUC may be used to characterize a method of treating a neurological disease wherein one or more of a TDP-43 and/or metal channel activator compound according to Formulas 1 – 180, Formulas 200 – 238, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof are administered to a subject. In some embodiments, the C _max /AUC ratio may be from about 80 – 125 % of a given C _max /AUC ratio. In some embodiments, the C _max /AUC ratio may be from about 80 – 125 % of about 0.01, 0.03, 0.05, 0.08, 0.1, 0.13, 0.17, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, and 0.9. [1201] In some embodiments, the T _max may range from about 0.1 – 16 hours, or from about 0.3 – 8 hours, or from about 0.5 – 4 hours, or from 0.5 – 2 hours, or from about 1 – 2 hours. In some embodiments, the route of administration, which may be any route described herein or known to a person of skill in the art, may affect the T _max of a compound according to Formulas 1 – 180, Formulas 200 – 238, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof. Excipients or other pharmaceutically acceptable carriers in pharmaceutical compositions of one or more compounds according to Formulas 1 – 180, Formulas 200 – 238, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof may alter the T _max value by making it larger or smaller than a pharmaceutical composition having the excipient or carrier excluded. [1202] Solid compositions are normally formulated in dosage units providing from about 0.1 to about 1000 mg of the active ingredient per dose. Some examples of solid dosage units are 0.1 mg, 1 mg, 10 mg, 100 mg, 500 mg, and 1000 mg. Liquid compositions are generally in a unit dosage range of 0.1-100 mg/mL. Some examples of liquid dosage units are 0.1 mg/mL, 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. [1203] In some embodiments, a dose is daily. In some embodiments, a dose is twice daily. In some embodiments, a does is one, two, three, four, or five times daily. In some embodiments, a dose is once every other day, once every second day, once every third day, once every fourth day, once every fifth day, once every sixth day, weekly, bi-weekly, or monthly. Typically, a dose may be from 0.01-100 mg/kg body weight, or from .05 – 50 mg/kg body weight, or from 0.1 – 10 mg/kg body weight, or from 0.15 – 5 mg/kg body weight, or from 0.2 – 2 mg/kg body weight, or from 0.5 – 1.5 mg/kg body weight, or from 1 – 1.5 mg/kg body weight. In some embodiments, the dosing regimen may comprise one or more optional loading doses and a subsequent maintenance dose regimen. A loading dose may be larger than the doses given in a subsequent maintenance dose regimen. [1204] In some embodiments, the dosage is adjusted based upon neurological disease symptoms observed in the patient. A symptom-dependent regimen may have a larger treatment dose while symptoms are present and a smaller preventative dose while symptoms are lessened, in remission, controlled, etc. In some embodiments, a treatment dose may comprise a unit dosage of about 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, or 200 mg of a TDP- 43 modulator according to any one of Formulas 1 – 180, and/or a metal channel activator according to any one of Formulas 200 – 238, or a compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof . In some embodiments, a preventative dose may comprise a unit dosage of about 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 100 mg, 120 mg, or 140 mg of a TDP-43 modulator according to any one of Formulas 1 – 180, and/or a metal channel activator according to any one of Formulas 200 – 238, or a compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof . In some embodiments, the preventative dose is an amount that is about 7/8, 3/4, 5/8, 1/2, 3/8, 1/4, or about 1/8 of the amount of the treatment dose. In some embodiments, if a patient receiving a preventative dosing regimen experiences recurrence or onset of symptoms, a treatment dosing regimen may replace the preventative dosing regimen until symptoms have lessened or subsided. Each of the treatment and/or preventative doses may be adjusted during the regimen based upon the severity of neurological disorder symptoms.